[
  {
    "node": "start_processing",
    "status": "completed",
    "state_snapshot": {
      "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
      "pdf_file_paths": [
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
      ],
      "all_pdf_texts": [
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "text": "16. INNATE IMMUNITY: \nNONSPECIFIC DEFENSES OF \nTHE HOST\nHongsup Yoon, Ph.D.\nMicrobiology\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n2\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n3\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n4\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n• White blood cell (WBC) \ncounts measure \nleukocytes in the blood\n• High WBC counts may \nindicate bacterial \ninfections, autoimmune \ndiseases, or side effects \nof medications\n• Low WBC counts may \nindicate viral infections, \npneumonia, \nautoimmune diseases, \nor cancers\n\nTHE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse.\n14\nHOST DEFENSE: THE BIG PICTURE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n16\nPHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\n\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice.\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n23\nFORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\n\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\n\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n31\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\n\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\n\nPHAGOCYTOSIS: OVERVIEW\n\nPHAGOCYTOSIS: MECHANISM\n\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\n\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n39\nINFLAMMATION: OVERVIEW\n\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\n\nFigure 16.9a-b  The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ntaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\n\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n49\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n51\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\n\nCOMPLEMENT: ACTIVATION\n\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\n\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\n\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\n\nFigure 16.12  Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13  Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBIAL PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n68\nSUMMARY (1/3)\n• The growth of microorganisms can be controlled by physical, chemical, \nmechanical, and biological means.\n• The body’s first line of defense against infections is a physical barrier and \nthe nonspecific chemicals of the skin and mucous membranes. \n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways.\n• A microbe’s penetration of the first line of defense encourages production \nof phagocytes, inflammation, fever, and antimicrobial substances. \n• Blood consists of plasma (fluid) and formed elements (cells and cell \nfragments). Leukocytes (white blood cells) are divided into granulocytes \n(neutrophils, basophils,  eosinophils) and agranulocytes. During many \ninfections, the number of leukocytes increases (leukocytosis); some  \ninfections are characterized by leucopenia (decrease in leukocytes). \nSUMMARY (2/3)\n• Phagocytosis is the ingestion of microorganisms or particulate matter by a \ncell. Phagocytosis is performed by phagocytes, certain types of white \nblood cells or their  derivatives. Among the granulocytes, neutrophils are \nthe most important phagocytes. Granulocytes predominate during the \nearly stages of infection, whereas monocytes  predominate as the \ninfection subsides. \n• Inflammation is a bodily response to cell damage; it is characterized by \nredness,  pain, heat, swelling, and sometimes the loss of function. TNF -α \nstimulates production of acute -phase proteins. \n• A tissue is repaired when the stroma (supporting tissue) or parenchyma \n(functioning  tissue) produces new cells. Stromal repair by fibroblasts \nproduces scar tissue. \n• Fever is an abnormally high body temperature produced in response to a \nbacterial or  viral infection. \nSUMMARY (3/3)\n• The complement system consists of a group of serum proteins that \nactivate one another to destroy invading microorganisms. Complement \nproteins are activated in a cascade. Complement is activated via the \nclassical pathway, the alternative pathway, and the lectin pathway. \n• IFN-α and IFN-β are antiviral proteins produced in response to viral \ninfection. The mode of action of IFN -α and IFN-β is to induce uninfected \ncells to produce antiviral proteins (AVPs) that prevent viral replication. IFN -\nα and IFN-β are host-cell-specific but not virus-specific. IFN-γ activates \nneutrophils and macrophages to kill bacteria. \n• Iron-binding proteins transport and store iron and deprive most pathogens \nof the  available iron.\n• Antimicrobial peptides (AMPs) inhibit cell wall synthesis; form pores in \nplasma  membranes, resulting in lysis; and destroy DNA and RNA."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "text": "17. ADAPTIVE IMMUNITY: \nSPECIFIC DEFENSES OF \nTHE HOST\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n2\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n3\nTHE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n5\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\n\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n11\nCYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n14\nAntibody A\nEpitopes (antigenic \ndeterminants)\non antigen\nAntigens:\ncomponents\nof cell wall\nAntibody B\nBacterial cell\nBinding sites\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\n\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\n\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n34\nCELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\n\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\n\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\n\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\n\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\n\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n51\nIMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\n \n\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\n\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n55\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\n\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Summary\n58\nFigure 17.20  The Dual Nature of the Adaptive Immune System.\n\nSUMMARY (1/3)\n• Adaptive immunity is the body’s ability to react specifically to a microbial \ninfection. The body’s response to the first contact with an antigen is called the \nprimary response. Subsequent contact with the same antigen results in a \nsecondary or memory response to that antigen.\n• Humoral immunity involves antibodies, which are found in serum and lymph and \nare produced by B cells. Lymphocytes that mature in red bone marrow become \nB cells. \n• Cellular immunity involves T cells. Lymphocytes that migrate through the thymus \nbecome T cells. T cell receptors recognize antigens presented on MHC. Cellular \nimmunity responds to intracellular antigens; humoral immunity responds to \nantigens in body fluids.\n• Cells of the immune system communicate with each other by means of \nchemicals called cytokines. Interleukins (IL) are cytokines that serve as \ncommunicators between leukocytes. Chemokines cause leukocytes to migrate \nto an infection. Some interferons stimulate the immune response; others protect \ncells against viruses. Tumor necrosis factor promotes the inflammatory reaction. \nHematopoietic cytokines promote development of white blood cells. \nOverproduction of cytokines leads to a cytokine storm, which results in tissue \ndamage.\nSUMMARY (2/3)\n• An antigen (or immunogen) is a chemical substance that causes the body \nto produce specific antibodies. Antibodies are formed against specific \nregions on antigens called epitopes, or antigenic determinants.\n• An antibody, or immunoglobulin, is a protein produced by B cells in \nresponse to an  antigen and is capable of combining specifically with that \nantigen. IgG antibodies are the most prevalent in serum; they provide \nnaturally acquired passive immunity, neutralize bacterial toxins, participate \nin complement fixation, and enhance phagocytosis.\n• T cells mature in the thymus gland. Thymic selection removes T cells that \ndon’t recognize MHC molecules of the host and T cells that will attack host \ncells presenting self-proteins in MHC. Helper T cells recognize antigens \nprocessed by antigen-presenting cells and presented in MHC II. Cytotoxic \nT cells recognize antigens processed by all host cells and presented in \nMHC I.\nSUMMARY (3/3)\n• APCs include B cells, dendritic cells, and macrophages. Dendritic cells are \nthe primary APCs. Dendritic cells are the primary APCs. APCs carry \nantigens to lymphoid tissues where T cells that recognize the antigen are \nlocated.\n• T helper (CD4+ T) cells differentiate into TH1 cells, which are involved in \ncellular immunity; TH2 cells, which are involved in humoral immunity and \nare associated with allergic reactions and parasitic infections; and TH17 \ncells, which activate innate immunity.\n• T regulatory cells (Treg) suppress T cells against self. Cytotoxic \nlymphocytes (CTLs), or CD8+ T cells, are activated by endogenous \nantigens and MHC class I on a target cell and are transformed into effector \nand memory CTLs.\n• CTLs lyse or induce apoptosis in the target cell."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
          "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n18. PRACTICAL \nAPPLICATIONS OF \nIMMUNOLOGY – PART I\n2\nRECENT VIRUS OUTBREAKS\n• 2002 SARS outbreak (~9.5 % mortality rate)\n• 2004 Global spread of H5N1 avian influenza (60% mortality rate)\n• 2009 H1N1/09 swine Flu pandemic\n• 2015 MERS in Korea (~40 % mortality rate)\n• 2018 Influenza B outbreak in Korea\n• 2019 COV-19 (SARS-CoV2) pandemic (~2 – 3 % mortality rate)\n?\nHISTORICAL PANDEMIC: BLACK DEATH\nKilled 30 – 60% of European\n\nEDWARD JENNER (1749 – 1823)\n\nMILKMAID (AROUND THE TIME OF JENNER)\n\nVACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\n\nVACCINES: FUNCTION\n\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -drug \nusers, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1  Influenza viruses are grown in embryonated eggs.\n\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\n\nRNA VACCINES\nVACCINES: TYPES\n\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\n\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren\nDIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nPRODUCTION OF MONOCLONAL \nANTIBODIES\n\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\n\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\n\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\n\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\n\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\n\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\n\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\n\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy\nSUMMARY (1/6)\n• Edward Jenner developed the modern practice of vaccination when he \ninoculated people with cowpox virus to protect them against smallpox. \n• Herd immunity results when most of a population is immune to a disease.\n• Bacteria have unique cell structures that can be targets for antibiotics, \nimmunity, and phage infection.\n•  Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Humans utilize \nand harness microorganisms and their products.\n• Attenuated vaccines consist of attenuated (weakened) microorganisms; \nattenuated virus vaccines generally provide lifelong immunity. Inactivated \nvaccines consist of killed bacteria or viruses. Subunit vaccines consist of \nantigenic fragments of a microorganism; these include  recombinant \nvaccines and toxoids. \nSUMMARY (2/6)\n• Conjugated vaccines combine the desired antigen with a protein that \nboosts the immune response. Nucleic acid (DNA) vaccines cause the \nrecipient to make the antigenic protein.\n• Viruses for vaccines may be grown in animals, cell cultures, or chick \nembryos. Recombinant vaccines and nucleic acid vaccines do not need to \nbe grown in cells or animals. Genetically modified plants may someday \nprovide edible vaccines.\n• Combining several vaccines would eliminate the number of injections. Dry \nskin patch vaccines don’t need refrigeration.\n• Adjuvants improve the effectiveness of some antigens. \n• Vaccines are the safest and most effective means of controlling infectious \ndiseases.\nSUMMARY (3/6)\n• Many tests based on the interactions of antibodies and antigens have \nbeen developed to determine the presence of antibodies or antigens in a \npatient. The sensitivity of a diagnostic test is determined by the percentage \nof positive samples it correctly detects; and its specificity is determined by \nthe percentage of false positive  results it gives.\n• Hybridomas are produced in the laboratory by fusing a cancerous cell with \nan antibody-secreting plasma cell. A hybridoma cell culture produces large \nquantities of the plasma cell’s antibodies, called monoclonal antibodies. \nMonoclonal antibodies are used in serological identification tests, to \nprevent tissue  rejections, and to make immunotoxins to treat cancer.\n• The interaction of soluble antigens with IgG or IgM antibodies leads to \nprecipitation  reactions. Precipitation reactions depend on the formation of \nlattices and occur best when antigen and antibody are present in optimal \nproportions. Excesses of either component decrease lattice formation and \nsubsequent precipitation.\nSUMMARY (4/6)\n• Immunodiffusion procedures are precipitation reactions carried out in an \nagar gel  medium. Immunoelectrophoresis combines electrophoresis with \nimmunodiffusion for the analysis of serum proteins.\n• The interaction of particulate antigens (cells that carry antigens) with \nantibodies leads to agglutination reactions. Diseases may be diagnosed \nby combining the patient’s serum with a known antigen. Diseases can be \ndiagnosed by a rising titer or seroconversion (from no antibodies to the \npresence of antibodies). Direct agglutination reactions can be used to \ndetermine antibody titer. Antibodies cause visible agglutination of soluble \nantigens affixed to latex spheres in indirect or passive agglutination tests. \nHemagglutination reactions involve agglutination reactions using red blood \ncells.  Hemagglutination reactions are used in blood typing, the diagnosis \nof certain diseases, and the identification of viruses. \nSUMMARY (5/6)\n• In neutralization reactions, the harmful effects of a bacterial exotoxin or \nvirus are  eliminated by a specific antibody. An antitoxin is an antibody \nproduced in response to a bacterial exotoxin or a toxoid that neutralizes \nthe exotoxin. In a virus neutralization test, the presence of antibodies \nagainst a virus can be detected by the antibodies’ ability to prevent \ncytopathic effects of viruses in cell cultures. Antibodies against certain \nviruses can be detected by their ability to interfere with viral \nhemagglutination in viral hemagglutination inhibition tests.\n• Complement-fixation reactions are serological tests based on the \ndepletion of a fixed amount of complement in the presence of an antigen –\nantibody reaction.\n• Fluorescent-antibody techniques use antibodies labeled with fluorescent \ndyes. Direct fluorescent-antibody tests are used to identify specific \nmicroorganisms. \nSUMMARY (6/6)\n• Indirect fluorescent-antibody tests are used to demonstrate the presence \nof antibody  in serum. A fluorescence-activated cell sorter can be used to \ndetect and count cells labeled with fluorescent antibodies.\n• ELISA techniques use antibodies linked to an enzyme. Antigen –antibody \nreactions are detected by enzyme activity. If the indicator enzyme is \npresent in the test well, an antigen –antibody reaction has occurred. The \ndirect ELISA is used to detect antigens against a specific antibody bound \nin a test well. The indirect ELISA is used to detect antibodies against an \nantigen bound in a test well.\n• Serum antibodies separated by electrophoresis are identified with an \nenzyme-linked  antibody. \n• The use of monoclonal antibodies will continue to make new diagnostic \ntests possible."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n19. DISORDERS \nASSOCIATED WITH THE \nIMMUNE SYSTEM – PART 1\n2\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n3\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n4\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Dysbiosis: \nimbalance that \ncauses adverse \neffects in humans\n• Antibiotic therapy \nkills normal gut \nmicrobiota, causing \nClostridium difficile \nto proliferate\n• Possible cause of \nIBDs such as \nulcerative colitis and \nCrohn's disease\n\nBIG PICTURE: THE HYGIENE HYPOTHESIS\n• Allergies and asthma\n• Observation that tribal populations and children growing up on farms \nhave less prevalence of allergies than children in urban settings\n• Possibly due to wider range of microbial exposures in farm setting; also \nled to lower asthma rates\n• Inflammatory bowel diseases\n• Possible link of lack of normal microbiota metabolic products leading to \nchronic inflammatory state\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Treating Crohn's \ndisease with worms\n• Whipworm eggs \nsuppress T helper cell \npathways\n• Fecal transplants for C. \ndifficile infections\n• Taking gut microbiota \nfrom a healthy \nindividual and \ntransplanting it into the \npatient\n\nHYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\n\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\n\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\n\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\n\nFigure 19.8  Allergic contact dermatitis.\n\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n21\nAUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\n\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555) \nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n28\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\n\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2\nSUMMARY (1/3)\n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Hay fever, \ntransplant rejection, and autoimmunity are examples of harmful immune  \nreactions. Immunosuppression is inhibition of the immune system. \nSuperantigens activate many T cell receptors that can cause adverse host \nresponses.\n• Hypersensitivity reactions represent immunological responses to an \nantigen (allergen) that lead to tissue damage rather than immunity. \nHypersensitivity reactions occur when a person has been sensitized to an \nantigen. Hypersensitivity reactions can be divided into four classes: types \nI, II, and III are immediate reactions based on humoral immunity, and type \nIV is a delayed reaction  based on cell -mediated immunity. \n• Childhood exposure to microbes may decrease development of allergies.\nSUMMARY (2/3)\n• Autoimmunity results from a loss of self -tolerance. Self-tolerance occurs \nduring fetal development; T cells that will target host cells are eliminated \n(clonal deletion) or inactivated. Autoimmunity may be due to antibodies \nagainst infectious agents. Graves’ disease and myasthenia gravis are \ncytotoxic autoimmune reactions in which  antibodies react to cell -surface \nantigens.\n• Systemic lupus erythematosus and rheumatoid arthritis are immune \ncomplex autoimmune reactions in which the deposition of immune \ncomplexes results in tissue damage. Multiple sclerosis, insulin -dependent \ndiabetes mellitus, and psoriasis are cell -mediated autoimmune reactions \nmediated by T cells.\nSUMMARY (3/3)\n• MHC self molecules located on cell surfaces express genetic differences \namong individuals; these antigens are called HLAs in humans. To prevent \nthe rejection of transplants, HLA and ABO blood group antigens of the \ndonor and recipient are matched as closely as possible. Transplants \nrecognized as foreign antigens may be lysed by T cells and attacked by \nmacrophages and complement -fixing antibodies. Transplantation to a \nprivileged site (such as the cornea) or of a privileged tissue (such as pig \nheart valves) does not cause an immune response. Pluripotent stem cells \ndifferentiate into a variety of tissues that may provide tissues for \ntransplant.\n• Four types of transplants have been defined on the basis of genetic \nrelationships between the donor and the recipient: autografts, isografts, \nallografts, and xenotransplants. Bone marrow transplants (with \nimmunocompetent cells) can cause graft -versus-host  disease.  \nSuccessful transplant surgery often requires immunosuppressant drugs to \nprevent an immune response to the transplanted tissue. \nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n40\nTHE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\n\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n46\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\n\nFigure 19.12  A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES\n\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n52\nACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\n\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14  Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15  Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\n\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\n\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n\n70\n\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\n\nHIV MANAGEMENT\n\nFigure 19.18  Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\n\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\n\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable\nSUMMARY (1/3)\n• Cancer cells are normal cells that have undergone transformation, divide \nuncontrollably, and possess tumor-associated antigens. The response of the \nimmune system to cancer is called immunological surveillance. TC cells \nrecognize and lyse cancerous cells. Cancer cells can escape detection and \ndestruction by the immune system. Cancer cells may grow faster than the \nimmune system can respond.\n• Novel therapeutic strategies, such as immune checkpoint inhibitors and CAR T \ncell therapy, are effective approaches to treat patients with cancer.\n• Vaccines against liver and cervical cancer are available; a therapeutic vaccine \nagainst prostate cancer also has been approved. Herceptin consists of \nmonoclonal antibodies against a breast cancer growth factor. Immunotoxins are \nchemical poisons linked to a monoclonal antibody; the antibody  selectively \nlocates the cancer cell for release of the poison.\n• Immunodeficiencies can be congenital or acquired. Congenital \nimmunodeficiencies are due to defective or absent genes. A variety of drugs, \ncancers, and infectious diseases can cause acquired  immunodeficiencies. \n• HIV is thought to have originated in central Africa and was brought to other \ncountries by modern transportation and unsafe sexual practices.\nSUMMARY (2/3)\n• AIDS is the final stage of HIV infection. HIV is a retrovirus with single -\nstranded RNA, reverse transcriptase, and a phospholipid envelope with \ngp120 spikes. HIV spikes attach to CD4+ and coreceptors on host cells; \nthe CD4+ receptor is found on  T helper cells, macrophages, and dendritic \ncells. Viral RNA is transcribed to DNA by reverse transcriptase. The viral \nDNA becomes  integrated into the host chromosome to direct synthesis of \nnew viruses or to remain latent as a provirus. HIV evades the immune \nsystem in latency, in vacuoles, by using cell–cell fusion, and by antigenic \nchange. HIV-1 accounts for most HIV infections. Subtype B of HIV -1 is the \nmost common type in the United States. HIV infection is categorized by \nsymptoms: phase 1 (asymptomatic), phase 2 (indicator opportunistic \ninfections), and phase 3 (CD4+  cells <200 cells/μ1). The progression from \nHIV infection to AIDS takes about 10 years. The life of an AIDS patient can \nbe prolonged by the proper treatment of opportunistic  infections. People \nlacking CCR5 are resistant to HIV infection. Elite controllers are long -term \nsurvivors who may hold the key to HIV treatment. \nSUMMARY (3/3)\n• HIV antibodies are detected by ELISA and Western blotting. Plasma viral \nload tests detect viral nucleic acid and are used to quantify HIV in blood.\n• HIV is transmitted by sexual contact, breast milk, contaminated needles, \ntransplacental infection, artificial insemination, and blood transfusion. In \ndeveloped countries, blood transfusions are not a likely source of infection \nbecause blood is tested for HIV antibodies. \n• Heterosexual intercourse is the primary method of HIV transmission.\n• Discouraging sexual promiscuity and using condoms and sterile needles \nprevent the transmission of HIV. Vaccine development is difficult because \nthe virus remains inside host cells and there is no model of natural \nimmunity to mimic. Current chemotherapeutic agents target the virus \nenzymes, including reverse transcriptase, integrase, and protease. Other \ninhibitors include cell entry inhibitors, maturation inhibitors, and tetherins."
        }
      ],
      "notebook_title": "",
      "holistic_chapters": [],
      "generated_content": [],
      "log_entries": [
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        }
      ],
      "final_result": ""
    }
  },
  {
    "node": "analyze_overall_structure",
    "status": "completed",
    "state_snapshot": {
      "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
      "pdf_file_paths": [
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
      ],
      "all_pdf_texts": [
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "text": "16. INNATE IMMUNITY: \nNONSPECIFIC DEFENSES OF \nTHE HOST\nHongsup Yoon, Ph.D.\nMicrobiology\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n2\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n3\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n4\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n• White blood cell (WBC) \ncounts measure \nleukocytes in the blood\n• High WBC counts may \nindicate bacterial \ninfections, autoimmune \ndiseases, or side effects \nof medications\n• Low WBC counts may \nindicate viral infections, \npneumonia, \nautoimmune diseases, \nor cancers\n\nTHE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse.\n14\nHOST DEFENSE: THE BIG PICTURE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n16\nPHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\n\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice.\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n23\nFORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\n\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\n\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n31\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\n\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\n\nPHAGOCYTOSIS: OVERVIEW\n\nPHAGOCYTOSIS: MECHANISM\n\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\n\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n39\nINFLAMMATION: OVERVIEW\n\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\n\nFigure 16.9a-b  The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ntaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\n\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n49\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n51\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\n\nCOMPLEMENT: ACTIVATION\n\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\n\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\n\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\n\nFigure 16.12  Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13  Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBIAL PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n68\nSUMMARY (1/3)\n• The growth of microorganisms can be controlled by physical, chemical, \nmechanical, and biological means.\n• The body’s first line of defense against infections is a physical barrier and \nthe nonspecific chemicals of the skin and mucous membranes. \n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways.\n• A microbe’s penetration of the first line of defense encourages production \nof phagocytes, inflammation, fever, and antimicrobial substances. \n• Blood consists of plasma (fluid) and formed elements (cells and cell \nfragments). Leukocytes (white blood cells) are divided into granulocytes \n(neutrophils, basophils,  eosinophils) and agranulocytes. During many \ninfections, the number of leukocytes increases (leukocytosis); some  \ninfections are characterized by leucopenia (decrease in leukocytes). \nSUMMARY (2/3)\n• Phagocytosis is the ingestion of microorganisms or particulate matter by a \ncell. Phagocytosis is performed by phagocytes, certain types of white \nblood cells or their  derivatives. Among the granulocytes, neutrophils are \nthe most important phagocytes. Granulocytes predominate during the \nearly stages of infection, whereas monocytes  predominate as the \ninfection subsides. \n• Inflammation is a bodily response to cell damage; it is characterized by \nredness,  pain, heat, swelling, and sometimes the loss of function. TNF -α \nstimulates production of acute -phase proteins. \n• A tissue is repaired when the stroma (supporting tissue) or parenchyma \n(functioning  tissue) produces new cells. Stromal repair by fibroblasts \nproduces scar tissue. \n• Fever is an abnormally high body temperature produced in response to a \nbacterial or  viral infection. \nSUMMARY (3/3)\n• The complement system consists of a group of serum proteins that \nactivate one another to destroy invading microorganisms. Complement \nproteins are activated in a cascade. Complement is activated via the \nclassical pathway, the alternative pathway, and the lectin pathway. \n• IFN-α and IFN-β are antiviral proteins produced in response to viral \ninfection. The mode of action of IFN -α and IFN-β is to induce uninfected \ncells to produce antiviral proteins (AVPs) that prevent viral replication. IFN -\nα and IFN-β are host-cell-specific but not virus-specific. IFN-γ activates \nneutrophils and macrophages to kill bacteria. \n• Iron-binding proteins transport and store iron and deprive most pathogens \nof the  available iron.\n• Antimicrobial peptides (AMPs) inhibit cell wall synthesis; form pores in \nplasma  membranes, resulting in lysis; and destroy DNA and RNA."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "text": "17. ADAPTIVE IMMUNITY: \nSPECIFIC DEFENSES OF \nTHE HOST\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n2\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n3\nTHE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n5\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\n\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n11\nCYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n14\nAntibody A\nEpitopes (antigenic \ndeterminants)\non antigen\nAntigens:\ncomponents\nof cell wall\nAntibody B\nBacterial cell\nBinding sites\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\n\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\n\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n34\nCELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\n\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\n\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\n\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\n\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\n\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n51\nIMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\n \n\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\n\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n55\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\n\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Summary\n58\nFigure 17.20  The Dual Nature of the Adaptive Immune System.\n\nSUMMARY (1/3)\n• Adaptive immunity is the body’s ability to react specifically to a microbial \ninfection. The body’s response to the first contact with an antigen is called the \nprimary response. Subsequent contact with the same antigen results in a \nsecondary or memory response to that antigen.\n• Humoral immunity involves antibodies, which are found in serum and lymph and \nare produced by B cells. Lymphocytes that mature in red bone marrow become \nB cells. \n• Cellular immunity involves T cells. Lymphocytes that migrate through the thymus \nbecome T cells. T cell receptors recognize antigens presented on MHC. Cellular \nimmunity responds to intracellular antigens; humoral immunity responds to \nantigens in body fluids.\n• Cells of the immune system communicate with each other by means of \nchemicals called cytokines. Interleukins (IL) are cytokines that serve as \ncommunicators between leukocytes. Chemokines cause leukocytes to migrate \nto an infection. Some interferons stimulate the immune response; others protect \ncells against viruses. Tumor necrosis factor promotes the inflammatory reaction. \nHematopoietic cytokines promote development of white blood cells. \nOverproduction of cytokines leads to a cytokine storm, which results in tissue \ndamage.\nSUMMARY (2/3)\n• An antigen (or immunogen) is a chemical substance that causes the body \nto produce specific antibodies. Antibodies are formed against specific \nregions on antigens called epitopes, or antigenic determinants.\n• An antibody, or immunoglobulin, is a protein produced by B cells in \nresponse to an  antigen and is capable of combining specifically with that \nantigen. IgG antibodies are the most prevalent in serum; they provide \nnaturally acquired passive immunity, neutralize bacterial toxins, participate \nin complement fixation, and enhance phagocytosis.\n• T cells mature in the thymus gland. Thymic selection removes T cells that \ndon’t recognize MHC molecules of the host and T cells that will attack host \ncells presenting self-proteins in MHC. Helper T cells recognize antigens \nprocessed by antigen-presenting cells and presented in MHC II. Cytotoxic \nT cells recognize antigens processed by all host cells and presented in \nMHC I.\nSUMMARY (3/3)\n• APCs include B cells, dendritic cells, and macrophages. Dendritic cells are \nthe primary APCs. Dendritic cells are the primary APCs. APCs carry \nantigens to lymphoid tissues where T cells that recognize the antigen are \nlocated.\n• T helper (CD4+ T) cells differentiate into TH1 cells, which are involved in \ncellular immunity; TH2 cells, which are involved in humoral immunity and \nare associated with allergic reactions and parasitic infections; and TH17 \ncells, which activate innate immunity.\n• T regulatory cells (Treg) suppress T cells against self. Cytotoxic \nlymphocytes (CTLs), or CD8+ T cells, are activated by endogenous \nantigens and MHC class I on a target cell and are transformed into effector \nand memory CTLs.\n• CTLs lyse or induce apoptosis in the target cell."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
          "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n18. PRACTICAL \nAPPLICATIONS OF \nIMMUNOLOGY – PART I\n2\nRECENT VIRUS OUTBREAKS\n• 2002 SARS outbreak (~9.5 % mortality rate)\n• 2004 Global spread of H5N1 avian influenza (60% mortality rate)\n• 2009 H1N1/09 swine Flu pandemic\n• 2015 MERS in Korea (~40 % mortality rate)\n• 2018 Influenza B outbreak in Korea\n• 2019 COV-19 (SARS-CoV2) pandemic (~2 – 3 % mortality rate)\n?\nHISTORICAL PANDEMIC: BLACK DEATH\nKilled 30 – 60% of European\n\nEDWARD JENNER (1749 – 1823)\n\nMILKMAID (AROUND THE TIME OF JENNER)\n\nVACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\n\nVACCINES: FUNCTION\n\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -drug \nusers, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1  Influenza viruses are grown in embryonated eggs.\n\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\n\nRNA VACCINES\nVACCINES: TYPES\n\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\n\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren\nDIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nPRODUCTION OF MONOCLONAL \nANTIBODIES\n\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\n\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\n\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\n\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\n\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\n\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\n\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\n\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy\nSUMMARY (1/6)\n• Edward Jenner developed the modern practice of vaccination when he \ninoculated people with cowpox virus to protect them against smallpox. \n• Herd immunity results when most of a population is immune to a disease.\n• Bacteria have unique cell structures that can be targets for antibiotics, \nimmunity, and phage infection.\n•  Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Humans utilize \nand harness microorganisms and their products.\n• Attenuated vaccines consist of attenuated (weakened) microorganisms; \nattenuated virus vaccines generally provide lifelong immunity. Inactivated \nvaccines consist of killed bacteria or viruses. Subunit vaccines consist of \nantigenic fragments of a microorganism; these include  recombinant \nvaccines and toxoids. \nSUMMARY (2/6)\n• Conjugated vaccines combine the desired antigen with a protein that \nboosts the immune response. Nucleic acid (DNA) vaccines cause the \nrecipient to make the antigenic protein.\n• Viruses for vaccines may be grown in animals, cell cultures, or chick \nembryos. Recombinant vaccines and nucleic acid vaccines do not need to \nbe grown in cells or animals. Genetically modified plants may someday \nprovide edible vaccines.\n• Combining several vaccines would eliminate the number of injections. Dry \nskin patch vaccines don’t need refrigeration.\n• Adjuvants improve the effectiveness of some antigens. \n• Vaccines are the safest and most effective means of controlling infectious \ndiseases.\nSUMMARY (3/6)\n• Many tests based on the interactions of antibodies and antigens have \nbeen developed to determine the presence of antibodies or antigens in a \npatient. The sensitivity of a diagnostic test is determined by the percentage \nof positive samples it correctly detects; and its specificity is determined by \nthe percentage of false positive  results it gives.\n• Hybridomas are produced in the laboratory by fusing a cancerous cell with \nan antibody-secreting plasma cell. A hybridoma cell culture produces large \nquantities of the plasma cell’s antibodies, called monoclonal antibodies. \nMonoclonal antibodies are used in serological identification tests, to \nprevent tissue  rejections, and to make immunotoxins to treat cancer.\n• The interaction of soluble antigens with IgG or IgM antibodies leads to \nprecipitation  reactions. Precipitation reactions depend on the formation of \nlattices and occur best when antigen and antibody are present in optimal \nproportions. Excesses of either component decrease lattice formation and \nsubsequent precipitation.\nSUMMARY (4/6)\n• Immunodiffusion procedures are precipitation reactions carried out in an \nagar gel  medium. Immunoelectrophoresis combines electrophoresis with \nimmunodiffusion for the analysis of serum proteins.\n• The interaction of particulate antigens (cells that carry antigens) with \nantibodies leads to agglutination reactions. Diseases may be diagnosed \nby combining the patient’s serum with a known antigen. Diseases can be \ndiagnosed by a rising titer or seroconversion (from no antibodies to the \npresence of antibodies). Direct agglutination reactions can be used to \ndetermine antibody titer. Antibodies cause visible agglutination of soluble \nantigens affixed to latex spheres in indirect or passive agglutination tests. \nHemagglutination reactions involve agglutination reactions using red blood \ncells.  Hemagglutination reactions are used in blood typing, the diagnosis \nof certain diseases, and the identification of viruses. \nSUMMARY (5/6)\n• In neutralization reactions, the harmful effects of a bacterial exotoxin or \nvirus are  eliminated by a specific antibody. An antitoxin is an antibody \nproduced in response to a bacterial exotoxin or a toxoid that neutralizes \nthe exotoxin. In a virus neutralization test, the presence of antibodies \nagainst a virus can be detected by the antibodies’ ability to prevent \ncytopathic effects of viruses in cell cultures. Antibodies against certain \nviruses can be detected by their ability to interfere with viral \nhemagglutination in viral hemagglutination inhibition tests.\n• Complement-fixation reactions are serological tests based on the \ndepletion of a fixed amount of complement in the presence of an antigen –\nantibody reaction.\n• Fluorescent-antibody techniques use antibodies labeled with fluorescent \ndyes. Direct fluorescent-antibody tests are used to identify specific \nmicroorganisms. \nSUMMARY (6/6)\n• Indirect fluorescent-antibody tests are used to demonstrate the presence \nof antibody  in serum. A fluorescence-activated cell sorter can be used to \ndetect and count cells labeled with fluorescent antibodies.\n• ELISA techniques use antibodies linked to an enzyme. Antigen –antibody \nreactions are detected by enzyme activity. If the indicator enzyme is \npresent in the test well, an antigen –antibody reaction has occurred. The \ndirect ELISA is used to detect antigens against a specific antibody bound \nin a test well. The indirect ELISA is used to detect antibodies against an \nantigen bound in a test well.\n• Serum antibodies separated by electrophoresis are identified with an \nenzyme-linked  antibody. \n• The use of monoclonal antibodies will continue to make new diagnostic \ntests possible."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n19. DISORDERS \nASSOCIATED WITH THE \nIMMUNE SYSTEM – PART 1\n2\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n3\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n4\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Dysbiosis: \nimbalance that \ncauses adverse \neffects in humans\n• Antibiotic therapy \nkills normal gut \nmicrobiota, causing \nClostridium difficile \nto proliferate\n• Possible cause of \nIBDs such as \nulcerative colitis and \nCrohn's disease\n\nBIG PICTURE: THE HYGIENE HYPOTHESIS\n• Allergies and asthma\n• Observation that tribal populations and children growing up on farms \nhave less prevalence of allergies than children in urban settings\n• Possibly due to wider range of microbial exposures in farm setting; also \nled to lower asthma rates\n• Inflammatory bowel diseases\n• Possible link of lack of normal microbiota metabolic products leading to \nchronic inflammatory state\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Treating Crohn's \ndisease with worms\n• Whipworm eggs \nsuppress T helper cell \npathways\n• Fecal transplants for C. \ndifficile infections\n• Taking gut microbiota \nfrom a healthy \nindividual and \ntransplanting it into the \npatient\n\nHYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\n\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\n\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\n\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\n\nFigure 19.8  Allergic contact dermatitis.\n\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n21\nAUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\n\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555) \nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n28\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\n\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2\nSUMMARY (1/3)\n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Hay fever, \ntransplant rejection, and autoimmunity are examples of harmful immune  \nreactions. Immunosuppression is inhibition of the immune system. \nSuperantigens activate many T cell receptors that can cause adverse host \nresponses.\n• Hypersensitivity reactions represent immunological responses to an \nantigen (allergen) that lead to tissue damage rather than immunity. \nHypersensitivity reactions occur when a person has been sensitized to an \nantigen. Hypersensitivity reactions can be divided into four classes: types \nI, II, and III are immediate reactions based on humoral immunity, and type \nIV is a delayed reaction  based on cell -mediated immunity. \n• Childhood exposure to microbes may decrease development of allergies.\nSUMMARY (2/3)\n• Autoimmunity results from a loss of self -tolerance. Self-tolerance occurs \nduring fetal development; T cells that will target host cells are eliminated \n(clonal deletion) or inactivated. Autoimmunity may be due to antibodies \nagainst infectious agents. Graves’ disease and myasthenia gravis are \ncytotoxic autoimmune reactions in which  antibodies react to cell -surface \nantigens.\n• Systemic lupus erythematosus and rheumatoid arthritis are immune \ncomplex autoimmune reactions in which the deposition of immune \ncomplexes results in tissue damage. Multiple sclerosis, insulin -dependent \ndiabetes mellitus, and psoriasis are cell -mediated autoimmune reactions \nmediated by T cells.\nSUMMARY (3/3)\n• MHC self molecules located on cell surfaces express genetic differences \namong individuals; these antigens are called HLAs in humans. To prevent \nthe rejection of transplants, HLA and ABO blood group antigens of the \ndonor and recipient are matched as closely as possible. Transplants \nrecognized as foreign antigens may be lysed by T cells and attacked by \nmacrophages and complement -fixing antibodies. Transplantation to a \nprivileged site (such as the cornea) or of a privileged tissue (such as pig \nheart valves) does not cause an immune response. Pluripotent stem cells \ndifferentiate into a variety of tissues that may provide tissues for \ntransplant.\n• Four types of transplants have been defined on the basis of genetic \nrelationships between the donor and the recipient: autografts, isografts, \nallografts, and xenotransplants. Bone marrow transplants (with \nimmunocompetent cells) can cause graft -versus-host  disease.  \nSuccessful transplant surgery often requires immunosuppressant drugs to \nprevent an immune response to the transplanted tissue. \nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n40\nTHE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\n\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n46\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\n\nFigure 19.12  A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES\n\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n52\nACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\n\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14  Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15  Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\n\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\n\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n\n70\n\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\n\nHIV MANAGEMENT\n\nFigure 19.18  Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\n\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\n\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable\nSUMMARY (1/3)\n• Cancer cells are normal cells that have undergone transformation, divide \nuncontrollably, and possess tumor-associated antigens. The response of the \nimmune system to cancer is called immunological surveillance. TC cells \nrecognize and lyse cancerous cells. Cancer cells can escape detection and \ndestruction by the immune system. Cancer cells may grow faster than the \nimmune system can respond.\n• Novel therapeutic strategies, such as immune checkpoint inhibitors and CAR T \ncell therapy, are effective approaches to treat patients with cancer.\n• Vaccines against liver and cervical cancer are available; a therapeutic vaccine \nagainst prostate cancer also has been approved. Herceptin consists of \nmonoclonal antibodies against a breast cancer growth factor. Immunotoxins are \nchemical poisons linked to a monoclonal antibody; the antibody  selectively \nlocates the cancer cell for release of the poison.\n• Immunodeficiencies can be congenital or acquired. Congenital \nimmunodeficiencies are due to defective or absent genes. A variety of drugs, \ncancers, and infectious diseases can cause acquired  immunodeficiencies. \n• HIV is thought to have originated in central Africa and was brought to other \ncountries by modern transportation and unsafe sexual practices.\nSUMMARY (2/3)\n• AIDS is the final stage of HIV infection. HIV is a retrovirus with single -\nstranded RNA, reverse transcriptase, and a phospholipid envelope with \ngp120 spikes. HIV spikes attach to CD4+ and coreceptors on host cells; \nthe CD4+ receptor is found on  T helper cells, macrophages, and dendritic \ncells. Viral RNA is transcribed to DNA by reverse transcriptase. The viral \nDNA becomes  integrated into the host chromosome to direct synthesis of \nnew viruses or to remain latent as a provirus. HIV evades the immune \nsystem in latency, in vacuoles, by using cell–cell fusion, and by antigenic \nchange. HIV-1 accounts for most HIV infections. Subtype B of HIV -1 is the \nmost common type in the United States. HIV infection is categorized by \nsymptoms: phase 1 (asymptomatic), phase 2 (indicator opportunistic \ninfections), and phase 3 (CD4+  cells <200 cells/μ1). The progression from \nHIV infection to AIDS takes about 10 years. The life of an AIDS patient can \nbe prolonged by the proper treatment of opportunistic  infections. People \nlacking CCR5 are resistant to HIV infection. Elite controllers are long -term \nsurvivors who may hold the key to HIV treatment. \nSUMMARY (3/3)\n• HIV antibodies are detected by ELISA and Western blotting. Plasma viral \nload tests detect viral nucleic acid and are used to quantify HIV in blood.\n• HIV is transmitted by sexual contact, breast milk, contaminated needles, \ntransplacental infection, artificial insemination, and blood transfusion. In \ndeveloped countries, blood transfusions are not a likely source of infection \nbecause blood is tested for HIV antibodies. \n• Heterosexual intercourse is the primary method of HIV transmission.\n• Discouraging sexual promiscuity and using condoms and sterile needles \nprevent the transmission of HIV. Vaccine development is difficult because \nthe virus remains inside host cells and there is no model of natural \nimmunity to mimic. Current chemotherapeutic agents target the virus \nenzymes, including reverse transcriptase, integrase, and protease. Other \ninhibitors include cell entry inhibitors, maturation inhibitors, and tetherins."
        }
      ],
      "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
      "holistic_chapters": [
        {
          "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
          "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
        },
        {
          "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
          "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
        },
        {
          "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
          "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
        },
        {
          "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
          "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
        },
        {
          "chapter_title": "적응성 면역: 개요 및 이중적 특성",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
          "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
        },
        {
          "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
          "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
        },
        {
          "chapter_title": "적응성 면역: 체액성 면역 반응",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
          "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
        },
        {
          "chapter_title": "적응성 면역: 세포성 면역 반응",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
          "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
        },
        {
          "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
          "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
        },
        {
          "chapter_title": "면역학의 실제 적용: 백신",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
          "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
          "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
        },
        {
          "chapter_title": "면역학의 실제 적용: 진단 면역학",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
          "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
          "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 과민 반응",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
          "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
          "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
          "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
          "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
          "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
        }
      ],
      "generated_content": [],
      "log_entries": [
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "analyze_overall_structure",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [],
            "final_result": ""
          }
        }
      ],
      "final_result": ""
    }
  },
  {
    "node": "generate_chapter_content",
    "status": "completed",
    "state_snapshot": {
      "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
      "pdf_file_paths": [
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
      ],
      "all_pdf_texts": [
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "text": "16. INNATE IMMUNITY: \nNONSPECIFIC DEFENSES OF \nTHE HOST\nHongsup Yoon, Ph.D.\nMicrobiology\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n2\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n3\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n4\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n• White blood cell (WBC) \ncounts measure \nleukocytes in the blood\n• High WBC counts may \nindicate bacterial \ninfections, autoimmune \ndiseases, or side effects \nof medications\n• Low WBC counts may \nindicate viral infections, \npneumonia, \nautoimmune diseases, \nor cancers\n\nTHE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse.\n14\nHOST DEFENSE: THE BIG PICTURE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n16\nPHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\n\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice.\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n23\nFORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\n\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\n\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n31\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\n\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\n\nPHAGOCYTOSIS: OVERVIEW\n\nPHAGOCYTOSIS: MECHANISM\n\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\n\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n39\nINFLAMMATION: OVERVIEW\n\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\n\nFigure 16.9a-b  The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ntaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\n\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n49\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n51\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\n\nCOMPLEMENT: ACTIVATION\n\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\n\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\n\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\n\nFigure 16.12  Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13  Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBIAL PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n68\nSUMMARY (1/3)\n• The growth of microorganisms can be controlled by physical, chemical, \nmechanical, and biological means.\n• The body’s first line of defense against infections is a physical barrier and \nthe nonspecific chemicals of the skin and mucous membranes. \n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways.\n• A microbe’s penetration of the first line of defense encourages production \nof phagocytes, inflammation, fever, and antimicrobial substances. \n• Blood consists of plasma (fluid) and formed elements (cells and cell \nfragments). Leukocytes (white blood cells) are divided into granulocytes \n(neutrophils, basophils,  eosinophils) and agranulocytes. During many \ninfections, the number of leukocytes increases (leukocytosis); some  \ninfections are characterized by leucopenia (decrease in leukocytes). \nSUMMARY (2/3)\n• Phagocytosis is the ingestion of microorganisms or particulate matter by a \ncell. Phagocytosis is performed by phagocytes, certain types of white \nblood cells or their  derivatives. Among the granulocytes, neutrophils are \nthe most important phagocytes. Granulocytes predominate during the \nearly stages of infection, whereas monocytes  predominate as the \ninfection subsides. \n• Inflammation is a bodily response to cell damage; it is characterized by \nredness,  pain, heat, swelling, and sometimes the loss of function. TNF -α \nstimulates production of acute -phase proteins. \n• A tissue is repaired when the stroma (supporting tissue) or parenchyma \n(functioning  tissue) produces new cells. Stromal repair by fibroblasts \nproduces scar tissue. \n• Fever is an abnormally high body temperature produced in response to a \nbacterial or  viral infection. \nSUMMARY (3/3)\n• The complement system consists of a group of serum proteins that \nactivate one another to destroy invading microorganisms. Complement \nproteins are activated in a cascade. Complement is activated via the \nclassical pathway, the alternative pathway, and the lectin pathway. \n• IFN-α and IFN-β are antiviral proteins produced in response to viral \ninfection. The mode of action of IFN -α and IFN-β is to induce uninfected \ncells to produce antiviral proteins (AVPs) that prevent viral replication. IFN -\nα and IFN-β are host-cell-specific but not virus-specific. IFN-γ activates \nneutrophils and macrophages to kill bacteria. \n• Iron-binding proteins transport and store iron and deprive most pathogens \nof the  available iron.\n• Antimicrobial peptides (AMPs) inhibit cell wall synthesis; form pores in \nplasma  membranes, resulting in lysis; and destroy DNA and RNA."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "text": "17. ADAPTIVE IMMUNITY: \nSPECIFIC DEFENSES OF \nTHE HOST\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n2\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n3\nTHE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n5\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\n\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n11\nCYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n14\nAntibody A\nEpitopes (antigenic \ndeterminants)\non antigen\nAntigens:\ncomponents\nof cell wall\nAntibody B\nBacterial cell\nBinding sites\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\n\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\n\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n34\nCELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\n\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\n\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\n\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\n\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\n\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n51\nIMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\n \n\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\n\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n55\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\n\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Summary\n58\nFigure 17.20  The Dual Nature of the Adaptive Immune System.\n\nSUMMARY (1/3)\n• Adaptive immunity is the body’s ability to react specifically to a microbial \ninfection. The body’s response to the first contact with an antigen is called the \nprimary response. Subsequent contact with the same antigen results in a \nsecondary or memory response to that antigen.\n• Humoral immunity involves antibodies, which are found in serum and lymph and \nare produced by B cells. Lymphocytes that mature in red bone marrow become \nB cells. \n• Cellular immunity involves T cells. Lymphocytes that migrate through the thymus \nbecome T cells. T cell receptors recognize antigens presented on MHC. Cellular \nimmunity responds to intracellular antigens; humoral immunity responds to \nantigens in body fluids.\n• Cells of the immune system communicate with each other by means of \nchemicals called cytokines. Interleukins (IL) are cytokines that serve as \ncommunicators between leukocytes. Chemokines cause leukocytes to migrate \nto an infection. Some interferons stimulate the immune response; others protect \ncells against viruses. Tumor necrosis factor promotes the inflammatory reaction. \nHematopoietic cytokines promote development of white blood cells. \nOverproduction of cytokines leads to a cytokine storm, which results in tissue \ndamage.\nSUMMARY (2/3)\n• An antigen (or immunogen) is a chemical substance that causes the body \nto produce specific antibodies. Antibodies are formed against specific \nregions on antigens called epitopes, or antigenic determinants.\n• An antibody, or immunoglobulin, is a protein produced by B cells in \nresponse to an  antigen and is capable of combining specifically with that \nantigen. IgG antibodies are the most prevalent in serum; they provide \nnaturally acquired passive immunity, neutralize bacterial toxins, participate \nin complement fixation, and enhance phagocytosis.\n• T cells mature in the thymus gland. Thymic selection removes T cells that \ndon’t recognize MHC molecules of the host and T cells that will attack host \ncells presenting self-proteins in MHC. Helper T cells recognize antigens \nprocessed by antigen-presenting cells and presented in MHC II. Cytotoxic \nT cells recognize antigens processed by all host cells and presented in \nMHC I.\nSUMMARY (3/3)\n• APCs include B cells, dendritic cells, and macrophages. Dendritic cells are \nthe primary APCs. Dendritic cells are the primary APCs. APCs carry \nantigens to lymphoid tissues where T cells that recognize the antigen are \nlocated.\n• T helper (CD4+ T) cells differentiate into TH1 cells, which are involved in \ncellular immunity; TH2 cells, which are involved in humoral immunity and \nare associated with allergic reactions and parasitic infections; and TH17 \ncells, which activate innate immunity.\n• T regulatory cells (Treg) suppress T cells against self. Cytotoxic \nlymphocytes (CTLs), or CD8+ T cells, are activated by endogenous \nantigens and MHC class I on a target cell and are transformed into effector \nand memory CTLs.\n• CTLs lyse or induce apoptosis in the target cell."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
          "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n18. PRACTICAL \nAPPLICATIONS OF \nIMMUNOLOGY – PART I\n2\nRECENT VIRUS OUTBREAKS\n• 2002 SARS outbreak (~9.5 % mortality rate)\n• 2004 Global spread of H5N1 avian influenza (60% mortality rate)\n• 2009 H1N1/09 swine Flu pandemic\n• 2015 MERS in Korea (~40 % mortality rate)\n• 2018 Influenza B outbreak in Korea\n• 2019 COV-19 (SARS-CoV2) pandemic (~2 – 3 % mortality rate)\n?\nHISTORICAL PANDEMIC: BLACK DEATH\nKilled 30 – 60% of European\n\nEDWARD JENNER (1749 – 1823)\n\nMILKMAID (AROUND THE TIME OF JENNER)\n\nVACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\n\nVACCINES: FUNCTION\n\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -drug \nusers, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1  Influenza viruses are grown in embryonated eggs.\n\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\n\nRNA VACCINES\nVACCINES: TYPES\n\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\n\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren\nDIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nPRODUCTION OF MONOCLONAL \nANTIBODIES\n\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\n\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\n\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\n\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\n\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\n\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\n\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\n\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy\nSUMMARY (1/6)\n• Edward Jenner developed the modern practice of vaccination when he \ninoculated people with cowpox virus to protect them against smallpox. \n• Herd immunity results when most of a population is immune to a disease.\n• Bacteria have unique cell structures that can be targets for antibiotics, \nimmunity, and phage infection.\n•  Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Humans utilize \nand harness microorganisms and their products.\n• Attenuated vaccines consist of attenuated (weakened) microorganisms; \nattenuated virus vaccines generally provide lifelong immunity. Inactivated \nvaccines consist of killed bacteria or viruses. Subunit vaccines consist of \nantigenic fragments of a microorganism; these include  recombinant \nvaccines and toxoids. \nSUMMARY (2/6)\n• Conjugated vaccines combine the desired antigen with a protein that \nboosts the immune response. Nucleic acid (DNA) vaccines cause the \nrecipient to make the antigenic protein.\n• Viruses for vaccines may be grown in animals, cell cultures, or chick \nembryos. Recombinant vaccines and nucleic acid vaccines do not need to \nbe grown in cells or animals. Genetically modified plants may someday \nprovide edible vaccines.\n• Combining several vaccines would eliminate the number of injections. Dry \nskin patch vaccines don’t need refrigeration.\n• Adjuvants improve the effectiveness of some antigens. \n• Vaccines are the safest and most effective means of controlling infectious \ndiseases.\nSUMMARY (3/6)\n• Many tests based on the interactions of antibodies and antigens have \nbeen developed to determine the presence of antibodies or antigens in a \npatient. The sensitivity of a diagnostic test is determined by the percentage \nof positive samples it correctly detects; and its specificity is determined by \nthe percentage of false positive  results it gives.\n• Hybridomas are produced in the laboratory by fusing a cancerous cell with \nan antibody-secreting plasma cell. A hybridoma cell culture produces large \nquantities of the plasma cell’s antibodies, called monoclonal antibodies. \nMonoclonal antibodies are used in serological identification tests, to \nprevent tissue  rejections, and to make immunotoxins to treat cancer.\n• The interaction of soluble antigens with IgG or IgM antibodies leads to \nprecipitation  reactions. Precipitation reactions depend on the formation of \nlattices and occur best when antigen and antibody are present in optimal \nproportions. Excesses of either component decrease lattice formation and \nsubsequent precipitation.\nSUMMARY (4/6)\n• Immunodiffusion procedures are precipitation reactions carried out in an \nagar gel  medium. Immunoelectrophoresis combines electrophoresis with \nimmunodiffusion for the analysis of serum proteins.\n• The interaction of particulate antigens (cells that carry antigens) with \nantibodies leads to agglutination reactions. Diseases may be diagnosed \nby combining the patient’s serum with a known antigen. Diseases can be \ndiagnosed by a rising titer or seroconversion (from no antibodies to the \npresence of antibodies). Direct agglutination reactions can be used to \ndetermine antibody titer. Antibodies cause visible agglutination of soluble \nantigens affixed to latex spheres in indirect or passive agglutination tests. \nHemagglutination reactions involve agglutination reactions using red blood \ncells.  Hemagglutination reactions are used in blood typing, the diagnosis \nof certain diseases, and the identification of viruses. \nSUMMARY (5/6)\n• In neutralization reactions, the harmful effects of a bacterial exotoxin or \nvirus are  eliminated by a specific antibody. An antitoxin is an antibody \nproduced in response to a bacterial exotoxin or a toxoid that neutralizes \nthe exotoxin. In a virus neutralization test, the presence of antibodies \nagainst a virus can be detected by the antibodies’ ability to prevent \ncytopathic effects of viruses in cell cultures. Antibodies against certain \nviruses can be detected by their ability to interfere with viral \nhemagglutination in viral hemagglutination inhibition tests.\n• Complement-fixation reactions are serological tests based on the \ndepletion of a fixed amount of complement in the presence of an antigen –\nantibody reaction.\n• Fluorescent-antibody techniques use antibodies labeled with fluorescent \ndyes. Direct fluorescent-antibody tests are used to identify specific \nmicroorganisms. \nSUMMARY (6/6)\n• Indirect fluorescent-antibody tests are used to demonstrate the presence \nof antibody  in serum. A fluorescence-activated cell sorter can be used to \ndetect and count cells labeled with fluorescent antibodies.\n• ELISA techniques use antibodies linked to an enzyme. Antigen –antibody \nreactions are detected by enzyme activity. If the indicator enzyme is \npresent in the test well, an antigen –antibody reaction has occurred. The \ndirect ELISA is used to detect antigens against a specific antibody bound \nin a test well. The indirect ELISA is used to detect antibodies against an \nantigen bound in a test well.\n• Serum antibodies separated by electrophoresis are identified with an \nenzyme-linked  antibody. \n• The use of monoclonal antibodies will continue to make new diagnostic \ntests possible."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n19. DISORDERS \nASSOCIATED WITH THE \nIMMUNE SYSTEM – PART 1\n2\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n3\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n4\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Dysbiosis: \nimbalance that \ncauses adverse \neffects in humans\n• Antibiotic therapy \nkills normal gut \nmicrobiota, causing \nClostridium difficile \nto proliferate\n• Possible cause of \nIBDs such as \nulcerative colitis and \nCrohn's disease\n\nBIG PICTURE: THE HYGIENE HYPOTHESIS\n• Allergies and asthma\n• Observation that tribal populations and children growing up on farms \nhave less prevalence of allergies than children in urban settings\n• Possibly due to wider range of microbial exposures in farm setting; also \nled to lower asthma rates\n• Inflammatory bowel diseases\n• Possible link of lack of normal microbiota metabolic products leading to \nchronic inflammatory state\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Treating Crohn's \ndisease with worms\n• Whipworm eggs \nsuppress T helper cell \npathways\n• Fecal transplants for C. \ndifficile infections\n• Taking gut microbiota \nfrom a healthy \nindividual and \ntransplanting it into the \npatient\n\nHYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\n\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\n\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\n\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\n\nFigure 19.8  Allergic contact dermatitis.\n\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n21\nAUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\n\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555) \nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n28\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\n\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2\nSUMMARY (1/3)\n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Hay fever, \ntransplant rejection, and autoimmunity are examples of harmful immune  \nreactions. Immunosuppression is inhibition of the immune system. \nSuperantigens activate many T cell receptors that can cause adverse host \nresponses.\n• Hypersensitivity reactions represent immunological responses to an \nantigen (allergen) that lead to tissue damage rather than immunity. \nHypersensitivity reactions occur when a person has been sensitized to an \nantigen. Hypersensitivity reactions can be divided into four classes: types \nI, II, and III are immediate reactions based on humoral immunity, and type \nIV is a delayed reaction  based on cell -mediated immunity. \n• Childhood exposure to microbes may decrease development of allergies.\nSUMMARY (2/3)\n• Autoimmunity results from a loss of self -tolerance. Self-tolerance occurs \nduring fetal development; T cells that will target host cells are eliminated \n(clonal deletion) or inactivated. Autoimmunity may be due to antibodies \nagainst infectious agents. Graves’ disease and myasthenia gravis are \ncytotoxic autoimmune reactions in which  antibodies react to cell -surface \nantigens.\n• Systemic lupus erythematosus and rheumatoid arthritis are immune \ncomplex autoimmune reactions in which the deposition of immune \ncomplexes results in tissue damage. Multiple sclerosis, insulin -dependent \ndiabetes mellitus, and psoriasis are cell -mediated autoimmune reactions \nmediated by T cells.\nSUMMARY (3/3)\n• MHC self molecules located on cell surfaces express genetic differences \namong individuals; these antigens are called HLAs in humans. To prevent \nthe rejection of transplants, HLA and ABO blood group antigens of the \ndonor and recipient are matched as closely as possible. Transplants \nrecognized as foreign antigens may be lysed by T cells and attacked by \nmacrophages and complement -fixing antibodies. Transplantation to a \nprivileged site (such as the cornea) or of a privileged tissue (such as pig \nheart valves) does not cause an immune response. Pluripotent stem cells \ndifferentiate into a variety of tissues that may provide tissues for \ntransplant.\n• Four types of transplants have been defined on the basis of genetic \nrelationships between the donor and the recipient: autografts, isografts, \nallografts, and xenotransplants. Bone marrow transplants (with \nimmunocompetent cells) can cause graft -versus-host  disease.  \nSuccessful transplant surgery often requires immunosuppressant drugs to \nprevent an immune response to the transplanted tissue. \nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n40\nTHE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\n\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n46\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\n\nFigure 19.12  A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES\n\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n52\nACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\n\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14  Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15  Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\n\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\n\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n\n70\n\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\n\nHIV MANAGEMENT\n\nFigure 19.18  Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\n\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\n\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable\nSUMMARY (1/3)\n• Cancer cells are normal cells that have undergone transformation, divide \nuncontrollably, and possess tumor-associated antigens. The response of the \nimmune system to cancer is called immunological surveillance. TC cells \nrecognize and lyse cancerous cells. Cancer cells can escape detection and \ndestruction by the immune system. Cancer cells may grow faster than the \nimmune system can respond.\n• Novel therapeutic strategies, such as immune checkpoint inhibitors and CAR T \ncell therapy, are effective approaches to treat patients with cancer.\n• Vaccines against liver and cervical cancer are available; a therapeutic vaccine \nagainst prostate cancer also has been approved. Herceptin consists of \nmonoclonal antibodies against a breast cancer growth factor. Immunotoxins are \nchemical poisons linked to a monoclonal antibody; the antibody  selectively \nlocates the cancer cell for release of the poison.\n• Immunodeficiencies can be congenital or acquired. Congenital \nimmunodeficiencies are due to defective or absent genes. A variety of drugs, \ncancers, and infectious diseases can cause acquired  immunodeficiencies. \n• HIV is thought to have originated in central Africa and was brought to other \ncountries by modern transportation and unsafe sexual practices.\nSUMMARY (2/3)\n• AIDS is the final stage of HIV infection. HIV is a retrovirus with single -\nstranded RNA, reverse transcriptase, and a phospholipid envelope with \ngp120 spikes. HIV spikes attach to CD4+ and coreceptors on host cells; \nthe CD4+ receptor is found on  T helper cells, macrophages, and dendritic \ncells. Viral RNA is transcribed to DNA by reverse transcriptase. The viral \nDNA becomes  integrated into the host chromosome to direct synthesis of \nnew viruses or to remain latent as a provirus. HIV evades the immune \nsystem in latency, in vacuoles, by using cell–cell fusion, and by antigenic \nchange. HIV-1 accounts for most HIV infections. Subtype B of HIV -1 is the \nmost common type in the United States. HIV infection is categorized by \nsymptoms: phase 1 (asymptomatic), phase 2 (indicator opportunistic \ninfections), and phase 3 (CD4+  cells <200 cells/μ1). The progression from \nHIV infection to AIDS takes about 10 years. The life of an AIDS patient can \nbe prolonged by the proper treatment of opportunistic  infections. People \nlacking CCR5 are resistant to HIV infection. Elite controllers are long -term \nsurvivors who may hold the key to HIV treatment. \nSUMMARY (3/3)\n• HIV antibodies are detected by ELISA and Western blotting. Plasma viral \nload tests detect viral nucleic acid and are used to quantify HIV in blood.\n• HIV is transmitted by sexual contact, breast milk, contaminated needles, \ntransplacental infection, artificial insemination, and blood transfusion. In \ndeveloped countries, blood transfusions are not a likely source of infection \nbecause blood is tested for HIV antibodies. \n• Heterosexual intercourse is the primary method of HIV transmission.\n• Discouraging sexual promiscuity and using condoms and sterile needles \nprevent the transmission of HIV. Vaccine development is difficult because \nthe virus remains inside host cells and there is no model of natural \nimmunity to mimic. Current chemotherapeutic agents target the virus \nenzymes, including reverse transcriptase, integrase, and protease. Other \ninhibitors include cell entry inhibitors, maturation inhibitors, and tetherins."
        }
      ],
      "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
      "holistic_chapters": [
        {
          "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
          "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
        },
        {
          "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
          "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
        },
        {
          "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
          "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
        },
        {
          "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
          "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
        },
        {
          "chapter_title": "적응성 면역: 개요 및 이중적 특성",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
          "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
        },
        {
          "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
          "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
        },
        {
          "chapter_title": "적응성 면역: 체액성 면역 반응",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
          "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
        },
        {
          "chapter_title": "적응성 면역: 세포성 면역 반응",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
          "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
        },
        {
          "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
          "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
        },
        {
          "chapter_title": "면역학의 실제 적용: 백신",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
          "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
          "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
        },
        {
          "chapter_title": "면역학의 실제 적용: 진단 면역학",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
          "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
          "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 과민 반응",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
          "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
          "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
          "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
          "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
          "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
        }
      ],
      "generated_content": [
        {
          "title": "면역 시스템의 이해: 선천성 및 적응성 면역",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2042 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "면역의 개념",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "면역은 질병을 막는 능력을 의미하며, 감수성은 질병에 대한 저항력이 부족한 상태를 뜻합니다. 면역은 크게 두 가지로 나뉩니다. 선천성 면역은 모든 병원체에 대한 방어 기전으로, 신속하며 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 면역 또는 저항력으로, 반응 속도가 느리지만 기억 구성 요소를 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "선천성 면역",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "선천성 면역은 자연 면역, 타고난 면역이라고도 불립니다. 식세포, 수지상 세포, 비만 세포, 자연 살해 세포 등 다양한 선천성 면역 세포들이 관여합니다. 이들은 감염이 발생하기 전부터 존재하며 면역 파수꾼 역할을 합니다. 일부 선천성 면역 세포는 항원을 T 세포에 제시하여 적응성 면역을 활성화시키기도 합니다. 또한, 조직 항상성과 염증에 중요하며, 치유자이자 파괴자 역할을 동시에 수행할 수 있습니다. 병원체 패턴, 사이토카인, 매개체에 의해 활성화되며, 항원에 대해 특이적이지 않습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "적응성 면역",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "적응성 면역은 특이적 면역, 후천성 면역이라고도 불립니다. 림프구인 T 세포와 B 세포가 주요 적응성 면역 세포입니다. 이들은 이차 림프 기관에서 미성숙한 형태로 존재하며, 클론 선택과 증식을 통해 특정 항원에 반응하는 세포로 발달합니다. 적응성 면역은 기억 기능을 가지며, 자가 관용 능력을 통해 자신의 몸을 공격하지 않습니다. 항원 제시 세포에 의해 활성화되며, 항원에 대해 매우 특이적입니다. 적응성 면역은 세포 매개 면역과 체액성 면역으로 나뉩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "숙주 세포에 있는 톨 유사 수용체(TLR)는 병원체 관련 분자 패턴(PAMP)에 결합합니다. TLR이 PAMP에 결합하면 숙주 세포에서 사이토카인 방출을 유도하여 면역 반응의 강도와 지속 시간을 조절합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "다양한 PAMP 인식",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "포유류 TLR은 다양한 PAMP를 인식합니다. 세균성 PAMP에는 그람 음성 세균 세포벽의 지질다당류(TLR4), 세균 리보솜 RNA(TLR13), 세균 DNA의 비메틸화 CpG(TLR9), 지단백질(TLR2/1, TLR2/6), 편모 단백질(TLR5) 등이 있습니다. 바이러스성 PAMP에는 이중 가닥 RNA(TLR3), 단일 가닥 RNA(TLR7, TLR8), 비메틸화 CpG DNA(TLR9) 등이 있습니다. 기생충성 PAMP에는 지단백질(TLR2/1, TLR2/6), 비메틸화 CpG DNA(TLR9), 단일 가닥 RNA(TLR7), 액틴 결합 단백질 프로필린(TLR11/12) 등이 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "TLR의 위치 및 내인성 PAMP 인식",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "TLR은 세포 표면과 세포 내막에 존재하여 다양한 세포 위치에서 미생물을 인식합니다. TLR은 또한 내인성 PAMP도 인식할 수 있습니다. 세포 스트레스 시 유도되는 샤페론인 열충격 단백질(HSP)과 풍부한 게놈 DNA 결합 단백질인 고이동성 그룹 박스 1(HMGB1) 단백질 등이 내인성 PAMP의 예시입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "TLR 신호 전달 경로",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "TLR이 미생물 리간드를 인식하면 여러 신호 전달 경로와 궁극적으로는 전사 인자가 활성화되어, 염증 및 항바이러스 반응에 중요한 유전자의 발현을 유도합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "면역은 질병에 저항하는 능력으로, 선천성 면역과 적응성 면역으로 나뉩니다. 선천성 면역은 모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 특이적 반응으로, 느리지만 기억 기능을 가집니다. 톨 유사 수용체(TLR)는 숙주 세포에서 병원체 관련 분자 패턴(PAMP)을 인식하여 사이토카인 방출을 유도하고 면역 반응을 조절합니다. TLR은 세포 표면과 세포 내막에 존재하며, 다양한 세균, 바이러스, 기생충 PAMP뿐만 아니라 내인성 PAMP도 인식하여 염증 및 항바이러스 반응에 중요한 유전자 발현을 유도하는 신호 전달 경로를 활성화합니다.",
            "keyConcepts": [
              {
                "term": "선천성 면역",
                "definition": "모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재하는 면역 방어 체계."
              },
              {
                "term": "적응성 면역",
                "definition": "특정 병원체에 대한 특이적 반응을 보이며, 기억 기능을 통해 재감염 시 더 빠르고 강력하게 반응하는 면역 방어 체계."
              },
              {
                "term": "톨 유사 수용체 (TLR)",
                "definition": "숙주 세포에 존재하며, 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 유도하는 주요 패턴 인식 수용체."
              },
              {
                "term": "병원체 관련 분자 패턴 (PAMP)",
                "definition": "미생물에 공통적으로 존재하는 특징적인 분자 구조로, 숙주의 톨 유사 수용체(TLR)에 의해 인식되어 면역 반응을 유발한다."
              },
              {
                "term": "사이토카인",
                "definition": "면역 세포 간의 신호 전달을 매개하고 면역 반응의 강도와 지속 시간을 조절하는 단백질."
              }
            ],
            "importantTerms": [
              {
                "term": "면역 (Immunity)",
                "definition": "질병을 막는 능력."
              },
              {
                "term": "감수성 (Susceptibility)",
                "definition": "질병에 대한 저항력 부족."
              },
              {
                "term": "식세포 (Phagocytes)",
                "definition": "미생물이나 이물질을 삼켜 제거하는 면역 세포."
              },
              {
                "term": "기억 구성 요소 (Memory component)",
                "definition": "적응성 면역이 이전에 노출된 병원체를 기억하여 재감염 시 더 빠르고 강력하게 반응하는 능력."
              },
              {
                "term": "자가 관용 (Self tolerance)",
                "definition": "면역 시스템이 자신의 세포와 조직을 공격하지 않고 구분하는 능력."
              },
              {
                "term": "전사 인자 (Transcription factors)",
                "definition": "DNA에 결합하여 특정 유전자의 전사(발현)를 조절하는 단백질."
              },
              {
                "term": "내인성 PAMP (Endogenous PAMPs)",
                "definition": "병원체가 아닌 숙주 세포 자체에서 발생한 손상 또는 스트레스 신호로 TLR이 인식할 수 있는 분자."
              }
            ],
            "outline": [
              {
                "text": "면역의 개념",
                "id": "면역의-개념",
                "children": [
                  {
                    "text": "면역 및 감수성 정의",
                    "id": "면역-및-감수성-정의",
                    "children": null
                  },
                  {
                    "text": "선천성 면역과 적응성 면역의 특징",
                    "id": "선천성-면역과-적응성-면역의-특징",
                    "children": null
                  }
                ]
              },
              {
                "text": "선천성 면역",
                "id": "선천성-면역",
                "children": [
                  {
                    "text": "선천성 면역의 다른 이름",
                    "id": "선천성-면역의-다른-이름",
                    "children": null
                  },
                  {
                    "text": "선천성 면역 세포의 종류 및 특징",
                    "id": "선천성-면역-세포의-종류-및-특징",
                    "children": null
                  },
                  {
                    "text": "적응성 면역과의 연계성",
                    "id": "적응성-면역과의-연계성",
                    "children": null
                  }
                ]
              },
              {
                "text": "적응성 면역",
                "id": "적응성-면역",
                "children": [
                  {
                    "text": "적응성 면역의 다른 이름",
                    "id": "적응성-면역의-다른-이름",
                    "children": null
                  },
                  {
                    "text": "적응성 면역 세포의 종류 및 특징",
                    "id": "적응성-면역-세포의-종류-및-특징",
                    "children": null
                  },
                  {
                    "text": "클론 선택, 기억, 자가 관용",
                    "id": "클론-선택-기억-자가-관용",
                    "children": null
                  },
                  {
                    "text": "세포 매개 및 체액성 면역",
                    "id": "세포-매개-및-체액성-면역",
                    "children": null
                  }
                ]
              },
              {
                "text": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
                "id": "톨-유사-수용체-tlr-및-병원체-관련-분자-패턴-pamp",
                "children": [
                  {
                    "text": "TLR과 PAMP의 상호작용",
                    "id": "tlr과-pamp의-상호작용",
                    "children": null
                  },
                  {
                    "text": "사이토카인 방출 및 면역 반응 조절",
                    "id": "사이토카인-방출-및-면역-반응-조절",
                    "children": null
                  }
                ]
              },
              {
                "text": "다양한 PAMP 인식",
                "id": "다양한-pamp-인식",
                "children": [
                  {
                    "text": "포유류 TLR의 PAMP 인식 범위",
                    "id": "포유류-tlr의-pamp-인식-범위",
                    "children": null
                  },
                  {
                    "text": "세균성 PAMP의 종류",
                    "id": "세균성-pamp의-종류",
                    "children": null
                  },
                  {
                    "text": "바이러스성 PAMP의 종류",
                    "id": "바이러스성-pamp의-종류",
                    "children": null
                  },
                  {
                    "text": "기생충성 PAMP의 종류",
                    "id": "기생충성-pamp의-종류",
                    "children": null
                  }
                ]
              },
              {
                "text": "TLR의 위치 및 내인성 PAMP 인식",
                "id": "tlr의-위치-및-내인성-pamp-인식",
                "children": [
                  {
                    "text": "세포 표면 및 세포 내막에서의 TLR 위치",
                    "id": "세포-표면-및-세포-내막에서의-tlr-위치",
                    "children": null
                  },
                  {
                    "text": "내인성 PAMP의 인식 (HSP, HMGB1)",
                    "id": "내인성-pamp의-인식-hsp-hmgb1",
                    "children": null
                  }
                ]
              },
              {
                "text": "TLR 신호 전달 경로",
                "id": "tlr-신호-전달-경로",
                "children": [
                  {
                    "text": "미생물 리간드 인식의 결과",
                    "id": "미생물-리간드-인식의-결과",
                    "children": null
                  },
                  {
                    "text": "염증 및 항바이러스 반응 유도",
                    "id": "염증-및-항바이러스-반응-유도",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "선천성 면역과 적응성 면역의 주요 차이점은 무엇인가요?",
              "options": [
                "선천성 면역은 태어날 때부터 존재하며 비특이적인 반면, 적응성 면역은 특정 병원체에 특이적이며 기억 기능을 가집니다.",
                "선천성 면역은 특정 병원체에 특이적이지만 반응이 느리고, 적응성 면역은 모든 병원체에 빠르게 반응합니다.",
                "선천성 면역은 기억 기능이 있지만 T세포와 B세포가 관여하지 않고, 적응성 면역은 기억 기능이 없습니다.",
                "선천성 면역은 항원 제시 세포에 의해 활성화되고, 적응성 면역은 병원체 패턴에 의해 활성화됩니다."
              ],
              "answerIndex": 0,
              "explanation": "선천성 면역은 타고난 비특이적 방어이며, 적응성 면역은 특정 항원에 대한 후천적, 기억 기반 방어입니다."
            },
            {
              "question": "톨 유사 수용체(TLR)의 주요 기능은 무엇인가요?",
              "options": [
                "항체를 생산하여 병원체를 직접 중화시키는 기능",
                "병원체 관련 분자 패턴(PAMP)을 인식하고 사이토카인 방출을 유도하여 면역 반응을 조절하는 기능",
                "감염된 세포를 직접 파괴하는 자연 살해 세포의 기능을 억제하는 기능",
                "면역 반응 후 기억 세포를 형성하여 다음 감염에 대비하는 기능"
              ],
              "answerIndex": 1,
              "explanation": "TLR은 숙주 세포에서 PAMP를 인식하여 사이토카인 방출을 유도하고 면역 반응의 강도와 지속 시간을 조절하는 역할을 합니다."
            },
            {
              "question": "다음 중 세균성 PAMP에 해당하지 않는 것은 무엇인가요?",
              "options": [
                "지질다당류 (Lipopolysaccharide)",
                "세균 리보솜 RNA (Bacterial ribosomal RNA)",
                "이중 가닥 RNA (Double-stranded RNA)",
                "비메틸화 CpG (Unmethylated CpG in the bacterial DNA)"
              ],
              "answerIndex": 2,
              "explanation": "이중 가닥 RNA(Double-stranded RNA)는 바이러스성 PAMP에 해당합니다. 지질다당류, 세균 리보솜 RNA, 비메틸화 CpG는 세균성 PAMP입니다."
            }
          ]
        },
        {
          "title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 1284 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "물리적 요인",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "피부는 선천성 면역의 중요한 물리적 방어선입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "진피는 결합 조직으로 구성된 내부 부분입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성된 외부 부분입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "피부가 벗겨지고 건조한 상태를 유지하는 것은 미생물 성장을 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "점막은 위장관, 호흡기, 비뇨생식기를 덮는 상피층입니다. 점액은 미생물을 가두고 관이 건조해지는 것을 막는 점성 당단백질입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "누액 기관은 눈물을 배출하여 눈을 씻어냅니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "섬모 승강기는 점액에 갇힌 미생물을 폐에서 멀리 운반합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "귀지는 미생물이 귀에 들어가는 것을 막습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "소변은 흐름을 통해 요도를 청소합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "연동 운동, 배변, 구토, 설사 또한 미생물 배출에 기여하는 물리적 방어 기전입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "화학적 요인",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "피지는 보호막을 형성하고 피부의 pH를 3~5로 낮춥니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "땀, 눈물, 침, 소변에 있는 리소자임은 세균 세포벽을 파괴합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "위액의 낮은 pH (1.2~3.0)는 대부분의 세균과 독소를 파괴합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "질 분비물의 낮은 pH (3~5)는 미생물을 억제합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "정상 미생물총과 선천성 면역",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "정상 미생물총은 미생물 길항 작용 (경쟁적 배제)을 통해 병원균과 경쟁합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이는 공간과 영양분에 대한 경쟁 우위를 점하거나, 병원균에 해로운 물질을 생산하거나, 병원균 생존에 영향을 미치는 조건을 변경함으로써 이루어집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "공생은 한 유기체는 이득을 얻고 다른 유기체 (숙주)는 해를 입지 않는 관계를 의미합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "프로바이오틱스는 유익한 효과를 발휘하기 위해 투여되는 살아있는 미생물 배양물입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "무균 쥐를 사육하기 위해서는 엄격한 무균 상태가 요구됩니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 선천성 면역의 1차 방어선인 물리적 및 화학적 장벽과 정상 미생물총의 역할을 다룹니다. 피부, 점막, 누액 기관, 섬모 승강기, 귀지, 소변, 연동 운동, 배변, 구토, 설사 등 다양한 물리적 요인들이 미생물 침입을 막는 역할을 합니다. 또한, 피지, 리소자임, 위액 및 질 분비물의 낮은 pH와 같은 화학적 요인들이 미생물 성장을 억제하거나 파괴합니다. 정상 미생물총은 경쟁적 배제를 통해 병원균과 경쟁하며 숙주 방어에 기여합니다. 마지막으로, 마이크로바이옴이 선천성 면역 형성에 중요한 영향을 미친다는 점이 강조됩니다.",
            "keyConcepts": [
              {
                "term": "선천성 면역의 물리적 방어선",
                "definition": "피부, 점막, 눈물, 섬모 등 신체 외부 및 내부 표면에서 미생물 침입을 물리적으로 막는 방어 기전."
              },
              {
                "term": "선천성 면역의 화학적 방어선",
                "definition": "피지, 리소자임, 위액, 질 분비물 등의 화학 물질이 미생물 성장을 억제하거나 파괴하는 방어 기전."
              },
              {
                "term": "정상 미생물총의 역할",
                "definition": "인체에 상주하는 유익한 미생물들이 공간 및 영양분 경쟁, 유해 물질 생산 등을 통해 병원균의 침입과 증식을 억제하는 현상 (미생물 길항 작용)."
              },
              {
                "term": "마이크로바이옴과 선천성 면역",
                "definition": "인체 내 미생물 군집인 마이크로바이옴이 숙주의 선천성 면역 시스템 발달 및 기능에 중요한 영향을 미친다는 개념."
              }
            ],
            "importantTerms": [
              {
                "term": "케라틴",
                "definition": "피부 표피에 존재하는 보호 단백질로, 피부의 물리적 장벽을 형성하는 데 기여한다."
              },
              {
                "term": "점액",
                "definition": "점막에서 분비되는 점성 당단백질로, 미생물을 가두고 점막이 건조해지는 것을 방지한다."
              },
              {
                "term": "누액 기관",
                "definition": "눈물을 생성하고 배출하여 눈을 지속적으로 씻어내 미생물을 제거하는 역할을 하는 기관."
              },
              {
                "term": "섬모 승강기",
                "definition": "호흡기 점막의 섬모가 움직여 점액에 갇힌 미생물을 폐에서 멀리 이동시키는 메커니즘."
              },
              {
                "term": "리소자임",
                "definition": "땀, 눈물, 침, 소변 등에 존재하는 효소로, 세균의 세포벽을 파괴하여 항균 작용을 한다."
              },
              {
                "term": "미생물 길항 작용",
                "definition": "정상 미생물총이 공간, 영양분 경쟁 또는 병원균에 해로운 물질 생산을 통해 병원균의 성장을 억제하는 현상."
              },
              {
                "term": "공생",
                "definition": "두 유기체가 함께 살아가며 한 유기체는 이득을 얻지만 다른 유기체(숙주)는 해를 입지 않는 관계."
              }
            ],
            "outline": [
              {
                "text": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "id": "선천성-면역-1차-방어선",
                "children": [
                  {
                    "text": "물리적 요인",
                    "id": "물리적-요인",
                    "children": [
                      {
                        "text": "피부",
                        "id": "피부",
                        "children": null
                      },
                      {
                        "text": "점막",
                        "id": "점막",
                        "children": null
                      },
                      {
                        "text": "누액 기관",
                        "id": "누액-기관",
                        "children": null
                      },
                      {
                        "text": "기타 물리적 방어 (섬모 승강기, 귀지, 소변, 연동 운동 등)",
                        "id": "기타-물리적-방어",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "화학적 요인",
                    "id": "화학적-요인",
                    "children": [
                      {
                        "text": "피지",
                        "id": "피지",
                        "children": null
                      },
                      {
                        "text": "리소자임",
                        "id": "리소자임",
                        "children": null
                      },
                      {
                        "text": "위액의 낮은 pH",
                        "id": "위액의-낮은-ph",
                        "children": null
                      },
                      {
                        "text": "질 분비물의 낮은 pH",
                        "id": "질-분비물의-낮은-ph",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "정상 미생물총과 선천성 면역",
                    "id": "정상-미생물총과-선천성-면역",
                    "children": [
                      {
                        "text": "미생물 길항 작용",
                        "id": "미생물-길항-작용",
                        "children": null
                      },
                      {
                        "text": "공생 및 프로바이오틱스",
                        "id": "공생-및-프로바이오틱스",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
                    "id": "마이크로바이옴-탐구",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "피부의 표피층에 포함되어 미생물 성장을 억제하는 보호 단백질은 무엇입니까?",
              "options": [
                "케라틴",
                "콜라겐",
                "엘라스틴",
                "멜라닌"
              ],
              "answerIndex": 0,
              "explanation": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성되어 있으며, 이는 미생물 성장을 억제하는 데 기여합니다."
            },
            {
              "question": "선천성 면역의 화학적 방어선 중, 땀, 눈물, 침, 소변에 존재하며 세균 세포벽을 파괴하는 효소는 무엇입니까?",
              "options": [
                "펩신",
                "아밀레이스",
                "리소자임",
                "트립신"
              ],
              "answerIndex": 2,
              "explanation": "리소자임은 땀, 눈물, 침, 소변에 존재하며 세균의 세포벽을 파괴하는 강력한 항균 효소입니다."
            },
            {
              "question": "정상 미생물총이 병원균과 경쟁하여 성장을 억제하는 주요 메커니즘을 설명하는 용어는 무엇입니까?",
              "options": [
                "변이원성",
                "미생물 길항 작용",
                "자가면역",
                "과민 반응"
              ],
              "answerIndex": 1,
              "explanation": "정상 미생물총은 '미생물 길항 작용' 또는 '경쟁적 배제'를 통해 공간, 영양분 경쟁 및 유해 물질 생산으로 병원균의 성장을 억제합니다."
            }
          ]
        },
        {
          "title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2110 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "I. 혈액의 구성 요소",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "혈액은 혈장 내에 부유하는 세포 및 세포 조각으로 구성됩니다. 주요 구성 요소는 적혈구(red blood cells), 백혈구(white blood cells), 혈소판(platelets)이며, 이들은 적골수 줄기세포에서 조혈 작용(hematopoiesis)을 통해 생성됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "과립구 (Granulocytes)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "과립구는 세포질 내에 광학 현미경으로 볼 수 있는 과립을 가진 백혈구입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 호중구(Neutrophils): 식균 작용을 하며 감염 초기 단계에서 활동합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 호염기구(Basophils): 히스타민을 방출하며 알레르기 반응에 관여합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 호산구(Eosinophils): 식균 작용을 하며 기생충과 연충류에 대해 독성을 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "무과립구 (Agranulocytes)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "무과립구는 세포질 내에 과립이 있지만 광학 현미경으로 보이지 않는 백혈구입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 단핵구(Monocytes): 조직에서 대식세포(macrophages)로 성숙하여 식균 작용을 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 수지상 세포(Dendritic cells): 피부, 점막, 흉선에서 발견되며 식균 작용을 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 림프구(Lymphocytes): T세포, B세포, NK세포를 포함하며 적응 면역에 중요한 역할을 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "II. 림프계",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "림프계는 림프, 림프관, 림프 조직, 적골수로 구성됩니다. 림프구와 식세포를 포함하며, 림프는 미생물을 림프절로 운반하여 림프구와 대식세포가 병원균을 파괴하도록 돕습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "림프계의 주요 구성 요소 및 기관에는 흉관(좌측 림프관), 우측 림프관, 좌측 쇄골하정맥, 우측 쇄골하정맥, 편도, 흉선, 림프절, 비장, 대장, 소장, 파이어판(Peyer’s patch), 림프관, 적골수, 림프 모세혈관 등이 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "III. 숙주 방어: 개요 및 식세포",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "식세포(Phagocytes)는 '먹다'를 의미하는 그리스어 'Phago'와 '세포'를 의미하는 'Cyte'에서 유래했습니다. 식세포에는 조직과 장기에 상주하는 고정 대식세포(Fixed macrophages)와 조직을 돌아다니며 감염 부위에 모이는 자유(유리) 대식세포(Free (wandering) macrophages)가 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "IV. 식균 작용의 메커니즘",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "식균 작용은 다음 단계를 거쳐 진행됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 주화성(Chemotaxis): 화학적 신호가 식세포를 미생물로 유인합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 부착(Adherence): 식세포가 미생물 표면에 부착합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 섭취(Ingestion): 미생물이 혈청 단백질로 코팅되어(옵소닌화, Opsonization) 섭취가 용이해집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 소화(Digestion): 미생물이 식포-리소좀(phagolysosome) 내부에서 소화됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "V. 미생물의 식균 작용 회피 전략",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "일부 미생물은 숙주의 방어 체계를 회피하기 위한 다양한 병원성 인자(Virulence factors)를 가지고 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 부착 억제: M 단백질, 캡슐 (예: Streptococcus pyogenes, S. pneumoniae)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 식세포 사멸: 백혈구용해소(leukocidins) (예: Staphylococcus aureus)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 식세포 용해: 막 공격 복합체(membrane attack complex) (예: Listeria monocytogenes)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 식포 탈출: (예: Shigella, Rickettsia)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 식포-리소좀 융합 방지: (예: HIV, Mycobacterium tuberculosis)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 식포-리소좀 내 생존: (예: Coxiella burnetii)",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 선천성 면역의 2차 방어선으로서 혈액의 구성 요소와 식세포의 역할에 대해 설명합니다. 혈액의 주요 구성 요소(적혈구, 백혈구, 혈소판)와 조혈 작용을 소개하고, 백혈구를 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 분류하여 각 유형의 기능과 특징을 설명합니다. 또한, 림프계의 구성 요소와 병원균 제거에서의 역할을 다루고, 식세포의 정의와 고정/자유 대식세포의 종류를 설명합니다. 이어서 식균 작용의 네 가지 주요 단계(주화성, 부착, 섭취, 소화)를 자세히 설명하며, 특히 옵소닌화의 중요성을 강조합니다. 마지막으로, 미생물이 식균 작용을 회피하기 위해 사용하는 다양한 전략(부착 억제, 식세포 사멸, 식포 탈출 등)과 관련 미생물 예를 제시합니다.",
            "keyConcepts": [
              {
                "term": "혈액의 구성 요소",
                "definition": "혈액을 구성하는 주요 성분으로, 혈장 내에 부유하는 적혈구, 백혈구, 혈소판을 포함하며, 조혈 작용을 통해 생성됩니다."
              },
              {
                "term": "백혈구의 종류와 기능",
                "definition": "감염 및 알레르기 반응에 관여하는 면역 세포로, 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 나뉘며 각각 특정한 면역 기능을 수행합니다."
              },
              {
                "term": "림프계의 역할",
                "definition": "림프, 림프관, 림프 조직, 적골수로 구성되며 림프구와 식세포를 포함하여 병원균을 림프절로 운반하고 파괴함으로써 면역 방어에 기여하는 시스템입니다."
              },
              {
                "term": "식균 작용",
                "definition": "식세포가 미생물이나 세포 잔해를 섭취하고 소화하여 제거하는 과정으로, 주화성, 부착, 섭취(옵소닌화 포함), 소화의 단계를 거칩니다."
              },
              {
                "term": "미생물의 식균 작용 회피",
                "definition": "미생물이 숙주의 식균 작용으로부터 자신을 보호하기 위해 사용하는 다양한 전략으로, 부착 억제, 식세포 사멸, 식포 탈출, 식포-리소좀 융합 방지, 식포-리소좀 내 생존 등이 있습니다."
              }
            ],
            "importantTerms": [
              {
                "term": "조혈 작용 (Hematopoiesis)",
                "definition": "적골수 줄기세포에서 혈액 세포(적혈구, 백혈구, 혈소판)가 생성되는 과정입니다."
              },
              {
                "term": "과립구 (Granulocytes)",
                "definition": "세포질 내에 과립을 가진 백혈구로, 호중구, 호염기구, 호산구가 포함됩니다."
              },
              {
                "term": "무과립구 (Agranulocytes)",
                "definition": "세포질 내에 과립이 뚜렷하지 않은 백혈구로, 단핵구, 수지상 세포, 림프구가 포함됩니다."
              },
              {
                "term": "식세포 (Phagocytes)",
                "definition": "미생물이나 이물질을 섭취하고 소화하는 세포(예: 대식세포, 호중구)를 총칭합니다."
              },
              {
                "term": "옵소닌화 (Opsonization)",
                "definition": "미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포에 의한 섭취가 용이해지는 과정입니다."
              },
              {
                "term": "주화성 (Chemotaxis)",
                "definition": "화학적 신호에 의해 세포가 특정 방향으로 이동하는 현상으로, 식세포가 미생물로 유인되는 과정입니다."
              },
              {
                "term": "병원성 인자 (Virulence factors)",
                "definition": "미생물이 숙주에게 질병을 일으키거나 숙주의 면역 체계를 회피하는 데 도움이 되는 특징 또는 물질입니다."
              }
            ],
            "outline": [
              {
                "text": "I. 혈액의 구성 요소",
                "id": "i-혈액의-구성-요소",
                "children": [
                  {
                    "text": "과립구 (Granulocytes)",
                    "id": "과립구-granulocytes",
                    "children": null
                  },
                  {
                    "text": "무과립구 (Agranulocytes)",
                    "id": "무과립구-agranulocytes",
                    "children": null
                  }
                ]
              },
              {
                "text": "II. 림프계",
                "id": "ii-림프계",
                "children": null
              },
              {
                "text": "III. 숙주 방어: 개요 및 식세포",
                "id": "iii-숙주-방어-개요-및-식세포",
                "children": null
              },
              {
                "text": "IV. 식균 작용의 메커니즘",
                "id": "iv-식균-작용의-메커니즘",
                "children": null
              },
              {
                "text": "V. 미생물의 식균 작용 회피 전략",
                "id": "v-미생물의-식균-작용-회피-전략",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "다음 중 과립구에 해당하지 않는 백혈구는 무엇입니까?",
              "options": [
                "단핵구",
                "호중구",
                "호염기구",
                "호산구"
              ],
              "answerIndex": 0,
              "explanation": "단핵구는 무과립구에 속하며, 조직에서 대식세포로 성숙하여 식균 작용을 합니다. 호중구, 호염기구, 호산구는 모두 과립구에 해당합니다."
            },
            {
              "question": "식균 작용의 단계 중, 미생물이 혈청 단백질로 코팅되어 식세포에 의한 섭취가 용이해지는 과정을 무엇이라고 합니까?",
              "options": [
                "주화성",
                "부착",
                "옵소닌화",
                "소화"
              ],
              "answerIndex": 2,
              "explanation": "옵소닌화는 미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포의 섭취(Ingestion)를 돕는 과정입니다."
            },
            {
              "question": "다음 미생물 중 식포-리소좀 융합을 방지하여 식균 작용을 회피하는 것으로 알려진 것은 무엇입니까?",
              "options": [
                "Streptococcus pyogenes",
                "Staphylococcus aureus",
                "Listeria monocytogenes",
                "Mycobacterium tuberculosis"
              ],
              "answerIndex": 3,
              "explanation": "Mycobacterium tuberculosis는 식포-리소좀 융합을 방지하여 식세포 내에서 생존함으로써 식균 작용을 회피합니다. Streptococcus pyogenes는 부착을 억제하고, Staphylococcus aureus는 백혈구용해소를 통해 식세포를 사멸시키며, Listeria monocytogenes는 식세포를 용해시킵니다."
            }
          ]
        },
        {
          "title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 3719 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "염증: 개요",
              "level": 1
            },
            {
              "type": "heading",
              "content": "염증",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "염증의 네 가지 징후 및 증상: 발적(redness), 부종(edema), 통증(pain), 열(heat).",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "손상 인자를 파괴하거나 신체에 미치는 영향을 제한합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "손상 인자에 의해 손상된 조직을 복구하고 대체합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "염증 유발 물질",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "염증은 간에서 급성기 단백질을 활성화시켜 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "주요 염증 매개체는 다음과 같습니다:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "히스타민 (Histamine): 비만 세포, 호염기구, 혈소판에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "키닌 (Kinins): 혈장 내에 존재하며 호중구를 유인하여 화학주성(chemotaxis)을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "프로스타글란딘 (Prostaglandins): 손상된 세포에서 분비되며 히스타민과 키닌의 효과를 강화하고 식세포가 모세혈관 벽을 통과하는 것을 돕습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "류코트리엔 (Leukotrienes): 비만 세포와 호염기구에서 분비되며 혈관 투과성을 증가시키고 식세포가 병원체에 부착되는 것을 돕습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "보체 (Complement): 혈장 내에 존재하며 히스타민 분비를 자극하고 식세포를 유인하며 식균 작용을 촉진합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사이토카인 (Cytokines): 고정된 대식세포에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "염증 과정 단계",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "그림 16.9a-b 염증 과정: 조직 손상, 혈관 반응 및 식균 작용을 포함합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "염증 과정",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "조직 손상이 발생하면 손상된 세포에서 히스타민, 키닌, 프로스타글란딘, 류코트리엔, 사이토카인과 같은 화학 물질이 방출됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈액 응고가 형성되기 시작하고 농양(abscess)이 형성되기 시작합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "식세포 이동 및 식균 작용",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "마지네이션(Margination)은 염증 부위의 사이토카인에 반응하여 식세포가 혈관에 달라붙는 현상입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "식세포는 다이아페데시스(diapedesis)를 통해 혈관 내피 세포 사이를 비집고 나옵니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "조직 복구",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "모든 유해 물질이 제거되거나 중화될 때까지 완료될 수 없습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "기질(Stroma)은 복구되는 지지 결합 조직입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "실질(Parenchyma)은 복구되는 조직의 기능적인 부분입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "발열",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "비정상적으로 높은 체온입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "시상하부(Hypothalamus)는 일반적으로 37°C로 설정되어 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사이토카인이 시상하부로 하여금 프로스타글란딘을 방출하게 하여 시상하부의 온도를 더 높게 재설정합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "몸은 혈관을 수축시키고 떨림(shivering)이 발생하여 체온이 상승합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "체온이 떨어지면 (위기, crisis) 혈관 확장과 땀이 발생합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체 시스템",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "간에서 생산되는 혈청 단백질로, 미생물 파괴에 면역계를 보조합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "보체 활성화라고 불리는 과정에서 캐스케이드(cascade) 방식으로 작용합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "단백질은 대문자 C로 표시되며 발견 순서대로 번호가 매겨집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "활성화된 단편은 소문자 a와 b로 표시됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체: 활성화",
              "level": 1
            },
            {
              "type": "heading",
              "content": "고전적 경로",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "항체가 항원에 결합하여 C1을 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C1은 분열하여 C2와 C4를 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C2a와 C4b가 결합하여 C3을 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C3a는 염증에 관여합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C3b는 세포 용해(cytolysis)와 옵소닌화(opsonization)에 관여합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "대체 경로",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "혈액 내 C3가 미생물 표면의 B, D, P 인자와 결합합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C3는 C3a와 C3b로 분열하며, 고전적 경로와 동일하게 기능합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "렉틴 경로",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "대식세포가 병원체를 섭취하여 사이토카인을 방출하고, 이는 간에서 렉틴 생산을 자극합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "만노스 결합 렉틴(Mannose-binding lectin, MBL)이 만노스에 결합하여 C2와 C4를 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C2a와 C4b가 C3을 활성화하며, 이는 고전적 경로 및 대체 경로와 동일하게 기능합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체 활성화의 결과",
              "level": 1
            },
            {
              "type": "heading",
              "content": "세포 용해",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "활성화된 보체 단백질이 막 공격 복합체(Membrane Attack Complex, MAC)를 형성합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "옵소닌화",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "식세포가 미생물에 부착되는 것을 촉진합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "염증",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "활성화된 보체 단백질이 비만 세포에 결합하여 히스타민을 방출합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그림 16.12 보체 활성화의 결과. 그림 16.13 보체에 의해 자극된 염증.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "보체 시스템은 신체가 감염과 병원체를 퇴치하는 또 다른 방법입니다. 선천성 면역의 이 구성 요소는 다른 면역 반응을 '보완'합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "보체는 혈청에 순환하는 30개 이상의 단백질 그룹으로, 캐스케이드 방식으로 활성화됩니다: 한 보체 단백질이 다음 단백질을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이 캐스케이드는 병원체에 의해 직접 활성화되거나 항체-항원 반응에 의해 활성화될 수 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이 단백질들은 함께 (1) 세포 용해, (2) 강화된 식균 작용, (3) 염증을 통해 미생물을 파괴합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체: 결과",
              "level": 1
            },
            {
              "type": "heading",
              "content": "보체 활성화의 조절",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "조절 단백질은 보체 단백질을 쉽게 분해하여 숙주 세포 손상을 최소화합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체와 질병",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "보체 단백질의 부족은 감염에 대한 취약성을 유발합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체 시스템 회피",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "캡슐은 보체 활성화를 방지합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "인터페론",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "세포에서 생산되는 사이토카인으로, 항바이러스 활동을 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IFN-α 및 IFN-β: 바이러스 감염에 반응하여 세포에서 생산되며, 이웃 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IFN-γ: 호중구와 대식세포가 박테리아를 죽이도록 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "알파 및 베타 인터페론(IFN)의 항바이러스 작용",
              "level": 2
            },
            {
              "type": "heading",
              "content": "철 결합 단백질",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "트랜스페린(Transferrin): 혈액 및 조직액에서 발견됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "락토페린(Lactoferrin): 우유, 침, 점액에서 발견됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "페리틴(Ferritin): 간, 비장, 적골수에서 발견됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "헤모글로빈(Hemoglobin): 적혈구에 위치합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "박테리아는 철 결합 단백질과 경쟁하기 위해 시데로포어(siderophores)를 생산합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항균 펩타이드",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "미생물의 단백질 및 당 분자에 반응하여 생산되는 짧은 펩타이드입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포벽 합성을 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "원형질막에 구멍을 형성합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "광범위한 활성 스펙트럼을 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "기타 요인",
              "level": 1
            },
            {
              "type": "heading",
              "content": "유전적 저항성",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "선택적 생존 이점을 부여합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "예: 겸상 적혈구 특성 및 열대열원충(Plasmodium falciparum).",
              "level": null
            },
            {
              "type": "heading",
              "content": "연령",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "매우 어린 연령과 노인들은 질병에 더 취약합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "건강 프로토콜 준수",
              "level": 2
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 선천성 면역의 핵심 구성 요소인 염증, 발열, 보체 시스템, 인터페론, 철 결합 단백질 및 항균 펩타이드에 대해 설명합니다. 염증의 징후, 매개체, 과정 및 조직 복구를 다루고, 발열의 메커니즘과 체온 조절을 설명합니다. 또한 보체 시스템의 세 가지 활성화 경로(고전적, 대체, 렉틴)와 그 결과(세포 용해, 옵소닌화, 염증)를 상세히 제시합니다. 마지막으로, 인터페론의 항바이러스 역할, 철 결합 단백질의 기능, 항균 펩타이드의 작용 방식, 그리고 유전적 저항성 및 연령과 같은 기타 면역 관련 요인들을 소개합니다.",
            "keyConcepts": [
              {
                "term": "염증 (Inflammation)",
                "definition": "손상된 조직을 파괴하거나 유해 물질의 영향을 제한하고, 손상된 조직을 복구 및 대체하는 신체의 방어 반응입니다. 발적, 부종, 통증, 열의 네 가지 주요 징후를 가집니다."
              },
              {
                "term": "발열 (Fever)",
                "definition": "비정상적으로 높은 체온으로, 사이토카인에 의해 시상하부의 체온 설정점이 높아져 발생합니다. 병원체 성장을 억제하고 면역 반응을 강화하는 데 도움을 줄 수 있습니다."
              },
              {
                "term": "보체 시스템 (Complement System)",
                "definition": "간에서 생산되는 30개 이상의 혈청 단백질로 구성된 캐스케이드 시스템입니다. 병원체 파괴를 돕기 위해 세포 용해, 옵소닌화, 염증을 유발하는 세 가지 활성화 경로(고전적, 대체, 렉틴)를 통해 작동합니다."
              },
              {
                "term": "인터페론 (Interferons)",
                "definition": "세포에서 생산되는 사이토카인으로, 특히 IFN-α와 IFN-β는 바이러스 감염에 반응하여 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질을 생산하도록 유도하는 항바이러스 활성을 가집니다."
              },
              {
                "term": "항균 물질 (Antimicrobial Substances)",
                "definition": "철 결합 단백질(트랜스페린, 락토페린, 페리틴, 헤모글로빈)과 항균 펩타이드를 포함하며, 미생물의 성장을 억제하거나 직접 파괴하여 숙주를 보호하는 역할을 합니다."
              }
            ],
            "importantTerms": [
              {
                "term": "히스타민 (Histamine)",
                "definition": "비만 세포 등에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발하는 혈관 활성 매개체입니다."
              },
              {
                "term": "다이아페데시스 (Diapedesis)",
                "definition": "식세포가 혈관 내피 세포 사이를 비집고 나와 조직 손상 부위로 이동하는 과정입니다."
              },
              {
                "term": "마지네이션 (Margination)",
                "definition": "염증 부위의 사이토카인에 반응하여 식세포가 혈관 내피에 달라붙는 현상입니다."
              },
              {
                "term": "막 공격 복합체 (Membrane Attack Complex, MAC)",
                "definition": "활성화된 보체 단백질에 의해 형성되며, 미생물 세포막에 구멍을 뚫어 세포 용해를 유발하는 구조입니다."
              },
              {
                "term": "옵소닌화 (Opsonization)",
                "definition": "보체 단백질(C3b) 등이 미생물을 코팅하여 식세포가 미생물을 더 쉽게 인식하고 식균 작용을 하도록 촉진하는 과정입니다."
              },
              {
                "term": "시데로포어 (Siderophores)",
                "definition": "박테리아가 숙주의 철 결합 단백질과 경쟁하여 철을 획득하기 위해 생산하는 물질입니다."
              },
              {
                "term": "항바이러스 단백질 (Antiviral Proteins, AVPs)",
                "definition": "인터페론의 유도에 의해 세포에서 생산되며, 바이러스 복제를 억제하는 단백질입니다."
              }
            ],
            "outline": [
              {
                "text": "염증",
                "id": "inflammation",
                "children": [
                  {
                    "text": "개요 및 징후",
                    "id": "inflammation-overview-signs",
                    "children": null
                  },
                  {
                    "text": "염증 반응 유발 물질",
                    "id": "inflammation-mediators",
                    "children": null
                  },
                  {
                    "text": "염증 과정 단계",
                    "id": "inflammation-steps",
                    "children": null
                  },
                  {
                    "text": "식세포 이동 및 식균 작용",
                    "id": "phagocyte-migration-phagocytosis",
                    "children": null
                  },
                  {
                    "text": "조직 복구",
                    "id": "tissue-repair",
                    "children": null
                  }
                ]
              },
              {
                "text": "발열",
                "id": "fever",
                "children": [
                  {
                    "text": "체온 조절 및 발열 메커니즘",
                    "id": "fever-mechanism",
                    "children": null
                  }
                ]
              },
              {
                "text": "보체 시스템",
                "id": "complement-system",
                "children": [
                  {
                    "text": "개요 및 기능",
                    "id": "complement-overview",
                    "children": null
                  },
                  {
                    "text": "보체 활성화 경로",
                    "id": "complement-activation-pathways",
                    "children": [
                      {
                        "text": "고전적 경로",
                        "id": "classical-pathway",
                        "children": null
                      },
                      {
                        "text": "대체 경로",
                        "id": "alternative-pathway",
                        "children": null
                      },
                      {
                        "text": "렉틴 경로",
                        "id": "lectin-pathway",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "보체 활성화의 결과",
                    "id": "complement-activation-outcomes",
                    "children": [
                      {
                        "text": "세포 용해",
                        "id": "cytolysis",
                        "children": null
                      },
                      {
                        "text": "옵소닌화",
                        "id": "opsonization",
                        "children": null
                      },
                      {
                        "text": "염증",
                        "id": "complement-inflammation",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "보체 조절 및 질병",
                    "id": "complement-regulation-disease",
                    "children": null
                  }
                ]
              },
              {
                "text": "항균 물질",
                "id": "antimicrobial-substances",
                "children": [
                  {
                    "text": "인터페론",
                    "id": "interferons",
                    "children": null
                  },
                  {
                    "text": "철 결합 단백질",
                    "id": "iron-binding-proteins",
                    "children": null
                  },
                  {
                    "text": "항균 펩타이드",
                    "id": "antimicrobial-peptides",
                    "children": null
                  }
                ]
              },
              {
                "text": "기타 요인",
                "id": "other-factors",
                "children": [
                  {
                    "text": "유전적 저항성",
                    "id": "genetic-resistance",
                    "children": null
                  },
                  {
                    "text": "연령",
                    "id": "age",
                    "children": null
                  },
                  {
                    "text": "건강 프로토콜 준수",
                    "id": "observing-healthy-protocols",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "염증의 네 가지 주요 징후에 해당하지 않는 것은 무엇입니까?",
              "options": [
                "발적",
                "부종",
                "가려움",
                "열"
              ],
              "answerIndex": 2,
              "explanation": "염증의 네 가지 주요 징후는 발적(redness), 부종(swelling), 통증(pain), 열(heat)입니다. 가려움은 일반적인 염증의 주요 징후에 해당하지 않습니다."
            },
            {
              "question": "보체 활성화의 세 가지 주요 결과에 속하지 않는 것은 무엇입니까?",
              "options": [
                "세포 용해 (Cytolysis)",
                "옵소닌화 (Opsonization)",
                "항체 생산 (Antibody production)",
                "염증 (Inflammation)"
              ],
              "answerIndex": 2,
              "explanation": "보체 활성화의 주요 결과는 세포 용해, 옵소닌화, 염증입니다. 항체 생산은 보체 시스템의 직접적인 결과가 아닌 적응 면역 반응의 일부입니다."
            },
            {
              "question": "인터페론(IFN-α 및 IFN-β)의 주요 역할은 무엇입니까?",
              "options": [
                "세균을 직접 죽인다.",
                "발열을 유도한다.",
                "바이러스 감염에 반응하여 항바이러스 단백질 생성을 유도한다.",
                "조직 복구를 돕는다."
              ],
              "answerIndex": 2,
              "explanation": "IFN-α와 IFN-β는 바이러스 감염에 의해 생성되어 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다."
            }
          ]
        },
        {
          "title": "적응성 면역: 개요 및 이중적 특성",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1042 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "적응성 면역 체계",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "적응성 면역은 특정 병원체를 표적으로 하는 방어 체계입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이는 감염이나 백신 접종을 통해 획득됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것을 의미합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이차 반응은 동일한 외래 물질과의 이후 상호 작용으로, '기억' 덕분에 더 빠르고 효과적입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "적응성 면역 체계의 이중적 특성",
              "level": 1
            },
            {
              "type": "heading",
              "content": "체액성 면역",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "체액성 면역은 항원(antigens)으로 알려진 외래 분자와 싸우는 항체를 생성합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "B 세포는 적골수에서 생성되고 성숙하는 림프구입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "B 세포는 항원을 인식하고 항체를 만듭니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "B 세포는 조류의 파브리시우스 낭(bursa of Fabricius)에서 이름을 따왔습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "애니메이션: 체액성 면역 개요",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포성 면역 (세포 매개 면역)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "세포성 면역은 T 림프구를 생성합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 림프구는 식세포에 의해 처리된 항원 펩타이드를 인식합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 세포는 흉선에서 성숙합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 세포 표면의 T 세포 수용체(TCRs)가 항원과 접촉하면 T 세포는 항체 대신 사이토카인을 분비합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 세포 및 B 세포 발달",
              "level": null
            },
            {
              "type": "heading",
              "content": "체액성 면역과 세포성 면역의 공격 대상 비교",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "세포성 면역은 세포 내부에 있는 항원을 공격합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이는 바이러스나 M. leprae, L. monocytogenes와 같은 일부 세포 내 세균에 해당합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "체액성 면역은 세포 외부의 침입자와 위협에 맞서 싸웁니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이는 세포 외 세균과 독소, 그리고 숙주 세포에 들어가기 전의 바이러스를 포함합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "제공된 텍스트는 특정 병원체를 표적으로 하는 방어 체계인 적응성 면역에 대해 설명합니다. 적응성 면역은 감염이나 백신을 통해 획득되며, 일차 반응과 이차 반응으로 구분됩니다. 또한, 적응성 면역의 이중적 특성으로 체액성 면역(B 세포, 항체 생성, 세포 외부 위협 방어)과 세포성 면역(T 세포, 사이토카인 분비, 세포 내부 위협 방어)을 상세히 다루고, 각 면역 체계가 공격하는 대상의 차이점을 비교합니다.",
            "keyConcepts": [
              {
                "term": "적응성 면역",
                "definition": "특정 병원체를 표적으로 삼는 방어 체계로, 감염이나 백신 접종을 통해 획득되며, 기억을 통해 더 빠르고 효과적인 이차 반응을 가능하게 합니다."
              },
              {
                "term": "체액성 면역",
                "definition": "B 세포가 항원을 인식하고 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸우는 면역 반응입니다."
              },
              {
                "term": "세포성 면역",
                "definition": "T 림프구가 식세포에 의해 처리된 항원 펩타이드를 인식하고 사이토카인을 분비하여 세포 내부에 있는 항원(예: 바이러스, 일부 세포 내 세균)을 공격하는 면역 반응입니다."
              },
              {
                "term": "일차 반응 및 이차 반응",
                "definition": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것이며, 이차 반응은 동일한 물질과의 이후 상호 작용으로, 기억 덕분에 더 빠르고 효과적입니다."
              }
            ],
            "importantTerms": [
              {
                "term": "항원 (Antigen)",
                "definition": "면역 반응, 특히 항체 생성을 유도하는 외래 분자입니다."
              },
              {
                "term": "항체 (Antibody)",
                "definition": "B 세포에 의해 생성되며 특정 항원과 결합하여 중화하거나 제거하는 Y자 모양의 단백질입니다."
              },
              {
                "term": "B 세포 (B cell)",
                "definition": "적골수에서 생성 및 성숙하며 항원을 인식하고 항체를 만드는 림프구입니다."
              },
              {
                "term": "T 세포 (T cell)",
                "definition": "흉선에서 성숙하며 항원 제시 세포에 의해 처리된 항원 펩타이드를 인식하고 항체 대신 사이토카인을 분비하는 림프구입니다."
              },
              {
                "term": "사이토카인 (Cytokine)",
                "definition": "T 세포 등 면역 세포가 분비하는 작은 단백질로, 면역 반응과 염증을 조절하는 신호 분자 역할을 합니다."
              },
              {
                "term": "T 세포 수용체 (TCR)",
                "definition": "T 세포 표면에 위치하며 특정 항원 펩타이드를 인식하고 결합하는 수용체입니다."
              }
            ],
            "outline": [
              {
                "text": "적응성 면역 체계",
                "id": "adaptive-immune-system",
                "children": [
                  {
                    "text": "적응성 면역의 정의 및 획득 경로",
                    "id": "definition-acquisition-of-adaptive-immunity",
                    "children": null
                  },
                  {
                    "text": "일차 반응과 이차 반응",
                    "id": "primary-and-secondary-response",
                    "children": null
                  }
                ]
              },
              {
                "text": "적응성 면역 체계의 이중적 특성",
                "id": "dual-nature-of-adaptive-immune-system",
                "children": [
                  {
                    "text": "체액성 면역",
                    "id": "humoral-immunity",
                    "children": [
                      {
                        "text": "항체 생성 및 항원 공격",
                        "id": "antibody-production-and-antigen-attack",
                        "children": null
                      },
                      {
                        "text": "B 세포의 역할 및 특징",
                        "id": "role-and-characteristics-of-b-cells",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "세포성 면역 (세포 매개 면역)",
                    "id": "cellular-immunity",
                    "children": [
                      {
                        "text": "T 림프구 생성 및 역할",
                        "id": "t-lymphocyte-production-and-role",
                        "children": null
                      },
                      {
                        "text": "T 세포의 성숙 및 항원 인식",
                        "id": "t-cell-maturation-and-antigen-recognition",
                        "children": null
                      },
                      {
                        "text": "T 세포 수용체(TCR) 및 사이토카인 분비",
                        "id": "tcr-and-cytokine-secretion",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "체액성 면역과 세포성 면역의 공격 대상 비교",
                    "id": "comparison-of-humoral-and-cellular-immunity-targets",
                    "children": [
                      {
                        "text": "세포성 면역의 대상 (세포 내부 항원)",
                        "id": "targets-of-cellular-immunity",
                        "children": null
                      },
                      {
                        "text": "체액성 면역의 대상 (세포 외부 위협)",
                        "id": "targets-of-humoral-immunity",
                        "children": null
                      }
                    ]
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "적응성 면역의 주요 특징은 무엇입니까?",
              "options": [
                "비특이적 방어",
                "특정 병원체를 표적으로 함",
                "즉각적인 반응",
                "항상 식세포 작용을 포함함"
              ],
              "answerIndex": 1,
              "explanation": "적응성 면역은 특정 병원체를 표적으로 삼는 방어 체계입니다."
            },
            {
              "question": "항체를 생성하고 세포 외부의 위협을 공격하는 면역 유형은 무엇입니까?",
              "options": [
                "선천성 면역",
                "세포성 면역",
                "체액성 면역",
                "비특이적 면역"
              ],
              "answerIndex": 2,
              "explanation": "체액성 면역은 B 세포가 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸웁니다."
            },
            {
              "question": "T 세포는 어디에서 성숙합니까?",
              "options": [
                "적골수",
                "비장",
                "림프절",
                "흉선"
              ],
              "answerIndex": 3,
              "explanation": "T 세포는 흉선(thymus)에서 성숙합니다."
            }
          ]
        },
        {
          "title": "적응성 면역: 사이토카인, 항원 및 항체",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1989 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "사이토카인: 면역 세포의 화학적 전달자",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "사이토카인은 자극에 반응하여 생성되는 화학적 전달자입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "인터루킨(Interleukins): 백혈구 사이의 사이토카인입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "케모카인(Chemokines): 백혈구의 이동을 유도합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "인터페론(Interferons, IFNs): 숙주 세포의 바이러스 감염을 방해합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "종양 괴사 인자(Tumor necrosis factor, TNF): 자가면역 질환의 염증과 관련이 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "조혈 사이토카인(Hematopoietic cytokines): 적혈구와 백혈구로 발달하는 줄기세포를 조절합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사이토카인의 과잉 생산은 사이토카인 폭풍(cytokine storm)으로 이어집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "주요 사이토카인 및 그 역할",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "IL-4: TH2 세포에서 생성되며, 미감염 TH 세포와 B 세포에 작용하여 TH2 세포 증식을 유도하고 IgE로의 클래스 전환을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IL-12: 수지상 세포, 대식세포, 호중구에서 생성되며, 미감염 TH 세포와 NK 세포에 작용하여 TH1 세포의 성장과 기능을 자극하고 IFN-γ 및 TNF-α를 자극합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IL-17: TH17 세포에서 생성되며, 호중구에 작용하여 염증을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IL-22: TH17 세포에서 생성되며, 상피세포에 작용하여 항균 단백질 생성을 자극합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "감마 인터페론(IFN-γ): TH1 세포에서 생성되며, CTL(세포독성 T 림프구)과 대식세포에 작용하여 식세포 작용을 촉진하고 대식세포 및 체액성 면역 반응을 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "케모카인: 다양한 세포(대식세포, 상피세포)에서 생성되며, 호중구에 작용하여 화학주성(chemotaxis)을 유도합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "TNF-알파(TNF-α): 대식세포, TH 세포, NK 세포에서 생성되며, 종양 세포에 작용하여 염증을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "GM-CSF: 대식세포, T 세포, NK 세포에서 생성되며, 골수 줄기세포에 작용하여 대식세포와 과립구 수를 증가시킵니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항원",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "항원은 항체 생성을 유발하는 물질입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "일반적으로 침입하는 미생물이나 이물질의 구성 요소입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항체는 항원상의 에피토프(epitopes) 또는 항원결정인자(antigenic determinants)와 상호작용합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "합텐",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "합텐은 면역 반응을 유발하기에는 너무 작은 항원입니다; 운반 분자에 부착되어야 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항체",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "항체는 면역글로불린(Immunoglobulins, Ig)이라고 불리는 구형 단백질입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "가(Valence)는 항체에 있는 항원 결합 부위의 수를 의미합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이중가(Bivalent) 항체는 두 개의 결합 부위를 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "전형적인 항체 분자의 구조",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "네 개의 단백질 사슬이 Y자 모양을 이룹니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "두 개의 동일한 경쇄(light chains)와 두 개의 동일한 중쇄(heavy chains)가 이황화 결합으로 연결되어 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "가변(V) 부위는 팔의 끝 부분에 위치하며 에피토프와 결합합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "정상(Fc) 부위는 줄기 부분으로, 특정 Ig 클래스에 대해 동일합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역글로불린은 5가지 클래스(IgG, IgM, IgA, IgD, IgE)로 나뉩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역글로불린 클래스 요약",
              "level": 1
            },
            {
              "type": "heading",
              "content": "IgG",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "단량체(Monomer)입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈청 항체의 80%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈액, 림프, 장에 존재합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "태반을 통과하여 태아를 보호하고; 보체(complement)를 활성화하며; 식세포 작용을 강화하고; 독소와 바이러스를 중화합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "IgM",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "다섯 개의 단량체가 J 사슬로 연결된 오량체(Pentamer)입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈청 항체의 6%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈관 내에 남아있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포와 바이러스의 응집을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "감염에 대한 첫 번째 반응이며; 수명이 짧습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "IgA",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "혈청에서는 단량체, 분비물에서는 이량체(Dimer)입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈청 항체의 13%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "점막, 침, 눈물, 모유에서 흔히 발견됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "미생물이 점막에 부착하는 것을 방지합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "IgD",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "단량체입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈청 항체의 0.02%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IgG와 유사한 구조를 가집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈액, 림프, B 세포에 존재합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "명확히 정의된 기능은 없으나; B 세포의 면역 반응을 돕습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "IgE",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "단량체입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈청 항체의 0.002%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "비만세포, 호염기구, 혈액에 존재합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항원과 결합하면 히스타민 방출을 유발하고; 기생충을 용해합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "본 문서는 적응성 면역의 핵심 요소인 사이토카인, 항원, 항체에 대해 설명합니다. 사이토카인은 면역 세포 간의 화학적 전달자로, 다양한 종류(인터루킨, 케모카인, 인터페론, TNF 등)와 기능(염증 유발, 백혈구 이동 유도, 바이러스 감염 방해 등)을 가지며, 과잉 생산 시 사이토카인 폭풍을 유발할 수 있습니다. 항원은 항체 생성을 유발하는 물질이며, 항체가 결합하는 특정 부위를 에피토프라고 합니다. 합텐은 면역 반응을 유발하기에 너무 작아 운반 분자에 부착해야 하는 항원입니다. 항체는 면역글로불린(Ig)이라는 단백질로, Y자 모양의 구조를 가지며 가변부위와 정상부위로 구성됩니다. IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 클래스가 있으며, 각 클래스는 고유한 구조적 특성과 면역 기능을 수행합니다.",
            "keyConcepts": [
              {
                "term": "사이토카인 (Cytokines)",
                "definition": "면역 세포 간의 통신을 담당하는 화학적 전달 물질로, 다양한 면역 반응을 조절합니다."
              },
              {
                "term": "항원 (Antigens)",
                "definition": "면역 반응, 특히 항체 생성을 유발하는 물질입니다."
              },
              {
                "term": "항체 (Antibodies/Immunoglobulins)",
                "definition": "항원에 특이적으로 결합하여 항원을 중화하거나 제거하는 면역 단백질입니다."
              },
              {
                "term": "면역글로불린 클래스 (Immunoglobulin Classes)",
                "definition": "항체의 기능과 구조에 따라 IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 분류로 나뉩니다."
              },
              {
                "term": "사이토카인 폭풍 (Cytokine Storm)",
                "definition": "사이토카인이 과도하게 생산되어 전신 염증 반응과 조직 손상을 유발할 수 있는 심각한 면역 반응입니다."
              }
            ],
            "importantTerms": [
              {
                "term": "인터루킨 (Interleukins)",
                "definition": "백혈구 사이에서 작용하는 사이토카인입니다."
              },
              {
                "term": "케모카인 (Chemokines)",
                "definition": "백혈구의 이동(화학주성)을 유도하는 사이토카인입니다."
              },
              {
                "term": "인터페론 (Interferons, IFNs)",
                "definition": "바이러스 감염을 방해하는 사이토카인입니다."
              },
              {
                "term": "종양 괴사 인자 (Tumor Necrosis Factor, TNF)",
                "definition": "염증 반응과 관련된 사이토카인입니다."
              },
              {
                "term": "에피토프 (Epitopes)",
                "definition": "항원 상에서 항체가 특이적으로 결합하는 특정 부위 또는 항원결정인자입니다."
              },
              {
                "term": "합텐 (Haptens)",
                "definition": "단독으로는 면역 반응을 유발하지 못하지만, 운반 분자에 부착되면 면역원성을 획득하는 작은 분자입니다."
              },
              {
                "term": "가변 부위 (Variable regions)",
                "definition": "항체 팔의 끝 부분에 위치하며 항원의 에피토프와 결합하는 부위입니다."
              },
              {
                "term": "정상 부위 (Constant region, Fc)",
                "definition": "항체 분자의 줄기 부분으로, 특정 Ig 클래스에 대해 동일하며 면역 세포와의 상호작용에 관여합니다."
              }
            ],
            "outline": [
              {
                "text": "사이토카인: 면역 세포의 화학적 전달자",
                "id": "cytokines-chemical-messengers-of-immune-cells",
                "children": [
                  {
                    "text": "사이토카인의 정의 및 종류",
                    "id": "cytokines-definition-types",
                    "children": null
                  },
                  {
                    "text": "주요 사이토카인 및 그 역할",
                    "id": "key-cytokines-roles",
                    "children": null
                  },
                  {
                    "text": "사이토카인 폭풍",
                    "id": "cytokine-storm",
                    "children": null
                  }
                ]
              },
              {
                "text": "항원",
                "id": "antigens",
                "children": [
                  {
                    "text": "항원의 정의",
                    "id": "antigens-definition",
                    "children": null
                  },
                  {
                    "text": "에피토프",
                    "id": "epitopes",
                    "children": null
                  }
                ]
              },
              {
                "text": "합텐",
                "id": "haptens",
                "children": null
              },
              {
                "text": "항체",
                "id": "antibodies",
                "children": [
                  {
                    "text": "항체의 정의 및 구조",
                    "id": "antibodies-definition-structure",
                    "children": null
                  },
                  {
                    "text": "전형적인 항체 분자의 구조",
                    "id": "typical-antibody-structure",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역글로불린 클래스 요약",
                "id": "summary-of-immunoglobulin-classes",
                "children": [
                  {
                    "text": "IgG",
                    "id": "igg",
                    "children": null
                  },
                  {
                    "text": "IgM",
                    "id": "igm",
                    "children": null
                  },
                  {
                    "text": "IgA",
                    "id": "iga",
                    "children": null
                  },
                  {
                    "text": "IgD",
                    "id": "igd",
                    "children": null
                  },
                  {
                    "text": "IgE",
                    "id": "ige",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "사이토카인 폭풍(Cytokine storm)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
              "options": [
                "면역 세포가 바이러스 감염을 방해하기 위해 사이토카인을 과도하게 생산하는 현상",
                "염증 반응을 억제하기 위해 사이토카인이 부족하게 생산되는 현상",
                "사이토카인이 과도하게 생산되어 조직 손상과 장기 부전을 초래할 수 있는 현상",
                "항체 생산을 촉진하기 위해 특정 사이토카인이 의도적으로 증가하는 현상"
              ],
              "answerIndex": 2,
              "explanation": "사이토카인 폭풍은 사이토카인이 과도하게 생산되어 전신 염증 반응, 조직 손상 및 장기 부전을 초래할 수 있는 현상입니다."
            },
            {
              "question": "다음 면역글로불린(Ig) 클래스 중, 태반을 통과하여 태아를 보호하고 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 하는 것은 무엇입니까?",
              "options": [
                "IgM",
                "IgA",
                "IgG",
                "IgE"
              ],
              "answerIndex": 2,
              "explanation": "IgG는 태반을 통과하여 태아를 보호하며, 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 수행합니다."
            },
            {
              "question": "합텐(Hapten)에 대한 설명으로 옳은 것은 무엇입니까?",
              "options": [
                "항체를 생산하는 모든 물질을 의미한다.",
                "면역 반응을 유발하기에 너무 작아서 운반 분자에 부착해야 하는 항원이다.",
                "항체와 상호작용하는 항원의 특정 부위를 의미한다.",
                "혈액에 가장 많이 존재하는 면역글로불린의 한 종류이다."
              ],
              "answerIndex": 1,
              "explanation": "합텐은 단독으로는 면역 반응을 유발하기에 너무 작지만, 운반 분자에 부착되면 면역원성을 획득하여 항체 생성을 유도할 수 있는 물질입니다."
            }
          ]
        },
        {
          "title": "적응성 면역: 체액성 면역 반응",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2199 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "항체 생성 세포의 활성화 및 클론 선택",
              "level": 1
            },
            {
              "type": "heading",
              "content": "주조직적합복합체(MHC)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "주조직적합복합체(MHC) 유전자는 세포 표면에 존재하는 분자를 암호화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "Class I MHC는 모든 유핵 동물 세포의 막에 존재하며, '자기(self)'를 식별하는 역할을 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "Class II MHC는 B 세포를 포함한 전문 항원제시세포(APCs)의 표면에 존재합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "B 세포의 활성화 및 클론 선택 과정",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "비활성 B 세포는 항원에 결합하는 표면 면역글로불린(Ig)을 가지고 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "B 세포는 항원을 내재화하고 처리합니다. 처리된 항원 조각들은 MHC Class II 분자에 제시됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이 제시된 항원 조각을 T 도우미 세포(TH cell)가 접촉하고, B 세포를 활성화시키는 사이토카인을 방출합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "활성화된 B 세포는 증식(클론 확장)을 겪습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "클론 선택은 활성화된 B 세포를 다음 두 가지로 분화시킵니다:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1. 항체를 생산하는 형질세포(Plasma cells)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "2. 기억 세포(Memory cells)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "또한, 클론 제거(Clonal deletion) 과정을 통해 유해한 B 세포는 제거됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "줄기세포는 특정 항원에 대한 표면 면역글로불린을 가진 성숙한 B 세포로 분화합니다. B 세포가 특정 항원을 만나면 증식합니다. 일부 B 세포는 장수하는 기억 세포로 증식하여, 나중에 항체를 생산하는 형질세포로 자극될 수 있습니다. 다른 B 세포는 항체 생산 형질세포로 증식하며, 이 형질세포는 혈액 순환계로 항체를 분비합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "T 세포 의존성 및 비의존성 항원",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "T 세포 의존성 항원은 항체를 생산하기 위해 T 도우미 세포(TH cell)의 도움이 필요한 항원입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 직접 자극할 수 있습니다. 이러한 항원은 일반적으로 약한 면역 반응을 유발하며, 주로 IgM을 생산하고 기억 세포는 생성되지 않습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항원-항체 결합 및 그 결과",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "항체가 항원에 결합할 때 항원-항체 복합체가 형성됩니다. 이 결합의 강도를 친화도(affinity)라고 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항원-항체 결합은 외래 분자나 세포를 파괴하도록 표지함으로써 숙주를 보호합니다. 주요 보호 메커니즘은 다음과 같습니다:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1. **응집(Agglutination)**: 감염 단위의 수를 줄여 처리해야 할 대상을 감소시킵니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "2. **옵소닌화(Opsonization)**: 항원으로 항원을 코팅하여 식균작용을 강화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "3. **항체 의존성 세포 매개성 세포독성(Antibody-dependent cell-mediated cytotoxicity, ADCC)**: 항체가 표적 세포에 부착되어 대식세포, 호산구, NK 세포에 의한 파괴를 유도합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "4. **중화(Neutralization)**: 박테리아와 바이러스가 점막에 부착되는 것을 차단하고 독소가 부착되는 것을 막습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "5. **보체계 활성화(Activation of the complement system)**: 염증 및 세포 용해를 유발합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "본 문서는 적응성 면역 중 체액성 면역 반응에 초점을 맞춰 항체 생성 세포의 활성화 및 클론 선택 과정을 설명합니다. MHC(주조직적합복합체)의 역할, B 세포가 항원을 인식하고 T 도우미 세포의 도움을 받아 활성화되며 형질세포와 기억 세포로 분화하는 과정이 상세히 다뤄집니다. 또한, T 세포 의존성 및 비의존성 항원의 특징과 항원-항체 결합이 숙주를 보호하는 응집, 옵소닌화, ADCC, 중화, 보체계 활성화 등 다양한 메커니즘을 제시합니다.",
            "keyConcepts": [
              {
                "term": "MHC (주조직적합복합체)",
                "definition": "세포 표면에 존재하며, Class I은 '자기' 식별, Class II는 항원제시세포에서 항원 조각을 T 세포에 제시하는 역할을 하는 분자를 암호화하는 유전자 복합체."
              },
              {
                "term": "B 세포 활성화",
                "definition": "비활성 B 세포가 항원을 인식하고, T 도우미 세포의 사이토카인 도움을 받아 증식하고 분화하는 과정."
              },
              {
                "term": "클론 선택 (Clonal Selection)",
                "definition": "특정 항원에 반응하는 B 세포 클론이 선택적으로 증식하여 항체 생성 형질세포와 기억 세포로 분화하는 면역 과정."
              },
              {
                "term": "T 세포 의존성/비의존성 항원",
                "definition": "항체 생산에 T 도우미 세포의 도움이 필요한지 여부에 따라 항원을 분류하는 방식. 비의존성 항원은 약한 IgM 반응과 기억 세포 부재를 특징으로 함."
              },
              {
                "term": "항체 기능",
                "definition": "항원-항체 복합체 형성 후 숙주를 보호하는 다양한 메커니즘 (응집, 옵소닌화, ADCC, 중화, 보체계 활성화)."
              }
            ],
            "importantTerms": [
              {
                "term": "MHC (주조직적합복합체)",
                "definition": "세포 표면에 항원 펩타이드를 제시하는 데 관여하는 단백질 복합체."
              },
              {
                "term": "T 도우미 세포 (T Helper Cell, TH cell)",
                "definition": "B 세포 활성화 및 다른 면역 세포 기능을 조절하는 사이토카인을 분비하는 림프구."
              },
              {
                "term": "사이토카인 (Cytokines)",
                "definition": "세포 간 신호 전달에 관여하며 면역 반응을 조절하는 작은 단백질."
              },
              {
                "term": "형질세포 (Plasma Cell)",
                "definition": "활성화된 B 세포로부터 분화하여 다량의 항체를 생산하고 분비하는 세포."
              },
              {
                "term": "기억 세포 (Memory Cell)",
                "definition": "면역 반응 후 장기간 생존하며, 동일한 항원 재침입 시 빠르고 강력한 2차 면역 반응을 유도하는 림프구."
              },
              {
                "term": "응집 (Agglutination)",
                "definition": "항체가 여러 항원 입자(예: 세균)를 서로 묶어 침전시키는 과정."
              },
              {
                "term": "옵소닌화 (Opsonization)",
                "definition": "항체가 항원 표면을 코팅하여 식세포가 이를 더 쉽게 인식하고 포식할 수 있도록 돕는 과정."
              }
            ],
            "outline": [
              {
                "text": "항체 생성 세포의 활성화 및 클론 선택",
                "id": "항체-생성-세포의-활성화-및-클론-선택",
                "children": [
                  {
                    "text": "주조직적합복합체(MHC)",
                    "id": "주조직적합복합체-mhc",
                    "children": null
                  },
                  {
                    "text": "B 세포의 활성화 및 클론 선택 과정",
                    "id": "b-세포의-활성화-및-클론-선택-과정",
                    "children": null
                  },
                  {
                    "text": "T 세포 의존성 및 비의존성 항원",
                    "id": "t-세포-의존성-및-비의존성-항원",
                    "children": null
                  }
                ]
              },
              {
                "text": "항원-항체 결합 및 그 결과",
                "id": "항원-항체-결합-및-그-결과",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "다음 중 MHC Class II 분자가 주로 발견되는 세포와 그 역할은 무엇입니까?",
              "options": [
                "모든 유핵 동물 세포의 막; '자기' 식별",
                "전문 항원제시세포(APCs)의 표면; 항원 조각 제시",
                "적혈구; 산소 운반",
                "신경 세포; 신경 신호 전달"
              ],
              "answerIndex": 1,
              "explanation": "MHC Class II는 B 세포를 포함한 전문 항원제시세포의 표면에 존재하며, 처리된 항원 조각을 T 도우미 세포에 제시하는 역할을 합니다."
            },
            {
              "question": "B 세포가 항원을 내재화하고 처리한 후, T 도우미 세포의 도움을 받아 활성화될 때 T 도우미 세포가 방출하는 물질은 무엇입니까?",
              "options": [
                "항체",
                "항원",
                "사이토카인",
                "면역글로불린"
              ],
              "answerIndex": 2,
              "explanation": "T 도우미 세포는 제시된 항원 조각을 인식한 후 사이토카인을 방출하여 B 세포의 활성화를 유도합니다."
            },
            {
              "question": "T 세포 비의존성 항원에 대한 면역 반응의 특징으로 옳지 않은 것은 무엇입니까?",
              "options": [
                "T 세포의 도움 없이 B 세포를 직접 자극한다.",
                "주로 IgM 항체를 생산한다.",
                "약한 면역 반응을 유발한다.",
                "강력한 기억 세포 반응을 생성한다."
              ],
              "answerIndex": 3,
              "explanation": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 자극하지만, 일반적으로 약한 면역 반응을 유발하고 기억 세포가 생성되지 않습니다."
            }
          ]
        },
        {
          "title": "적응성 면역: 세포성 면역 반응",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2963 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "세포성 면역 반응 과정",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "T 세포는 세포내 병원체와 싸웁니다. T 세포는 흉선에서 성숙하며, 흉선 선택을 통해 미성숙 T 세포가 제거됩니다. 성숙한 T 세포는 흉선에서 림프 조직으로 이동하며, T 세포 수용체(TCR)를 통해 항원에 부착합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "위장관으로 들어오는 병원체는 파이어스 패치(Peyer's patches) 위에 위치한 미세주름 세포(M cells)를 통과합니다. 이 세포들은 항원을 림프구와 항원제시세포(APCs)로 전달합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항원제시세포 (APCs)",
              "level": 1
            },
            {
              "type": "heading",
              "content": "수지상 세포 (Dendritic cells, DCs)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "수지상 세포는 미생물을 삼켜 분해하고 T 세포에 제시합니다. 이들은 피부, 생식기, 림프절, 비장, 흉선 및 혈액에서 발견됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "대식세포 (Macrophages)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "대식세포는 사이토카인 또는 항원 물질의 섭취에 의해 활성화됩니다. 이들은 림프 조직으로 이동하여 T 세포에 항원을 제시합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항원 처리 및 제시: MHC",
              "level": 1
            },
            {
              "type": "heading",
              "content": "T 세포의 종류",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "T 세포는 분화군(Clusters of differentiation, CD) 표지자를 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "CD4+ T 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "CD4+ T 세포는 T 도우미 세포(TH)라고도 불립니다. 이들은 B 세포와 사이토카인 신호를 주고받으며 항원과 직접 상호작용합니다. B 세포 및 APC의 MHC class II 분자에 결합합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "CD8+ T 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "CD8+ T 세포는 세포독성 T 림프구(Cytotoxic T lymphocytes, CTL)라고 불립니다. 이들은 MHC class I 분자에 결합합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "CD4+ 세포의 TCR은 APC의 항원 조각과 MHC class II에 결합하여 인식합니다. APC 또는 TH는 보조 자극 분자를 분비하여 CD4+ 세포를 활성화합니다. 활성화된 TH 세포는 사이토카인을 생성하고 TH1, TH2, TH17 세포 및 기억 세포로 분화합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "TH17 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "TH17 세포는 IL-17을 생성하여 염증 반응에 기여하고, 세포외 세균 및 곰팡이에 대한 방어를 위해 호중구를 모집합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "TH1 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "TH1 세포는 IFN-γ를 생성하여 대식세포를 활성화하고, 보체를 강화하며, 식세포 작용을 촉진하는 항체 생성을 자극합니다. TH1 세포는 세포성 면역의 중요한 요소이며, 이들의 사이토카인(예: IFN-γ 및 IL-2)은 CD8+ T 세포와 NK 세포를 활성화하여 감염된 숙주 세포를 죽임으로써 세포내 병원체를 제어합니다. 또한, 대식세포와 같은 항원제시세포의 식세포 작용을 강화합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "TH2 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "TH2 세포는 B 세포를 활성화하여 IgE를 생성하게 하고 호산구를 활성화합니다. 특히 IgE 생성을 통한 알레르기 반응에 중요하며, 헬민스와 같은 세포외 기생충을 제어하기 위해 호산구를 활성화합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "조절 T 세포 (Treg)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "조절 T 세포(Treg)는 CD4+ 세포의 하위 집합으로, 추가적인 CD25 분자를 가지고 있습니다. 이들은 자가 반응성 T 세포를 억제하여 자기 관용을 유지하고, 소화에 필요한 장내 세균을 보호하며, 태아를 보호합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포독성 T 림프구 (CD8+ T 세포)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "전구 세포독성 T 세포(CTLp)는 TH 세포와 보조 자극 신호의 도움으로 활성화되어 세포독성 T 림프구(CTLs)가 됩니다. CTLs는 감염에 의해 변형된 자가 세포를 인식하고 죽입니다. 감염된 자가 세포는 MHC class I 분자와 함께 표면에 내인성 항원을 운반합니다. CTL은 퍼포린(perforin)과 그랜자임(granzymes)을 방출하여 감염된 세포의 세포자멸사를 유도합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포자멸사 (Apoptosis)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "세포자멸사는 프로그램된 세포 사멸입니다. 이는 감염성 바이러스가 다른 세포로 퍼지는 것을 방지합니다. 세포는 게놈을 조각으로 절단하며, 세포막은 수포(blebbing)를 통해 바깥쪽으로 부풀어 오릅니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "정상 세포는 세포독성 T 림프구(CTL)에 의해 반응을 유발하지 않지만, 바이러스 감염 세포나 암세포는 비정상적인 내인성 항원을 생성합니다. 이 비정상적인 항원은 MHC class I 분자와 결합하여 세포 표면에 제시됩니다. TH1 세포의 결합은 사이토카인 분비를 촉진합니다. 이 사이토카인은 전구 CTL을 활성화하여 CTL 클론을 생성합니다. CTL은 세포자멸사를 통해 바이러스 감염 세포의 파괴를 유도합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역계에 의한 세포외 살상",
              "level": 1
            },
            {
              "type": "heading",
              "content": "자연살해 (NK) 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "자연살해(NK) 세포는 과립성 백혈구로, MHC class I 자가 항원을 발현하지 않는 세포를 파괴합니다. 이들은 바이러스 감염 세포와 종양 세포를 죽이고 기생충을 공격합니다. 항상 항원에 의해 자극되는 것은 아니며, 표적 세포에 구멍을 형성하여 용해 또는 세포자멸사를 유도합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포성 면역에 관여하는 주요 세포 기능",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "T 도우미 (TH1) 세포: 세포 매개 면역 관련 세포(대식세포, CTLs, 자연살해 세포)를 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 도우미 (TH2) 세포: 호산구, IgM, IgE 생성을 자극합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 도우미 (TH17) 세포: 호중구를 모집하고 항균 단백질 생성을 자극합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포독성 T 림프구 (CTL): 세포자멸사를 유도하여 접촉하는 표적 세포를 파괴합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "조절 T (Treg) 세포: 면역 반응을 조절하고 자기 관용을 유지하는 데 도움을 줍니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "활성화된 대식세포: 식세포 활동이 강화되고 암세포를 공격합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "자연살해 (NK) 세포: 표적 세포를 공격하고 파괴하며, 항체 의존성 세포 매개 세포독성(ADCC)에 참여합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항체 의존성 세포 매개 세포독성 (ADCC)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "원생동물과 헬민스는 식세포 작용으로 삼키기에는 너무 큽니다. 원생동물 또는 헬민스 표적 세포는 항체로 코팅됩니다. 면역계 세포는 항체의 Fc 영역에 부착합니다. 표적 세포는 면역계 세포가 분비하는 화학 물질에 의해 용해됩니다. 많은 기생충과 같이 식세포에 의해 섭취하기에는 너무 큰 유기체는 외부에서 공격받아야 합니다. 호산구는 기생성 흡충의 유충 단계에 부착합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 세포성 면역의 과정을 상세히 설명하며, T 세포, 항원제시세포(APCs) 및 이들의 상호작용에 중점을 둡니다. T 세포의 성숙 과정과 다양한 T 세포 유형(TH1, TH2, TH17, 세포독성 T 림프구, 조절 T 세포)의 기능, 그리고 이들이 세포내 병원체 퇴치, 면역 반응 조절 및 특정 면역 반응 매개에 어떻게 기여하는지 다룹니다. 또한, 자연살해(NK) 세포의 세포외 살상 역할과 대형 기생충에 대한 항체 의존성 세포 매개 세포독성(ADCC) 기전도 설명합니다.",
            "keyConcepts": [
              {
                "term": "T 세포의 성숙 및 기능",
                "definition": "흉선에서 성숙하며, 세포내 병원체와 싸우고 항원제시세포(APCs)가 제시하는 항원에 특이적으로 반응하는 림프구."
              },
              {
                "term": "항원제시세포 (APCs)",
                "definition": "미생물을 삼켜 분해하고 그 항원 조각을 MHC 분자를 통해 T 세포에 제시하여 T 세포 반응을 유도하는 세포 (예: 수지상 세포, 대식세포)."
              },
              {
                "term": "T 세포 유형 및 역할",
                "definition": "CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)는 다른 면역 세포의 활성화를 돕고, CD8+ T 세포(세포독성 T 림프구)는 감염된 세포를 직접 파괴하며, 조절 T 세포는 면역 반응을 억제하여 자기 관용을 유지한다."
              },
              {
                "term": "세포독성 T 림프구 (CTLs) 및 세포자멸사 (Apoptosis)",
                "definition": "CTL은 감염된 자가 세포를 인식하여 퍼포린과 그랜자임을 방출, 세포자멸사(프로그램된 세포 사멸)를 유도하여 바이러스 확산을 막는다."
              },
              {
                "term": "자연살해(NK) 세포 및 항체 의존성 세포 매개 세포독성 (ADCC)",
                "definition": "NK 세포는 MHC class I을 발현하지 않는 세포를 파괴하며, ADCC는 항체로 코팅된 표적 세포를 면역 세포가 용해시키는 기전으로, 특히 대형 기생충에 효과적이다."
              }
            ],
            "importantTerms": [
              {
                "term": "T 세포 (T cell)",
                "definition": "흉선에서 성숙하며 세포내 병원체와 싸우는 림프구."
              },
              {
                "term": "항원제시세포 (Antigen-Presenting Cells, APCs)",
                "definition": "미생물을 삼켜 분해하고 T 세포에 항원을 제시하는 세포 (예: 수지상 세포, 대식세포)."
              },
              {
                "term": "MHC (Major Histocompatibility Complex)",
                "definition": "항원 제시를 위해 세포 표면에 항원 조각을 표시하는 분자."
              },
              {
                "term": "T 도우미 세포 (T Helper cells, TH)",
                "definition": "CD4+ T 세포로, B 세포와 사이토카인 신호를 주고받으며 다른 면역 세포의 활성화를 돕는다."
              },
              {
                "term": "세포독성 T 림프구 (Cytotoxic T Lymphocytes, CTLs)",
                "definition": "CD8+ T 세포로, 감염된 자가 세포를 인식하고 세포자멸사를 유도하여 파괴한다."
              },
              {
                "term": "세포자멸사 (Apoptosis)",
                "definition": "프로그램된 세포 사멸로, 감염성 바이러스가 다른 세포로 퍼지는 것을 방지한다."
              },
              {
                "term": "자연살해 세포 (Natural Killer cells, NK cells)",
                "definition": "MHC class I 자가 항원을 발현하지 않는 세포를 파괴하며, 바이러스 감염 세포, 종양 세포 및 기생충을 공격한다."
              },
              {
                "term": "항체 의존성 세포 매개 세포독성 (Antibody-Dependent Cell-mediated Cytotoxicity, ADCC)",
                "definition": "항체로 코팅된 표적 세포를 면역 세포가 파괴하는 기전."
              }
            ],
            "outline": [
              {
                "text": "세포성 면역 반응 과정",
                "id": "세포성-면역-반응-과정",
                "children": [
                  {
                    "text": "T 세포의 역할과 성숙",
                    "id": "t-세포의-역할과-성숙",
                    "children": null
                  },
                  {
                    "text": "소화관 내 병원체 처리",
                    "id": "소화관-내-병원체-처리",
                    "children": null
                  }
                ]
              },
              {
                "text": "항원제시세포 (APCs)",
                "id": "항원제시세포-apcs",
                "children": [
                  {
                    "text": "수지상 세포 (Dendritic cells, DCs)",
                    "id": "수지상-세포-dendritic-cells-dcs",
                    "children": null
                  },
                  {
                    "text": "대식세포 (Macrophages)",
                    "id": "대식세포-macrophages",
                    "children": null
                  }
                ]
              },
              {
                "text": "항원 처리 및 제시: MHC",
                "id": "항원-처리-및-제시-mhc",
                "children": null
              },
              {
                "text": "T 세포의 종류",
                "id": "t-세포의-종류",
                "children": [
                  {
                    "text": "CD4+ T 세포",
                    "id": "cd4-t-세포",
                    "children": null
                  },
                  {
                    "text": "CD8+ T 세포",
                    "id": "cd8-t-세포",
                    "children": null
                  }
                ]
              },
              {
                "text": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
                "id": "t-도우미-세포-cd4-t-세포의-활성화-및-분화",
                "children": [
                  {
                    "text": "TH17 세포",
                    "id": "th17-세포",
                    "children": null
                  },
                  {
                    "text": "TH1 세포",
                    "id": "th1-세포",
                    "children": null
                  },
                  {
                    "text": "TH2 세포",
                    "id": "th2-세포",
                    "children": null
                  }
                ]
              },
              {
                "text": "조절 T 세포 (Treg)",
                "id": "조절-t-세포-treg",
                "children": null
              },
              {
                "text": "세포독성 T 림프구 (CD8+ T 세포)",
                "id": "세포독성-t-림프구-cd8-t-세포",
                "children": [
                  {
                    "text": "세포자멸사 (Apoptosis)",
                    "id": "세포자멸사-apoptosis",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역계에 의한 세포외 살상",
                "id": "면역계에-의한-세포외-살상",
                "children": [
                  {
                    "text": "자연살해 (NK) 세포",
                    "id": "자연살해-nk-세포",
                    "children": null
                  }
                ]
              },
              {
                "text": "세포성 면역에 관여하는 주요 세포 기능",
                "id": "세포성-면역에-관여하는-주요-세포-기능",
                "children": null
              },
              {
                "text": "항체 의존성 세포 매개 세포독성 (ADCC)",
                "id": "항체-의존성-세포-매개-세포독성-adcc",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "T 세포가 성숙하는 주요 장소는 어디인가요?",
              "options": [
                "골수",
                "비장",
                "흉선",
                "림프절"
              ],
              "answerIndex": 2,
              "explanation": "T 세포는 흉선(thymus)에서 성숙 과정을 거칩니다."
            },
            {
              "question": "다음 중 세포독성 T 림프구(CTL)의 주된 기능은 무엇인가요?",
              "options": [
                "B 세포 활성화",
                "대식세포 활성화",
                "감염된 자가 세포 파괴",
                "염증 반응 촉진"
              ],
              "answerIndex": 2,
              "explanation": "세포독성 T 림프구(CTL)는 감염된 자가 세포나 암세포를 인식하고 세포자멸사를 유도하여 파괴하는 역할을 합니다."
            },
            {
              "question": "다음 중 항원제시세포(APC)에 해당하지 않는 것은 무엇인가요?",
              "options": [
                "수지상 세포",
                "대식세포",
                "T 도우미 세포",
                "B 세포"
              ],
              "answerIndex": 2,
              "explanation": "수지상 세포, 대식세포, B 세포는 모두 항원제시세포(APC)의 역할을 수행합니다. T 도우미 세포는 APC에 의해 활성화되는 세포이지, 스스로 항원을 제시하는 세포는 아닙니다."
            }
          ]
        },
        {
          "title": "적응성 면역: 면역학적 기억 및 면역 유형",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75f3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1056 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "면역학적 기억",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "이차 (기억 또는 아남네스틱) 반응은 항원에 두 번째 노출된 후에 발생합니다. 이 반응은 더 빠르고, 며칠 동안 지속되며, 그 규모가 훨씬 더 큽니다. 초기 노출에 반응하여 생성된 기억 세포는 이차 노출에 의해 활성화됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "초기 IgM 반응이 IgG, IgE 또는 IgA로 전환되는 '클래스 전환(Class switching)' 현상이 이차 반응에서 발생합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항체 역가(Antibody titer)는 혈청 내 항체의 상대적인 양을 나타내며, 체액 면역 반응의 강도를 반영합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "체액 면역",
              "level": 1
            },
            {
              "type": "heading",
              "content": "일차 면역 반응",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "제공된 텍스트에는 일차 면역 반응에 대한 구체적인 내용은 포함되어 있지 않습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "이차 면역 반응",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "이차 면역 반응은 '면역학적 기억' 섹션에서 상세히 설명된 바와 같이, 항원에 대한 두 번째 노출 시 발생하는 빠르고 강력하며 지속적인 반응입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "적응성 면역의 유형",
              "level": 1
            },
            {
              "type": "heading",
              "content": "자연 획득 면역",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "자연 획득 능동 면역은 감염을 통해 발생하며, 신체가 항원에 직접 노출되어 면역 반응을 일으키고 기억 세포를 형성하는 것을 의미합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "자연 획득 수동 면역은 태반을 통해 또는 초유를 통해 어머니로부터 항체를 전달받아 발생하는 면역입니다. 이는 일시적인 면역을 제공합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "인공 획득 면역",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "인공 획득 능동 면역은 예방 접종(백신 접종)을 통해 발생합니다. 이는 약화되거나 비활성화된 항원을 주입하여 신체 스스로 면역 반응을 일으키고 기억 세포를 형성하도록 유도합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "인공 획득 수동 면역은 항체 주사를 통해 발생합니다. 이는 특정 질병에 대한 즉각적인 보호를 제공하지만, 신체가 스스로 면역 반응을 일으킨 것이 아니므로 기억 세포가 형성되지 않아 일시적입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "관련 용어",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "혈청(Antiserum)은 항체를 포함하는 혈액 유래 액체입니다. 혈청학(Serology)은 항체와 항원 간의 반응을 연구하는 학문입니다. 글로불린(Globulins)은 혈청 단백질을 총칭하며, 감마(γ) 글로불린은 항체를 포함하는 혈청 분획입니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 면역학적 기억과 적응성 면역의 다양한 유형에 대해 설명합니다. 면역학적 기억은 항원에 두 번째 노출되었을 때 발생하는 이차 면역 반응(더 빠르고 강력하며 지속적)의 특징과 클래스 전환, 그리고 항체 역가의 개념을 포함합니다. 적응성 면역은 자연 획득(능동/수동)과 인공 획득(능동/수동) 면역으로 분류되며, 각각의 특징과 발생 원리를 다룹니다. 또한, 혈청, 혈청학, 글로불린, 감마 글로불린과 같은 관련 용어의 정의도 제공합니다.",
            "keyConcepts": [
              {
                "term": "면역학적 기억",
                "definition": "항원에 대한 첫 노출 후 형성되어, 재노출 시 더 빠르고 강력한 이차 면역 반응을 유도하는 능력."
              },
              {
                "term": "이차 면역 반응",
                "definition": "항원에 두 번째 노출되었을 때 나타나는 면역 반응으로, 일차 반응보다 빠르고 강하며 오래 지속되는 특징을 가집니다."
              },
              {
                "term": "적응성 면역의 유형",
                "definition": "면역 획득 방식에 따라 자연 획득 능동/수동 면역과 인공 획득 능동/수동 면역으로 나뉩니다."
              },
              {
                "term": "클래스 전환",
                "definition": "초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상."
              }
            ],
            "importantTerms": [
              {
                "term": "이차 (기억 또는 아남네스틱) 반응",
                "definition": "항원에 두 번째 노출되었을 때 발생하는 면역 반응."
              },
              {
                "term": "클래스 전환",
                "definition": "면역 반응 시 초기 IgM 항체에서 IgG, IgE, IgA 등 다른 항체 유형으로 전환되는 현상."
              },
              {
                "term": "항체 역가",
                "definition": "혈청 내 항체의 상대적인 양을 나타내는 지표."
              },
              {
                "term": "자연 획득 능동 면역",
                "definition": "감염을 통해 자연적으로 항원에 노출되어 획득하는 면역."
              },
              {
                "term": "인공 획득 능동 면역",
                "definition": "예방 접종(백신)을 통해 인위적으로 항원에 노출되어 획득하는 면역."
              },
              {
                "term": "혈청",
                "definition": "항체를 포함하는 혈액 유래 액체."
              },
              {
                "term": "감마 글로불린",
                "definition": "항체를 포함하는 혈청 단백질 분획."
              }
            ],
            "outline": [
              {
                "text": "면역학적 기억",
                "id": "immunological-memory",
                "children": [
                  {
                    "text": "이차 면역 반응의 특성",
                    "id": "secondary-immune-response-characteristics",
                    "children": null
                  },
                  {
                    "text": "클래스 전환 및 기억 세포",
                    "id": "class-switching-and-memory-cells",
                    "children": null
                  },
                  {
                    "text": "항체 역가",
                    "id": "antibody-titer",
                    "children": null
                  }
                ]
              },
              {
                "text": "체액 면역",
                "id": "humoral-immunity",
                "children": [
                  {
                    "text": "일차 면역 반응",
                    "id": "primary-immune-response",
                    "children": null
                  },
                  {
                    "text": "이차 면역 반응",
                    "id": "secondary-immune-response-humoral",
                    "children": null
                  }
                ]
              },
              {
                "text": "적응성 면역의 유형",
                "id": "types-of-adaptive-immunity",
                "children": [
                  {
                    "text": "자연 획득 면역",
                    "id": "naturally-acquired-immunity",
                    "children": [
                      {
                        "text": "자연 획득 능동 면역",
                        "id": "naturally-acquired-active-immunity",
                        "children": null
                      },
                      {
                        "text": "자연 획득 수동 면역",
                        "id": "naturally-acquired-passive-immunity",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "인공 획득 면역",
                    "id": "artificially-acquired-immunity",
                    "children": [
                      {
                        "text": "인공 획득 능동 면역",
                        "id": "artificially-acquired-active-immunity",
                        "children": null
                      },
                      {
                        "text": "인공 획득 수동 면역",
                        "id": "artificially-acquired-passive-immunity",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "관련 용어",
                    "id": "related-terms",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "이차 면역 반응의 주요 특징이 아닌 것은 무엇입니까?",
              "options": [
                "일차 반응보다 느리게 발생한다.",
                "더 오랫동안 지속된다.",
                "규모가 더 크다.",
                "기억 세포에 의해 활성화된다."
              ],
              "answerIndex": 0,
              "explanation": "이차 면역 반응은 일차 반응보다 '더 빠르게' 발생하며, 더 오랫동안 지속되고 규모가 더 크다는 특징을 가집니다."
            },
            {
              "question": "예방 접종(백신 접종)을 통해 획득하는 면역 유형은 무엇입니까?",
              "options": [
                "자연 획득 능동 면역",
                "자연 획득 수동 면역",
                "인공 획득 능동 면역",
                "인공 획득 수동 면역"
              ],
              "answerIndex": 2,
              "explanation": "예방 접종은 인위적으로 항원을 주입하여 신체 스스로 면역 반응을 일으키도록 유도하는 '인공 획득 능동 면역'에 해당합니다."
            },
            {
              "question": "면역학적 기억에서 '클래스 전환'은 무엇을 의미합니까?",
              "options": [
                "면역 세포의 종류가 바뀌는 것",
                "초기 IgM 반응이 다른 유형의 항체(IgG, IgE, IgA)로 바뀌는 것",
                "항체가 항원에 결합하는 방식이 바뀌는 것",
                "면역 반응의 강도가 약해지는 것"
              ],
              "answerIndex": 1,
              "explanation": "클래스 전환은 초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상을 말합니다."
            }
          ]
        },
        {
          "title": "면역학의 실제 적용: 백신",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 3538 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "백신 개요",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "면역학의 실제 적용 중 하나인 백신은 질병 예방에 있어 핵심적인 역할을 합니다. 백신의 역사는 천연두 접종법(Variolation)에서 시작되었는데, 이는 천연두를 피부에 접종하여 질병을 예방하는 방식이었습니다. 이후 제너(Jenner)는 우두를 접종하여 천연두를 예방하는 방법을 발견했습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "백신(Vaccine)이라는 용어는 파스퇴르(Pasteur)에 의해 만들어졌으며, 'vacca'(소)에서 유래했습니다. 백신은 면역을 유도하는 유기체 또는 유기체의 일부 현탁액으로 정의됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "백신의 기능 및 원리",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "백신 접종은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이는 실제 병원체에 노출되었을 때 빠르고 강렬한 이차 면역 반응을 생성하는 데 기여합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "집단 면역(Herd immunity)은 인구 대부분의 면역 상태를 의미하며, 감수성 있는 개체의 부족으로 질병 발생이 산발적으로 나타나게 하여 전염병 확산을 막는 중요한 효과를 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "CDC 권장 세균성 질환 백신",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "미국 질병통제예방센터(CDC)는 다양한 세균성 질환 예방을 위한 백신을 권장하고 있습니다. 이에는 헤모필루스 인플루엔자 b형 수막염, 수막구균성 수막염, 폐렴구균성 폐렴, 파상풍, 디프테리아, 백일해 백신 등이 포함됩니다. 각 백신은 특정 연령대 또는 위험군에 대한 권장 사항과 추가 접종 여부가 명시되어 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "CDC 권장 바이러스성 질환 백신",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "CDC는 또한 수두, A형 간염, B형 간염, 대상포진, 인유두종바이러스, 인플루엔자, 홍역, 유행성 이하선염, 소아마비, 광견병, 로타바이러스, 풍진, 천연두 등 다양한 바이러스성 질환 예방을 위한 백신을 권장하고 있습니다. 이들 백신 역시 접종 대상, 시기, 그리고 추가 접종의 필요성에 대한 구체적인 지침을 따릅니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "백신의 종류 및 특성",
              "level": 1
            },
            {
              "type": "heading",
              "content": "약독화 생백신 (Live attenuated vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "약독화 생백신은 약화된 병원체를 사용하여 실제 감염과 유사한 면역 반응을 유도하며, 평생 지속되는 세포성 및 체액성 면역을 부여합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "불활성화 사백신 (Inactivated killed vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "불활성화 사백신은 생백신보다 안전하지만, 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "서브유닛 백신 (Subunit vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "서브유닛 백신은 항원성 조각을 사용하여 면역 반응을 자극합니다. 유전적 변형을 통해 생산되는 서브유닛 백신을 재조합 백신(Recombinant vaccines)이라고 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "톡소이드 (Toxoids)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "톡소이드는 불활성화된 독소이며, 항독소(Antitoxins)는 독소에 대한 항체를 포함하는 혈청입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "VLP 백신은 온전한 바이러스와 유사하지만 바이러스 유전 물질을 포함하지 않습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "다당류 백신 (Polysaccharide vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "다당류 백신은 병원체의 캡슐 분자로 만들어지며 면역원성이 강하지 않습니다. 캡슐 다당류에 대한 면역 반응이 약한 어린이 질병에 사용되는 백신을 접합 백신(Conjugated vaccines)이라고 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "핵산(DNA) 백신은 DNA에 암호화된 단백질 항원을 생성하기 위해 주사된 DNA를 사용하며, 체액성 및 세포성 면역을 모두 자극합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "재조합 벡터 백신 (Recombinant vector vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "재조합 벡터 백신은 항원을 코딩하는 유전자를 전달하도록 유전적으로 변형된 비병원성 바이러스 또는 박테리아를 사용합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "RNA 백신 (RNA vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "RNA 백신은 새로운 유형의 백신으로, 특정 항원 단백질을 생산하도록 세포에 지시하는 RNA 서열을 사용합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "백신 생산, 전달 방법 및 제형",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "백신 개발은 동물 숙주를 사용하지 않는 방향으로 발전하고 있으며, 식물을 백신 공급원으로 활용하는 연구도 진행 중입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "경구 백신 및 건조 백신(피부 패치)의 개발이 증가하고 있으며, 나노패치(Nanopatch)는 건조 형태의 백신을 피부에 전달하여 냉장 보관이 필요 없으며 다수의 항원제시세포(APC)를 활용합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "다중 조합 백신, 만성 질환 백신 개발, 그리고 세포성 면역 개발을 위한 \"역 백신학(Reverse vaccinology)\" 연구도 활발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 미국에서는 명반(Alums)과 모노포스포릴 지질 A(monophosphoryl lipid A)만이 승인되어 있으며, 선천 면역 반응을 개선하는 역할을 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "마이크로바이옴과 경구 백신 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "젖산균인 비피도박테리움(Bifidobacterium)은 장내 마이크로바이옴의 정상적인 일부이며, 마이크로바이옴이 경구 백신에 대한 반응을 향상시킬 수 있다는 연구가 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "백신의 안전성",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "드물게 백신이 질병을 유발할 수 있지만, MMR 백신이 자폐증과 연관되어 있다는 의학적 또는 과학적 증거는 없습니다. 백신은 어린이의 감염성 질환을 예방하는 가장 안전하고 효과적인 수단으로 간주됩니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 백신의 역사적 배경, 기능, 다양한 종류, 생산 및 전달 방법, 그리고 안전성에 대해 설명합니다. 백신은 일차 면역 반응을 유도하여 항체와 기억 세포를 형성하고, 이를 통해 집단 면역을 구축하여 질병 확산을 막는 원리를 가지고 있습니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 여러 유형의 백신이 각자의 특성과 함께 소개되며, 아쥬반트의 역할과 백신 안전성에 대한 중요한 정보도 포함되어 있습니다.",
            "keyConcepts": [
              {
                "term": "집단 면역 (Herd Immunity)",
                "definition": "인구 대부분이 면역을 가지게 되어 감수성 개체의 부족으로 질병 발생이 산발적으로 나타나게 하는 현상으로, 전염병 확산을 막는 데 중요합니다."
              },
              {
                "term": "백신의 종류 (Types of Vaccines)",
                "definition": "약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 다양한 백신 유형이 있으며, 각각 다른 방식으로 면역 반응을 유도합니다."
              },
              {
                "term": "아쥬반트 (Adjuvants)",
                "definition": "백신의 효능을 높이고 면역 반응을 강화하기 위해 백신에 첨가되는 화학 물질입니다. 주로 선천 면역 반응을 개선하는 역할을 합니다."
              },
              {
                "term": "기억 세포 (Memory Cells)",
                "definition": "백신 접종 후 형성되는 면역 세포로, 실제 병원체에 재노출되었을 때 빠르고 강렬한 이차 면역 반응을 가능하게 하여 장기적인 면역력을 제공합니다."
              }
            ],
            "importantTerms": [
              {
                "term": "천연두 접종법 (Variolation)",
                "definition": "천연두를 피부에 접종하여 면역을 유도하던 초기 질병 예방 방법입니다."
              },
              {
                "term": "백신 접종 (Vaccination)",
                "definition": "면역을 유도하기 위해 유기체 또는 유기체의 일부를 현탁액 형태로 인체에 주입하는 행위를 말합니다."
              },
              {
                "term": "약독화 생백신 (Live Attenuated Vaccine)",
                "definition": "병원체를 약화시켜 만든 백신으로, 실제 감염과 유사한 면역 반응을 유도하며 세포성 및 체액성 면역을 부여합니다."
              },
              {
                "term": "불활성화 사백신 (Inactivated Killed Vaccine)",
                "definition": "죽은 병원체나 그 일부를 사용하여 만든 백신으로, 약독화 생백신보다 안전하지만 주로 체액성 면역을 유도하고 반복적인 추가 접종이 필요합니다."
              },
              {
                "term": "서브유닛 백신 (Subunit Vaccine)",
                "definition": "병원체의 특정 항원성 조각만을 사용하여 만든 백신으로, 면역 반응을 자극합니다."
              },
              {
                "term": "톡소이드 (Toxoid)",
                "definition": "독소의 독성을 제거하고 면역원성만 남긴 백신으로, 독소에 의해 발생하는 질병을 예방하는 데 사용됩니다."
              },
              {
                "term": "아쥬반트 (Adjuvant)",
                "definition": "백신의 면역 반응을 강화하기 위해 첨가되는 물질로, 백신의 효능을 높이고 선천 면역 반응을 개선합니다."
              }
            ],
            "outline": [
              {
                "text": "백신 개요",
                "id": "백신-개요",
                "children": [
                  {
                    "text": "백신의 역사",
                    "id": "백신의-역사",
                    "children": null
                  },
                  {
                    "text": "백신의 정의",
                    "id": "백신의-정의",
                    "children": null
                  }
                ]
              },
              {
                "text": "백신의 기능 및 원리",
                "id": "백신의-기능-및-원리",
                "children": [
                  {
                    "text": "면역 반응 유도",
                    "id": "면역-반응-유도",
                    "children": null
                  },
                  {
                    "text": "집단 면역",
                    "id": "집단-면역",
                    "children": null
                  }
                ]
              },
              {
                "text": "CDC 권장 백신",
                "id": "cdc-권장-백신",
                "children": [
                  {
                    "text": "세균성 질환 백신",
                    "id": "세균성-질환-백신",
                    "children": null
                  },
                  {
                    "text": "바이러스성 질환 백신",
                    "id": "바이러스성-질환-백신",
                    "children": null
                  }
                ]
              },
              {
                "text": "백신의 종류 및 특성",
                "id": "백신의-종류-및-특성",
                "children": [
                  {
                    "text": "약독화 생백신 (Live attenuated vaccines)",
                    "id": "약독화-생백신-live-attenuated-vaccines",
                    "children": null
                  },
                  {
                    "text": "불활성화 사백신 (Inactivated killed vaccines)",
                    "id": "불활성화-사백신-inactivated-killed-vaccines",
                    "children": null
                  },
                  {
                    "text": "서브유닛 백신 (Subunit vaccines)",
                    "id": "서브유닛-백신-subunit-vaccines",
                    "children": null
                  },
                  {
                    "text": "톡소이드 (Toxoids)",
                    "id": "톡소이드-toxoids",
                    "children": null
                  },
                  {
                    "text": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
                    "id": "바이러스-유사-입자-vlp-백신-virus-like-particle-vlp-vaccines",
                    "children": null
                  },
                  {
                    "text": "다당류 백신 (Polysaccharide vaccines)",
                    "id": "다당류-백신-polysaccharide-vaccines",
                    "children": null
                  },
                  {
                    "text": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
                    "id": "핵산-dna-백신-nucleic-acid-dna-vaccines",
                    "children": null
                  },
                  {
                    "text": "재조합 벡터 백신 (Recombinant vector vaccines)",
                    "id": "재조합-벡터-백신-recombinant-vector-vaccines",
                    "children": null
                  },
                  {
                    "text": "RNA 백신 (RNA vaccines)",
                    "id": "rna-백신-rna-vaccines",
                    "children": null
                  }
                ]
              },
              {
                "text": "백신 생산, 전달 방법 및 제형",
                "id": "백신-생산-전달-방법-및-제형",
                "children": [
                  {
                    "text": "생산 기술의 발전",
                    "id": "생산-기술의-발전",
                    "children": null
                  },
                  {
                    "text": "새로운 전달 방식",
                    "id": "새로운-전달-방식",
                    "children": null
                  },
                  {
                    "text": "아쥬반트의 역할",
                    "id": "아쥬반트의-역할",
                    "children": null
                  }
                ]
              },
              {
                "text": "마이크로바이옴과 경구 백신 반응",
                "id": "마이크로바이옴과-경구-백신-반응",
                "children": null
              },
              {
                "text": "백신의 안전성",
                "id": "백신의-안전성",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "백신 접종이 유도하는 주요 면역학적 반응은 무엇이며, 이 반응의 결과로 형성되는 중요한 세포는 무엇입니까?",
              "options": [
                "일차 면역 반응, 기억 세포",
                "이차 면역 반응, 비만 세포",
                "알레르기 반응, 형질 세포",
                "자가면역 반응, T 세포"
              ],
              "answerIndex": 0,
              "explanation": "백신은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이 기억 세포 덕분에 실제 병원체 노출 시 빠르고 강렬한 이차 면역 반응이 가능해집니다."
            },
            {
              "question": "다음 중 약독화 생백신과 불활성화 사백신의 주요 차이점에 대한 설명으로 올바른 것은 무엇입니까?",
              "options": [
                "약독화 생백신은 평생 면역을 부여하지만, 불활성화 사백신은 추가 접종이 필요하다.",
                "약독화 생백신은 주로 체액성 면역을 유도하고, 불활성화 사백신은 세포성 면역을 유도한다.",
                "약독화 생백신은 불활성화 사백신보다 안전하다.",
                "약독화 생백신은 유전 물질을 포함하지 않지만, 불활성화 사백신은 포함한다."
              ],
              "answerIndex": 0,
              "explanation": "약독화 생백신은 실제 감염과 유사하게 평생 지속되는 세포성 및 체액성 면역을 부여하는 경향이 있는 반면, 불활성화 사백신은 더 안전하지만 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다."
            },
            {
              "question": "백신에 첨가되어 효능을 향상시키고 선천 면역 반응을 개선하는 화학 첨가제는 무엇이라고 불립니까?",
              "options": [
                "항독소",
                "톡소이드",
                "아쥬반트",
                "폴리사카라이드"
              ],
              "answerIndex": 2,
              "explanation": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 선천 면역 반응을 개선하는 역할을 합니다."
            }
          ]
        },
        {
          "title": "면역학의 실제 적용: 진단 면역학",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 2187 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "진단 면역학 개요",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "민감도(Sensitivity): 검사가 진양성 표본에 대해 반응할 확률",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "특이도(Specificity): 양성 검사가 진음성 표본에 대해 반응하지 않을 확률",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역학 기반 진단 검사는 체액 항체와 항원의 상호작용을 이용한다. 알려진 항체를 통해 미지의 병원체를 식별하거나, 알려진 병원체를 통해 미지의 항체를 식별할 수 있다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "단일클론 항체 (Monoclonal Antibodies)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "하이브리도마(Hybridoma): \"불멸의\" 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합한 세포.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "하이브리도마는 단일클론 항체(Mabs)를 생산한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "Mabs는 균일하고, 특이성이 높으며, 대량 생산이 가능하다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "진단 도구 및 인체 치료에 사용된다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "류마티스 관절염에서 TNF를 중화하거나, 비만세포와 호염기구에 IgE 결합을 막아 알레르기성 천식을 치료하는 데 활용된다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "주로 쥐 세포에서 유래하여 부작용을 일으킬 수 있다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "키메라 단일클론 항체: 쥐의 가변 영역과 인간의 불변 영역을 가진 Mabs.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "인간화 항체: 쥐 항원 결합 부위를 제외하고 대부분 인간 유래인 Mabs.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "완전 인간 항체: 쥐에 삽입된 인간 유전자로부터 생산된 Mabs.",
              "level": null
            },
            {
              "type": "heading",
              "content": "단일클론 항체의 생산",
              "level": 2
            },
            {
              "type": "heading",
              "content": "침강 반응 (Precipitation Reactions)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "가용성 항원과 항체가 반응하여 격자(lattices)라고 불리는 크고 서로 맞물린 응집체를 형성하는 반응이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항원-항체 복합체가 형성된 후, 용액에서 침전되는 격자가 형성된다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "침강링 테스트(Precipitin ring test): 최적의 항원-항체 비율 지점에서 흐린 선이 형성된다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역확산 테스트(Immunodiffusion tests): 한천 젤 배지에서 수행되는 침강 반응이다. 최적의 항원-항체 비율 지점에서 침전물이 형성된다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역 전기영동(Immunoelectrophoresis): 전기영동과 면역확산을 결합한 것으로, 인간 혈청의 단백질을 분리한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "응집 반응 (Agglutination Reactions)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "입자성 항원이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "직접 응집 테스트(Direct agglutination tests): 큰 세포성 항원에 대한 항체를 검출한다. 혈청 항체 농도(역가, titer)를 측정하며, 역가 증가는 질병에 대한 더 큰 면역을 나타낸다. 혈청 전환(Seroconversion)은 질병이 진행됨에 따라 역가에 유의미한 변화가 나타나는 것을 의미한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "간접(수동) 응집 테스트(Indirect (passive) agglutination tests): 항체가 입자에 부착된 가용성 항원과 반응하거나 그 반대로 반응한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈구 응집(Hemagglutination): 적혈구 표면 항원과 보체 항체의 응집으로, 혈액형 판별에 사용된다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "진단 면역학 학습 목표 (1)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "응집 테스트와 침강 테스트의 차이점을 구별한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈구 응집을 정의한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "중화 테스트가 어떻게 작동하는지 설명한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "침강 테스트와 중화 테스트의 차이점을 구별한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "보체 고정 테스트의 기본 원리를 설명한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "중화 반응 (Neutralization Reactions)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "바이러스성 혈구 응집(Viral hemagglutination): 바이러스가 항원-항체 반응 없이 적혈구를 응집시키는 현상 (예: 볼거리, 홍역, 인플루엔자).",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항체(항독소)에 의해 외독소나 바이러스의 유해한 효과가 차단되는 항원-항체 반응이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스성 혈구 응집 억제 테스트(Viral hemagglutination inhibition test): 바이러스 아형을 분류하는 데 사용된다. 바이러스와 적혈구를 환자의 혈청과 혼합한다. 혈청에 바이러스에 대한 항체가 포함되어 있으면, 항체가 바이러스를 중화하여 혈구 응집을 억제한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체 고정 반응 (Complement-Fixation Reactions)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "보체 고정(Complement fixation): 보체 혈청 단백질이 항원-항체 복합체에 결합하고 고정되는 반응이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "소량의 항체를 검출할 수 있다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "침강 또는 응집 반응에 적합하지 않은 항체에도 사용될 수 있다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "진단 면역학 학습 목표 (2)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "직접 및 간접 형광 항체 테스트를 비교하고 대조한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "직접 및 간접 ELISA 테스트가 어떻게 작동하는지 설명한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "웨스턴 블롯이 어떻게 작동하는지 설명한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "단일클론 항체의 중요성을 설명한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "형광 염료를 항체와 결합시킨다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "직접 FA 테스트: 임상 검체에서 미생물을 식별한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "간접 FA 테스트: 혈청에서 특정 항체를 검출한다. 항인간 면역 혈청 글로불린(anti-HISG)을 추가하며, 결과가 양성이면 혈청 내 모든 항체와 반응한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "형광 활성화 세포 분류기(Fluorescence-activated cell sorter, FACS): 레이저 빔이 세포를 포함하는 액적에 닿으면, 감지기가 표면 분자의 크기와 형광을 측정한다. 세포에 전하를 부여하여 세포를 분리한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "효소결합 면역흡착 분석법 (ELISA)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "직접 ELISA: 항원을 검출한다. 항원을 포함하는 샘플을 항체와 혼합한다. 효소 연결 항체가 항원과 반응한다. 연결된 효소를 위한 기질을 추가하여 색이 생성되는 것으로 검출한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "간접 ELISA: 항체를 검출한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "웨스턴 블롯 (Western Blotting)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "전기영동과 블롯을 통해 단백질을 식별한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "진단 및 치료 면역학의 미래",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "인간의 판단과 인력이 덜 필요한 테스트가 개발될 것이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "PCR 및 DNA 프로브가 활용될 것이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "개발도상국을 위한 저렴하고 간단한 테스트가 필요하다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "질병 예방 및 치료에 기여할 것이다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 면역학의 실제 적용, 특히 진단 면역학에 대해 설명합니다. 검사의 민감도와 특이도 같은 기본 개념부터 시작하여, 단일클론 항체의 생산, 종류 및 치료적 활용에 대해 다룹니다. 또한, 침강 반응, 응집 반응, 중화 반응, 보체 고정 반응, 형광 항체 기법, ELISA, 웨스턴 블롯 등 다양한 면역학 기반 진단 테스트의 원리와 적용 방법을 상세히 설명합니다. 마지막으로 진단 및 치료 면역학의 미래 방향에 대해서도 간략하게 언급합니다.",
            "keyConcepts": [
              {
                "term": "진단 면역학의 기본 원리",
                "definition": "검사의 민감도(Sensitivity)와 특이도(Specificity)는 진단 검사의 정확성을 나타내는 핵심 지표이며, 항원-항체 상호작용이 면역학 기반 진단 테스트의 근간을 이룬다."
              },
              {
                "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                "definition": "하이브리도마 기술을 통해 대량 생산되는 균일하고 고도로 특이적인 항체로, 진단 및 류마티스 관절염, 알레르기성 천식 등 다양한 질병의 치료에 활용된다. 쥐 유래 항체는 부작용을 일으킬 수 있어 키메라, 인간화, 완전 인간 항체 등으로 발전하고 있다."
              },
              {
                "term": "면역 반응 기반 진단 테스트 유형",
                "definition": "침강(Precipitation), 응집(Agglutination), 중화(Neutralization), 보체 고정(Complement-Fixation), 형광 항체(Fluorescent-Antibody), ELISA(Enzyme-Linked Immunosorbent Assay), 웨스턴 블롯(Western Blotting) 등 항원-항체 반응을 시각적으로 또는 정량적으로 확인하여 질병을 진단하는 다양한 기법들이 있다."
              },
              {
                "term": "항체 역가 측정",
                "definition": "직접 응집 테스트 등을 통해 혈청 내 특정 항체의 농도(역가)를 측정하는 것으로, 역가 증가는 질병에 대한 면역력 증가를 나타내며, 혈청 전환은 질병 진행에 따른 역가의 유의미한 변화를 의미한다."
              }
            ],
            "importantTerms": [
              {
                "term": "민감도 (Sensitivity)",
                "definition": "검사가 진양성 표본에 대해 반응할 확률"
              },
              {
                "term": "특이도 (Specificity)",
                "definition": "양성 검사가 진음성 표본에 대해 반응하지 않을 확률"
              },
              {
                "term": "하이브리도마 (Hybridoma)",
                "definition": "암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포"
              },
              {
                "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                "definition": "하이브리도마에서 생산되는 균일하고 특이성이 높은 항체로, 진단 및 치료에 사용된다."
              },
              {
                "term": "침강 반응 (Precipitation Reactions)",
                "definition": "가용성 항원과 항체가 반응하여 불용성 복합체(격자)를 형성하고 침전되는 반응"
              },
              {
                "term": "응집 반응 (Agglutination Reactions)",
                "definition": "입자성 항원(예: 세포)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응"
              },
              {
                "term": "중화 반응 (Neutralization Reactions)",
                "definition": "항체가 독소나 바이러스의 유해한 효과를 차단하는 항원-항체 반응"
              },
              {
                "term": "보체 고정 반응 (Complement-Fixation Reactions)",
                "definition": "보체 단백질이 항원-항체 복합체에 결합하고 고정되는 반응으로, 소량의 항체도 검출 가능하다."
              },
              {
                "term": "효소결합 면역흡착 분석법 (ELISA)",
                "definition": "효소와 항체를 이용하여 항원 또는 항체를 검출하는 면역학적 분석법으로, 색 변화를 통해 결과를 확인한다."
              },
              {
                "term": "웨스턴 블롯 (Western Blotting)",
                "definition": "전기영동으로 분리된 단백질을 막에 옮겨 특정 항체를 이용하여 식별하는 기법"
              }
            ],
            "outline": [
              {
                "text": "진단 면역학 개요",
                "id": "진단-면역학-개요",
                "children": null
              },
              {
                "text": "단일클론 항체 (Monoclonal Antibodies)",
                "id": "단일클론-항체-monoclonal-antibodies",
                "children": [
                  {
                    "text": "단일클론 항체의 생산",
                    "id": "단일클론-항체의-생산",
                    "children": null
                  }
                ]
              },
              {
                "text": "침강 반응 (Precipitation Reactions)",
                "id": "침강-반응-precipitation-reactions",
                "children": null
              },
              {
                "text": "응집 반응 (Agglutination Reactions)",
                "id": "응집-반응-agglutination-reactions",
                "children": null
              },
              {
                "text": "진단 면역학 학습 목표 (1)",
                "id": "진단-면역학-학습-목표-1",
                "children": null
              },
              {
                "text": "중화 반응 (Neutralization Reactions)",
                "id": "중화-반응-neutralization-reactions",
                "children": null
              },
              {
                "text": "보체 고정 반응 (Complement-Fixation Reactions)",
                "id": "보체-고정-반응-complement-fixation-reactions",
                "children": null
              },
              {
                "text": "진단 면역학 학습 목표 (2)",
                "id": "진단-면역학-학습-목표-2",
                "children": null
              },
              {
                "text": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
                "id": "형광-항체-기법-fluorescent-antibody-techniques",
                "children": null
              },
              {
                "text": "효소결합 면역흡착 분석법 (ELISA)",
                "id": "효소결합-면역흡착-분석법-elisa",
                "children": null
              },
              {
                "text": "웨스턴 블롯 (Western Blotting)",
                "id": "웨스턴-블롯-western-blotting",
                "children": null
              },
              {
                "text": "진단 및 치료 면역학의 미래",
                "id": "진단-및-치료-면역학의-미래",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "다음 중 하이브리도마(Hybridoma)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
              "options": [
                "암성 B 세포와 항체 생산 정상 B 세포를 결합한 세포",
                "항원을 직접 생산하는 세포",
                "체내에서 바이러스성 감염을 중화하는 세포",
                "면역 반응을 억제하는 데 사용되는 세포"
              ],
              "answerIndex": 0,
              "explanation": "하이브리도마는 '불멸의' 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포입니다."
            },
            {
              "question": "침강 반응(Precipitation Reactions)과 응집 반응(Agglutination Reactions)의 주요 차이점은 무엇입니까?",
              "options": [
                "침강 반응은 가용성 항원을, 응집 반응은 입자성 항원을 사용한다.",
                "침강 반응은 항체를 검출하고, 응집 반응은 항원을 검출한다.",
                "침강 반응은 육안으로 볼 수 없지만, 응집 반응은 육안으로 볼 수 있다.",
                "침강 반응은 보체를 필요로 하지만, 응집 반응은 그렇지 않다."
              ],
              "answerIndex": 0,
              "explanation": "침강 반응은 가용성 항원과 항체의 상호작용으로 불용성 복합체가 형성되는 것이고, 응집 반응은 입자성 항원(예: 세포 또는 입자에 부착된 항원)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 것입니다."
            },
            {
              "question": "효소결합 면역흡착 분석법(ELISA)에 대한 설명으로 옳지 않은 것은 무엇입니까?",
              "options": [
                "직접 ELISA는 항원을 검출하는 데 사용된다.",
                "간접 ELISA는 항체를 검출하는 데 사용된다.",
                "효소 연결 항체가 항원 또는 항체와 반응하여 색 변화를 유도한다.",
                "ELISA는 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법이다."
              ],
              "answerIndex": 3,
              "explanation": "ELISA는 효소와 항체를 이용하여 항원 또는 항체를 검출하며 색 변화를 통해 결과를 확인합니다. 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법은 웨스턴 블롯(Western Blotting)입니다."
            }
          ]
        },
        {
          "title": "면역 시스템 관련 질환: 과민 반응",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 3760 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "과민 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "과민 반응(Hypersensitivity)은 정상 범위를 넘어선 과도한 항원(알레르겐) 반응을 의미합니다. 이는 이전에 항원에 노출되어 민감해진 경우에 발생합니다. 과민 반응은 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 유형으로 분류됩니다. 과민 반응을 연구하는 학문은 면역병리학(Immunopathology)이라고 합니다. 위생 가설(Hygiene hypothesis)은 병원균에 대한 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다고 제안합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "과민 반응의 유형",
              "level": 1
            },
            {
              "type": "heading",
              "content": "제1형 (아나필락시스형)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "임상 증상 발현까지 30분 미만이 소요됩니다. IgE 항체가 비만세포나 호염기구에 결합하여 비만세포 또는 호염기구의 탈과립을 유발하고 히스타민과 같은 반응성 물질을 방출하게 합니다. 약물 주사 및 곤충 독에 의한 아나필락시스 쇼크, 건초열, 천식과 같은 일반적인 알레르기 증상이 여기에 해당합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제2형 (세포 독성형)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "임상 증상 발현까지 5-12시간이 소요됩니다. 항원이 표적 세포에 결합하는 IgM 및 IgG 항체 형성을 유발하며, 보체의 작용과 결합하여 표적 세포를 파괴합니다. 수혈 반응, Rh 부적합성이 여기에 해당합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제3형 (면역 복합체형)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "임상 증상 발현까지 3-8시간이 소요됩니다. 항체와 항원이 복합체를 형성하여 손상적인 염증을 유발합니다. 아르투스 반응, 혈청병이 여기에 해당합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제4형 (지연형 세포 매개성 또는 지연형 과민 반응)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "임상 증상 발현까지 24-48시간이 소요됩니다. 항원이 세포독성 T 림프구(CTLs)를 활성화시켜 표적 세포를 사멸시킵니다. 이식 조직 거부 반응, 옻나무에 의한 접촉 피부염, 특정 만성 질환(예: 결핵) 등이 여기에 해당합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제1형 (아나필락시스형) 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "이 반응은 항원에 민감해진 사람이 해당 항원에 재노출된 후 수 분 내에 발생합니다. 항원이 IgE 항체와 결합하며, IgE는 비만세포와 호염기구에 부착됩니다. 비만세포와 호염기구는 탈과립을 겪으며 다음과 같은 매개체를 방출합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 히스타민: 혈액 모세혈관의 투과성을 증가시킵니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 류코트리엔: 평활근의 지속적인 수축을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 프로스타글란딘: 평활근에 영향을 미치고 점액 분비를 증가시킵니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항원에 반응하여 생성된 IgE 항체는 비만세포와 호염기구를 감싸게 됩니다. 항원이 동일한 특이성을 가진 두 개의 인접한 항체 분자 사이의 간격을 연결할 때, 세포는 탈과립을 겪고 히스타민 및 기타 매개체를 방출합니다. 이는 항원과 반응하여 히스타민 및 기타 반응성 매개체 과립을 방출한 탈과립 비만세포의 모습입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "전신 아나필락시스 (아나필락시스 쇼크)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "항원에 민감해진 개체가 다시 노출될 때 발생합니다. 순환계 허탈 및 사망에 이를 수 있으며, 에피네프린으로 치료합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "국소 아나필락시스",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "주로 섭취되거나 흡입된 항원과 관련이 있습니다. 증상은 침입 경로에 따라 다르며, 두드러기, 건초열, 천식 등이 포함됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "아나필락시스 반응 예방",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "알레르겐을 식별하기 위한 피부 검사는 항원을 표피 아래에 접종하여 빠른 염증 반응(팽진)을 확인합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "탈감작(Desensitization)은 항원을 피부 아래에 증가하는 용량으로 주사하는 방법입니다. 이는 IgG를 생성하게 하는데, 이 IgG는 블로킹 항체(blocking antibodies) 역할을 하여 항원을 가로채고 중화시킵니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제2형 (세포 독성형) 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "IgG 또는 IgM 항체와 항원성 세포의 결합에 의한 보체 활성화로 발생합니다. 이는 세포 용해 또는 대식세포에 의한 손상을 유발합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "ABO 혈액형 시스템",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "적혈구에 있는 특정 탄수화물 항원에 대해 항체가 형성됩니다. A 항원, B 항원 또는 둘 다를 가질 수 있습니다. O형 적혈구는 항원이 없습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "Rh 혈액형 시스템",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "인구의 85%에서 적혈구에 Rh 인자 항원(Rh+)이 발견됩니다. Rh+ 혈액이 Rh- 수혈자에게 주입되면 수혈자의 몸에서 항Rh 항체 생성을 자극합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "용혈성 신생아 질환 (HDNB)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "Rh- 어머니가 Rh+ 태아를 임신할 경우 어머니의 몸에서 항Rh 항체가 생성됩니다. 첫 Rh+ 태아를 임신한 Rh- 어머니의 경우, 분만 중 태아의 Rh 항원이 어머니의 혈액으로 들어갈 수 있습니다. 이 태아 Rh 항원에 반응하여 어머니는 항Rh 항체를 생산할 것입니다. 두 번째 Rh+ 태아를 임신하게 되면, 어머니의 항Rh 항체가 태반을 통과하여 태아의 적혈구를 손상시킬 것입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "약물 유발 세포 독성 반응",
              "level": 2
            },
            {
              "type": "heading",
              "content": "혈소판 감소성 자반증 (Thrombocytopenic purpura)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "혈소판이 약물과 결합하여 항원성 복합체를 형성합니다. 항체와 보체가 혈소판을 파괴합니다. 약물(합텐)이 혈소판에 결합하여 합텐-혈소판 복합체를 형성합니다. 이 복합체는 합텐에 대한 항체 형성을 유도합니다. 항체와 보체의 작용은 혈소판 파괴를 일으킵s니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "무과립구증 (Agranulocytosis)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "약물 유발 과립구의 면역 파괴입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "용혈성 빈혈 (Hemolytic anemia)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "약물 유발 적혈구의 면역 파괴입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제3형 (면역 복합체형) 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "항체가 혈청 내 가용성 항원에 대해 형성됩니다. 세포 아래 기저막에 침착되는 면역 복합체를 형성하여 보체를 활성화시키고 염증을 유발합니다. 면역 복합체는 혈관벽에 침착됩니다. 면역 복합체의 존재는 보체를 활성화시키고 호중구와 같은 염증 세포를 유인합니다. 호중구에서 방출된 효소는 기저막의 내피 세포에 손상을 입힙니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "아르투스 반응 (Arthus reaction)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "톡소이드 함유 백신의 드문 부작용입니다. 주사된 항원에 대해 이미 순환하는 IgG를 가진 환자에서 보체 활성화로 인해 사구체 및 기타 혈관벽에서 발생합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "혈청병 (Serum sickness)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "이종 혈청 주입으로 인한 부종 및 염증과 함께 발생할 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제4형 (지연형 세포 매개성) 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "T 세포에 의해 유발되는 세포 매개 면역 반응입니다. 이는 지연형 과민 반응으로 알려져 있습니다. 항원은 식세포화되어 T 세포 수용체에 제시되어 민감화를 유발합니다. 항원에 재노출되면 기억 세포가 파괴적인 사이토카인을 방출합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "알레르기성 접촉 피부염 (Allergic contact dermatitis)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "합텐이 피부의 단백질과 결합하여 면역 반응을 일으킵니다. 옻나무, 화장품, 금속, 라텍스 등에 대한 알레르기 반응이 여기에 해당합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "본문은 면역 시스템 관련 질환 중 '과민 반응'에 대해 설명합니다. 과민 반응은 정상 범위를 넘어선 과도한 면역 반응으로, 이전 항원 노출로 인해 민감해진 상태에서 발생합니다. 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 주요 유형으로 분류되며, 각 유형은 발현 시간, 기전, 임상 증상 및 예시가 다릅니다. 제1형은 즉각적인 알레르기 반응(예: 아나필락시스 쇼크)을, 제2형은 세포 파괴(예: 수혈 부작용)를, 제3형은 면역 복합체 침착으로 인한 염증(예: 혈청병)을, 제4형은 T세포 매개 지연 반응(예: 접촉 피부염)을 특징으로 합니다. 각 유형의 발생 기전과 예방 및 치료법이 상세히 다루어집니다.",
            "keyConcepts": [
              {
                "term": "과민 반응 (Hypersensitivity)",
                "definition": "정상 범위를 넘어선 과도한 항원 반응으로, 이전에 항원에 노출되어 민감해진 경우에 발생합니다."
              },
              {
                "term": "아나필락시스 (Anaphylaxis)",
                "definition": "제1형 과민 반응의 심각한 형태로, 비만세포 및 호염기구의 탈과립으로 인한 매개체 방출로 발생하며, 전신 또는 국소적으로 나타나 생명을 위협할 수 있습니다."
              },
              {
                "term": "위생 가설 (Hygiene Hypothesis)",
                "definition": "병원균 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다는 가설입니다."
              },
              {
                "term": "탈감작 (Desensitization)",
                "definition": "알레르기 반응을 예방하기 위해 항원을 점진적으로 증가시켜 주사하는 치료법으로, 블로킹 항체(IgG) 생성을 유도하여 알레르겐을 중화시킵니다."
              },
              {
                "term": "용혈성 신생아 질환 (HDNB)",
                "definition": "Rh 혈액형 불일치로 인해 Rh- 어머니가 Rh+ 태아에 대한 항체를 생성하여 두 번째 Rh+ 태아의 적혈구를 파괴하는 질환입니다."
              }
            ],
            "importantTerms": [
              {
                "term": "알레르겐 (Allergen)",
                "definition": "알레르기 반응을 유발하는 항원입니다."
              },
              {
                "term": "면역병리학 (Immunopathology)",
                "definition": "과민 반응을 연구하는 학문입니다."
              },
              {
                "term": "히스타민 (Histamine)",
                "definition": "제1형 과민 반응 시 비만세포에서 방출되어 혈관 투과성을 증가시키는 주요 염증 매개체입니다."
              },
              {
                "term": "류코트리엔 (Leukotrienes)",
                "definition": "제1형 과민 반응 시 방출되어 평활근의 지속적인 수축을 유발하는 매개체입니다."
              },
              {
                "term": "프로스타글란딘 (Prostaglandins)",
                "definition": "제1형 과민 반응 시 방출되어 평활근에 영향을 미치고 점액 분비를 증가시키는 매개체입니다."
              },
              {
                "term": "보체 (Complement)",
                "definition": "면역 반응에서 항체와 함께 작용하여 세포 파괴를 돕는 단백질 시스템입니다."
              },
              {
                "term": "합텐 (Hapten)",
                "definition": "단독으로는 면역 반응을 유발하지 못하지만, 단백질과 결합 시 항원성을 띠는 작은 분자입니다."
              }
            ],
            "outline": [
              {
                "text": "과민 반응의 개요",
                "id": "hypersensitivity-overview",
                "children": [
                  {
                    "text": "정의 및 특징",
                    "id": "definition-features",
                    "children": null
                  },
                  {
                    "text": "과민 반응의 네 가지 유형",
                    "id": "four-types-hypersensitivity",
                    "children": null
                  },
                  {
                    "text": "면역병리학 및 위생 가설",
                    "id": "immunopathology-hygiene-hypothesis",
                    "children": null
                  }
                ]
              },
              {
                "text": "과민 반응 유형별 상세 설명",
                "id": "detailed-hypersensitivity-types",
                "children": [
                  {
                    "text": "제1형 과민 반응 (아나필락시스형)",
                    "id": "type-i-anaphylactic",
                    "children": [
                      {
                        "text": "발생 기전 및 특징",
                        "id": "type-i-mechanism-features",
                        "children": null
                      },
                      {
                        "text": "매개체 (히스타민, 류코트리엔, 프로스타글란딘)",
                        "id": "type-i-mediators",
                        "children": null
                      },
                      {
                        "text": "전신 아나필락시스 및 국소 아나필락시스",
                        "id": "systemic-local-anaphylaxis",
                        "children": null
                      },
                      {
                        "text": "예방 및 치료",
                        "id": "type-i-prevention-treatment",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "제2형 과민 반응 (세포 독성형)",
                    "id": "type-ii-cytotoxic",
                    "children": [
                      {
                        "text": "발생 기전 및 특징",
                        "id": "type-ii-mechanism-features",
                        "children": null
                      },
                      {
                        "text": "ABO 혈액형 시스템",
                        "id": "abo-blood-group",
                        "children": null
                      },
                      {
                        "text": "Rh 혈액형 시스템 및 용혈성 신생아 질환",
                        "id": "rh-blood-group-hdnb",
                        "children": null
                      },
                      {
                        "text": "약물 유발 세포 독성 반응",
                        "id": "drug-induced-cytotoxic",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "제3형 과민 반응 (면역 복합체형)",
                    "id": "type-iii-immune-complex",
                    "children": [
                      {
                        "text": "발생 기전 및 특징",
                        "id": "type-iii-mechanism-features",
                        "children": null
                      },
                      {
                        "text": "아르투스 반응",
                        "id": "arthus-reaction",
                        "children": null
                      },
                      {
                        "text": "혈청병",
                        "id": "serum-sickness",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "제4형 과민 반응 (지연형 세포 매개성)",
                    "id": "type-iv-delayed-cell-mediated",
                    "children": [
                      {
                        "text": "발생 기전 및 특징",
                        "id": "type-iv-mechanism-features",
                        "children": null
                      },
                      {
                        "text": "알레르기성 접촉 피부염",
                        "id": "allergic-contact-dermatitis",
                        "children": null
                      }
                    ]
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "제1형 과민 반응 시 혈액 모세혈관의 투과성을 증가시키는 주요 매개체는 무엇입니까?",
              "options": [
                "히스타민",
                "류코트리엔",
                "프로스타글란딘",
                "사이토카인"
              ],
              "answerIndex": 0,
              "explanation": "제1형 과민 반응은 비만세포의 탈과립을 통해 히스타민을 방출하며, 히스타민은 혈액 모세혈관의 투과성을 증가시키는 역할을 합니다."
            },
            {
              "question": "이식 조직 거부 반응 및 접촉 피부염과 주로 관련된 과민 반응 유형은 무엇입니까?",
              "options": [
                "제1형 (아나필락시스형)",
                "제2형 (세포 독성형)",
                "제3형 (면역 복합체형)",
                "제4형 (지연형 세포 매개성)"
              ],
              "answerIndex": 3,
              "explanation": "제4형 과민 반응은 T세포에 의해 매개되는 지연형 반응으로, 이식 조직 거부 반응과 접촉 피부염이 대표적인 예시입니다."
            },
            {
              "question": "아나필락시스 반응 예방을 위한 탈감작의 주요 기전은 무엇입니까?",
              "options": [
                "히스타민 방출 억제",
                "IgE 항체 생성 촉진",
                "비만세포 탈과립 유도",
                "IgG 블로킹 항체 생성"
              ],
              "answerIndex": 3,
              "explanation": "탈감작은 증가하는 용량의 항원 주사를 통해 IgG 블로킹 항체를 생성하게 하여, 이 항체가 알레르겐을 가로채고 중화시켜 IgE 매개 반응을 예방합니다."
            }
          ]
        },
        {
          "title": "자가면역 질환의 이해: 유형 및 주요 사례",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1640 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "자가면역 질환 (AUTOIMMUNE DISEASES)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "면역 체계가 자가 항원에 반응하여 장기에 손상을 입히는 질환입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "자가면역은 자가 관용(self-tolerance)의 상실을 의미합니다. 이는 면역 체계가 자신과 비자신을 구별하는 능력을 잃어버릴 때 발생합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "자가면역 반응은 세포독성(Cytotoxic), 면역 복합체(Immune complex), 또는 세포 매개성(Cell-mediated)의 형태로 나타날 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포독성 자가면역 반응 (CYTOTOXIC AUTOIMMUNE REACTIONS)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "항체가 세포 표면 항원과 반응하여 세포를 손상시키거나 기능을 방해하는 유형입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "다발성 경화증 (Multiple sclerosis)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "자가항체, T 세포, 그리고 대식세포가 신경의 미엘린 수초를 공격하여 신경 임펄스 전달을 손상시킵니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "증상은 피로와 쇠약부터 심한 마비에 이릅니다. 원인은 알려지지 않았지만, 유전적 취약성 및/또는 감염성 물질과 관련될 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "그레이브스병 (Graves' disease)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "갑상선 내 비정상 항체가 과도한 양의 호르몬을 생성하게 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "중증 근무력증 (Myasthenia gravis)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "항체가 아세틸콜린 수용체를 코팅하여 근육이 신경 신호를 받지 못하게 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역 복합체 자가면역 반응 (IMMUNE COMPLEX AUTOIMMUNE REACTIONS)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "항체와 보체의 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "전신성 홍반성 루푸스 (Systemic lupus erythematosus)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "신장 사구체에 면역 복합체가 형성됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "류마티스 관절염 (Rheumatoid arthritis)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "관절에 면역 복합체가 형성됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포 매개성 자가면역 반응 (CELL-MEDIATED AUTOIMMUNE REACTIONS)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "조직을 공격하는 T 세포에 의해 매개되는 유형입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "인슐린 의존성 당뇨병 (Insulin-dependent diabetes mellitus, 1형 당뇨병)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "T 세포가 인슐린 분비 세포를 파괴합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "건선 및 건선성 관절염 (Psoriasis and psoriatic arthritis)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "피부의 자가면역 질환입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "주요 자가면역 질환 및 원인 (SELECTED AUTOIMMUNE DISORDERS)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "다음은 몇 가지 주요 자가면역 질환과 가능한 원인입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "만성 피로 증후군: 신경 세포의 아세틸콜린 수용체에 항체가 부착되어 발생할 수 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "류마티스 관절염: 연쇄상구균 항체에 대한 교차 반응.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "전신성 홍반성 루푸스: DNA에 대한 항체를 포함하는 면역 복합체.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "다발성 경화증: T 세포와 대식세포가 미엘린 수초를 공격.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1형 당뇨병: T 세포가 인슐린 분비 세포를 파괴.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "길랑-바레 증후군: T 세포가 신경 세포의 미엘린 수초 파괴를 유발하는 사이토카인을 생성.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "건선: T 세포가 각질 형성 세포(피부 세포) 성장을 유도할 수 있는 사이토카인을 생성.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그레이브스병: 갑상선 특정 수용체에 부착된 항체가 갑상선을 비대하게 하고 과도한 호르몬을 생성하게 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "중증 근무력증: 아세틸콜린 수용체에 대한 항체.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "크론병: 항균 항체가 장 점막과 반응.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "염증성 장 질환: 항균 항체가 장 점막과 반응.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "자가면역 질환은 면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 상태입니다. 이는 자가 관용의 상실로 인해 발생하며, 세포독성, 면역 복합체, 세포 매개성 반응의 세 가지 주요 유형으로 분류될 수 있습니다. 각 유형은 특정 질병과 관련이 있으며, 신경, 갑상선, 관절, 췌장 등 다양한 장기에 영향을 미칩니다. 주요 자가면역 질환으로는 다발성 경화증, 그레이브스병, 중증 근무력증, 전신성 홍반성 루푸스, 류마티스 관절염, 1형 당뇨병, 건선 등이 있으며, 각 질환의 원인과 면역학적 메커니즘이 설명됩니다.",
            "keyConcepts": [
              {
                "term": "자가면역",
                "definition": {
                  "easy": null,
                  "medium": "면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 현상입니다.",
                  "hard": null
                }
              },
              {
                "term": "자가 관용",
                "definition": {
                  "easy": null,
                  "medium": "면역 체계가 자신의 항원에 반응하지 않고 구별하는 능력입니다. 자가면역 질환은 이 자가 관용의 상실로 발생합니다.",
                  "hard": null
                }
              },
              {
                "term": "세포독성 자가면역 반응",
                "definition": {
                  "easy": null,
                  "medium": "항체가 세포 표면 항원과 반응하여 세포를 파괴하거나 기능을 손상시키는 유형의 자가면역 반응입니다. (예: 다발성 경화증, 그레이브스병, 중증 근무력증)",
                  "hard": null
                }
              },
              {
                "term": "면역 복합체 자가면역 반응",
                "definition": {
                  "easy": null,
                  "medium": "항체와 항원이 결합하여 형성된 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형의 자가면역 반응입니다. (예: 전신성 홍반성 루푸스, 류마티스 관절염)",
                  "hard": null
                }
              },
              {
                "term": "세포 매개성 자가면역 반응",
                "definition": {
                  "easy": null,
                  "medium": "T 세포가 직접 조직을 공격하여 손상을 일으키는 유형의 자가면역 반응입니다. (예: 1형 당뇨병, 건선)",
                  "hard": null
                }
              }
            ],
            "importantTerms": [
              {
                "term": "자가 항원",
                "definition": "자신의 신체에 존재하는 항원으로, 면역 체계가 실수로 공격하는 대상이 됩니다."
              },
              {
                "term": "미엘린 수초",
                "definition": "신경 세포를 둘러싸고 있는 절연성 막으로, 손상 시 신경 신호 전달에 문제가 발생합니다."
              },
              {
                "term": "아세틸콜린 수용체",
                "definition": "신경 전달 물질인 아세틸콜린이 결합하는 근육 세포 표면의 단백질로, 중증 근무력증에서 항체에 의해 기능이 저해됩니다."
              },
              {
                "term": "면역 복합체",
                "definition": "항체와 항원이 결합하여 형성된 복합체로, 특정 조직에 침착되어 염증을 유발할 수 있습니다."
              },
              {
                "term": "T 세포",
                "definition": "세포 매개 면역 반응을 담당하는 림프구의 일종으로, 일부 자가면역 질환에서 직접 조직을 공격합니다."
              },
              {
                "term": "사구체",
                "definition": "신장의 혈액 여과 단위로, 전신성 홍반성 루푸스에서 면역 복합체가 형성되는 주요 부위입니다."
              },
              {
                "term": "사이토카인",
                "definition": "면역 세포 간의 신호 전달에 관여하는 단백질로, 일부 자가면역 질환에서 조직 손상을 유발할 수 있습니다."
              }
            ],
            "outline": [
              {
                "text": "자가면역 질환 개요",
                "id": "autoimmune-diseases-overview",
                "children": [
                  {
                    "text": "자가면역의 정의 및 특징",
                    "id": "definition-and-characteristics-of-autoimmunity",
                    "children": null
                  },
                  {
                    "text": "주요 반응 유형",
                    "id": "main-types-of-reactions",
                    "children": null
                  }
                ]
              },
              {
                "text": "세포독성 자가면역 반응",
                "id": "cytotoxic-autoimmune-reactions",
                "children": [
                  {
                    "text": "다발성 경화증",
                    "id": "multiple-sclerosis",
                    "children": null
                  },
                  {
                    "text": "그레이브스병",
                    "id": "graves-disease",
                    "children": null
                  },
                  {
                    "text": "중증 근무력증",
                    "id": "myasthenia-gravis",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역 복합체 자가면역 반응",
                "id": "immune-complex-autoimmune-reactions",
                "children": [
                  {
                    "text": "전신성 홍반성 루푸스",
                    "id": "systemic-lupus-erythematosus",
                    "children": null
                  },
                  {
                    "text": "류마티스 관절염",
                    "id": "rheumatoid-arthritis",
                    "children": null
                  }
                ]
              },
              {
                "text": "세포 매개성 자가면역 반응",
                "id": "cell-mediated-autoimmune-reactions",
                "children": [
                  {
                    "text": "인슐린 의존성 당뇨병 (1형 당뇨병)",
                    "id": "insulin-dependent-diabetes-mellitus-type-1",
                    "children": null
                  },
                  {
                    "text": "건선 및 건선성 관절염",
                    "id": "psoriasis-and-psoriatic-arthritis",
                    "children": null
                  }
                ]
              },
              {
                "text": "주요 자가면역 질환 및 원인",
                "id": "selected-autoimmune-disorders-and-causes",
                "children": [
                  {
                    "text": "만성 피로 증후군",
                    "id": "chronic-fatigue-syndrome",
                    "children": null
                  },
                  {
                    "text": "류마티스 관절염",
                    "id": "rheumatoid-arthritis-cause",
                    "children": null
                  },
                  {
                    "text": "전신성 홍반성 루푸스",
                    "id": "systemic-lupus-erythematosus-cause",
                    "children": null
                  },
                  {
                    "text": "다발성 경화증",
                    "id": "multiple-sclerosis-cause",
                    "children": null
                  },
                  {
                    "text": "1형 당뇨병",
                    "id": "type-1-diabetes-cause",
                    "children": null
                  },
                  {
                    "text": "길랑-바레 증후군",
                    "id": "guillain-barre-syndrome",
                    "children": null
                  },
                  {
                    "text": "건선",
                    "id": "psoriasis-cause",
                    "children": null
                  },
                  {
                    "text": "그레이브스병",
                    "id": "graves-disease-cause",
                    "children": null
                  },
                  {
                    "text": "중증 근무력증",
                    "id": "myasthenia-gravis-cause",
                    "children": null
                  },
                  {
                    "text": "크론병",
                    "id": "crohns-disease",
                    "children": null
                  },
                  {
                    "text": "염증성 장 질환",
                    "id": "inflammatory-bowel-disease",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "자가면역 질환에서 면역 체계가 공격하는 대상은 무엇입니까?",
              "options": [
                "외부 병원체",
                "알레르기 유발 물질",
                "자가 항원",
                "독성 물질"
              ],
              "answerIndex": 2,
              "explanation": "자가면역 질환은 면역 체계가 자신의 신체 조직, 즉 자가 항원을 외부 침입자로 오인하여 공격하는 상태입니다."
            },
            {
              "question": "다음 중 세포독성 자가면역 반응에 해당하는 질환이 아닌 것은 무엇입니까?",
              "options": [
                "다발성 경화증",
                "그레이브스병",
                "중증 근무력증",
                "류마티스 관절염"
              ],
              "answerIndex": 3,
              "explanation": "류마티스 관절염은 면역 복합체가 관절에 형성되어 발생하는 면역 복합체 자가면역 반응에 해당합니다. 다발성 경화증, 그레이브스병, 중증 근무력증은 세포독성 자가면역 반응의 예시입니다."
            },
            {
              "question": "1형 당뇨병(인슐린 의존성 당뇨병)의 주요 원인으로 설명된 면역 반응은 무엇입니까?",
              "options": [
                "항체에 의한 아세틸콜린 수용체 코팅",
                "면역 복합체의 신장 사구체 침착",
                "T 세포에 의한 인슐린 분비 세포 파괴",
                "갑상선 항체의 과도한 호르몬 생성 유발"
              ],
              "answerIndex": 2,
              "explanation": "1형 당뇨병은 T 세포가 인슐린을 분비하는 췌장의 세포를 파괴하여 발생하는 세포 매개성 자가면역 반응입니다."
            }
          ]
        },
        {
          "title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1848 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "인간 백혈구 항원(HLA) 복합체 관련 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "조직적합성 항원(Histocompatibility antigens): 세포 표면에 존재하는 자가 항원입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "주요 조직적합성 복합체(MHC): 조직적합성 항원을 암호화하는 유전자입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "인간 백혈구 항원(HLA) 복합체: 인간의 MHC 유전자입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "특정 HLA는 특정 질병에 대한 감수성 증가와 관련이 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HLA 타이핑 및 이식 수술",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "HLA 타이핑은 HLA를 식별하고 비교하는 과정입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이식 수술에서 공여자와 수혜자는 조직 타이핑을 통해 일치해야 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "표준화된 항혈청 또는 HLA에 특이적인 단일클론 항체를 사용합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HLA 타이핑 과정: 검사 중인 림프구에 항-HLA 항체가 부착됩니다. 보체와 트립판 블루 염료가 추가되면, 보체에 의해 손상된 세포가 염료를 흡수합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역 특권 부위 및 면역 특권 조직",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "이식편은 T 세포, 대식세포, 그리고 보체 고정 항체에 의해 공격받을 수 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역 특권 부위 및 면역 특권 조직으로의 이식은 면역 반응을 일으키지 않습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "예시로는 각막 이식, 심장 판막 이식이 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "줄기세포",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "줄기세포는 여러 다른 세포 유형을 생성할 수 있는 마스터 세포입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "배아 줄기세포(ESCs)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "배반포에서 채취되며, 조직과 장기를 재생하는 데 사용됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "다능성(Pluripotent)으로, 모든 종류의 세포를 생성할 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "성체 줄기세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "분화된 성체 조직에 있는 줄기세포입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "유전자 도입을 통해 유도만능줄기세포(induced pluripotent stem cells)가 될 수 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "줄기세포 배양 과정: (1일) 일반적으로 시험관 아기 시술에서 폐기된 수정란인 배아가 사용됩니다. (1-5일) 배아는 반복적으로 분열하여 속이 빈 세포 덩어리인 배반포 단계를 형성합니다. 배아줄기세포는 배반포의 속세포덩어리에서 채취되어 배양 배지의 피더(feeder) 세포 위에서 성장합니다. 줄기세포주와 줄기세포 그룹은 배양 배지에서 콜로니를 형성합니다. 다양한 조건과 배양 배지에 추가된 성장 인자는 줄기세포가 신체의 다양한 조직(예: 혈액 및 림프 세포, 췌장 섬 세포, 신경 세포)을 위한 줄기세포주가 되도록 유도합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "골수 이식",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "조혈모세포 이식으로도 알려져 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "수혜자가 건강한 혈액 세포를 생산할 수 있도록 하는 것이 목표입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역능력 있는 세포를 포함하는 이식된 골수로 인해 이식편대숙주병(Graft-versus-host, GVH)이 발생할 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "이식편(Grafts)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "자가이식(Autograft): 자신의 조직을 사용하는 것입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "동계이식(Isograft): 일란성 쌍둥이의 조직을 사용하는 것입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "동종이식(Allografts): 다른 사람의 조직을 사용하는 것입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이종이식(Xenotransplantation product): 비인간 조직을 사용하는 것입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "비인간 항원에 대한 반응인 초급성 거부 반응을 극복해야 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "이식 거부 반응 방지를 위한 면역 억제",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "이식된 조직에 대한 세포 매개 면역 반응을 방지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사이클로스포린(Cyclosporine)과 타크로리무스(tacrolimus)는 IL-2를 억제하여 세포독성 T 세포를 방해합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "시롤리무스(Sirolimus)는 세포성 및 체액성 면역을 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "마이코페놀레이트(Mycophenolate)는 T 세포와 B 세포의 증식을 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바실리시맙(Basiliximab)은 IL-2를 차단하는 키메라 단일클론 항체입니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "제공된 텍스트는 인간 백혈구 항원(HLA) 복합체의 역할과 이식 면역학에서 이의 중요성을 설명합니다. HLA 타이핑을 통한 조직 일치의 필요성, 면역 반응을 일으키지 않는 면역 특권 부위, 그리고 배아 및 성체 줄기세포의 종류와 활용에 대해 다룹니다. 또한, 자가이식, 동계이식, 동종이식, 이종이식과 같은 다양한 이식편의 유형과 이식편대숙주병(GVH)과 같은 이식 관련 합병증을 설명합니다. 마지막으로, 이식 거부 반응을 방지하기 위한 사이클로스포린, 타크로리무스, 시롤리무스, 마이코페놀레이트, 바실리시맙 등 주요 면역 억제제와 그 작용 기전을 소개합니다.",
            "keyConcepts": [
              {
                "term": "인간 백혈구 항원(HLA) 복합체",
                "definition": "인간의 주요 조직적합성 복합체(MHC) 유전자로, 이식 수술에서 조직 일치에 결정적인 역할을 하며 특정 질병 감수성과 관련이 있습니다."
              },
              {
                "term": "줄기세포",
                "definition": "다양한 세포 유형으로 분화할 수 있는 마스터 세포로, 배아 줄기세포와 성체 줄기세포로 나뉩니다. 조직 재생 및 치료에 잠재적으로 활용됩니다."
              },
              {
                "term": "이식편의 종류",
                "definition": "조직의 출처에 따라 자가이식(자신의 조직), 동계이식(일란성 쌍둥이), 동종이식(다른 사람), 이종이식(비인간 조직)으로 분류됩니다."
              },
              {
                "term": "이식 거부 반응 및 GVH 질환",
                "definition": "이식된 조직에 대한 수혜자의 면역 반응(이식 거부 반응) 또는 이식된 면역 세포가 수혜자의 조직을 공격하는 현상(이식편대숙주병)입니다."
              },
              {
                "term": "면역 억제",
                "definition": "이식 거부 반응을 방지하기 위해 특정 약물을 사용하여 수혜자의 면역 반응을 억제하는 치료법입니다."
              }
            ],
            "importantTerms": [
              {
                "term": "조직적합성 항원",
                "definition": "세포 표면에 존재하는 자가 항원입니다."
              },
              {
                "term": "주요 조직적합성 복합체(MHC)",
                "definition": "조직적합성 항원을 암호화하는 유전자입니다."
              },
              {
                "term": "인간 백혈구 항원(HLA) 복합체",
                "definition": "인간의 MHC 유전자입니다."
              },
              {
                "term": "면역 특권 부위",
                "definition": "이식 시 면역 반응을 일으키지 않는 신체 부위 또는 조직입니다."
              },
              {
                "term": "이식편대숙주병(GVH)",
                "definition": "이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격하는 질환입니다."
              },
              {
                "term": "자가이식",
                "definition": "자신의 조직을 사용하는 이식 방법입니다."
              },
              {
                "term": "면역 억제제",
                "definition": "이식 거부 반응을 방지하기 위해 면역 반응을 억제하는 약물입니다."
              }
            ],
            "outline": [
              {
                "text": "인간 백혈구 항원(HLA) 복합체 관련 반응",
                "id": "인간-백혈구-항원-hla-복합체-관련-반응",
                "children": [
                  {
                    "text": "조직적합성 항원",
                    "id": "조직적합성-항원",
                    "children": null
                  },
                  {
                    "text": "주요 조직적합성 복합체(MHC)",
                    "id": "주요-조직적합성-복합체-mhc",
                    "children": null
                  },
                  {
                    "text": "인간 백혈구 항원(HLA) 복합체",
                    "id": "인간-백혈구-항원-hla-복합체",
                    "children": null
                  },
                  {
                    "text": "특정 질병에 대한 감수성",
                    "id": "특정-질병에-대한-감수성",
                    "children": null
                  }
                ]
              },
              {
                "text": "HLA 타이핑 및 이식 수술",
                "id": "hla-타이핑-및-이식-수술",
                "children": [
                  {
                    "text": "HLA 타이핑의 역할",
                    "id": "hla-타이핑의-역할",
                    "children": null
                  },
                  {
                    "text": "조직 타이핑의 중요성",
                    "id": "조직-타이핑의-중요성",
                    "children": null
                  },
                  {
                    "text": "HLA 타이핑 과정",
                    "id": "hla-타이핑-과정",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역 특권 부위 및 면역 특권 조직",
                "id": "면역-특권-부위-및-면역-특권-조직",
                "children": [
                  {
                    "text": "이식 거부 반응의 메커니즘",
                    "id": "이식-거부-반응의-메커니즘",
                    "children": null
                  },
                  {
                    "text": "면역 특권 부위의 특징",
                    "id": "면역-특권-부위의-특징",
                    "children": null
                  },
                  {
                    "text": "예시: 각막 이식, 심장 판막 이식",
                    "id": "예시-각막-이식-심장-판막-이식",
                    "children": null
                  }
                ]
              },
              {
                "text": "줄기세포",
                "id": "줄기세포",
                "children": [
                  {
                    "text": "줄기세포의 정의",
                    "id": "줄기세포의-정의",
                    "children": null
                  },
                  {
                    "text": "배아 줄기세포(ESCs)",
                    "id": "배아-줄기세포-escs",
                    "children": null
                  },
                  {
                    "text": "성체 줄기세포",
                    "id": "성체-줄기세포",
                    "children": null
                  },
                  {
                    "text": "줄기세포 배양 및 분화",
                    "id": "줄기세포-배양-및-분화",
                    "children": null
                  }
                ]
              },
              {
                "text": "골수 이식",
                "id": "골수-이식",
                "children": [
                  {
                    "text": "조혈모세포 이식",
                    "id": "조혈모세포-이식",
                    "children": null
                  },
                  {
                    "text": "골수 이식의 목표",
                    "id": "골수-이식의-목표",
                    "children": null
                  },
                  {
                    "text": "이식편대숙주병(GVH)",
                    "id": "이식편대숙주병-gvh",
                    "children": null
                  }
                ]
              },
              {
                "text": "이식편(Grafts)",
                "id": "이식편-grafts",
                "children": [
                  {
                    "text": "자가이식(Autograft)",
                    "id": "자가이식-autograft",
                    "children": null
                  },
                  {
                    "text": "동계이식(Isograft)",
                    "id": "동계이식-isograft",
                    "children": null
                  },
                  {
                    "text": "동종이식(Allografts)",
                    "id": "동종이식-allografts",
                    "children": null
                  },
                  {
                    "text": "이종이식(Xenotransplantation)",
                    "id": "이종이식-xenotransplantation",
                    "children": null
                  },
                  {
                    "text": "초급성 거부 반응 극복",
                    "id": "초급성-거부-반응-극복",
                    "children": null
                  }
                ]
              },
              {
                "text": "이식 거부 반응 방지를 위한 면역 억제",
                "id": "이식-거부-반응-방지를-위한-면역-억제",
                "children": [
                  {
                    "text": "면역 억제의 목적",
                    "id": "면역-억제의-목적",
                    "children": null
                  },
                  {
                    "text": "주요 면역 억제제 및 작용 기전",
                    "id": "주요-면역-억제제-및-작용-기전",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "이식 수술에서 공여자와 수혜자의 조직 일치가 중요한 주된 이유는 무엇입니까?",
              "options": [
                "감염 위험을 줄이기 위해",
                "수술 시간을 단축하기 위해",
                "이식 거부 반응을 최소화하기 위해",
                "환자의 회복 속도를 높이기 위해"
              ],
              "answerIndex": 2,
              "explanation": "HLA 타이핑을 통한 조직 일치는 이식된 조직에 대한 수혜자의 면역 반응, 즉 거부 반응을 줄이는 데 필수적입니다."
            },
            {
              "question": "다음 중 '이식편대숙주병(Graft-versus-host disease, GVH)'이 발생할 수 있는 이식 유형은 무엇입니까?",
              "options": [
                "자가이식 (Autograft)",
                "동계이식 (Isograft)",
                "골수 이식 (Bone marrow transplant)",
                "각막 이식 (Cornea transplant)"
              ],
              "answerIndex": 2,
              "explanation": "이식편대숙주병은 이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격할 때 발생합니다."
            },
            {
              "question": "다음 중 면역 억제제 시롤리무스(Sirolimus)의 주요 작용 기전은 무엇입니까?",
              "options": [
                "IL-2 생성을 억제하여 세포독성 T 세포를 방해한다.",
                "T 세포와 B 세포의 증식을 억제한다.",
                "세포성 및 체액성 면역을 모두 억제한다.",
                "IL-2를 차단하는 키메라 단일클론 항체이다."
              ],
              "answerIndex": 2,
              "explanation": "텍스트에 따르면 시롤리무스는 세포성 및 체액성 면역을 모두 억제한다고 명시되어 있습니다."
            }
          ]
        },
        {
          "title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1530 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "면역 시스템과 암",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "암세포는 면역 감시에 의해 제거됩니다. 암세포는 비자기로 표시되는 종양 관련 항원을 가지고 있습니다. CTL(활성화된 TC 세포)과 대식세포는 암세포를 용해합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그러나 면역 시스템의 암 제거에는 몇 가지 제한 사항이 있습니다. 면역 시스템이 표적으로 삼을 항원성 에피토프가 없거나, 종양 세포가 너무 빠르게 증식하거나, 종양이 혈관화되어 면역 시스템에 보이지 않게 될 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
              "level": 2
            },
            {
              "type": "heading",
              "content": "암에 대한 면역 요법",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "암 치료를 위한 다양한 면역 요법이 개발되었습니다. 박테리아 내독소(Coley's toxins)는 암의 혈액 공급을 방해하는 TNF를 자극하여 사용될 수 있습니다. HPV(자궁경부암, 항문암, 인후암) 및 B형 간염(간암)과 같은 바이러스 관련 암에 대한 예방 백신이 사용됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "또한 단클론항체(Monoclonal antibodies)가 사용되는데, 예를 들어 유방암 치료제 허셉틴이 있습니다. 면역독소(Immunotoxin)는 단클론항체와 독성 물질을 결합하여 건강한 세포에 손상을 주지 않고 종양을 표적하여 죽입니다. 면역 관문 억제제와 CAR T 세포와 같은 세포 치료법도 암 치료에 활용되고 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역 결핍증",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "면역 결핍증은 충분한 면역 반응이 부재하는 상태를 말합니다. 이는 선천성 면역 결핍증과 후천성 면역 결핍증으로 나눌 수 있습니다. 선천성 면역 결핍증은 결함이 있거나 없는 유전자 때문에 발생하며, 후천성 면역 결핍증은 약물, 암, 감염 등으로 인해 개인의 삶 동안 발병합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역 결핍 질환",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "선천성 면역 결핍 질환은 유전적 유전자 결함에 의해 발생합니다. T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있으며, 항원 수용체 유전자 재배열의 결함 또한 SCID를 유발할 수 있습니다. T세포 항원 수용체로부터의 신호 전달 결함이나 T세포 발달을 차단하는 흉선 기능의 유전적 결함 역시 중증 면역 결핍증을 초래할 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "림프구 발달의 결함이 중증 복합 면역 결핍증을 초래할 수 있음",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "그림 19.12 나병균에 감염된 누드(털 없는) 쥐의 뒷발. M. leprae 박테리아 위치.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "본문은 면역 시스템이 암과 싸우는 방식, 그 한계, 그리고 다양한 암 면역 요법에 대해 설명합니다. 또한 면역 결핍증을 선천성 및 후천성으로 구분하고, T세포 발달 또는 항원 수용체 결함으로 인한 SCID와 같은 선천성 면역 결핍 질환의 구체적인 원인을 다룹니다.",
            "keyConcepts": [
              {
                "term": "면역 감시",
                "definition": "면역 시스템이 암세포를 인식하고 제거하는 과정."
              },
              {
                "term": "면역 요법",
                "definition": "면역 시스템을 활용하여 암을 치료하는 방법으로, 백신, 단클론항체, 면역관문억제제, 세포 치료 등이 포함됩니다."
              },
              {
                "term": "선천성 면역 결핍증",
                "definition": "유전적 결함으로 인해 발생하는 면역 반응의 부재."
              },
              {
                "term": "후천성 면역 결핍증",
                "definition": "약물, 암, 감염 등으로 인해 개인의 삶 동안 발병하는 면역 결핍."
              },
              {
                "term": "중증 복합 면역 결핍증 (SCID)",
                "definition": "T세포 발달 결함이나 항원 수용체 유전자 재배열 결함 등으로 인해 발생하는 심각한 면역 결핍 질환."
              }
            ],
            "importantTerms": [
              {
                "term": "종양 관련 항원",
                "definition": "암세포 표면에 존재하며 면역 시스템이 비자기로 인식하는 항원."
              },
              {
                "term": "세포독성 T 림프구 (CTLs)",
                "definition": "활성화된 T 세포로, 암세포나 감염된 세포를 직접 용해(파괴)하는 역할을 합니다."
              },
              {
                "term": "코리 독소",
                "definition": "박테리아 내독소로, TNF 분비를 자극하여 암의 혈액 공급을 방해하는 데 사용되었던 물질."
              },
              {
                "term": "단클론항체 (Mab)",
                "definition": "특정 항원에만 결합하도록 만들어진 항체로, 암 치료에 사용될 수 있습니다 (예: 허셉틴)."
              },
              {
                "term": "면역독소",
                "definition": "단클론항체와 독성 물질을 결합하여 암세포만을 표적하여 죽이는 치료제."
              },
              {
                "term": "면역 관문 억제제",
                "definition": "면역 반응을 억제하는 경로를 차단하여 면역 시스템이 암세포를 더 효과적으로 공격하도록 돕는 약물."
              },
              {
                "term": "CAR T 세포",
                "definition": "환자의 T 세포를 유전자 조작하여 암세포를 인식하고 공격하도록 만든 세포 치료제."
              }
            ],
            "outline": [
              {
                "text": "면역 시스템과 암",
                "id": "면역-시스템과-암",
                "children": [
                  {
                    "text": "면역 감시를 통한 암세포 제거",
                    "id": "면역-감시를-통한-암세포-제거",
                    "children": null
                  },
                  {
                    "text": "면역 시스템의 암 제거 제한 사항",
                    "id": "면역-시스템의-암-제거-제한-사항",
                    "children": null
                  }
                ]
              },
              {
                "text": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
                "id": "세포독성-t-림프구ctl와-암세포의-상호작용",
                "children": null
              },
              {
                "text": "암에 대한 면역 요법",
                "id": "암에-대한-면역-요법",
                "children": [
                  {
                    "text": "박테리아 내독소",
                    "id": "박테리아-내독소",
                    "children": null
                  },
                  {
                    "text": "백신",
                    "id": "백신",
                    "children": null
                  },
                  {
                    "text": "단클론항체 및 면역독소",
                    "id": "단클론항체-및-면역독소",
                    "children": null
                  },
                  {
                    "text": "면역 관문 억제제",
                    "id": "면역-관문-억제제",
                    "children": null
                  },
                  {
                    "text": "세포 치료",
                    "id": "세포-치료",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역 결핍증",
                "id": "면역-결핍증",
                "children": [
                  {
                    "text": "선천성 면역 결핍증",
                    "id": "선천성-면역-결핍증",
                    "children": null
                  },
                  {
                    "text": "후천성 면역 결핍증",
                    "id": "후천성-면역-결핍증",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역 결핍 질환",
                "id": "면역-결핍-질환",
                "children": [
                  {
                    "text": "선천성 면역 결핍 질환의 원인",
                    "id": "선천성-면역-결핍-질환의-원인",
                    "children": null
                  },
                  {
                    "text": "T세포 발달 및 항원 수용체 관련 결함",
                    "id": "t세포-발달-및-항원-수용체-관련-결함",
                    "children": null
                  }
                ]
              },
              {
                "text": "림프구 발달 결함과 중증 복합 면역 결핍증 (SCID)",
                "id": "림프구-발달-결함과-중증-복합-면역-결핍증-scid",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "면역 시스템이 암세포를 제거하는 데 있어 주요 제한 사항이 아닌 것은 무엇입니까?",
              "options": [
                "면역 시스템이 표적으로 삼을 항원성 에피토프가 없음",
                "종양 세포가 너무 빠르게 증식함",
                "종양이 혈관화되어 면역 시스템에 보이지 않게 됨",
                "대식세포가 암세포를 용해하지 못함"
              ],
              "answerIndex": 3,
              "explanation": "본문에서는 CTL(활성화된 TC 세포)과 대식세포가 암세포를 용해한다고 명시되어 있으므로, 대식세포가 암세포를 용해하지 못하는 것은 면역 시스템의 제한 사항이 아닙니다."
            },
            {
              "question": "다음 중 암에 대한 면역 요법으로 언급되지 않은 것은 무엇입니까?",
              "options": [
                "박테리아 내독소 (Coley's toxins)",
                "예방 백신 (HPV, B형 간염)",
                "항생제",
                "CAR T 세포 치료"
              ],
              "answerIndex": 2,
              "explanation": "본문에서 박테리아 내독소, 예방 백신, CAR T 세포 치료는 암에 대한 면역 요법으로 언급되었지만, 항생제는 언급되지 않았습니다. 항생제는 주로 세균 감염 치료에 사용됩니다."
            },
            {
              "question": "중증 복합 면역 결핍증(SCID)의 주요 원인이 될 수 있는 유전적 결함은 무엇입니까?",
              "options": [
                "B세포의 과도한 증식",
                "T세포 발달의 결함",
                "항체 생산 능력의 증가",
                "대식세포 기능의 활성화"
              ],
              "answerIndex": 1,
              "explanation": "본문에서는 'T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있습니다'라고 명확히 언급되어 있습니다."
            }
          ]
        },
        {
          "title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 5576 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "후천성 면역 결핍 증후군 (AIDS)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "1981년, 미국에서 젊은 동성애 남성들 사이에서 폐포자충 폐렴, 카포시 육종, 그리고 면역 기능 상실 사례들이 집단으로 발견되었습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1983년, 면역 기능 상실을 유발하는 바이러스(HIV)가 발견되었습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV는 T 보조 세포를 선택적으로 감염시킵니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "AIDS의 기원",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "HIV는 서아프리카와 중앙아프리카의 침팬지(약 1908년, 부시미트로부터)로부터 인간 개체군으로 넘어왔습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "도시화와 성적 문란의 증가로 아프리카 전역으로 퍼졌습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "가장 오래된 HIV 샘플은 1920년 콩고민주공화국의 킨샤사에서 발견되었습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1976년에 사망한 노르웨이 선원은 서구 세계에서 알려진 첫 번째 사례입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1969년 미주리주의 한 환자로부터 채취한 샘플에서 HIV 감염이 확인되었습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV의 구조",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "렌티바이러스(Lentivirus) 속에 속합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "레트로바이러스(Retrovirus)입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "두 개의 동일한 양성 가닥 RNA 유전체 분자, 역전사 효소, 인지질 외피를 가지고 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "gp120 당단백질 스파이크를 가지고 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 구조 및 CD4+ T 세포 감염: gp120 당단백질 스파이크는 CD4+ 세포의 수용체에 부착합니다. gp41 막관통 당단백질은 CD4+ 세포의 융합 수용체에 부착하여 융합을 촉진합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV의 감염성과 병원성",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "수지상 세포에 의해 퍼지고 림프 기관으로 운반되며, 활성화된 T 세포와 접촉합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "gp120은 CD4+ 수용체 및 CCR5 또는 CXCR4 공동수용체와 결합합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "CD4 분자는 T 보조 세포, 대식세포, 수지상 세포에 존재합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스는 세포와 융합하여 세포 안으로 들어갑니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "부착: gp120 스파이크는 세포의 수용체 및 CCR5 또는 CXCR4 공동수용체에 부착합니다. 융합: gp41은 HIV와 세포의 융합에 참여합니다. 진입: 세포와의 융합 후, 진입 구멍이 생성됩니다. 진입 후, 바이러스 외피는 뒤에 남고 HIV는 탈피하여 새로운 바이러스 합성을 지시할 RNA 핵을 방출합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포 내에서 바이러스 RNA는 역전사 효소를 사용하여 DNA로 전사됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "DNA는 숙주 염색체 DNA에 통합됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "활동성 감염: 새로운 바이러스가 숙주 세포에서 출아합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "잠복 감염: DNA는 프로바이러스 형태로 염색체에 숨겨져 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "일부는 HIV의 저장소 역할을 하는 기억 T 세포가 됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스는 빠른 항원성 변화와 높은 돌연변이율을 겪습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그림 19.14 CD4+ T 세포의 잠복 및 활동성 HIV 감염. 잠복 감염: 바이러스 DNA는 세포 DNA에 프로바이러스로 통합되며, 나중에 활성화되어 감염성 바이러스를 생성할 수 있습니다. 활동성 감염: 프로바이러스가 활성화되어 새로운 바이러스의 합성을 제어할 수 있게 합니다. 최종 조립은 세포막에서 이루어지며, 바이러스가 세포에서 출아할 때 바이러스 외피 단백질을 가져갑니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그림 19.15 대식세포 및 수지상 세포의 잠복 및 활동성 HIV 감염. 잠복 감염된 대식세포: HIV는 프로바이러스 또는 액포 내 완전한 비리온 형태로 지속될 수 있습니다. 활성화된 대식세포: 프로바이러스로부터 새로운 바이러스가 생성됩니다. 완성된 비리온은 방출되거나 액포 내 대식세포에 지속될 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV의 아형",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "HIV-1:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "침팬지와 고릴라를 감염시키는 바이러스와 관련이 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사례의 99%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그룹 M (대다수)이 90%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV-2:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "서아프리카 외에서는 자주 발견되지 않습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV-1보다 병원성이 낮습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV-1보다 바이러스 부하와 사망률이 낮고 무증상 기간이 더 깁니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 감염의 단계",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "1단계: 무증상 또는 림프절병증.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "2단계: CD4+ T 세포가 꾸준히 감소하며, 감염된 소수의 세포만이 바이러스를 방출합니다. 심각한 질병 증상은 거의 없습니다 (지속적인 감염, 발열, 구강 백반증).",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "3단계: AIDS가 발병합니다. CD4+ 수치가 200 cells/μl 미만이며, 지표 질환이 나타납니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 감염의 진행 및 병원성",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "초기에는 강력하고 효과적인 면역 반응이 나타납니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포독성 T 림프구(CTLs)가 바이러스 수를 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "일단 HIV가 잠복 감염된 CD4+ T 세포의 저장소를 형성하면 감염을 제거하는 것은 불가능합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "백신 개발에 어려움이 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 노출에 대한 반응의 변이",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "HIV 감염 생존에 대한 연령의 영향:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "고령자와 어린이는 면역 체계가 완전히 기능하지 않아 감염에 더 취약합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "노출되었지만 감염되지 않은 인구:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "CCR5 돌연변이를 가집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "장기 생존자:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "낮은 바이러스 부하를 가집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "효과적인 CTLs를 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "기회 감염",
              "level": 2
            },
            {
              "type": "heading",
              "content": "진단 방법",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "혈청 전환은 감염과 항체 출현 사이의 기간입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "최대 3개월이 소요됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 항체는 ELISA로 검출됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스는 Western blotting 또는 APTIMA (RNA 검사)로 검출됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈장 바이러스 부하 (PVL)는 PCR 또는 핵산 혼성화로 결정됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 전파",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "HIV는 세포 밖에서 6시간 생존합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV는 세포 내에서 1.5일 이상 생존할 수 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "전파 경로: 친밀한 성 접촉, 모유, 태반 감염, 오염된 주사바늘, 장기 이식, 수혈.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항문 성교는 가장 위험한 형태의 성 접촉입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "전 세계 AIDS 현황",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "전 세계적으로 3천 5백만 명이 감염되었습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사하라 이남 아프리카에 70%가 집중되어 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이성애자 간 전파가 HIV 전파의 가장 흔한 방식입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "동유럽과 중앙 및 동남아시아 사례의 ⅓은 주사 약물 사용으로 인한 것입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "전 세계 지역별 HIV 감염 및 AIDS 분포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "70",
              "level": null
            },
            {
              "type": "heading",
              "content": "AIDS 예방 및 치료",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "생물의학적 개입:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "콘돔 사용, 보건 서비스/HIV 검사, 주사바늘 프로그램.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "행동적 개입:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "성 교육, 안전한 영아 수유 프로그램, 상담.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "구조적 개입:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 취약성을 줄이기 위해 사회, 경제, 정치, 환경적 요인에 변화를 줍니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이제 선진국에서는 치료 가능한 만성 질환으로 간주됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "고활성 항레트로바이러스 치료 (HAART)를 사용합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "내성 균주의 생존을 최소화하기 위해 약물 조합을 사용합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "73",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 관리",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "그림 19.18 HIV 생명 주기를 억제하는 약물: 융합/진입 억제제 (엔푸비르타이드, 마라비록), 역전사 효소 억제제 (테노포비르, 엠트리시타빈), 통합효소 억제제 (랄테그라비르), 프로테아제 억제제 (아타자나비르, 인디나비르, 사퀴나비르) 등이 있습니다. 이 약물들은 HIV의 gp41, gp120, CCR5, CD4 수용체 및 역전사 효소 등에 작용하여 바이러스 복제를 억제합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 치료 약물의 종류",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "융합/세포 진입 억제제:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스 외피의 gp41 영역을 표적으로 하여 바이러스가 세포와 융합하는 것을 방지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "엔푸비르타이드(Enfuvirtide)와 마라비록(Maraviroc)이 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "역전사 효소 억제제:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "뉴클레오사이드 역전사 효소 억제제 (NRTIs) - 테노포비르(Tenofovir)와 엠트리시타빈(Emtricitabrine)이 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "비뉴클레오사이드 역전사 효소 억제제 (NNRTIs) - 에파비렌즈(Efavirenz)가 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "77",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "통합효소 억제제:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 통합효소가 cDNA를 숙주 염색체에 통합하는 것을 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "랄테그라비르(Raltegravir)가 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "프로테아제 억제제:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스 전구 단백질을 구조 및 기능 단백질로 분해하는 프로테아제를 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "아타자나비르(Atazanavir), 인디나비르(Indinavir), 사퀴나비르(Saquinavir)가 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "성숙 억제제:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "테더린(Tetherins)은 바이러스를 세포에 묶어 방출 및 확산을 방지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "감염 과정에서 HIV는 많은 돌연변이를 축적하여 약물 내성 변이체의 증식으로 이어집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 백신 개발의 과제",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "모방할 자연 면역 모델이 없습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "연구 동물이 부족합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "레트로바이러스 메커니즘에 대한 이해가 부족합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "높은 돌연변이율로 인해 내성 균주가 발생합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이상적인 백신은 다음과 같아야 합니다:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "잠복 바이러스 저장소가 확립되기 전에 면역을 유도해야 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포독성 T 림프구(CTLs)의 생성을 자극해야 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "합리적인 가격이어야 합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 후천성 면역 결핍 증후군(AIDS)의 기원, 원인 바이러스인 HIV의 구조, 감염 메커니즘 및 병원성, 바이러스 아형, 감염 단계, 진단 방법, 전파 경로, 전 세계적 현황, 예방 및 치료법, 그리고 백신 개발의 과제에 대해 상세히 설명합니다. HIV는 CD4+ T 세포를 선택적으로 감염시키는 레트로바이러스이며, 잠복 감염과 활동성 감염 단계를 거치며 면역 체계를 파괴합니다. HAART(고활성 항레트로바이러스 치료)를 통해 HIV 복제를 억제하고 환자의 삶의 질을 향상시킬 수 있지만, 바이러스의 높은 돌연변이율로 인해 백신 개발에는 어려움이 있습니다.",
            "keyConcepts": [
              {
                "term": "HIV (Human Immunodeficiency Virus)",
                "definition": {
                  "easy": null,
                  "medium": "AIDS의 원인 바이러스로, 인체의 면역 체계를 공격하고 파괴하는 레트로바이러스입니다.",
                  "hard": null
                }
              },
              {
                "term": "CD4+ T 세포",
                "definition": {
                  "easy": null,
                  "medium": "HIV가 주로 감염시키고 파괴하는 면역 세포로, 이 세포의 감소는 면역 결핍을 초래합니다.",
                  "hard": null
                }
              },
              {
                "term": "역전사 효소 (Reverse Transcriptase)",
                "definition": {
                  "easy": null,
                  "medium": "HIV를 포함한 레트로바이러스가 자신의 RNA 유전체를 DNA로 역전사하는 데 사용하는 효소입니다.",
                  "hard": null
                }
              },
              {
                "term": "HAART (Highly Active Antiretroviral Therapy)",
                "definition": {
                  "easy": null,
                  "medium": "HIV 감염 치료를 위해 여러 종류의 항레트로바이러스 약물을 병용하는 치료법으로, 바이러스 복제를 효과적으로 억제합니다.",
                  "hard": null
                }
              },
              {
                "term": "기회 감염 (Opportunistic Infections)",
                "definition": {
                  "easy": null,
                  "medium": "면역 체계가 약해진 상태에서 일반적으로 건강한 사람에게는 질병을 일으키지 않는 미생물에 의해 발생하는 감염입니다.",
                  "hard": null
                }
              }
            ],
            "importantTerms": [
              {
                "term": "AIDS (Acquired Immunodeficiency Syndrome)",
                "definition": "후천성 면역 결핍 증후군. HIV 감염의 마지막 단계로, 심각한 면역 결핍과 기회 감염 및 특정 암을 특징으로 합니다."
              },
              {
                "term": "레트로바이러스 (Retrovirus)",
                "definition": "RNA 유전체를 가지고 있으며, 역전사 효소를 사용하여 RNA를 DNA로 전환하고 이를 숙주 게놈에 통합시키는 바이러스입니다."
              },
              {
                "term": "gp120 및 gp41",
                "definition": "HIV 외피에 존재하는 당단백질 스파이크로, gp120은 CD4 수용체에 부착하고 gp41은 바이러스와 세포막의 융합을 촉진합니다."
              },
              {
                "term": "프로바이러스 (Provirus)",
                "definition": "레트로바이러스의 DNA 유전체가 숙주 세포의 염색체 DNA에 통합된 형태입니다."
              },
              {
                "term": "혈청 전환 (Seroconversion)",
                "definition": "감염 후 특정 병원체에 대한 항체가 혈액에서 처음으로 검출되는 시기입니다."
              },
              {
                "term": "CD4+ T 세포 수치",
                "definition": "면역 상태를 나타내는 중요한 지표로, AIDS 진단 기준 중 하나는 이 수치가 200 cells/μl 미만인 경우입니다."
              },
              {
                "term": "CCR5 돌연변이",
                "definition": "일부 개인에게서 발견되는 유전적 돌연변이로, HIV가 세포에 진입하는 데 필요한 공동수용체인 CCR5를 변경하여 HIV 감염에 대한 저항성을 부여합니다."
              }
            ],
            "outline": [
              {
                "text": "후천성 면역 결핍 증후군 (AIDS)",
                "id": "후천성-면역-결핍-증후군-aids",
                "children": null
              },
              {
                "text": "AIDS의 기원",
                "id": "aids의-기원",
                "children": null
              },
              {
                "text": "HIV의 구조",
                "id": "hiv의-구조",
                "children": null
              },
              {
                "text": "HIV의 감염성과 병원성",
                "id": "hiv의-감염성과-병원성",
                "children": null
              },
              {
                "text": "HIV의 아형",
                "id": "hiv의-아형",
                "children": null
              },
              {
                "text": "HIV 감염의 단계",
                "id": "hiv-감염의-단계",
                "children": null
              },
              {
                "text": "HIV 감염의 진행 및 병원성",
                "id": "hiv-감염의-진행-및-병원성",
                "children": null
              },
              {
                "text": "HIV 노출에 대한 반응의 변이",
                "id": "hiv-노출에-대한-반응의-변이",
                "children": null
              },
              {
                "text": "기회 감염",
                "id": "기회-감염",
                "children": null
              },
              {
                "text": "진단 방법",
                "id": "진단-방법",
                "children": null
              },
              {
                "text": "HIV 전파",
                "id": "hiv-전파",
                "children": null
              },
              {
                "text": "전 세계 AIDS 현황",
                "id": "전-세계-aids-현황",
                "children": null
              },
              {
                "text": "전 세계 지역별 HIV 감염 및 AIDS 분포",
                "id": "전-세계-지역별-hiv-감염-및-aids-분포",
                "children": null
              },
              {
                "text": "AIDS 예방 및 치료",
                "id": "aids-예방-및-치료",
                "children": [
                  {
                    "text": "HIV 관리",
                    "id": "hiv-관리",
                    "children": null
                  },
                  {
                    "text": "HIV 치료 약물의 종류",
                    "id": "hiv-치료-약물의-종류",
                    "children": null
                  }
                ]
              },
              {
                "text": "HIV 백신 개발의 과제",
                "id": "hiv-백신-개발의-과제",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "HIV가 주로 감염시키고 파괴하는 면역 세포는 무엇입니까?",
              "options": [
                "B 세포",
                "CD4+ T 세포",
                "대식세포",
                "자연 살해(NK) 세포"
              ],
              "answerIndex": 1,
              "explanation": "HIV는 CD4+ 수용체를 가진 세포를 감염시키며, 특히 CD4+ T 세포는 HIV 감염의 주요 표적 세포입니다. 이 세포의 파괴는 면역 결핍을 초래합니다."
            },
            {
              "question": "HIV 감염 진단에 사용되는 방법 중 HIV 항체를 검출하는 검사는 무엇입니까?",
              "options": [
                "PCR",
                "Western blotting",
                "ELISA",
                "핵산 혼성화"
              ],
              "answerIndex": 2,
              "explanation": "HIV 항체는 ELISA(효소결합 면역흡착법)를 통해 검출됩니다. Western blotting은 항체 검출을 확인하는 데 사용될 수 있으며, PCR과 핵산 혼성화는 바이러스 자체(RNA 또는 DNA)를 검출하는 데 사용됩니다."
            },
            {
              "question": "HAART(고활성 항레트로바이러스 치료)의 주요 특징은 무엇입니까?",
              "options": [
                "단일 약물을 고용량으로 투여합니다.",
                "수술적 방법으로 바이러스를 제거합니다.",
                "여러 종류의 항레트로바이러스 약물을 병용합니다.",
                "면역 증강제만을 사용하여 면역력을 높입니다."
              ],
              "answerIndex": 2,
              "explanation": "HAART는 여러 종류의 항레트로바이러스 약물을 병용하여 HIV 복제를 다양한 단계에서 억제하고 약물 내성 균주의 출현을 최소화하는 치료법입니다."
            }
          ]
        }
      ],
      "log_entries": [
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "analyze_overall_structure",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "analyze_overall_structure",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "generate_chapter_content",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "all_pdf_texts": [
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "text": "16. INNATE IMMUNITY: \nNONSPECIFIC DEFENSES OF \nTHE HOST\nHongsup Yoon, Ph.D.\nMicrobiology\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n2\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n3\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n4\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n• White blood cell (WBC) \ncounts measure \nleukocytes in the blood\n• High WBC counts may \nindicate bacterial \ninfections, autoimmune \ndiseases, or side effects \nof medications\n• Low WBC counts may \nindicate viral infections, \npneumonia, \nautoimmune diseases, \nor cancers\n\nTHE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse.\n14\nHOST DEFENSE: THE BIG PICTURE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n16\nPHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\n\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice.\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n23\nFORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\n\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\n\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n31\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\n\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\n\nPHAGOCYTOSIS: OVERVIEW\n\nPHAGOCYTOSIS: MECHANISM\n\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\n\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n39\nINFLAMMATION: OVERVIEW\n\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\n\nFigure 16.9a-b  The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ntaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\n\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n49\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n51\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\n\nCOMPLEMENT: ACTIVATION\n\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\n\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\n\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\n\nFigure 16.12  Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13  Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBIAL PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n68\nSUMMARY (1/3)\n• The growth of microorganisms can be controlled by physical, chemical, \nmechanical, and biological means.\n• The body’s first line of defense against infections is a physical barrier and \nthe nonspecific chemicals of the skin and mucous membranes. \n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways.\n• A microbe’s penetration of the first line of defense encourages production \nof phagocytes, inflammation, fever, and antimicrobial substances. \n• Blood consists of plasma (fluid) and formed elements (cells and cell \nfragments). Leukocytes (white blood cells) are divided into granulocytes \n(neutrophils, basophils,  eosinophils) and agranulocytes. During many \ninfections, the number of leukocytes increases (leukocytosis); some  \ninfections are characterized by leucopenia (decrease in leukocytes). \nSUMMARY (2/3)\n• Phagocytosis is the ingestion of microorganisms or particulate matter by a \ncell. Phagocytosis is performed by phagocytes, certain types of white \nblood cells or their  derivatives. Among the granulocytes, neutrophils are \nthe most important phagocytes. Granulocytes predominate during the \nearly stages of infection, whereas monocytes  predominate as the \ninfection subsides. \n• Inflammation is a bodily response to cell damage; it is characterized by \nredness,  pain, heat, swelling, and sometimes the loss of function. TNF -α \nstimulates production of acute -phase proteins. \n• A tissue is repaired when the stroma (supporting tissue) or parenchyma \n(functioning  tissue) produces new cells. Stromal repair by fibroblasts \nproduces scar tissue. \n• Fever is an abnormally high body temperature produced in response to a \nbacterial or  viral infection. \nSUMMARY (3/3)\n• The complement system consists of a group of serum proteins that \nactivate one another to destroy invading microorganisms. Complement \nproteins are activated in a cascade. Complement is activated via the \nclassical pathway, the alternative pathway, and the lectin pathway. \n• IFN-α and IFN-β are antiviral proteins produced in response to viral \ninfection. The mode of action of IFN -α and IFN-β is to induce uninfected \ncells to produce antiviral proteins (AVPs) that prevent viral replication. IFN -\nα and IFN-β are host-cell-specific but not virus-specific. IFN-γ activates \nneutrophils and macrophages to kill bacteria. \n• Iron-binding proteins transport and store iron and deprive most pathogens \nof the  available iron.\n• Antimicrobial peptides (AMPs) inhibit cell wall synthesis; form pores in \nplasma  membranes, resulting in lysis; and destroy DNA and RNA."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "text": "17. ADAPTIVE IMMUNITY: \nSPECIFIC DEFENSES OF \nTHE HOST\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n2\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n3\nTHE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n5\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\n\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n11\nCYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n14\nAntibody A\nEpitopes (antigenic \ndeterminants)\non antigen\nAntigens:\ncomponents\nof cell wall\nAntibody B\nBacterial cell\nBinding sites\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\n\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\n\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n34\nCELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\n\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\n\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\n\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\n\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\n\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n51\nIMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\n \n\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\n\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n55\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\n\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Summary\n58\nFigure 17.20  The Dual Nature of the Adaptive Immune System.\n\nSUMMARY (1/3)\n• Adaptive immunity is the body’s ability to react specifically to a microbial \ninfection. The body’s response to the first contact with an antigen is called the \nprimary response. Subsequent contact with the same antigen results in a \nsecondary or memory response to that antigen.\n• Humoral immunity involves antibodies, which are found in serum and lymph and \nare produced by B cells. Lymphocytes that mature in red bone marrow become \nB cells. \n• Cellular immunity involves T cells. Lymphocytes that migrate through the thymus \nbecome T cells. T cell receptors recognize antigens presented on MHC. Cellular \nimmunity responds to intracellular antigens; humoral immunity responds to \nantigens in body fluids.\n• Cells of the immune system communicate with each other by means of \nchemicals called cytokines. Interleukins (IL) are cytokines that serve as \ncommunicators between leukocytes. Chemokines cause leukocytes to migrate \nto an infection. Some interferons stimulate the immune response; others protect \ncells against viruses. Tumor necrosis factor promotes the inflammatory reaction. \nHematopoietic cytokines promote development of white blood cells. \nOverproduction of cytokines leads to a cytokine storm, which results in tissue \ndamage.\nSUMMARY (2/3)\n• An antigen (or immunogen) is a chemical substance that causes the body \nto produce specific antibodies. Antibodies are formed against specific \nregions on antigens called epitopes, or antigenic determinants.\n• An antibody, or immunoglobulin, is a protein produced by B cells in \nresponse to an  antigen and is capable of combining specifically with that \nantigen. IgG antibodies are the most prevalent in serum; they provide \nnaturally acquired passive immunity, neutralize bacterial toxins, participate \nin complement fixation, and enhance phagocytosis.\n• T cells mature in the thymus gland. Thymic selection removes T cells that \ndon’t recognize MHC molecules of the host and T cells that will attack host \ncells presenting self-proteins in MHC. Helper T cells recognize antigens \nprocessed by antigen-presenting cells and presented in MHC II. Cytotoxic \nT cells recognize antigens processed by all host cells and presented in \nMHC I.\nSUMMARY (3/3)\n• APCs include B cells, dendritic cells, and macrophages. Dendritic cells are \nthe primary APCs. Dendritic cells are the primary APCs. APCs carry \nantigens to lymphoid tissues where T cells that recognize the antigen are \nlocated.\n• T helper (CD4+ T) cells differentiate into TH1 cells, which are involved in \ncellular immunity; TH2 cells, which are involved in humoral immunity and \nare associated with allergic reactions and parasitic infections; and TH17 \ncells, which activate innate immunity.\n• T regulatory cells (Treg) suppress T cells against self. Cytotoxic \nlymphocytes (CTLs), or CD8+ T cells, are activated by endogenous \nantigens and MHC class I on a target cell and are transformed into effector \nand memory CTLs.\n• CTLs lyse or induce apoptosis in the target cell."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n18. PRACTICAL \nAPPLICATIONS OF \nIMMUNOLOGY – PART I\n2\nRECENT VIRUS OUTBREAKS\n• 2002 SARS outbreak (~9.5 % mortality rate)\n• 2004 Global spread of H5N1 avian influenza (60% mortality rate)\n• 2009 H1N1/09 swine Flu pandemic\n• 2015 MERS in Korea (~40 % mortality rate)\n• 2018 Influenza B outbreak in Korea\n• 2019 COV-19 (SARS-CoV2) pandemic (~2 – 3 % mortality rate)\n?\nHISTORICAL PANDEMIC: BLACK DEATH\nKilled 30 – 60% of European\n\nEDWARD JENNER (1749 – 1823)\n\nMILKMAID (AROUND THE TIME OF JENNER)\n\nVACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\n\nVACCINES: FUNCTION\n\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -drug \nusers, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1  Influenza viruses are grown in embryonated eggs.\n\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\n\nRNA VACCINES\nVACCINES: TYPES\n\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\n\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren\nDIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nPRODUCTION OF MONOCLONAL \nANTIBODIES\n\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\n\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\n\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\n\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\n\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\n\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\n\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\n\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy\nSUMMARY (1/6)\n• Edward Jenner developed the modern practice of vaccination when he \ninoculated people with cowpox virus to protect them against smallpox. \n• Herd immunity results when most of a population is immune to a disease.\n• Bacteria have unique cell structures that can be targets for antibiotics, \nimmunity, and phage infection.\n•  Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Humans utilize \nand harness microorganisms and their products.\n• Attenuated vaccines consist of attenuated (weakened) microorganisms; \nattenuated virus vaccines generally provide lifelong immunity. Inactivated \nvaccines consist of killed bacteria or viruses. Subunit vaccines consist of \nantigenic fragments of a microorganism; these include  recombinant \nvaccines and toxoids. \nSUMMARY (2/6)\n• Conjugated vaccines combine the desired antigen with a protein that \nboosts the immune response. Nucleic acid (DNA) vaccines cause the \nrecipient to make the antigenic protein.\n• Viruses for vaccines may be grown in animals, cell cultures, or chick \nembryos. Recombinant vaccines and nucleic acid vaccines do not need to \nbe grown in cells or animals. Genetically modified plants may someday \nprovide edible vaccines.\n• Combining several vaccines would eliminate the number of injections. Dry \nskin patch vaccines don’t need refrigeration.\n• Adjuvants improve the effectiveness of some antigens. \n• Vaccines are the safest and most effective means of controlling infectious \ndiseases.\nSUMMARY (3/6)\n• Many tests based on the interactions of antibodies and antigens have \nbeen developed to determine the presence of antibodies or antigens in a \npatient. The sensitivity of a diagnostic test is determined by the percentage \nof positive samples it correctly detects; and its specificity is determined by \nthe percentage of false positive  results it gives.\n• Hybridomas are produced in the laboratory by fusing a cancerous cell with \nan antibody-secreting plasma cell. A hybridoma cell culture produces large \nquantities of the plasma cell’s antibodies, called monoclonal antibodies. \nMonoclonal antibodies are used in serological identification tests, to \nprevent tissue  rejections, and to make immunotoxins to treat cancer.\n• The interaction of soluble antigens with IgG or IgM antibodies leads to \nprecipitation  reactions. Precipitation reactions depend on the formation of \nlattices and occur best when antigen and antibody are present in optimal \nproportions. Excesses of either component decrease lattice formation and \nsubsequent precipitation.\nSUMMARY (4/6)\n• Immunodiffusion procedures are precipitation reactions carried out in an \nagar gel  medium. Immunoelectrophoresis combines electrophoresis with \nimmunodiffusion for the analysis of serum proteins.\n• The interaction of particulate antigens (cells that carry antigens) with \nantibodies leads to agglutination reactions. Diseases may be diagnosed \nby combining the patient’s serum with a known antigen. Diseases can be \ndiagnosed by a rising titer or seroconversion (from no antibodies to the \npresence of antibodies). Direct agglutination reactions can be used to \ndetermine antibody titer. Antibodies cause visible agglutination of soluble \nantigens affixed to latex spheres in indirect or passive agglutination tests. \nHemagglutination reactions involve agglutination reactions using red blood \ncells.  Hemagglutination reactions are used in blood typing, the diagnosis \nof certain diseases, and the identification of viruses. \nSUMMARY (5/6)\n• In neutralization reactions, the harmful effects of a bacterial exotoxin or \nvirus are  eliminated by a specific antibody. An antitoxin is an antibody \nproduced in response to a bacterial exotoxin or a toxoid that neutralizes \nthe exotoxin. In a virus neutralization test, the presence of antibodies \nagainst a virus can be detected by the antibodies’ ability to prevent \ncytopathic effects of viruses in cell cultures. Antibodies against certain \nviruses can be detected by their ability to interfere with viral \nhemagglutination in viral hemagglutination inhibition tests.\n• Complement-fixation reactions are serological tests based on the \ndepletion of a fixed amount of complement in the presence of an antigen –\nantibody reaction.\n• Fluorescent-antibody techniques use antibodies labeled with fluorescent \ndyes. Direct fluorescent-antibody tests are used to identify specific \nmicroorganisms. \nSUMMARY (6/6)\n• Indirect fluorescent-antibody tests are used to demonstrate the presence \nof antibody  in serum. A fluorescence-activated cell sorter can be used to \ndetect and count cells labeled with fluorescent antibodies.\n• ELISA techniques use antibodies linked to an enzyme. Antigen –antibody \nreactions are detected by enzyme activity. If the indicator enzyme is \npresent in the test well, an antigen –antibody reaction has occurred. The \ndirect ELISA is used to detect antigens against a specific antibody bound \nin a test well. The indirect ELISA is used to detect antibodies against an \nantigen bound in a test well.\n• Serum antibodies separated by electrophoresis are identified with an \nenzyme-linked  antibody. \n• The use of monoclonal antibodies will continue to make new diagnostic \ntests possible."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n19. DISORDERS \nASSOCIATED WITH THE \nIMMUNE SYSTEM – PART 1\n2\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n3\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n4\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Dysbiosis: \nimbalance that \ncauses adverse \neffects in humans\n• Antibiotic therapy \nkills normal gut \nmicrobiota, causing \nClostridium difficile \nto proliferate\n• Possible cause of \nIBDs such as \nulcerative colitis and \nCrohn's disease\n\nBIG PICTURE: THE HYGIENE HYPOTHESIS\n• Allergies and asthma\n• Observation that tribal populations and children growing up on farms \nhave less prevalence of allergies than children in urban settings\n• Possibly due to wider range of microbial exposures in farm setting; also \nled to lower asthma rates\n• Inflammatory bowel diseases\n• Possible link of lack of normal microbiota metabolic products leading to \nchronic inflammatory state\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Treating Crohn's \ndisease with worms\n• Whipworm eggs \nsuppress T helper cell \npathways\n• Fecal transplants for C. \ndifficile infections\n• Taking gut microbiota \nfrom a healthy \nindividual and \ntransplanting it into the \npatient\n\nHYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\n\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\n\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\n\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\n\nFigure 19.8  Allergic contact dermatitis.\n\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n21\nAUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\n\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555) \nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n28\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\n\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2\nSUMMARY (1/3)\n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Hay fever, \ntransplant rejection, and autoimmunity are examples of harmful immune  \nreactions. Immunosuppression is inhibition of the immune system. \nSuperantigens activate many T cell receptors that can cause adverse host \nresponses.\n• Hypersensitivity reactions represent immunological responses to an \nantigen (allergen) that lead to tissue damage rather than immunity. \nHypersensitivity reactions occur when a person has been sensitized to an \nantigen. Hypersensitivity reactions can be divided into four classes: types \nI, II, and III are immediate reactions based on humoral immunity, and type \nIV is a delayed reaction  based on cell -mediated immunity. \n• Childhood exposure to microbes may decrease development of allergies.\nSUMMARY (2/3)\n• Autoimmunity results from a loss of self -tolerance. Self-tolerance occurs \nduring fetal development; T cells that will target host cells are eliminated \n(clonal deletion) or inactivated. Autoimmunity may be due to antibodies \nagainst infectious agents. Graves’ disease and myasthenia gravis are \ncytotoxic autoimmune reactions in which  antibodies react to cell -surface \nantigens.\n• Systemic lupus erythematosus and rheumatoid arthritis are immune \ncomplex autoimmune reactions in which the deposition of immune \ncomplexes results in tissue damage. Multiple sclerosis, insulin -dependent \ndiabetes mellitus, and psoriasis are cell -mediated autoimmune reactions \nmediated by T cells.\nSUMMARY (3/3)\n• MHC self molecules located on cell surfaces express genetic differences \namong individuals; these antigens are called HLAs in humans. To prevent \nthe rejection of transplants, HLA and ABO blood group antigens of the \ndonor and recipient are matched as closely as possible. Transplants \nrecognized as foreign antigens may be lysed by T cells and attacked by \nmacrophages and complement -fixing antibodies. Transplantation to a \nprivileged site (such as the cornea) or of a privileged tissue (such as pig \nheart valves) does not cause an immune response. Pluripotent stem cells \ndifferentiate into a variety of tissues that may provide tissues for \ntransplant.\n• Four types of transplants have been defined on the basis of genetic \nrelationships between the donor and the recipient: autografts, isografts, \nallografts, and xenotransplants. Bone marrow transplants (with \nimmunocompetent cells) can cause graft -versus-host  disease.  \nSuccessful transplant surgery often requires immunosuppressant drugs to \nprevent an immune response to the transplanted tissue. \nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n40\nTHE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\n\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n46\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\n\nFigure 19.12  A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES\n\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n52\nACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\n\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14  Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15  Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\n\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\n\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n\n70\n\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\n\nHIV MANAGEMENT\n\nFigure 19.18  Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\n\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\n\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable\nSUMMARY (1/3)\n• Cancer cells are normal cells that have undergone transformation, divide \nuncontrollably, and possess tumor-associated antigens. The response of the \nimmune system to cancer is called immunological surveillance. TC cells \nrecognize and lyse cancerous cells. Cancer cells can escape detection and \ndestruction by the immune system. Cancer cells may grow faster than the \nimmune system can respond.\n• Novel therapeutic strategies, such as immune checkpoint inhibitors and CAR T \ncell therapy, are effective approaches to treat patients with cancer.\n• Vaccines against liver and cervical cancer are available; a therapeutic vaccine \nagainst prostate cancer also has been approved. Herceptin consists of \nmonoclonal antibodies against a breast cancer growth factor. Immunotoxins are \nchemical poisons linked to a monoclonal antibody; the antibody  selectively \nlocates the cancer cell for release of the poison.\n• Immunodeficiencies can be congenital or acquired. Congenital \nimmunodeficiencies are due to defective or absent genes. A variety of drugs, \ncancers, and infectious diseases can cause acquired  immunodeficiencies. \n• HIV is thought to have originated in central Africa and was brought to other \ncountries by modern transportation and unsafe sexual practices.\nSUMMARY (2/3)\n• AIDS is the final stage of HIV infection. HIV is a retrovirus with single -\nstranded RNA, reverse transcriptase, and a phospholipid envelope with \ngp120 spikes. HIV spikes attach to CD4+ and coreceptors on host cells; \nthe CD4+ receptor is found on  T helper cells, macrophages, and dendritic \ncells. Viral RNA is transcribed to DNA by reverse transcriptase. The viral \nDNA becomes  integrated into the host chromosome to direct synthesis of \nnew viruses or to remain latent as a provirus. HIV evades the immune \nsystem in latency, in vacuoles, by using cell–cell fusion, and by antigenic \nchange. HIV-1 accounts for most HIV infections. Subtype B of HIV -1 is the \nmost common type in the United States. HIV infection is categorized by \nsymptoms: phase 1 (asymptomatic), phase 2 (indicator opportunistic \ninfections), and phase 3 (CD4+  cells <200 cells/μ1). The progression from \nHIV infection to AIDS takes about 10 years. The life of an AIDS patient can \nbe prolonged by the proper treatment of opportunistic  infections. People \nlacking CCR5 are resistant to HIV infection. Elite controllers are long -term \nsurvivors who may hold the key to HIV treatment. \nSUMMARY (3/3)\n• HIV antibodies are detected by ELISA and Western blotting. Plasma viral \nload tests detect viral nucleic acid and are used to quantify HIV in blood.\n• HIV is transmitted by sexual contact, breast milk, contaminated needles, \ntransplacental infection, artificial insemination, and blood transfusion. In \ndeveloped countries, blood transfusions are not a likely source of infection \nbecause blood is tested for HIV antibodies. \n• Heterosexual intercourse is the primary method of HIV transmission.\n• Discouraging sexual promiscuity and using condoms and sterile needles \nprevent the transmission of HIV. Vaccine development is difficult because \nthe virus remains inside host cells and there is no model of natural \nimmunity to mimic. Current chemotherapeutic agents target the virus \nenzymes, including reverse transcriptase, integrase, and protease. Other \ninhibitors include cell entry inhibitors, maturation inhibitors, and tetherins."
              }
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [
              {
                "title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2042 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역의 개념",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역은 질병을 막는 능력을 의미하며, 감수성은 질병에 대한 저항력이 부족한 상태를 뜻합니다. 면역은 크게 두 가지로 나뉩니다. 선천성 면역은 모든 병원체에 대한 방어 기전으로, 신속하며 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 면역 또는 저항력으로, 반응 속도가 느리지만 기억 구성 요소를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "선천성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "선천성 면역은 자연 면역, 타고난 면역이라고도 불립니다. 식세포, 수지상 세포, 비만 세포, 자연 살해 세포 등 다양한 선천성 면역 세포들이 관여합니다. 이들은 감염이 발생하기 전부터 존재하며 면역 파수꾼 역할을 합니다. 일부 선천성 면역 세포는 항원을 T 세포에 제시하여 적응성 면역을 활성화시키기도 합니다. 또한, 조직 항상성과 염증에 중요하며, 치유자이자 파괴자 역할을 동시에 수행할 수 있습니다. 병원체 패턴, 사이토카인, 매개체에 의해 활성화되며, 항원에 대해 특이적이지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "적응성 면역은 특이적 면역, 후천성 면역이라고도 불립니다. 림프구인 T 세포와 B 세포가 주요 적응성 면역 세포입니다. 이들은 이차 림프 기관에서 미성숙한 형태로 존재하며, 클론 선택과 증식을 통해 특정 항원에 반응하는 세포로 발달합니다. 적응성 면역은 기억 기능을 가지며, 자가 관용 능력을 통해 자신의 몸을 공격하지 않습니다. 항원 제시 세포에 의해 활성화되며, 항원에 대해 매우 특이적입니다. 적응성 면역은 세포 매개 면역과 체액성 면역으로 나뉩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "숙주 세포에 있는 톨 유사 수용체(TLR)는 병원체 관련 분자 패턴(PAMP)에 결합합니다. TLR이 PAMP에 결합하면 숙주 세포에서 사이토카인 방출을 유도하여 면역 반응의 강도와 지속 시간을 조절합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다양한 PAMP 인식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "포유류 TLR은 다양한 PAMP를 인식합니다. 세균성 PAMP에는 그람 음성 세균 세포벽의 지질다당류(TLR4), 세균 리보솜 RNA(TLR13), 세균 DNA의 비메틸화 CpG(TLR9), 지단백질(TLR2/1, TLR2/6), 편모 단백질(TLR5) 등이 있습니다. 바이러스성 PAMP에는 이중 가닥 RNA(TLR3), 단일 가닥 RNA(TLR7, TLR8), 비메틸화 CpG DNA(TLR9) 등이 있습니다. 기생충성 PAMP에는 지단백질(TLR2/1, TLR2/6), 비메틸화 CpG DNA(TLR9), 단일 가닥 RNA(TLR7), 액틴 결합 단백질 프로필린(TLR11/12) 등이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TLR의 위치 및 내인성 PAMP 인식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "TLR은 세포 표면과 세포 내막에 존재하여 다양한 세포 위치에서 미생물을 인식합니다. TLR은 또한 내인성 PAMP도 인식할 수 있습니다. 세포 스트레스 시 유도되는 샤페론인 열충격 단백질(HSP)과 풍부한 게놈 DNA 결합 단백질인 고이동성 그룹 박스 1(HMGB1) 단백질 등이 내인성 PAMP의 예시입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TLR 신호 전달 경로",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "TLR이 미생물 리간드를 인식하면 여러 신호 전달 경로와 궁극적으로는 전사 인자가 활성화되어, 염증 및 항바이러스 반응에 중요한 유전자의 발현을 유도합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "면역은 질병에 저항하는 능력으로, 선천성 면역과 적응성 면역으로 나뉩니다. 선천성 면역은 모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 특이적 반응으로, 느리지만 기억 기능을 가집니다. 톨 유사 수용체(TLR)는 숙주 세포에서 병원체 관련 분자 패턴(PAMP)을 인식하여 사이토카인 방출을 유도하고 면역 반응을 조절합니다. TLR은 세포 표면과 세포 내막에 존재하며, 다양한 세균, 바이러스, 기생충 PAMP뿐만 아니라 내인성 PAMP도 인식하여 염증 및 항바이러스 반응에 중요한 유전자 발현을 유도하는 신호 전달 경로를 활성화합니다.",
                  "keyConcepts": [
                    {
                      "term": "선천성 면역",
                      "definition": "모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재하는 면역 방어 체계."
                    },
                    {
                      "term": "적응성 면역",
                      "definition": "특정 병원체에 대한 특이적 반응을 보이며, 기억 기능을 통해 재감염 시 더 빠르고 강력하게 반응하는 면역 방어 체계."
                    },
                    {
                      "term": "톨 유사 수용체 (TLR)",
                      "definition": "숙주 세포에 존재하며, 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 유도하는 주요 패턴 인식 수용체."
                    },
                    {
                      "term": "병원체 관련 분자 패턴 (PAMP)",
                      "definition": "미생물에 공통적으로 존재하는 특징적인 분자 구조로, 숙주의 톨 유사 수용체(TLR)에 의해 인식되어 면역 반응을 유발한다."
                    },
                    {
                      "term": "사이토카인",
                      "definition": "면역 세포 간의 신호 전달을 매개하고 면역 반응의 강도와 지속 시간을 조절하는 단백질."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "면역 (Immunity)",
                      "definition": "질병을 막는 능력."
                    },
                    {
                      "term": "감수성 (Susceptibility)",
                      "definition": "질병에 대한 저항력 부족."
                    },
                    {
                      "term": "식세포 (Phagocytes)",
                      "definition": "미생물이나 이물질을 삼켜 제거하는 면역 세포."
                    },
                    {
                      "term": "기억 구성 요소 (Memory component)",
                      "definition": "적응성 면역이 이전에 노출된 병원체를 기억하여 재감염 시 더 빠르고 강력하게 반응하는 능력."
                    },
                    {
                      "term": "자가 관용 (Self tolerance)",
                      "definition": "면역 시스템이 자신의 세포와 조직을 공격하지 않고 구분하는 능력."
                    },
                    {
                      "term": "전사 인자 (Transcription factors)",
                      "definition": "DNA에 결합하여 특정 유전자의 전사(발현)를 조절하는 단백질."
                    },
                    {
                      "term": "내인성 PAMP (Endogenous PAMPs)",
                      "definition": "병원체가 아닌 숙주 세포 자체에서 발생한 손상 또는 스트레스 신호로 TLR이 인식할 수 있는 분자."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역의 개념",
                      "id": "면역의-개념",
                      "children": [
                        {
                          "text": "면역 및 감수성 정의",
                          "id": "면역-및-감수성-정의",
                          "children": null
                        },
                        {
                          "text": "선천성 면역과 적응성 면역의 특징",
                          "id": "선천성-면역과-적응성-면역의-특징",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "선천성 면역",
                      "id": "선천성-면역",
                      "children": [
                        {
                          "text": "선천성 면역의 다른 이름",
                          "id": "선천성-면역의-다른-이름",
                          "children": null
                        },
                        {
                          "text": "선천성 면역 세포의 종류 및 특징",
                          "id": "선천성-면역-세포의-종류-및-특징",
                          "children": null
                        },
                        {
                          "text": "적응성 면역과의 연계성",
                          "id": "적응성-면역과의-연계성",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역",
                      "id": "적응성-면역",
                      "children": [
                        {
                          "text": "적응성 면역의 다른 이름",
                          "id": "적응성-면역의-다른-이름",
                          "children": null
                        },
                        {
                          "text": "적응성 면역 세포의 종류 및 특징",
                          "id": "적응성-면역-세포의-종류-및-특징",
                          "children": null
                        },
                        {
                          "text": "클론 선택, 기억, 자가 관용",
                          "id": "클론-선택-기억-자가-관용",
                          "children": null
                        },
                        {
                          "text": "세포 매개 및 체액성 면역",
                          "id": "세포-매개-및-체액성-면역",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
                      "id": "톨-유사-수용체-tlr-및-병원체-관련-분자-패턴-pamp",
                      "children": [
                        {
                          "text": "TLR과 PAMP의 상호작용",
                          "id": "tlr과-pamp의-상호작용",
                          "children": null
                        },
                        {
                          "text": "사이토카인 방출 및 면역 반응 조절",
                          "id": "사이토카인-방출-및-면역-반응-조절",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "다양한 PAMP 인식",
                      "id": "다양한-pamp-인식",
                      "children": [
                        {
                          "text": "포유류 TLR의 PAMP 인식 범위",
                          "id": "포유류-tlr의-pamp-인식-범위",
                          "children": null
                        },
                        {
                          "text": "세균성 PAMP의 종류",
                          "id": "세균성-pamp의-종류",
                          "children": null
                        },
                        {
                          "text": "바이러스성 PAMP의 종류",
                          "id": "바이러스성-pamp의-종류",
                          "children": null
                        },
                        {
                          "text": "기생충성 PAMP의 종류",
                          "id": "기생충성-pamp의-종류",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "TLR의 위치 및 내인성 PAMP 인식",
                      "id": "tlr의-위치-및-내인성-pamp-인식",
                      "children": [
                        {
                          "text": "세포 표면 및 세포 내막에서의 TLR 위치",
                          "id": "세포-표면-및-세포-내막에서의-tlr-위치",
                          "children": null
                        },
                        {
                          "text": "내인성 PAMP의 인식 (HSP, HMGB1)",
                          "id": "내인성-pamp의-인식-hsp-hmgb1",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "TLR 신호 전달 경로",
                      "id": "tlr-신호-전달-경로",
                      "children": [
                        {
                          "text": "미생물 리간드 인식의 결과",
                          "id": "미생물-리간드-인식의-결과",
                          "children": null
                        },
                        {
                          "text": "염증 및 항바이러스 반응 유도",
                          "id": "염증-및-항바이러스-반응-유도",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "선천성 면역과 적응성 면역의 주요 차이점은 무엇인가요?",
                    "options": [
                      "선천성 면역은 태어날 때부터 존재하며 비특이적인 반면, 적응성 면역은 특정 병원체에 특이적이며 기억 기능을 가집니다.",
                      "선천성 면역은 특정 병원체에 특이적이지만 반응이 느리고, 적응성 면역은 모든 병원체에 빠르게 반응합니다.",
                      "선천성 면역은 기억 기능이 있지만 T세포와 B세포가 관여하지 않고, 적응성 면역은 기억 기능이 없습니다.",
                      "선천성 면역은 항원 제시 세포에 의해 활성화되고, 적응성 면역은 병원체 패턴에 의해 활성화됩니다."
                    ],
                    "answerIndex": 0,
                    "explanation": "선천성 면역은 타고난 비특이적 방어이며, 적응성 면역은 특정 항원에 대한 후천적, 기억 기반 방어입니다."
                  },
                  {
                    "question": "톨 유사 수용체(TLR)의 주요 기능은 무엇인가요?",
                    "options": [
                      "항체를 생산하여 병원체를 직접 중화시키는 기능",
                      "병원체 관련 분자 패턴(PAMP)을 인식하고 사이토카인 방출을 유도하여 면역 반응을 조절하는 기능",
                      "감염된 세포를 직접 파괴하는 자연 살해 세포의 기능을 억제하는 기능",
                      "면역 반응 후 기억 세포를 형성하여 다음 감염에 대비하는 기능"
                    ],
                    "answerIndex": 1,
                    "explanation": "TLR은 숙주 세포에서 PAMP를 인식하여 사이토카인 방출을 유도하고 면역 반응의 강도와 지속 시간을 조절하는 역할을 합니다."
                  },
                  {
                    "question": "다음 중 세균성 PAMP에 해당하지 않는 것은 무엇인가요?",
                    "options": [
                      "지질다당류 (Lipopolysaccharide)",
                      "세균 리보솜 RNA (Bacterial ribosomal RNA)",
                      "이중 가닥 RNA (Double-stranded RNA)",
                      "비메틸화 CpG (Unmethylated CpG in the bacterial DNA)"
                    ],
                    "answerIndex": 2,
                    "explanation": "이중 가닥 RNA(Double-stranded RNA)는 바이러스성 PAMP에 해당합니다. 지질다당류, 세균 리보솜 RNA, 비메틸화 CpG는 세균성 PAMP입니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 1284 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "물리적 요인",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "피부는 선천성 면역의 중요한 물리적 방어선입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "진피는 결합 조직으로 구성된 내부 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성된 외부 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "피부가 벗겨지고 건조한 상태를 유지하는 것은 미생물 성장을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "점막은 위장관, 호흡기, 비뇨생식기를 덮는 상피층입니다. 점액은 미생물을 가두고 관이 건조해지는 것을 막는 점성 당단백질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "누액 기관은 눈물을 배출하여 눈을 씻어냅니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "섬모 승강기는 점액에 갇힌 미생물을 폐에서 멀리 운반합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "귀지는 미생물이 귀에 들어가는 것을 막습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "소변은 흐름을 통해 요도를 청소합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "연동 운동, 배변, 구토, 설사 또한 미생물 배출에 기여하는 물리적 방어 기전입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "화학적 요인",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "피지는 보호막을 형성하고 피부의 pH를 3~5로 낮춥니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "땀, 눈물, 침, 소변에 있는 리소자임은 세균 세포벽을 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "위액의 낮은 pH (1.2~3.0)는 대부분의 세균과 독소를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "질 분비물의 낮은 pH (3~5)는 미생물을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "정상 미생물총과 선천성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "정상 미생물총은 미생물 길항 작용 (경쟁적 배제)을 통해 병원균과 경쟁합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 공간과 영양분에 대한 경쟁 우위를 점하거나, 병원균에 해로운 물질을 생산하거나, 병원균 생존에 영향을 미치는 조건을 변경함으로써 이루어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "공생은 한 유기체는 이득을 얻고 다른 유기체 (숙주)는 해를 입지 않는 관계를 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로바이오틱스는 유익한 효과를 발휘하기 위해 투여되는 살아있는 미생물 배양물입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "무균 쥐를 사육하기 위해서는 엄격한 무균 상태가 요구됩니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 1차 방어선인 물리적 및 화학적 장벽과 정상 미생물총의 역할을 다룹니다. 피부, 점막, 누액 기관, 섬모 승강기, 귀지, 소변, 연동 운동, 배변, 구토, 설사 등 다양한 물리적 요인들이 미생물 침입을 막는 역할을 합니다. 또한, 피지, 리소자임, 위액 및 질 분비물의 낮은 pH와 같은 화학적 요인들이 미생물 성장을 억제하거나 파괴합니다. 정상 미생물총은 경쟁적 배제를 통해 병원균과 경쟁하며 숙주 방어에 기여합니다. 마지막으로, 마이크로바이옴이 선천성 면역 형성에 중요한 영향을 미친다는 점이 강조됩니다.",
                  "keyConcepts": [
                    {
                      "term": "선천성 면역의 물리적 방어선",
                      "definition": "피부, 점막, 눈물, 섬모 등 신체 외부 및 내부 표면에서 미생물 침입을 물리적으로 막는 방어 기전."
                    },
                    {
                      "term": "선천성 면역의 화학적 방어선",
                      "definition": "피지, 리소자임, 위액, 질 분비물 등의 화학 물질이 미생물 성장을 억제하거나 파괴하는 방어 기전."
                    },
                    {
                      "term": "정상 미생물총의 역할",
                      "definition": "인체에 상주하는 유익한 미생물들이 공간 및 영양분 경쟁, 유해 물질 생산 등을 통해 병원균의 침입과 증식을 억제하는 현상 (미생물 길항 작용)."
                    },
                    {
                      "term": "마이크로바이옴과 선천성 면역",
                      "definition": "인체 내 미생물 군집인 마이크로바이옴이 숙주의 선천성 면역 시스템 발달 및 기능에 중요한 영향을 미친다는 개념."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "케라틴",
                      "definition": "피부 표피에 존재하는 보호 단백질로, 피부의 물리적 장벽을 형성하는 데 기여한다."
                    },
                    {
                      "term": "점액",
                      "definition": "점막에서 분비되는 점성 당단백질로, 미생물을 가두고 점막이 건조해지는 것을 방지한다."
                    },
                    {
                      "term": "누액 기관",
                      "definition": "눈물을 생성하고 배출하여 눈을 지속적으로 씻어내 미생물을 제거하는 역할을 하는 기관."
                    },
                    {
                      "term": "섬모 승강기",
                      "definition": "호흡기 점막의 섬모가 움직여 점액에 갇힌 미생물을 폐에서 멀리 이동시키는 메커니즘."
                    },
                    {
                      "term": "리소자임",
                      "definition": "땀, 눈물, 침, 소변 등에 존재하는 효소로, 세균의 세포벽을 파괴하여 항균 작용을 한다."
                    },
                    {
                      "term": "미생물 길항 작용",
                      "definition": "정상 미생물총이 공간, 영양분 경쟁 또는 병원균에 해로운 물질 생산을 통해 병원균의 성장을 억제하는 현상."
                    },
                    {
                      "term": "공생",
                      "definition": "두 유기체가 함께 살아가며 한 유기체는 이득을 얻지만 다른 유기체(숙주)는 해를 입지 않는 관계."
                    }
                  ],
                  "outline": [
                    {
                      "text": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                      "id": "선천성-면역-1차-방어선",
                      "children": [
                        {
                          "text": "물리적 요인",
                          "id": "물리적-요인",
                          "children": [
                            {
                              "text": "피부",
                              "id": "피부",
                              "children": null
                            },
                            {
                              "text": "점막",
                              "id": "점막",
                              "children": null
                            },
                            {
                              "text": "누액 기관",
                              "id": "누액-기관",
                              "children": null
                            },
                            {
                              "text": "기타 물리적 방어 (섬모 승강기, 귀지, 소변, 연동 운동 등)",
                              "id": "기타-물리적-방어",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "화학적 요인",
                          "id": "화학적-요인",
                          "children": [
                            {
                              "text": "피지",
                              "id": "피지",
                              "children": null
                            },
                            {
                              "text": "리소자임",
                              "id": "리소자임",
                              "children": null
                            },
                            {
                              "text": "위액의 낮은 pH",
                              "id": "위액의-낮은-ph",
                              "children": null
                            },
                            {
                              "text": "질 분비물의 낮은 pH",
                              "id": "질-분비물의-낮은-ph",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "정상 미생물총과 선천성 면역",
                          "id": "정상-미생물총과-선천성-면역",
                          "children": [
                            {
                              "text": "미생물 길항 작용",
                              "id": "미생물-길항-작용",
                              "children": null
                            },
                            {
                              "text": "공생 및 프로바이오틱스",
                              "id": "공생-및-프로바이오틱스",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
                          "id": "마이크로바이옴-탐구",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "피부의 표피층에 포함되어 미생물 성장을 억제하는 보호 단백질은 무엇입니까?",
                    "options": [
                      "케라틴",
                      "콜라겐",
                      "엘라스틴",
                      "멜라닌"
                    ],
                    "answerIndex": 0,
                    "explanation": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성되어 있으며, 이는 미생물 성장을 억제하는 데 기여합니다."
                  },
                  {
                    "question": "선천성 면역의 화학적 방어선 중, 땀, 눈물, 침, 소변에 존재하며 세균 세포벽을 파괴하는 효소는 무엇입니까?",
                    "options": [
                      "펩신",
                      "아밀레이스",
                      "리소자임",
                      "트립신"
                    ],
                    "answerIndex": 2,
                    "explanation": "리소자임은 땀, 눈물, 침, 소변에 존재하며 세균의 세포벽을 파괴하는 강력한 항균 효소입니다."
                  },
                  {
                    "question": "정상 미생물총이 병원균과 경쟁하여 성장을 억제하는 주요 메커니즘을 설명하는 용어는 무엇입니까?",
                    "options": [
                      "변이원성",
                      "미생물 길항 작용",
                      "자가면역",
                      "과민 반응"
                    ],
                    "answerIndex": 1,
                    "explanation": "정상 미생물총은 '미생물 길항 작용' 또는 '경쟁적 배제'를 통해 공간, 영양분 경쟁 및 유해 물질 생산으로 병원균의 성장을 억제합니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2110 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "I. 혈액의 구성 요소",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액은 혈장 내에 부유하는 세포 및 세포 조각으로 구성됩니다. 주요 구성 요소는 적혈구(red blood cells), 백혈구(white blood cells), 혈소판(platelets)이며, 이들은 적골수 줄기세포에서 조혈 작용(hematopoiesis)을 통해 생성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "과립구 (Granulocytes)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "과립구는 세포질 내에 광학 현미경으로 볼 수 있는 과립을 가진 백혈구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호중구(Neutrophils): 식균 작용을 하며 감염 초기 단계에서 활동합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호염기구(Basophils): 히스타민을 방출하며 알레르기 반응에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호산구(Eosinophils): 식균 작용을 하며 기생충과 연충류에 대해 독성을 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "무과립구 (Agranulocytes)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "무과립구는 세포질 내에 과립이 있지만 광학 현미경으로 보이지 않는 백혈구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 단핵구(Monocytes): 조직에서 대식세포(macrophages)로 성숙하여 식균 작용을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 수지상 세포(Dendritic cells): 피부, 점막, 흉선에서 발견되며 식균 작용을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 림프구(Lymphocytes): T세포, B세포, NK세포를 포함하며 적응 면역에 중요한 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "II. 림프계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "림프계는 림프, 림프관, 림프 조직, 적골수로 구성됩니다. 림프구와 식세포를 포함하며, 림프는 미생물을 림프절로 운반하여 림프구와 대식세포가 병원균을 파괴하도록 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "림프계의 주요 구성 요소 및 기관에는 흉관(좌측 림프관), 우측 림프관, 좌측 쇄골하정맥, 우측 쇄골하정맥, 편도, 흉선, 림프절, 비장, 대장, 소장, 파이어판(Peyer’s patch), 림프관, 적골수, 림프 모세혈관 등이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "III. 숙주 방어: 개요 및 식세포",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포(Phagocytes)는 '먹다'를 의미하는 그리스어 'Phago'와 '세포'를 의미하는 'Cyte'에서 유래했습니다. 식세포에는 조직과 장기에 상주하는 고정 대식세포(Fixed macrophages)와 조직을 돌아다니며 감염 부위에 모이는 자유(유리) 대식세포(Free (wandering) macrophages)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IV. 식균 작용의 메커니즘",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "식균 작용은 다음 단계를 거쳐 진행됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 주화성(Chemotaxis): 화학적 신호가 식세포를 미생물로 유인합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 부착(Adherence): 식세포가 미생물 표면에 부착합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 섭취(Ingestion): 미생물이 혈청 단백질로 코팅되어(옵소닌화, Opsonization) 섭취가 용이해집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 소화(Digestion): 미생물이 식포-리소좀(phagolysosome) 내부에서 소화됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "V. 미생물의 식균 작용 회피 전략",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "일부 미생물은 숙주의 방어 체계를 회피하기 위한 다양한 병원성 인자(Virulence factors)를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 부착 억제: M 단백질, 캡슐 (예: Streptococcus pyogenes, S. pneumoniae)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식세포 사멸: 백혈구용해소(leukocidins) (예: Staphylococcus aureus)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식세포 용해: 막 공격 복합체(membrane attack complex) (예: Listeria monocytogenes)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포 탈출: (예: Shigella, Rickettsia)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포-리소좀 융합 방지: (예: HIV, Mycobacterium tuberculosis)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포-리소좀 내 생존: (예: Coxiella burnetii)",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 2차 방어선으로서 혈액의 구성 요소와 식세포의 역할에 대해 설명합니다. 혈액의 주요 구성 요소(적혈구, 백혈구, 혈소판)와 조혈 작용을 소개하고, 백혈구를 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 분류하여 각 유형의 기능과 특징을 설명합니다. 또한, 림프계의 구성 요소와 병원균 제거에서의 역할을 다루고, 식세포의 정의와 고정/자유 대식세포의 종류를 설명합니다. 이어서 식균 작용의 네 가지 주요 단계(주화성, 부착, 섭취, 소화)를 자세히 설명하며, 특히 옵소닌화의 중요성을 강조합니다. 마지막으로, 미생물이 식균 작용을 회피하기 위해 사용하는 다양한 전략(부착 억제, 식세포 사멸, 식포 탈출 등)과 관련 미생물 예를 제시합니다.",
                  "keyConcepts": [
                    {
                      "term": "혈액의 구성 요소",
                      "definition": "혈액을 구성하는 주요 성분으로, 혈장 내에 부유하는 적혈구, 백혈구, 혈소판을 포함하며, 조혈 작용을 통해 생성됩니다."
                    },
                    {
                      "term": "백혈구의 종류와 기능",
                      "definition": "감염 및 알레르기 반응에 관여하는 면역 세포로, 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 나뉘며 각각 특정한 면역 기능을 수행합니다."
                    },
                    {
                      "term": "림프계의 역할",
                      "definition": "림프, 림프관, 림프 조직, 적골수로 구성되며 림프구와 식세포를 포함하여 병원균을 림프절로 운반하고 파괴함으로써 면역 방어에 기여하는 시스템입니다."
                    },
                    {
                      "term": "식균 작용",
                      "definition": "식세포가 미생물이나 세포 잔해를 섭취하고 소화하여 제거하는 과정으로, 주화성, 부착, 섭취(옵소닌화 포함), 소화의 단계를 거칩니다."
                    },
                    {
                      "term": "미생물의 식균 작용 회피",
                      "definition": "미생물이 숙주의 식균 작용으로부터 자신을 보호하기 위해 사용하는 다양한 전략으로, 부착 억제, 식세포 사멸, 식포 탈출, 식포-리소좀 융합 방지, 식포-리소좀 내 생존 등이 있습니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "조혈 작용 (Hematopoiesis)",
                      "definition": "적골수 줄기세포에서 혈액 세포(적혈구, 백혈구, 혈소판)가 생성되는 과정입니다."
                    },
                    {
                      "term": "과립구 (Granulocytes)",
                      "definition": "세포질 내에 과립을 가진 백혈구로, 호중구, 호염기구, 호산구가 포함됩니다."
                    },
                    {
                      "term": "무과립구 (Agranulocytes)",
                      "definition": "세포질 내에 과립이 뚜렷하지 않은 백혈구로, 단핵구, 수지상 세포, 림프구가 포함됩니다."
                    },
                    {
                      "term": "식세포 (Phagocytes)",
                      "definition": "미생물이나 이물질을 섭취하고 소화하는 세포(예: 대식세포, 호중구)를 총칭합니다."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포에 의한 섭취가 용이해지는 과정입니다."
                    },
                    {
                      "term": "주화성 (Chemotaxis)",
                      "definition": "화학적 신호에 의해 세포가 특정 방향으로 이동하는 현상으로, 식세포가 미생물로 유인되는 과정입니다."
                    },
                    {
                      "term": "병원성 인자 (Virulence factors)",
                      "definition": "미생물이 숙주에게 질병을 일으키거나 숙주의 면역 체계를 회피하는 데 도움이 되는 특징 또는 물질입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "I. 혈액의 구성 요소",
                      "id": "i-혈액의-구성-요소",
                      "children": [
                        {
                          "text": "과립구 (Granulocytes)",
                          "id": "과립구-granulocytes",
                          "children": null
                        },
                        {
                          "text": "무과립구 (Agranulocytes)",
                          "id": "무과립구-agranulocytes",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "II. 림프계",
                      "id": "ii-림프계",
                      "children": null
                    },
                    {
                      "text": "III. 숙주 방어: 개요 및 식세포",
                      "id": "iii-숙주-방어-개요-및-식세포",
                      "children": null
                    },
                    {
                      "text": "IV. 식균 작용의 메커니즘",
                      "id": "iv-식균-작용의-메커니즘",
                      "children": null
                    },
                    {
                      "text": "V. 미생물의 식균 작용 회피 전략",
                      "id": "v-미생물의-식균-작용-회피-전략",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 과립구에 해당하지 않는 백혈구는 무엇입니까?",
                    "options": [
                      "단핵구",
                      "호중구",
                      "호염기구",
                      "호산구"
                    ],
                    "answerIndex": 0,
                    "explanation": "단핵구는 무과립구에 속하며, 조직에서 대식세포로 성숙하여 식균 작용을 합니다. 호중구, 호염기구, 호산구는 모두 과립구에 해당합니다."
                  },
                  {
                    "question": "식균 작용의 단계 중, 미생물이 혈청 단백질로 코팅되어 식세포에 의한 섭취가 용이해지는 과정을 무엇이라고 합니까?",
                    "options": [
                      "주화성",
                      "부착",
                      "옵소닌화",
                      "소화"
                    ],
                    "answerIndex": 2,
                    "explanation": "옵소닌화는 미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포의 섭취(Ingestion)를 돕는 과정입니다."
                  },
                  {
                    "question": "다음 미생물 중 식포-리소좀 융합을 방지하여 식균 작용을 회피하는 것으로 알려진 것은 무엇입니까?",
                    "options": [
                      "Streptococcus pyogenes",
                      "Staphylococcus aureus",
                      "Listeria monocytogenes",
                      "Mycobacterium tuberculosis"
                    ],
                    "answerIndex": 3,
                    "explanation": "Mycobacterium tuberculosis는 식포-리소좀 융합을 방지하여 식세포 내에서 생존함으로써 식균 작용을 회피합니다. Streptococcus pyogenes는 부착을 억제하고, Staphylococcus aureus는 백혈구용해소를 통해 식세포를 사멸시키며, Listeria monocytogenes는 식세포를 용해시킵니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 3719 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "염증: 개요",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "염증",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "염증의 네 가지 징후 및 증상: 발적(redness), 부종(edema), 통증(pain), 열(heat).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "손상 인자를 파괴하거나 신체에 미치는 영향을 제한합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "손상 인자에 의해 손상된 조직을 복구하고 대체합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 유발 물질",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "염증은 간에서 급성기 단백질을 활성화시켜 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주요 염증 매개체는 다음과 같습니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "히스타민 (Histamine): 비만 세포, 호염기구, 혈소판에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "키닌 (Kinins): 혈장 내에 존재하며 호중구를 유인하여 화학주성(chemotaxis)을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로스타글란딘 (Prostaglandins): 손상된 세포에서 분비되며 히스타민과 키닌의 효과를 강화하고 식세포가 모세혈관 벽을 통과하는 것을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류코트리엔 (Leukotrienes): 비만 세포와 호염기구에서 분비되며 혈관 투과성을 증가시키고 식세포가 병원체에 부착되는 것을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 (Complement): 혈장 내에 존재하며 히스타민 분비를 자극하고 식세포를 유인하며 식균 작용을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인 (Cytokines): 고정된 대식세포에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 과정 단계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 16.9a-b 염증 과정: 조직 손상, 혈관 반응 및 식균 작용을 포함합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 과정",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조직 손상이 발생하면 손상된 세포에서 히스타민, 키닌, 프로스타글란딘, 류코트리엔, 사이토카인과 같은 화학 물질이 방출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액 응고가 형성되기 시작하고 농양(abscess)이 형성되기 시작합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "식세포 이동 및 식균 작용",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "마지네이션(Margination)은 염증 부위의 사이토카인에 반응하여 식세포가 혈관에 달라붙는 현상입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포는 다이아페데시스(diapedesis)를 통해 혈관 내피 세포 사이를 비집고 나옵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "조직 복구",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "모든 유해 물질이 제거되거나 중화될 때까지 완료될 수 없습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "기질(Stroma)은 복구되는 지지 결합 조직입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "실질(Parenchyma)은 복구되는 조직의 기능적인 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "발열",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "비정상적으로 높은 체온입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "시상하부(Hypothalamus)는 일반적으로 37°C로 설정되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인이 시상하부로 하여금 프로스타글란딘을 방출하게 하여 시상하부의 온도를 더 높게 재설정합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "몸은 혈관을 수축시키고 떨림(shivering)이 발생하여 체온이 상승합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "체온이 떨어지면 (위기, crisis) 혈관 확장과 땀이 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 시스템",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "간에서 생산되는 혈청 단백질로, 미생물 파괴에 면역계를 보조합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 활성화라고 불리는 과정에서 캐스케이드(cascade) 방식으로 작용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "단백질은 대문자 C로 표시되며 발견 순서대로 번호가 매겨집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 단편은 소문자 a와 b로 표시됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체: 활성화",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "고전적 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 항원에 결합하여 C1을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C1은 분열하여 C2와 C4를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C2a와 C4b가 결합하여 C3을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3a는 염증에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3b는 세포 용해(cytolysis)와 옵소닌화(opsonization)에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "대체 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액 내 C3가 미생물 표면의 B, D, P 인자와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3는 C3a와 C3b로 분열하며, 고전적 경로와 동일하게 기능합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "렉틴 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "대식세포가 병원체를 섭취하여 사이토카인을 방출하고, 이는 간에서 렉틴 생산을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "만노스 결합 렉틴(Mannose-binding lectin, MBL)이 만노스에 결합하여 C2와 C4를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C2a와 C4b가 C3을 활성화하며, 이는 고전적 경로 및 대체 경로와 동일하게 기능합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 활성화의 결과",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "세포 용해",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 보체 단백질이 막 공격 복합체(Membrane Attack Complex, MAC)를 형성합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "옵소닌화",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포가 미생물에 부착되는 것을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 보체 단백질이 비만 세포에 결합하여 히스타민을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 16.12 보체 활성화의 결과. 그림 16.13 보체에 의해 자극된 염증.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 시스템은 신체가 감염과 병원체를 퇴치하는 또 다른 방법입니다. 선천성 면역의 이 구성 요소는 다른 면역 반응을 '보완'합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체는 혈청에 순환하는 30개 이상의 단백질 그룹으로, 캐스케이드 방식으로 활성화됩니다: 한 보체 단백질이 다음 단백질을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 캐스케이드는 병원체에 의해 직접 활성화되거나 항체-항원 반응에 의해 활성화될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 단백질들은 함께 (1) 세포 용해, (2) 강화된 식균 작용, (3) 염증을 통해 미생물을 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체: 결과",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "보체 활성화의 조절",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 단백질은 보체 단백질을 쉽게 분해하여 숙주 세포 손상을 최소화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체와 질병",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 단백질의 부족은 감염에 대한 취약성을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 시스템 회피",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "캡슐은 보체 활성화를 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인터페론",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "세포에서 생산되는 사이토카인으로, 항바이러스 활동을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IFN-α 및 IFN-β: 바이러스 감염에 반응하여 세포에서 생산되며, 이웃 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IFN-γ: 호중구와 대식세포가 박테리아를 죽이도록 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "알파 및 베타 인터페론(IFN)의 항바이러스 작용",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "철 결합 단백질",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "트랜스페린(Transferrin): 혈액 및 조직액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "락토페린(Lactoferrin): 우유, 침, 점액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "페리틴(Ferritin): 간, 비장, 적골수에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "헤모글로빈(Hemoglobin): 적혈구에 위치합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "박테리아는 철 결합 단백질과 경쟁하기 위해 시데로포어(siderophores)를 생산합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항균 펩타이드",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "미생물의 단백질 및 당 분자에 반응하여 생산되는 짧은 펩타이드입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포벽 합성을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "원형질막에 구멍을 형성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "광범위한 활성 스펙트럼을 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "기타 요인",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "유전적 저항성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "선택적 생존 이점을 부여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "예: 겸상 적혈구 특성 및 열대열원충(Plasmodium falciparum).",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "연령",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "매우 어린 연령과 노인들은 질병에 더 취약합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "건강 프로토콜 준수",
                    "level": 2
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 핵심 구성 요소인 염증, 발열, 보체 시스템, 인터페론, 철 결합 단백질 및 항균 펩타이드에 대해 설명합니다. 염증의 징후, 매개체, 과정 및 조직 복구를 다루고, 발열의 메커니즘과 체온 조절을 설명합니다. 또한 보체 시스템의 세 가지 활성화 경로(고전적, 대체, 렉틴)와 그 결과(세포 용해, 옵소닌화, 염증)를 상세히 제시합니다. 마지막으로, 인터페론의 항바이러스 역할, 철 결합 단백질의 기능, 항균 펩타이드의 작용 방식, 그리고 유전적 저항성 및 연령과 같은 기타 면역 관련 요인들을 소개합니다.",
                  "keyConcepts": [
                    {
                      "term": "염증 (Inflammation)",
                      "definition": "손상된 조직을 파괴하거나 유해 물질의 영향을 제한하고, 손상된 조직을 복구 및 대체하는 신체의 방어 반응입니다. 발적, 부종, 통증, 열의 네 가지 주요 징후를 가집니다."
                    },
                    {
                      "term": "발열 (Fever)",
                      "definition": "비정상적으로 높은 체온으로, 사이토카인에 의해 시상하부의 체온 설정점이 높아져 발생합니다. 병원체 성장을 억제하고 면역 반응을 강화하는 데 도움을 줄 수 있습니다."
                    },
                    {
                      "term": "보체 시스템 (Complement System)",
                      "definition": "간에서 생산되는 30개 이상의 혈청 단백질로 구성된 캐스케이드 시스템입니다. 병원체 파괴를 돕기 위해 세포 용해, 옵소닌화, 염증을 유발하는 세 가지 활성화 경로(고전적, 대체, 렉틴)를 통해 작동합니다."
                    },
                    {
                      "term": "인터페론 (Interferons)",
                      "definition": "세포에서 생산되는 사이토카인으로, 특히 IFN-α와 IFN-β는 바이러스 감염에 반응하여 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질을 생산하도록 유도하는 항바이러스 활성을 가집니다."
                    },
                    {
                      "term": "항균 물질 (Antimicrobial Substances)",
                      "definition": "철 결합 단백질(트랜스페린, 락토페린, 페리틴, 헤모글로빈)과 항균 펩타이드를 포함하며, 미생물의 성장을 억제하거나 직접 파괴하여 숙주를 보호하는 역할을 합니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "히스타민 (Histamine)",
                      "definition": "비만 세포 등에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발하는 혈관 활성 매개체입니다."
                    },
                    {
                      "term": "다이아페데시스 (Diapedesis)",
                      "definition": "식세포가 혈관 내피 세포 사이를 비집고 나와 조직 손상 부위로 이동하는 과정입니다."
                    },
                    {
                      "term": "마지네이션 (Margination)",
                      "definition": "염증 부위의 사이토카인에 반응하여 식세포가 혈관 내피에 달라붙는 현상입니다."
                    },
                    {
                      "term": "막 공격 복합체 (Membrane Attack Complex, MAC)",
                      "definition": "활성화된 보체 단백질에 의해 형성되며, 미생물 세포막에 구멍을 뚫어 세포 용해를 유발하는 구조입니다."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "보체 단백질(C3b) 등이 미생물을 코팅하여 식세포가 미생물을 더 쉽게 인식하고 식균 작용을 하도록 촉진하는 과정입니다."
                    },
                    {
                      "term": "시데로포어 (Siderophores)",
                      "definition": "박테리아가 숙주의 철 결합 단백질과 경쟁하여 철을 획득하기 위해 생산하는 물질입니다."
                    },
                    {
                      "term": "항바이러스 단백질 (Antiviral Proteins, AVPs)",
                      "definition": "인터페론의 유도에 의해 세포에서 생산되며, 바이러스 복제를 억제하는 단백질입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "염증",
                      "id": "inflammation",
                      "children": [
                        {
                          "text": "개요 및 징후",
                          "id": "inflammation-overview-signs",
                          "children": null
                        },
                        {
                          "text": "염증 반응 유발 물질",
                          "id": "inflammation-mediators",
                          "children": null
                        },
                        {
                          "text": "염증 과정 단계",
                          "id": "inflammation-steps",
                          "children": null
                        },
                        {
                          "text": "식세포 이동 및 식균 작용",
                          "id": "phagocyte-migration-phagocytosis",
                          "children": null
                        },
                        {
                          "text": "조직 복구",
                          "id": "tissue-repair",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "발열",
                      "id": "fever",
                      "children": [
                        {
                          "text": "체온 조절 및 발열 메커니즘",
                          "id": "fever-mechanism",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "보체 시스템",
                      "id": "complement-system",
                      "children": [
                        {
                          "text": "개요 및 기능",
                          "id": "complement-overview",
                          "children": null
                        },
                        {
                          "text": "보체 활성화 경로",
                          "id": "complement-activation-pathways",
                          "children": [
                            {
                              "text": "고전적 경로",
                              "id": "classical-pathway",
                              "children": null
                            },
                            {
                              "text": "대체 경로",
                              "id": "alternative-pathway",
                              "children": null
                            },
                            {
                              "text": "렉틴 경로",
                              "id": "lectin-pathway",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "보체 활성화의 결과",
                          "id": "complement-activation-outcomes",
                          "children": [
                            {
                              "text": "세포 용해",
                              "id": "cytolysis",
                              "children": null
                            },
                            {
                              "text": "옵소닌화",
                              "id": "opsonization",
                              "children": null
                            },
                            {
                              "text": "염증",
                              "id": "complement-inflammation",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "보체 조절 및 질병",
                          "id": "complement-regulation-disease",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항균 물질",
                      "id": "antimicrobial-substances",
                      "children": [
                        {
                          "text": "인터페론",
                          "id": "interferons",
                          "children": null
                        },
                        {
                          "text": "철 결합 단백질",
                          "id": "iron-binding-proteins",
                          "children": null
                        },
                        {
                          "text": "항균 펩타이드",
                          "id": "antimicrobial-peptides",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "기타 요인",
                      "id": "other-factors",
                      "children": [
                        {
                          "text": "유전적 저항성",
                          "id": "genetic-resistance",
                          "children": null
                        },
                        {
                          "text": "연령",
                          "id": "age",
                          "children": null
                        },
                        {
                          "text": "건강 프로토콜 준수",
                          "id": "observing-healthy-protocols",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "염증의 네 가지 주요 징후에 해당하지 않는 것은 무엇입니까?",
                    "options": [
                      "발적",
                      "부종",
                      "가려움",
                      "열"
                    ],
                    "answerIndex": 2,
                    "explanation": "염증의 네 가지 주요 징후는 발적(redness), 부종(swelling), 통증(pain), 열(heat)입니다. 가려움은 일반적인 염증의 주요 징후에 해당하지 않습니다."
                  },
                  {
                    "question": "보체 활성화의 세 가지 주요 결과에 속하지 않는 것은 무엇입니까?",
                    "options": [
                      "세포 용해 (Cytolysis)",
                      "옵소닌화 (Opsonization)",
                      "항체 생산 (Antibody production)",
                      "염증 (Inflammation)"
                    ],
                    "answerIndex": 2,
                    "explanation": "보체 활성화의 주요 결과는 세포 용해, 옵소닌화, 염증입니다. 항체 생산은 보체 시스템의 직접적인 결과가 아닌 적응 면역 반응의 일부입니다."
                  },
                  {
                    "question": "인터페론(IFN-α 및 IFN-β)의 주요 역할은 무엇입니까?",
                    "options": [
                      "세균을 직접 죽인다.",
                      "발열을 유도한다.",
                      "바이러스 감염에 반응하여 항바이러스 단백질 생성을 유도한다.",
                      "조직 복구를 돕는다."
                    ],
                    "answerIndex": 2,
                    "explanation": "IFN-α와 IFN-β는 바이러스 감염에 의해 생성되어 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 개요 및 이중적 특성",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1042 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "적응성 면역 체계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "적응성 면역은 특정 병원체를 표적으로 하는 방어 체계입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 감염이나 백신 접종을 통해 획득됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것을 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 반응은 동일한 외래 물질과의 이후 상호 작용으로, '기억' 덕분에 더 빠르고 효과적입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역 체계의 이중적 특성",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "체액성 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "체액성 면역은 항원(antigens)으로 알려진 외래 분자와 싸우는 항체를 생성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 적골수에서 생성되고 성숙하는 림프구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 항원을 인식하고 항체를 만듭니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 조류의 파브리시우스 낭(bursa of Fabricius)에서 이름을 따왔습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "애니메이션: 체액성 면역 개요",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포성 면역 (세포 매개 면역)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포성 면역은 T 림프구를 생성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 림프구는 식세포에 의해 처리된 항원 펩타이드를 인식합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 흉선에서 성숙합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 표면의 T 세포 수용체(TCRs)가 항원과 접촉하면 T 세포는 항체 대신 사이토카인을 분비합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 및 B 세포 발달",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "체액성 면역과 세포성 면역의 공격 대상 비교",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포성 면역은 세포 내부에 있는 항원을 공격합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 바이러스나 M. leprae, L. monocytogenes와 같은 일부 세포 내 세균에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "체액성 면역은 세포 외부의 침입자와 위협에 맞서 싸웁니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 세포 외 세균과 독소, 그리고 숙주 세포에 들어가기 전의 바이러스를 포함합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "제공된 텍스트는 특정 병원체를 표적으로 하는 방어 체계인 적응성 면역에 대해 설명합니다. 적응성 면역은 감염이나 백신을 통해 획득되며, 일차 반응과 이차 반응으로 구분됩니다. 또한, 적응성 면역의 이중적 특성으로 체액성 면역(B 세포, 항체 생성, 세포 외부 위협 방어)과 세포성 면역(T 세포, 사이토카인 분비, 세포 내부 위협 방어)을 상세히 다루고, 각 면역 체계가 공격하는 대상의 차이점을 비교합니다.",
                  "keyConcepts": [
                    {
                      "term": "적응성 면역",
                      "definition": "특정 병원체를 표적으로 삼는 방어 체계로, 감염이나 백신 접종을 통해 획득되며, 기억을 통해 더 빠르고 효과적인 이차 반응을 가능하게 합니다."
                    },
                    {
                      "term": "체액성 면역",
                      "definition": "B 세포가 항원을 인식하고 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸우는 면역 반응입니다."
                    },
                    {
                      "term": "세포성 면역",
                      "definition": "T 림프구가 식세포에 의해 처리된 항원 펩타이드를 인식하고 사이토카인을 분비하여 세포 내부에 있는 항원(예: 바이러스, 일부 세포 내 세균)을 공격하는 면역 반응입니다."
                    },
                    {
                      "term": "일차 반응 및 이차 반응",
                      "definition": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것이며, 이차 반응은 동일한 물질과의 이후 상호 작용으로, 기억 덕분에 더 빠르고 효과적입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "항원 (Antigen)",
                      "definition": "면역 반응, 특히 항체 생성을 유도하는 외래 분자입니다."
                    },
                    {
                      "term": "항체 (Antibody)",
                      "definition": "B 세포에 의해 생성되며 특정 항원과 결합하여 중화하거나 제거하는 Y자 모양의 단백질입니다."
                    },
                    {
                      "term": "B 세포 (B cell)",
                      "definition": "적골수에서 생성 및 성숙하며 항원을 인식하고 항체를 만드는 림프구입니다."
                    },
                    {
                      "term": "T 세포 (T cell)",
                      "definition": "흉선에서 성숙하며 항원 제시 세포에 의해 처리된 항원 펩타이드를 인식하고 항체 대신 사이토카인을 분비하는 림프구입니다."
                    },
                    {
                      "term": "사이토카인 (Cytokine)",
                      "definition": "T 세포 등 면역 세포가 분비하는 작은 단백질로, 면역 반응과 염증을 조절하는 신호 분자 역할을 합니다."
                    },
                    {
                      "term": "T 세포 수용체 (TCR)",
                      "definition": "T 세포 표면에 위치하며 특정 항원 펩타이드를 인식하고 결합하는 수용체입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "적응성 면역 체계",
                      "id": "adaptive-immune-system",
                      "children": [
                        {
                          "text": "적응성 면역의 정의 및 획득 경로",
                          "id": "definition-acquisition-of-adaptive-immunity",
                          "children": null
                        },
                        {
                          "text": "일차 반응과 이차 반응",
                          "id": "primary-and-secondary-response",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역 체계의 이중적 특성",
                      "id": "dual-nature-of-adaptive-immune-system",
                      "children": [
                        {
                          "text": "체액성 면역",
                          "id": "humoral-immunity",
                          "children": [
                            {
                              "text": "항체 생성 및 항원 공격",
                              "id": "antibody-production-and-antigen-attack",
                              "children": null
                            },
                            {
                              "text": "B 세포의 역할 및 특징",
                              "id": "role-and-characteristics-of-b-cells",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "세포성 면역 (세포 매개 면역)",
                          "id": "cellular-immunity",
                          "children": [
                            {
                              "text": "T 림프구 생성 및 역할",
                              "id": "t-lymphocyte-production-and-role",
                              "children": null
                            },
                            {
                              "text": "T 세포의 성숙 및 항원 인식",
                              "id": "t-cell-maturation-and-antigen-recognition",
                              "children": null
                            },
                            {
                              "text": "T 세포 수용체(TCR) 및 사이토카인 분비",
                              "id": "tcr-and-cytokine-secretion",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "체액성 면역과 세포성 면역의 공격 대상 비교",
                          "id": "comparison-of-humoral-and-cellular-immunity-targets",
                          "children": [
                            {
                              "text": "세포성 면역의 대상 (세포 내부 항원)",
                              "id": "targets-of-cellular-immunity",
                              "children": null
                            },
                            {
                              "text": "체액성 면역의 대상 (세포 외부 위협)",
                              "id": "targets-of-humoral-immunity",
                              "children": null
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "적응성 면역의 주요 특징은 무엇입니까?",
                    "options": [
                      "비특이적 방어",
                      "특정 병원체를 표적으로 함",
                      "즉각적인 반응",
                      "항상 식세포 작용을 포함함"
                    ],
                    "answerIndex": 1,
                    "explanation": "적응성 면역은 특정 병원체를 표적으로 삼는 방어 체계입니다."
                  },
                  {
                    "question": "항체를 생성하고 세포 외부의 위협을 공격하는 면역 유형은 무엇입니까?",
                    "options": [
                      "선천성 면역",
                      "세포성 면역",
                      "체액성 면역",
                      "비특이적 면역"
                    ],
                    "answerIndex": 2,
                    "explanation": "체액성 면역은 B 세포가 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸웁니다."
                  },
                  {
                    "question": "T 세포는 어디에서 성숙합니까?",
                    "options": [
                      "적골수",
                      "비장",
                      "림프절",
                      "흉선"
                    ],
                    "answerIndex": 3,
                    "explanation": "T 세포는 흉선(thymus)에서 성숙합니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 사이토카인, 항원 및 항체",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1989 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "사이토카인: 면역 세포의 화학적 전달자",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인은 자극에 반응하여 생성되는 화학적 전달자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인터루킨(Interleukins): 백혈구 사이의 사이토카인입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "케모카인(Chemokines): 백혈구의 이동을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인터페론(Interferons, IFNs): 숙주 세포의 바이러스 감염을 방해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "종양 괴사 인자(Tumor necrosis factor, TNF): 자가면역 질환의 염증과 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "조혈 사이토카인(Hematopoietic cytokines): 적혈구와 백혈구로 발달하는 줄기세포를 조절합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인의 과잉 생산은 사이토카인 폭풍(cytokine storm)으로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "주요 사이토카인 및 그 역할",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-4: TH2 세포에서 생성되며, 미감염 TH 세포와 B 세포에 작용하여 TH2 세포 증식을 유도하고 IgE로의 클래스 전환을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-12: 수지상 세포, 대식세포, 호중구에서 생성되며, 미감염 TH 세포와 NK 세포에 작용하여 TH1 세포의 성장과 기능을 자극하고 IFN-γ 및 TNF-α를 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-17: TH17 세포에서 생성되며, 호중구에 작용하여 염증을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-22: TH17 세포에서 생성되며, 상피세포에 작용하여 항균 단백질 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감마 인터페론(IFN-γ): TH1 세포에서 생성되며, CTL(세포독성 T 림프구)과 대식세포에 작용하여 식세포 작용을 촉진하고 대식세포 및 체액성 면역 반응을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "케모카인: 다양한 세포(대식세포, 상피세포)에서 생성되며, 호중구에 작용하여 화학주성(chemotaxis)을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "TNF-알파(TNF-α): 대식세포, TH 세포, NK 세포에서 생성되며, 종양 세포에 작용하여 염증을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "GM-CSF: 대식세포, T 세포, NK 세포에서 생성되며, 골수 줄기세포에 작용하여 대식세포와 과립구 수를 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항원은 항체 생성을 유발하는 물질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일반적으로 침입하는 미생물이나 이물질의 구성 요소입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체는 항원상의 에피토프(epitopes) 또는 항원결정인자(antigenic determinants)와 상호작용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "합텐",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "합텐은 면역 반응을 유발하기에는 너무 작은 항원입니다; 운반 분자에 부착되어야 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항체",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체는 면역글로불린(Immunoglobulins, Ig)이라고 불리는 구형 단백질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가(Valence)는 항체에 있는 항원 결합 부위의 수를 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이중가(Bivalent) 항체는 두 개의 결합 부위를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전형적인 항체 분자의 구조",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "네 개의 단백질 사슬이 Y자 모양을 이룹니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "두 개의 동일한 경쇄(light chains)와 두 개의 동일한 중쇄(heavy chains)가 이황화 결합으로 연결되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가변(V) 부위는 팔의 끝 부분에 위치하며 에피토프와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "정상(Fc) 부위는 줄기 부분으로, 특정 Ig 클래스에 대해 동일합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역글로불린은 5가지 클래스(IgG, IgM, IgA, IgD, IgE)로 나뉩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역글로불린 클래스 요약",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "IgG",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체(Monomer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 80%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액, 림프, 장에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "태반을 통과하여 태아를 보호하고; 보체(complement)를 활성화하며; 식세포 작용을 강화하고; 독소와 바이러스를 중화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgM",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다섯 개의 단량체가 J 사슬로 연결된 오량체(Pentamer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 6%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈관 내에 남아있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포와 바이러스의 응집을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감염에 대한 첫 번째 반응이며; 수명이 짧습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgA",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청에서는 단량체, 분비물에서는 이량체(Dimer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 13%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "점막, 침, 눈물, 모유에서 흔히 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "미생물이 점막에 부착하는 것을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgD",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 0.02%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IgG와 유사한 구조를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액, 림프, B 세포에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "명확히 정의된 기능은 없으나; B 세포의 면역 반응을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgE",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 0.002%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비만세포, 호염기구, 혈액에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원과 결합하면 히스타민 방출을 유발하고; 기생충을 용해합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본 문서는 적응성 면역의 핵심 요소인 사이토카인, 항원, 항체에 대해 설명합니다. 사이토카인은 면역 세포 간의 화학적 전달자로, 다양한 종류(인터루킨, 케모카인, 인터페론, TNF 등)와 기능(염증 유발, 백혈구 이동 유도, 바이러스 감염 방해 등)을 가지며, 과잉 생산 시 사이토카인 폭풍을 유발할 수 있습니다. 항원은 항체 생성을 유발하는 물질이며, 항체가 결합하는 특정 부위를 에피토프라고 합니다. 합텐은 면역 반응을 유발하기에 너무 작아 운반 분자에 부착해야 하는 항원입니다. 항체는 면역글로불린(Ig)이라는 단백질로, Y자 모양의 구조를 가지며 가변부위와 정상부위로 구성됩니다. IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 클래스가 있으며, 각 클래스는 고유한 구조적 특성과 면역 기능을 수행합니다.",
                  "keyConcepts": [
                    {
                      "term": "사이토카인 (Cytokines)",
                      "definition": "면역 세포 간의 통신을 담당하는 화학적 전달 물질로, 다양한 면역 반응을 조절합니다."
                    },
                    {
                      "term": "항원 (Antigens)",
                      "definition": "면역 반응, 특히 항체 생성을 유발하는 물질입니다."
                    },
                    {
                      "term": "항체 (Antibodies/Immunoglobulins)",
                      "definition": "항원에 특이적으로 결합하여 항원을 중화하거나 제거하는 면역 단백질입니다."
                    },
                    {
                      "term": "면역글로불린 클래스 (Immunoglobulin Classes)",
                      "definition": "항체의 기능과 구조에 따라 IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 분류로 나뉩니다."
                    },
                    {
                      "term": "사이토카인 폭풍 (Cytokine Storm)",
                      "definition": "사이토카인이 과도하게 생산되어 전신 염증 반응과 조직 손상을 유발할 수 있는 심각한 면역 반응입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "인터루킨 (Interleukins)",
                      "definition": "백혈구 사이에서 작용하는 사이토카인입니다."
                    },
                    {
                      "term": "케모카인 (Chemokines)",
                      "definition": "백혈구의 이동(화학주성)을 유도하는 사이토카인입니다."
                    },
                    {
                      "term": "인터페론 (Interferons, IFNs)",
                      "definition": "바이러스 감염을 방해하는 사이토카인입니다."
                    },
                    {
                      "term": "종양 괴사 인자 (Tumor Necrosis Factor, TNF)",
                      "definition": "염증 반응과 관련된 사이토카인입니다."
                    },
                    {
                      "term": "에피토프 (Epitopes)",
                      "definition": "항원 상에서 항체가 특이적으로 결합하는 특정 부위 또는 항원결정인자입니다."
                    },
                    {
                      "term": "합텐 (Haptens)",
                      "definition": "단독으로는 면역 반응을 유발하지 못하지만, 운반 분자에 부착되면 면역원성을 획득하는 작은 분자입니다."
                    },
                    {
                      "term": "가변 부위 (Variable regions)",
                      "definition": "항체 팔의 끝 부분에 위치하며 항원의 에피토프와 결합하는 부위입니다."
                    },
                    {
                      "term": "정상 부위 (Constant region, Fc)",
                      "definition": "항체 분자의 줄기 부분으로, 특정 Ig 클래스에 대해 동일하며 면역 세포와의 상호작용에 관여합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "사이토카인: 면역 세포의 화학적 전달자",
                      "id": "cytokines-chemical-messengers-of-immune-cells",
                      "children": [
                        {
                          "text": "사이토카인의 정의 및 종류",
                          "id": "cytokines-definition-types",
                          "children": null
                        },
                        {
                          "text": "주요 사이토카인 및 그 역할",
                          "id": "key-cytokines-roles",
                          "children": null
                        },
                        {
                          "text": "사이토카인 폭풍",
                          "id": "cytokine-storm",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원",
                      "id": "antigens",
                      "children": [
                        {
                          "text": "항원의 정의",
                          "id": "antigens-definition",
                          "children": null
                        },
                        {
                          "text": "에피토프",
                          "id": "epitopes",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "합텐",
                      "id": "haptens",
                      "children": null
                    },
                    {
                      "text": "항체",
                      "id": "antibodies",
                      "children": [
                        {
                          "text": "항체의 정의 및 구조",
                          "id": "antibodies-definition-structure",
                          "children": null
                        },
                        {
                          "text": "전형적인 항체 분자의 구조",
                          "id": "typical-antibody-structure",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역글로불린 클래스 요약",
                      "id": "summary-of-immunoglobulin-classes",
                      "children": [
                        {
                          "text": "IgG",
                          "id": "igg",
                          "children": null
                        },
                        {
                          "text": "IgM",
                          "id": "igm",
                          "children": null
                        },
                        {
                          "text": "IgA",
                          "id": "iga",
                          "children": null
                        },
                        {
                          "text": "IgD",
                          "id": "igd",
                          "children": null
                        },
                        {
                          "text": "IgE",
                          "id": "ige",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "사이토카인 폭풍(Cytokine storm)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
                    "options": [
                      "면역 세포가 바이러스 감염을 방해하기 위해 사이토카인을 과도하게 생산하는 현상",
                      "염증 반응을 억제하기 위해 사이토카인이 부족하게 생산되는 현상",
                      "사이토카인이 과도하게 생산되어 조직 손상과 장기 부전을 초래할 수 있는 현상",
                      "항체 생산을 촉진하기 위해 특정 사이토카인이 의도적으로 증가하는 현상"
                    ],
                    "answerIndex": 2,
                    "explanation": "사이토카인 폭풍은 사이토카인이 과도하게 생산되어 전신 염증 반응, 조직 손상 및 장기 부전을 초래할 수 있는 현상입니다."
                  },
                  {
                    "question": "다음 면역글로불린(Ig) 클래스 중, 태반을 통과하여 태아를 보호하고 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 하는 것은 무엇입니까?",
                    "options": [
                      "IgM",
                      "IgA",
                      "IgG",
                      "IgE"
                    ],
                    "answerIndex": 2,
                    "explanation": "IgG는 태반을 통과하여 태아를 보호하며, 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 수행합니다."
                  },
                  {
                    "question": "합텐(Hapten)에 대한 설명으로 옳은 것은 무엇입니까?",
                    "options": [
                      "항체를 생산하는 모든 물질을 의미한다.",
                      "면역 반응을 유발하기에 너무 작아서 운반 분자에 부착해야 하는 항원이다.",
                      "항체와 상호작용하는 항원의 특정 부위를 의미한다.",
                      "혈액에 가장 많이 존재하는 면역글로불린의 한 종류이다."
                    ],
                    "answerIndex": 1,
                    "explanation": "합텐은 단독으로는 면역 반응을 유발하기에 너무 작지만, 운반 분자에 부착되면 면역원성을 획득하여 항체 생성을 유도할 수 있는 물질입니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 체액성 면역 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2199 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "항체 생성 세포의 활성화 및 클론 선택",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "주조직적합복합체(MHC)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "주조직적합복합체(MHC) 유전자는 세포 표면에 존재하는 분자를 암호화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Class I MHC는 모든 유핵 동물 세포의 막에 존재하며, '자기(self)'를 식별하는 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Class II MHC는 B 세포를 포함한 전문 항원제시세포(APCs)의 표면에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "B 세포의 활성화 및 클론 선택 과정",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "비활성 B 세포는 항원에 결합하는 표면 면역글로불린(Ig)을 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 항원을 내재화하고 처리합니다. 처리된 항원 조각들은 MHC Class II 분자에 제시됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 제시된 항원 조각을 T 도우미 세포(TH cell)가 접촉하고, B 세포를 활성화시키는 사이토카인을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 B 세포는 증식(클론 확장)을 겪습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "클론 선택은 활성화된 B 세포를 다음 두 가지로 분화시킵니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1. 항체를 생산하는 형질세포(Plasma cells)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2. 기억 세포(Memory cells)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "또한, 클론 제거(Clonal deletion) 과정을 통해 유해한 B 세포는 제거됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포는 특정 항원에 대한 표면 면역글로불린을 가진 성숙한 B 세포로 분화합니다. B 세포가 특정 항원을 만나면 증식합니다. 일부 B 세포는 장수하는 기억 세포로 증식하여, 나중에 항체를 생산하는 형질세포로 자극될 수 있습니다. 다른 B 세포는 항체 생산 형질세포로 증식하며, 이 형질세포는 혈액 순환계로 항체를 분비합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "T 세포 의존성 및 비의존성 항원",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 의존성 항원은 항체를 생산하기 위해 T 도우미 세포(TH cell)의 도움이 필요한 항원입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 직접 자극할 수 있습니다. 이러한 항원은 일반적으로 약한 면역 반응을 유발하며, 주로 IgM을 생산하고 기억 세포는 생성되지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원-항체 결합 및 그 결과",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 항원에 결합할 때 항원-항체 복합체가 형성됩니다. 이 결합의 강도를 친화도(affinity)라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원-항체 결합은 외래 분자나 세포를 파괴하도록 표지함으로써 숙주를 보호합니다. 주요 보호 메커니즘은 다음과 같습니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1. **응집(Agglutination)**: 감염 단위의 수를 줄여 처리해야 할 대상을 감소시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2. **옵소닌화(Opsonization)**: 항원으로 항원을 코팅하여 식균작용을 강화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "3. **항체 의존성 세포 매개성 세포독성(Antibody-dependent cell-mediated cytotoxicity, ADCC)**: 항체가 표적 세포에 부착되어 대식세포, 호산구, NK 세포에 의한 파괴를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "4. **중화(Neutralization)**: 박테리아와 바이러스가 점막에 부착되는 것을 차단하고 독소가 부착되는 것을 막습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "5. **보체계 활성화(Activation of the complement system)**: 염증 및 세포 용해를 유발합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본 문서는 적응성 면역 중 체액성 면역 반응에 초점을 맞춰 항체 생성 세포의 활성화 및 클론 선택 과정을 설명합니다. MHC(주조직적합복합체)의 역할, B 세포가 항원을 인식하고 T 도우미 세포의 도움을 받아 활성화되며 형질세포와 기억 세포로 분화하는 과정이 상세히 다뤄집니다. 또한, T 세포 의존성 및 비의존성 항원의 특징과 항원-항체 결합이 숙주를 보호하는 응집, 옵소닌화, ADCC, 중화, 보체계 활성화 등 다양한 메커니즘을 제시합니다.",
                  "keyConcepts": [
                    {
                      "term": "MHC (주조직적합복합체)",
                      "definition": "세포 표면에 존재하며, Class I은 '자기' 식별, Class II는 항원제시세포에서 항원 조각을 T 세포에 제시하는 역할을 하는 분자를 암호화하는 유전자 복합체."
                    },
                    {
                      "term": "B 세포 활성화",
                      "definition": "비활성 B 세포가 항원을 인식하고, T 도우미 세포의 사이토카인 도움을 받아 증식하고 분화하는 과정."
                    },
                    {
                      "term": "클론 선택 (Clonal Selection)",
                      "definition": "특정 항원에 반응하는 B 세포 클론이 선택적으로 증식하여 항체 생성 형질세포와 기억 세포로 분화하는 면역 과정."
                    },
                    {
                      "term": "T 세포 의존성/비의존성 항원",
                      "definition": "항체 생산에 T 도우미 세포의 도움이 필요한지 여부에 따라 항원을 분류하는 방식. 비의존성 항원은 약한 IgM 반응과 기억 세포 부재를 특징으로 함."
                    },
                    {
                      "term": "항체 기능",
                      "definition": "항원-항체 복합체 형성 후 숙주를 보호하는 다양한 메커니즘 (응집, 옵소닌화, ADCC, 중화, 보체계 활성화)."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "MHC (주조직적합복합체)",
                      "definition": "세포 표면에 항원 펩타이드를 제시하는 데 관여하는 단백질 복합체."
                    },
                    {
                      "term": "T 도우미 세포 (T Helper Cell, TH cell)",
                      "definition": "B 세포 활성화 및 다른 면역 세포 기능을 조절하는 사이토카인을 분비하는 림프구."
                    },
                    {
                      "term": "사이토카인 (Cytokines)",
                      "definition": "세포 간 신호 전달에 관여하며 면역 반응을 조절하는 작은 단백질."
                    },
                    {
                      "term": "형질세포 (Plasma Cell)",
                      "definition": "활성화된 B 세포로부터 분화하여 다량의 항체를 생산하고 분비하는 세포."
                    },
                    {
                      "term": "기억 세포 (Memory Cell)",
                      "definition": "면역 반응 후 장기간 생존하며, 동일한 항원 재침입 시 빠르고 강력한 2차 면역 반응을 유도하는 림프구."
                    },
                    {
                      "term": "응집 (Agglutination)",
                      "definition": "항체가 여러 항원 입자(예: 세균)를 서로 묶어 침전시키는 과정."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "항체가 항원 표면을 코팅하여 식세포가 이를 더 쉽게 인식하고 포식할 수 있도록 돕는 과정."
                    }
                  ],
                  "outline": [
                    {
                      "text": "항체 생성 세포의 활성화 및 클론 선택",
                      "id": "항체-생성-세포의-활성화-및-클론-선택",
                      "children": [
                        {
                          "text": "주조직적합복합체(MHC)",
                          "id": "주조직적합복합체-mhc",
                          "children": null
                        },
                        {
                          "text": "B 세포의 활성화 및 클론 선택 과정",
                          "id": "b-세포의-활성화-및-클론-선택-과정",
                          "children": null
                        },
                        {
                          "text": "T 세포 의존성 및 비의존성 항원",
                          "id": "t-세포-의존성-및-비의존성-항원",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원-항체 결합 및 그 결과",
                      "id": "항원-항체-결합-및-그-결과",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 MHC Class II 분자가 주로 발견되는 세포와 그 역할은 무엇입니까?",
                    "options": [
                      "모든 유핵 동물 세포의 막; '자기' 식별",
                      "전문 항원제시세포(APCs)의 표면; 항원 조각 제시",
                      "적혈구; 산소 운반",
                      "신경 세포; 신경 신호 전달"
                    ],
                    "answerIndex": 1,
                    "explanation": "MHC Class II는 B 세포를 포함한 전문 항원제시세포의 표면에 존재하며, 처리된 항원 조각을 T 도우미 세포에 제시하는 역할을 합니다."
                  },
                  {
                    "question": "B 세포가 항원을 내재화하고 처리한 후, T 도우미 세포의 도움을 받아 활성화될 때 T 도우미 세포가 방출하는 물질은 무엇입니까?",
                    "options": [
                      "항체",
                      "항원",
                      "사이토카인",
                      "면역글로불린"
                    ],
                    "answerIndex": 2,
                    "explanation": "T 도우미 세포는 제시된 항원 조각을 인식한 후 사이토카인을 방출하여 B 세포의 활성화를 유도합니다."
                  },
                  {
                    "question": "T 세포 비의존성 항원에 대한 면역 반응의 특징으로 옳지 않은 것은 무엇입니까?",
                    "options": [
                      "T 세포의 도움 없이 B 세포를 직접 자극한다.",
                      "주로 IgM 항체를 생산한다.",
                      "약한 면역 반응을 유발한다.",
                      "강력한 기억 세포 반응을 생성한다."
                    ],
                    "answerIndex": 3,
                    "explanation": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 자극하지만, 일반적으로 약한 면역 반응을 유발하고 기억 세포가 생성되지 않습니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 세포성 면역 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2963 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "세포성 면역 반응 과정",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 세포내 병원체와 싸웁니다. T 세포는 흉선에서 성숙하며, 흉선 선택을 통해 미성숙 T 세포가 제거됩니다. 성숙한 T 세포는 흉선에서 림프 조직으로 이동하며, T 세포 수용체(TCR)를 통해 항원에 부착합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "위장관으로 들어오는 병원체는 파이어스 패치(Peyer's patches) 위에 위치한 미세주름 세포(M cells)를 통과합니다. 이 세포들은 항원을 림프구와 항원제시세포(APCs)로 전달합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원제시세포 (APCs)",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "수지상 세포 (Dendritic cells, DCs)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "수지상 세포는 미생물을 삼켜 분해하고 T 세포에 제시합니다. 이들은 피부, 생식기, 림프절, 비장, 흉선 및 혈액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "대식세포 (Macrophages)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "대식세포는 사이토카인 또는 항원 물질의 섭취에 의해 활성화됩니다. 이들은 림프 조직으로 이동하여 T 세포에 항원을 제시합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원 처리 및 제시: MHC",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "T 세포의 종류",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 분화군(Clusters of differentiation, CD) 표지자를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CD4+ T 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4+ T 세포는 T 도우미 세포(TH)라고도 불립니다. 이들은 B 세포와 사이토카인 신호를 주고받으며 항원과 직접 상호작용합니다. B 세포 및 APC의 MHC class II 분자에 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CD8+ T 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "CD8+ T 세포는 세포독성 T 림프구(Cytotoxic T lymphocytes, CTL)라고 불립니다. 이들은 MHC class I 분자에 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4+ 세포의 TCR은 APC의 항원 조각과 MHC class II에 결합하여 인식합니다. APC 또는 TH는 보조 자극 분자를 분비하여 CD4+ 세포를 활성화합니다. 활성화된 TH 세포는 사이토카인을 생성하고 TH1, TH2, TH17 세포 및 기억 세포로 분화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH17 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH17 세포는 IL-17을 생성하여 염증 반응에 기여하고, 세포외 세균 및 곰팡이에 대한 방어를 위해 호중구를 모집합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH1 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH1 세포는 IFN-γ를 생성하여 대식세포를 활성화하고, 보체를 강화하며, 식세포 작용을 촉진하는 항체 생성을 자극합니다. TH1 세포는 세포성 면역의 중요한 요소이며, 이들의 사이토카인(예: IFN-γ 및 IL-2)은 CD8+ T 세포와 NK 세포를 활성화하여 감염된 숙주 세포를 죽임으로써 세포내 병원체를 제어합니다. 또한, 대식세포와 같은 항원제시세포의 식세포 작용을 강화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH2 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH2 세포는 B 세포를 활성화하여 IgE를 생성하게 하고 호산구를 활성화합니다. 특히 IgE 생성을 통한 알레르기 반응에 중요하며, 헬민스와 같은 세포외 기생충을 제어하기 위해 호산구를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "조절 T 세포 (Treg)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 T 세포(Treg)는 CD4+ 세포의 하위 집합으로, 추가적인 CD25 분자를 가지고 있습니다. 이들은 자가 반응성 T 세포를 억제하여 자기 관용을 유지하고, 소화에 필요한 장내 세균을 보호하며, 태아를 보호합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 T 림프구 (CD8+ T 세포)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "전구 세포독성 T 세포(CTLp)는 TH 세포와 보조 자극 신호의 도움으로 활성화되어 세포독성 T 림프구(CTLs)가 됩니다. CTLs는 감염에 의해 변형된 자가 세포를 인식하고 죽입니다. 감염된 자가 세포는 MHC class I 분자와 함께 표면에 내인성 항원을 운반합니다. CTL은 퍼포린(perforin)과 그랜자임(granzymes)을 방출하여 감염된 세포의 세포자멸사를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포자멸사 (Apoptosis)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포자멸사는 프로그램된 세포 사멸입니다. 이는 감염성 바이러스가 다른 세포로 퍼지는 것을 방지합니다. 세포는 게놈을 조각으로 절단하며, 세포막은 수포(blebbing)를 통해 바깥쪽으로 부풀어 오릅니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "정상 세포는 세포독성 T 림프구(CTL)에 의해 반응을 유발하지 않지만, 바이러스 감염 세포나 암세포는 비정상적인 내인성 항원을 생성합니다. 이 비정상적인 항원은 MHC class I 분자와 결합하여 세포 표면에 제시됩니다. TH1 세포의 결합은 사이토카인 분비를 촉진합니다. 이 사이토카인은 전구 CTL을 활성화하여 CTL 클론을 생성합니다. CTL은 세포자멸사를 통해 바이러스 감염 세포의 파괴를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역계에 의한 세포외 살상",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "자연살해 (NK) 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "자연살해(NK) 세포는 과립성 백혈구로, MHC class I 자가 항원을 발현하지 않는 세포를 파괴합니다. 이들은 바이러스 감염 세포와 종양 세포를 죽이고 기생충을 공격합니다. 항상 항원에 의해 자극되는 것은 아니며, 표적 세포에 구멍을 형성하여 용해 또는 세포자멸사를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포성 면역에 관여하는 주요 세포 기능",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH1) 세포: 세포 매개 면역 관련 세포(대식세포, CTLs, 자연살해 세포)를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH2) 세포: 호산구, IgM, IgE 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH17) 세포: 호중구를 모집하고 항균 단백질 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구 (CTL): 세포자멸사를 유도하여 접촉하는 표적 세포를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 T (Treg) 세포: 면역 반응을 조절하고 자기 관용을 유지하는 데 도움을 줍니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 대식세포: 식세포 활동이 강화되고 암세포를 공격합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자연살해 (NK) 세포: 표적 세포를 공격하고 파괴하며, 항체 의존성 세포 매개 세포독성(ADCC)에 참여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항체 의존성 세포 매개 세포독성 (ADCC)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "원생동물과 헬민스는 식세포 작용으로 삼키기에는 너무 큽니다. 원생동물 또는 헬민스 표적 세포는 항체로 코팅됩니다. 면역계 세포는 항체의 Fc 영역에 부착합니다. 표적 세포는 면역계 세포가 분비하는 화학 물질에 의해 용해됩니다. 많은 기생충과 같이 식세포에 의해 섭취하기에는 너무 큰 유기체는 외부에서 공격받아야 합니다. 호산구는 기생성 흡충의 유충 단계에 부착합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 세포성 면역의 과정을 상세히 설명하며, T 세포, 항원제시세포(APCs) 및 이들의 상호작용에 중점을 둡니다. T 세포의 성숙 과정과 다양한 T 세포 유형(TH1, TH2, TH17, 세포독성 T 림프구, 조절 T 세포)의 기능, 그리고 이들이 세포내 병원체 퇴치, 면역 반응 조절 및 특정 면역 반응 매개에 어떻게 기여하는지 다룹니다. 또한, 자연살해(NK) 세포의 세포외 살상 역할과 대형 기생충에 대한 항체 의존성 세포 매개 세포독성(ADCC) 기전도 설명합니다.",
                  "keyConcepts": [
                    {
                      "term": "T 세포의 성숙 및 기능",
                      "definition": "흉선에서 성숙하며, 세포내 병원체와 싸우고 항원제시세포(APCs)가 제시하는 항원에 특이적으로 반응하는 림프구."
                    },
                    {
                      "term": "항원제시세포 (APCs)",
                      "definition": "미생물을 삼켜 분해하고 그 항원 조각을 MHC 분자를 통해 T 세포에 제시하여 T 세포 반응을 유도하는 세포 (예: 수지상 세포, 대식세포)."
                    },
                    {
                      "term": "T 세포 유형 및 역할",
                      "definition": "CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)는 다른 면역 세포의 활성화를 돕고, CD8+ T 세포(세포독성 T 림프구)는 감염된 세포를 직접 파괴하며, 조절 T 세포는 면역 반응을 억제하여 자기 관용을 유지한다."
                    },
                    {
                      "term": "세포독성 T 림프구 (CTLs) 및 세포자멸사 (Apoptosis)",
                      "definition": "CTL은 감염된 자가 세포를 인식하여 퍼포린과 그랜자임을 방출, 세포자멸사(프로그램된 세포 사멸)를 유도하여 바이러스 확산을 막는다."
                    },
                    {
                      "term": "자연살해(NK) 세포 및 항체 의존성 세포 매개 세포독성 (ADCC)",
                      "definition": "NK 세포는 MHC class I을 발현하지 않는 세포를 파괴하며, ADCC는 항체로 코팅된 표적 세포를 면역 세포가 용해시키는 기전으로, 특히 대형 기생충에 효과적이다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "T 세포 (T cell)",
                      "definition": "흉선에서 성숙하며 세포내 병원체와 싸우는 림프구."
                    },
                    {
                      "term": "항원제시세포 (Antigen-Presenting Cells, APCs)",
                      "definition": "미생물을 삼켜 분해하고 T 세포에 항원을 제시하는 세포 (예: 수지상 세포, 대식세포)."
                    },
                    {
                      "term": "MHC (Major Histocompatibility Complex)",
                      "definition": "항원 제시를 위해 세포 표면에 항원 조각을 표시하는 분자."
                    },
                    {
                      "term": "T 도우미 세포 (T Helper cells, TH)",
                      "definition": "CD4+ T 세포로, B 세포와 사이토카인 신호를 주고받으며 다른 면역 세포의 활성화를 돕는다."
                    },
                    {
                      "term": "세포독성 T 림프구 (Cytotoxic T Lymphocytes, CTLs)",
                      "definition": "CD8+ T 세포로, 감염된 자가 세포를 인식하고 세포자멸사를 유도하여 파괴한다."
                    },
                    {
                      "term": "세포자멸사 (Apoptosis)",
                      "definition": "프로그램된 세포 사멸로, 감염성 바이러스가 다른 세포로 퍼지는 것을 방지한다."
                    },
                    {
                      "term": "자연살해 세포 (Natural Killer cells, NK cells)",
                      "definition": "MHC class I 자가 항원을 발현하지 않는 세포를 파괴하며, 바이러스 감염 세포, 종양 세포 및 기생충을 공격한다."
                    },
                    {
                      "term": "항체 의존성 세포 매개 세포독성 (Antibody-Dependent Cell-mediated Cytotoxicity, ADCC)",
                      "definition": "항체로 코팅된 표적 세포를 면역 세포가 파괴하는 기전."
                    }
                  ],
                  "outline": [
                    {
                      "text": "세포성 면역 반응 과정",
                      "id": "세포성-면역-반응-과정",
                      "children": [
                        {
                          "text": "T 세포의 역할과 성숙",
                          "id": "t-세포의-역할과-성숙",
                          "children": null
                        },
                        {
                          "text": "소화관 내 병원체 처리",
                          "id": "소화관-내-병원체-처리",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원제시세포 (APCs)",
                      "id": "항원제시세포-apcs",
                      "children": [
                        {
                          "text": "수지상 세포 (Dendritic cells, DCs)",
                          "id": "수지상-세포-dendritic-cells-dcs",
                          "children": null
                        },
                        {
                          "text": "대식세포 (Macrophages)",
                          "id": "대식세포-macrophages",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원 처리 및 제시: MHC",
                      "id": "항원-처리-및-제시-mhc",
                      "children": null
                    },
                    {
                      "text": "T 세포의 종류",
                      "id": "t-세포의-종류",
                      "children": [
                        {
                          "text": "CD4+ T 세포",
                          "id": "cd4-t-세포",
                          "children": null
                        },
                        {
                          "text": "CD8+ T 세포",
                          "id": "cd8-t-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
                      "id": "t-도우미-세포-cd4-t-세포의-활성화-및-분화",
                      "children": [
                        {
                          "text": "TH17 세포",
                          "id": "th17-세포",
                          "children": null
                        },
                        {
                          "text": "TH1 세포",
                          "id": "th1-세포",
                          "children": null
                        },
                        {
                          "text": "TH2 세포",
                          "id": "th2-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "조절 T 세포 (Treg)",
                      "id": "조절-t-세포-treg",
                      "children": null
                    },
                    {
                      "text": "세포독성 T 림프구 (CD8+ T 세포)",
                      "id": "세포독성-t-림프구-cd8-t-세포",
                      "children": [
                        {
                          "text": "세포자멸사 (Apoptosis)",
                          "id": "세포자멸사-apoptosis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역계에 의한 세포외 살상",
                      "id": "면역계에-의한-세포외-살상",
                      "children": [
                        {
                          "text": "자연살해 (NK) 세포",
                          "id": "자연살해-nk-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포성 면역에 관여하는 주요 세포 기능",
                      "id": "세포성-면역에-관여하는-주요-세포-기능",
                      "children": null
                    },
                    {
                      "text": "항체 의존성 세포 매개 세포독성 (ADCC)",
                      "id": "항체-의존성-세포-매개-세포독성-adcc",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "T 세포가 성숙하는 주요 장소는 어디인가요?",
                    "options": [
                      "골수",
                      "비장",
                      "흉선",
                      "림프절"
                    ],
                    "answerIndex": 2,
                    "explanation": "T 세포는 흉선(thymus)에서 성숙 과정을 거칩니다."
                  },
                  {
                    "question": "다음 중 세포독성 T 림프구(CTL)의 주된 기능은 무엇인가요?",
                    "options": [
                      "B 세포 활성화",
                      "대식세포 활성화",
                      "감염된 자가 세포 파괴",
                      "염증 반응 촉진"
                    ],
                    "answerIndex": 2,
                    "explanation": "세포독성 T 림프구(CTL)는 감염된 자가 세포나 암세포를 인식하고 세포자멸사를 유도하여 파괴하는 역할을 합니다."
                  },
                  {
                    "question": "다음 중 항원제시세포(APC)에 해당하지 않는 것은 무엇인가요?",
                    "options": [
                      "수지상 세포",
                      "대식세포",
                      "T 도우미 세포",
                      "B 세포"
                    ],
                    "answerIndex": 2,
                    "explanation": "수지상 세포, 대식세포, B 세포는 모두 항원제시세포(APC)의 역할을 수행합니다. T 도우미 세포는 APC에 의해 활성화되는 세포이지, 스스로 항원을 제시하는 세포는 아닙니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75f3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1056 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역학적 기억",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 (기억 또는 아남네스틱) 반응은 항원에 두 번째 노출된 후에 발생합니다. 이 반응은 더 빠르고, 며칠 동안 지속되며, 그 규모가 훨씬 더 큽니다. 초기 노출에 반응하여 생성된 기억 세포는 이차 노출에 의해 활성화됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "초기 IgM 반응이 IgG, IgE 또는 IgA로 전환되는 '클래스 전환(Class switching)' 현상이 이차 반응에서 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체 역가(Antibody titer)는 혈청 내 항체의 상대적인 양을 나타내며, 체액 면역 반응의 강도를 반영합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "체액 면역",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "일차 면역 반응",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "제공된 텍스트에는 일차 면역 반응에 대한 구체적인 내용은 포함되어 있지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이차 면역 반응",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 면역 반응은 '면역학적 기억' 섹션에서 상세히 설명된 바와 같이, 항원에 대한 두 번째 노출 시 발생하는 빠르고 강력하며 지속적인 반응입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역의 유형",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "자연 획득 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "자연 획득 능동 면역은 감염을 통해 발생하며, 신체가 항원에 직접 노출되어 면역 반응을 일으키고 기억 세포를 형성하는 것을 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자연 획득 수동 면역은 태반을 통해 또는 초유를 통해 어머니로부터 항체를 전달받아 발생하는 면역입니다. 이는 일시적인 면역을 제공합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인공 획득 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "인공 획득 능동 면역은 예방 접종(백신 접종)을 통해 발생합니다. 이는 약화되거나 비활성화된 항원을 주입하여 신체 스스로 면역 반응을 일으키고 기억 세포를 형성하도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인공 획득 수동 면역은 항체 주사를 통해 발생합니다. 이는 특정 질병에 대한 즉각적인 보호를 제공하지만, 신체가 스스로 면역 반응을 일으킨 것이 아니므로 기억 세포가 형성되지 않아 일시적입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "관련 용어",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청(Antiserum)은 항체를 포함하는 혈액 유래 액체입니다. 혈청학(Serology)은 항체와 항원 간의 반응을 연구하는 학문입니다. 글로불린(Globulins)은 혈청 단백질을 총칭하며, 감마(γ) 글로불린은 항체를 포함하는 혈청 분획입니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 면역학적 기억과 적응성 면역의 다양한 유형에 대해 설명합니다. 면역학적 기억은 항원에 두 번째 노출되었을 때 발생하는 이차 면역 반응(더 빠르고 강력하며 지속적)의 특징과 클래스 전환, 그리고 항체 역가의 개념을 포함합니다. 적응성 면역은 자연 획득(능동/수동)과 인공 획득(능동/수동) 면역으로 분류되며, 각각의 특징과 발생 원리를 다룹니다. 또한, 혈청, 혈청학, 글로불린, 감마 글로불린과 같은 관련 용어의 정의도 제공합니다.",
                  "keyConcepts": [
                    {
                      "term": "면역학적 기억",
                      "definition": "항원에 대한 첫 노출 후 형성되어, 재노출 시 더 빠르고 강력한 이차 면역 반응을 유도하는 능력."
                    },
                    {
                      "term": "이차 면역 반응",
                      "definition": "항원에 두 번째 노출되었을 때 나타나는 면역 반응으로, 일차 반응보다 빠르고 강하며 오래 지속되는 특징을 가집니다."
                    },
                    {
                      "term": "적응성 면역의 유형",
                      "definition": "면역 획득 방식에 따라 자연 획득 능동/수동 면역과 인공 획득 능동/수동 면역으로 나뉩니다."
                    },
                    {
                      "term": "클래스 전환",
                      "definition": "초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "이차 (기억 또는 아남네스틱) 반응",
                      "definition": "항원에 두 번째 노출되었을 때 발생하는 면역 반응."
                    },
                    {
                      "term": "클래스 전환",
                      "definition": "면역 반응 시 초기 IgM 항체에서 IgG, IgE, IgA 등 다른 항체 유형으로 전환되는 현상."
                    },
                    {
                      "term": "항체 역가",
                      "definition": "혈청 내 항체의 상대적인 양을 나타내는 지표."
                    },
                    {
                      "term": "자연 획득 능동 면역",
                      "definition": "감염을 통해 자연적으로 항원에 노출되어 획득하는 면역."
                    },
                    {
                      "term": "인공 획득 능동 면역",
                      "definition": "예방 접종(백신)을 통해 인위적으로 항원에 노출되어 획득하는 면역."
                    },
                    {
                      "term": "혈청",
                      "definition": "항체를 포함하는 혈액 유래 액체."
                    },
                    {
                      "term": "감마 글로불린",
                      "definition": "항체를 포함하는 혈청 단백질 분획."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역학적 기억",
                      "id": "immunological-memory",
                      "children": [
                        {
                          "text": "이차 면역 반응의 특성",
                          "id": "secondary-immune-response-characteristics",
                          "children": null
                        },
                        {
                          "text": "클래스 전환 및 기억 세포",
                          "id": "class-switching-and-memory-cells",
                          "children": null
                        },
                        {
                          "text": "항체 역가",
                          "id": "antibody-titer",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "체액 면역",
                      "id": "humoral-immunity",
                      "children": [
                        {
                          "text": "일차 면역 반응",
                          "id": "primary-immune-response",
                          "children": null
                        },
                        {
                          "text": "이차 면역 반응",
                          "id": "secondary-immune-response-humoral",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역의 유형",
                      "id": "types-of-adaptive-immunity",
                      "children": [
                        {
                          "text": "자연 획득 면역",
                          "id": "naturally-acquired-immunity",
                          "children": [
                            {
                              "text": "자연 획득 능동 면역",
                              "id": "naturally-acquired-active-immunity",
                              "children": null
                            },
                            {
                              "text": "자연 획득 수동 면역",
                              "id": "naturally-acquired-passive-immunity",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "인공 획득 면역",
                          "id": "artificially-acquired-immunity",
                          "children": [
                            {
                              "text": "인공 획득 능동 면역",
                              "id": "artificially-acquired-active-immunity",
                              "children": null
                            },
                            {
                              "text": "인공 획득 수동 면역",
                              "id": "artificially-acquired-passive-immunity",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "관련 용어",
                          "id": "related-terms",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "이차 면역 반응의 주요 특징이 아닌 것은 무엇입니까?",
                    "options": [
                      "일차 반응보다 느리게 발생한다.",
                      "더 오랫동안 지속된다.",
                      "규모가 더 크다.",
                      "기억 세포에 의해 활성화된다."
                    ],
                    "answerIndex": 0,
                    "explanation": "이차 면역 반응은 일차 반응보다 '더 빠르게' 발생하며, 더 오랫동안 지속되고 규모가 더 크다는 특징을 가집니다."
                  },
                  {
                    "question": "예방 접종(백신 접종)을 통해 획득하는 면역 유형은 무엇입니까?",
                    "options": [
                      "자연 획득 능동 면역",
                      "자연 획득 수동 면역",
                      "인공 획득 능동 면역",
                      "인공 획득 수동 면역"
                    ],
                    "answerIndex": 2,
                    "explanation": "예방 접종은 인위적으로 항원을 주입하여 신체 스스로 면역 반응을 일으키도록 유도하는 '인공 획득 능동 면역'에 해당합니다."
                  },
                  {
                    "question": "면역학적 기억에서 '클래스 전환'은 무엇을 의미합니까?",
                    "options": [
                      "면역 세포의 종류가 바뀌는 것",
                      "초기 IgM 반응이 다른 유형의 항체(IgG, IgE, IgA)로 바뀌는 것",
                      "항체가 항원에 결합하는 방식이 바뀌는 것",
                      "면역 반응의 강도가 약해지는 것"
                    ],
                    "answerIndex": 1,
                    "explanation": "클래스 전환은 초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상을 말합니다."
                  }
                ]
              },
              {
                "title": "면역학의 실제 적용: 백신",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 3538 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "백신 개요",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역학의 실제 적용 중 하나인 백신은 질병 예방에 있어 핵심적인 역할을 합니다. 백신의 역사는 천연두 접종법(Variolation)에서 시작되었는데, 이는 천연두를 피부에 접종하여 질병을 예방하는 방식이었습니다. 이후 제너(Jenner)는 우두를 접종하여 천연두를 예방하는 방법을 발견했습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "백신(Vaccine)이라는 용어는 파스퇴르(Pasteur)에 의해 만들어졌으며, 'vacca'(소)에서 유래했습니다. 백신은 면역을 유도하는 유기체 또는 유기체의 일부 현탁액으로 정의됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 기능 및 원리",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 접종은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이는 실제 병원체에 노출되었을 때 빠르고 강렬한 이차 면역 반응을 생성하는 데 기여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "집단 면역(Herd immunity)은 인구 대부분의 면역 상태를 의미하며, 감수성 있는 개체의 부족으로 질병 발생이 산발적으로 나타나게 하여 전염병 확산을 막는 중요한 효과를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CDC 권장 세균성 질환 백신",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "미국 질병통제예방센터(CDC)는 다양한 세균성 질환 예방을 위한 백신을 권장하고 있습니다. 이에는 헤모필루스 인플루엔자 b형 수막염, 수막구균성 수막염, 폐렴구균성 폐렴, 파상풍, 디프테리아, 백일해 백신 등이 포함됩니다. 각 백신은 특정 연령대 또는 위험군에 대한 권장 사항과 추가 접종 여부가 명시되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CDC 권장 바이러스성 질환 백신",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "CDC는 또한 수두, A형 간염, B형 간염, 대상포진, 인유두종바이러스, 인플루엔자, 홍역, 유행성 이하선염, 소아마비, 광견병, 로타바이러스, 풍진, 천연두 등 다양한 바이러스성 질환 예방을 위한 백신을 권장하고 있습니다. 이들 백신 역시 접종 대상, 시기, 그리고 추가 접종의 필요성에 대한 구체적인 지침을 따릅니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 종류 및 특성",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "약독화 생백신 (Live attenuated vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "약독화 생백신은 약화된 병원체를 사용하여 실제 감염과 유사한 면역 반응을 유도하며, 평생 지속되는 세포성 및 체액성 면역을 부여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "불활성화 사백신 (Inactivated killed vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "불활성화 사백신은 생백신보다 안전하지만, 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "서브유닛 백신 (Subunit vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "서브유닛 백신은 항원성 조각을 사용하여 면역 반응을 자극합니다. 유전적 변형을 통해 생산되는 서브유닛 백신을 재조합 백신(Recombinant vaccines)이라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "톡소이드 (Toxoids)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "톡소이드는 불활성화된 독소이며, 항독소(Antitoxins)는 독소에 대한 항체를 포함하는 혈청입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "VLP 백신은 온전한 바이러스와 유사하지만 바이러스 유전 물질을 포함하지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다당류 백신 (Polysaccharide vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다당류 백신은 병원체의 캡슐 분자로 만들어지며 면역원성이 강하지 않습니다. 캡슐 다당류에 대한 면역 반응이 약한 어린이 질병에 사용되는 백신을 접합 백신(Conjugated vaccines)이라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "핵산(DNA) 백신은 DNA에 암호화된 단백질 항원을 생성하기 위해 주사된 DNA를 사용하며, 체액성 및 세포성 면역을 모두 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "재조합 벡터 백신 (Recombinant vector vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "재조합 벡터 백신은 항원을 코딩하는 유전자를 전달하도록 유전적으로 변형된 비병원성 바이러스 또는 박테리아를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "RNA 백신 (RNA vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "RNA 백신은 새로운 유형의 백신으로, 특정 항원 단백질을 생산하도록 세포에 지시하는 RNA 서열을 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신 생산, 전달 방법 및 제형",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 개발은 동물 숙주를 사용하지 않는 방향으로 발전하고 있으며, 식물을 백신 공급원으로 활용하는 연구도 진행 중입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "경구 백신 및 건조 백신(피부 패치)의 개발이 증가하고 있으며, 나노패치(Nanopatch)는 건조 형태의 백신을 피부에 전달하여 냉장 보관이 필요 없으며 다수의 항원제시세포(APC)를 활용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다중 조합 백신, 만성 질환 백신 개발, 그리고 세포성 면역 개발을 위한 \"역 백신학(Reverse vaccinology)\" 연구도 활발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 미국에서는 명반(Alums)과 모노포스포릴 지질 A(monophosphoryl lipid A)만이 승인되어 있으며, 선천 면역 반응을 개선하는 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "마이크로바이옴과 경구 백신 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "젖산균인 비피도박테리움(Bifidobacterium)은 장내 마이크로바이옴의 정상적인 일부이며, 마이크로바이옴이 경구 백신에 대한 반응을 향상시킬 수 있다는 연구가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 안전성",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "드물게 백신이 질병을 유발할 수 있지만, MMR 백신이 자폐증과 연관되어 있다는 의학적 또는 과학적 증거는 없습니다. 백신은 어린이의 감염성 질환을 예방하는 가장 안전하고 효과적인 수단으로 간주됩니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 백신의 역사적 배경, 기능, 다양한 종류, 생산 및 전달 방법, 그리고 안전성에 대해 설명합니다. 백신은 일차 면역 반응을 유도하여 항체와 기억 세포를 형성하고, 이를 통해 집단 면역을 구축하여 질병 확산을 막는 원리를 가지고 있습니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 여러 유형의 백신이 각자의 특성과 함께 소개되며, 아쥬반트의 역할과 백신 안전성에 대한 중요한 정보도 포함되어 있습니다.",
                  "keyConcepts": [
                    {
                      "term": "집단 면역 (Herd Immunity)",
                      "definition": "인구 대부분이 면역을 가지게 되어 감수성 개체의 부족으로 질병 발생이 산발적으로 나타나게 하는 현상으로, 전염병 확산을 막는 데 중요합니다."
                    },
                    {
                      "term": "백신의 종류 (Types of Vaccines)",
                      "definition": "약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 다양한 백신 유형이 있으며, 각각 다른 방식으로 면역 반응을 유도합니다."
                    },
                    {
                      "term": "아쥬반트 (Adjuvants)",
                      "definition": "백신의 효능을 높이고 면역 반응을 강화하기 위해 백신에 첨가되는 화학 물질입니다. 주로 선천 면역 반응을 개선하는 역할을 합니다."
                    },
                    {
                      "term": "기억 세포 (Memory Cells)",
                      "definition": "백신 접종 후 형성되는 면역 세포로, 실제 병원체에 재노출되었을 때 빠르고 강렬한 이차 면역 반응을 가능하게 하여 장기적인 면역력을 제공합니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "천연두 접종법 (Variolation)",
                      "definition": "천연두를 피부에 접종하여 면역을 유도하던 초기 질병 예방 방법입니다."
                    },
                    {
                      "term": "백신 접종 (Vaccination)",
                      "definition": "면역을 유도하기 위해 유기체 또는 유기체의 일부를 현탁액 형태로 인체에 주입하는 행위를 말합니다."
                    },
                    {
                      "term": "약독화 생백신 (Live Attenuated Vaccine)",
                      "definition": "병원체를 약화시켜 만든 백신으로, 실제 감염과 유사한 면역 반응을 유도하며 세포성 및 체액성 면역을 부여합니다."
                    },
                    {
                      "term": "불활성화 사백신 (Inactivated Killed Vaccine)",
                      "definition": "죽은 병원체나 그 일부를 사용하여 만든 백신으로, 약독화 생백신보다 안전하지만 주로 체액성 면역을 유도하고 반복적인 추가 접종이 필요합니다."
                    },
                    {
                      "term": "서브유닛 백신 (Subunit Vaccine)",
                      "definition": "병원체의 특정 항원성 조각만을 사용하여 만든 백신으로, 면역 반응을 자극합니다."
                    },
                    {
                      "term": "톡소이드 (Toxoid)",
                      "definition": "독소의 독성을 제거하고 면역원성만 남긴 백신으로, 독소에 의해 발생하는 질병을 예방하는 데 사용됩니다."
                    },
                    {
                      "term": "아쥬반트 (Adjuvant)",
                      "definition": "백신의 면역 반응을 강화하기 위해 첨가되는 물질로, 백신의 효능을 높이고 선천 면역 반응을 개선합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "백신 개요",
                      "id": "백신-개요",
                      "children": [
                        {
                          "text": "백신의 역사",
                          "id": "백신의-역사",
                          "children": null
                        },
                        {
                          "text": "백신의 정의",
                          "id": "백신의-정의",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신의 기능 및 원리",
                      "id": "백신의-기능-및-원리",
                      "children": [
                        {
                          "text": "면역 반응 유도",
                          "id": "면역-반응-유도",
                          "children": null
                        },
                        {
                          "text": "집단 면역",
                          "id": "집단-면역",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "CDC 권장 백신",
                      "id": "cdc-권장-백신",
                      "children": [
                        {
                          "text": "세균성 질환 백신",
                          "id": "세균성-질환-백신",
                          "children": null
                        },
                        {
                          "text": "바이러스성 질환 백신",
                          "id": "바이러스성-질환-백신",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신의 종류 및 특성",
                      "id": "백신의-종류-및-특성",
                      "children": [
                        {
                          "text": "약독화 생백신 (Live attenuated vaccines)",
                          "id": "약독화-생백신-live-attenuated-vaccines",
                          "children": null
                        },
                        {
                          "text": "불활성화 사백신 (Inactivated killed vaccines)",
                          "id": "불활성화-사백신-inactivated-killed-vaccines",
                          "children": null
                        },
                        {
                          "text": "서브유닛 백신 (Subunit vaccines)",
                          "id": "서브유닛-백신-subunit-vaccines",
                          "children": null
                        },
                        {
                          "text": "톡소이드 (Toxoids)",
                          "id": "톡소이드-toxoids",
                          "children": null
                        },
                        {
                          "text": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
                          "id": "바이러스-유사-입자-vlp-백신-virus-like-particle-vlp-vaccines",
                          "children": null
                        },
                        {
                          "text": "다당류 백신 (Polysaccharide vaccines)",
                          "id": "다당류-백신-polysaccharide-vaccines",
                          "children": null
                        },
                        {
                          "text": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
                          "id": "핵산-dna-백신-nucleic-acid-dna-vaccines",
                          "children": null
                        },
                        {
                          "text": "재조합 벡터 백신 (Recombinant vector vaccines)",
                          "id": "재조합-벡터-백신-recombinant-vector-vaccines",
                          "children": null
                        },
                        {
                          "text": "RNA 백신 (RNA vaccines)",
                          "id": "rna-백신-rna-vaccines",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신 생산, 전달 방법 및 제형",
                      "id": "백신-생산-전달-방법-및-제형",
                      "children": [
                        {
                          "text": "생산 기술의 발전",
                          "id": "생산-기술의-발전",
                          "children": null
                        },
                        {
                          "text": "새로운 전달 방식",
                          "id": "새로운-전달-방식",
                          "children": null
                        },
                        {
                          "text": "아쥬반트의 역할",
                          "id": "아쥬반트의-역할",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "마이크로바이옴과 경구 백신 반응",
                      "id": "마이크로바이옴과-경구-백신-반응",
                      "children": null
                    },
                    {
                      "text": "백신의 안전성",
                      "id": "백신의-안전성",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "백신 접종이 유도하는 주요 면역학적 반응은 무엇이며, 이 반응의 결과로 형성되는 중요한 세포는 무엇입니까?",
                    "options": [
                      "일차 면역 반응, 기억 세포",
                      "이차 면역 반응, 비만 세포",
                      "알레르기 반응, 형질 세포",
                      "자가면역 반응, T 세포"
                    ],
                    "answerIndex": 0,
                    "explanation": "백신은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이 기억 세포 덕분에 실제 병원체 노출 시 빠르고 강렬한 이차 면역 반응이 가능해집니다."
                  },
                  {
                    "question": "다음 중 약독화 생백신과 불활성화 사백신의 주요 차이점에 대한 설명으로 올바른 것은 무엇입니까?",
                    "options": [
                      "약독화 생백신은 평생 면역을 부여하지만, 불활성화 사백신은 추가 접종이 필요하다.",
                      "약독화 생백신은 주로 체액성 면역을 유도하고, 불활성화 사백신은 세포성 면역을 유도한다.",
                      "약독화 생백신은 불활성화 사백신보다 안전하다.",
                      "약독화 생백신은 유전 물질을 포함하지 않지만, 불활성화 사백신은 포함한다."
                    ],
                    "answerIndex": 0,
                    "explanation": "약독화 생백신은 실제 감염과 유사하게 평생 지속되는 세포성 및 체액성 면역을 부여하는 경향이 있는 반면, 불활성화 사백신은 더 안전하지만 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다."
                  },
                  {
                    "question": "백신에 첨가되어 효능을 향상시키고 선천 면역 반응을 개선하는 화학 첨가제는 무엇이라고 불립니까?",
                    "options": [
                      "항독소",
                      "톡소이드",
                      "아쥬반트",
                      "폴리사카라이드"
                    ],
                    "answerIndex": 2,
                    "explanation": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 선천 면역 반응을 개선하는 역할을 합니다."
                  }
                ]
              },
              {
                "title": "면역학의 실제 적용: 진단 면역학",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 2187 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "진단 면역학 개요",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "민감도(Sensitivity): 검사가 진양성 표본에 대해 반응할 확률",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "특이도(Specificity): 양성 검사가 진음성 표본에 대해 반응하지 않을 확률",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역학 기반 진단 검사는 체액 항체와 항원의 상호작용을 이용한다. 알려진 항체를 통해 미지의 병원체를 식별하거나, 알려진 병원체를 통해 미지의 항체를 식별할 수 있다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "단일클론 항체 (Monoclonal Antibodies)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "하이브리도마(Hybridoma): \"불멸의\" 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합한 세포.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "하이브리도마는 단일클론 항체(Mabs)를 생산한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Mabs는 균일하고, 특이성이 높으며, 대량 생산이 가능하다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "진단 도구 및 인체 치료에 사용된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류마티스 관절염에서 TNF를 중화하거나, 비만세포와 호염기구에 IgE 결합을 막아 알레르기성 천식을 치료하는 데 활용된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주로 쥐 세포에서 유래하여 부작용을 일으킬 수 있다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "키메라 단일클론 항체: 쥐의 가변 영역과 인간의 불변 영역을 가진 Mabs.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인간화 항체: 쥐 항원 결합 부위를 제외하고 대부분 인간 유래인 Mabs.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "완전 인간 항체: 쥐에 삽입된 인간 유전자로부터 생산된 Mabs.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "단일클론 항체의 생산",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "침강 반응 (Precipitation Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "가용성 항원과 항체가 반응하여 격자(lattices)라고 불리는 크고 서로 맞물린 응집체를 형성하는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원-항체 복합체가 형성된 후, 용액에서 침전되는 격자가 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강링 테스트(Precipitin ring test): 최적의 항원-항체 비율 지점에서 흐린 선이 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역확산 테스트(Immunodiffusion tests): 한천 젤 배지에서 수행되는 침강 반응이다. 최적의 항원-항체 비율 지점에서 침전물이 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 전기영동(Immunoelectrophoresis): 전기영동과 면역확산을 결합한 것으로, 인간 혈청의 단백질을 분리한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "응집 반응 (Agglutination Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "입자성 항원이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 응집 테스트(Direct agglutination tests): 큰 세포성 항원에 대한 항체를 검출한다. 혈청 항체 농도(역가, titer)를 측정하며, 역가 증가는 질병에 대한 더 큰 면역을 나타낸다. 혈청 전환(Seroconversion)은 질병이 진행됨에 따라 역가에 유의미한 변화가 나타나는 것을 의미한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접(수동) 응집 테스트(Indirect (passive) agglutination tests): 항체가 입자에 부착된 가용성 항원과 반응하거나 그 반대로 반응한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈구 응집(Hemagglutination): 적혈구 표면 항원과 보체 항체의 응집으로, 혈액형 판별에 사용된다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 면역학 학습 목표 (1)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "응집 테스트와 침강 테스트의 차이점을 구별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈구 응집을 정의한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "중화 테스트가 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강 테스트와 중화 테스트의 차이점을 구별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 고정 테스트의 기본 원리를 설명한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "중화 반응 (Neutralization Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스성 혈구 응집(Viral hemagglutination): 바이러스가 항원-항체 반응 없이 적혈구를 응집시키는 현상 (예: 볼거리, 홍역, 인플루엔자).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체(항독소)에 의해 외독소나 바이러스의 유해한 효과가 차단되는 항원-항체 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스성 혈구 응집 억제 테스트(Viral hemagglutination inhibition test): 바이러스 아형을 분류하는 데 사용된다. 바이러스와 적혈구를 환자의 혈청과 혼합한다. 혈청에 바이러스에 대한 항체가 포함되어 있으면, 항체가 바이러스를 중화하여 혈구 응집을 억제한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 고정 반응 (Complement-Fixation Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 고정(Complement fixation): 보체 혈청 단백질이 항원-항체 복합체에 결합하고 고정되는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "소량의 항체를 검출할 수 있다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강 또는 응집 반응에 적합하지 않은 항체에도 사용될 수 있다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 면역학 학습 목표 (2)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 및 간접 형광 항체 테스트를 비교하고 대조한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 및 간접 ELISA 테스트가 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "웨스턴 블롯이 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "단일클론 항체의 중요성을 설명한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "형광 염료를 항체와 결합시킨다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 FA 테스트: 임상 검체에서 미생물을 식별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접 FA 테스트: 혈청에서 특정 항체를 검출한다. 항인간 면역 혈청 글로불린(anti-HISG)을 추가하며, 결과가 양성이면 혈청 내 모든 항체와 반응한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "형광 활성화 세포 분류기(Fluorescence-activated cell sorter, FACS): 레이저 빔이 세포를 포함하는 액적에 닿으면, 감지기가 표면 분자의 크기와 형광을 측정한다. 세포에 전하를 부여하여 세포를 분리한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "효소결합 면역흡착 분석법 (ELISA)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 ELISA: 항원을 검출한다. 항원을 포함하는 샘플을 항체와 혼합한다. 효소 연결 항체가 항원과 반응한다. 연결된 효소를 위한 기질을 추가하여 색이 생성되는 것으로 검출한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접 ELISA: 항체를 검출한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "웨스턴 블롯 (Western Blotting)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "전기영동과 블롯을 통해 단백질을 식별한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 및 치료 면역학의 미래",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "인간의 판단과 인력이 덜 필요한 테스트가 개발될 것이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "PCR 및 DNA 프로브가 활용될 것이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "개발도상국을 위한 저렴하고 간단한 테스트가 필요하다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "질병 예방 및 치료에 기여할 것이다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 면역학의 실제 적용, 특히 진단 면역학에 대해 설명합니다. 검사의 민감도와 특이도 같은 기본 개념부터 시작하여, 단일클론 항체의 생산, 종류 및 치료적 활용에 대해 다룹니다. 또한, 침강 반응, 응집 반응, 중화 반응, 보체 고정 반응, 형광 항체 기법, ELISA, 웨스턴 블롯 등 다양한 면역학 기반 진단 테스트의 원리와 적용 방법을 상세히 설명합니다. 마지막으로 진단 및 치료 면역학의 미래 방향에 대해서도 간략하게 언급합니다.",
                  "keyConcepts": [
                    {
                      "term": "진단 면역학의 기본 원리",
                      "definition": "검사의 민감도(Sensitivity)와 특이도(Specificity)는 진단 검사의 정확성을 나타내는 핵심 지표이며, 항원-항체 상호작용이 면역학 기반 진단 테스트의 근간을 이룬다."
                    },
                    {
                      "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                      "definition": "하이브리도마 기술을 통해 대량 생산되는 균일하고 고도로 특이적인 항체로, 진단 및 류마티스 관절염, 알레르기성 천식 등 다양한 질병의 치료에 활용된다. 쥐 유래 항체는 부작용을 일으킬 수 있어 키메라, 인간화, 완전 인간 항체 등으로 발전하고 있다."
                    },
                    {
                      "term": "면역 반응 기반 진단 테스트 유형",
                      "definition": "침강(Precipitation), 응집(Agglutination), 중화(Neutralization), 보체 고정(Complement-Fixation), 형광 항체(Fluorescent-Antibody), ELISA(Enzyme-Linked Immunosorbent Assay), 웨스턴 블롯(Western Blotting) 등 항원-항체 반응을 시각적으로 또는 정량적으로 확인하여 질병을 진단하는 다양한 기법들이 있다."
                    },
                    {
                      "term": "항체 역가 측정",
                      "definition": "직접 응집 테스트 등을 통해 혈청 내 특정 항체의 농도(역가)를 측정하는 것으로, 역가 증가는 질병에 대한 면역력 증가를 나타내며, 혈청 전환은 질병 진행에 따른 역가의 유의미한 변화를 의미한다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "민감도 (Sensitivity)",
                      "definition": "검사가 진양성 표본에 대해 반응할 확률"
                    },
                    {
                      "term": "특이도 (Specificity)",
                      "definition": "양성 검사가 진음성 표본에 대해 반응하지 않을 확률"
                    },
                    {
                      "term": "하이브리도마 (Hybridoma)",
                      "definition": "암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포"
                    },
                    {
                      "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                      "definition": "하이브리도마에서 생산되는 균일하고 특이성이 높은 항체로, 진단 및 치료에 사용된다."
                    },
                    {
                      "term": "침강 반응 (Precipitation Reactions)",
                      "definition": "가용성 항원과 항체가 반응하여 불용성 복합체(격자)를 형성하고 침전되는 반응"
                    },
                    {
                      "term": "응집 반응 (Agglutination Reactions)",
                      "definition": "입자성 항원(예: 세포)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응"
                    },
                    {
                      "term": "중화 반응 (Neutralization Reactions)",
                      "definition": "항체가 독소나 바이러스의 유해한 효과를 차단하는 항원-항체 반응"
                    },
                    {
                      "term": "보체 고정 반응 (Complement-Fixation Reactions)",
                      "definition": "보체 단백질이 항원-항체 복합체에 결합하고 고정되는 반응으로, 소량의 항체도 검출 가능하다."
                    },
                    {
                      "term": "효소결합 면역흡착 분석법 (ELISA)",
                      "definition": "효소와 항체를 이용하여 항원 또는 항체를 검출하는 면역학적 분석법으로, 색 변화를 통해 결과를 확인한다."
                    },
                    {
                      "term": "웨스턴 블롯 (Western Blotting)",
                      "definition": "전기영동으로 분리된 단백질을 막에 옮겨 특정 항체를 이용하여 식별하는 기법"
                    }
                  ],
                  "outline": [
                    {
                      "text": "진단 면역학 개요",
                      "id": "진단-면역학-개요",
                      "children": null
                    },
                    {
                      "text": "단일클론 항체 (Monoclonal Antibodies)",
                      "id": "단일클론-항체-monoclonal-antibodies",
                      "children": [
                        {
                          "text": "단일클론 항체의 생산",
                          "id": "단일클론-항체의-생산",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "침강 반응 (Precipitation Reactions)",
                      "id": "침강-반응-precipitation-reactions",
                      "children": null
                    },
                    {
                      "text": "응집 반응 (Agglutination Reactions)",
                      "id": "응집-반응-agglutination-reactions",
                      "children": null
                    },
                    {
                      "text": "진단 면역학 학습 목표 (1)",
                      "id": "진단-면역학-학습-목표-1",
                      "children": null
                    },
                    {
                      "text": "중화 반응 (Neutralization Reactions)",
                      "id": "중화-반응-neutralization-reactions",
                      "children": null
                    },
                    {
                      "text": "보체 고정 반응 (Complement-Fixation Reactions)",
                      "id": "보체-고정-반응-complement-fixation-reactions",
                      "children": null
                    },
                    {
                      "text": "진단 면역학 학습 목표 (2)",
                      "id": "진단-면역학-학습-목표-2",
                      "children": null
                    },
                    {
                      "text": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
                      "id": "형광-항체-기법-fluorescent-antibody-techniques",
                      "children": null
                    },
                    {
                      "text": "효소결합 면역흡착 분석법 (ELISA)",
                      "id": "효소결합-면역흡착-분석법-elisa",
                      "children": null
                    },
                    {
                      "text": "웨스턴 블롯 (Western Blotting)",
                      "id": "웨스턴-블롯-western-blotting",
                      "children": null
                    },
                    {
                      "text": "진단 및 치료 면역학의 미래",
                      "id": "진단-및-치료-면역학의-미래",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 하이브리도마(Hybridoma)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
                    "options": [
                      "암성 B 세포와 항체 생산 정상 B 세포를 결합한 세포",
                      "항원을 직접 생산하는 세포",
                      "체내에서 바이러스성 감염을 중화하는 세포",
                      "면역 반응을 억제하는 데 사용되는 세포"
                    ],
                    "answerIndex": 0,
                    "explanation": "하이브리도마는 '불멸의' 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포입니다."
                  },
                  {
                    "question": "침강 반응(Precipitation Reactions)과 응집 반응(Agglutination Reactions)의 주요 차이점은 무엇입니까?",
                    "options": [
                      "침강 반응은 가용성 항원을, 응집 반응은 입자성 항원을 사용한다.",
                      "침강 반응은 항체를 검출하고, 응집 반응은 항원을 검출한다.",
                      "침강 반응은 육안으로 볼 수 없지만, 응집 반응은 육안으로 볼 수 있다.",
                      "침강 반응은 보체를 필요로 하지만, 응집 반응은 그렇지 않다."
                    ],
                    "answerIndex": 0,
                    "explanation": "침강 반응은 가용성 항원과 항체의 상호작용으로 불용성 복합체가 형성되는 것이고, 응집 반응은 입자성 항원(예: 세포 또는 입자에 부착된 항원)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 것입니다."
                  },
                  {
                    "question": "효소결합 면역흡착 분석법(ELISA)에 대한 설명으로 옳지 않은 것은 무엇입니까?",
                    "options": [
                      "직접 ELISA는 항원을 검출하는 데 사용된다.",
                      "간접 ELISA는 항체를 검출하는 데 사용된다.",
                      "효소 연결 항체가 항원 또는 항체와 반응하여 색 변화를 유도한다.",
                      "ELISA는 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법이다."
                    ],
                    "answerIndex": 3,
                    "explanation": "ELISA는 효소와 항체를 이용하여 항원 또는 항체를 검출하며 색 변화를 통해 결과를 확인합니다. 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법은 웨스턴 블롯(Western Blotting)입니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 과민 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 3760 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "과민 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "과민 반응(Hypersensitivity)은 정상 범위를 넘어선 과도한 항원(알레르겐) 반응을 의미합니다. 이는 이전에 항원에 노출되어 민감해진 경우에 발생합니다. 과민 반응은 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 유형으로 분류됩니다. 과민 반응을 연구하는 학문은 면역병리학(Immunopathology)이라고 합니다. 위생 가설(Hygiene hypothesis)은 병원균에 대한 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다고 제안합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "과민 반응의 유형",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "제1형 (아나필락시스형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 30분 미만이 소요됩니다. IgE 항체가 비만세포나 호염기구에 결합하여 비만세포 또는 호염기구의 탈과립을 유발하고 히스타민과 같은 반응성 물질을 방출하게 합니다. 약물 주사 및 곤충 독에 의한 아나필락시스 쇼크, 건초열, 천식과 같은 일반적인 알레르기 증상이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제2형 (세포 독성형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 5-12시간이 소요됩니다. 항원이 표적 세포에 결합하는 IgM 및 IgG 항체 형성을 유발하며, 보체의 작용과 결합하여 표적 세포를 파괴합니다. 수혈 반응, Rh 부적합성이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제3형 (면역 복합체형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 3-8시간이 소요됩니다. 항체와 항원이 복합체를 형성하여 손상적인 염증을 유발합니다. 아르투스 반응, 혈청병이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제4형 (지연형 세포 매개성 또는 지연형 과민 반응)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 24-48시간이 소요됩니다. 항원이 세포독성 T 림프구(CTLs)를 활성화시켜 표적 세포를 사멸시킵니다. 이식 조직 거부 반응, 옻나무에 의한 접촉 피부염, 특정 만성 질환(예: 결핵) 등이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제1형 (아나필락시스형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이 반응은 항원에 민감해진 사람이 해당 항원에 재노출된 후 수 분 내에 발생합니다. 항원이 IgE 항체와 결합하며, IgE는 비만세포와 호염기구에 부착됩니다. 비만세포와 호염기구는 탈과립을 겪으며 다음과 같은 매개체를 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 히스타민: 혈액 모세혈관의 투과성을 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 류코트리엔: 평활근의 지속적인 수축을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 프로스타글란딘: 평활근에 영향을 미치고 점액 분비를 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원에 반응하여 생성된 IgE 항체는 비만세포와 호염기구를 감싸게 됩니다. 항원이 동일한 특이성을 가진 두 개의 인접한 항체 분자 사이의 간격을 연결할 때, 세포는 탈과립을 겪고 히스타민 및 기타 매개체를 방출합니다. 이는 항원과 반응하여 히스타민 및 기타 반응성 매개체 과립을 방출한 탈과립 비만세포의 모습입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전신 아나필락시스 (아나필락시스 쇼크)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항원에 민감해진 개체가 다시 노출될 때 발생합니다. 순환계 허탈 및 사망에 이를 수 있으며, 에피네프린으로 치료합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "국소 아나필락시스",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "주로 섭취되거나 흡입된 항원과 관련이 있습니다. 증상은 침입 경로에 따라 다르며, 두드러기, 건초열, 천식 등이 포함됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "아나필락시스 반응 예방",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "알레르겐을 식별하기 위한 피부 검사는 항원을 표피 아래에 접종하여 빠른 염증 반응(팽진)을 확인합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "탈감작(Desensitization)은 항원을 피부 아래에 증가하는 용량으로 주사하는 방법입니다. 이는 IgG를 생성하게 하는데, 이 IgG는 블로킹 항체(blocking antibodies) 역할을 하여 항원을 가로채고 중화시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제2형 (세포 독성형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "IgG 또는 IgM 항체와 항원성 세포의 결합에 의한 보체 활성화로 발생합니다. 이는 세포 용해 또는 대식세포에 의한 손상을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "ABO 혈액형 시스템",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "적혈구에 있는 특정 탄수화물 항원에 대해 항체가 형성됩니다. A 항원, B 항원 또는 둘 다를 가질 수 있습니다. O형 적혈구는 항원이 없습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "Rh 혈액형 시스템",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "인구의 85%에서 적혈구에 Rh 인자 항원(Rh+)이 발견됩니다. Rh+ 혈액이 Rh- 수혈자에게 주입되면 수혈자의 몸에서 항Rh 항체 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "용혈성 신생아 질환 (HDNB)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "Rh- 어머니가 Rh+ 태아를 임신할 경우 어머니의 몸에서 항Rh 항체가 생성됩니다. 첫 Rh+ 태아를 임신한 Rh- 어머니의 경우, 분만 중 태아의 Rh 항원이 어머니의 혈액으로 들어갈 수 있습니다. 이 태아 Rh 항원에 반응하여 어머니는 항Rh 항체를 생산할 것입니다. 두 번째 Rh+ 태아를 임신하게 되면, 어머니의 항Rh 항체가 태반을 통과하여 태아의 적혈구를 손상시킬 것입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "약물 유발 세포 독성 반응",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "혈소판 감소성 자반증 (Thrombocytopenic purpura)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "혈소판이 약물과 결합하여 항원성 복합체를 형성합니다. 항체와 보체가 혈소판을 파괴합니다. 약물(합텐)이 혈소판에 결합하여 합텐-혈소판 복합체를 형성합니다. 이 복합체는 합텐에 대한 항체 형성을 유도합니다. 항체와 보체의 작용은 혈소판 파괴를 일으킵s니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "무과립구증 (Agranulocytosis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "약물 유발 과립구의 면역 파괴입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "용혈성 빈혈 (Hemolytic anemia)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "약물 유발 적혈구의 면역 파괴입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제3형 (면역 복합체형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 혈청 내 가용성 항원에 대해 형성됩니다. 세포 아래 기저막에 침착되는 면역 복합체를 형성하여 보체를 활성화시키고 염증을 유발합니다. 면역 복합체는 혈관벽에 침착됩니다. 면역 복합체의 존재는 보체를 활성화시키고 호중구와 같은 염증 세포를 유인합니다. 호중구에서 방출된 효소는 기저막의 내피 세포에 손상을 입힙니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "아르투스 반응 (Arthus reaction)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "톡소이드 함유 백신의 드문 부작용입니다. 주사된 항원에 대해 이미 순환하는 IgG를 가진 환자에서 보체 활성화로 인해 사구체 및 기타 혈관벽에서 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "혈청병 (Serum sickness)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "이종 혈청 주입으로 인한 부종 및 염증과 함께 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제4형 (지연형 세포 매개성) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포에 의해 유발되는 세포 매개 면역 반응입니다. 이는 지연형 과민 반응으로 알려져 있습니다. 항원은 식세포화되어 T 세포 수용체에 제시되어 민감화를 유발합니다. 항원에 재노출되면 기억 세포가 파괴적인 사이토카인을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "알레르기성 접촉 피부염 (Allergic contact dermatitis)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "합텐이 피부의 단백질과 결합하여 면역 반응을 일으킵니다. 옻나무, 화장품, 금속, 라텍스 등에 대한 알레르기 반응이 여기에 해당합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본문은 면역 시스템 관련 질환 중 '과민 반응'에 대해 설명합니다. 과민 반응은 정상 범위를 넘어선 과도한 면역 반응으로, 이전 항원 노출로 인해 민감해진 상태에서 발생합니다. 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 주요 유형으로 분류되며, 각 유형은 발현 시간, 기전, 임상 증상 및 예시가 다릅니다. 제1형은 즉각적인 알레르기 반응(예: 아나필락시스 쇼크)을, 제2형은 세포 파괴(예: 수혈 부작용)를, 제3형은 면역 복합체 침착으로 인한 염증(예: 혈청병)을, 제4형은 T세포 매개 지연 반응(예: 접촉 피부염)을 특징으로 합니다. 각 유형의 발생 기전과 예방 및 치료법이 상세히 다루어집니다.",
                  "keyConcepts": [
                    {
                      "term": "과민 반응 (Hypersensitivity)",
                      "definition": "정상 범위를 넘어선 과도한 항원 반응으로, 이전에 항원에 노출되어 민감해진 경우에 발생합니다."
                    },
                    {
                      "term": "아나필락시스 (Anaphylaxis)",
                      "definition": "제1형 과민 반응의 심각한 형태로, 비만세포 및 호염기구의 탈과립으로 인한 매개체 방출로 발생하며, 전신 또는 국소적으로 나타나 생명을 위협할 수 있습니다."
                    },
                    {
                      "term": "위생 가설 (Hygiene Hypothesis)",
                      "definition": "병원균 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다는 가설입니다."
                    },
                    {
                      "term": "탈감작 (Desensitization)",
                      "definition": "알레르기 반응을 예방하기 위해 항원을 점진적으로 증가시켜 주사하는 치료법으로, 블로킹 항체(IgG) 생성을 유도하여 알레르겐을 중화시킵니다."
                    },
                    {
                      "term": "용혈성 신생아 질환 (HDNB)",
                      "definition": "Rh 혈액형 불일치로 인해 Rh- 어머니가 Rh+ 태아에 대한 항체를 생성하여 두 번째 Rh+ 태아의 적혈구를 파괴하는 질환입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "알레르겐 (Allergen)",
                      "definition": "알레르기 반응을 유발하는 항원입니다."
                    },
                    {
                      "term": "면역병리학 (Immunopathology)",
                      "definition": "과민 반응을 연구하는 학문입니다."
                    },
                    {
                      "term": "히스타민 (Histamine)",
                      "definition": "제1형 과민 반응 시 비만세포에서 방출되어 혈관 투과성을 증가시키는 주요 염증 매개체입니다."
                    },
                    {
                      "term": "류코트리엔 (Leukotrienes)",
                      "definition": "제1형 과민 반응 시 방출되어 평활근의 지속적인 수축을 유발하는 매개체입니다."
                    },
                    {
                      "term": "프로스타글란딘 (Prostaglandins)",
                      "definition": "제1형 과민 반응 시 방출되어 평활근에 영향을 미치고 점액 분비를 증가시키는 매개체입니다."
                    },
                    {
                      "term": "보체 (Complement)",
                      "definition": "면역 반응에서 항체와 함께 작용하여 세포 파괴를 돕는 단백질 시스템입니다."
                    },
                    {
                      "term": "합텐 (Hapten)",
                      "definition": "단독으로는 면역 반응을 유발하지 못하지만, 단백질과 결합 시 항원성을 띠는 작은 분자입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "과민 반응의 개요",
                      "id": "hypersensitivity-overview",
                      "children": [
                        {
                          "text": "정의 및 특징",
                          "id": "definition-features",
                          "children": null
                        },
                        {
                          "text": "과민 반응의 네 가지 유형",
                          "id": "four-types-hypersensitivity",
                          "children": null
                        },
                        {
                          "text": "면역병리학 및 위생 가설",
                          "id": "immunopathology-hygiene-hypothesis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "과민 반응 유형별 상세 설명",
                      "id": "detailed-hypersensitivity-types",
                      "children": [
                        {
                          "text": "제1형 과민 반응 (아나필락시스형)",
                          "id": "type-i-anaphylactic",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-i-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "매개체 (히스타민, 류코트리엔, 프로스타글란딘)",
                              "id": "type-i-mediators",
                              "children": null
                            },
                            {
                              "text": "전신 아나필락시스 및 국소 아나필락시스",
                              "id": "systemic-local-anaphylaxis",
                              "children": null
                            },
                            {
                              "text": "예방 및 치료",
                              "id": "type-i-prevention-treatment",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제2형 과민 반응 (세포 독성형)",
                          "id": "type-ii-cytotoxic",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-ii-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "ABO 혈액형 시스템",
                              "id": "abo-blood-group",
                              "children": null
                            },
                            {
                              "text": "Rh 혈액형 시스템 및 용혈성 신생아 질환",
                              "id": "rh-blood-group-hdnb",
                              "children": null
                            },
                            {
                              "text": "약물 유발 세포 독성 반응",
                              "id": "drug-induced-cytotoxic",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제3형 과민 반응 (면역 복합체형)",
                          "id": "type-iii-immune-complex",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-iii-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "아르투스 반응",
                              "id": "arthus-reaction",
                              "children": null
                            },
                            {
                              "text": "혈청병",
                              "id": "serum-sickness",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제4형 과민 반응 (지연형 세포 매개성)",
                          "id": "type-iv-delayed-cell-mediated",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-iv-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "알레르기성 접촉 피부염",
                              "id": "allergic-contact-dermatitis",
                              "children": null
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "제1형 과민 반응 시 혈액 모세혈관의 투과성을 증가시키는 주요 매개체는 무엇입니까?",
                    "options": [
                      "히스타민",
                      "류코트리엔",
                      "프로스타글란딘",
                      "사이토카인"
                    ],
                    "answerIndex": 0,
                    "explanation": "제1형 과민 반응은 비만세포의 탈과립을 통해 히스타민을 방출하며, 히스타민은 혈액 모세혈관의 투과성을 증가시키는 역할을 합니다."
                  },
                  {
                    "question": "이식 조직 거부 반응 및 접촉 피부염과 주로 관련된 과민 반응 유형은 무엇입니까?",
                    "options": [
                      "제1형 (아나필락시스형)",
                      "제2형 (세포 독성형)",
                      "제3형 (면역 복합체형)",
                      "제4형 (지연형 세포 매개성)"
                    ],
                    "answerIndex": 3,
                    "explanation": "제4형 과민 반응은 T세포에 의해 매개되는 지연형 반응으로, 이식 조직 거부 반응과 접촉 피부염이 대표적인 예시입니다."
                  },
                  {
                    "question": "아나필락시스 반응 예방을 위한 탈감작의 주요 기전은 무엇입니까?",
                    "options": [
                      "히스타민 방출 억제",
                      "IgE 항체 생성 촉진",
                      "비만세포 탈과립 유도",
                      "IgG 블로킹 항체 생성"
                    ],
                    "answerIndex": 3,
                    "explanation": "탈감작은 증가하는 용량의 항원 주사를 통해 IgG 블로킹 항체를 생성하게 하여, 이 항체가 알레르겐을 가로채고 중화시켜 IgE 매개 반응을 예방합니다."
                  }
                ]
              },
              {
                "title": "자가면역 질환의 이해: 유형 및 주요 사례",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1640 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "자가면역 질환 (AUTOIMMUNE DISEASES)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 체계가 자가 항원에 반응하여 장기에 손상을 입히는 질환입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자가면역은 자가 관용(self-tolerance)의 상실을 의미합니다. 이는 면역 체계가 자신과 비자신을 구별하는 능력을 잃어버릴 때 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자가면역 반응은 세포독성(Cytotoxic), 면역 복합체(Immune complex), 또는 세포 매개성(Cell-mediated)의 형태로 나타날 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 자가면역 반응 (CYTOTOXIC AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 세포 표면 항원과 반응하여 세포를 손상시키거나 기능을 방해하는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다발성 경화증 (Multiple sclerosis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "자가항체, T 세포, 그리고 대식세포가 신경의 미엘린 수초를 공격하여 신경 임펄스 전달을 손상시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "증상은 피로와 쇠약부터 심한 마비에 이릅니다. 원인은 알려지지 않았지만, 유전적 취약성 및/또는 감염성 물질과 관련될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "그레이브스병 (Graves' disease)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "갑상선 내 비정상 항체가 과도한 양의 호르몬을 생성하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "중증 근무력증 (Myasthenia gravis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 아세틸콜린 수용체를 코팅하여 근육이 신경 신호를 받지 못하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 복합체 자가면역 반응 (IMMUNE COMPLEX AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체와 보체의 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전신성 홍반성 루푸스 (Systemic lupus erythematosus)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "신장 사구체에 면역 복합체가 형성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "류마티스 관절염 (Rheumatoid arthritis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "관절에 면역 복합체가 형성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포 매개성 자가면역 반응 (CELL-MEDIATED AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조직을 공격하는 T 세포에 의해 매개되는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인슐린 의존성 당뇨병 (Insulin-dependent diabetes mellitus, 1형 당뇨병)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포가 인슐린 분비 세포를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "건선 및 건선성 관절염 (Psoriasis and psoriatic arthritis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "피부의 자가면역 질환입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "주요 자가면역 질환 및 원인 (SELECTED AUTOIMMUNE DISORDERS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다음은 몇 가지 주요 자가면역 질환과 가능한 원인입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "만성 피로 증후군: 신경 세포의 아세틸콜린 수용체에 항체가 부착되어 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류마티스 관절염: 연쇄상구균 항체에 대한 교차 반응.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "전신성 홍반성 루푸스: DNA에 대한 항체를 포함하는 면역 복합체.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다발성 경화증: T 세포와 대식세포가 미엘린 수초를 공격.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1형 당뇨병: T 세포가 인슐린 분비 세포를 파괴.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "길랑-바레 증후군: T 세포가 신경 세포의 미엘린 수초 파괴를 유발하는 사이토카인을 생성.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "건선: T 세포가 각질 형성 세포(피부 세포) 성장을 유도할 수 있는 사이토카인을 생성.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그레이브스병: 갑상선 특정 수용체에 부착된 항체가 갑상선을 비대하게 하고 과도한 호르몬을 생성하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "중증 근무력증: 아세틸콜린 수용체에 대한 항체.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "크론병: 항균 항체가 장 점막과 반응.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "염증성 장 질환: 항균 항체가 장 점막과 반응.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "자가면역 질환은 면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 상태입니다. 이는 자가 관용의 상실로 인해 발생하며, 세포독성, 면역 복합체, 세포 매개성 반응의 세 가지 주요 유형으로 분류될 수 있습니다. 각 유형은 특정 질병과 관련이 있으며, 신경, 갑상선, 관절, 췌장 등 다양한 장기에 영향을 미칩니다. 주요 자가면역 질환으로는 다발성 경화증, 그레이브스병, 중증 근무력증, 전신성 홍반성 루푸스, 류마티스 관절염, 1형 당뇨병, 건선 등이 있으며, 각 질환의 원인과 면역학적 메커니즘이 설명됩니다.",
                  "keyConcepts": [
                    {
                      "term": "자가면역",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 현상입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "자가 관용",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 자신의 항원에 반응하지 않고 구별하는 능력입니다. 자가면역 질환은 이 자가 관용의 상실로 발생합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "세포독성 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "항체가 세포 표면 항원과 반응하여 세포를 파괴하거나 기능을 손상시키는 유형의 자가면역 반응입니다. (예: 다발성 경화증, 그레이브스병, 중증 근무력증)",
                        "hard": null
                      }
                    },
                    {
                      "term": "면역 복합체 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "항체와 항원이 결합하여 형성된 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형의 자가면역 반응입니다. (예: 전신성 홍반성 루푸스, 류마티스 관절염)",
                        "hard": null
                      }
                    },
                    {
                      "term": "세포 매개성 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "T 세포가 직접 조직을 공격하여 손상을 일으키는 유형의 자가면역 반응입니다. (예: 1형 당뇨병, 건선)",
                        "hard": null
                      }
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "자가 항원",
                      "definition": "자신의 신체에 존재하는 항원으로, 면역 체계가 실수로 공격하는 대상이 됩니다."
                    },
                    {
                      "term": "미엘린 수초",
                      "definition": "신경 세포를 둘러싸고 있는 절연성 막으로, 손상 시 신경 신호 전달에 문제가 발생합니다."
                    },
                    {
                      "term": "아세틸콜린 수용체",
                      "definition": "신경 전달 물질인 아세틸콜린이 결합하는 근육 세포 표면의 단백질로, 중증 근무력증에서 항체에 의해 기능이 저해됩니다."
                    },
                    {
                      "term": "면역 복합체",
                      "definition": "항체와 항원이 결합하여 형성된 복합체로, 특정 조직에 침착되어 염증을 유발할 수 있습니다."
                    },
                    {
                      "term": "T 세포",
                      "definition": "세포 매개 면역 반응을 담당하는 림프구의 일종으로, 일부 자가면역 질환에서 직접 조직을 공격합니다."
                    },
                    {
                      "term": "사구체",
                      "definition": "신장의 혈액 여과 단위로, 전신성 홍반성 루푸스에서 면역 복합체가 형성되는 주요 부위입니다."
                    },
                    {
                      "term": "사이토카인",
                      "definition": "면역 세포 간의 신호 전달에 관여하는 단백질로, 일부 자가면역 질환에서 조직 손상을 유발할 수 있습니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "자가면역 질환 개요",
                      "id": "autoimmune-diseases-overview",
                      "children": [
                        {
                          "text": "자가면역의 정의 및 특징",
                          "id": "definition-and-characteristics-of-autoimmunity",
                          "children": null
                        },
                        {
                          "text": "주요 반응 유형",
                          "id": "main-types-of-reactions",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포독성 자가면역 반응",
                      "id": "cytotoxic-autoimmune-reactions",
                      "children": [
                        {
                          "text": "다발성 경화증",
                          "id": "multiple-sclerosis",
                          "children": null
                        },
                        {
                          "text": "그레이브스병",
                          "id": "graves-disease",
                          "children": null
                        },
                        {
                          "text": "중증 근무력증",
                          "id": "myasthenia-gravis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 복합체 자가면역 반응",
                      "id": "immune-complex-autoimmune-reactions",
                      "children": [
                        {
                          "text": "전신성 홍반성 루푸스",
                          "id": "systemic-lupus-erythematosus",
                          "children": null
                        },
                        {
                          "text": "류마티스 관절염",
                          "id": "rheumatoid-arthritis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포 매개성 자가면역 반응",
                      "id": "cell-mediated-autoimmune-reactions",
                      "children": [
                        {
                          "text": "인슐린 의존성 당뇨병 (1형 당뇨병)",
                          "id": "insulin-dependent-diabetes-mellitus-type-1",
                          "children": null
                        },
                        {
                          "text": "건선 및 건선성 관절염",
                          "id": "psoriasis-and-psoriatic-arthritis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "주요 자가면역 질환 및 원인",
                      "id": "selected-autoimmune-disorders-and-causes",
                      "children": [
                        {
                          "text": "만성 피로 증후군",
                          "id": "chronic-fatigue-syndrome",
                          "children": null
                        },
                        {
                          "text": "류마티스 관절염",
                          "id": "rheumatoid-arthritis-cause",
                          "children": null
                        },
                        {
                          "text": "전신성 홍반성 루푸스",
                          "id": "systemic-lupus-erythematosus-cause",
                          "children": null
                        },
                        {
                          "text": "다발성 경화증",
                          "id": "multiple-sclerosis-cause",
                          "children": null
                        },
                        {
                          "text": "1형 당뇨병",
                          "id": "type-1-diabetes-cause",
                          "children": null
                        },
                        {
                          "text": "길랑-바레 증후군",
                          "id": "guillain-barre-syndrome",
                          "children": null
                        },
                        {
                          "text": "건선",
                          "id": "psoriasis-cause",
                          "children": null
                        },
                        {
                          "text": "그레이브스병",
                          "id": "graves-disease-cause",
                          "children": null
                        },
                        {
                          "text": "중증 근무력증",
                          "id": "myasthenia-gravis-cause",
                          "children": null
                        },
                        {
                          "text": "크론병",
                          "id": "crohns-disease",
                          "children": null
                        },
                        {
                          "text": "염증성 장 질환",
                          "id": "inflammatory-bowel-disease",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "자가면역 질환에서 면역 체계가 공격하는 대상은 무엇입니까?",
                    "options": [
                      "외부 병원체",
                      "알레르기 유발 물질",
                      "자가 항원",
                      "독성 물질"
                    ],
                    "answerIndex": 2,
                    "explanation": "자가면역 질환은 면역 체계가 자신의 신체 조직, 즉 자가 항원을 외부 침입자로 오인하여 공격하는 상태입니다."
                  },
                  {
                    "question": "다음 중 세포독성 자가면역 반응에 해당하는 질환이 아닌 것은 무엇입니까?",
                    "options": [
                      "다발성 경화증",
                      "그레이브스병",
                      "중증 근무력증",
                      "류마티스 관절염"
                    ],
                    "answerIndex": 3,
                    "explanation": "류마티스 관절염은 면역 복합체가 관절에 형성되어 발생하는 면역 복합체 자가면역 반응에 해당합니다. 다발성 경화증, 그레이브스병, 중증 근무력증은 세포독성 자가면역 반응의 예시입니다."
                  },
                  {
                    "question": "1형 당뇨병(인슐린 의존성 당뇨병)의 주요 원인으로 설명된 면역 반응은 무엇입니까?",
                    "options": [
                      "항체에 의한 아세틸콜린 수용체 코팅",
                      "면역 복합체의 신장 사구체 침착",
                      "T 세포에 의한 인슐린 분비 세포 파괴",
                      "갑상선 항체의 과도한 호르몬 생성 유발"
                    ],
                    "answerIndex": 2,
                    "explanation": "1형 당뇨병은 T 세포가 인슐린을 분비하는 췌장의 세포를 파괴하여 발생하는 세포 매개성 자가면역 반응입니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1848 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "인간 백혈구 항원(HLA) 복합체 관련 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조직적합성 항원(Histocompatibility antigens): 세포 표면에 존재하는 자가 항원입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주요 조직적합성 복합체(MHC): 조직적합성 항원을 암호화하는 유전자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인간 백혈구 항원(HLA) 복합체: 인간의 MHC 유전자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "특정 HLA는 특정 질병에 대한 감수성 증가와 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HLA 타이핑 및 이식 수술",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "HLA 타이핑은 HLA를 식별하고 비교하는 과정입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이식 수술에서 공여자와 수혜자는 조직 타이핑을 통해 일치해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "표준화된 항혈청 또는 HLA에 특이적인 단일클론 항체를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HLA 타이핑 과정: 검사 중인 림프구에 항-HLA 항체가 부착됩니다. 보체와 트립판 블루 염료가 추가되면, 보체에 의해 손상된 세포가 염료를 흡수합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 특권 부위 및 면역 특권 조직",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이식편은 T 세포, 대식세포, 그리고 보체 고정 항체에 의해 공격받을 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 특권 부위 및 면역 특권 조직으로의 이식은 면역 반응을 일으키지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "예시로는 각막 이식, 심장 판막 이식이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "줄기세포",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포는 여러 다른 세포 유형을 생성할 수 있는 마스터 세포입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "배아 줄기세포(ESCs)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "배반포에서 채취되며, 조직과 장기를 재생하는 데 사용됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다능성(Pluripotent)으로, 모든 종류의 세포를 생성할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "성체 줄기세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "분화된 성체 조직에 있는 줄기세포입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "유전자 도입을 통해 유도만능줄기세포(induced pluripotent stem cells)가 될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포 배양 과정: (1일) 일반적으로 시험관 아기 시술에서 폐기된 수정란인 배아가 사용됩니다. (1-5일) 배아는 반복적으로 분열하여 속이 빈 세포 덩어리인 배반포 단계를 형성합니다. 배아줄기세포는 배반포의 속세포덩어리에서 채취되어 배양 배지의 피더(feeder) 세포 위에서 성장합니다. 줄기세포주와 줄기세포 그룹은 배양 배지에서 콜로니를 형성합니다. 다양한 조건과 배양 배지에 추가된 성장 인자는 줄기세포가 신체의 다양한 조직(예: 혈액 및 림프 세포, 췌장 섬 세포, 신경 세포)을 위한 줄기세포주가 되도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "골수 이식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조혈모세포 이식으로도 알려져 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "수혜자가 건강한 혈액 세포를 생산할 수 있도록 하는 것이 목표입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역능력 있는 세포를 포함하는 이식된 골수로 인해 이식편대숙주병(Graft-versus-host, GVH)이 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이식편(Grafts)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "자가이식(Autograft): 자신의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동계이식(Isograft): 일란성 쌍둥이의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동종이식(Allografts): 다른 사람의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이종이식(Xenotransplantation product): 비인간 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비인간 항원에 대한 반응인 초급성 거부 반응을 극복해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이식 거부 반응 방지를 위한 면역 억제",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이식된 조직에 대한 세포 매개 면역 반응을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이클로스포린(Cyclosporine)과 타크로리무스(tacrolimus)는 IL-2를 억제하여 세포독성 T 세포를 방해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "시롤리무스(Sirolimus)는 세포성 및 체액성 면역을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "마이코페놀레이트(Mycophenolate)는 T 세포와 B 세포의 증식을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바실리시맙(Basiliximab)은 IL-2를 차단하는 키메라 단일클론 항체입니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "제공된 텍스트는 인간 백혈구 항원(HLA) 복합체의 역할과 이식 면역학에서 이의 중요성을 설명합니다. HLA 타이핑을 통한 조직 일치의 필요성, 면역 반응을 일으키지 않는 면역 특권 부위, 그리고 배아 및 성체 줄기세포의 종류와 활용에 대해 다룹니다. 또한, 자가이식, 동계이식, 동종이식, 이종이식과 같은 다양한 이식편의 유형과 이식편대숙주병(GVH)과 같은 이식 관련 합병증을 설명합니다. 마지막으로, 이식 거부 반응을 방지하기 위한 사이클로스포린, 타크로리무스, 시롤리무스, 마이코페놀레이트, 바실리시맙 등 주요 면역 억제제와 그 작용 기전을 소개합니다.",
                  "keyConcepts": [
                    {
                      "term": "인간 백혈구 항원(HLA) 복합체",
                      "definition": "인간의 주요 조직적합성 복합체(MHC) 유전자로, 이식 수술에서 조직 일치에 결정적인 역할을 하며 특정 질병 감수성과 관련이 있습니다."
                    },
                    {
                      "term": "줄기세포",
                      "definition": "다양한 세포 유형으로 분화할 수 있는 마스터 세포로, 배아 줄기세포와 성체 줄기세포로 나뉩니다. 조직 재생 및 치료에 잠재적으로 활용됩니다."
                    },
                    {
                      "term": "이식편의 종류",
                      "definition": "조직의 출처에 따라 자가이식(자신의 조직), 동계이식(일란성 쌍둥이), 동종이식(다른 사람), 이종이식(비인간 조직)으로 분류됩니다."
                    },
                    {
                      "term": "이식 거부 반응 및 GVH 질환",
                      "definition": "이식된 조직에 대한 수혜자의 면역 반응(이식 거부 반응) 또는 이식된 면역 세포가 수혜자의 조직을 공격하는 현상(이식편대숙주병)입니다."
                    },
                    {
                      "term": "면역 억제",
                      "definition": "이식 거부 반응을 방지하기 위해 특정 약물을 사용하여 수혜자의 면역 반응을 억제하는 치료법입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "조직적합성 항원",
                      "definition": "세포 표면에 존재하는 자가 항원입니다."
                    },
                    {
                      "term": "주요 조직적합성 복합체(MHC)",
                      "definition": "조직적합성 항원을 암호화하는 유전자입니다."
                    },
                    {
                      "term": "인간 백혈구 항원(HLA) 복합체",
                      "definition": "인간의 MHC 유전자입니다."
                    },
                    {
                      "term": "면역 특권 부위",
                      "definition": "이식 시 면역 반응을 일으키지 않는 신체 부위 또는 조직입니다."
                    },
                    {
                      "term": "이식편대숙주병(GVH)",
                      "definition": "이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격하는 질환입니다."
                    },
                    {
                      "term": "자가이식",
                      "definition": "자신의 조직을 사용하는 이식 방법입니다."
                    },
                    {
                      "term": "면역 억제제",
                      "definition": "이식 거부 반응을 방지하기 위해 면역 반응을 억제하는 약물입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "인간 백혈구 항원(HLA) 복합체 관련 반응",
                      "id": "인간-백혈구-항원-hla-복합체-관련-반응",
                      "children": [
                        {
                          "text": "조직적합성 항원",
                          "id": "조직적합성-항원",
                          "children": null
                        },
                        {
                          "text": "주요 조직적합성 복합체(MHC)",
                          "id": "주요-조직적합성-복합체-mhc",
                          "children": null
                        },
                        {
                          "text": "인간 백혈구 항원(HLA) 복합체",
                          "id": "인간-백혈구-항원-hla-복합체",
                          "children": null
                        },
                        {
                          "text": "특정 질병에 대한 감수성",
                          "id": "특정-질병에-대한-감수성",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "HLA 타이핑 및 이식 수술",
                      "id": "hla-타이핑-및-이식-수술",
                      "children": [
                        {
                          "text": "HLA 타이핑의 역할",
                          "id": "hla-타이핑의-역할",
                          "children": null
                        },
                        {
                          "text": "조직 타이핑의 중요성",
                          "id": "조직-타이핑의-중요성",
                          "children": null
                        },
                        {
                          "text": "HLA 타이핑 과정",
                          "id": "hla-타이핑-과정",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 특권 부위 및 면역 특권 조직",
                      "id": "면역-특권-부위-및-면역-특권-조직",
                      "children": [
                        {
                          "text": "이식 거부 반응의 메커니즘",
                          "id": "이식-거부-반응의-메커니즘",
                          "children": null
                        },
                        {
                          "text": "면역 특권 부위의 특징",
                          "id": "면역-특권-부위의-특징",
                          "children": null
                        },
                        {
                          "text": "예시: 각막 이식, 심장 판막 이식",
                          "id": "예시-각막-이식-심장-판막-이식",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "줄기세포",
                      "id": "줄기세포",
                      "children": [
                        {
                          "text": "줄기세포의 정의",
                          "id": "줄기세포의-정의",
                          "children": null
                        },
                        {
                          "text": "배아 줄기세포(ESCs)",
                          "id": "배아-줄기세포-escs",
                          "children": null
                        },
                        {
                          "text": "성체 줄기세포",
                          "id": "성체-줄기세포",
                          "children": null
                        },
                        {
                          "text": "줄기세포 배양 및 분화",
                          "id": "줄기세포-배양-및-분화",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "골수 이식",
                      "id": "골수-이식",
                      "children": [
                        {
                          "text": "조혈모세포 이식",
                          "id": "조혈모세포-이식",
                          "children": null
                        },
                        {
                          "text": "골수 이식의 목표",
                          "id": "골수-이식의-목표",
                          "children": null
                        },
                        {
                          "text": "이식편대숙주병(GVH)",
                          "id": "이식편대숙주병-gvh",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "이식편(Grafts)",
                      "id": "이식편-grafts",
                      "children": [
                        {
                          "text": "자가이식(Autograft)",
                          "id": "자가이식-autograft",
                          "children": null
                        },
                        {
                          "text": "동계이식(Isograft)",
                          "id": "동계이식-isograft",
                          "children": null
                        },
                        {
                          "text": "동종이식(Allografts)",
                          "id": "동종이식-allografts",
                          "children": null
                        },
                        {
                          "text": "이종이식(Xenotransplantation)",
                          "id": "이종이식-xenotransplantation",
                          "children": null
                        },
                        {
                          "text": "초급성 거부 반응 극복",
                          "id": "초급성-거부-반응-극복",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "이식 거부 반응 방지를 위한 면역 억제",
                      "id": "이식-거부-반응-방지를-위한-면역-억제",
                      "children": [
                        {
                          "text": "면역 억제의 목적",
                          "id": "면역-억제의-목적",
                          "children": null
                        },
                        {
                          "text": "주요 면역 억제제 및 작용 기전",
                          "id": "주요-면역-억제제-및-작용-기전",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "이식 수술에서 공여자와 수혜자의 조직 일치가 중요한 주된 이유는 무엇입니까?",
                    "options": [
                      "감염 위험을 줄이기 위해",
                      "수술 시간을 단축하기 위해",
                      "이식 거부 반응을 최소화하기 위해",
                      "환자의 회복 속도를 높이기 위해"
                    ],
                    "answerIndex": 2,
                    "explanation": "HLA 타이핑을 통한 조직 일치는 이식된 조직에 대한 수혜자의 면역 반응, 즉 거부 반응을 줄이는 데 필수적입니다."
                  },
                  {
                    "question": "다음 중 '이식편대숙주병(Graft-versus-host disease, GVH)'이 발생할 수 있는 이식 유형은 무엇입니까?",
                    "options": [
                      "자가이식 (Autograft)",
                      "동계이식 (Isograft)",
                      "골수 이식 (Bone marrow transplant)",
                      "각막 이식 (Cornea transplant)"
                    ],
                    "answerIndex": 2,
                    "explanation": "이식편대숙주병은 이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격할 때 발생합니다."
                  },
                  {
                    "question": "다음 중 면역 억제제 시롤리무스(Sirolimus)의 주요 작용 기전은 무엇입니까?",
                    "options": [
                      "IL-2 생성을 억제하여 세포독성 T 세포를 방해한다.",
                      "T 세포와 B 세포의 증식을 억제한다.",
                      "세포성 및 체액성 면역을 모두 억제한다.",
                      "IL-2를 차단하는 키메라 단일클론 항체이다."
                    ],
                    "answerIndex": 2,
                    "explanation": "텍스트에 따르면 시롤리무스는 세포성 및 체액성 면역을 모두 억제한다고 명시되어 있습니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1530 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역 시스템과 암",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "암세포는 면역 감시에 의해 제거됩니다. 암세포는 비자기로 표시되는 종양 관련 항원을 가지고 있습니다. CTL(활성화된 TC 세포)과 대식세포는 암세포를 용해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그러나 면역 시스템의 암 제거에는 몇 가지 제한 사항이 있습니다. 면역 시스템이 표적으로 삼을 항원성 에피토프가 없거나, 종양 세포가 너무 빠르게 증식하거나, 종양이 혈관화되어 면역 시스템에 보이지 않게 될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "암에 대한 면역 요법",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "암 치료를 위한 다양한 면역 요법이 개발되었습니다. 박테리아 내독소(Coley's toxins)는 암의 혈액 공급을 방해하는 TNF를 자극하여 사용될 수 있습니다. HPV(자궁경부암, 항문암, 인후암) 및 B형 간염(간암)과 같은 바이러스 관련 암에 대한 예방 백신이 사용됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "또한 단클론항체(Monoclonal antibodies)가 사용되는데, 예를 들어 유방암 치료제 허셉틴이 있습니다. 면역독소(Immunotoxin)는 단클론항체와 독성 물질을 결합하여 건강한 세포에 손상을 주지 않고 종양을 표적하여 죽입니다. 면역 관문 억제제와 CAR T 세포와 같은 세포 치료법도 암 치료에 활용되고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 결핍증",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 결핍증은 충분한 면역 반응이 부재하는 상태를 말합니다. 이는 선천성 면역 결핍증과 후천성 면역 결핍증으로 나눌 수 있습니다. 선천성 면역 결핍증은 결함이 있거나 없는 유전자 때문에 발생하며, 후천성 면역 결핍증은 약물, 암, 감염 등으로 인해 개인의 삶 동안 발병합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 결핍 질환",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "선천성 면역 결핍 질환은 유전적 유전자 결함에 의해 발생합니다. T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있으며, 항원 수용체 유전자 재배열의 결함 또한 SCID를 유발할 수 있습니다. T세포 항원 수용체로부터의 신호 전달 결함이나 T세포 발달을 차단하는 흉선 기능의 유전적 결함 역시 중증 면역 결핍증을 초래할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "림프구 발달의 결함이 중증 복합 면역 결핍증을 초래할 수 있음",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.12 나병균에 감염된 누드(털 없는) 쥐의 뒷발. M. leprae 박테리아 위치.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본문은 면역 시스템이 암과 싸우는 방식, 그 한계, 그리고 다양한 암 면역 요법에 대해 설명합니다. 또한 면역 결핍증을 선천성 및 후천성으로 구분하고, T세포 발달 또는 항원 수용체 결함으로 인한 SCID와 같은 선천성 면역 결핍 질환의 구체적인 원인을 다룹니다.",
                  "keyConcepts": [
                    {
                      "term": "면역 감시",
                      "definition": "면역 시스템이 암세포를 인식하고 제거하는 과정."
                    },
                    {
                      "term": "면역 요법",
                      "definition": "면역 시스템을 활용하여 암을 치료하는 방법으로, 백신, 단클론항체, 면역관문억제제, 세포 치료 등이 포함됩니다."
                    },
                    {
                      "term": "선천성 면역 결핍증",
                      "definition": "유전적 결함으로 인해 발생하는 면역 반응의 부재."
                    },
                    {
                      "term": "후천성 면역 결핍증",
                      "definition": "약물, 암, 감염 등으로 인해 개인의 삶 동안 발병하는 면역 결핍."
                    },
                    {
                      "term": "중증 복합 면역 결핍증 (SCID)",
                      "definition": "T세포 발달 결함이나 항원 수용체 유전자 재배열 결함 등으로 인해 발생하는 심각한 면역 결핍 질환."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "종양 관련 항원",
                      "definition": "암세포 표면에 존재하며 면역 시스템이 비자기로 인식하는 항원."
                    },
                    {
                      "term": "세포독성 T 림프구 (CTLs)",
                      "definition": "활성화된 T 세포로, 암세포나 감염된 세포를 직접 용해(파괴)하는 역할을 합니다."
                    },
                    {
                      "term": "코리 독소",
                      "definition": "박테리아 내독소로, TNF 분비를 자극하여 암의 혈액 공급을 방해하는 데 사용되었던 물질."
                    },
                    {
                      "term": "단클론항체 (Mab)",
                      "definition": "특정 항원에만 결합하도록 만들어진 항체로, 암 치료에 사용될 수 있습니다 (예: 허셉틴)."
                    },
                    {
                      "term": "면역독소",
                      "definition": "단클론항체와 독성 물질을 결합하여 암세포만을 표적하여 죽이는 치료제."
                    },
                    {
                      "term": "면역 관문 억제제",
                      "definition": "면역 반응을 억제하는 경로를 차단하여 면역 시스템이 암세포를 더 효과적으로 공격하도록 돕는 약물."
                    },
                    {
                      "term": "CAR T 세포",
                      "definition": "환자의 T 세포를 유전자 조작하여 암세포를 인식하고 공격하도록 만든 세포 치료제."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역 시스템과 암",
                      "id": "면역-시스템과-암",
                      "children": [
                        {
                          "text": "면역 감시를 통한 암세포 제거",
                          "id": "면역-감시를-통한-암세포-제거",
                          "children": null
                        },
                        {
                          "text": "면역 시스템의 암 제거 제한 사항",
                          "id": "면역-시스템의-암-제거-제한-사항",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
                      "id": "세포독성-t-림프구ctl와-암세포의-상호작용",
                      "children": null
                    },
                    {
                      "text": "암에 대한 면역 요법",
                      "id": "암에-대한-면역-요법",
                      "children": [
                        {
                          "text": "박테리아 내독소",
                          "id": "박테리아-내독소",
                          "children": null
                        },
                        {
                          "text": "백신",
                          "id": "백신",
                          "children": null
                        },
                        {
                          "text": "단클론항체 및 면역독소",
                          "id": "단클론항체-및-면역독소",
                          "children": null
                        },
                        {
                          "text": "면역 관문 억제제",
                          "id": "면역-관문-억제제",
                          "children": null
                        },
                        {
                          "text": "세포 치료",
                          "id": "세포-치료",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 결핍증",
                      "id": "면역-결핍증",
                      "children": [
                        {
                          "text": "선천성 면역 결핍증",
                          "id": "선천성-면역-결핍증",
                          "children": null
                        },
                        {
                          "text": "후천성 면역 결핍증",
                          "id": "후천성-면역-결핍증",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 결핍 질환",
                      "id": "면역-결핍-질환",
                      "children": [
                        {
                          "text": "선천성 면역 결핍 질환의 원인",
                          "id": "선천성-면역-결핍-질환의-원인",
                          "children": null
                        },
                        {
                          "text": "T세포 발달 및 항원 수용체 관련 결함",
                          "id": "t세포-발달-및-항원-수용체-관련-결함",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "림프구 발달 결함과 중증 복합 면역 결핍증 (SCID)",
                      "id": "림프구-발달-결함과-중증-복합-면역-결핍증-scid",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "면역 시스템이 암세포를 제거하는 데 있어 주요 제한 사항이 아닌 것은 무엇입니까?",
                    "options": [
                      "면역 시스템이 표적으로 삼을 항원성 에피토프가 없음",
                      "종양 세포가 너무 빠르게 증식함",
                      "종양이 혈관화되어 면역 시스템에 보이지 않게 됨",
                      "대식세포가 암세포를 용해하지 못함"
                    ],
                    "answerIndex": 3,
                    "explanation": "본문에서는 CTL(활성화된 TC 세포)과 대식세포가 암세포를 용해한다고 명시되어 있으므로, 대식세포가 암세포를 용해하지 못하는 것은 면역 시스템의 제한 사항이 아닙니다."
                  },
                  {
                    "question": "다음 중 암에 대한 면역 요법으로 언급되지 않은 것은 무엇입니까?",
                    "options": [
                      "박테리아 내독소 (Coley's toxins)",
                      "예방 백신 (HPV, B형 간염)",
                      "항생제",
                      "CAR T 세포 치료"
                    ],
                    "answerIndex": 2,
                    "explanation": "본문에서 박테리아 내독소, 예방 백신, CAR T 세포 치료는 암에 대한 면역 요법으로 언급되었지만, 항생제는 언급되지 않았습니다. 항생제는 주로 세균 감염 치료에 사용됩니다."
                  },
                  {
                    "question": "중증 복합 면역 결핍증(SCID)의 주요 원인이 될 수 있는 유전적 결함은 무엇입니까?",
                    "options": [
                      "B세포의 과도한 증식",
                      "T세포 발달의 결함",
                      "항체 생산 능력의 증가",
                      "대식세포 기능의 활성화"
                    ],
                    "answerIndex": 1,
                    "explanation": "본문에서는 'T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있습니다'라고 명확히 언급되어 있습니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 5576 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "후천성 면역 결핍 증후군 (AIDS)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "1981년, 미국에서 젊은 동성애 남성들 사이에서 폐포자충 폐렴, 카포시 육종, 그리고 면역 기능 상실 사례들이 집단으로 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1983년, 면역 기능 상실을 유발하는 바이러스(HIV)가 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 T 보조 세포를 선택적으로 감염시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "AIDS의 기원",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 서아프리카와 중앙아프리카의 침팬지(약 1908년, 부시미트로부터)로부터 인간 개체군으로 넘어왔습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "도시화와 성적 문란의 증가로 아프리카 전역으로 퍼졌습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가장 오래된 HIV 샘플은 1920년 콩고민주공화국의 킨샤사에서 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1976년에 사망한 노르웨이 선원은 서구 세계에서 알려진 첫 번째 사례입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1969년 미주리주의 한 환자로부터 채취한 샘플에서 HIV 감염이 확인되었습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 구조",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "렌티바이러스(Lentivirus) 속에 속합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "레트로바이러스(Retrovirus)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "두 개의 동일한 양성 가닥 RNA 유전체 분자, 역전사 효소, 인지질 외피를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "gp120 당단백질 스파이크를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 구조 및 CD4+ T 세포 감염: gp120 당단백질 스파이크는 CD4+ 세포의 수용체에 부착합니다. gp41 막관통 당단백질은 CD4+ 세포의 융합 수용체에 부착하여 융합을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 감염성과 병원성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "수지상 세포에 의해 퍼지고 림프 기관으로 운반되며, 활성화된 T 세포와 접촉합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "gp120은 CD4+ 수용체 및 CCR5 또는 CXCR4 공동수용체와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4 분자는 T 보조 세포, 대식세포, 수지상 세포에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 세포와 융합하여 세포 안으로 들어갑니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "부착: gp120 스파이크는 세포의 수용체 및 CCR5 또는 CXCR4 공동수용체에 부착합니다. 융합: gp41은 HIV와 세포의 융합에 참여합니다. 진입: 세포와의 융합 후, 진입 구멍이 생성됩니다. 진입 후, 바이러스 외피는 뒤에 남고 HIV는 탈피하여 새로운 바이러스 합성을 지시할 RNA 핵을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포 내에서 바이러스 RNA는 역전사 효소를 사용하여 DNA로 전사됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "DNA는 숙주 염색체 DNA에 통합됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활동성 감염: 새로운 바이러스가 숙주 세포에서 출아합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "잠복 감염: DNA는 프로바이러스 형태로 염색체에 숨겨져 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일부는 HIV의 저장소 역할을 하는 기억 T 세포가 됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 빠른 항원성 변화와 높은 돌연변이율을 겪습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.14 CD4+ T 세포의 잠복 및 활동성 HIV 감염. 잠복 감염: 바이러스 DNA는 세포 DNA에 프로바이러스로 통합되며, 나중에 활성화되어 감염성 바이러스를 생성할 수 있습니다. 활동성 감염: 프로바이러스가 활성화되어 새로운 바이러스의 합성을 제어할 수 있게 합니다. 최종 조립은 세포막에서 이루어지며, 바이러스가 세포에서 출아할 때 바이러스 외피 단백질을 가져갑니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.15 대식세포 및 수지상 세포의 잠복 및 활동성 HIV 감염. 잠복 감염된 대식세포: HIV는 프로바이러스 또는 액포 내 완전한 비리온 형태로 지속될 수 있습니다. 활성화된 대식세포: 프로바이러스로부터 새로운 바이러스가 생성됩니다. 완성된 비리온은 방출되거나 액포 내 대식세포에 지속될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 아형",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침팬지와 고릴라를 감염시키는 바이러스와 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사례의 99%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그룹 M (대다수)이 90%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-2:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "서아프리카 외에서는 자주 발견되지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1보다 병원성이 낮습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1보다 바이러스 부하와 사망률이 낮고 무증상 기간이 더 깁니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 감염의 단계",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "1단계: 무증상 또는 림프절병증.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2단계: CD4+ T 세포가 꾸준히 감소하며, 감염된 소수의 세포만이 바이러스를 방출합니다. 심각한 질병 증상은 거의 없습니다 (지속적인 감염, 발열, 구강 백반증).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "3단계: AIDS가 발병합니다. CD4+ 수치가 200 cells/μl 미만이며, 지표 질환이 나타납니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 감염의 진행 및 병원성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "초기에는 강력하고 효과적인 면역 반응이 나타납니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구(CTLs)가 바이러스 수를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일단 HIV가 잠복 감염된 CD4+ T 세포의 저장소를 형성하면 감염을 제거하는 것은 불가능합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 개발에 어려움이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 노출에 대한 반응의 변이",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 감염 생존에 대한 연령의 영향:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "고령자와 어린이는 면역 체계가 완전히 기능하지 않아 감염에 더 취약합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "노출되었지만 감염되지 않은 인구:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "CCR5 돌연변이를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "장기 생존자:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "낮은 바이러스 부하를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "효과적인 CTLs를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "기회 감염",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "진단 방법",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 전환은 감염과 항체 출현 사이의 기간입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "최대 3개월이 소요됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 항체는 ELISA로 검출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 Western blotting 또는 APTIMA (RNA 검사)로 검출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈장 바이러스 부하 (PVL)는 PCR 또는 핵산 혼성화로 결정됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 전파",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 세포 밖에서 6시간 생존합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 세포 내에서 1.5일 이상 생존할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "전파 경로: 친밀한 성 접촉, 모유, 태반 감염, 오염된 주사바늘, 장기 이식, 수혈.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항문 성교는 가장 위험한 형태의 성 접촉입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전 세계 AIDS 현황",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "전 세계적으로 3천 5백만 명이 감염되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사하라 이남 아프리카에 70%가 집중되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이성애자 간 전파가 HIV 전파의 가장 흔한 방식입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동유럽과 중앙 및 동남아시아 사례의 ⅓은 주사 약물 사용으로 인한 것입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전 세계 지역별 HIV 감염 및 AIDS 분포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "70",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "AIDS 예방 및 치료",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "생물의학적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "콘돔 사용, 보건 서비스/HIV 검사, 주사바늘 프로그램.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "행동적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "성 교육, 안전한 영아 수유 프로그램, 상담.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "구조적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 취약성을 줄이기 위해 사회, 경제, 정치, 환경적 요인에 변화를 줍니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이제 선진국에서는 치료 가능한 만성 질환으로 간주됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "고활성 항레트로바이러스 치료 (HAART)를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "내성 균주의 생존을 최소화하기 위해 약물 조합을 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "73",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 관리",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.18 HIV 생명 주기를 억제하는 약물: 융합/진입 억제제 (엔푸비르타이드, 마라비록), 역전사 효소 억제제 (테노포비르, 엠트리시타빈), 통합효소 억제제 (랄테그라비르), 프로테아제 억제제 (아타자나비르, 인디나비르, 사퀴나비르) 등이 있습니다. 이 약물들은 HIV의 gp41, gp120, CCR5, CD4 수용체 및 역전사 효소 등에 작용하여 바이러스 복제를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 치료 약물의 종류",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "융합/세포 진입 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스 외피의 gp41 영역을 표적으로 하여 바이러스가 세포와 융합하는 것을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "엔푸비르타이드(Enfuvirtide)와 마라비록(Maraviroc)이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "역전사 효소 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "뉴클레오사이드 역전사 효소 억제제 (NRTIs) - 테노포비르(Tenofovir)와 엠트리시타빈(Emtricitabrine)이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비뉴클레오사이드 역전사 효소 억제제 (NNRTIs) - 에파비렌즈(Efavirenz)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "77",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "통합효소 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 통합효소가 cDNA를 숙주 염색체에 통합하는 것을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "랄테그라비르(Raltegravir)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로테아제 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스 전구 단백질을 구조 및 기능 단백질로 분해하는 프로테아제를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "아타자나비르(Atazanavir), 인디나비르(Indinavir), 사퀴나비르(Saquinavir)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "성숙 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "테더린(Tetherins)은 바이러스를 세포에 묶어 방출 및 확산을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감염 과정에서 HIV는 많은 돌연변이를 축적하여 약물 내성 변이체의 증식으로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 백신 개발의 과제",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "모방할 자연 면역 모델이 없습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "연구 동물이 부족합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "레트로바이러스 메커니즘에 대한 이해가 부족합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "높은 돌연변이율로 인해 내성 균주가 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이상적인 백신은 다음과 같아야 합니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "잠복 바이러스 저장소가 확립되기 전에 면역을 유도해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구(CTLs)의 생성을 자극해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "합리적인 가격이어야 합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 후천성 면역 결핍 증후군(AIDS)의 기원, 원인 바이러스인 HIV의 구조, 감염 메커니즘 및 병원성, 바이러스 아형, 감염 단계, 진단 방법, 전파 경로, 전 세계적 현황, 예방 및 치료법, 그리고 백신 개발의 과제에 대해 상세히 설명합니다. HIV는 CD4+ T 세포를 선택적으로 감염시키는 레트로바이러스이며, 잠복 감염과 활동성 감염 단계를 거치며 면역 체계를 파괴합니다. HAART(고활성 항레트로바이러스 치료)를 통해 HIV 복제를 억제하고 환자의 삶의 질을 향상시킬 수 있지만, 바이러스의 높은 돌연변이율로 인해 백신 개발에는 어려움이 있습니다.",
                  "keyConcepts": [
                    {
                      "term": "HIV (Human Immunodeficiency Virus)",
                      "definition": {
                        "easy": null,
                        "medium": "AIDS의 원인 바이러스로, 인체의 면역 체계를 공격하고 파괴하는 레트로바이러스입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "CD4+ T 세포",
                      "definition": {
                        "easy": null,
                        "medium": "HIV가 주로 감염시키고 파괴하는 면역 세포로, 이 세포의 감소는 면역 결핍을 초래합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "역전사 효소 (Reverse Transcriptase)",
                      "definition": {
                        "easy": null,
                        "medium": "HIV를 포함한 레트로바이러스가 자신의 RNA 유전체를 DNA로 역전사하는 데 사용하는 효소입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "HAART (Highly Active Antiretroviral Therapy)",
                      "definition": {
                        "easy": null,
                        "medium": "HIV 감염 치료를 위해 여러 종류의 항레트로바이러스 약물을 병용하는 치료법으로, 바이러스 복제를 효과적으로 억제합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "기회 감염 (Opportunistic Infections)",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 약해진 상태에서 일반적으로 건강한 사람에게는 질병을 일으키지 않는 미생물에 의해 발생하는 감염입니다.",
                        "hard": null
                      }
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "AIDS (Acquired Immunodeficiency Syndrome)",
                      "definition": "후천성 면역 결핍 증후군. HIV 감염의 마지막 단계로, 심각한 면역 결핍과 기회 감염 및 특정 암을 특징으로 합니다."
                    },
                    {
                      "term": "레트로바이러스 (Retrovirus)",
                      "definition": "RNA 유전체를 가지고 있으며, 역전사 효소를 사용하여 RNA를 DNA로 전환하고 이를 숙주 게놈에 통합시키는 바이러스입니다."
                    },
                    {
                      "term": "gp120 및 gp41",
                      "definition": "HIV 외피에 존재하는 당단백질 스파이크로, gp120은 CD4 수용체에 부착하고 gp41은 바이러스와 세포막의 융합을 촉진합니다."
                    },
                    {
                      "term": "프로바이러스 (Provirus)",
                      "definition": "레트로바이러스의 DNA 유전체가 숙주 세포의 염색체 DNA에 통합된 형태입니다."
                    },
                    {
                      "term": "혈청 전환 (Seroconversion)",
                      "definition": "감염 후 특정 병원체에 대한 항체가 혈액에서 처음으로 검출되는 시기입니다."
                    },
                    {
                      "term": "CD4+ T 세포 수치",
                      "definition": "면역 상태를 나타내는 중요한 지표로, AIDS 진단 기준 중 하나는 이 수치가 200 cells/μl 미만인 경우입니다."
                    },
                    {
                      "term": "CCR5 돌연변이",
                      "definition": "일부 개인에게서 발견되는 유전적 돌연변이로, HIV가 세포에 진입하는 데 필요한 공동수용체인 CCR5를 변경하여 HIV 감염에 대한 저항성을 부여합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "후천성 면역 결핍 증후군 (AIDS)",
                      "id": "후천성-면역-결핍-증후군-aids",
                      "children": null
                    },
                    {
                      "text": "AIDS의 기원",
                      "id": "aids의-기원",
                      "children": null
                    },
                    {
                      "text": "HIV의 구조",
                      "id": "hiv의-구조",
                      "children": null
                    },
                    {
                      "text": "HIV의 감염성과 병원성",
                      "id": "hiv의-감염성과-병원성",
                      "children": null
                    },
                    {
                      "text": "HIV의 아형",
                      "id": "hiv의-아형",
                      "children": null
                    },
                    {
                      "text": "HIV 감염의 단계",
                      "id": "hiv-감염의-단계",
                      "children": null
                    },
                    {
                      "text": "HIV 감염의 진행 및 병원성",
                      "id": "hiv-감염의-진행-및-병원성",
                      "children": null
                    },
                    {
                      "text": "HIV 노출에 대한 반응의 변이",
                      "id": "hiv-노출에-대한-반응의-변이",
                      "children": null
                    },
                    {
                      "text": "기회 감염",
                      "id": "기회-감염",
                      "children": null
                    },
                    {
                      "text": "진단 방법",
                      "id": "진단-방법",
                      "children": null
                    },
                    {
                      "text": "HIV 전파",
                      "id": "hiv-전파",
                      "children": null
                    },
                    {
                      "text": "전 세계 AIDS 현황",
                      "id": "전-세계-aids-현황",
                      "children": null
                    },
                    {
                      "text": "전 세계 지역별 HIV 감염 및 AIDS 분포",
                      "id": "전-세계-지역별-hiv-감염-및-aids-분포",
                      "children": null
                    },
                    {
                      "text": "AIDS 예방 및 치료",
                      "id": "aids-예방-및-치료",
                      "children": [
                        {
                          "text": "HIV 관리",
                          "id": "hiv-관리",
                          "children": null
                        },
                        {
                          "text": "HIV 치료 약물의 종류",
                          "id": "hiv-치료-약물의-종류",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "HIV 백신 개발의 과제",
                      "id": "hiv-백신-개발의-과제",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "HIV가 주로 감염시키고 파괴하는 면역 세포는 무엇입니까?",
                    "options": [
                      "B 세포",
                      "CD4+ T 세포",
                      "대식세포",
                      "자연 살해(NK) 세포"
                    ],
                    "answerIndex": 1,
                    "explanation": "HIV는 CD4+ 수용체를 가진 세포를 감염시키며, 특히 CD4+ T 세포는 HIV 감염의 주요 표적 세포입니다. 이 세포의 파괴는 면역 결핍을 초래합니다."
                  },
                  {
                    "question": "HIV 감염 진단에 사용되는 방법 중 HIV 항체를 검출하는 검사는 무엇입니까?",
                    "options": [
                      "PCR",
                      "Western blotting",
                      "ELISA",
                      "핵산 혼성화"
                    ],
                    "answerIndex": 2,
                    "explanation": "HIV 항체는 ELISA(효소결합 면역흡착법)를 통해 검출됩니다. Western blotting은 항체 검출을 확인하는 데 사용될 수 있으며, PCR과 핵산 혼성화는 바이러스 자체(RNA 또는 DNA)를 검출하는 데 사용됩니다."
                  },
                  {
                    "question": "HAART(고활성 항레트로바이러스 치료)의 주요 특징은 무엇입니까?",
                    "options": [
                      "단일 약물을 고용량으로 투여합니다.",
                      "수술적 방법으로 바이러스를 제거합니다.",
                      "여러 종류의 항레트로바이러스 약물을 병용합니다.",
                      "면역 증강제만을 사용하여 면역력을 높입니다."
                    ],
                    "answerIndex": 2,
                    "explanation": "HAART는 여러 종류의 항레트로바이러스 약물을 병용하여 HIV 복제를 다양한 단계에서 억제하고 약물 내성 균주의 출현을 최소화하는 치료법입니다."
                  }
                ]
              }
            ],
            "final_result": ""
          }
        }
      ],
      "final_result": ""
    }
  },
  {
    "node": "finish_processing",
    "status": "completed",
    "state_snapshot": {
      "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
      "pdf_file_paths": [
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
        "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
      ],
      "all_pdf_texts": [
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "text": "16. INNATE IMMUNITY: \nNONSPECIFIC DEFENSES OF \nTHE HOST\nHongsup Yoon, Ph.D.\nMicrobiology\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n2\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n3\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n4\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n• White blood cell (WBC) \ncounts measure \nleukocytes in the blood\n• High WBC counts may \nindicate bacterial \ninfections, autoimmune \ndiseases, or side effects \nof medications\n• Low WBC counts may \nindicate viral infections, \npneumonia, \nautoimmune diseases, \nor cancers\n\nTHE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse.\n14\nHOST DEFENSE: THE BIG PICTURE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n16\nPHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\n\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice.\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n23\nFORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\n\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\n\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n31\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\n\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\n\nPHAGOCYTOSIS: OVERVIEW\n\nPHAGOCYTOSIS: MECHANISM\n\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\n\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n39\nINFLAMMATION: OVERVIEW\n\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\n\nFigure 16.9a-b  The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ntaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\n\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n49\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n51\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\n\nCOMPLEMENT: ACTIVATION\n\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\n\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\n\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\n\nFigure 16.12  Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13  Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBIAL PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n68\nSUMMARY (1/3)\n• The growth of microorganisms can be controlled by physical, chemical, \nmechanical, and biological means.\n• The body’s first line of defense against infections is a physical barrier and \nthe nonspecific chemicals of the skin and mucous membranes. \n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways.\n• A microbe’s penetration of the first line of defense encourages production \nof phagocytes, inflammation, fever, and antimicrobial substances. \n• Blood consists of plasma (fluid) and formed elements (cells and cell \nfragments). Leukocytes (white blood cells) are divided into granulocytes \n(neutrophils, basophils,  eosinophils) and agranulocytes. During many \ninfections, the number of leukocytes increases (leukocytosis); some  \ninfections are characterized by leucopenia (decrease in leukocytes). \nSUMMARY (2/3)\n• Phagocytosis is the ingestion of microorganisms or particulate matter by a \ncell. Phagocytosis is performed by phagocytes, certain types of white \nblood cells or their  derivatives. Among the granulocytes, neutrophils are \nthe most important phagocytes. Granulocytes predominate during the \nearly stages of infection, whereas monocytes  predominate as the \ninfection subsides. \n• Inflammation is a bodily response to cell damage; it is characterized by \nredness,  pain, heat, swelling, and sometimes the loss of function. TNF -α \nstimulates production of acute -phase proteins. \n• A tissue is repaired when the stroma (supporting tissue) or parenchyma \n(functioning  tissue) produces new cells. Stromal repair by fibroblasts \nproduces scar tissue. \n• Fever is an abnormally high body temperature produced in response to a \nbacterial or  viral infection. \nSUMMARY (3/3)\n• The complement system consists of a group of serum proteins that \nactivate one another to destroy invading microorganisms. Complement \nproteins are activated in a cascade. Complement is activated via the \nclassical pathway, the alternative pathway, and the lectin pathway. \n• IFN-α and IFN-β are antiviral proteins produced in response to viral \ninfection. The mode of action of IFN -α and IFN-β is to induce uninfected \ncells to produce antiviral proteins (AVPs) that prevent viral replication. IFN -\nα and IFN-β are host-cell-specific but not virus-specific. IFN-γ activates \nneutrophils and macrophages to kill bacteria. \n• Iron-binding proteins transport and store iron and deprive most pathogens \nof the  available iron.\n• Antimicrobial peptides (AMPs) inhibit cell wall synthesis; form pores in \nplasma  membranes, resulting in lysis; and destroy DNA and RNA."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "text": "17. ADAPTIVE IMMUNITY: \nSPECIFIC DEFENSES OF \nTHE HOST\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n2\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n3\nTHE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n5\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\n\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n11\nCYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n14\nAntibody A\nEpitopes (antigenic \ndeterminants)\non antigen\nAntigens:\ncomponents\nof cell wall\nAntibody B\nBacterial cell\nBinding sites\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\n\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\n\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n34\nCELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\n\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\n\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\n\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\n\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\n\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n51\nIMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\n \n\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\n\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n55\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\n\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Summary\n58\nFigure 17.20  The Dual Nature of the Adaptive Immune System.\n\nSUMMARY (1/3)\n• Adaptive immunity is the body’s ability to react specifically to a microbial \ninfection. The body’s response to the first contact with an antigen is called the \nprimary response. Subsequent contact with the same antigen results in a \nsecondary or memory response to that antigen.\n• Humoral immunity involves antibodies, which are found in serum and lymph and \nare produced by B cells. Lymphocytes that mature in red bone marrow become \nB cells. \n• Cellular immunity involves T cells. Lymphocytes that migrate through the thymus \nbecome T cells. T cell receptors recognize antigens presented on MHC. Cellular \nimmunity responds to intracellular antigens; humoral immunity responds to \nantigens in body fluids.\n• Cells of the immune system communicate with each other by means of \nchemicals called cytokines. Interleukins (IL) are cytokines that serve as \ncommunicators between leukocytes. Chemokines cause leukocytes to migrate \nto an infection. Some interferons stimulate the immune response; others protect \ncells against viruses. Tumor necrosis factor promotes the inflammatory reaction. \nHematopoietic cytokines promote development of white blood cells. \nOverproduction of cytokines leads to a cytokine storm, which results in tissue \ndamage.\nSUMMARY (2/3)\n• An antigen (or immunogen) is a chemical substance that causes the body \nto produce specific antibodies. Antibodies are formed against specific \nregions on antigens called epitopes, or antigenic determinants.\n• An antibody, or immunoglobulin, is a protein produced by B cells in \nresponse to an  antigen and is capable of combining specifically with that \nantigen. IgG antibodies are the most prevalent in serum; they provide \nnaturally acquired passive immunity, neutralize bacterial toxins, participate \nin complement fixation, and enhance phagocytosis.\n• T cells mature in the thymus gland. Thymic selection removes T cells that \ndon’t recognize MHC molecules of the host and T cells that will attack host \ncells presenting self-proteins in MHC. Helper T cells recognize antigens \nprocessed by antigen-presenting cells and presented in MHC II. Cytotoxic \nT cells recognize antigens processed by all host cells and presented in \nMHC I.\nSUMMARY (3/3)\n• APCs include B cells, dendritic cells, and macrophages. Dendritic cells are \nthe primary APCs. Dendritic cells are the primary APCs. APCs carry \nantigens to lymphoid tissues where T cells that recognize the antigen are \nlocated.\n• T helper (CD4+ T) cells differentiate into TH1 cells, which are involved in \ncellular immunity; TH2 cells, which are involved in humoral immunity and \nare associated with allergic reactions and parasitic infections; and TH17 \ncells, which activate innate immunity.\n• T regulatory cells (Treg) suppress T cells against self. Cytotoxic \nlymphocytes (CTLs), or CD8+ T cells, are activated by endogenous \nantigens and MHC class I on a target cell and are transformed into effector \nand memory CTLs.\n• CTLs lyse or induce apoptosis in the target cell."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
          "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n18. PRACTICAL \nAPPLICATIONS OF \nIMMUNOLOGY – PART I\n2\nRECENT VIRUS OUTBREAKS\n• 2002 SARS outbreak (~9.5 % mortality rate)\n• 2004 Global spread of H5N1 avian influenza (60% mortality rate)\n• 2009 H1N1/09 swine Flu pandemic\n• 2015 MERS in Korea (~40 % mortality rate)\n• 2018 Influenza B outbreak in Korea\n• 2019 COV-19 (SARS-CoV2) pandemic (~2 – 3 % mortality rate)\n?\nHISTORICAL PANDEMIC: BLACK DEATH\nKilled 30 – 60% of European\n\nEDWARD JENNER (1749 – 1823)\n\nMILKMAID (AROUND THE TIME OF JENNER)\n\nVACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\n\nVACCINES: FUNCTION\n\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -drug \nusers, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1  Influenza viruses are grown in embryonated eggs.\n\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\n\nRNA VACCINES\nVACCINES: TYPES\n\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\n\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren\nDIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nPRODUCTION OF MONOCLONAL \nANTIBODIES\n\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\n\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\n\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\n\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\n\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\n\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\n\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\n\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy\nSUMMARY (1/6)\n• Edward Jenner developed the modern practice of vaccination when he \ninoculated people with cowpox virus to protect them against smallpox. \n• Herd immunity results when most of a population is immune to a disease.\n• Bacteria have unique cell structures that can be targets for antibiotics, \nimmunity, and phage infection.\n•  Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Humans utilize \nand harness microorganisms and their products.\n• Attenuated vaccines consist of attenuated (weakened) microorganisms; \nattenuated virus vaccines generally provide lifelong immunity. Inactivated \nvaccines consist of killed bacteria or viruses. Subunit vaccines consist of \nantigenic fragments of a microorganism; these include  recombinant \nvaccines and toxoids. \nSUMMARY (2/6)\n• Conjugated vaccines combine the desired antigen with a protein that \nboosts the immune response. Nucleic acid (DNA) vaccines cause the \nrecipient to make the antigenic protein.\n• Viruses for vaccines may be grown in animals, cell cultures, or chick \nembryos. Recombinant vaccines and nucleic acid vaccines do not need to \nbe grown in cells or animals. Genetically modified plants may someday \nprovide edible vaccines.\n• Combining several vaccines would eliminate the number of injections. Dry \nskin patch vaccines don’t need refrigeration.\n• Adjuvants improve the effectiveness of some antigens. \n• Vaccines are the safest and most effective means of controlling infectious \ndiseases.\nSUMMARY (3/6)\n• Many tests based on the interactions of antibodies and antigens have \nbeen developed to determine the presence of antibodies or antigens in a \npatient. The sensitivity of a diagnostic test is determined by the percentage \nof positive samples it correctly detects; and its specificity is determined by \nthe percentage of false positive  results it gives.\n• Hybridomas are produced in the laboratory by fusing a cancerous cell with \nan antibody-secreting plasma cell. A hybridoma cell culture produces large \nquantities of the plasma cell’s antibodies, called monoclonal antibodies. \nMonoclonal antibodies are used in serological identification tests, to \nprevent tissue  rejections, and to make immunotoxins to treat cancer.\n• The interaction of soluble antigens with IgG or IgM antibodies leads to \nprecipitation  reactions. Precipitation reactions depend on the formation of \nlattices and occur best when antigen and antibody are present in optimal \nproportions. Excesses of either component decrease lattice formation and \nsubsequent precipitation.\nSUMMARY (4/6)\n• Immunodiffusion procedures are precipitation reactions carried out in an \nagar gel  medium. Immunoelectrophoresis combines electrophoresis with \nimmunodiffusion for the analysis of serum proteins.\n• The interaction of particulate antigens (cells that carry antigens) with \nantibodies leads to agglutination reactions. Diseases may be diagnosed \nby combining the patient’s serum with a known antigen. Diseases can be \ndiagnosed by a rising titer or seroconversion (from no antibodies to the \npresence of antibodies). Direct agglutination reactions can be used to \ndetermine antibody titer. Antibodies cause visible agglutination of soluble \nantigens affixed to latex spheres in indirect or passive agglutination tests. \nHemagglutination reactions involve agglutination reactions using red blood \ncells.  Hemagglutination reactions are used in blood typing, the diagnosis \nof certain diseases, and the identification of viruses. \nSUMMARY (5/6)\n• In neutralization reactions, the harmful effects of a bacterial exotoxin or \nvirus are  eliminated by a specific antibody. An antitoxin is an antibody \nproduced in response to a bacterial exotoxin or a toxoid that neutralizes \nthe exotoxin. In a virus neutralization test, the presence of antibodies \nagainst a virus can be detected by the antibodies’ ability to prevent \ncytopathic effects of viruses in cell cultures. Antibodies against certain \nviruses can be detected by their ability to interfere with viral \nhemagglutination in viral hemagglutination inhibition tests.\n• Complement-fixation reactions are serological tests based on the \ndepletion of a fixed amount of complement in the presence of an antigen –\nantibody reaction.\n• Fluorescent-antibody techniques use antibodies labeled with fluorescent \ndyes. Direct fluorescent-antibody tests are used to identify specific \nmicroorganisms. \nSUMMARY (6/6)\n• Indirect fluorescent-antibody tests are used to demonstrate the presence \nof antibody  in serum. A fluorescence-activated cell sorter can be used to \ndetect and count cells labeled with fluorescent antibodies.\n• ELISA techniques use antibodies linked to an enzyme. Antigen –antibody \nreactions are detected by enzyme activity. If the indicator enzyme is \npresent in the test well, an antigen –antibody reaction has occurred. The \ndirect ELISA is used to detect antigens against a specific antibody bound \nin a test well. The indirect ELISA is used to detect antibodies against an \nantigen bound in a test well.\n• Serum antibodies separated by electrophoresis are identified with an \nenzyme-linked  antibody. \n• The use of monoclonal antibodies will continue to make new diagnostic \ntests possible."
        },
        {
          "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n19. DISORDERS \nASSOCIATED WITH THE \nIMMUNE SYSTEM – PART 1\n2\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n3\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n4\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Dysbiosis: \nimbalance that \ncauses adverse \neffects in humans\n• Antibiotic therapy \nkills normal gut \nmicrobiota, causing \nClostridium difficile \nto proliferate\n• Possible cause of \nIBDs such as \nulcerative colitis and \nCrohn's disease\n\nBIG PICTURE: THE HYGIENE HYPOTHESIS\n• Allergies and asthma\n• Observation that tribal populations and children growing up on farms \nhave less prevalence of allergies than children in urban settings\n• Possibly due to wider range of microbial exposures in farm setting; also \nled to lower asthma rates\n• Inflammatory bowel diseases\n• Possible link of lack of normal microbiota metabolic products leading to \nchronic inflammatory state\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Treating Crohn's \ndisease with worms\n• Whipworm eggs \nsuppress T helper cell \npathways\n• Fecal transplants for C. \ndifficile infections\n• Taking gut microbiota \nfrom a healthy \nindividual and \ntransplanting it into the \npatient\n\nHYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\n\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\n\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\n\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\n\nFigure 19.8  Allergic contact dermatitis.\n\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n21\nAUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\n\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555) \nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n28\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\n\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2\nSUMMARY (1/3)\n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Hay fever, \ntransplant rejection, and autoimmunity are examples of harmful immune  \nreactions. Immunosuppression is inhibition of the immune system. \nSuperantigens activate many T cell receptors that can cause adverse host \nresponses.\n• Hypersensitivity reactions represent immunological responses to an \nantigen (allergen) that lead to tissue damage rather than immunity. \nHypersensitivity reactions occur when a person has been sensitized to an \nantigen. Hypersensitivity reactions can be divided into four classes: types \nI, II, and III are immediate reactions based on humoral immunity, and type \nIV is a delayed reaction  based on cell -mediated immunity. \n• Childhood exposure to microbes may decrease development of allergies.\nSUMMARY (2/3)\n• Autoimmunity results from a loss of self -tolerance. Self-tolerance occurs \nduring fetal development; T cells that will target host cells are eliminated \n(clonal deletion) or inactivated. Autoimmunity may be due to antibodies \nagainst infectious agents. Graves’ disease and myasthenia gravis are \ncytotoxic autoimmune reactions in which  antibodies react to cell -surface \nantigens.\n• Systemic lupus erythematosus and rheumatoid arthritis are immune \ncomplex autoimmune reactions in which the deposition of immune \ncomplexes results in tissue damage. Multiple sclerosis, insulin -dependent \ndiabetes mellitus, and psoriasis are cell -mediated autoimmune reactions \nmediated by T cells.\nSUMMARY (3/3)\n• MHC self molecules located on cell surfaces express genetic differences \namong individuals; these antigens are called HLAs in humans. To prevent \nthe rejection of transplants, HLA and ABO blood group antigens of the \ndonor and recipient are matched as closely as possible. Transplants \nrecognized as foreign antigens may be lysed by T cells and attacked by \nmacrophages and complement -fixing antibodies. Transplantation to a \nprivileged site (such as the cornea) or of a privileged tissue (such as pig \nheart valves) does not cause an immune response. Pluripotent stem cells \ndifferentiate into a variety of tissues that may provide tissues for \ntransplant.\n• Four types of transplants have been defined on the basis of genetic \nrelationships between the donor and the recipient: autografts, isografts, \nallografts, and xenotransplants. Bone marrow transplants (with \nimmunocompetent cells) can cause graft -versus-host  disease.  \nSuccessful transplant surgery often requires immunosuppressant drugs to \nprevent an immune response to the transplanted tissue. \nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n40\nTHE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\n\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n46\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\n\nFigure 19.12  A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES\n\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n52\nACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\n\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14  Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15  Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\n\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\n\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n\n70\n\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\n\nHIV MANAGEMENT\n\nFigure 19.18  Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\n\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\n\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable\nSUMMARY (1/3)\n• Cancer cells are normal cells that have undergone transformation, divide \nuncontrollably, and possess tumor-associated antigens. The response of the \nimmune system to cancer is called immunological surveillance. TC cells \nrecognize and lyse cancerous cells. Cancer cells can escape detection and \ndestruction by the immune system. Cancer cells may grow faster than the \nimmune system can respond.\n• Novel therapeutic strategies, such as immune checkpoint inhibitors and CAR T \ncell therapy, are effective approaches to treat patients with cancer.\n• Vaccines against liver and cervical cancer are available; a therapeutic vaccine \nagainst prostate cancer also has been approved. Herceptin consists of \nmonoclonal antibodies against a breast cancer growth factor. Immunotoxins are \nchemical poisons linked to a monoclonal antibody; the antibody  selectively \nlocates the cancer cell for release of the poison.\n• Immunodeficiencies can be congenital or acquired. Congenital \nimmunodeficiencies are due to defective or absent genes. A variety of drugs, \ncancers, and infectious diseases can cause acquired  immunodeficiencies. \n• HIV is thought to have originated in central Africa and was brought to other \ncountries by modern transportation and unsafe sexual practices.\nSUMMARY (2/3)\n• AIDS is the final stage of HIV infection. HIV is a retrovirus with single -\nstranded RNA, reverse transcriptase, and a phospholipid envelope with \ngp120 spikes. HIV spikes attach to CD4+ and coreceptors on host cells; \nthe CD4+ receptor is found on  T helper cells, macrophages, and dendritic \ncells. Viral RNA is transcribed to DNA by reverse transcriptase. The viral \nDNA becomes  integrated into the host chromosome to direct synthesis of \nnew viruses or to remain latent as a provirus. HIV evades the immune \nsystem in latency, in vacuoles, by using cell–cell fusion, and by antigenic \nchange. HIV-1 accounts for most HIV infections. Subtype B of HIV -1 is the \nmost common type in the United States. HIV infection is categorized by \nsymptoms: phase 1 (asymptomatic), phase 2 (indicator opportunistic \ninfections), and phase 3 (CD4+  cells <200 cells/μ1). The progression from \nHIV infection to AIDS takes about 10 years. The life of an AIDS patient can \nbe prolonged by the proper treatment of opportunistic  infections. People \nlacking CCR5 are resistant to HIV infection. Elite controllers are long -term \nsurvivors who may hold the key to HIV treatment. \nSUMMARY (3/3)\n• HIV antibodies are detected by ELISA and Western blotting. Plasma viral \nload tests detect viral nucleic acid and are used to quantify HIV in blood.\n• HIV is transmitted by sexual contact, breast milk, contaminated needles, \ntransplacental infection, artificial insemination, and blood transfusion. In \ndeveloped countries, blood transfusions are not a likely source of infection \nbecause blood is tested for HIV antibodies. \n• Heterosexual intercourse is the primary method of HIV transmission.\n• Discouraging sexual promiscuity and using condoms and sterile needles \nprevent the transmission of HIV. Vaccine development is difficult because \nthe virus remains inside host cells and there is no model of natural \nimmunity to mimic. Current chemotherapeutic agents target the virus \nenzymes, including reverse transcriptase, integrase, and protease. Other \ninhibitors include cell entry inhibitors, maturation inhibitors, and tetherins."
        }
      ],
      "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
      "holistic_chapters": [
        {
          "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
          "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
        },
        {
          "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
          "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
        },
        {
          "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
          "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
        },
        {
          "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
          "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
          "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
        },
        {
          "chapter_title": "적응성 면역: 개요 및 이중적 특성",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
          "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
        },
        {
          "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
          "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
        },
        {
          "chapter_title": "적응성 면역: 체액성 면역 반응",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
          "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
        },
        {
          "chapter_title": "적응성 면역: 세포성 면역 반응",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
          "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
        },
        {
          "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
          "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
          "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
        },
        {
          "chapter_title": "면역학의 실제 적용: 백신",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
          "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
          "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
        },
        {
          "chapter_title": "면역학의 실제 적용: 진단 면역학",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
          "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
          "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 과민 반응",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
          "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
          "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
          "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
          "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
        },
        {
          "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
          "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
          "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
          "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
        }
      ],
      "generated_content": [
        {
          "title": "면역 시스템의 이해: 선천성 및 적응성 면역",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2042 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "면역의 개념",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "면역은 질병을 막는 능력을 의미하며, 감수성은 질병에 대한 저항력이 부족한 상태를 뜻합니다. 면역은 크게 두 가지로 나뉩니다. 선천성 면역은 모든 병원체에 대한 방어 기전으로, 신속하며 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 면역 또는 저항력으로, 반응 속도가 느리지만 기억 구성 요소를 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "선천성 면역",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "선천성 면역은 자연 면역, 타고난 면역이라고도 불립니다. 식세포, 수지상 세포, 비만 세포, 자연 살해 세포 등 다양한 선천성 면역 세포들이 관여합니다. 이들은 감염이 발생하기 전부터 존재하며 면역 파수꾼 역할을 합니다. 일부 선천성 면역 세포는 항원을 T 세포에 제시하여 적응성 면역을 활성화시키기도 합니다. 또한, 조직 항상성과 염증에 중요하며, 치유자이자 파괴자 역할을 동시에 수행할 수 있습니다. 병원체 패턴, 사이토카인, 매개체에 의해 활성화되며, 항원에 대해 특이적이지 않습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "적응성 면역",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "적응성 면역은 특이적 면역, 후천성 면역이라고도 불립니다. 림프구인 T 세포와 B 세포가 주요 적응성 면역 세포입니다. 이들은 이차 림프 기관에서 미성숙한 형태로 존재하며, 클론 선택과 증식을 통해 특정 항원에 반응하는 세포로 발달합니다. 적응성 면역은 기억 기능을 가지며, 자가 관용 능력을 통해 자신의 몸을 공격하지 않습니다. 항원 제시 세포에 의해 활성화되며, 항원에 대해 매우 특이적입니다. 적응성 면역은 세포 매개 면역과 체액성 면역으로 나뉩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "숙주 세포에 있는 톨 유사 수용체(TLR)는 병원체 관련 분자 패턴(PAMP)에 결합합니다. TLR이 PAMP에 결합하면 숙주 세포에서 사이토카인 방출을 유도하여 면역 반응의 강도와 지속 시간을 조절합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "다양한 PAMP 인식",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "포유류 TLR은 다양한 PAMP를 인식합니다. 세균성 PAMP에는 그람 음성 세균 세포벽의 지질다당류(TLR4), 세균 리보솜 RNA(TLR13), 세균 DNA의 비메틸화 CpG(TLR9), 지단백질(TLR2/1, TLR2/6), 편모 단백질(TLR5) 등이 있습니다. 바이러스성 PAMP에는 이중 가닥 RNA(TLR3), 단일 가닥 RNA(TLR7, TLR8), 비메틸화 CpG DNA(TLR9) 등이 있습니다. 기생충성 PAMP에는 지단백질(TLR2/1, TLR2/6), 비메틸화 CpG DNA(TLR9), 단일 가닥 RNA(TLR7), 액틴 결합 단백질 프로필린(TLR11/12) 등이 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "TLR의 위치 및 내인성 PAMP 인식",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "TLR은 세포 표면과 세포 내막에 존재하여 다양한 세포 위치에서 미생물을 인식합니다. TLR은 또한 내인성 PAMP도 인식할 수 있습니다. 세포 스트레스 시 유도되는 샤페론인 열충격 단백질(HSP)과 풍부한 게놈 DNA 결합 단백질인 고이동성 그룹 박스 1(HMGB1) 단백질 등이 내인성 PAMP의 예시입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "TLR 신호 전달 경로",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "TLR이 미생물 리간드를 인식하면 여러 신호 전달 경로와 궁극적으로는 전사 인자가 활성화되어, 염증 및 항바이러스 반응에 중요한 유전자의 발현을 유도합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "면역은 질병에 저항하는 능력으로, 선천성 면역과 적응성 면역으로 나뉩니다. 선천성 면역은 모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 특이적 반응으로, 느리지만 기억 기능을 가집니다. 톨 유사 수용체(TLR)는 숙주 세포에서 병원체 관련 분자 패턴(PAMP)을 인식하여 사이토카인 방출을 유도하고 면역 반응을 조절합니다. TLR은 세포 표면과 세포 내막에 존재하며, 다양한 세균, 바이러스, 기생충 PAMP뿐만 아니라 내인성 PAMP도 인식하여 염증 및 항바이러스 반응에 중요한 유전자 발현을 유도하는 신호 전달 경로를 활성화합니다.",
            "keyConcepts": [
              {
                "term": "선천성 면역",
                "definition": "모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재하는 면역 방어 체계."
              },
              {
                "term": "적응성 면역",
                "definition": "특정 병원체에 대한 특이적 반응을 보이며, 기억 기능을 통해 재감염 시 더 빠르고 강력하게 반응하는 면역 방어 체계."
              },
              {
                "term": "톨 유사 수용체 (TLR)",
                "definition": "숙주 세포에 존재하며, 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 유도하는 주요 패턴 인식 수용체."
              },
              {
                "term": "병원체 관련 분자 패턴 (PAMP)",
                "definition": "미생물에 공통적으로 존재하는 특징적인 분자 구조로, 숙주의 톨 유사 수용체(TLR)에 의해 인식되어 면역 반응을 유발한다."
              },
              {
                "term": "사이토카인",
                "definition": "면역 세포 간의 신호 전달을 매개하고 면역 반응의 강도와 지속 시간을 조절하는 단백질."
              }
            ],
            "importantTerms": [
              {
                "term": "면역 (Immunity)",
                "definition": "질병을 막는 능력."
              },
              {
                "term": "감수성 (Susceptibility)",
                "definition": "질병에 대한 저항력 부족."
              },
              {
                "term": "식세포 (Phagocytes)",
                "definition": "미생물이나 이물질을 삼켜 제거하는 면역 세포."
              },
              {
                "term": "기억 구성 요소 (Memory component)",
                "definition": "적응성 면역이 이전에 노출된 병원체를 기억하여 재감염 시 더 빠르고 강력하게 반응하는 능력."
              },
              {
                "term": "자가 관용 (Self tolerance)",
                "definition": "면역 시스템이 자신의 세포와 조직을 공격하지 않고 구분하는 능력."
              },
              {
                "term": "전사 인자 (Transcription factors)",
                "definition": "DNA에 결합하여 특정 유전자의 전사(발현)를 조절하는 단백질."
              },
              {
                "term": "내인성 PAMP (Endogenous PAMPs)",
                "definition": "병원체가 아닌 숙주 세포 자체에서 발생한 손상 또는 스트레스 신호로 TLR이 인식할 수 있는 분자."
              }
            ],
            "outline": [
              {
                "text": "면역의 개념",
                "id": "면역의-개념",
                "children": [
                  {
                    "text": "면역 및 감수성 정의",
                    "id": "면역-및-감수성-정의",
                    "children": null
                  },
                  {
                    "text": "선천성 면역과 적응성 면역의 특징",
                    "id": "선천성-면역과-적응성-면역의-특징",
                    "children": null
                  }
                ]
              },
              {
                "text": "선천성 면역",
                "id": "선천성-면역",
                "children": [
                  {
                    "text": "선천성 면역의 다른 이름",
                    "id": "선천성-면역의-다른-이름",
                    "children": null
                  },
                  {
                    "text": "선천성 면역 세포의 종류 및 특징",
                    "id": "선천성-면역-세포의-종류-및-특징",
                    "children": null
                  },
                  {
                    "text": "적응성 면역과의 연계성",
                    "id": "적응성-면역과의-연계성",
                    "children": null
                  }
                ]
              },
              {
                "text": "적응성 면역",
                "id": "적응성-면역",
                "children": [
                  {
                    "text": "적응성 면역의 다른 이름",
                    "id": "적응성-면역의-다른-이름",
                    "children": null
                  },
                  {
                    "text": "적응성 면역 세포의 종류 및 특징",
                    "id": "적응성-면역-세포의-종류-및-특징",
                    "children": null
                  },
                  {
                    "text": "클론 선택, 기억, 자가 관용",
                    "id": "클론-선택-기억-자가-관용",
                    "children": null
                  },
                  {
                    "text": "세포 매개 및 체액성 면역",
                    "id": "세포-매개-및-체액성-면역",
                    "children": null
                  }
                ]
              },
              {
                "text": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
                "id": "톨-유사-수용체-tlr-및-병원체-관련-분자-패턴-pamp",
                "children": [
                  {
                    "text": "TLR과 PAMP의 상호작용",
                    "id": "tlr과-pamp의-상호작용",
                    "children": null
                  },
                  {
                    "text": "사이토카인 방출 및 면역 반응 조절",
                    "id": "사이토카인-방출-및-면역-반응-조절",
                    "children": null
                  }
                ]
              },
              {
                "text": "다양한 PAMP 인식",
                "id": "다양한-pamp-인식",
                "children": [
                  {
                    "text": "포유류 TLR의 PAMP 인식 범위",
                    "id": "포유류-tlr의-pamp-인식-범위",
                    "children": null
                  },
                  {
                    "text": "세균성 PAMP의 종류",
                    "id": "세균성-pamp의-종류",
                    "children": null
                  },
                  {
                    "text": "바이러스성 PAMP의 종류",
                    "id": "바이러스성-pamp의-종류",
                    "children": null
                  },
                  {
                    "text": "기생충성 PAMP의 종류",
                    "id": "기생충성-pamp의-종류",
                    "children": null
                  }
                ]
              },
              {
                "text": "TLR의 위치 및 내인성 PAMP 인식",
                "id": "tlr의-위치-및-내인성-pamp-인식",
                "children": [
                  {
                    "text": "세포 표면 및 세포 내막에서의 TLR 위치",
                    "id": "세포-표면-및-세포-내막에서의-tlr-위치",
                    "children": null
                  },
                  {
                    "text": "내인성 PAMP의 인식 (HSP, HMGB1)",
                    "id": "내인성-pamp의-인식-hsp-hmgb1",
                    "children": null
                  }
                ]
              },
              {
                "text": "TLR 신호 전달 경로",
                "id": "tlr-신호-전달-경로",
                "children": [
                  {
                    "text": "미생물 리간드 인식의 결과",
                    "id": "미생물-리간드-인식의-결과",
                    "children": null
                  },
                  {
                    "text": "염증 및 항바이러스 반응 유도",
                    "id": "염증-및-항바이러스-반응-유도",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "선천성 면역과 적응성 면역의 주요 차이점은 무엇인가요?",
              "options": [
                "선천성 면역은 태어날 때부터 존재하며 비특이적인 반면, 적응성 면역은 특정 병원체에 특이적이며 기억 기능을 가집니다.",
                "선천성 면역은 특정 병원체에 특이적이지만 반응이 느리고, 적응성 면역은 모든 병원체에 빠르게 반응합니다.",
                "선천성 면역은 기억 기능이 있지만 T세포와 B세포가 관여하지 않고, 적응성 면역은 기억 기능이 없습니다.",
                "선천성 면역은 항원 제시 세포에 의해 활성화되고, 적응성 면역은 병원체 패턴에 의해 활성화됩니다."
              ],
              "answerIndex": 0,
              "explanation": "선천성 면역은 타고난 비특이적 방어이며, 적응성 면역은 특정 항원에 대한 후천적, 기억 기반 방어입니다."
            },
            {
              "question": "톨 유사 수용체(TLR)의 주요 기능은 무엇인가요?",
              "options": [
                "항체를 생산하여 병원체를 직접 중화시키는 기능",
                "병원체 관련 분자 패턴(PAMP)을 인식하고 사이토카인 방출을 유도하여 면역 반응을 조절하는 기능",
                "감염된 세포를 직접 파괴하는 자연 살해 세포의 기능을 억제하는 기능",
                "면역 반응 후 기억 세포를 형성하여 다음 감염에 대비하는 기능"
              ],
              "answerIndex": 1,
              "explanation": "TLR은 숙주 세포에서 PAMP를 인식하여 사이토카인 방출을 유도하고 면역 반응의 강도와 지속 시간을 조절하는 역할을 합니다."
            },
            {
              "question": "다음 중 세균성 PAMP에 해당하지 않는 것은 무엇인가요?",
              "options": [
                "지질다당류 (Lipopolysaccharide)",
                "세균 리보솜 RNA (Bacterial ribosomal RNA)",
                "이중 가닥 RNA (Double-stranded RNA)",
                "비메틸화 CpG (Unmethylated CpG in the bacterial DNA)"
              ],
              "answerIndex": 2,
              "explanation": "이중 가닥 RNA(Double-stranded RNA)는 바이러스성 PAMP에 해당합니다. 지질다당류, 세균 리보솜 RNA, 비메틸화 CpG는 세균성 PAMP입니다."
            }
          ]
        },
        {
          "title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 1284 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "물리적 요인",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "피부는 선천성 면역의 중요한 물리적 방어선입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "진피는 결합 조직으로 구성된 내부 부분입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성된 외부 부분입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "피부가 벗겨지고 건조한 상태를 유지하는 것은 미생물 성장을 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "점막은 위장관, 호흡기, 비뇨생식기를 덮는 상피층입니다. 점액은 미생물을 가두고 관이 건조해지는 것을 막는 점성 당단백질입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "누액 기관은 눈물을 배출하여 눈을 씻어냅니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "섬모 승강기는 점액에 갇힌 미생물을 폐에서 멀리 운반합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "귀지는 미생물이 귀에 들어가는 것을 막습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "소변은 흐름을 통해 요도를 청소합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "연동 운동, 배변, 구토, 설사 또한 미생물 배출에 기여하는 물리적 방어 기전입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "화학적 요인",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "피지는 보호막을 형성하고 피부의 pH를 3~5로 낮춥니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "땀, 눈물, 침, 소변에 있는 리소자임은 세균 세포벽을 파괴합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "위액의 낮은 pH (1.2~3.0)는 대부분의 세균과 독소를 파괴합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "질 분비물의 낮은 pH (3~5)는 미생물을 억제합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "정상 미생물총과 선천성 면역",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "정상 미생물총은 미생물 길항 작용 (경쟁적 배제)을 통해 병원균과 경쟁합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이는 공간과 영양분에 대한 경쟁 우위를 점하거나, 병원균에 해로운 물질을 생산하거나, 병원균 생존에 영향을 미치는 조건을 변경함으로써 이루어집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "공생은 한 유기체는 이득을 얻고 다른 유기체 (숙주)는 해를 입지 않는 관계를 의미합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "프로바이오틱스는 유익한 효과를 발휘하기 위해 투여되는 살아있는 미생물 배양물입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "무균 쥐를 사육하기 위해서는 엄격한 무균 상태가 요구됩니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 선천성 면역의 1차 방어선인 물리적 및 화학적 장벽과 정상 미생물총의 역할을 다룹니다. 피부, 점막, 누액 기관, 섬모 승강기, 귀지, 소변, 연동 운동, 배변, 구토, 설사 등 다양한 물리적 요인들이 미생물 침입을 막는 역할을 합니다. 또한, 피지, 리소자임, 위액 및 질 분비물의 낮은 pH와 같은 화학적 요인들이 미생물 성장을 억제하거나 파괴합니다. 정상 미생물총은 경쟁적 배제를 통해 병원균과 경쟁하며 숙주 방어에 기여합니다. 마지막으로, 마이크로바이옴이 선천성 면역 형성에 중요한 영향을 미친다는 점이 강조됩니다.",
            "keyConcepts": [
              {
                "term": "선천성 면역의 물리적 방어선",
                "definition": "피부, 점막, 눈물, 섬모 등 신체 외부 및 내부 표면에서 미생물 침입을 물리적으로 막는 방어 기전."
              },
              {
                "term": "선천성 면역의 화학적 방어선",
                "definition": "피지, 리소자임, 위액, 질 분비물 등의 화학 물질이 미생물 성장을 억제하거나 파괴하는 방어 기전."
              },
              {
                "term": "정상 미생물총의 역할",
                "definition": "인체에 상주하는 유익한 미생물들이 공간 및 영양분 경쟁, 유해 물질 생산 등을 통해 병원균의 침입과 증식을 억제하는 현상 (미생물 길항 작용)."
              },
              {
                "term": "마이크로바이옴과 선천성 면역",
                "definition": "인체 내 미생물 군집인 마이크로바이옴이 숙주의 선천성 면역 시스템 발달 및 기능에 중요한 영향을 미친다는 개념."
              }
            ],
            "importantTerms": [
              {
                "term": "케라틴",
                "definition": "피부 표피에 존재하는 보호 단백질로, 피부의 물리적 장벽을 형성하는 데 기여한다."
              },
              {
                "term": "점액",
                "definition": "점막에서 분비되는 점성 당단백질로, 미생물을 가두고 점막이 건조해지는 것을 방지한다."
              },
              {
                "term": "누액 기관",
                "definition": "눈물을 생성하고 배출하여 눈을 지속적으로 씻어내 미생물을 제거하는 역할을 하는 기관."
              },
              {
                "term": "섬모 승강기",
                "definition": "호흡기 점막의 섬모가 움직여 점액에 갇힌 미생물을 폐에서 멀리 이동시키는 메커니즘."
              },
              {
                "term": "리소자임",
                "definition": "땀, 눈물, 침, 소변 등에 존재하는 효소로, 세균의 세포벽을 파괴하여 항균 작용을 한다."
              },
              {
                "term": "미생물 길항 작용",
                "definition": "정상 미생물총이 공간, 영양분 경쟁 또는 병원균에 해로운 물질 생산을 통해 병원균의 성장을 억제하는 현상."
              },
              {
                "term": "공생",
                "definition": "두 유기체가 함께 살아가며 한 유기체는 이득을 얻지만 다른 유기체(숙주)는 해를 입지 않는 관계."
              }
            ],
            "outline": [
              {
                "text": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "id": "선천성-면역-1차-방어선",
                "children": [
                  {
                    "text": "물리적 요인",
                    "id": "물리적-요인",
                    "children": [
                      {
                        "text": "피부",
                        "id": "피부",
                        "children": null
                      },
                      {
                        "text": "점막",
                        "id": "점막",
                        "children": null
                      },
                      {
                        "text": "누액 기관",
                        "id": "누액-기관",
                        "children": null
                      },
                      {
                        "text": "기타 물리적 방어 (섬모 승강기, 귀지, 소변, 연동 운동 등)",
                        "id": "기타-물리적-방어",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "화학적 요인",
                    "id": "화학적-요인",
                    "children": [
                      {
                        "text": "피지",
                        "id": "피지",
                        "children": null
                      },
                      {
                        "text": "리소자임",
                        "id": "리소자임",
                        "children": null
                      },
                      {
                        "text": "위액의 낮은 pH",
                        "id": "위액의-낮은-ph",
                        "children": null
                      },
                      {
                        "text": "질 분비물의 낮은 pH",
                        "id": "질-분비물의-낮은-ph",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "정상 미생물총과 선천성 면역",
                    "id": "정상-미생물총과-선천성-면역",
                    "children": [
                      {
                        "text": "미생물 길항 작용",
                        "id": "미생물-길항-작용",
                        "children": null
                      },
                      {
                        "text": "공생 및 프로바이오틱스",
                        "id": "공생-및-프로바이오틱스",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
                    "id": "마이크로바이옴-탐구",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "피부의 표피층에 포함되어 미생물 성장을 억제하는 보호 단백질은 무엇입니까?",
              "options": [
                "케라틴",
                "콜라겐",
                "엘라스틴",
                "멜라닌"
              ],
              "answerIndex": 0,
              "explanation": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성되어 있으며, 이는 미생물 성장을 억제하는 데 기여합니다."
            },
            {
              "question": "선천성 면역의 화학적 방어선 중, 땀, 눈물, 침, 소변에 존재하며 세균 세포벽을 파괴하는 효소는 무엇입니까?",
              "options": [
                "펩신",
                "아밀레이스",
                "리소자임",
                "트립신"
              ],
              "answerIndex": 2,
              "explanation": "리소자임은 땀, 눈물, 침, 소변에 존재하며 세균의 세포벽을 파괴하는 강력한 항균 효소입니다."
            },
            {
              "question": "정상 미생물총이 병원균과 경쟁하여 성장을 억제하는 주요 메커니즘을 설명하는 용어는 무엇입니까?",
              "options": [
                "변이원성",
                "미생물 길항 작용",
                "자가면역",
                "과민 반응"
              ],
              "answerIndex": 1,
              "explanation": "정상 미생물총은 '미생물 길항 작용' 또는 '경쟁적 배제'를 통해 공간, 영양분 경쟁 및 유해 물질 생산으로 병원균의 성장을 억제합니다."
            }
          ]
        },
        {
          "title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2110 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "I. 혈액의 구성 요소",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "혈액은 혈장 내에 부유하는 세포 및 세포 조각으로 구성됩니다. 주요 구성 요소는 적혈구(red blood cells), 백혈구(white blood cells), 혈소판(platelets)이며, 이들은 적골수 줄기세포에서 조혈 작용(hematopoiesis)을 통해 생성됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "과립구 (Granulocytes)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "과립구는 세포질 내에 광학 현미경으로 볼 수 있는 과립을 가진 백혈구입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 호중구(Neutrophils): 식균 작용을 하며 감염 초기 단계에서 활동합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 호염기구(Basophils): 히스타민을 방출하며 알레르기 반응에 관여합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 호산구(Eosinophils): 식균 작용을 하며 기생충과 연충류에 대해 독성을 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "무과립구 (Agranulocytes)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "무과립구는 세포질 내에 과립이 있지만 광학 현미경으로 보이지 않는 백혈구입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 단핵구(Monocytes): 조직에서 대식세포(macrophages)로 성숙하여 식균 작용을 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 수지상 세포(Dendritic cells): 피부, 점막, 흉선에서 발견되며 식균 작용을 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 림프구(Lymphocytes): T세포, B세포, NK세포를 포함하며 적응 면역에 중요한 역할을 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "II. 림프계",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "림프계는 림프, 림프관, 림프 조직, 적골수로 구성됩니다. 림프구와 식세포를 포함하며, 림프는 미생물을 림프절로 운반하여 림프구와 대식세포가 병원균을 파괴하도록 돕습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "림프계의 주요 구성 요소 및 기관에는 흉관(좌측 림프관), 우측 림프관, 좌측 쇄골하정맥, 우측 쇄골하정맥, 편도, 흉선, 림프절, 비장, 대장, 소장, 파이어판(Peyer’s patch), 림프관, 적골수, 림프 모세혈관 등이 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "III. 숙주 방어: 개요 및 식세포",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "식세포(Phagocytes)는 '먹다'를 의미하는 그리스어 'Phago'와 '세포'를 의미하는 'Cyte'에서 유래했습니다. 식세포에는 조직과 장기에 상주하는 고정 대식세포(Fixed macrophages)와 조직을 돌아다니며 감염 부위에 모이는 자유(유리) 대식세포(Free (wandering) macrophages)가 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "IV. 식균 작용의 메커니즘",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "식균 작용은 다음 단계를 거쳐 진행됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 주화성(Chemotaxis): 화학적 신호가 식세포를 미생물로 유인합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 부착(Adherence): 식세포가 미생물 표면에 부착합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 섭취(Ingestion): 미생물이 혈청 단백질로 코팅되어(옵소닌화, Opsonization) 섭취가 용이해집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 소화(Digestion): 미생물이 식포-리소좀(phagolysosome) 내부에서 소화됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "V. 미생물의 식균 작용 회피 전략",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "일부 미생물은 숙주의 방어 체계를 회피하기 위한 다양한 병원성 인자(Virulence factors)를 가지고 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 부착 억제: M 단백질, 캡슐 (예: Streptococcus pyogenes, S. pneumoniae)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 식세포 사멸: 백혈구용해소(leukocidins) (예: Staphylococcus aureus)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 식세포 용해: 막 공격 복합체(membrane attack complex) (예: Listeria monocytogenes)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 식포 탈출: (예: Shigella, Rickettsia)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 식포-리소좀 융합 방지: (예: HIV, Mycobacterium tuberculosis)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 식포-리소좀 내 생존: (예: Coxiella burnetii)",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 선천성 면역의 2차 방어선으로서 혈액의 구성 요소와 식세포의 역할에 대해 설명합니다. 혈액의 주요 구성 요소(적혈구, 백혈구, 혈소판)와 조혈 작용을 소개하고, 백혈구를 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 분류하여 각 유형의 기능과 특징을 설명합니다. 또한, 림프계의 구성 요소와 병원균 제거에서의 역할을 다루고, 식세포의 정의와 고정/자유 대식세포의 종류를 설명합니다. 이어서 식균 작용의 네 가지 주요 단계(주화성, 부착, 섭취, 소화)를 자세히 설명하며, 특히 옵소닌화의 중요성을 강조합니다. 마지막으로, 미생물이 식균 작용을 회피하기 위해 사용하는 다양한 전략(부착 억제, 식세포 사멸, 식포 탈출 등)과 관련 미생물 예를 제시합니다.",
            "keyConcepts": [
              {
                "term": "혈액의 구성 요소",
                "definition": "혈액을 구성하는 주요 성분으로, 혈장 내에 부유하는 적혈구, 백혈구, 혈소판을 포함하며, 조혈 작용을 통해 생성됩니다."
              },
              {
                "term": "백혈구의 종류와 기능",
                "definition": "감염 및 알레르기 반응에 관여하는 면역 세포로, 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 나뉘며 각각 특정한 면역 기능을 수행합니다."
              },
              {
                "term": "림프계의 역할",
                "definition": "림프, 림프관, 림프 조직, 적골수로 구성되며 림프구와 식세포를 포함하여 병원균을 림프절로 운반하고 파괴함으로써 면역 방어에 기여하는 시스템입니다."
              },
              {
                "term": "식균 작용",
                "definition": "식세포가 미생물이나 세포 잔해를 섭취하고 소화하여 제거하는 과정으로, 주화성, 부착, 섭취(옵소닌화 포함), 소화의 단계를 거칩니다."
              },
              {
                "term": "미생물의 식균 작용 회피",
                "definition": "미생물이 숙주의 식균 작용으로부터 자신을 보호하기 위해 사용하는 다양한 전략으로, 부착 억제, 식세포 사멸, 식포 탈출, 식포-리소좀 융합 방지, 식포-리소좀 내 생존 등이 있습니다."
              }
            ],
            "importantTerms": [
              {
                "term": "조혈 작용 (Hematopoiesis)",
                "definition": "적골수 줄기세포에서 혈액 세포(적혈구, 백혈구, 혈소판)가 생성되는 과정입니다."
              },
              {
                "term": "과립구 (Granulocytes)",
                "definition": "세포질 내에 과립을 가진 백혈구로, 호중구, 호염기구, 호산구가 포함됩니다."
              },
              {
                "term": "무과립구 (Agranulocytes)",
                "definition": "세포질 내에 과립이 뚜렷하지 않은 백혈구로, 단핵구, 수지상 세포, 림프구가 포함됩니다."
              },
              {
                "term": "식세포 (Phagocytes)",
                "definition": "미생물이나 이물질을 섭취하고 소화하는 세포(예: 대식세포, 호중구)를 총칭합니다."
              },
              {
                "term": "옵소닌화 (Opsonization)",
                "definition": "미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포에 의한 섭취가 용이해지는 과정입니다."
              },
              {
                "term": "주화성 (Chemotaxis)",
                "definition": "화학적 신호에 의해 세포가 특정 방향으로 이동하는 현상으로, 식세포가 미생물로 유인되는 과정입니다."
              },
              {
                "term": "병원성 인자 (Virulence factors)",
                "definition": "미생물이 숙주에게 질병을 일으키거나 숙주의 면역 체계를 회피하는 데 도움이 되는 특징 또는 물질입니다."
              }
            ],
            "outline": [
              {
                "text": "I. 혈액의 구성 요소",
                "id": "i-혈액의-구성-요소",
                "children": [
                  {
                    "text": "과립구 (Granulocytes)",
                    "id": "과립구-granulocytes",
                    "children": null
                  },
                  {
                    "text": "무과립구 (Agranulocytes)",
                    "id": "무과립구-agranulocytes",
                    "children": null
                  }
                ]
              },
              {
                "text": "II. 림프계",
                "id": "ii-림프계",
                "children": null
              },
              {
                "text": "III. 숙주 방어: 개요 및 식세포",
                "id": "iii-숙주-방어-개요-및-식세포",
                "children": null
              },
              {
                "text": "IV. 식균 작용의 메커니즘",
                "id": "iv-식균-작용의-메커니즘",
                "children": null
              },
              {
                "text": "V. 미생물의 식균 작용 회피 전략",
                "id": "v-미생물의-식균-작용-회피-전략",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "다음 중 과립구에 해당하지 않는 백혈구는 무엇입니까?",
              "options": [
                "단핵구",
                "호중구",
                "호염기구",
                "호산구"
              ],
              "answerIndex": 0,
              "explanation": "단핵구는 무과립구에 속하며, 조직에서 대식세포로 성숙하여 식균 작용을 합니다. 호중구, 호염기구, 호산구는 모두 과립구에 해당합니다."
            },
            {
              "question": "식균 작용의 단계 중, 미생물이 혈청 단백질로 코팅되어 식세포에 의한 섭취가 용이해지는 과정을 무엇이라고 합니까?",
              "options": [
                "주화성",
                "부착",
                "옵소닌화",
                "소화"
              ],
              "answerIndex": 2,
              "explanation": "옵소닌화는 미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포의 섭취(Ingestion)를 돕는 과정입니다."
            },
            {
              "question": "다음 미생물 중 식포-리소좀 융합을 방지하여 식균 작용을 회피하는 것으로 알려진 것은 무엇입니까?",
              "options": [
                "Streptococcus pyogenes",
                "Staphylococcus aureus",
                "Listeria monocytogenes",
                "Mycobacterium tuberculosis"
              ],
              "answerIndex": 3,
              "explanation": "Mycobacterium tuberculosis는 식포-리소좀 융합을 방지하여 식세포 내에서 생존함으로써 식균 작용을 회피합니다. Streptococcus pyogenes는 부착을 억제하고, Staphylococcus aureus는 백혈구용해소를 통해 식세포를 사멸시키며, Listeria monocytogenes는 식세포를 용해시킵니다."
            }
          ]
        },
        {
          "title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 3719 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "염증: 개요",
              "level": 1
            },
            {
              "type": "heading",
              "content": "염증",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "염증의 네 가지 징후 및 증상: 발적(redness), 부종(edema), 통증(pain), 열(heat).",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "손상 인자를 파괴하거나 신체에 미치는 영향을 제한합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "손상 인자에 의해 손상된 조직을 복구하고 대체합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "염증 유발 물질",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "염증은 간에서 급성기 단백질을 활성화시켜 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "주요 염증 매개체는 다음과 같습니다:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "히스타민 (Histamine): 비만 세포, 호염기구, 혈소판에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "키닌 (Kinins): 혈장 내에 존재하며 호중구를 유인하여 화학주성(chemotaxis)을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "프로스타글란딘 (Prostaglandins): 손상된 세포에서 분비되며 히스타민과 키닌의 효과를 강화하고 식세포가 모세혈관 벽을 통과하는 것을 돕습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "류코트리엔 (Leukotrienes): 비만 세포와 호염기구에서 분비되며 혈관 투과성을 증가시키고 식세포가 병원체에 부착되는 것을 돕습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "보체 (Complement): 혈장 내에 존재하며 히스타민 분비를 자극하고 식세포를 유인하며 식균 작용을 촉진합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사이토카인 (Cytokines): 고정된 대식세포에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "염증 과정 단계",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "그림 16.9a-b 염증 과정: 조직 손상, 혈관 반응 및 식균 작용을 포함합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "염증 과정",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "조직 손상이 발생하면 손상된 세포에서 히스타민, 키닌, 프로스타글란딘, 류코트리엔, 사이토카인과 같은 화학 물질이 방출됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈액 응고가 형성되기 시작하고 농양(abscess)이 형성되기 시작합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "식세포 이동 및 식균 작용",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "마지네이션(Margination)은 염증 부위의 사이토카인에 반응하여 식세포가 혈관에 달라붙는 현상입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "식세포는 다이아페데시스(diapedesis)를 통해 혈관 내피 세포 사이를 비집고 나옵니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "조직 복구",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "모든 유해 물질이 제거되거나 중화될 때까지 완료될 수 없습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "기질(Stroma)은 복구되는 지지 결합 조직입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "실질(Parenchyma)은 복구되는 조직의 기능적인 부분입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "발열",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "비정상적으로 높은 체온입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "시상하부(Hypothalamus)는 일반적으로 37°C로 설정되어 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사이토카인이 시상하부로 하여금 프로스타글란딘을 방출하게 하여 시상하부의 온도를 더 높게 재설정합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "몸은 혈관을 수축시키고 떨림(shivering)이 발생하여 체온이 상승합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "체온이 떨어지면 (위기, crisis) 혈관 확장과 땀이 발생합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체 시스템",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "간에서 생산되는 혈청 단백질로, 미생물 파괴에 면역계를 보조합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "보체 활성화라고 불리는 과정에서 캐스케이드(cascade) 방식으로 작용합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "단백질은 대문자 C로 표시되며 발견 순서대로 번호가 매겨집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "활성화된 단편은 소문자 a와 b로 표시됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체: 활성화",
              "level": 1
            },
            {
              "type": "heading",
              "content": "고전적 경로",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "항체가 항원에 결합하여 C1을 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C1은 분열하여 C2와 C4를 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C2a와 C4b가 결합하여 C3을 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C3a는 염증에 관여합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C3b는 세포 용해(cytolysis)와 옵소닌화(opsonization)에 관여합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "대체 경로",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "혈액 내 C3가 미생물 표면의 B, D, P 인자와 결합합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C3는 C3a와 C3b로 분열하며, 고전적 경로와 동일하게 기능합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "렉틴 경로",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "대식세포가 병원체를 섭취하여 사이토카인을 방출하고, 이는 간에서 렉틴 생산을 자극합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "만노스 결합 렉틴(Mannose-binding lectin, MBL)이 만노스에 결합하여 C2와 C4를 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "C2a와 C4b가 C3을 활성화하며, 이는 고전적 경로 및 대체 경로와 동일하게 기능합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체 활성화의 결과",
              "level": 1
            },
            {
              "type": "heading",
              "content": "세포 용해",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "활성화된 보체 단백질이 막 공격 복합체(Membrane Attack Complex, MAC)를 형성합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "옵소닌화",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "식세포가 미생물에 부착되는 것을 촉진합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "염증",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "활성화된 보체 단백질이 비만 세포에 결합하여 히스타민을 방출합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그림 16.12 보체 활성화의 결과. 그림 16.13 보체에 의해 자극된 염증.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "보체 시스템은 신체가 감염과 병원체를 퇴치하는 또 다른 방법입니다. 선천성 면역의 이 구성 요소는 다른 면역 반응을 '보완'합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "보체는 혈청에 순환하는 30개 이상의 단백질 그룹으로, 캐스케이드 방식으로 활성화됩니다: 한 보체 단백질이 다음 단백질을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이 캐스케이드는 병원체에 의해 직접 활성화되거나 항체-항원 반응에 의해 활성화될 수 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이 단백질들은 함께 (1) 세포 용해, (2) 강화된 식균 작용, (3) 염증을 통해 미생물을 파괴합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체: 결과",
              "level": 1
            },
            {
              "type": "heading",
              "content": "보체 활성화의 조절",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "조절 단백질은 보체 단백질을 쉽게 분해하여 숙주 세포 손상을 최소화합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체와 질병",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "보체 단백질의 부족은 감염에 대한 취약성을 유발합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체 시스템 회피",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "캡슐은 보체 활성화를 방지합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "인터페론",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "세포에서 생산되는 사이토카인으로, 항바이러스 활동을 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IFN-α 및 IFN-β: 바이러스 감염에 반응하여 세포에서 생산되며, 이웃 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IFN-γ: 호중구와 대식세포가 박테리아를 죽이도록 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "알파 및 베타 인터페론(IFN)의 항바이러스 작용",
              "level": 2
            },
            {
              "type": "heading",
              "content": "철 결합 단백질",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "트랜스페린(Transferrin): 혈액 및 조직액에서 발견됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "락토페린(Lactoferrin): 우유, 침, 점액에서 발견됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "페리틴(Ferritin): 간, 비장, 적골수에서 발견됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "헤모글로빈(Hemoglobin): 적혈구에 위치합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "박테리아는 철 결합 단백질과 경쟁하기 위해 시데로포어(siderophores)를 생산합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항균 펩타이드",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "미생물의 단백질 및 당 분자에 반응하여 생산되는 짧은 펩타이드입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포벽 합성을 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "원형질막에 구멍을 형성합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "광범위한 활성 스펙트럼을 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "기타 요인",
              "level": 1
            },
            {
              "type": "heading",
              "content": "유전적 저항성",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "선택적 생존 이점을 부여합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "예: 겸상 적혈구 특성 및 열대열원충(Plasmodium falciparum).",
              "level": null
            },
            {
              "type": "heading",
              "content": "연령",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "매우 어린 연령과 노인들은 질병에 더 취약합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "건강 프로토콜 준수",
              "level": 2
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 선천성 면역의 핵심 구성 요소인 염증, 발열, 보체 시스템, 인터페론, 철 결합 단백질 및 항균 펩타이드에 대해 설명합니다. 염증의 징후, 매개체, 과정 및 조직 복구를 다루고, 발열의 메커니즘과 체온 조절을 설명합니다. 또한 보체 시스템의 세 가지 활성화 경로(고전적, 대체, 렉틴)와 그 결과(세포 용해, 옵소닌화, 염증)를 상세히 제시합니다. 마지막으로, 인터페론의 항바이러스 역할, 철 결합 단백질의 기능, 항균 펩타이드의 작용 방식, 그리고 유전적 저항성 및 연령과 같은 기타 면역 관련 요인들을 소개합니다.",
            "keyConcepts": [
              {
                "term": "염증 (Inflammation)",
                "definition": "손상된 조직을 파괴하거나 유해 물질의 영향을 제한하고, 손상된 조직을 복구 및 대체하는 신체의 방어 반응입니다. 발적, 부종, 통증, 열의 네 가지 주요 징후를 가집니다."
              },
              {
                "term": "발열 (Fever)",
                "definition": "비정상적으로 높은 체온으로, 사이토카인에 의해 시상하부의 체온 설정점이 높아져 발생합니다. 병원체 성장을 억제하고 면역 반응을 강화하는 데 도움을 줄 수 있습니다."
              },
              {
                "term": "보체 시스템 (Complement System)",
                "definition": "간에서 생산되는 30개 이상의 혈청 단백질로 구성된 캐스케이드 시스템입니다. 병원체 파괴를 돕기 위해 세포 용해, 옵소닌화, 염증을 유발하는 세 가지 활성화 경로(고전적, 대체, 렉틴)를 통해 작동합니다."
              },
              {
                "term": "인터페론 (Interferons)",
                "definition": "세포에서 생산되는 사이토카인으로, 특히 IFN-α와 IFN-β는 바이러스 감염에 반응하여 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질을 생산하도록 유도하는 항바이러스 활성을 가집니다."
              },
              {
                "term": "항균 물질 (Antimicrobial Substances)",
                "definition": "철 결합 단백질(트랜스페린, 락토페린, 페리틴, 헤모글로빈)과 항균 펩타이드를 포함하며, 미생물의 성장을 억제하거나 직접 파괴하여 숙주를 보호하는 역할을 합니다."
              }
            ],
            "importantTerms": [
              {
                "term": "히스타민 (Histamine)",
                "definition": "비만 세포 등에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발하는 혈관 활성 매개체입니다."
              },
              {
                "term": "다이아페데시스 (Diapedesis)",
                "definition": "식세포가 혈관 내피 세포 사이를 비집고 나와 조직 손상 부위로 이동하는 과정입니다."
              },
              {
                "term": "마지네이션 (Margination)",
                "definition": "염증 부위의 사이토카인에 반응하여 식세포가 혈관 내피에 달라붙는 현상입니다."
              },
              {
                "term": "막 공격 복합체 (Membrane Attack Complex, MAC)",
                "definition": "활성화된 보체 단백질에 의해 형성되며, 미생물 세포막에 구멍을 뚫어 세포 용해를 유발하는 구조입니다."
              },
              {
                "term": "옵소닌화 (Opsonization)",
                "definition": "보체 단백질(C3b) 등이 미생물을 코팅하여 식세포가 미생물을 더 쉽게 인식하고 식균 작용을 하도록 촉진하는 과정입니다."
              },
              {
                "term": "시데로포어 (Siderophores)",
                "definition": "박테리아가 숙주의 철 결합 단백질과 경쟁하여 철을 획득하기 위해 생산하는 물질입니다."
              },
              {
                "term": "항바이러스 단백질 (Antiviral Proteins, AVPs)",
                "definition": "인터페론의 유도에 의해 세포에서 생산되며, 바이러스 복제를 억제하는 단백질입니다."
              }
            ],
            "outline": [
              {
                "text": "염증",
                "id": "inflammation",
                "children": [
                  {
                    "text": "개요 및 징후",
                    "id": "inflammation-overview-signs",
                    "children": null
                  },
                  {
                    "text": "염증 반응 유발 물질",
                    "id": "inflammation-mediators",
                    "children": null
                  },
                  {
                    "text": "염증 과정 단계",
                    "id": "inflammation-steps",
                    "children": null
                  },
                  {
                    "text": "식세포 이동 및 식균 작용",
                    "id": "phagocyte-migration-phagocytosis",
                    "children": null
                  },
                  {
                    "text": "조직 복구",
                    "id": "tissue-repair",
                    "children": null
                  }
                ]
              },
              {
                "text": "발열",
                "id": "fever",
                "children": [
                  {
                    "text": "체온 조절 및 발열 메커니즘",
                    "id": "fever-mechanism",
                    "children": null
                  }
                ]
              },
              {
                "text": "보체 시스템",
                "id": "complement-system",
                "children": [
                  {
                    "text": "개요 및 기능",
                    "id": "complement-overview",
                    "children": null
                  },
                  {
                    "text": "보체 활성화 경로",
                    "id": "complement-activation-pathways",
                    "children": [
                      {
                        "text": "고전적 경로",
                        "id": "classical-pathway",
                        "children": null
                      },
                      {
                        "text": "대체 경로",
                        "id": "alternative-pathway",
                        "children": null
                      },
                      {
                        "text": "렉틴 경로",
                        "id": "lectin-pathway",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "보체 활성화의 결과",
                    "id": "complement-activation-outcomes",
                    "children": [
                      {
                        "text": "세포 용해",
                        "id": "cytolysis",
                        "children": null
                      },
                      {
                        "text": "옵소닌화",
                        "id": "opsonization",
                        "children": null
                      },
                      {
                        "text": "염증",
                        "id": "complement-inflammation",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "보체 조절 및 질병",
                    "id": "complement-regulation-disease",
                    "children": null
                  }
                ]
              },
              {
                "text": "항균 물질",
                "id": "antimicrobial-substances",
                "children": [
                  {
                    "text": "인터페론",
                    "id": "interferons",
                    "children": null
                  },
                  {
                    "text": "철 결합 단백질",
                    "id": "iron-binding-proteins",
                    "children": null
                  },
                  {
                    "text": "항균 펩타이드",
                    "id": "antimicrobial-peptides",
                    "children": null
                  }
                ]
              },
              {
                "text": "기타 요인",
                "id": "other-factors",
                "children": [
                  {
                    "text": "유전적 저항성",
                    "id": "genetic-resistance",
                    "children": null
                  },
                  {
                    "text": "연령",
                    "id": "age",
                    "children": null
                  },
                  {
                    "text": "건강 프로토콜 준수",
                    "id": "observing-healthy-protocols",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "염증의 네 가지 주요 징후에 해당하지 않는 것은 무엇입니까?",
              "options": [
                "발적",
                "부종",
                "가려움",
                "열"
              ],
              "answerIndex": 2,
              "explanation": "염증의 네 가지 주요 징후는 발적(redness), 부종(swelling), 통증(pain), 열(heat)입니다. 가려움은 일반적인 염증의 주요 징후에 해당하지 않습니다."
            },
            {
              "question": "보체 활성화의 세 가지 주요 결과에 속하지 않는 것은 무엇입니까?",
              "options": [
                "세포 용해 (Cytolysis)",
                "옵소닌화 (Opsonization)",
                "항체 생산 (Antibody production)",
                "염증 (Inflammation)"
              ],
              "answerIndex": 2,
              "explanation": "보체 활성화의 주요 결과는 세포 용해, 옵소닌화, 염증입니다. 항체 생산은 보체 시스템의 직접적인 결과가 아닌 적응 면역 반응의 일부입니다."
            },
            {
              "question": "인터페론(IFN-α 및 IFN-β)의 주요 역할은 무엇입니까?",
              "options": [
                "세균을 직접 죽인다.",
                "발열을 유도한다.",
                "바이러스 감염에 반응하여 항바이러스 단백질 생성을 유도한다.",
                "조직 복구를 돕는다."
              ],
              "answerIndex": 2,
              "explanation": "IFN-α와 IFN-β는 바이러스 감염에 의해 생성되어 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다."
            }
          ]
        },
        {
          "title": "적응성 면역: 개요 및 이중적 특성",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1042 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "적응성 면역 체계",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "적응성 면역은 특정 병원체를 표적으로 하는 방어 체계입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이는 감염이나 백신 접종을 통해 획득됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것을 의미합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이차 반응은 동일한 외래 물질과의 이후 상호 작용으로, '기억' 덕분에 더 빠르고 효과적입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "적응성 면역 체계의 이중적 특성",
              "level": 1
            },
            {
              "type": "heading",
              "content": "체액성 면역",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "체액성 면역은 항원(antigens)으로 알려진 외래 분자와 싸우는 항체를 생성합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "B 세포는 적골수에서 생성되고 성숙하는 림프구입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "B 세포는 항원을 인식하고 항체를 만듭니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "B 세포는 조류의 파브리시우스 낭(bursa of Fabricius)에서 이름을 따왔습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "애니메이션: 체액성 면역 개요",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포성 면역 (세포 매개 면역)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "세포성 면역은 T 림프구를 생성합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 림프구는 식세포에 의해 처리된 항원 펩타이드를 인식합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 세포는 흉선에서 성숙합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 세포 표면의 T 세포 수용체(TCRs)가 항원과 접촉하면 T 세포는 항체 대신 사이토카인을 분비합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 세포 및 B 세포 발달",
              "level": null
            },
            {
              "type": "heading",
              "content": "체액성 면역과 세포성 면역의 공격 대상 비교",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "세포성 면역은 세포 내부에 있는 항원을 공격합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이는 바이러스나 M. leprae, L. monocytogenes와 같은 일부 세포 내 세균에 해당합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "체액성 면역은 세포 외부의 침입자와 위협에 맞서 싸웁니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이는 세포 외 세균과 독소, 그리고 숙주 세포에 들어가기 전의 바이러스를 포함합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "제공된 텍스트는 특정 병원체를 표적으로 하는 방어 체계인 적응성 면역에 대해 설명합니다. 적응성 면역은 감염이나 백신을 통해 획득되며, 일차 반응과 이차 반응으로 구분됩니다. 또한, 적응성 면역의 이중적 특성으로 체액성 면역(B 세포, 항체 생성, 세포 외부 위협 방어)과 세포성 면역(T 세포, 사이토카인 분비, 세포 내부 위협 방어)을 상세히 다루고, 각 면역 체계가 공격하는 대상의 차이점을 비교합니다.",
            "keyConcepts": [
              {
                "term": "적응성 면역",
                "definition": "특정 병원체를 표적으로 삼는 방어 체계로, 감염이나 백신 접종을 통해 획득되며, 기억을 통해 더 빠르고 효과적인 이차 반응을 가능하게 합니다."
              },
              {
                "term": "체액성 면역",
                "definition": "B 세포가 항원을 인식하고 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸우는 면역 반응입니다."
              },
              {
                "term": "세포성 면역",
                "definition": "T 림프구가 식세포에 의해 처리된 항원 펩타이드를 인식하고 사이토카인을 분비하여 세포 내부에 있는 항원(예: 바이러스, 일부 세포 내 세균)을 공격하는 면역 반응입니다."
              },
              {
                "term": "일차 반응 및 이차 반응",
                "definition": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것이며, 이차 반응은 동일한 물질과의 이후 상호 작용으로, 기억 덕분에 더 빠르고 효과적입니다."
              }
            ],
            "importantTerms": [
              {
                "term": "항원 (Antigen)",
                "definition": "면역 반응, 특히 항체 생성을 유도하는 외래 분자입니다."
              },
              {
                "term": "항체 (Antibody)",
                "definition": "B 세포에 의해 생성되며 특정 항원과 결합하여 중화하거나 제거하는 Y자 모양의 단백질입니다."
              },
              {
                "term": "B 세포 (B cell)",
                "definition": "적골수에서 생성 및 성숙하며 항원을 인식하고 항체를 만드는 림프구입니다."
              },
              {
                "term": "T 세포 (T cell)",
                "definition": "흉선에서 성숙하며 항원 제시 세포에 의해 처리된 항원 펩타이드를 인식하고 항체 대신 사이토카인을 분비하는 림프구입니다."
              },
              {
                "term": "사이토카인 (Cytokine)",
                "definition": "T 세포 등 면역 세포가 분비하는 작은 단백질로, 면역 반응과 염증을 조절하는 신호 분자 역할을 합니다."
              },
              {
                "term": "T 세포 수용체 (TCR)",
                "definition": "T 세포 표면에 위치하며 특정 항원 펩타이드를 인식하고 결합하는 수용체입니다."
              }
            ],
            "outline": [
              {
                "text": "적응성 면역 체계",
                "id": "adaptive-immune-system",
                "children": [
                  {
                    "text": "적응성 면역의 정의 및 획득 경로",
                    "id": "definition-acquisition-of-adaptive-immunity",
                    "children": null
                  },
                  {
                    "text": "일차 반응과 이차 반응",
                    "id": "primary-and-secondary-response",
                    "children": null
                  }
                ]
              },
              {
                "text": "적응성 면역 체계의 이중적 특성",
                "id": "dual-nature-of-adaptive-immune-system",
                "children": [
                  {
                    "text": "체액성 면역",
                    "id": "humoral-immunity",
                    "children": [
                      {
                        "text": "항체 생성 및 항원 공격",
                        "id": "antibody-production-and-antigen-attack",
                        "children": null
                      },
                      {
                        "text": "B 세포의 역할 및 특징",
                        "id": "role-and-characteristics-of-b-cells",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "세포성 면역 (세포 매개 면역)",
                    "id": "cellular-immunity",
                    "children": [
                      {
                        "text": "T 림프구 생성 및 역할",
                        "id": "t-lymphocyte-production-and-role",
                        "children": null
                      },
                      {
                        "text": "T 세포의 성숙 및 항원 인식",
                        "id": "t-cell-maturation-and-antigen-recognition",
                        "children": null
                      },
                      {
                        "text": "T 세포 수용체(TCR) 및 사이토카인 분비",
                        "id": "tcr-and-cytokine-secretion",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "체액성 면역과 세포성 면역의 공격 대상 비교",
                    "id": "comparison-of-humoral-and-cellular-immunity-targets",
                    "children": [
                      {
                        "text": "세포성 면역의 대상 (세포 내부 항원)",
                        "id": "targets-of-cellular-immunity",
                        "children": null
                      },
                      {
                        "text": "체액성 면역의 대상 (세포 외부 위협)",
                        "id": "targets-of-humoral-immunity",
                        "children": null
                      }
                    ]
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "적응성 면역의 주요 특징은 무엇입니까?",
              "options": [
                "비특이적 방어",
                "특정 병원체를 표적으로 함",
                "즉각적인 반응",
                "항상 식세포 작용을 포함함"
              ],
              "answerIndex": 1,
              "explanation": "적응성 면역은 특정 병원체를 표적으로 삼는 방어 체계입니다."
            },
            {
              "question": "항체를 생성하고 세포 외부의 위협을 공격하는 면역 유형은 무엇입니까?",
              "options": [
                "선천성 면역",
                "세포성 면역",
                "체액성 면역",
                "비특이적 면역"
              ],
              "answerIndex": 2,
              "explanation": "체액성 면역은 B 세포가 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸웁니다."
            },
            {
              "question": "T 세포는 어디에서 성숙합니까?",
              "options": [
                "적골수",
                "비장",
                "림프절",
                "흉선"
              ],
              "answerIndex": 3,
              "explanation": "T 세포는 흉선(thymus)에서 성숙합니다."
            }
          ]
        },
        {
          "title": "적응성 면역: 사이토카인, 항원 및 항체",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1989 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "사이토카인: 면역 세포의 화학적 전달자",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "사이토카인은 자극에 반응하여 생성되는 화학적 전달자입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "인터루킨(Interleukins): 백혈구 사이의 사이토카인입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "케모카인(Chemokines): 백혈구의 이동을 유도합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "인터페론(Interferons, IFNs): 숙주 세포의 바이러스 감염을 방해합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "종양 괴사 인자(Tumor necrosis factor, TNF): 자가면역 질환의 염증과 관련이 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "조혈 사이토카인(Hematopoietic cytokines): 적혈구와 백혈구로 발달하는 줄기세포를 조절합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사이토카인의 과잉 생산은 사이토카인 폭풍(cytokine storm)으로 이어집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "주요 사이토카인 및 그 역할",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "IL-4: TH2 세포에서 생성되며, 미감염 TH 세포와 B 세포에 작용하여 TH2 세포 증식을 유도하고 IgE로의 클래스 전환을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IL-12: 수지상 세포, 대식세포, 호중구에서 생성되며, 미감염 TH 세포와 NK 세포에 작용하여 TH1 세포의 성장과 기능을 자극하고 IFN-γ 및 TNF-α를 자극합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IL-17: TH17 세포에서 생성되며, 호중구에 작용하여 염증을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IL-22: TH17 세포에서 생성되며, 상피세포에 작용하여 항균 단백질 생성을 자극합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "감마 인터페론(IFN-γ): TH1 세포에서 생성되며, CTL(세포독성 T 림프구)과 대식세포에 작용하여 식세포 작용을 촉진하고 대식세포 및 체액성 면역 반응을 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "케모카인: 다양한 세포(대식세포, 상피세포)에서 생성되며, 호중구에 작용하여 화학주성(chemotaxis)을 유도합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "TNF-알파(TNF-α): 대식세포, TH 세포, NK 세포에서 생성되며, 종양 세포에 작용하여 염증을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "GM-CSF: 대식세포, T 세포, NK 세포에서 생성되며, 골수 줄기세포에 작용하여 대식세포와 과립구 수를 증가시킵니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항원",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "항원은 항체 생성을 유발하는 물질입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "일반적으로 침입하는 미생물이나 이물질의 구성 요소입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항체는 항원상의 에피토프(epitopes) 또는 항원결정인자(antigenic determinants)와 상호작용합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "합텐",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "합텐은 면역 반응을 유발하기에는 너무 작은 항원입니다; 운반 분자에 부착되어야 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항체",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "항체는 면역글로불린(Immunoglobulins, Ig)이라고 불리는 구형 단백질입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "가(Valence)는 항체에 있는 항원 결합 부위의 수를 의미합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이중가(Bivalent) 항체는 두 개의 결합 부위를 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "전형적인 항체 분자의 구조",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "네 개의 단백질 사슬이 Y자 모양을 이룹니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "두 개의 동일한 경쇄(light chains)와 두 개의 동일한 중쇄(heavy chains)가 이황화 결합으로 연결되어 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "가변(V) 부위는 팔의 끝 부분에 위치하며 에피토프와 결합합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "정상(Fc) 부위는 줄기 부분으로, 특정 Ig 클래스에 대해 동일합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역글로불린은 5가지 클래스(IgG, IgM, IgA, IgD, IgE)로 나뉩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역글로불린 클래스 요약",
              "level": 1
            },
            {
              "type": "heading",
              "content": "IgG",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "단량체(Monomer)입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈청 항체의 80%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈액, 림프, 장에 존재합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "태반을 통과하여 태아를 보호하고; 보체(complement)를 활성화하며; 식세포 작용을 강화하고; 독소와 바이러스를 중화합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "IgM",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "다섯 개의 단량체가 J 사슬로 연결된 오량체(Pentamer)입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈청 항체의 6%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈관 내에 남아있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포와 바이러스의 응집을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "감염에 대한 첫 번째 반응이며; 수명이 짧습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "IgA",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "혈청에서는 단량체, 분비물에서는 이량체(Dimer)입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈청 항체의 13%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "점막, 침, 눈물, 모유에서 흔히 발견됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "미생물이 점막에 부착하는 것을 방지합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "IgD",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "단량체입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈청 항체의 0.02%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "IgG와 유사한 구조를 가집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈액, 림프, B 세포에 존재합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "명확히 정의된 기능은 없으나; B 세포의 면역 반응을 돕습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "IgE",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "단량체입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈청 항체의 0.002%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "비만세포, 호염기구, 혈액에 존재합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항원과 결합하면 히스타민 방출을 유발하고; 기생충을 용해합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "본 문서는 적응성 면역의 핵심 요소인 사이토카인, 항원, 항체에 대해 설명합니다. 사이토카인은 면역 세포 간의 화학적 전달자로, 다양한 종류(인터루킨, 케모카인, 인터페론, TNF 등)와 기능(염증 유발, 백혈구 이동 유도, 바이러스 감염 방해 등)을 가지며, 과잉 생산 시 사이토카인 폭풍을 유발할 수 있습니다. 항원은 항체 생성을 유발하는 물질이며, 항체가 결합하는 특정 부위를 에피토프라고 합니다. 합텐은 면역 반응을 유발하기에 너무 작아 운반 분자에 부착해야 하는 항원입니다. 항체는 면역글로불린(Ig)이라는 단백질로, Y자 모양의 구조를 가지며 가변부위와 정상부위로 구성됩니다. IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 클래스가 있으며, 각 클래스는 고유한 구조적 특성과 면역 기능을 수행합니다.",
            "keyConcepts": [
              {
                "term": "사이토카인 (Cytokines)",
                "definition": "면역 세포 간의 통신을 담당하는 화학적 전달 물질로, 다양한 면역 반응을 조절합니다."
              },
              {
                "term": "항원 (Antigens)",
                "definition": "면역 반응, 특히 항체 생성을 유발하는 물질입니다."
              },
              {
                "term": "항체 (Antibodies/Immunoglobulins)",
                "definition": "항원에 특이적으로 결합하여 항원을 중화하거나 제거하는 면역 단백질입니다."
              },
              {
                "term": "면역글로불린 클래스 (Immunoglobulin Classes)",
                "definition": "항체의 기능과 구조에 따라 IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 분류로 나뉩니다."
              },
              {
                "term": "사이토카인 폭풍 (Cytokine Storm)",
                "definition": "사이토카인이 과도하게 생산되어 전신 염증 반응과 조직 손상을 유발할 수 있는 심각한 면역 반응입니다."
              }
            ],
            "importantTerms": [
              {
                "term": "인터루킨 (Interleukins)",
                "definition": "백혈구 사이에서 작용하는 사이토카인입니다."
              },
              {
                "term": "케모카인 (Chemokines)",
                "definition": "백혈구의 이동(화학주성)을 유도하는 사이토카인입니다."
              },
              {
                "term": "인터페론 (Interferons, IFNs)",
                "definition": "바이러스 감염을 방해하는 사이토카인입니다."
              },
              {
                "term": "종양 괴사 인자 (Tumor Necrosis Factor, TNF)",
                "definition": "염증 반응과 관련된 사이토카인입니다."
              },
              {
                "term": "에피토프 (Epitopes)",
                "definition": "항원 상에서 항체가 특이적으로 결합하는 특정 부위 또는 항원결정인자입니다."
              },
              {
                "term": "합텐 (Haptens)",
                "definition": "단독으로는 면역 반응을 유발하지 못하지만, 운반 분자에 부착되면 면역원성을 획득하는 작은 분자입니다."
              },
              {
                "term": "가변 부위 (Variable regions)",
                "definition": "항체 팔의 끝 부분에 위치하며 항원의 에피토프와 결합하는 부위입니다."
              },
              {
                "term": "정상 부위 (Constant region, Fc)",
                "definition": "항체 분자의 줄기 부분으로, 특정 Ig 클래스에 대해 동일하며 면역 세포와의 상호작용에 관여합니다."
              }
            ],
            "outline": [
              {
                "text": "사이토카인: 면역 세포의 화학적 전달자",
                "id": "cytokines-chemical-messengers-of-immune-cells",
                "children": [
                  {
                    "text": "사이토카인의 정의 및 종류",
                    "id": "cytokines-definition-types",
                    "children": null
                  },
                  {
                    "text": "주요 사이토카인 및 그 역할",
                    "id": "key-cytokines-roles",
                    "children": null
                  },
                  {
                    "text": "사이토카인 폭풍",
                    "id": "cytokine-storm",
                    "children": null
                  }
                ]
              },
              {
                "text": "항원",
                "id": "antigens",
                "children": [
                  {
                    "text": "항원의 정의",
                    "id": "antigens-definition",
                    "children": null
                  },
                  {
                    "text": "에피토프",
                    "id": "epitopes",
                    "children": null
                  }
                ]
              },
              {
                "text": "합텐",
                "id": "haptens",
                "children": null
              },
              {
                "text": "항체",
                "id": "antibodies",
                "children": [
                  {
                    "text": "항체의 정의 및 구조",
                    "id": "antibodies-definition-structure",
                    "children": null
                  },
                  {
                    "text": "전형적인 항체 분자의 구조",
                    "id": "typical-antibody-structure",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역글로불린 클래스 요약",
                "id": "summary-of-immunoglobulin-classes",
                "children": [
                  {
                    "text": "IgG",
                    "id": "igg",
                    "children": null
                  },
                  {
                    "text": "IgM",
                    "id": "igm",
                    "children": null
                  },
                  {
                    "text": "IgA",
                    "id": "iga",
                    "children": null
                  },
                  {
                    "text": "IgD",
                    "id": "igd",
                    "children": null
                  },
                  {
                    "text": "IgE",
                    "id": "ige",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "사이토카인 폭풍(Cytokine storm)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
              "options": [
                "면역 세포가 바이러스 감염을 방해하기 위해 사이토카인을 과도하게 생산하는 현상",
                "염증 반응을 억제하기 위해 사이토카인이 부족하게 생산되는 현상",
                "사이토카인이 과도하게 생산되어 조직 손상과 장기 부전을 초래할 수 있는 현상",
                "항체 생산을 촉진하기 위해 특정 사이토카인이 의도적으로 증가하는 현상"
              ],
              "answerIndex": 2,
              "explanation": "사이토카인 폭풍은 사이토카인이 과도하게 생산되어 전신 염증 반응, 조직 손상 및 장기 부전을 초래할 수 있는 현상입니다."
            },
            {
              "question": "다음 면역글로불린(Ig) 클래스 중, 태반을 통과하여 태아를 보호하고 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 하는 것은 무엇입니까?",
              "options": [
                "IgM",
                "IgA",
                "IgG",
                "IgE"
              ],
              "answerIndex": 2,
              "explanation": "IgG는 태반을 통과하여 태아를 보호하며, 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 수행합니다."
            },
            {
              "question": "합텐(Hapten)에 대한 설명으로 옳은 것은 무엇입니까?",
              "options": [
                "항체를 생산하는 모든 물질을 의미한다.",
                "면역 반응을 유발하기에 너무 작아서 운반 분자에 부착해야 하는 항원이다.",
                "항체와 상호작용하는 항원의 특정 부위를 의미한다.",
                "혈액에 가장 많이 존재하는 면역글로불린의 한 종류이다."
              ],
              "answerIndex": 1,
              "explanation": "합텐은 단독으로는 면역 반응을 유발하기에 너무 작지만, 운반 분자에 부착되면 면역원성을 획득하여 항체 생성을 유도할 수 있는 물질입니다."
            }
          ]
        },
        {
          "title": "적응성 면역: 체액성 면역 반응",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2199 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "항체 생성 세포의 활성화 및 클론 선택",
              "level": 1
            },
            {
              "type": "heading",
              "content": "주조직적합복합체(MHC)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "주조직적합복합체(MHC) 유전자는 세포 표면에 존재하는 분자를 암호화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "Class I MHC는 모든 유핵 동물 세포의 막에 존재하며, '자기(self)'를 식별하는 역할을 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "Class II MHC는 B 세포를 포함한 전문 항원제시세포(APCs)의 표면에 존재합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "B 세포의 활성화 및 클론 선택 과정",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "비활성 B 세포는 항원에 결합하는 표면 면역글로불린(Ig)을 가지고 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "B 세포는 항원을 내재화하고 처리합니다. 처리된 항원 조각들은 MHC Class II 분자에 제시됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이 제시된 항원 조각을 T 도우미 세포(TH cell)가 접촉하고, B 세포를 활성화시키는 사이토카인을 방출합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "활성화된 B 세포는 증식(클론 확장)을 겪습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "클론 선택은 활성화된 B 세포를 다음 두 가지로 분화시킵니다:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1. 항체를 생산하는 형질세포(Plasma cells)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "2. 기억 세포(Memory cells)",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "또한, 클론 제거(Clonal deletion) 과정을 통해 유해한 B 세포는 제거됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "줄기세포는 특정 항원에 대한 표면 면역글로불린을 가진 성숙한 B 세포로 분화합니다. B 세포가 특정 항원을 만나면 증식합니다. 일부 B 세포는 장수하는 기억 세포로 증식하여, 나중에 항체를 생산하는 형질세포로 자극될 수 있습니다. 다른 B 세포는 항체 생산 형질세포로 증식하며, 이 형질세포는 혈액 순환계로 항체를 분비합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "T 세포 의존성 및 비의존성 항원",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "T 세포 의존성 항원은 항체를 생산하기 위해 T 도우미 세포(TH cell)의 도움이 필요한 항원입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 직접 자극할 수 있습니다. 이러한 항원은 일반적으로 약한 면역 반응을 유발하며, 주로 IgM을 생산하고 기억 세포는 생성되지 않습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항원-항체 결합 및 그 결과",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "항체가 항원에 결합할 때 항원-항체 복합체가 형성됩니다. 이 결합의 강도를 친화도(affinity)라고 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항원-항체 결합은 외래 분자나 세포를 파괴하도록 표지함으로써 숙주를 보호합니다. 주요 보호 메커니즘은 다음과 같습니다:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1. **응집(Agglutination)**: 감염 단위의 수를 줄여 처리해야 할 대상을 감소시킵니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "2. **옵소닌화(Opsonization)**: 항원으로 항원을 코팅하여 식균작용을 강화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "3. **항체 의존성 세포 매개성 세포독성(Antibody-dependent cell-mediated cytotoxicity, ADCC)**: 항체가 표적 세포에 부착되어 대식세포, 호산구, NK 세포에 의한 파괴를 유도합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "4. **중화(Neutralization)**: 박테리아와 바이러스가 점막에 부착되는 것을 차단하고 독소가 부착되는 것을 막습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "5. **보체계 활성화(Activation of the complement system)**: 염증 및 세포 용해를 유발합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "본 문서는 적응성 면역 중 체액성 면역 반응에 초점을 맞춰 항체 생성 세포의 활성화 및 클론 선택 과정을 설명합니다. MHC(주조직적합복합체)의 역할, B 세포가 항원을 인식하고 T 도우미 세포의 도움을 받아 활성화되며 형질세포와 기억 세포로 분화하는 과정이 상세히 다뤄집니다. 또한, T 세포 의존성 및 비의존성 항원의 특징과 항원-항체 결합이 숙주를 보호하는 응집, 옵소닌화, ADCC, 중화, 보체계 활성화 등 다양한 메커니즘을 제시합니다.",
            "keyConcepts": [
              {
                "term": "MHC (주조직적합복합체)",
                "definition": "세포 표면에 존재하며, Class I은 '자기' 식별, Class II는 항원제시세포에서 항원 조각을 T 세포에 제시하는 역할을 하는 분자를 암호화하는 유전자 복합체."
              },
              {
                "term": "B 세포 활성화",
                "definition": "비활성 B 세포가 항원을 인식하고, T 도우미 세포의 사이토카인 도움을 받아 증식하고 분화하는 과정."
              },
              {
                "term": "클론 선택 (Clonal Selection)",
                "definition": "특정 항원에 반응하는 B 세포 클론이 선택적으로 증식하여 항체 생성 형질세포와 기억 세포로 분화하는 면역 과정."
              },
              {
                "term": "T 세포 의존성/비의존성 항원",
                "definition": "항체 생산에 T 도우미 세포의 도움이 필요한지 여부에 따라 항원을 분류하는 방식. 비의존성 항원은 약한 IgM 반응과 기억 세포 부재를 특징으로 함."
              },
              {
                "term": "항체 기능",
                "definition": "항원-항체 복합체 형성 후 숙주를 보호하는 다양한 메커니즘 (응집, 옵소닌화, ADCC, 중화, 보체계 활성화)."
              }
            ],
            "importantTerms": [
              {
                "term": "MHC (주조직적합복합체)",
                "definition": "세포 표면에 항원 펩타이드를 제시하는 데 관여하는 단백질 복합체."
              },
              {
                "term": "T 도우미 세포 (T Helper Cell, TH cell)",
                "definition": "B 세포 활성화 및 다른 면역 세포 기능을 조절하는 사이토카인을 분비하는 림프구."
              },
              {
                "term": "사이토카인 (Cytokines)",
                "definition": "세포 간 신호 전달에 관여하며 면역 반응을 조절하는 작은 단백질."
              },
              {
                "term": "형질세포 (Plasma Cell)",
                "definition": "활성화된 B 세포로부터 분화하여 다량의 항체를 생산하고 분비하는 세포."
              },
              {
                "term": "기억 세포 (Memory Cell)",
                "definition": "면역 반응 후 장기간 생존하며, 동일한 항원 재침입 시 빠르고 강력한 2차 면역 반응을 유도하는 림프구."
              },
              {
                "term": "응집 (Agglutination)",
                "definition": "항체가 여러 항원 입자(예: 세균)를 서로 묶어 침전시키는 과정."
              },
              {
                "term": "옵소닌화 (Opsonization)",
                "definition": "항체가 항원 표면을 코팅하여 식세포가 이를 더 쉽게 인식하고 포식할 수 있도록 돕는 과정."
              }
            ],
            "outline": [
              {
                "text": "항체 생성 세포의 활성화 및 클론 선택",
                "id": "항체-생성-세포의-활성화-및-클론-선택",
                "children": [
                  {
                    "text": "주조직적합복합체(MHC)",
                    "id": "주조직적합복합체-mhc",
                    "children": null
                  },
                  {
                    "text": "B 세포의 활성화 및 클론 선택 과정",
                    "id": "b-세포의-활성화-및-클론-선택-과정",
                    "children": null
                  },
                  {
                    "text": "T 세포 의존성 및 비의존성 항원",
                    "id": "t-세포-의존성-및-비의존성-항원",
                    "children": null
                  }
                ]
              },
              {
                "text": "항원-항체 결합 및 그 결과",
                "id": "항원-항체-결합-및-그-결과",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "다음 중 MHC Class II 분자가 주로 발견되는 세포와 그 역할은 무엇입니까?",
              "options": [
                "모든 유핵 동물 세포의 막; '자기' 식별",
                "전문 항원제시세포(APCs)의 표면; 항원 조각 제시",
                "적혈구; 산소 운반",
                "신경 세포; 신경 신호 전달"
              ],
              "answerIndex": 1,
              "explanation": "MHC Class II는 B 세포를 포함한 전문 항원제시세포의 표면에 존재하며, 처리된 항원 조각을 T 도우미 세포에 제시하는 역할을 합니다."
            },
            {
              "question": "B 세포가 항원을 내재화하고 처리한 후, T 도우미 세포의 도움을 받아 활성화될 때 T 도우미 세포가 방출하는 물질은 무엇입니까?",
              "options": [
                "항체",
                "항원",
                "사이토카인",
                "면역글로불린"
              ],
              "answerIndex": 2,
              "explanation": "T 도우미 세포는 제시된 항원 조각을 인식한 후 사이토카인을 방출하여 B 세포의 활성화를 유도합니다."
            },
            {
              "question": "T 세포 비의존성 항원에 대한 면역 반응의 특징으로 옳지 않은 것은 무엇입니까?",
              "options": [
                "T 세포의 도움 없이 B 세포를 직접 자극한다.",
                "주로 IgM 항체를 생산한다.",
                "약한 면역 반응을 유발한다.",
                "강력한 기억 세포 반응을 생성한다."
              ],
              "answerIndex": 3,
              "explanation": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 자극하지만, 일반적으로 약한 면역 반응을 유발하고 기억 세포가 생성되지 않습니다."
            }
          ]
        },
        {
          "title": "적응성 면역: 세포성 면역 반응",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2963 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "세포성 면역 반응 과정",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "T 세포는 세포내 병원체와 싸웁니다. T 세포는 흉선에서 성숙하며, 흉선 선택을 통해 미성숙 T 세포가 제거됩니다. 성숙한 T 세포는 흉선에서 림프 조직으로 이동하며, T 세포 수용체(TCR)를 통해 항원에 부착합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "위장관으로 들어오는 병원체는 파이어스 패치(Peyer's patches) 위에 위치한 미세주름 세포(M cells)를 통과합니다. 이 세포들은 항원을 림프구와 항원제시세포(APCs)로 전달합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항원제시세포 (APCs)",
              "level": 1
            },
            {
              "type": "heading",
              "content": "수지상 세포 (Dendritic cells, DCs)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "수지상 세포는 미생물을 삼켜 분해하고 T 세포에 제시합니다. 이들은 피부, 생식기, 림프절, 비장, 흉선 및 혈액에서 발견됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "대식세포 (Macrophages)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "대식세포는 사이토카인 또는 항원 물질의 섭취에 의해 활성화됩니다. 이들은 림프 조직으로 이동하여 T 세포에 항원을 제시합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항원 처리 및 제시: MHC",
              "level": 1
            },
            {
              "type": "heading",
              "content": "T 세포의 종류",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "T 세포는 분화군(Clusters of differentiation, CD) 표지자를 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "CD4+ T 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "CD4+ T 세포는 T 도우미 세포(TH)라고도 불립니다. 이들은 B 세포와 사이토카인 신호를 주고받으며 항원과 직접 상호작용합니다. B 세포 및 APC의 MHC class II 분자에 결합합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "CD8+ T 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "CD8+ T 세포는 세포독성 T 림프구(Cytotoxic T lymphocytes, CTL)라고 불립니다. 이들은 MHC class I 분자에 결합합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "CD4+ 세포의 TCR은 APC의 항원 조각과 MHC class II에 결합하여 인식합니다. APC 또는 TH는 보조 자극 분자를 분비하여 CD4+ 세포를 활성화합니다. 활성화된 TH 세포는 사이토카인을 생성하고 TH1, TH2, TH17 세포 및 기억 세포로 분화합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "TH17 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "TH17 세포는 IL-17을 생성하여 염증 반응에 기여하고, 세포외 세균 및 곰팡이에 대한 방어를 위해 호중구를 모집합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "TH1 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "TH1 세포는 IFN-γ를 생성하여 대식세포를 활성화하고, 보체를 강화하며, 식세포 작용을 촉진하는 항체 생성을 자극합니다. TH1 세포는 세포성 면역의 중요한 요소이며, 이들의 사이토카인(예: IFN-γ 및 IL-2)은 CD8+ T 세포와 NK 세포를 활성화하여 감염된 숙주 세포를 죽임으로써 세포내 병원체를 제어합니다. 또한, 대식세포와 같은 항원제시세포의 식세포 작용을 강화합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "TH2 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "TH2 세포는 B 세포를 활성화하여 IgE를 생성하게 하고 호산구를 활성화합니다. 특히 IgE 생성을 통한 알레르기 반응에 중요하며, 헬민스와 같은 세포외 기생충을 제어하기 위해 호산구를 활성화합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "조절 T 세포 (Treg)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "조절 T 세포(Treg)는 CD4+ 세포의 하위 집합으로, 추가적인 CD25 분자를 가지고 있습니다. 이들은 자가 반응성 T 세포를 억제하여 자기 관용을 유지하고, 소화에 필요한 장내 세균을 보호하며, 태아를 보호합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포독성 T 림프구 (CD8+ T 세포)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "전구 세포독성 T 세포(CTLp)는 TH 세포와 보조 자극 신호의 도움으로 활성화되어 세포독성 T 림프구(CTLs)가 됩니다. CTLs는 감염에 의해 변형된 자가 세포를 인식하고 죽입니다. 감염된 자가 세포는 MHC class I 분자와 함께 표면에 내인성 항원을 운반합니다. CTL은 퍼포린(perforin)과 그랜자임(granzymes)을 방출하여 감염된 세포의 세포자멸사를 유도합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포자멸사 (Apoptosis)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "세포자멸사는 프로그램된 세포 사멸입니다. 이는 감염성 바이러스가 다른 세포로 퍼지는 것을 방지합니다. 세포는 게놈을 조각으로 절단하며, 세포막은 수포(blebbing)를 통해 바깥쪽으로 부풀어 오릅니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "정상 세포는 세포독성 T 림프구(CTL)에 의해 반응을 유발하지 않지만, 바이러스 감염 세포나 암세포는 비정상적인 내인성 항원을 생성합니다. 이 비정상적인 항원은 MHC class I 분자와 결합하여 세포 표면에 제시됩니다. TH1 세포의 결합은 사이토카인 분비를 촉진합니다. 이 사이토카인은 전구 CTL을 활성화하여 CTL 클론을 생성합니다. CTL은 세포자멸사를 통해 바이러스 감염 세포의 파괴를 유도합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역계에 의한 세포외 살상",
              "level": 1
            },
            {
              "type": "heading",
              "content": "자연살해 (NK) 세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "자연살해(NK) 세포는 과립성 백혈구로, MHC class I 자가 항원을 발현하지 않는 세포를 파괴합니다. 이들은 바이러스 감염 세포와 종양 세포를 죽이고 기생충을 공격합니다. 항상 항원에 의해 자극되는 것은 아니며, 표적 세포에 구멍을 형성하여 용해 또는 세포자멸사를 유도합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포성 면역에 관여하는 주요 세포 기능",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "T 도우미 (TH1) 세포: 세포 매개 면역 관련 세포(대식세포, CTLs, 자연살해 세포)를 활성화합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 도우미 (TH2) 세포: 호산구, IgM, IgE 생성을 자극합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "T 도우미 (TH17) 세포: 호중구를 모집하고 항균 단백질 생성을 자극합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포독성 T 림프구 (CTL): 세포자멸사를 유도하여 접촉하는 표적 세포를 파괴합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "조절 T (Treg) 세포: 면역 반응을 조절하고 자기 관용을 유지하는 데 도움을 줍니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "활성화된 대식세포: 식세포 활동이 강화되고 암세포를 공격합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "자연살해 (NK) 세포: 표적 세포를 공격하고 파괴하며, 항체 의존성 세포 매개 세포독성(ADCC)에 참여합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "항체 의존성 세포 매개 세포독성 (ADCC)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "원생동물과 헬민스는 식세포 작용으로 삼키기에는 너무 큽니다. 원생동물 또는 헬민스 표적 세포는 항체로 코팅됩니다. 면역계 세포는 항체의 Fc 영역에 부착합니다. 표적 세포는 면역계 세포가 분비하는 화학 물질에 의해 용해됩니다. 많은 기생충과 같이 식세포에 의해 섭취하기에는 너무 큰 유기체는 외부에서 공격받아야 합니다. 호산구는 기생성 흡충의 유충 단계에 부착합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 세포성 면역의 과정을 상세히 설명하며, T 세포, 항원제시세포(APCs) 및 이들의 상호작용에 중점을 둡니다. T 세포의 성숙 과정과 다양한 T 세포 유형(TH1, TH2, TH17, 세포독성 T 림프구, 조절 T 세포)의 기능, 그리고 이들이 세포내 병원체 퇴치, 면역 반응 조절 및 특정 면역 반응 매개에 어떻게 기여하는지 다룹니다. 또한, 자연살해(NK) 세포의 세포외 살상 역할과 대형 기생충에 대한 항체 의존성 세포 매개 세포독성(ADCC) 기전도 설명합니다.",
            "keyConcepts": [
              {
                "term": "T 세포의 성숙 및 기능",
                "definition": "흉선에서 성숙하며, 세포내 병원체와 싸우고 항원제시세포(APCs)가 제시하는 항원에 특이적으로 반응하는 림프구."
              },
              {
                "term": "항원제시세포 (APCs)",
                "definition": "미생물을 삼켜 분해하고 그 항원 조각을 MHC 분자를 통해 T 세포에 제시하여 T 세포 반응을 유도하는 세포 (예: 수지상 세포, 대식세포)."
              },
              {
                "term": "T 세포 유형 및 역할",
                "definition": "CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)는 다른 면역 세포의 활성화를 돕고, CD8+ T 세포(세포독성 T 림프구)는 감염된 세포를 직접 파괴하며, 조절 T 세포는 면역 반응을 억제하여 자기 관용을 유지한다."
              },
              {
                "term": "세포독성 T 림프구 (CTLs) 및 세포자멸사 (Apoptosis)",
                "definition": "CTL은 감염된 자가 세포를 인식하여 퍼포린과 그랜자임을 방출, 세포자멸사(프로그램된 세포 사멸)를 유도하여 바이러스 확산을 막는다."
              },
              {
                "term": "자연살해(NK) 세포 및 항체 의존성 세포 매개 세포독성 (ADCC)",
                "definition": "NK 세포는 MHC class I을 발현하지 않는 세포를 파괴하며, ADCC는 항체로 코팅된 표적 세포를 면역 세포가 용해시키는 기전으로, 특히 대형 기생충에 효과적이다."
              }
            ],
            "importantTerms": [
              {
                "term": "T 세포 (T cell)",
                "definition": "흉선에서 성숙하며 세포내 병원체와 싸우는 림프구."
              },
              {
                "term": "항원제시세포 (Antigen-Presenting Cells, APCs)",
                "definition": "미생물을 삼켜 분해하고 T 세포에 항원을 제시하는 세포 (예: 수지상 세포, 대식세포)."
              },
              {
                "term": "MHC (Major Histocompatibility Complex)",
                "definition": "항원 제시를 위해 세포 표면에 항원 조각을 표시하는 분자."
              },
              {
                "term": "T 도우미 세포 (T Helper cells, TH)",
                "definition": "CD4+ T 세포로, B 세포와 사이토카인 신호를 주고받으며 다른 면역 세포의 활성화를 돕는다."
              },
              {
                "term": "세포독성 T 림프구 (Cytotoxic T Lymphocytes, CTLs)",
                "definition": "CD8+ T 세포로, 감염된 자가 세포를 인식하고 세포자멸사를 유도하여 파괴한다."
              },
              {
                "term": "세포자멸사 (Apoptosis)",
                "definition": "프로그램된 세포 사멸로, 감염성 바이러스가 다른 세포로 퍼지는 것을 방지한다."
              },
              {
                "term": "자연살해 세포 (Natural Killer cells, NK cells)",
                "definition": "MHC class I 자가 항원을 발현하지 않는 세포를 파괴하며, 바이러스 감염 세포, 종양 세포 및 기생충을 공격한다."
              },
              {
                "term": "항체 의존성 세포 매개 세포독성 (Antibody-Dependent Cell-mediated Cytotoxicity, ADCC)",
                "definition": "항체로 코팅된 표적 세포를 면역 세포가 파괴하는 기전."
              }
            ],
            "outline": [
              {
                "text": "세포성 면역 반응 과정",
                "id": "세포성-면역-반응-과정",
                "children": [
                  {
                    "text": "T 세포의 역할과 성숙",
                    "id": "t-세포의-역할과-성숙",
                    "children": null
                  },
                  {
                    "text": "소화관 내 병원체 처리",
                    "id": "소화관-내-병원체-처리",
                    "children": null
                  }
                ]
              },
              {
                "text": "항원제시세포 (APCs)",
                "id": "항원제시세포-apcs",
                "children": [
                  {
                    "text": "수지상 세포 (Dendritic cells, DCs)",
                    "id": "수지상-세포-dendritic-cells-dcs",
                    "children": null
                  },
                  {
                    "text": "대식세포 (Macrophages)",
                    "id": "대식세포-macrophages",
                    "children": null
                  }
                ]
              },
              {
                "text": "항원 처리 및 제시: MHC",
                "id": "항원-처리-및-제시-mhc",
                "children": null
              },
              {
                "text": "T 세포의 종류",
                "id": "t-세포의-종류",
                "children": [
                  {
                    "text": "CD4+ T 세포",
                    "id": "cd4-t-세포",
                    "children": null
                  },
                  {
                    "text": "CD8+ T 세포",
                    "id": "cd8-t-세포",
                    "children": null
                  }
                ]
              },
              {
                "text": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
                "id": "t-도우미-세포-cd4-t-세포의-활성화-및-분화",
                "children": [
                  {
                    "text": "TH17 세포",
                    "id": "th17-세포",
                    "children": null
                  },
                  {
                    "text": "TH1 세포",
                    "id": "th1-세포",
                    "children": null
                  },
                  {
                    "text": "TH2 세포",
                    "id": "th2-세포",
                    "children": null
                  }
                ]
              },
              {
                "text": "조절 T 세포 (Treg)",
                "id": "조절-t-세포-treg",
                "children": null
              },
              {
                "text": "세포독성 T 림프구 (CD8+ T 세포)",
                "id": "세포독성-t-림프구-cd8-t-세포",
                "children": [
                  {
                    "text": "세포자멸사 (Apoptosis)",
                    "id": "세포자멸사-apoptosis",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역계에 의한 세포외 살상",
                "id": "면역계에-의한-세포외-살상",
                "children": [
                  {
                    "text": "자연살해 (NK) 세포",
                    "id": "자연살해-nk-세포",
                    "children": null
                  }
                ]
              },
              {
                "text": "세포성 면역에 관여하는 주요 세포 기능",
                "id": "세포성-면역에-관여하는-주요-세포-기능",
                "children": null
              },
              {
                "text": "항체 의존성 세포 매개 세포독성 (ADCC)",
                "id": "항체-의존성-세포-매개-세포독성-adcc",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "T 세포가 성숙하는 주요 장소는 어디인가요?",
              "options": [
                "골수",
                "비장",
                "흉선",
                "림프절"
              ],
              "answerIndex": 2,
              "explanation": "T 세포는 흉선(thymus)에서 성숙 과정을 거칩니다."
            },
            {
              "question": "다음 중 세포독성 T 림프구(CTL)의 주된 기능은 무엇인가요?",
              "options": [
                "B 세포 활성화",
                "대식세포 활성화",
                "감염된 자가 세포 파괴",
                "염증 반응 촉진"
              ],
              "answerIndex": 2,
              "explanation": "세포독성 T 림프구(CTL)는 감염된 자가 세포나 암세포를 인식하고 세포자멸사를 유도하여 파괴하는 역할을 합니다."
            },
            {
              "question": "다음 중 항원제시세포(APC)에 해당하지 않는 것은 무엇인가요?",
              "options": [
                "수지상 세포",
                "대식세포",
                "T 도우미 세포",
                "B 세포"
              ],
              "answerIndex": 2,
              "explanation": "수지상 세포, 대식세포, B 세포는 모두 항원제시세포(APC)의 역할을 수행합니다. T 도우미 세포는 APC에 의해 활성화되는 세포이지, 스스로 항원을 제시하는 세포는 아닙니다."
            }
          ]
        },
        {
          "title": "적응성 면역: 면역학적 기억 및 면역 유형",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75f3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1056 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "면역학적 기억",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "이차 (기억 또는 아남네스틱) 반응은 항원에 두 번째 노출된 후에 발생합니다. 이 반응은 더 빠르고, 며칠 동안 지속되며, 그 규모가 훨씬 더 큽니다. 초기 노출에 반응하여 생성된 기억 세포는 이차 노출에 의해 활성화됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "초기 IgM 반응이 IgG, IgE 또는 IgA로 전환되는 '클래스 전환(Class switching)' 현상이 이차 반응에서 발생합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항체 역가(Antibody titer)는 혈청 내 항체의 상대적인 양을 나타내며, 체액 면역 반응의 강도를 반영합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "체액 면역",
              "level": 1
            },
            {
              "type": "heading",
              "content": "일차 면역 반응",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "제공된 텍스트에는 일차 면역 반응에 대한 구체적인 내용은 포함되어 있지 않습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "이차 면역 반응",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "이차 면역 반응은 '면역학적 기억' 섹션에서 상세히 설명된 바와 같이, 항원에 대한 두 번째 노출 시 발생하는 빠르고 강력하며 지속적인 반응입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "적응성 면역의 유형",
              "level": 1
            },
            {
              "type": "heading",
              "content": "자연 획득 면역",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "자연 획득 능동 면역은 감염을 통해 발생하며, 신체가 항원에 직접 노출되어 면역 반응을 일으키고 기억 세포를 형성하는 것을 의미합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "자연 획득 수동 면역은 태반을 통해 또는 초유를 통해 어머니로부터 항체를 전달받아 발생하는 면역입니다. 이는 일시적인 면역을 제공합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "인공 획득 면역",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "인공 획득 능동 면역은 예방 접종(백신 접종)을 통해 발생합니다. 이는 약화되거나 비활성화된 항원을 주입하여 신체 스스로 면역 반응을 일으키고 기억 세포를 형성하도록 유도합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "인공 획득 수동 면역은 항체 주사를 통해 발생합니다. 이는 특정 질병에 대한 즉각적인 보호를 제공하지만, 신체가 스스로 면역 반응을 일으킨 것이 아니므로 기억 세포가 형성되지 않아 일시적입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "관련 용어",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "혈청(Antiserum)은 항체를 포함하는 혈액 유래 액체입니다. 혈청학(Serology)은 항체와 항원 간의 반응을 연구하는 학문입니다. 글로불린(Globulins)은 혈청 단백질을 총칭하며, 감마(γ) 글로불린은 항체를 포함하는 혈청 분획입니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 면역학적 기억과 적응성 면역의 다양한 유형에 대해 설명합니다. 면역학적 기억은 항원에 두 번째 노출되었을 때 발생하는 이차 면역 반응(더 빠르고 강력하며 지속적)의 특징과 클래스 전환, 그리고 항체 역가의 개념을 포함합니다. 적응성 면역은 자연 획득(능동/수동)과 인공 획득(능동/수동) 면역으로 분류되며, 각각의 특징과 발생 원리를 다룹니다. 또한, 혈청, 혈청학, 글로불린, 감마 글로불린과 같은 관련 용어의 정의도 제공합니다.",
            "keyConcepts": [
              {
                "term": "면역학적 기억",
                "definition": "항원에 대한 첫 노출 후 형성되어, 재노출 시 더 빠르고 강력한 이차 면역 반응을 유도하는 능력."
              },
              {
                "term": "이차 면역 반응",
                "definition": "항원에 두 번째 노출되었을 때 나타나는 면역 반응으로, 일차 반응보다 빠르고 강하며 오래 지속되는 특징을 가집니다."
              },
              {
                "term": "적응성 면역의 유형",
                "definition": "면역 획득 방식에 따라 자연 획득 능동/수동 면역과 인공 획득 능동/수동 면역으로 나뉩니다."
              },
              {
                "term": "클래스 전환",
                "definition": "초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상."
              }
            ],
            "importantTerms": [
              {
                "term": "이차 (기억 또는 아남네스틱) 반응",
                "definition": "항원에 두 번째 노출되었을 때 발생하는 면역 반응."
              },
              {
                "term": "클래스 전환",
                "definition": "면역 반응 시 초기 IgM 항체에서 IgG, IgE, IgA 등 다른 항체 유형으로 전환되는 현상."
              },
              {
                "term": "항체 역가",
                "definition": "혈청 내 항체의 상대적인 양을 나타내는 지표."
              },
              {
                "term": "자연 획득 능동 면역",
                "definition": "감염을 통해 자연적으로 항원에 노출되어 획득하는 면역."
              },
              {
                "term": "인공 획득 능동 면역",
                "definition": "예방 접종(백신)을 통해 인위적으로 항원에 노출되어 획득하는 면역."
              },
              {
                "term": "혈청",
                "definition": "항체를 포함하는 혈액 유래 액체."
              },
              {
                "term": "감마 글로불린",
                "definition": "항체를 포함하는 혈청 단백질 분획."
              }
            ],
            "outline": [
              {
                "text": "면역학적 기억",
                "id": "immunological-memory",
                "children": [
                  {
                    "text": "이차 면역 반응의 특성",
                    "id": "secondary-immune-response-characteristics",
                    "children": null
                  },
                  {
                    "text": "클래스 전환 및 기억 세포",
                    "id": "class-switching-and-memory-cells",
                    "children": null
                  },
                  {
                    "text": "항체 역가",
                    "id": "antibody-titer",
                    "children": null
                  }
                ]
              },
              {
                "text": "체액 면역",
                "id": "humoral-immunity",
                "children": [
                  {
                    "text": "일차 면역 반응",
                    "id": "primary-immune-response",
                    "children": null
                  },
                  {
                    "text": "이차 면역 반응",
                    "id": "secondary-immune-response-humoral",
                    "children": null
                  }
                ]
              },
              {
                "text": "적응성 면역의 유형",
                "id": "types-of-adaptive-immunity",
                "children": [
                  {
                    "text": "자연 획득 면역",
                    "id": "naturally-acquired-immunity",
                    "children": [
                      {
                        "text": "자연 획득 능동 면역",
                        "id": "naturally-acquired-active-immunity",
                        "children": null
                      },
                      {
                        "text": "자연 획득 수동 면역",
                        "id": "naturally-acquired-passive-immunity",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "인공 획득 면역",
                    "id": "artificially-acquired-immunity",
                    "children": [
                      {
                        "text": "인공 획득 능동 면역",
                        "id": "artificially-acquired-active-immunity",
                        "children": null
                      },
                      {
                        "text": "인공 획득 수동 면역",
                        "id": "artificially-acquired-passive-immunity",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "관련 용어",
                    "id": "related-terms",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "이차 면역 반응의 주요 특징이 아닌 것은 무엇입니까?",
              "options": [
                "일차 반응보다 느리게 발생한다.",
                "더 오랫동안 지속된다.",
                "규모가 더 크다.",
                "기억 세포에 의해 활성화된다."
              ],
              "answerIndex": 0,
              "explanation": "이차 면역 반응은 일차 반응보다 '더 빠르게' 발생하며, 더 오랫동안 지속되고 규모가 더 크다는 특징을 가집니다."
            },
            {
              "question": "예방 접종(백신 접종)을 통해 획득하는 면역 유형은 무엇입니까?",
              "options": [
                "자연 획득 능동 면역",
                "자연 획득 수동 면역",
                "인공 획득 능동 면역",
                "인공 획득 수동 면역"
              ],
              "answerIndex": 2,
              "explanation": "예방 접종은 인위적으로 항원을 주입하여 신체 스스로 면역 반응을 일으키도록 유도하는 '인공 획득 능동 면역'에 해당합니다."
            },
            {
              "question": "면역학적 기억에서 '클래스 전환'은 무엇을 의미합니까?",
              "options": [
                "면역 세포의 종류가 바뀌는 것",
                "초기 IgM 반응이 다른 유형의 항체(IgG, IgE, IgA)로 바뀌는 것",
                "항체가 항원에 결합하는 방식이 바뀌는 것",
                "면역 반응의 강도가 약해지는 것"
              ],
              "answerIndex": 1,
              "explanation": "클래스 전환은 초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상을 말합니다."
            }
          ]
        },
        {
          "title": "면역학의 실제 적용: 백신",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 3538 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "백신 개요",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "면역학의 실제 적용 중 하나인 백신은 질병 예방에 있어 핵심적인 역할을 합니다. 백신의 역사는 천연두 접종법(Variolation)에서 시작되었는데, 이는 천연두를 피부에 접종하여 질병을 예방하는 방식이었습니다. 이후 제너(Jenner)는 우두를 접종하여 천연두를 예방하는 방법을 발견했습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "백신(Vaccine)이라는 용어는 파스퇴르(Pasteur)에 의해 만들어졌으며, 'vacca'(소)에서 유래했습니다. 백신은 면역을 유도하는 유기체 또는 유기체의 일부 현탁액으로 정의됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "백신의 기능 및 원리",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "백신 접종은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이는 실제 병원체에 노출되었을 때 빠르고 강렬한 이차 면역 반응을 생성하는 데 기여합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "집단 면역(Herd immunity)은 인구 대부분의 면역 상태를 의미하며, 감수성 있는 개체의 부족으로 질병 발생이 산발적으로 나타나게 하여 전염병 확산을 막는 중요한 효과를 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "CDC 권장 세균성 질환 백신",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "미국 질병통제예방센터(CDC)는 다양한 세균성 질환 예방을 위한 백신을 권장하고 있습니다. 이에는 헤모필루스 인플루엔자 b형 수막염, 수막구균성 수막염, 폐렴구균성 폐렴, 파상풍, 디프테리아, 백일해 백신 등이 포함됩니다. 각 백신은 특정 연령대 또는 위험군에 대한 권장 사항과 추가 접종 여부가 명시되어 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "CDC 권장 바이러스성 질환 백신",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "CDC는 또한 수두, A형 간염, B형 간염, 대상포진, 인유두종바이러스, 인플루엔자, 홍역, 유행성 이하선염, 소아마비, 광견병, 로타바이러스, 풍진, 천연두 등 다양한 바이러스성 질환 예방을 위한 백신을 권장하고 있습니다. 이들 백신 역시 접종 대상, 시기, 그리고 추가 접종의 필요성에 대한 구체적인 지침을 따릅니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "백신의 종류 및 특성",
              "level": 1
            },
            {
              "type": "heading",
              "content": "약독화 생백신 (Live attenuated vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "약독화 생백신은 약화된 병원체를 사용하여 실제 감염과 유사한 면역 반응을 유도하며, 평생 지속되는 세포성 및 체액성 면역을 부여합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "불활성화 사백신 (Inactivated killed vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "불활성화 사백신은 생백신보다 안전하지만, 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "서브유닛 백신 (Subunit vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "서브유닛 백신은 항원성 조각을 사용하여 면역 반응을 자극합니다. 유전적 변형을 통해 생산되는 서브유닛 백신을 재조합 백신(Recombinant vaccines)이라고 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "톡소이드 (Toxoids)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "톡소이드는 불활성화된 독소이며, 항독소(Antitoxins)는 독소에 대한 항체를 포함하는 혈청입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "VLP 백신은 온전한 바이러스와 유사하지만 바이러스 유전 물질을 포함하지 않습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "다당류 백신 (Polysaccharide vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "다당류 백신은 병원체의 캡슐 분자로 만들어지며 면역원성이 강하지 않습니다. 캡슐 다당류에 대한 면역 반응이 약한 어린이 질병에 사용되는 백신을 접합 백신(Conjugated vaccines)이라고 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "핵산(DNA) 백신은 DNA에 암호화된 단백질 항원을 생성하기 위해 주사된 DNA를 사용하며, 체액성 및 세포성 면역을 모두 자극합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "재조합 벡터 백신 (Recombinant vector vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "재조합 벡터 백신은 항원을 코딩하는 유전자를 전달하도록 유전적으로 변형된 비병원성 바이러스 또는 박테리아를 사용합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "RNA 백신 (RNA vaccines)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "RNA 백신은 새로운 유형의 백신으로, 특정 항원 단백질을 생산하도록 세포에 지시하는 RNA 서열을 사용합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "백신 생산, 전달 방법 및 제형",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "백신 개발은 동물 숙주를 사용하지 않는 방향으로 발전하고 있으며, 식물을 백신 공급원으로 활용하는 연구도 진행 중입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "경구 백신 및 건조 백신(피부 패치)의 개발이 증가하고 있으며, 나노패치(Nanopatch)는 건조 형태의 백신을 피부에 전달하여 냉장 보관이 필요 없으며 다수의 항원제시세포(APC)를 활용합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "다중 조합 백신, 만성 질환 백신 개발, 그리고 세포성 면역 개발을 위한 \"역 백신학(Reverse vaccinology)\" 연구도 활발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 미국에서는 명반(Alums)과 모노포스포릴 지질 A(monophosphoryl lipid A)만이 승인되어 있으며, 선천 면역 반응을 개선하는 역할을 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "마이크로바이옴과 경구 백신 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "젖산균인 비피도박테리움(Bifidobacterium)은 장내 마이크로바이옴의 정상적인 일부이며, 마이크로바이옴이 경구 백신에 대한 반응을 향상시킬 수 있다는 연구가 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "백신의 안전성",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "드물게 백신이 질병을 유발할 수 있지만, MMR 백신이 자폐증과 연관되어 있다는 의학적 또는 과학적 증거는 없습니다. 백신은 어린이의 감염성 질환을 예방하는 가장 안전하고 효과적인 수단으로 간주됩니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 백신의 역사적 배경, 기능, 다양한 종류, 생산 및 전달 방법, 그리고 안전성에 대해 설명합니다. 백신은 일차 면역 반응을 유도하여 항체와 기억 세포를 형성하고, 이를 통해 집단 면역을 구축하여 질병 확산을 막는 원리를 가지고 있습니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 여러 유형의 백신이 각자의 특성과 함께 소개되며, 아쥬반트의 역할과 백신 안전성에 대한 중요한 정보도 포함되어 있습니다.",
            "keyConcepts": [
              {
                "term": "집단 면역 (Herd Immunity)",
                "definition": "인구 대부분이 면역을 가지게 되어 감수성 개체의 부족으로 질병 발생이 산발적으로 나타나게 하는 현상으로, 전염병 확산을 막는 데 중요합니다."
              },
              {
                "term": "백신의 종류 (Types of Vaccines)",
                "definition": "약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 다양한 백신 유형이 있으며, 각각 다른 방식으로 면역 반응을 유도합니다."
              },
              {
                "term": "아쥬반트 (Adjuvants)",
                "definition": "백신의 효능을 높이고 면역 반응을 강화하기 위해 백신에 첨가되는 화학 물질입니다. 주로 선천 면역 반응을 개선하는 역할을 합니다."
              },
              {
                "term": "기억 세포 (Memory Cells)",
                "definition": "백신 접종 후 형성되는 면역 세포로, 실제 병원체에 재노출되었을 때 빠르고 강렬한 이차 면역 반응을 가능하게 하여 장기적인 면역력을 제공합니다."
              }
            ],
            "importantTerms": [
              {
                "term": "천연두 접종법 (Variolation)",
                "definition": "천연두를 피부에 접종하여 면역을 유도하던 초기 질병 예방 방법입니다."
              },
              {
                "term": "백신 접종 (Vaccination)",
                "definition": "면역을 유도하기 위해 유기체 또는 유기체의 일부를 현탁액 형태로 인체에 주입하는 행위를 말합니다."
              },
              {
                "term": "약독화 생백신 (Live Attenuated Vaccine)",
                "definition": "병원체를 약화시켜 만든 백신으로, 실제 감염과 유사한 면역 반응을 유도하며 세포성 및 체액성 면역을 부여합니다."
              },
              {
                "term": "불활성화 사백신 (Inactivated Killed Vaccine)",
                "definition": "죽은 병원체나 그 일부를 사용하여 만든 백신으로, 약독화 생백신보다 안전하지만 주로 체액성 면역을 유도하고 반복적인 추가 접종이 필요합니다."
              },
              {
                "term": "서브유닛 백신 (Subunit Vaccine)",
                "definition": "병원체의 특정 항원성 조각만을 사용하여 만든 백신으로, 면역 반응을 자극합니다."
              },
              {
                "term": "톡소이드 (Toxoid)",
                "definition": "독소의 독성을 제거하고 면역원성만 남긴 백신으로, 독소에 의해 발생하는 질병을 예방하는 데 사용됩니다."
              },
              {
                "term": "아쥬반트 (Adjuvant)",
                "definition": "백신의 면역 반응을 강화하기 위해 첨가되는 물질로, 백신의 효능을 높이고 선천 면역 반응을 개선합니다."
              }
            ],
            "outline": [
              {
                "text": "백신 개요",
                "id": "백신-개요",
                "children": [
                  {
                    "text": "백신의 역사",
                    "id": "백신의-역사",
                    "children": null
                  },
                  {
                    "text": "백신의 정의",
                    "id": "백신의-정의",
                    "children": null
                  }
                ]
              },
              {
                "text": "백신의 기능 및 원리",
                "id": "백신의-기능-및-원리",
                "children": [
                  {
                    "text": "면역 반응 유도",
                    "id": "면역-반응-유도",
                    "children": null
                  },
                  {
                    "text": "집단 면역",
                    "id": "집단-면역",
                    "children": null
                  }
                ]
              },
              {
                "text": "CDC 권장 백신",
                "id": "cdc-권장-백신",
                "children": [
                  {
                    "text": "세균성 질환 백신",
                    "id": "세균성-질환-백신",
                    "children": null
                  },
                  {
                    "text": "바이러스성 질환 백신",
                    "id": "바이러스성-질환-백신",
                    "children": null
                  }
                ]
              },
              {
                "text": "백신의 종류 및 특성",
                "id": "백신의-종류-및-특성",
                "children": [
                  {
                    "text": "약독화 생백신 (Live attenuated vaccines)",
                    "id": "약독화-생백신-live-attenuated-vaccines",
                    "children": null
                  },
                  {
                    "text": "불활성화 사백신 (Inactivated killed vaccines)",
                    "id": "불활성화-사백신-inactivated-killed-vaccines",
                    "children": null
                  },
                  {
                    "text": "서브유닛 백신 (Subunit vaccines)",
                    "id": "서브유닛-백신-subunit-vaccines",
                    "children": null
                  },
                  {
                    "text": "톡소이드 (Toxoids)",
                    "id": "톡소이드-toxoids",
                    "children": null
                  },
                  {
                    "text": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
                    "id": "바이러스-유사-입자-vlp-백신-virus-like-particle-vlp-vaccines",
                    "children": null
                  },
                  {
                    "text": "다당류 백신 (Polysaccharide vaccines)",
                    "id": "다당류-백신-polysaccharide-vaccines",
                    "children": null
                  },
                  {
                    "text": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
                    "id": "핵산-dna-백신-nucleic-acid-dna-vaccines",
                    "children": null
                  },
                  {
                    "text": "재조합 벡터 백신 (Recombinant vector vaccines)",
                    "id": "재조합-벡터-백신-recombinant-vector-vaccines",
                    "children": null
                  },
                  {
                    "text": "RNA 백신 (RNA vaccines)",
                    "id": "rna-백신-rna-vaccines",
                    "children": null
                  }
                ]
              },
              {
                "text": "백신 생산, 전달 방법 및 제형",
                "id": "백신-생산-전달-방법-및-제형",
                "children": [
                  {
                    "text": "생산 기술의 발전",
                    "id": "생산-기술의-발전",
                    "children": null
                  },
                  {
                    "text": "새로운 전달 방식",
                    "id": "새로운-전달-방식",
                    "children": null
                  },
                  {
                    "text": "아쥬반트의 역할",
                    "id": "아쥬반트의-역할",
                    "children": null
                  }
                ]
              },
              {
                "text": "마이크로바이옴과 경구 백신 반응",
                "id": "마이크로바이옴과-경구-백신-반응",
                "children": null
              },
              {
                "text": "백신의 안전성",
                "id": "백신의-안전성",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "백신 접종이 유도하는 주요 면역학적 반응은 무엇이며, 이 반응의 결과로 형성되는 중요한 세포는 무엇입니까?",
              "options": [
                "일차 면역 반응, 기억 세포",
                "이차 면역 반응, 비만 세포",
                "알레르기 반응, 형질 세포",
                "자가면역 반응, T 세포"
              ],
              "answerIndex": 0,
              "explanation": "백신은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이 기억 세포 덕분에 실제 병원체 노출 시 빠르고 강렬한 이차 면역 반응이 가능해집니다."
            },
            {
              "question": "다음 중 약독화 생백신과 불활성화 사백신의 주요 차이점에 대한 설명으로 올바른 것은 무엇입니까?",
              "options": [
                "약독화 생백신은 평생 면역을 부여하지만, 불활성화 사백신은 추가 접종이 필요하다.",
                "약독화 생백신은 주로 체액성 면역을 유도하고, 불활성화 사백신은 세포성 면역을 유도한다.",
                "약독화 생백신은 불활성화 사백신보다 안전하다.",
                "약독화 생백신은 유전 물질을 포함하지 않지만, 불활성화 사백신은 포함한다."
              ],
              "answerIndex": 0,
              "explanation": "약독화 생백신은 실제 감염과 유사하게 평생 지속되는 세포성 및 체액성 면역을 부여하는 경향이 있는 반면, 불활성화 사백신은 더 안전하지만 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다."
            },
            {
              "question": "백신에 첨가되어 효능을 향상시키고 선천 면역 반응을 개선하는 화학 첨가제는 무엇이라고 불립니까?",
              "options": [
                "항독소",
                "톡소이드",
                "아쥬반트",
                "폴리사카라이드"
              ],
              "answerIndex": 2,
              "explanation": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 선천 면역 반응을 개선하는 역할을 합니다."
            }
          ]
        },
        {
          "title": "면역학의 실제 적용: 진단 면역학",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 2187 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "진단 면역학 개요",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "민감도(Sensitivity): 검사가 진양성 표본에 대해 반응할 확률",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "특이도(Specificity): 양성 검사가 진음성 표본에 대해 반응하지 않을 확률",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역학 기반 진단 검사는 체액 항체와 항원의 상호작용을 이용한다. 알려진 항체를 통해 미지의 병원체를 식별하거나, 알려진 병원체를 통해 미지의 항체를 식별할 수 있다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "단일클론 항체 (Monoclonal Antibodies)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "하이브리도마(Hybridoma): \"불멸의\" 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합한 세포.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "하이브리도마는 단일클론 항체(Mabs)를 생산한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "Mabs는 균일하고, 특이성이 높으며, 대량 생산이 가능하다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "진단 도구 및 인체 치료에 사용된다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "류마티스 관절염에서 TNF를 중화하거나, 비만세포와 호염기구에 IgE 결합을 막아 알레르기성 천식을 치료하는 데 활용된다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "주로 쥐 세포에서 유래하여 부작용을 일으킬 수 있다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "키메라 단일클론 항체: 쥐의 가변 영역과 인간의 불변 영역을 가진 Mabs.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "인간화 항체: 쥐 항원 결합 부위를 제외하고 대부분 인간 유래인 Mabs.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "완전 인간 항체: 쥐에 삽입된 인간 유전자로부터 생산된 Mabs.",
              "level": null
            },
            {
              "type": "heading",
              "content": "단일클론 항체의 생산",
              "level": 2
            },
            {
              "type": "heading",
              "content": "침강 반응 (Precipitation Reactions)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "가용성 항원과 항체가 반응하여 격자(lattices)라고 불리는 크고 서로 맞물린 응집체를 형성하는 반응이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항원-항체 복합체가 형성된 후, 용액에서 침전되는 격자가 형성된다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "침강링 테스트(Precipitin ring test): 최적의 항원-항체 비율 지점에서 흐린 선이 형성된다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역확산 테스트(Immunodiffusion tests): 한천 젤 배지에서 수행되는 침강 반응이다. 최적의 항원-항체 비율 지점에서 침전물이 형성된다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역 전기영동(Immunoelectrophoresis): 전기영동과 면역확산을 결합한 것으로, 인간 혈청의 단백질을 분리한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "응집 반응 (Agglutination Reactions)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "입자성 항원이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "직접 응집 테스트(Direct agglutination tests): 큰 세포성 항원에 대한 항체를 검출한다. 혈청 항체 농도(역가, titer)를 측정하며, 역가 증가는 질병에 대한 더 큰 면역을 나타낸다. 혈청 전환(Seroconversion)은 질병이 진행됨에 따라 역가에 유의미한 변화가 나타나는 것을 의미한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "간접(수동) 응집 테스트(Indirect (passive) agglutination tests): 항체가 입자에 부착된 가용성 항원과 반응하거나 그 반대로 반응한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈구 응집(Hemagglutination): 적혈구 표면 항원과 보체 항체의 응집으로, 혈액형 판별에 사용된다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "진단 면역학 학습 목표 (1)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "응집 테스트와 침강 테스트의 차이점을 구별한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈구 응집을 정의한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "중화 테스트가 어떻게 작동하는지 설명한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "침강 테스트와 중화 테스트의 차이점을 구별한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "보체 고정 테스트의 기본 원리를 설명한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "중화 반응 (Neutralization Reactions)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "바이러스성 혈구 응집(Viral hemagglutination): 바이러스가 항원-항체 반응 없이 적혈구를 응집시키는 현상 (예: 볼거리, 홍역, 인플루엔자).",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항체(항독소)에 의해 외독소나 바이러스의 유해한 효과가 차단되는 항원-항체 반응이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스성 혈구 응집 억제 테스트(Viral hemagglutination inhibition test): 바이러스 아형을 분류하는 데 사용된다. 바이러스와 적혈구를 환자의 혈청과 혼합한다. 혈청에 바이러스에 대한 항체가 포함되어 있으면, 항체가 바이러스를 중화하여 혈구 응집을 억제한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "보체 고정 반응 (Complement-Fixation Reactions)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "보체 고정(Complement fixation): 보체 혈청 단백질이 항원-항체 복합체에 결합하고 고정되는 반응이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "소량의 항체를 검출할 수 있다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "침강 또는 응집 반응에 적합하지 않은 항체에도 사용될 수 있다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "진단 면역학 학습 목표 (2)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "직접 및 간접 형광 항체 테스트를 비교하고 대조한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "직접 및 간접 ELISA 테스트가 어떻게 작동하는지 설명한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "웨스턴 블롯이 어떻게 작동하는지 설명한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "단일클론 항체의 중요성을 설명한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "형광 염료를 항체와 결합시킨다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "직접 FA 테스트: 임상 검체에서 미생물을 식별한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "간접 FA 테스트: 혈청에서 특정 항체를 검출한다. 항인간 면역 혈청 글로불린(anti-HISG)을 추가하며, 결과가 양성이면 혈청 내 모든 항체와 반응한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "형광 활성화 세포 분류기(Fluorescence-activated cell sorter, FACS): 레이저 빔이 세포를 포함하는 액적에 닿으면, 감지기가 표면 분자의 크기와 형광을 측정한다. 세포에 전하를 부여하여 세포를 분리한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "효소결합 면역흡착 분석법 (ELISA)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "직접 ELISA: 항원을 검출한다. 항원을 포함하는 샘플을 항체와 혼합한다. 효소 연결 항체가 항원과 반응한다. 연결된 효소를 위한 기질을 추가하여 색이 생성되는 것으로 검출한다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "간접 ELISA: 항체를 검출한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "웨스턴 블롯 (Western Blotting)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "전기영동과 블롯을 통해 단백질을 식별한다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "진단 및 치료 면역학의 미래",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "인간의 판단과 인력이 덜 필요한 테스트가 개발될 것이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "PCR 및 DNA 프로브가 활용될 것이다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "개발도상국을 위한 저렴하고 간단한 테스트가 필요하다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "질병 예방 및 치료에 기여할 것이다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 면역학의 실제 적용, 특히 진단 면역학에 대해 설명합니다. 검사의 민감도와 특이도 같은 기본 개념부터 시작하여, 단일클론 항체의 생산, 종류 및 치료적 활용에 대해 다룹니다. 또한, 침강 반응, 응집 반응, 중화 반응, 보체 고정 반응, 형광 항체 기법, ELISA, 웨스턴 블롯 등 다양한 면역학 기반 진단 테스트의 원리와 적용 방법을 상세히 설명합니다. 마지막으로 진단 및 치료 면역학의 미래 방향에 대해서도 간략하게 언급합니다.",
            "keyConcepts": [
              {
                "term": "진단 면역학의 기본 원리",
                "definition": "검사의 민감도(Sensitivity)와 특이도(Specificity)는 진단 검사의 정확성을 나타내는 핵심 지표이며, 항원-항체 상호작용이 면역학 기반 진단 테스트의 근간을 이룬다."
              },
              {
                "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                "definition": "하이브리도마 기술을 통해 대량 생산되는 균일하고 고도로 특이적인 항체로, 진단 및 류마티스 관절염, 알레르기성 천식 등 다양한 질병의 치료에 활용된다. 쥐 유래 항체는 부작용을 일으킬 수 있어 키메라, 인간화, 완전 인간 항체 등으로 발전하고 있다."
              },
              {
                "term": "면역 반응 기반 진단 테스트 유형",
                "definition": "침강(Precipitation), 응집(Agglutination), 중화(Neutralization), 보체 고정(Complement-Fixation), 형광 항체(Fluorescent-Antibody), ELISA(Enzyme-Linked Immunosorbent Assay), 웨스턴 블롯(Western Blotting) 등 항원-항체 반응을 시각적으로 또는 정량적으로 확인하여 질병을 진단하는 다양한 기법들이 있다."
              },
              {
                "term": "항체 역가 측정",
                "definition": "직접 응집 테스트 등을 통해 혈청 내 특정 항체의 농도(역가)를 측정하는 것으로, 역가 증가는 질병에 대한 면역력 증가를 나타내며, 혈청 전환은 질병 진행에 따른 역가의 유의미한 변화를 의미한다."
              }
            ],
            "importantTerms": [
              {
                "term": "민감도 (Sensitivity)",
                "definition": "검사가 진양성 표본에 대해 반응할 확률"
              },
              {
                "term": "특이도 (Specificity)",
                "definition": "양성 검사가 진음성 표본에 대해 반응하지 않을 확률"
              },
              {
                "term": "하이브리도마 (Hybridoma)",
                "definition": "암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포"
              },
              {
                "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                "definition": "하이브리도마에서 생산되는 균일하고 특이성이 높은 항체로, 진단 및 치료에 사용된다."
              },
              {
                "term": "침강 반응 (Precipitation Reactions)",
                "definition": "가용성 항원과 항체가 반응하여 불용성 복합체(격자)를 형성하고 침전되는 반응"
              },
              {
                "term": "응집 반응 (Agglutination Reactions)",
                "definition": "입자성 항원(예: 세포)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응"
              },
              {
                "term": "중화 반응 (Neutralization Reactions)",
                "definition": "항체가 독소나 바이러스의 유해한 효과를 차단하는 항원-항체 반응"
              },
              {
                "term": "보체 고정 반응 (Complement-Fixation Reactions)",
                "definition": "보체 단백질이 항원-항체 복합체에 결합하고 고정되는 반응으로, 소량의 항체도 검출 가능하다."
              },
              {
                "term": "효소결합 면역흡착 분석법 (ELISA)",
                "definition": "효소와 항체를 이용하여 항원 또는 항체를 검출하는 면역학적 분석법으로, 색 변화를 통해 결과를 확인한다."
              },
              {
                "term": "웨스턴 블롯 (Western Blotting)",
                "definition": "전기영동으로 분리된 단백질을 막에 옮겨 특정 항체를 이용하여 식별하는 기법"
              }
            ],
            "outline": [
              {
                "text": "진단 면역학 개요",
                "id": "진단-면역학-개요",
                "children": null
              },
              {
                "text": "단일클론 항체 (Monoclonal Antibodies)",
                "id": "단일클론-항체-monoclonal-antibodies",
                "children": [
                  {
                    "text": "단일클론 항체의 생산",
                    "id": "단일클론-항체의-생산",
                    "children": null
                  }
                ]
              },
              {
                "text": "침강 반응 (Precipitation Reactions)",
                "id": "침강-반응-precipitation-reactions",
                "children": null
              },
              {
                "text": "응집 반응 (Agglutination Reactions)",
                "id": "응집-반응-agglutination-reactions",
                "children": null
              },
              {
                "text": "진단 면역학 학습 목표 (1)",
                "id": "진단-면역학-학습-목표-1",
                "children": null
              },
              {
                "text": "중화 반응 (Neutralization Reactions)",
                "id": "중화-반응-neutralization-reactions",
                "children": null
              },
              {
                "text": "보체 고정 반응 (Complement-Fixation Reactions)",
                "id": "보체-고정-반응-complement-fixation-reactions",
                "children": null
              },
              {
                "text": "진단 면역학 학습 목표 (2)",
                "id": "진단-면역학-학습-목표-2",
                "children": null
              },
              {
                "text": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
                "id": "형광-항체-기법-fluorescent-antibody-techniques",
                "children": null
              },
              {
                "text": "효소결합 면역흡착 분석법 (ELISA)",
                "id": "효소결합-면역흡착-분석법-elisa",
                "children": null
              },
              {
                "text": "웨스턴 블롯 (Western Blotting)",
                "id": "웨스턴-블롯-western-blotting",
                "children": null
              },
              {
                "text": "진단 및 치료 면역학의 미래",
                "id": "진단-및-치료-면역학의-미래",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "다음 중 하이브리도마(Hybridoma)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
              "options": [
                "암성 B 세포와 항체 생산 정상 B 세포를 결합한 세포",
                "항원을 직접 생산하는 세포",
                "체내에서 바이러스성 감염을 중화하는 세포",
                "면역 반응을 억제하는 데 사용되는 세포"
              ],
              "answerIndex": 0,
              "explanation": "하이브리도마는 '불멸의' 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포입니다."
            },
            {
              "question": "침강 반응(Precipitation Reactions)과 응집 반응(Agglutination Reactions)의 주요 차이점은 무엇입니까?",
              "options": [
                "침강 반응은 가용성 항원을, 응집 반응은 입자성 항원을 사용한다.",
                "침강 반응은 항체를 검출하고, 응집 반응은 항원을 검출한다.",
                "침강 반응은 육안으로 볼 수 없지만, 응집 반응은 육안으로 볼 수 있다.",
                "침강 반응은 보체를 필요로 하지만, 응집 반응은 그렇지 않다."
              ],
              "answerIndex": 0,
              "explanation": "침강 반응은 가용성 항원과 항체의 상호작용으로 불용성 복합체가 형성되는 것이고, 응집 반응은 입자성 항원(예: 세포 또는 입자에 부착된 항원)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 것입니다."
            },
            {
              "question": "효소결합 면역흡착 분석법(ELISA)에 대한 설명으로 옳지 않은 것은 무엇입니까?",
              "options": [
                "직접 ELISA는 항원을 검출하는 데 사용된다.",
                "간접 ELISA는 항체를 검출하는 데 사용된다.",
                "효소 연결 항체가 항원 또는 항체와 반응하여 색 변화를 유도한다.",
                "ELISA는 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법이다."
              ],
              "answerIndex": 3,
              "explanation": "ELISA는 효소와 항체를 이용하여 항원 또는 항체를 검출하며 색 변화를 통해 결과를 확인합니다. 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법은 웨스턴 블롯(Western Blotting)입니다."
            }
          ]
        },
        {
          "title": "면역 시스템 관련 질환: 과민 반응",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 3760 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "과민 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "과민 반응(Hypersensitivity)은 정상 범위를 넘어선 과도한 항원(알레르겐) 반응을 의미합니다. 이는 이전에 항원에 노출되어 민감해진 경우에 발생합니다. 과민 반응은 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 유형으로 분류됩니다. 과민 반응을 연구하는 학문은 면역병리학(Immunopathology)이라고 합니다. 위생 가설(Hygiene hypothesis)은 병원균에 대한 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다고 제안합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "과민 반응의 유형",
              "level": 1
            },
            {
              "type": "heading",
              "content": "제1형 (아나필락시스형)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "임상 증상 발현까지 30분 미만이 소요됩니다. IgE 항체가 비만세포나 호염기구에 결합하여 비만세포 또는 호염기구의 탈과립을 유발하고 히스타민과 같은 반응성 물질을 방출하게 합니다. 약물 주사 및 곤충 독에 의한 아나필락시스 쇼크, 건초열, 천식과 같은 일반적인 알레르기 증상이 여기에 해당합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제2형 (세포 독성형)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "임상 증상 발현까지 5-12시간이 소요됩니다. 항원이 표적 세포에 결합하는 IgM 및 IgG 항체 형성을 유발하며, 보체의 작용과 결합하여 표적 세포를 파괴합니다. 수혈 반응, Rh 부적합성이 여기에 해당합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제3형 (면역 복합체형)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "임상 증상 발현까지 3-8시간이 소요됩니다. 항체와 항원이 복합체를 형성하여 손상적인 염증을 유발합니다. 아르투스 반응, 혈청병이 여기에 해당합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제4형 (지연형 세포 매개성 또는 지연형 과민 반응)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "임상 증상 발현까지 24-48시간이 소요됩니다. 항원이 세포독성 T 림프구(CTLs)를 활성화시켜 표적 세포를 사멸시킵니다. 이식 조직 거부 반응, 옻나무에 의한 접촉 피부염, 특정 만성 질환(예: 결핵) 등이 여기에 해당합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제1형 (아나필락시스형) 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "이 반응은 항원에 민감해진 사람이 해당 항원에 재노출된 후 수 분 내에 발생합니다. 항원이 IgE 항체와 결합하며, IgE는 비만세포와 호염기구에 부착됩니다. 비만세포와 호염기구는 탈과립을 겪으며 다음과 같은 매개체를 방출합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 히스타민: 혈액 모세혈관의 투과성을 증가시킵니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 류코트리엔: 평활근의 지속적인 수축을 유발합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "• 프로스타글란딘: 평활근에 영향을 미치고 점액 분비를 증가시킵니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항원에 반응하여 생성된 IgE 항체는 비만세포와 호염기구를 감싸게 됩니다. 항원이 동일한 특이성을 가진 두 개의 인접한 항체 분자 사이의 간격을 연결할 때, 세포는 탈과립을 겪고 히스타민 및 기타 매개체를 방출합니다. 이는 항원과 반응하여 히스타민 및 기타 반응성 매개체 과립을 방출한 탈과립 비만세포의 모습입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "전신 아나필락시스 (아나필락시스 쇼크)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "항원에 민감해진 개체가 다시 노출될 때 발생합니다. 순환계 허탈 및 사망에 이를 수 있으며, 에피네프린으로 치료합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "국소 아나필락시스",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "주로 섭취되거나 흡입된 항원과 관련이 있습니다. 증상은 침입 경로에 따라 다르며, 두드러기, 건초열, 천식 등이 포함됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "아나필락시스 반응 예방",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "알레르겐을 식별하기 위한 피부 검사는 항원을 표피 아래에 접종하여 빠른 염증 반응(팽진)을 확인합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "탈감작(Desensitization)은 항원을 피부 아래에 증가하는 용량으로 주사하는 방법입니다. 이는 IgG를 생성하게 하는데, 이 IgG는 블로킹 항체(blocking antibodies) 역할을 하여 항원을 가로채고 중화시킵니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제2형 (세포 독성형) 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "IgG 또는 IgM 항체와 항원성 세포의 결합에 의한 보체 활성화로 발생합니다. 이는 세포 용해 또는 대식세포에 의한 손상을 유발합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "ABO 혈액형 시스템",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "적혈구에 있는 특정 탄수화물 항원에 대해 항체가 형성됩니다. A 항원, B 항원 또는 둘 다를 가질 수 있습니다. O형 적혈구는 항원이 없습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "Rh 혈액형 시스템",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "인구의 85%에서 적혈구에 Rh 인자 항원(Rh+)이 발견됩니다. Rh+ 혈액이 Rh- 수혈자에게 주입되면 수혈자의 몸에서 항Rh 항체 생성을 자극합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "용혈성 신생아 질환 (HDNB)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "Rh- 어머니가 Rh+ 태아를 임신할 경우 어머니의 몸에서 항Rh 항체가 생성됩니다. 첫 Rh+ 태아를 임신한 Rh- 어머니의 경우, 분만 중 태아의 Rh 항원이 어머니의 혈액으로 들어갈 수 있습니다. 이 태아 Rh 항원에 반응하여 어머니는 항Rh 항체를 생산할 것입니다. 두 번째 Rh+ 태아를 임신하게 되면, 어머니의 항Rh 항체가 태반을 통과하여 태아의 적혈구를 손상시킬 것입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "약물 유발 세포 독성 반응",
              "level": 2
            },
            {
              "type": "heading",
              "content": "혈소판 감소성 자반증 (Thrombocytopenic purpura)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "혈소판이 약물과 결합하여 항원성 복합체를 형성합니다. 항체와 보체가 혈소판을 파괴합니다. 약물(합텐)이 혈소판에 결합하여 합텐-혈소판 복합체를 형성합니다. 이 복합체는 합텐에 대한 항체 형성을 유도합니다. 항체와 보체의 작용은 혈소판 파괴를 일으킵s니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "무과립구증 (Agranulocytosis)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "약물 유발 과립구의 면역 파괴입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "용혈성 빈혈 (Hemolytic anemia)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "약물 유발 적혈구의 면역 파괴입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제3형 (면역 복합체형) 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "항체가 혈청 내 가용성 항원에 대해 형성됩니다. 세포 아래 기저막에 침착되는 면역 복합체를 형성하여 보체를 활성화시키고 염증을 유발합니다. 면역 복합체는 혈관벽에 침착됩니다. 면역 복합체의 존재는 보체를 활성화시키고 호중구와 같은 염증 세포를 유인합니다. 호중구에서 방출된 효소는 기저막의 내피 세포에 손상을 입힙니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "아르투스 반응 (Arthus reaction)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "톡소이드 함유 백신의 드문 부작용입니다. 주사된 항원에 대해 이미 순환하는 IgG를 가진 환자에서 보체 활성화로 인해 사구체 및 기타 혈관벽에서 발생합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "혈청병 (Serum sickness)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "이종 혈청 주입으로 인한 부종 및 염증과 함께 발생할 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "제4형 (지연형 세포 매개성) 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "T 세포에 의해 유발되는 세포 매개 면역 반응입니다. 이는 지연형 과민 반응으로 알려져 있습니다. 항원은 식세포화되어 T 세포 수용체에 제시되어 민감화를 유발합니다. 항원에 재노출되면 기억 세포가 파괴적인 사이토카인을 방출합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "알레르기성 접촉 피부염 (Allergic contact dermatitis)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "합텐이 피부의 단백질과 결합하여 면역 반응을 일으킵니다. 옻나무, 화장품, 금속, 라텍스 등에 대한 알레르기 반응이 여기에 해당합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "본문은 면역 시스템 관련 질환 중 '과민 반응'에 대해 설명합니다. 과민 반응은 정상 범위를 넘어선 과도한 면역 반응으로, 이전 항원 노출로 인해 민감해진 상태에서 발생합니다. 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 주요 유형으로 분류되며, 각 유형은 발현 시간, 기전, 임상 증상 및 예시가 다릅니다. 제1형은 즉각적인 알레르기 반응(예: 아나필락시스 쇼크)을, 제2형은 세포 파괴(예: 수혈 부작용)를, 제3형은 면역 복합체 침착으로 인한 염증(예: 혈청병)을, 제4형은 T세포 매개 지연 반응(예: 접촉 피부염)을 특징으로 합니다. 각 유형의 발생 기전과 예방 및 치료법이 상세히 다루어집니다.",
            "keyConcepts": [
              {
                "term": "과민 반응 (Hypersensitivity)",
                "definition": "정상 범위를 넘어선 과도한 항원 반응으로, 이전에 항원에 노출되어 민감해진 경우에 발생합니다."
              },
              {
                "term": "아나필락시스 (Anaphylaxis)",
                "definition": "제1형 과민 반응의 심각한 형태로, 비만세포 및 호염기구의 탈과립으로 인한 매개체 방출로 발생하며, 전신 또는 국소적으로 나타나 생명을 위협할 수 있습니다."
              },
              {
                "term": "위생 가설 (Hygiene Hypothesis)",
                "definition": "병원균 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다는 가설입니다."
              },
              {
                "term": "탈감작 (Desensitization)",
                "definition": "알레르기 반응을 예방하기 위해 항원을 점진적으로 증가시켜 주사하는 치료법으로, 블로킹 항체(IgG) 생성을 유도하여 알레르겐을 중화시킵니다."
              },
              {
                "term": "용혈성 신생아 질환 (HDNB)",
                "definition": "Rh 혈액형 불일치로 인해 Rh- 어머니가 Rh+ 태아에 대한 항체를 생성하여 두 번째 Rh+ 태아의 적혈구를 파괴하는 질환입니다."
              }
            ],
            "importantTerms": [
              {
                "term": "알레르겐 (Allergen)",
                "definition": "알레르기 반응을 유발하는 항원입니다."
              },
              {
                "term": "면역병리학 (Immunopathology)",
                "definition": "과민 반응을 연구하는 학문입니다."
              },
              {
                "term": "히스타민 (Histamine)",
                "definition": "제1형 과민 반응 시 비만세포에서 방출되어 혈관 투과성을 증가시키는 주요 염증 매개체입니다."
              },
              {
                "term": "류코트리엔 (Leukotrienes)",
                "definition": "제1형 과민 반응 시 방출되어 평활근의 지속적인 수축을 유발하는 매개체입니다."
              },
              {
                "term": "프로스타글란딘 (Prostaglandins)",
                "definition": "제1형 과민 반응 시 방출되어 평활근에 영향을 미치고 점액 분비를 증가시키는 매개체입니다."
              },
              {
                "term": "보체 (Complement)",
                "definition": "면역 반응에서 항체와 함께 작용하여 세포 파괴를 돕는 단백질 시스템입니다."
              },
              {
                "term": "합텐 (Hapten)",
                "definition": "단독으로는 면역 반응을 유발하지 못하지만, 단백질과 결합 시 항원성을 띠는 작은 분자입니다."
              }
            ],
            "outline": [
              {
                "text": "과민 반응의 개요",
                "id": "hypersensitivity-overview",
                "children": [
                  {
                    "text": "정의 및 특징",
                    "id": "definition-features",
                    "children": null
                  },
                  {
                    "text": "과민 반응의 네 가지 유형",
                    "id": "four-types-hypersensitivity",
                    "children": null
                  },
                  {
                    "text": "면역병리학 및 위생 가설",
                    "id": "immunopathology-hygiene-hypothesis",
                    "children": null
                  }
                ]
              },
              {
                "text": "과민 반응 유형별 상세 설명",
                "id": "detailed-hypersensitivity-types",
                "children": [
                  {
                    "text": "제1형 과민 반응 (아나필락시스형)",
                    "id": "type-i-anaphylactic",
                    "children": [
                      {
                        "text": "발생 기전 및 특징",
                        "id": "type-i-mechanism-features",
                        "children": null
                      },
                      {
                        "text": "매개체 (히스타민, 류코트리엔, 프로스타글란딘)",
                        "id": "type-i-mediators",
                        "children": null
                      },
                      {
                        "text": "전신 아나필락시스 및 국소 아나필락시스",
                        "id": "systemic-local-anaphylaxis",
                        "children": null
                      },
                      {
                        "text": "예방 및 치료",
                        "id": "type-i-prevention-treatment",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "제2형 과민 반응 (세포 독성형)",
                    "id": "type-ii-cytotoxic",
                    "children": [
                      {
                        "text": "발생 기전 및 특징",
                        "id": "type-ii-mechanism-features",
                        "children": null
                      },
                      {
                        "text": "ABO 혈액형 시스템",
                        "id": "abo-blood-group",
                        "children": null
                      },
                      {
                        "text": "Rh 혈액형 시스템 및 용혈성 신생아 질환",
                        "id": "rh-blood-group-hdnb",
                        "children": null
                      },
                      {
                        "text": "약물 유발 세포 독성 반응",
                        "id": "drug-induced-cytotoxic",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "제3형 과민 반응 (면역 복합체형)",
                    "id": "type-iii-immune-complex",
                    "children": [
                      {
                        "text": "발생 기전 및 특징",
                        "id": "type-iii-mechanism-features",
                        "children": null
                      },
                      {
                        "text": "아르투스 반응",
                        "id": "arthus-reaction",
                        "children": null
                      },
                      {
                        "text": "혈청병",
                        "id": "serum-sickness",
                        "children": null
                      }
                    ]
                  },
                  {
                    "text": "제4형 과민 반응 (지연형 세포 매개성)",
                    "id": "type-iv-delayed-cell-mediated",
                    "children": [
                      {
                        "text": "발생 기전 및 특징",
                        "id": "type-iv-mechanism-features",
                        "children": null
                      },
                      {
                        "text": "알레르기성 접촉 피부염",
                        "id": "allergic-contact-dermatitis",
                        "children": null
                      }
                    ]
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "제1형 과민 반응 시 혈액 모세혈관의 투과성을 증가시키는 주요 매개체는 무엇입니까?",
              "options": [
                "히스타민",
                "류코트리엔",
                "프로스타글란딘",
                "사이토카인"
              ],
              "answerIndex": 0,
              "explanation": "제1형 과민 반응은 비만세포의 탈과립을 통해 히스타민을 방출하며, 히스타민은 혈액 모세혈관의 투과성을 증가시키는 역할을 합니다."
            },
            {
              "question": "이식 조직 거부 반응 및 접촉 피부염과 주로 관련된 과민 반응 유형은 무엇입니까?",
              "options": [
                "제1형 (아나필락시스형)",
                "제2형 (세포 독성형)",
                "제3형 (면역 복합체형)",
                "제4형 (지연형 세포 매개성)"
              ],
              "answerIndex": 3,
              "explanation": "제4형 과민 반응은 T세포에 의해 매개되는 지연형 반응으로, 이식 조직 거부 반응과 접촉 피부염이 대표적인 예시입니다."
            },
            {
              "question": "아나필락시스 반응 예방을 위한 탈감작의 주요 기전은 무엇입니까?",
              "options": [
                "히스타민 방출 억제",
                "IgE 항체 생성 촉진",
                "비만세포 탈과립 유도",
                "IgG 블로킹 항체 생성"
              ],
              "answerIndex": 3,
              "explanation": "탈감작은 증가하는 용량의 항원 주사를 통해 IgG 블로킹 항체를 생성하게 하여, 이 항체가 알레르겐을 가로채고 중화시켜 IgE 매개 반응을 예방합니다."
            }
          ]
        },
        {
          "title": "자가면역 질환의 이해: 유형 및 주요 사례",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1640 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "자가면역 질환 (AUTOIMMUNE DISEASES)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "면역 체계가 자가 항원에 반응하여 장기에 손상을 입히는 질환입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "자가면역은 자가 관용(self-tolerance)의 상실을 의미합니다. 이는 면역 체계가 자신과 비자신을 구별하는 능력을 잃어버릴 때 발생합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "자가면역 반응은 세포독성(Cytotoxic), 면역 복합체(Immune complex), 또는 세포 매개성(Cell-mediated)의 형태로 나타날 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포독성 자가면역 반응 (CYTOTOXIC AUTOIMMUNE REACTIONS)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "항체가 세포 표면 항원과 반응하여 세포를 손상시키거나 기능을 방해하는 유형입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "다발성 경화증 (Multiple sclerosis)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "자가항체, T 세포, 그리고 대식세포가 신경의 미엘린 수초를 공격하여 신경 임펄스 전달을 손상시킵니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "증상은 피로와 쇠약부터 심한 마비에 이릅니다. 원인은 알려지지 않았지만, 유전적 취약성 및/또는 감염성 물질과 관련될 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "그레이브스병 (Graves' disease)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "갑상선 내 비정상 항체가 과도한 양의 호르몬을 생성하게 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "중증 근무력증 (Myasthenia gravis)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "항체가 아세틸콜린 수용체를 코팅하여 근육이 신경 신호를 받지 못하게 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역 복합체 자가면역 반응 (IMMUNE COMPLEX AUTOIMMUNE REACTIONS)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "항체와 보체의 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "전신성 홍반성 루푸스 (Systemic lupus erythematosus)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "신장 사구체에 면역 복합체가 형성됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "류마티스 관절염 (Rheumatoid arthritis)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "관절에 면역 복합체가 형성됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포 매개성 자가면역 반응 (CELL-MEDIATED AUTOIMMUNE REACTIONS)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "조직을 공격하는 T 세포에 의해 매개되는 유형입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "인슐린 의존성 당뇨병 (Insulin-dependent diabetes mellitus, 1형 당뇨병)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "T 세포가 인슐린 분비 세포를 파괴합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "건선 및 건선성 관절염 (Psoriasis and psoriatic arthritis)",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "피부의 자가면역 질환입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "주요 자가면역 질환 및 원인 (SELECTED AUTOIMMUNE DISORDERS)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "다음은 몇 가지 주요 자가면역 질환과 가능한 원인입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "만성 피로 증후군: 신경 세포의 아세틸콜린 수용체에 항체가 부착되어 발생할 수 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "류마티스 관절염: 연쇄상구균 항체에 대한 교차 반응.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "전신성 홍반성 루푸스: DNA에 대한 항체를 포함하는 면역 복합체.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "다발성 경화증: T 세포와 대식세포가 미엘린 수초를 공격.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1형 당뇨병: T 세포가 인슐린 분비 세포를 파괴.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "길랑-바레 증후군: T 세포가 신경 세포의 미엘린 수초 파괴를 유발하는 사이토카인을 생성.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "건선: T 세포가 각질 형성 세포(피부 세포) 성장을 유도할 수 있는 사이토카인을 생성.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그레이브스병: 갑상선 특정 수용체에 부착된 항체가 갑상선을 비대하게 하고 과도한 호르몬을 생성하게 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "중증 근무력증: 아세틸콜린 수용체에 대한 항체.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "크론병: 항균 항체가 장 점막과 반응.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "염증성 장 질환: 항균 항체가 장 점막과 반응.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "자가면역 질환은 면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 상태입니다. 이는 자가 관용의 상실로 인해 발생하며, 세포독성, 면역 복합체, 세포 매개성 반응의 세 가지 주요 유형으로 분류될 수 있습니다. 각 유형은 특정 질병과 관련이 있으며, 신경, 갑상선, 관절, 췌장 등 다양한 장기에 영향을 미칩니다. 주요 자가면역 질환으로는 다발성 경화증, 그레이브스병, 중증 근무력증, 전신성 홍반성 루푸스, 류마티스 관절염, 1형 당뇨병, 건선 등이 있으며, 각 질환의 원인과 면역학적 메커니즘이 설명됩니다.",
            "keyConcepts": [
              {
                "term": "자가면역",
                "definition": {
                  "easy": null,
                  "medium": "면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 현상입니다.",
                  "hard": null
                }
              },
              {
                "term": "자가 관용",
                "definition": {
                  "easy": null,
                  "medium": "면역 체계가 자신의 항원에 반응하지 않고 구별하는 능력입니다. 자가면역 질환은 이 자가 관용의 상실로 발생합니다.",
                  "hard": null
                }
              },
              {
                "term": "세포독성 자가면역 반응",
                "definition": {
                  "easy": null,
                  "medium": "항체가 세포 표면 항원과 반응하여 세포를 파괴하거나 기능을 손상시키는 유형의 자가면역 반응입니다. (예: 다발성 경화증, 그레이브스병, 중증 근무력증)",
                  "hard": null
                }
              },
              {
                "term": "면역 복합체 자가면역 반응",
                "definition": {
                  "easy": null,
                  "medium": "항체와 항원이 결합하여 형성된 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형의 자가면역 반응입니다. (예: 전신성 홍반성 루푸스, 류마티스 관절염)",
                  "hard": null
                }
              },
              {
                "term": "세포 매개성 자가면역 반응",
                "definition": {
                  "easy": null,
                  "medium": "T 세포가 직접 조직을 공격하여 손상을 일으키는 유형의 자가면역 반응입니다. (예: 1형 당뇨병, 건선)",
                  "hard": null
                }
              }
            ],
            "importantTerms": [
              {
                "term": "자가 항원",
                "definition": "자신의 신체에 존재하는 항원으로, 면역 체계가 실수로 공격하는 대상이 됩니다."
              },
              {
                "term": "미엘린 수초",
                "definition": "신경 세포를 둘러싸고 있는 절연성 막으로, 손상 시 신경 신호 전달에 문제가 발생합니다."
              },
              {
                "term": "아세틸콜린 수용체",
                "definition": "신경 전달 물질인 아세틸콜린이 결합하는 근육 세포 표면의 단백질로, 중증 근무력증에서 항체에 의해 기능이 저해됩니다."
              },
              {
                "term": "면역 복합체",
                "definition": "항체와 항원이 결합하여 형성된 복합체로, 특정 조직에 침착되어 염증을 유발할 수 있습니다."
              },
              {
                "term": "T 세포",
                "definition": "세포 매개 면역 반응을 담당하는 림프구의 일종으로, 일부 자가면역 질환에서 직접 조직을 공격합니다."
              },
              {
                "term": "사구체",
                "definition": "신장의 혈액 여과 단위로, 전신성 홍반성 루푸스에서 면역 복합체가 형성되는 주요 부위입니다."
              },
              {
                "term": "사이토카인",
                "definition": "면역 세포 간의 신호 전달에 관여하는 단백질로, 일부 자가면역 질환에서 조직 손상을 유발할 수 있습니다."
              }
            ],
            "outline": [
              {
                "text": "자가면역 질환 개요",
                "id": "autoimmune-diseases-overview",
                "children": [
                  {
                    "text": "자가면역의 정의 및 특징",
                    "id": "definition-and-characteristics-of-autoimmunity",
                    "children": null
                  },
                  {
                    "text": "주요 반응 유형",
                    "id": "main-types-of-reactions",
                    "children": null
                  }
                ]
              },
              {
                "text": "세포독성 자가면역 반응",
                "id": "cytotoxic-autoimmune-reactions",
                "children": [
                  {
                    "text": "다발성 경화증",
                    "id": "multiple-sclerosis",
                    "children": null
                  },
                  {
                    "text": "그레이브스병",
                    "id": "graves-disease",
                    "children": null
                  },
                  {
                    "text": "중증 근무력증",
                    "id": "myasthenia-gravis",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역 복합체 자가면역 반응",
                "id": "immune-complex-autoimmune-reactions",
                "children": [
                  {
                    "text": "전신성 홍반성 루푸스",
                    "id": "systemic-lupus-erythematosus",
                    "children": null
                  },
                  {
                    "text": "류마티스 관절염",
                    "id": "rheumatoid-arthritis",
                    "children": null
                  }
                ]
              },
              {
                "text": "세포 매개성 자가면역 반응",
                "id": "cell-mediated-autoimmune-reactions",
                "children": [
                  {
                    "text": "인슐린 의존성 당뇨병 (1형 당뇨병)",
                    "id": "insulin-dependent-diabetes-mellitus-type-1",
                    "children": null
                  },
                  {
                    "text": "건선 및 건선성 관절염",
                    "id": "psoriasis-and-psoriatic-arthritis",
                    "children": null
                  }
                ]
              },
              {
                "text": "주요 자가면역 질환 및 원인",
                "id": "selected-autoimmune-disorders-and-causes",
                "children": [
                  {
                    "text": "만성 피로 증후군",
                    "id": "chronic-fatigue-syndrome",
                    "children": null
                  },
                  {
                    "text": "류마티스 관절염",
                    "id": "rheumatoid-arthritis-cause",
                    "children": null
                  },
                  {
                    "text": "전신성 홍반성 루푸스",
                    "id": "systemic-lupus-erythematosus-cause",
                    "children": null
                  },
                  {
                    "text": "다발성 경화증",
                    "id": "multiple-sclerosis-cause",
                    "children": null
                  },
                  {
                    "text": "1형 당뇨병",
                    "id": "type-1-diabetes-cause",
                    "children": null
                  },
                  {
                    "text": "길랑-바레 증후군",
                    "id": "guillain-barre-syndrome",
                    "children": null
                  },
                  {
                    "text": "건선",
                    "id": "psoriasis-cause",
                    "children": null
                  },
                  {
                    "text": "그레이브스병",
                    "id": "graves-disease-cause",
                    "children": null
                  },
                  {
                    "text": "중증 근무력증",
                    "id": "myasthenia-gravis-cause",
                    "children": null
                  },
                  {
                    "text": "크론병",
                    "id": "crohns-disease",
                    "children": null
                  },
                  {
                    "text": "염증성 장 질환",
                    "id": "inflammatory-bowel-disease",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "자가면역 질환에서 면역 체계가 공격하는 대상은 무엇입니까?",
              "options": [
                "외부 병원체",
                "알레르기 유발 물질",
                "자가 항원",
                "독성 물질"
              ],
              "answerIndex": 2,
              "explanation": "자가면역 질환은 면역 체계가 자신의 신체 조직, 즉 자가 항원을 외부 침입자로 오인하여 공격하는 상태입니다."
            },
            {
              "question": "다음 중 세포독성 자가면역 반응에 해당하는 질환이 아닌 것은 무엇입니까?",
              "options": [
                "다발성 경화증",
                "그레이브스병",
                "중증 근무력증",
                "류마티스 관절염"
              ],
              "answerIndex": 3,
              "explanation": "류마티스 관절염은 면역 복합체가 관절에 형성되어 발생하는 면역 복합체 자가면역 반응에 해당합니다. 다발성 경화증, 그레이브스병, 중증 근무력증은 세포독성 자가면역 반응의 예시입니다."
            },
            {
              "question": "1형 당뇨병(인슐린 의존성 당뇨병)의 주요 원인으로 설명된 면역 반응은 무엇입니까?",
              "options": [
                "항체에 의한 아세틸콜린 수용체 코팅",
                "면역 복합체의 신장 사구체 침착",
                "T 세포에 의한 인슐린 분비 세포 파괴",
                "갑상선 항체의 과도한 호르몬 생성 유발"
              ],
              "answerIndex": 2,
              "explanation": "1형 당뇨병은 T 세포가 인슐린을 분비하는 췌장의 세포를 파괴하여 발생하는 세포 매개성 자가면역 반응입니다."
            }
          ]
        },
        {
          "title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1848 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "인간 백혈구 항원(HLA) 복합체 관련 반응",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "조직적합성 항원(Histocompatibility antigens): 세포 표면에 존재하는 자가 항원입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "주요 조직적합성 복합체(MHC): 조직적합성 항원을 암호화하는 유전자입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "인간 백혈구 항원(HLA) 복합체: 인간의 MHC 유전자입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "특정 HLA는 특정 질병에 대한 감수성 증가와 관련이 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HLA 타이핑 및 이식 수술",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "HLA 타이핑은 HLA를 식별하고 비교하는 과정입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이식 수술에서 공여자와 수혜자는 조직 타이핑을 통해 일치해야 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "표준화된 항혈청 또는 HLA에 특이적인 단일클론 항체를 사용합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HLA 타이핑 과정: 검사 중인 림프구에 항-HLA 항체가 부착됩니다. 보체와 트립판 블루 염료가 추가되면, 보체에 의해 손상된 세포가 염료를 흡수합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역 특권 부위 및 면역 특권 조직",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "이식편은 T 세포, 대식세포, 그리고 보체 고정 항체에 의해 공격받을 수 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역 특권 부위 및 면역 특권 조직으로의 이식은 면역 반응을 일으키지 않습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "예시로는 각막 이식, 심장 판막 이식이 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "줄기세포",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "줄기세포는 여러 다른 세포 유형을 생성할 수 있는 마스터 세포입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "배아 줄기세포(ESCs)",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "배반포에서 채취되며, 조직과 장기를 재생하는 데 사용됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "다능성(Pluripotent)으로, 모든 종류의 세포를 생성할 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "성체 줄기세포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "분화된 성체 조직에 있는 줄기세포입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "유전자 도입을 통해 유도만능줄기세포(induced pluripotent stem cells)가 될 수 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "줄기세포 배양 과정: (1일) 일반적으로 시험관 아기 시술에서 폐기된 수정란인 배아가 사용됩니다. (1-5일) 배아는 반복적으로 분열하여 속이 빈 세포 덩어리인 배반포 단계를 형성합니다. 배아줄기세포는 배반포의 속세포덩어리에서 채취되어 배양 배지의 피더(feeder) 세포 위에서 성장합니다. 줄기세포주와 줄기세포 그룹은 배양 배지에서 콜로니를 형성합니다. 다양한 조건과 배양 배지에 추가된 성장 인자는 줄기세포가 신체의 다양한 조직(예: 혈액 및 림프 세포, 췌장 섬 세포, 신경 세포)을 위한 줄기세포주가 되도록 유도합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "골수 이식",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "조혈모세포 이식으로도 알려져 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "수혜자가 건강한 혈액 세포를 생산할 수 있도록 하는 것이 목표입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "면역능력 있는 세포를 포함하는 이식된 골수로 인해 이식편대숙주병(Graft-versus-host, GVH)이 발생할 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "이식편(Grafts)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "자가이식(Autograft): 자신의 조직을 사용하는 것입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "동계이식(Isograft): 일란성 쌍둥이의 조직을 사용하는 것입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "동종이식(Allografts): 다른 사람의 조직을 사용하는 것입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이종이식(Xenotransplantation product): 비인간 조직을 사용하는 것입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "비인간 항원에 대한 반응인 초급성 거부 반응을 극복해야 합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "이식 거부 반응 방지를 위한 면역 억제",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "이식된 조직에 대한 세포 매개 면역 반응을 방지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사이클로스포린(Cyclosporine)과 타크로리무스(tacrolimus)는 IL-2를 억제하여 세포독성 T 세포를 방해합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "시롤리무스(Sirolimus)는 세포성 및 체액성 면역을 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "마이코페놀레이트(Mycophenolate)는 T 세포와 B 세포의 증식을 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바실리시맙(Basiliximab)은 IL-2를 차단하는 키메라 단일클론 항체입니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "제공된 텍스트는 인간 백혈구 항원(HLA) 복합체의 역할과 이식 면역학에서 이의 중요성을 설명합니다. HLA 타이핑을 통한 조직 일치의 필요성, 면역 반응을 일으키지 않는 면역 특권 부위, 그리고 배아 및 성체 줄기세포의 종류와 활용에 대해 다룹니다. 또한, 자가이식, 동계이식, 동종이식, 이종이식과 같은 다양한 이식편의 유형과 이식편대숙주병(GVH)과 같은 이식 관련 합병증을 설명합니다. 마지막으로, 이식 거부 반응을 방지하기 위한 사이클로스포린, 타크로리무스, 시롤리무스, 마이코페놀레이트, 바실리시맙 등 주요 면역 억제제와 그 작용 기전을 소개합니다.",
            "keyConcepts": [
              {
                "term": "인간 백혈구 항원(HLA) 복합체",
                "definition": "인간의 주요 조직적합성 복합체(MHC) 유전자로, 이식 수술에서 조직 일치에 결정적인 역할을 하며 특정 질병 감수성과 관련이 있습니다."
              },
              {
                "term": "줄기세포",
                "definition": "다양한 세포 유형으로 분화할 수 있는 마스터 세포로, 배아 줄기세포와 성체 줄기세포로 나뉩니다. 조직 재생 및 치료에 잠재적으로 활용됩니다."
              },
              {
                "term": "이식편의 종류",
                "definition": "조직의 출처에 따라 자가이식(자신의 조직), 동계이식(일란성 쌍둥이), 동종이식(다른 사람), 이종이식(비인간 조직)으로 분류됩니다."
              },
              {
                "term": "이식 거부 반응 및 GVH 질환",
                "definition": "이식된 조직에 대한 수혜자의 면역 반응(이식 거부 반응) 또는 이식된 면역 세포가 수혜자의 조직을 공격하는 현상(이식편대숙주병)입니다."
              },
              {
                "term": "면역 억제",
                "definition": "이식 거부 반응을 방지하기 위해 특정 약물을 사용하여 수혜자의 면역 반응을 억제하는 치료법입니다."
              }
            ],
            "importantTerms": [
              {
                "term": "조직적합성 항원",
                "definition": "세포 표면에 존재하는 자가 항원입니다."
              },
              {
                "term": "주요 조직적합성 복합체(MHC)",
                "definition": "조직적합성 항원을 암호화하는 유전자입니다."
              },
              {
                "term": "인간 백혈구 항원(HLA) 복합체",
                "definition": "인간의 MHC 유전자입니다."
              },
              {
                "term": "면역 특권 부위",
                "definition": "이식 시 면역 반응을 일으키지 않는 신체 부위 또는 조직입니다."
              },
              {
                "term": "이식편대숙주병(GVH)",
                "definition": "이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격하는 질환입니다."
              },
              {
                "term": "자가이식",
                "definition": "자신의 조직을 사용하는 이식 방법입니다."
              },
              {
                "term": "면역 억제제",
                "definition": "이식 거부 반응을 방지하기 위해 면역 반응을 억제하는 약물입니다."
              }
            ],
            "outline": [
              {
                "text": "인간 백혈구 항원(HLA) 복합체 관련 반응",
                "id": "인간-백혈구-항원-hla-복합체-관련-반응",
                "children": [
                  {
                    "text": "조직적합성 항원",
                    "id": "조직적합성-항원",
                    "children": null
                  },
                  {
                    "text": "주요 조직적합성 복합체(MHC)",
                    "id": "주요-조직적합성-복합체-mhc",
                    "children": null
                  },
                  {
                    "text": "인간 백혈구 항원(HLA) 복합체",
                    "id": "인간-백혈구-항원-hla-복합체",
                    "children": null
                  },
                  {
                    "text": "특정 질병에 대한 감수성",
                    "id": "특정-질병에-대한-감수성",
                    "children": null
                  }
                ]
              },
              {
                "text": "HLA 타이핑 및 이식 수술",
                "id": "hla-타이핑-및-이식-수술",
                "children": [
                  {
                    "text": "HLA 타이핑의 역할",
                    "id": "hla-타이핑의-역할",
                    "children": null
                  },
                  {
                    "text": "조직 타이핑의 중요성",
                    "id": "조직-타이핑의-중요성",
                    "children": null
                  },
                  {
                    "text": "HLA 타이핑 과정",
                    "id": "hla-타이핑-과정",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역 특권 부위 및 면역 특권 조직",
                "id": "면역-특권-부위-및-면역-특권-조직",
                "children": [
                  {
                    "text": "이식 거부 반응의 메커니즘",
                    "id": "이식-거부-반응의-메커니즘",
                    "children": null
                  },
                  {
                    "text": "면역 특권 부위의 특징",
                    "id": "면역-특권-부위의-특징",
                    "children": null
                  },
                  {
                    "text": "예시: 각막 이식, 심장 판막 이식",
                    "id": "예시-각막-이식-심장-판막-이식",
                    "children": null
                  }
                ]
              },
              {
                "text": "줄기세포",
                "id": "줄기세포",
                "children": [
                  {
                    "text": "줄기세포의 정의",
                    "id": "줄기세포의-정의",
                    "children": null
                  },
                  {
                    "text": "배아 줄기세포(ESCs)",
                    "id": "배아-줄기세포-escs",
                    "children": null
                  },
                  {
                    "text": "성체 줄기세포",
                    "id": "성체-줄기세포",
                    "children": null
                  },
                  {
                    "text": "줄기세포 배양 및 분화",
                    "id": "줄기세포-배양-및-분화",
                    "children": null
                  }
                ]
              },
              {
                "text": "골수 이식",
                "id": "골수-이식",
                "children": [
                  {
                    "text": "조혈모세포 이식",
                    "id": "조혈모세포-이식",
                    "children": null
                  },
                  {
                    "text": "골수 이식의 목표",
                    "id": "골수-이식의-목표",
                    "children": null
                  },
                  {
                    "text": "이식편대숙주병(GVH)",
                    "id": "이식편대숙주병-gvh",
                    "children": null
                  }
                ]
              },
              {
                "text": "이식편(Grafts)",
                "id": "이식편-grafts",
                "children": [
                  {
                    "text": "자가이식(Autograft)",
                    "id": "자가이식-autograft",
                    "children": null
                  },
                  {
                    "text": "동계이식(Isograft)",
                    "id": "동계이식-isograft",
                    "children": null
                  },
                  {
                    "text": "동종이식(Allografts)",
                    "id": "동종이식-allografts",
                    "children": null
                  },
                  {
                    "text": "이종이식(Xenotransplantation)",
                    "id": "이종이식-xenotransplantation",
                    "children": null
                  },
                  {
                    "text": "초급성 거부 반응 극복",
                    "id": "초급성-거부-반응-극복",
                    "children": null
                  }
                ]
              },
              {
                "text": "이식 거부 반응 방지를 위한 면역 억제",
                "id": "이식-거부-반응-방지를-위한-면역-억제",
                "children": [
                  {
                    "text": "면역 억제의 목적",
                    "id": "면역-억제의-목적",
                    "children": null
                  },
                  {
                    "text": "주요 면역 억제제 및 작용 기전",
                    "id": "주요-면역-억제제-및-작용-기전",
                    "children": null
                  }
                ]
              }
            ]
          },
          "quiz": [
            {
              "question": "이식 수술에서 공여자와 수혜자의 조직 일치가 중요한 주된 이유는 무엇입니까?",
              "options": [
                "감염 위험을 줄이기 위해",
                "수술 시간을 단축하기 위해",
                "이식 거부 반응을 최소화하기 위해",
                "환자의 회복 속도를 높이기 위해"
              ],
              "answerIndex": 2,
              "explanation": "HLA 타이핑을 통한 조직 일치는 이식된 조직에 대한 수혜자의 면역 반응, 즉 거부 반응을 줄이는 데 필수적입니다."
            },
            {
              "question": "다음 중 '이식편대숙주병(Graft-versus-host disease, GVH)'이 발생할 수 있는 이식 유형은 무엇입니까?",
              "options": [
                "자가이식 (Autograft)",
                "동계이식 (Isograft)",
                "골수 이식 (Bone marrow transplant)",
                "각막 이식 (Cornea transplant)"
              ],
              "answerIndex": 2,
              "explanation": "이식편대숙주병은 이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격할 때 발생합니다."
            },
            {
              "question": "다음 중 면역 억제제 시롤리무스(Sirolimus)의 주요 작용 기전은 무엇입니까?",
              "options": [
                "IL-2 생성을 억제하여 세포독성 T 세포를 방해한다.",
                "T 세포와 B 세포의 증식을 억제한다.",
                "세포성 및 체액성 면역을 모두 억제한다.",
                "IL-2를 차단하는 키메라 단일클론 항체이다."
              ],
              "answerIndex": 2,
              "explanation": "텍스트에 따르면 시롤리무스는 세포성 및 체액성 면역을 모두 억제한다고 명시되어 있습니다."
            }
          ]
        },
        {
          "title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1530 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "면역 시스템과 암",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "암세포는 면역 감시에 의해 제거됩니다. 암세포는 비자기로 표시되는 종양 관련 항원을 가지고 있습니다. CTL(활성화된 TC 세포)과 대식세포는 암세포를 용해합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그러나 면역 시스템의 암 제거에는 몇 가지 제한 사항이 있습니다. 면역 시스템이 표적으로 삼을 항원성 에피토프가 없거나, 종양 세포가 너무 빠르게 증식하거나, 종양이 혈관화되어 면역 시스템에 보이지 않게 될 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
              "level": 2
            },
            {
              "type": "heading",
              "content": "암에 대한 면역 요법",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "암 치료를 위한 다양한 면역 요법이 개발되었습니다. 박테리아 내독소(Coley's toxins)는 암의 혈액 공급을 방해하는 TNF를 자극하여 사용될 수 있습니다. HPV(자궁경부암, 항문암, 인후암) 및 B형 간염(간암)과 같은 바이러스 관련 암에 대한 예방 백신이 사용됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "또한 단클론항체(Monoclonal antibodies)가 사용되는데, 예를 들어 유방암 치료제 허셉틴이 있습니다. 면역독소(Immunotoxin)는 단클론항체와 독성 물질을 결합하여 건강한 세포에 손상을 주지 않고 종양을 표적하여 죽입니다. 면역 관문 억제제와 CAR T 세포와 같은 세포 치료법도 암 치료에 활용되고 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역 결핍증",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "면역 결핍증은 충분한 면역 반응이 부재하는 상태를 말합니다. 이는 선천성 면역 결핍증과 후천성 면역 결핍증으로 나눌 수 있습니다. 선천성 면역 결핍증은 결함이 있거나 없는 유전자 때문에 발생하며, 후천성 면역 결핍증은 약물, 암, 감염 등으로 인해 개인의 삶 동안 발병합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "면역 결핍 질환",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "선천성 면역 결핍 질환은 유전적 유전자 결함에 의해 발생합니다. T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있으며, 항원 수용체 유전자 재배열의 결함 또한 SCID를 유발할 수 있습니다. T세포 항원 수용체로부터의 신호 전달 결함이나 T세포 발달을 차단하는 흉선 기능의 유전적 결함 역시 중증 면역 결핍증을 초래할 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "림프구 발달의 결함이 중증 복합 면역 결핍증을 초래할 수 있음",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "그림 19.12 나병균에 감염된 누드(털 없는) 쥐의 뒷발. M. leprae 박테리아 위치.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "본문은 면역 시스템이 암과 싸우는 방식, 그 한계, 그리고 다양한 암 면역 요법에 대해 설명합니다. 또한 면역 결핍증을 선천성 및 후천성으로 구분하고, T세포 발달 또는 항원 수용체 결함으로 인한 SCID와 같은 선천성 면역 결핍 질환의 구체적인 원인을 다룹니다.",
            "keyConcepts": [
              {
                "term": "면역 감시",
                "definition": "면역 시스템이 암세포를 인식하고 제거하는 과정."
              },
              {
                "term": "면역 요법",
                "definition": "면역 시스템을 활용하여 암을 치료하는 방법으로, 백신, 단클론항체, 면역관문억제제, 세포 치료 등이 포함됩니다."
              },
              {
                "term": "선천성 면역 결핍증",
                "definition": "유전적 결함으로 인해 발생하는 면역 반응의 부재."
              },
              {
                "term": "후천성 면역 결핍증",
                "definition": "약물, 암, 감염 등으로 인해 개인의 삶 동안 발병하는 면역 결핍."
              },
              {
                "term": "중증 복합 면역 결핍증 (SCID)",
                "definition": "T세포 발달 결함이나 항원 수용체 유전자 재배열 결함 등으로 인해 발생하는 심각한 면역 결핍 질환."
              }
            ],
            "importantTerms": [
              {
                "term": "종양 관련 항원",
                "definition": "암세포 표면에 존재하며 면역 시스템이 비자기로 인식하는 항원."
              },
              {
                "term": "세포독성 T 림프구 (CTLs)",
                "definition": "활성화된 T 세포로, 암세포나 감염된 세포를 직접 용해(파괴)하는 역할을 합니다."
              },
              {
                "term": "코리 독소",
                "definition": "박테리아 내독소로, TNF 분비를 자극하여 암의 혈액 공급을 방해하는 데 사용되었던 물질."
              },
              {
                "term": "단클론항체 (Mab)",
                "definition": "특정 항원에만 결합하도록 만들어진 항체로, 암 치료에 사용될 수 있습니다 (예: 허셉틴)."
              },
              {
                "term": "면역독소",
                "definition": "단클론항체와 독성 물질을 결합하여 암세포만을 표적하여 죽이는 치료제."
              },
              {
                "term": "면역 관문 억제제",
                "definition": "면역 반응을 억제하는 경로를 차단하여 면역 시스템이 암세포를 더 효과적으로 공격하도록 돕는 약물."
              },
              {
                "term": "CAR T 세포",
                "definition": "환자의 T 세포를 유전자 조작하여 암세포를 인식하고 공격하도록 만든 세포 치료제."
              }
            ],
            "outline": [
              {
                "text": "면역 시스템과 암",
                "id": "면역-시스템과-암",
                "children": [
                  {
                    "text": "면역 감시를 통한 암세포 제거",
                    "id": "면역-감시를-통한-암세포-제거",
                    "children": null
                  },
                  {
                    "text": "면역 시스템의 암 제거 제한 사항",
                    "id": "면역-시스템의-암-제거-제한-사항",
                    "children": null
                  }
                ]
              },
              {
                "text": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
                "id": "세포독성-t-림프구ctl와-암세포의-상호작용",
                "children": null
              },
              {
                "text": "암에 대한 면역 요법",
                "id": "암에-대한-면역-요법",
                "children": [
                  {
                    "text": "박테리아 내독소",
                    "id": "박테리아-내독소",
                    "children": null
                  },
                  {
                    "text": "백신",
                    "id": "백신",
                    "children": null
                  },
                  {
                    "text": "단클론항체 및 면역독소",
                    "id": "단클론항체-및-면역독소",
                    "children": null
                  },
                  {
                    "text": "면역 관문 억제제",
                    "id": "면역-관문-억제제",
                    "children": null
                  },
                  {
                    "text": "세포 치료",
                    "id": "세포-치료",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역 결핍증",
                "id": "면역-결핍증",
                "children": [
                  {
                    "text": "선천성 면역 결핍증",
                    "id": "선천성-면역-결핍증",
                    "children": null
                  },
                  {
                    "text": "후천성 면역 결핍증",
                    "id": "후천성-면역-결핍증",
                    "children": null
                  }
                ]
              },
              {
                "text": "면역 결핍 질환",
                "id": "면역-결핍-질환",
                "children": [
                  {
                    "text": "선천성 면역 결핍 질환의 원인",
                    "id": "선천성-면역-결핍-질환의-원인",
                    "children": null
                  },
                  {
                    "text": "T세포 발달 및 항원 수용체 관련 결함",
                    "id": "t세포-발달-및-항원-수용체-관련-결함",
                    "children": null
                  }
                ]
              },
              {
                "text": "림프구 발달 결함과 중증 복합 면역 결핍증 (SCID)",
                "id": "림프구-발달-결함과-중증-복합-면역-결핍증-scid",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "면역 시스템이 암세포를 제거하는 데 있어 주요 제한 사항이 아닌 것은 무엇입니까?",
              "options": [
                "면역 시스템이 표적으로 삼을 항원성 에피토프가 없음",
                "종양 세포가 너무 빠르게 증식함",
                "종양이 혈관화되어 면역 시스템에 보이지 않게 됨",
                "대식세포가 암세포를 용해하지 못함"
              ],
              "answerIndex": 3,
              "explanation": "본문에서는 CTL(활성화된 TC 세포)과 대식세포가 암세포를 용해한다고 명시되어 있으므로, 대식세포가 암세포를 용해하지 못하는 것은 면역 시스템의 제한 사항이 아닙니다."
            },
            {
              "question": "다음 중 암에 대한 면역 요법으로 언급되지 않은 것은 무엇입니까?",
              "options": [
                "박테리아 내독소 (Coley's toxins)",
                "예방 백신 (HPV, B형 간염)",
                "항생제",
                "CAR T 세포 치료"
              ],
              "answerIndex": 2,
              "explanation": "본문에서 박테리아 내독소, 예방 백신, CAR T 세포 치료는 암에 대한 면역 요법으로 언급되었지만, 항생제는 언급되지 않았습니다. 항생제는 주로 세균 감염 치료에 사용됩니다."
            },
            {
              "question": "중증 복합 면역 결핍증(SCID)의 주요 원인이 될 수 있는 유전적 결함은 무엇입니까?",
              "options": [
                "B세포의 과도한 증식",
                "T세포 발달의 결함",
                "항체 생산 능력의 증가",
                "대식세포 기능의 활성화"
              ],
              "answerIndex": 1,
              "explanation": "본문에서는 'T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있습니다'라고 명확히 언급되어 있습니다."
            }
          ]
        },
        {
          "title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
          "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 5576 chars",
          "documentContent": [
            {
              "type": "heading",
              "content": "후천성 면역 결핍 증후군 (AIDS)",
              "level": 1
            },
            {
              "type": "paragraph",
              "content": "1981년, 미국에서 젊은 동성애 남성들 사이에서 폐포자충 폐렴, 카포시 육종, 그리고 면역 기능 상실 사례들이 집단으로 발견되었습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1983년, 면역 기능 상실을 유발하는 바이러스(HIV)가 발견되었습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV는 T 보조 세포를 선택적으로 감염시킵니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "AIDS의 기원",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "HIV는 서아프리카와 중앙아프리카의 침팬지(약 1908년, 부시미트로부터)로부터 인간 개체군으로 넘어왔습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "도시화와 성적 문란의 증가로 아프리카 전역으로 퍼졌습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "가장 오래된 HIV 샘플은 1920년 콩고민주공화국의 킨샤사에서 발견되었습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1976년에 사망한 노르웨이 선원은 서구 세계에서 알려진 첫 번째 사례입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "1969년 미주리주의 한 환자로부터 채취한 샘플에서 HIV 감염이 확인되었습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV의 구조",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "렌티바이러스(Lentivirus) 속에 속합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "레트로바이러스(Retrovirus)입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "두 개의 동일한 양성 가닥 RNA 유전체 분자, 역전사 효소, 인지질 외피를 가지고 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "gp120 당단백질 스파이크를 가지고 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 구조 및 CD4+ T 세포 감염: gp120 당단백질 스파이크는 CD4+ 세포의 수용체에 부착합니다. gp41 막관통 당단백질은 CD4+ 세포의 융합 수용체에 부착하여 융합을 촉진합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV의 감염성과 병원성",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "수지상 세포에 의해 퍼지고 림프 기관으로 운반되며, 활성화된 T 세포와 접촉합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "gp120은 CD4+ 수용체 및 CCR5 또는 CXCR4 공동수용체와 결합합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "CD4 분자는 T 보조 세포, 대식세포, 수지상 세포에 존재합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스는 세포와 융합하여 세포 안으로 들어갑니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "부착: gp120 스파이크는 세포의 수용체 및 CCR5 또는 CXCR4 공동수용체에 부착합니다. 융합: gp41은 HIV와 세포의 융합에 참여합니다. 진입: 세포와의 융합 후, 진입 구멍이 생성됩니다. 진입 후, 바이러스 외피는 뒤에 남고 HIV는 탈피하여 새로운 바이러스 합성을 지시할 RNA 핵을 방출합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포 내에서 바이러스 RNA는 역전사 효소를 사용하여 DNA로 전사됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "DNA는 숙주 염색체 DNA에 통합됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "활동성 감염: 새로운 바이러스가 숙주 세포에서 출아합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "잠복 감염: DNA는 프로바이러스 형태로 염색체에 숨겨져 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "일부는 HIV의 저장소 역할을 하는 기억 T 세포가 됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스는 빠른 항원성 변화와 높은 돌연변이율을 겪습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그림 19.14 CD4+ T 세포의 잠복 및 활동성 HIV 감염. 잠복 감염: 바이러스 DNA는 세포 DNA에 프로바이러스로 통합되며, 나중에 활성화되어 감염성 바이러스를 생성할 수 있습니다. 활동성 감염: 프로바이러스가 활성화되어 새로운 바이러스의 합성을 제어할 수 있게 합니다. 최종 조립은 세포막에서 이루어지며, 바이러스가 세포에서 출아할 때 바이러스 외피 단백질을 가져갑니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그림 19.15 대식세포 및 수지상 세포의 잠복 및 활동성 HIV 감염. 잠복 감염된 대식세포: HIV는 프로바이러스 또는 액포 내 완전한 비리온 형태로 지속될 수 있습니다. 활성화된 대식세포: 프로바이러스로부터 새로운 바이러스가 생성됩니다. 완성된 비리온은 방출되거나 액포 내 대식세포에 지속될 수 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV의 아형",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "HIV-1:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "침팬지와 고릴라를 감염시키는 바이러스와 관련이 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사례의 99%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "그룹 M (대다수)이 90%를 차지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV-2:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "서아프리카 외에서는 자주 발견되지 않습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV-1보다 병원성이 낮습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV-1보다 바이러스 부하와 사망률이 낮고 무증상 기간이 더 깁니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 감염의 단계",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "1단계: 무증상 또는 림프절병증.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "2단계: CD4+ T 세포가 꾸준히 감소하며, 감염된 소수의 세포만이 바이러스를 방출합니다. 심각한 질병 증상은 거의 없습니다 (지속적인 감염, 발열, 구강 백반증).",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "3단계: AIDS가 발병합니다. CD4+ 수치가 200 cells/μl 미만이며, 지표 질환이 나타납니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 감염의 진행 및 병원성",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "초기에는 강력하고 효과적인 면역 반응이 나타납니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포독성 T 림프구(CTLs)가 바이러스 수를 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "일단 HIV가 잠복 감염된 CD4+ T 세포의 저장소를 형성하면 감염을 제거하는 것은 불가능합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "백신 개발에 어려움이 있습니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 노출에 대한 반응의 변이",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "HIV 감염 생존에 대한 연령의 영향:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "고령자와 어린이는 면역 체계가 완전히 기능하지 않아 감염에 더 취약합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "노출되었지만 감염되지 않은 인구:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "CCR5 돌연변이를 가집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "장기 생존자:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "낮은 바이러스 부하를 가집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "효과적인 CTLs를 가집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "기회 감염",
              "level": 2
            },
            {
              "type": "heading",
              "content": "진단 방법",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "혈청 전환은 감염과 항체 출현 사이의 기간입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "최대 3개월이 소요됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 항체는 ELISA로 검출됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스는 Western blotting 또는 APTIMA (RNA 검사)로 검출됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "혈장 바이러스 부하 (PVL)는 PCR 또는 핵산 혼성화로 결정됩니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 전파",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "HIV는 세포 밖에서 6시간 생존합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV는 세포 내에서 1.5일 이상 생존할 수 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "전파 경로: 친밀한 성 접촉, 모유, 태반 감염, 오염된 주사바늘, 장기 이식, 수혈.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "항문 성교는 가장 위험한 형태의 성 접촉입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "전 세계 AIDS 현황",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "전 세계적으로 3천 5백만 명이 감염되었습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "사하라 이남 아프리카에 70%가 집중되어 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이성애자 간 전파가 HIV 전파의 가장 흔한 방식입니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "동유럽과 중앙 및 동남아시아 사례의 ⅓은 주사 약물 사용으로 인한 것입니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "전 세계 지역별 HIV 감염 및 AIDS 분포",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "70",
              "level": null
            },
            {
              "type": "heading",
              "content": "AIDS 예방 및 치료",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "생물의학적 개입:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "콘돔 사용, 보건 서비스/HIV 검사, 주사바늘 프로그램.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "행동적 개입:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "성 교육, 안전한 영아 수유 프로그램, 상담.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "구조적 개입:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 취약성을 줄이기 위해 사회, 경제, 정치, 환경적 요인에 변화를 줍니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이제 선진국에서는 치료 가능한 만성 질환으로 간주됩니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "고활성 항레트로바이러스 치료 (HAART)를 사용합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "내성 균주의 생존을 최소화하기 위해 약물 조합을 사용합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "73",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 관리",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "그림 19.18 HIV 생명 주기를 억제하는 약물: 융합/진입 억제제 (엔푸비르타이드, 마라비록), 역전사 효소 억제제 (테노포비르, 엠트리시타빈), 통합효소 억제제 (랄테그라비르), 프로테아제 억제제 (아타자나비르, 인디나비르, 사퀴나비르) 등이 있습니다. 이 약물들은 HIV의 gp41, gp120, CCR5, CD4 수용체 및 역전사 효소 등에 작용하여 바이러스 복제를 억제합니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 치료 약물의 종류",
              "level": 3
            },
            {
              "type": "paragraph",
              "content": "융합/세포 진입 억제제:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스 외피의 gp41 영역을 표적으로 하여 바이러스가 세포와 융합하는 것을 방지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "엔푸비르타이드(Enfuvirtide)와 마라비록(Maraviroc)이 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "역전사 효소 억제제:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "뉴클레오사이드 역전사 효소 억제제 (NRTIs) - 테노포비르(Tenofovir)와 엠트리시타빈(Emtricitabrine)이 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "비뉴클레오사이드 역전사 효소 억제제 (NNRTIs) - 에파비렌즈(Efavirenz)가 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "77",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "통합효소 억제제:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "HIV 통합효소가 cDNA를 숙주 염색체에 통합하는 것을 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "랄테그라비르(Raltegravir)가 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "프로테아제 억제제:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "바이러스 전구 단백질을 구조 및 기능 단백질로 분해하는 프로테아제를 억제합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "아타자나비르(Atazanavir), 인디나비르(Indinavir), 사퀴나비르(Saquinavir)가 있습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "성숙 억제제:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "테더린(Tetherins)은 바이러스를 세포에 묶어 방출 및 확산을 방지합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "감염 과정에서 HIV는 많은 돌연변이를 축적하여 약물 내성 변이체의 증식으로 이어집니다.",
              "level": null
            },
            {
              "type": "heading",
              "content": "HIV 백신 개발의 과제",
              "level": 2
            },
            {
              "type": "paragraph",
              "content": "모방할 자연 면역 모델이 없습니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "연구 동물이 부족합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "레트로바이러스 메커니즘에 대한 이해가 부족합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "높은 돌연변이율로 인해 내성 균주가 발생합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "이상적인 백신은 다음과 같아야 합니다:",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "잠복 바이러스 저장소가 확립되기 전에 면역을 유도해야 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "세포독성 T 림프구(CTLs)의 생성을 자극해야 합니다.",
              "level": null
            },
            {
              "type": "paragraph",
              "content": "합리적인 가격이어야 합니다.",
              "level": null
            }
          ],
          "aiNotes": {
            "summary": "이 문서는 후천성 면역 결핍 증후군(AIDS)의 기원, 원인 바이러스인 HIV의 구조, 감염 메커니즘 및 병원성, 바이러스 아형, 감염 단계, 진단 방법, 전파 경로, 전 세계적 현황, 예방 및 치료법, 그리고 백신 개발의 과제에 대해 상세히 설명합니다. HIV는 CD4+ T 세포를 선택적으로 감염시키는 레트로바이러스이며, 잠복 감염과 활동성 감염 단계를 거치며 면역 체계를 파괴합니다. HAART(고활성 항레트로바이러스 치료)를 통해 HIV 복제를 억제하고 환자의 삶의 질을 향상시킬 수 있지만, 바이러스의 높은 돌연변이율로 인해 백신 개발에는 어려움이 있습니다.",
            "keyConcepts": [
              {
                "term": "HIV (Human Immunodeficiency Virus)",
                "definition": {
                  "easy": null,
                  "medium": "AIDS의 원인 바이러스로, 인체의 면역 체계를 공격하고 파괴하는 레트로바이러스입니다.",
                  "hard": null
                }
              },
              {
                "term": "CD4+ T 세포",
                "definition": {
                  "easy": null,
                  "medium": "HIV가 주로 감염시키고 파괴하는 면역 세포로, 이 세포의 감소는 면역 결핍을 초래합니다.",
                  "hard": null
                }
              },
              {
                "term": "역전사 효소 (Reverse Transcriptase)",
                "definition": {
                  "easy": null,
                  "medium": "HIV를 포함한 레트로바이러스가 자신의 RNA 유전체를 DNA로 역전사하는 데 사용하는 효소입니다.",
                  "hard": null
                }
              },
              {
                "term": "HAART (Highly Active Antiretroviral Therapy)",
                "definition": {
                  "easy": null,
                  "medium": "HIV 감염 치료를 위해 여러 종류의 항레트로바이러스 약물을 병용하는 치료법으로, 바이러스 복제를 효과적으로 억제합니다.",
                  "hard": null
                }
              },
              {
                "term": "기회 감염 (Opportunistic Infections)",
                "definition": {
                  "easy": null,
                  "medium": "면역 체계가 약해진 상태에서 일반적으로 건강한 사람에게는 질병을 일으키지 않는 미생물에 의해 발생하는 감염입니다.",
                  "hard": null
                }
              }
            ],
            "importantTerms": [
              {
                "term": "AIDS (Acquired Immunodeficiency Syndrome)",
                "definition": "후천성 면역 결핍 증후군. HIV 감염의 마지막 단계로, 심각한 면역 결핍과 기회 감염 및 특정 암을 특징으로 합니다."
              },
              {
                "term": "레트로바이러스 (Retrovirus)",
                "definition": "RNA 유전체를 가지고 있으며, 역전사 효소를 사용하여 RNA를 DNA로 전환하고 이를 숙주 게놈에 통합시키는 바이러스입니다."
              },
              {
                "term": "gp120 및 gp41",
                "definition": "HIV 외피에 존재하는 당단백질 스파이크로, gp120은 CD4 수용체에 부착하고 gp41은 바이러스와 세포막의 융합을 촉진합니다."
              },
              {
                "term": "프로바이러스 (Provirus)",
                "definition": "레트로바이러스의 DNA 유전체가 숙주 세포의 염색체 DNA에 통합된 형태입니다."
              },
              {
                "term": "혈청 전환 (Seroconversion)",
                "definition": "감염 후 특정 병원체에 대한 항체가 혈액에서 처음으로 검출되는 시기입니다."
              },
              {
                "term": "CD4+ T 세포 수치",
                "definition": "면역 상태를 나타내는 중요한 지표로, AIDS 진단 기준 중 하나는 이 수치가 200 cells/μl 미만인 경우입니다."
              },
              {
                "term": "CCR5 돌연변이",
                "definition": "일부 개인에게서 발견되는 유전적 돌연변이로, HIV가 세포에 진입하는 데 필요한 공동수용체인 CCR5를 변경하여 HIV 감염에 대한 저항성을 부여합니다."
              }
            ],
            "outline": [
              {
                "text": "후천성 면역 결핍 증후군 (AIDS)",
                "id": "후천성-면역-결핍-증후군-aids",
                "children": null
              },
              {
                "text": "AIDS의 기원",
                "id": "aids의-기원",
                "children": null
              },
              {
                "text": "HIV의 구조",
                "id": "hiv의-구조",
                "children": null
              },
              {
                "text": "HIV의 감염성과 병원성",
                "id": "hiv의-감염성과-병원성",
                "children": null
              },
              {
                "text": "HIV의 아형",
                "id": "hiv의-아형",
                "children": null
              },
              {
                "text": "HIV 감염의 단계",
                "id": "hiv-감염의-단계",
                "children": null
              },
              {
                "text": "HIV 감염의 진행 및 병원성",
                "id": "hiv-감염의-진행-및-병원성",
                "children": null
              },
              {
                "text": "HIV 노출에 대한 반응의 변이",
                "id": "hiv-노출에-대한-반응의-변이",
                "children": null
              },
              {
                "text": "기회 감염",
                "id": "기회-감염",
                "children": null
              },
              {
                "text": "진단 방법",
                "id": "진단-방법",
                "children": null
              },
              {
                "text": "HIV 전파",
                "id": "hiv-전파",
                "children": null
              },
              {
                "text": "전 세계 AIDS 현황",
                "id": "전-세계-aids-현황",
                "children": null
              },
              {
                "text": "전 세계 지역별 HIV 감염 및 AIDS 분포",
                "id": "전-세계-지역별-hiv-감염-및-aids-분포",
                "children": null
              },
              {
                "text": "AIDS 예방 및 치료",
                "id": "aids-예방-및-치료",
                "children": [
                  {
                    "text": "HIV 관리",
                    "id": "hiv-관리",
                    "children": null
                  },
                  {
                    "text": "HIV 치료 약물의 종류",
                    "id": "hiv-치료-약물의-종류",
                    "children": null
                  }
                ]
              },
              {
                "text": "HIV 백신 개발의 과제",
                "id": "hiv-백신-개발의-과제",
                "children": null
              }
            ]
          },
          "quiz": [
            {
              "question": "HIV가 주로 감염시키고 파괴하는 면역 세포는 무엇입니까?",
              "options": [
                "B 세포",
                "CD4+ T 세포",
                "대식세포",
                "자연 살해(NK) 세포"
              ],
              "answerIndex": 1,
              "explanation": "HIV는 CD4+ 수용체를 가진 세포를 감염시키며, 특히 CD4+ T 세포는 HIV 감염의 주요 표적 세포입니다. 이 세포의 파괴는 면역 결핍을 초래합니다."
            },
            {
              "question": "HIV 감염 진단에 사용되는 방법 중 HIV 항체를 검출하는 검사는 무엇입니까?",
              "options": [
                "PCR",
                "Western blotting",
                "ELISA",
                "핵산 혼성화"
              ],
              "answerIndex": 2,
              "explanation": "HIV 항체는 ELISA(효소결합 면역흡착법)를 통해 검출됩니다. Western blotting은 항체 검출을 확인하는 데 사용될 수 있으며, PCR과 핵산 혼성화는 바이러스 자체(RNA 또는 DNA)를 검출하는 데 사용됩니다."
            },
            {
              "question": "HAART(고활성 항레트로바이러스 치료)의 주요 특징은 무엇입니까?",
              "options": [
                "단일 약물을 고용량으로 투여합니다.",
                "수술적 방법으로 바이러스를 제거합니다.",
                "여러 종류의 항레트로바이러스 약물을 병용합니다.",
                "면역 증강제만을 사용하여 면역력을 높입니다."
              ],
              "answerIndex": 2,
              "explanation": "HAART는 여러 종류의 항레트로바이러스 약물을 병용하여 HIV 복제를 다양한 단계에서 억제하고 약물 내성 균주의 출현을 최소화하는 치료법입니다."
            }
          ]
        }
      ],
      "log_entries": [
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "analyze_overall_structure",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "analyze_overall_structure",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "generate_chapter_content",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "all_pdf_texts": [
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "text": "16. INNATE IMMUNITY: \nNONSPECIFIC DEFENSES OF \nTHE HOST\nHongsup Yoon, Ph.D.\nMicrobiology\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n2\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n3\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n4\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n• White blood cell (WBC) \ncounts measure \nleukocytes in the blood\n• High WBC counts may \nindicate bacterial \ninfections, autoimmune \ndiseases, or side effects \nof medications\n• Low WBC counts may \nindicate viral infections, \npneumonia, \nautoimmune diseases, \nor cancers\n\nTHE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse.\n14\nHOST DEFENSE: THE BIG PICTURE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n16\nPHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\n\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice.\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n23\nFORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\n\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\n\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n31\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\n\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\n\nPHAGOCYTOSIS: OVERVIEW\n\nPHAGOCYTOSIS: MECHANISM\n\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\n\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n39\nINFLAMMATION: OVERVIEW\n\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\n\nFigure 16.9a-b  The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ntaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\n\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n49\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n51\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\n\nCOMPLEMENT: ACTIVATION\n\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\n\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\n\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\n\nFigure 16.12  Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13  Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBIAL PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n68\nSUMMARY (1/3)\n• The growth of microorganisms can be controlled by physical, chemical, \nmechanical, and biological means.\n• The body’s first line of defense against infections is a physical barrier and \nthe nonspecific chemicals of the skin and mucous membranes. \n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways.\n• A microbe’s penetration of the first line of defense encourages production \nof phagocytes, inflammation, fever, and antimicrobial substances. \n• Blood consists of plasma (fluid) and formed elements (cells and cell \nfragments). Leukocytes (white blood cells) are divided into granulocytes \n(neutrophils, basophils,  eosinophils) and agranulocytes. During many \ninfections, the number of leukocytes increases (leukocytosis); some  \ninfections are characterized by leucopenia (decrease in leukocytes). \nSUMMARY (2/3)\n• Phagocytosis is the ingestion of microorganisms or particulate matter by a \ncell. Phagocytosis is performed by phagocytes, certain types of white \nblood cells or their  derivatives. Among the granulocytes, neutrophils are \nthe most important phagocytes. Granulocytes predominate during the \nearly stages of infection, whereas monocytes  predominate as the \ninfection subsides. \n• Inflammation is a bodily response to cell damage; it is characterized by \nredness,  pain, heat, swelling, and sometimes the loss of function. TNF -α \nstimulates production of acute -phase proteins. \n• A tissue is repaired when the stroma (supporting tissue) or parenchyma \n(functioning  tissue) produces new cells. Stromal repair by fibroblasts \nproduces scar tissue. \n• Fever is an abnormally high body temperature produced in response to a \nbacterial or  viral infection. \nSUMMARY (3/3)\n• The complement system consists of a group of serum proteins that \nactivate one another to destroy invading microorganisms. Complement \nproteins are activated in a cascade. Complement is activated via the \nclassical pathway, the alternative pathway, and the lectin pathway. \n• IFN-α and IFN-β are antiviral proteins produced in response to viral \ninfection. The mode of action of IFN -α and IFN-β is to induce uninfected \ncells to produce antiviral proteins (AVPs) that prevent viral replication. IFN -\nα and IFN-β are host-cell-specific but not virus-specific. IFN-γ activates \nneutrophils and macrophages to kill bacteria. \n• Iron-binding proteins transport and store iron and deprive most pathogens \nof the  available iron.\n• Antimicrobial peptides (AMPs) inhibit cell wall synthesis; form pores in \nplasma  membranes, resulting in lysis; and destroy DNA and RNA."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "text": "17. ADAPTIVE IMMUNITY: \nSPECIFIC DEFENSES OF \nTHE HOST\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n2\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n3\nTHE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n5\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\n\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n11\nCYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n14\nAntibody A\nEpitopes (antigenic \ndeterminants)\non antigen\nAntigens:\ncomponents\nof cell wall\nAntibody B\nBacterial cell\nBinding sites\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\n\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\n\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n34\nCELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\n\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\n\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\n\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\n\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\n\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n51\nIMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\n \n\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\n\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n55\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\n\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Summary\n58\nFigure 17.20  The Dual Nature of the Adaptive Immune System.\n\nSUMMARY (1/3)\n• Adaptive immunity is the body’s ability to react specifically to a microbial \ninfection. The body’s response to the first contact with an antigen is called the \nprimary response. Subsequent contact with the same antigen results in a \nsecondary or memory response to that antigen.\n• Humoral immunity involves antibodies, which are found in serum and lymph and \nare produced by B cells. Lymphocytes that mature in red bone marrow become \nB cells. \n• Cellular immunity involves T cells. Lymphocytes that migrate through the thymus \nbecome T cells. T cell receptors recognize antigens presented on MHC. Cellular \nimmunity responds to intracellular antigens; humoral immunity responds to \nantigens in body fluids.\n• Cells of the immune system communicate with each other by means of \nchemicals called cytokines. Interleukins (IL) are cytokines that serve as \ncommunicators between leukocytes. Chemokines cause leukocytes to migrate \nto an infection. Some interferons stimulate the immune response; others protect \ncells against viruses. Tumor necrosis factor promotes the inflammatory reaction. \nHematopoietic cytokines promote development of white blood cells. \nOverproduction of cytokines leads to a cytokine storm, which results in tissue \ndamage.\nSUMMARY (2/3)\n• An antigen (or immunogen) is a chemical substance that causes the body \nto produce specific antibodies. Antibodies are formed against specific \nregions on antigens called epitopes, or antigenic determinants.\n• An antibody, or immunoglobulin, is a protein produced by B cells in \nresponse to an  antigen and is capable of combining specifically with that \nantigen. IgG antibodies are the most prevalent in serum; they provide \nnaturally acquired passive immunity, neutralize bacterial toxins, participate \nin complement fixation, and enhance phagocytosis.\n• T cells mature in the thymus gland. Thymic selection removes T cells that \ndon’t recognize MHC molecules of the host and T cells that will attack host \ncells presenting self-proteins in MHC. Helper T cells recognize antigens \nprocessed by antigen-presenting cells and presented in MHC II. Cytotoxic \nT cells recognize antigens processed by all host cells and presented in \nMHC I.\nSUMMARY (3/3)\n• APCs include B cells, dendritic cells, and macrophages. Dendritic cells are \nthe primary APCs. Dendritic cells are the primary APCs. APCs carry \nantigens to lymphoid tissues where T cells that recognize the antigen are \nlocated.\n• T helper (CD4+ T) cells differentiate into TH1 cells, which are involved in \ncellular immunity; TH2 cells, which are involved in humoral immunity and \nare associated with allergic reactions and parasitic infections; and TH17 \ncells, which activate innate immunity.\n• T regulatory cells (Treg) suppress T cells against self. Cytotoxic \nlymphocytes (CTLs), or CD8+ T cells, are activated by endogenous \nantigens and MHC class I on a target cell and are transformed into effector \nand memory CTLs.\n• CTLs lyse or induce apoptosis in the target cell."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n18. PRACTICAL \nAPPLICATIONS OF \nIMMUNOLOGY – PART I\n2\nRECENT VIRUS OUTBREAKS\n• 2002 SARS outbreak (~9.5 % mortality rate)\n• 2004 Global spread of H5N1 avian influenza (60% mortality rate)\n• 2009 H1N1/09 swine Flu pandemic\n• 2015 MERS in Korea (~40 % mortality rate)\n• 2018 Influenza B outbreak in Korea\n• 2019 COV-19 (SARS-CoV2) pandemic (~2 – 3 % mortality rate)\n?\nHISTORICAL PANDEMIC: BLACK DEATH\nKilled 30 – 60% of European\n\nEDWARD JENNER (1749 – 1823)\n\nMILKMAID (AROUND THE TIME OF JENNER)\n\nVACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\n\nVACCINES: FUNCTION\n\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -drug \nusers, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1  Influenza viruses are grown in embryonated eggs.\n\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\n\nRNA VACCINES\nVACCINES: TYPES\n\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\n\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren\nDIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nPRODUCTION OF MONOCLONAL \nANTIBODIES\n\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\n\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\n\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\n\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\n\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\n\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\n\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\n\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy\nSUMMARY (1/6)\n• Edward Jenner developed the modern practice of vaccination when he \ninoculated people with cowpox virus to protect them against smallpox. \n• Herd immunity results when most of a population is immune to a disease.\n• Bacteria have unique cell structures that can be targets for antibiotics, \nimmunity, and phage infection.\n•  Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Humans utilize \nand harness microorganisms and their products.\n• Attenuated vaccines consist of attenuated (weakened) microorganisms; \nattenuated virus vaccines generally provide lifelong immunity. Inactivated \nvaccines consist of killed bacteria or viruses. Subunit vaccines consist of \nantigenic fragments of a microorganism; these include  recombinant \nvaccines and toxoids. \nSUMMARY (2/6)\n• Conjugated vaccines combine the desired antigen with a protein that \nboosts the immune response. Nucleic acid (DNA) vaccines cause the \nrecipient to make the antigenic protein.\n• Viruses for vaccines may be grown in animals, cell cultures, or chick \nembryos. Recombinant vaccines and nucleic acid vaccines do not need to \nbe grown in cells or animals. Genetically modified plants may someday \nprovide edible vaccines.\n• Combining several vaccines would eliminate the number of injections. Dry \nskin patch vaccines don’t need refrigeration.\n• Adjuvants improve the effectiveness of some antigens. \n• Vaccines are the safest and most effective means of controlling infectious \ndiseases.\nSUMMARY (3/6)\n• Many tests based on the interactions of antibodies and antigens have \nbeen developed to determine the presence of antibodies or antigens in a \npatient. The sensitivity of a diagnostic test is determined by the percentage \nof positive samples it correctly detects; and its specificity is determined by \nthe percentage of false positive  results it gives.\n• Hybridomas are produced in the laboratory by fusing a cancerous cell with \nan antibody-secreting plasma cell. A hybridoma cell culture produces large \nquantities of the plasma cell’s antibodies, called monoclonal antibodies. \nMonoclonal antibodies are used in serological identification tests, to \nprevent tissue  rejections, and to make immunotoxins to treat cancer.\n• The interaction of soluble antigens with IgG or IgM antibodies leads to \nprecipitation  reactions. Precipitation reactions depend on the formation of \nlattices and occur best when antigen and antibody are present in optimal \nproportions. Excesses of either component decrease lattice formation and \nsubsequent precipitation.\nSUMMARY (4/6)\n• Immunodiffusion procedures are precipitation reactions carried out in an \nagar gel  medium. Immunoelectrophoresis combines electrophoresis with \nimmunodiffusion for the analysis of serum proteins.\n• The interaction of particulate antigens (cells that carry antigens) with \nantibodies leads to agglutination reactions. Diseases may be diagnosed \nby combining the patient’s serum with a known antigen. Diseases can be \ndiagnosed by a rising titer or seroconversion (from no antibodies to the \npresence of antibodies). Direct agglutination reactions can be used to \ndetermine antibody titer. Antibodies cause visible agglutination of soluble \nantigens affixed to latex spheres in indirect or passive agglutination tests. \nHemagglutination reactions involve agglutination reactions using red blood \ncells.  Hemagglutination reactions are used in blood typing, the diagnosis \nof certain diseases, and the identification of viruses. \nSUMMARY (5/6)\n• In neutralization reactions, the harmful effects of a bacterial exotoxin or \nvirus are  eliminated by a specific antibody. An antitoxin is an antibody \nproduced in response to a bacterial exotoxin or a toxoid that neutralizes \nthe exotoxin. In a virus neutralization test, the presence of antibodies \nagainst a virus can be detected by the antibodies’ ability to prevent \ncytopathic effects of viruses in cell cultures. Antibodies against certain \nviruses can be detected by their ability to interfere with viral \nhemagglutination in viral hemagglutination inhibition tests.\n• Complement-fixation reactions are serological tests based on the \ndepletion of a fixed amount of complement in the presence of an antigen –\nantibody reaction.\n• Fluorescent-antibody techniques use antibodies labeled with fluorescent \ndyes. Direct fluorescent-antibody tests are used to identify specific \nmicroorganisms. \nSUMMARY (6/6)\n• Indirect fluorescent-antibody tests are used to demonstrate the presence \nof antibody  in serum. A fluorescence-activated cell sorter can be used to \ndetect and count cells labeled with fluorescent antibodies.\n• ELISA techniques use antibodies linked to an enzyme. Antigen –antibody \nreactions are detected by enzyme activity. If the indicator enzyme is \npresent in the test well, an antigen –antibody reaction has occurred. The \ndirect ELISA is used to detect antigens against a specific antibody bound \nin a test well. The indirect ELISA is used to detect antibodies against an \nantigen bound in a test well.\n• Serum antibodies separated by electrophoresis are identified with an \nenzyme-linked  antibody. \n• The use of monoclonal antibodies will continue to make new diagnostic \ntests possible."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n19. DISORDERS \nASSOCIATED WITH THE \nIMMUNE SYSTEM – PART 1\n2\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n3\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n4\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Dysbiosis: \nimbalance that \ncauses adverse \neffects in humans\n• Antibiotic therapy \nkills normal gut \nmicrobiota, causing \nClostridium difficile \nto proliferate\n• Possible cause of \nIBDs such as \nulcerative colitis and \nCrohn's disease\n\nBIG PICTURE: THE HYGIENE HYPOTHESIS\n• Allergies and asthma\n• Observation that tribal populations and children growing up on farms \nhave less prevalence of allergies than children in urban settings\n• Possibly due to wider range of microbial exposures in farm setting; also \nled to lower asthma rates\n• Inflammatory bowel diseases\n• Possible link of lack of normal microbiota metabolic products leading to \nchronic inflammatory state\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Treating Crohn's \ndisease with worms\n• Whipworm eggs \nsuppress T helper cell \npathways\n• Fecal transplants for C. \ndifficile infections\n• Taking gut microbiota \nfrom a healthy \nindividual and \ntransplanting it into the \npatient\n\nHYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\n\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\n\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\n\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\n\nFigure 19.8  Allergic contact dermatitis.\n\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n21\nAUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\n\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555) \nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n28\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\n\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2\nSUMMARY (1/3)\n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Hay fever, \ntransplant rejection, and autoimmunity are examples of harmful immune  \nreactions. Immunosuppression is inhibition of the immune system. \nSuperantigens activate many T cell receptors that can cause adverse host \nresponses.\n• Hypersensitivity reactions represent immunological responses to an \nantigen (allergen) that lead to tissue damage rather than immunity. \nHypersensitivity reactions occur when a person has been sensitized to an \nantigen. Hypersensitivity reactions can be divided into four classes: types \nI, II, and III are immediate reactions based on humoral immunity, and type \nIV is a delayed reaction  based on cell -mediated immunity. \n• Childhood exposure to microbes may decrease development of allergies.\nSUMMARY (2/3)\n• Autoimmunity results from a loss of self -tolerance. Self-tolerance occurs \nduring fetal development; T cells that will target host cells are eliminated \n(clonal deletion) or inactivated. Autoimmunity may be due to antibodies \nagainst infectious agents. Graves’ disease and myasthenia gravis are \ncytotoxic autoimmune reactions in which  antibodies react to cell -surface \nantigens.\n• Systemic lupus erythematosus and rheumatoid arthritis are immune \ncomplex autoimmune reactions in which the deposition of immune \ncomplexes results in tissue damage. Multiple sclerosis, insulin -dependent \ndiabetes mellitus, and psoriasis are cell -mediated autoimmune reactions \nmediated by T cells.\nSUMMARY (3/3)\n• MHC self molecules located on cell surfaces express genetic differences \namong individuals; these antigens are called HLAs in humans. To prevent \nthe rejection of transplants, HLA and ABO blood group antigens of the \ndonor and recipient are matched as closely as possible. Transplants \nrecognized as foreign antigens may be lysed by T cells and attacked by \nmacrophages and complement -fixing antibodies. Transplantation to a \nprivileged site (such as the cornea) or of a privileged tissue (such as pig \nheart valves) does not cause an immune response. Pluripotent stem cells \ndifferentiate into a variety of tissues that may provide tissues for \ntransplant.\n• Four types of transplants have been defined on the basis of genetic \nrelationships between the donor and the recipient: autografts, isografts, \nallografts, and xenotransplants. Bone marrow transplants (with \nimmunocompetent cells) can cause graft -versus-host  disease.  \nSuccessful transplant surgery often requires immunosuppressant drugs to \nprevent an immune response to the transplanted tissue. \nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n40\nTHE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\n\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n46\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\n\nFigure 19.12  A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES\n\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n52\nACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\n\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14  Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15  Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\n\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\n\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n\n70\n\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\n\nHIV MANAGEMENT\n\nFigure 19.18  Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\n\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\n\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable\nSUMMARY (1/3)\n• Cancer cells are normal cells that have undergone transformation, divide \nuncontrollably, and possess tumor-associated antigens. The response of the \nimmune system to cancer is called immunological surveillance. TC cells \nrecognize and lyse cancerous cells. Cancer cells can escape detection and \ndestruction by the immune system. Cancer cells may grow faster than the \nimmune system can respond.\n• Novel therapeutic strategies, such as immune checkpoint inhibitors and CAR T \ncell therapy, are effective approaches to treat patients with cancer.\n• Vaccines against liver and cervical cancer are available; a therapeutic vaccine \nagainst prostate cancer also has been approved. Herceptin consists of \nmonoclonal antibodies against a breast cancer growth factor. Immunotoxins are \nchemical poisons linked to a monoclonal antibody; the antibody  selectively \nlocates the cancer cell for release of the poison.\n• Immunodeficiencies can be congenital or acquired. Congenital \nimmunodeficiencies are due to defective or absent genes. A variety of drugs, \ncancers, and infectious diseases can cause acquired  immunodeficiencies. \n• HIV is thought to have originated in central Africa and was brought to other \ncountries by modern transportation and unsafe sexual practices.\nSUMMARY (2/3)\n• AIDS is the final stage of HIV infection. HIV is a retrovirus with single -\nstranded RNA, reverse transcriptase, and a phospholipid envelope with \ngp120 spikes. HIV spikes attach to CD4+ and coreceptors on host cells; \nthe CD4+ receptor is found on  T helper cells, macrophages, and dendritic \ncells. Viral RNA is transcribed to DNA by reverse transcriptase. The viral \nDNA becomes  integrated into the host chromosome to direct synthesis of \nnew viruses or to remain latent as a provirus. HIV evades the immune \nsystem in latency, in vacuoles, by using cell–cell fusion, and by antigenic \nchange. HIV-1 accounts for most HIV infections. Subtype B of HIV -1 is the \nmost common type in the United States. HIV infection is categorized by \nsymptoms: phase 1 (asymptomatic), phase 2 (indicator opportunistic \ninfections), and phase 3 (CD4+  cells <200 cells/μ1). The progression from \nHIV infection to AIDS takes about 10 years. The life of an AIDS patient can \nbe prolonged by the proper treatment of opportunistic  infections. People \nlacking CCR5 are resistant to HIV infection. Elite controllers are long -term \nsurvivors who may hold the key to HIV treatment. \nSUMMARY (3/3)\n• HIV antibodies are detected by ELISA and Western blotting. Plasma viral \nload tests detect viral nucleic acid and are used to quantify HIV in blood.\n• HIV is transmitted by sexual contact, breast milk, contaminated needles, \ntransplacental infection, artificial insemination, and blood transfusion. In \ndeveloped countries, blood transfusions are not a likely source of infection \nbecause blood is tested for HIV antibodies. \n• Heterosexual intercourse is the primary method of HIV transmission.\n• Discouraging sexual promiscuity and using condoms and sterile needles \nprevent the transmission of HIV. Vaccine development is difficult because \nthe virus remains inside host cells and there is no model of natural \nimmunity to mimic. Current chemotherapeutic agents target the virus \nenzymes, including reverse transcriptase, integrase, and protease. Other \ninhibitors include cell entry inhibitors, maturation inhibitors, and tetherins."
              }
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [
              {
                "title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2042 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역의 개념",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역은 질병을 막는 능력을 의미하며, 감수성은 질병에 대한 저항력이 부족한 상태를 뜻합니다. 면역은 크게 두 가지로 나뉩니다. 선천성 면역은 모든 병원체에 대한 방어 기전으로, 신속하며 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 면역 또는 저항력으로, 반응 속도가 느리지만 기억 구성 요소를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "선천성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "선천성 면역은 자연 면역, 타고난 면역이라고도 불립니다. 식세포, 수지상 세포, 비만 세포, 자연 살해 세포 등 다양한 선천성 면역 세포들이 관여합니다. 이들은 감염이 발생하기 전부터 존재하며 면역 파수꾼 역할을 합니다. 일부 선천성 면역 세포는 항원을 T 세포에 제시하여 적응성 면역을 활성화시키기도 합니다. 또한, 조직 항상성과 염증에 중요하며, 치유자이자 파괴자 역할을 동시에 수행할 수 있습니다. 병원체 패턴, 사이토카인, 매개체에 의해 활성화되며, 항원에 대해 특이적이지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "적응성 면역은 특이적 면역, 후천성 면역이라고도 불립니다. 림프구인 T 세포와 B 세포가 주요 적응성 면역 세포입니다. 이들은 이차 림프 기관에서 미성숙한 형태로 존재하며, 클론 선택과 증식을 통해 특정 항원에 반응하는 세포로 발달합니다. 적응성 면역은 기억 기능을 가지며, 자가 관용 능력을 통해 자신의 몸을 공격하지 않습니다. 항원 제시 세포에 의해 활성화되며, 항원에 대해 매우 특이적입니다. 적응성 면역은 세포 매개 면역과 체액성 면역으로 나뉩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "숙주 세포에 있는 톨 유사 수용체(TLR)는 병원체 관련 분자 패턴(PAMP)에 결합합니다. TLR이 PAMP에 결합하면 숙주 세포에서 사이토카인 방출을 유도하여 면역 반응의 강도와 지속 시간을 조절합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다양한 PAMP 인식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "포유류 TLR은 다양한 PAMP를 인식합니다. 세균성 PAMP에는 그람 음성 세균 세포벽의 지질다당류(TLR4), 세균 리보솜 RNA(TLR13), 세균 DNA의 비메틸화 CpG(TLR9), 지단백질(TLR2/1, TLR2/6), 편모 단백질(TLR5) 등이 있습니다. 바이러스성 PAMP에는 이중 가닥 RNA(TLR3), 단일 가닥 RNA(TLR7, TLR8), 비메틸화 CpG DNA(TLR9) 등이 있습니다. 기생충성 PAMP에는 지단백질(TLR2/1, TLR2/6), 비메틸화 CpG DNA(TLR9), 단일 가닥 RNA(TLR7), 액틴 결합 단백질 프로필린(TLR11/12) 등이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TLR의 위치 및 내인성 PAMP 인식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "TLR은 세포 표면과 세포 내막에 존재하여 다양한 세포 위치에서 미생물을 인식합니다. TLR은 또한 내인성 PAMP도 인식할 수 있습니다. 세포 스트레스 시 유도되는 샤페론인 열충격 단백질(HSP)과 풍부한 게놈 DNA 결합 단백질인 고이동성 그룹 박스 1(HMGB1) 단백질 등이 내인성 PAMP의 예시입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TLR 신호 전달 경로",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "TLR이 미생물 리간드를 인식하면 여러 신호 전달 경로와 궁극적으로는 전사 인자가 활성화되어, 염증 및 항바이러스 반응에 중요한 유전자의 발현을 유도합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "면역은 질병에 저항하는 능력으로, 선천성 면역과 적응성 면역으로 나뉩니다. 선천성 면역은 모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 특이적 반응으로, 느리지만 기억 기능을 가집니다. 톨 유사 수용체(TLR)는 숙주 세포에서 병원체 관련 분자 패턴(PAMP)을 인식하여 사이토카인 방출을 유도하고 면역 반응을 조절합니다. TLR은 세포 표면과 세포 내막에 존재하며, 다양한 세균, 바이러스, 기생충 PAMP뿐만 아니라 내인성 PAMP도 인식하여 염증 및 항바이러스 반응에 중요한 유전자 발현을 유도하는 신호 전달 경로를 활성화합니다.",
                  "keyConcepts": [
                    {
                      "term": "선천성 면역",
                      "definition": "모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재하는 면역 방어 체계."
                    },
                    {
                      "term": "적응성 면역",
                      "definition": "특정 병원체에 대한 특이적 반응을 보이며, 기억 기능을 통해 재감염 시 더 빠르고 강력하게 반응하는 면역 방어 체계."
                    },
                    {
                      "term": "톨 유사 수용체 (TLR)",
                      "definition": "숙주 세포에 존재하며, 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 유도하는 주요 패턴 인식 수용체."
                    },
                    {
                      "term": "병원체 관련 분자 패턴 (PAMP)",
                      "definition": "미생물에 공통적으로 존재하는 특징적인 분자 구조로, 숙주의 톨 유사 수용체(TLR)에 의해 인식되어 면역 반응을 유발한다."
                    },
                    {
                      "term": "사이토카인",
                      "definition": "면역 세포 간의 신호 전달을 매개하고 면역 반응의 강도와 지속 시간을 조절하는 단백질."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "면역 (Immunity)",
                      "definition": "질병을 막는 능력."
                    },
                    {
                      "term": "감수성 (Susceptibility)",
                      "definition": "질병에 대한 저항력 부족."
                    },
                    {
                      "term": "식세포 (Phagocytes)",
                      "definition": "미생물이나 이물질을 삼켜 제거하는 면역 세포."
                    },
                    {
                      "term": "기억 구성 요소 (Memory component)",
                      "definition": "적응성 면역이 이전에 노출된 병원체를 기억하여 재감염 시 더 빠르고 강력하게 반응하는 능력."
                    },
                    {
                      "term": "자가 관용 (Self tolerance)",
                      "definition": "면역 시스템이 자신의 세포와 조직을 공격하지 않고 구분하는 능력."
                    },
                    {
                      "term": "전사 인자 (Transcription factors)",
                      "definition": "DNA에 결합하여 특정 유전자의 전사(발현)를 조절하는 단백질."
                    },
                    {
                      "term": "내인성 PAMP (Endogenous PAMPs)",
                      "definition": "병원체가 아닌 숙주 세포 자체에서 발생한 손상 또는 스트레스 신호로 TLR이 인식할 수 있는 분자."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역의 개념",
                      "id": "면역의-개념",
                      "children": [
                        {
                          "text": "면역 및 감수성 정의",
                          "id": "면역-및-감수성-정의",
                          "children": null
                        },
                        {
                          "text": "선천성 면역과 적응성 면역의 특징",
                          "id": "선천성-면역과-적응성-면역의-특징",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "선천성 면역",
                      "id": "선천성-면역",
                      "children": [
                        {
                          "text": "선천성 면역의 다른 이름",
                          "id": "선천성-면역의-다른-이름",
                          "children": null
                        },
                        {
                          "text": "선천성 면역 세포의 종류 및 특징",
                          "id": "선천성-면역-세포의-종류-및-특징",
                          "children": null
                        },
                        {
                          "text": "적응성 면역과의 연계성",
                          "id": "적응성-면역과의-연계성",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역",
                      "id": "적응성-면역",
                      "children": [
                        {
                          "text": "적응성 면역의 다른 이름",
                          "id": "적응성-면역의-다른-이름",
                          "children": null
                        },
                        {
                          "text": "적응성 면역 세포의 종류 및 특징",
                          "id": "적응성-면역-세포의-종류-및-특징",
                          "children": null
                        },
                        {
                          "text": "클론 선택, 기억, 자가 관용",
                          "id": "클론-선택-기억-자가-관용",
                          "children": null
                        },
                        {
                          "text": "세포 매개 및 체액성 면역",
                          "id": "세포-매개-및-체액성-면역",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
                      "id": "톨-유사-수용체-tlr-및-병원체-관련-분자-패턴-pamp",
                      "children": [
                        {
                          "text": "TLR과 PAMP의 상호작용",
                          "id": "tlr과-pamp의-상호작용",
                          "children": null
                        },
                        {
                          "text": "사이토카인 방출 및 면역 반응 조절",
                          "id": "사이토카인-방출-및-면역-반응-조절",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "다양한 PAMP 인식",
                      "id": "다양한-pamp-인식",
                      "children": [
                        {
                          "text": "포유류 TLR의 PAMP 인식 범위",
                          "id": "포유류-tlr의-pamp-인식-범위",
                          "children": null
                        },
                        {
                          "text": "세균성 PAMP의 종류",
                          "id": "세균성-pamp의-종류",
                          "children": null
                        },
                        {
                          "text": "바이러스성 PAMP의 종류",
                          "id": "바이러스성-pamp의-종류",
                          "children": null
                        },
                        {
                          "text": "기생충성 PAMP의 종류",
                          "id": "기생충성-pamp의-종류",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "TLR의 위치 및 내인성 PAMP 인식",
                      "id": "tlr의-위치-및-내인성-pamp-인식",
                      "children": [
                        {
                          "text": "세포 표면 및 세포 내막에서의 TLR 위치",
                          "id": "세포-표면-및-세포-내막에서의-tlr-위치",
                          "children": null
                        },
                        {
                          "text": "내인성 PAMP의 인식 (HSP, HMGB1)",
                          "id": "내인성-pamp의-인식-hsp-hmgb1",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "TLR 신호 전달 경로",
                      "id": "tlr-신호-전달-경로",
                      "children": [
                        {
                          "text": "미생물 리간드 인식의 결과",
                          "id": "미생물-리간드-인식의-결과",
                          "children": null
                        },
                        {
                          "text": "염증 및 항바이러스 반응 유도",
                          "id": "염증-및-항바이러스-반응-유도",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "선천성 면역과 적응성 면역의 주요 차이점은 무엇인가요?",
                    "options": [
                      "선천성 면역은 태어날 때부터 존재하며 비특이적인 반면, 적응성 면역은 특정 병원체에 특이적이며 기억 기능을 가집니다.",
                      "선천성 면역은 특정 병원체에 특이적이지만 반응이 느리고, 적응성 면역은 모든 병원체에 빠르게 반응합니다.",
                      "선천성 면역은 기억 기능이 있지만 T세포와 B세포가 관여하지 않고, 적응성 면역은 기억 기능이 없습니다.",
                      "선천성 면역은 항원 제시 세포에 의해 활성화되고, 적응성 면역은 병원체 패턴에 의해 활성화됩니다."
                    ],
                    "answerIndex": 0,
                    "explanation": "선천성 면역은 타고난 비특이적 방어이며, 적응성 면역은 특정 항원에 대한 후천적, 기억 기반 방어입니다."
                  },
                  {
                    "question": "톨 유사 수용체(TLR)의 주요 기능은 무엇인가요?",
                    "options": [
                      "항체를 생산하여 병원체를 직접 중화시키는 기능",
                      "병원체 관련 분자 패턴(PAMP)을 인식하고 사이토카인 방출을 유도하여 면역 반응을 조절하는 기능",
                      "감염된 세포를 직접 파괴하는 자연 살해 세포의 기능을 억제하는 기능",
                      "면역 반응 후 기억 세포를 형성하여 다음 감염에 대비하는 기능"
                    ],
                    "answerIndex": 1,
                    "explanation": "TLR은 숙주 세포에서 PAMP를 인식하여 사이토카인 방출을 유도하고 면역 반응의 강도와 지속 시간을 조절하는 역할을 합니다."
                  },
                  {
                    "question": "다음 중 세균성 PAMP에 해당하지 않는 것은 무엇인가요?",
                    "options": [
                      "지질다당류 (Lipopolysaccharide)",
                      "세균 리보솜 RNA (Bacterial ribosomal RNA)",
                      "이중 가닥 RNA (Double-stranded RNA)",
                      "비메틸화 CpG (Unmethylated CpG in the bacterial DNA)"
                    ],
                    "answerIndex": 2,
                    "explanation": "이중 가닥 RNA(Double-stranded RNA)는 바이러스성 PAMP에 해당합니다. 지질다당류, 세균 리보솜 RNA, 비메틸화 CpG는 세균성 PAMP입니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 1284 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "물리적 요인",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "피부는 선천성 면역의 중요한 물리적 방어선입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "진피는 결합 조직으로 구성된 내부 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성된 외부 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "피부가 벗겨지고 건조한 상태를 유지하는 것은 미생물 성장을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "점막은 위장관, 호흡기, 비뇨생식기를 덮는 상피층입니다. 점액은 미생물을 가두고 관이 건조해지는 것을 막는 점성 당단백질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "누액 기관은 눈물을 배출하여 눈을 씻어냅니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "섬모 승강기는 점액에 갇힌 미생물을 폐에서 멀리 운반합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "귀지는 미생물이 귀에 들어가는 것을 막습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "소변은 흐름을 통해 요도를 청소합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "연동 운동, 배변, 구토, 설사 또한 미생물 배출에 기여하는 물리적 방어 기전입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "화학적 요인",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "피지는 보호막을 형성하고 피부의 pH를 3~5로 낮춥니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "땀, 눈물, 침, 소변에 있는 리소자임은 세균 세포벽을 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "위액의 낮은 pH (1.2~3.0)는 대부분의 세균과 독소를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "질 분비물의 낮은 pH (3~5)는 미생물을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "정상 미생물총과 선천성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "정상 미생물총은 미생물 길항 작용 (경쟁적 배제)을 통해 병원균과 경쟁합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 공간과 영양분에 대한 경쟁 우위를 점하거나, 병원균에 해로운 물질을 생산하거나, 병원균 생존에 영향을 미치는 조건을 변경함으로써 이루어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "공생은 한 유기체는 이득을 얻고 다른 유기체 (숙주)는 해를 입지 않는 관계를 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로바이오틱스는 유익한 효과를 발휘하기 위해 투여되는 살아있는 미생물 배양물입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "무균 쥐를 사육하기 위해서는 엄격한 무균 상태가 요구됩니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 1차 방어선인 물리적 및 화학적 장벽과 정상 미생물총의 역할을 다룹니다. 피부, 점막, 누액 기관, 섬모 승강기, 귀지, 소변, 연동 운동, 배변, 구토, 설사 등 다양한 물리적 요인들이 미생물 침입을 막는 역할을 합니다. 또한, 피지, 리소자임, 위액 및 질 분비물의 낮은 pH와 같은 화학적 요인들이 미생물 성장을 억제하거나 파괴합니다. 정상 미생물총은 경쟁적 배제를 통해 병원균과 경쟁하며 숙주 방어에 기여합니다. 마지막으로, 마이크로바이옴이 선천성 면역 형성에 중요한 영향을 미친다는 점이 강조됩니다.",
                  "keyConcepts": [
                    {
                      "term": "선천성 면역의 물리적 방어선",
                      "definition": "피부, 점막, 눈물, 섬모 등 신체 외부 및 내부 표면에서 미생물 침입을 물리적으로 막는 방어 기전."
                    },
                    {
                      "term": "선천성 면역의 화학적 방어선",
                      "definition": "피지, 리소자임, 위액, 질 분비물 등의 화학 물질이 미생물 성장을 억제하거나 파괴하는 방어 기전."
                    },
                    {
                      "term": "정상 미생물총의 역할",
                      "definition": "인체에 상주하는 유익한 미생물들이 공간 및 영양분 경쟁, 유해 물질 생산 등을 통해 병원균의 침입과 증식을 억제하는 현상 (미생물 길항 작용)."
                    },
                    {
                      "term": "마이크로바이옴과 선천성 면역",
                      "definition": "인체 내 미생물 군집인 마이크로바이옴이 숙주의 선천성 면역 시스템 발달 및 기능에 중요한 영향을 미친다는 개념."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "케라틴",
                      "definition": "피부 표피에 존재하는 보호 단백질로, 피부의 물리적 장벽을 형성하는 데 기여한다."
                    },
                    {
                      "term": "점액",
                      "definition": "점막에서 분비되는 점성 당단백질로, 미생물을 가두고 점막이 건조해지는 것을 방지한다."
                    },
                    {
                      "term": "누액 기관",
                      "definition": "눈물을 생성하고 배출하여 눈을 지속적으로 씻어내 미생물을 제거하는 역할을 하는 기관."
                    },
                    {
                      "term": "섬모 승강기",
                      "definition": "호흡기 점막의 섬모가 움직여 점액에 갇힌 미생물을 폐에서 멀리 이동시키는 메커니즘."
                    },
                    {
                      "term": "리소자임",
                      "definition": "땀, 눈물, 침, 소변 등에 존재하는 효소로, 세균의 세포벽을 파괴하여 항균 작용을 한다."
                    },
                    {
                      "term": "미생물 길항 작용",
                      "definition": "정상 미생물총이 공간, 영양분 경쟁 또는 병원균에 해로운 물질 생산을 통해 병원균의 성장을 억제하는 현상."
                    },
                    {
                      "term": "공생",
                      "definition": "두 유기체가 함께 살아가며 한 유기체는 이득을 얻지만 다른 유기체(숙주)는 해를 입지 않는 관계."
                    }
                  ],
                  "outline": [
                    {
                      "text": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                      "id": "선천성-면역-1차-방어선",
                      "children": [
                        {
                          "text": "물리적 요인",
                          "id": "물리적-요인",
                          "children": [
                            {
                              "text": "피부",
                              "id": "피부",
                              "children": null
                            },
                            {
                              "text": "점막",
                              "id": "점막",
                              "children": null
                            },
                            {
                              "text": "누액 기관",
                              "id": "누액-기관",
                              "children": null
                            },
                            {
                              "text": "기타 물리적 방어 (섬모 승강기, 귀지, 소변, 연동 운동 등)",
                              "id": "기타-물리적-방어",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "화학적 요인",
                          "id": "화학적-요인",
                          "children": [
                            {
                              "text": "피지",
                              "id": "피지",
                              "children": null
                            },
                            {
                              "text": "리소자임",
                              "id": "리소자임",
                              "children": null
                            },
                            {
                              "text": "위액의 낮은 pH",
                              "id": "위액의-낮은-ph",
                              "children": null
                            },
                            {
                              "text": "질 분비물의 낮은 pH",
                              "id": "질-분비물의-낮은-ph",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "정상 미생물총과 선천성 면역",
                          "id": "정상-미생물총과-선천성-면역",
                          "children": [
                            {
                              "text": "미생물 길항 작용",
                              "id": "미생물-길항-작용",
                              "children": null
                            },
                            {
                              "text": "공생 및 프로바이오틱스",
                              "id": "공생-및-프로바이오틱스",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
                          "id": "마이크로바이옴-탐구",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "피부의 표피층에 포함되어 미생물 성장을 억제하는 보호 단백질은 무엇입니까?",
                    "options": [
                      "케라틴",
                      "콜라겐",
                      "엘라스틴",
                      "멜라닌"
                    ],
                    "answerIndex": 0,
                    "explanation": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성되어 있으며, 이는 미생물 성장을 억제하는 데 기여합니다."
                  },
                  {
                    "question": "선천성 면역의 화학적 방어선 중, 땀, 눈물, 침, 소변에 존재하며 세균 세포벽을 파괴하는 효소는 무엇입니까?",
                    "options": [
                      "펩신",
                      "아밀레이스",
                      "리소자임",
                      "트립신"
                    ],
                    "answerIndex": 2,
                    "explanation": "리소자임은 땀, 눈물, 침, 소변에 존재하며 세균의 세포벽을 파괴하는 강력한 항균 효소입니다."
                  },
                  {
                    "question": "정상 미생물총이 병원균과 경쟁하여 성장을 억제하는 주요 메커니즘을 설명하는 용어는 무엇입니까?",
                    "options": [
                      "변이원성",
                      "미생물 길항 작용",
                      "자가면역",
                      "과민 반응"
                    ],
                    "answerIndex": 1,
                    "explanation": "정상 미생물총은 '미생물 길항 작용' 또는 '경쟁적 배제'를 통해 공간, 영양분 경쟁 및 유해 물질 생산으로 병원균의 성장을 억제합니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2110 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "I. 혈액의 구성 요소",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액은 혈장 내에 부유하는 세포 및 세포 조각으로 구성됩니다. 주요 구성 요소는 적혈구(red blood cells), 백혈구(white blood cells), 혈소판(platelets)이며, 이들은 적골수 줄기세포에서 조혈 작용(hematopoiesis)을 통해 생성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "과립구 (Granulocytes)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "과립구는 세포질 내에 광학 현미경으로 볼 수 있는 과립을 가진 백혈구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호중구(Neutrophils): 식균 작용을 하며 감염 초기 단계에서 활동합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호염기구(Basophils): 히스타민을 방출하며 알레르기 반응에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호산구(Eosinophils): 식균 작용을 하며 기생충과 연충류에 대해 독성을 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "무과립구 (Agranulocytes)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "무과립구는 세포질 내에 과립이 있지만 광학 현미경으로 보이지 않는 백혈구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 단핵구(Monocytes): 조직에서 대식세포(macrophages)로 성숙하여 식균 작용을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 수지상 세포(Dendritic cells): 피부, 점막, 흉선에서 발견되며 식균 작용을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 림프구(Lymphocytes): T세포, B세포, NK세포를 포함하며 적응 면역에 중요한 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "II. 림프계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "림프계는 림프, 림프관, 림프 조직, 적골수로 구성됩니다. 림프구와 식세포를 포함하며, 림프는 미생물을 림프절로 운반하여 림프구와 대식세포가 병원균을 파괴하도록 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "림프계의 주요 구성 요소 및 기관에는 흉관(좌측 림프관), 우측 림프관, 좌측 쇄골하정맥, 우측 쇄골하정맥, 편도, 흉선, 림프절, 비장, 대장, 소장, 파이어판(Peyer’s patch), 림프관, 적골수, 림프 모세혈관 등이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "III. 숙주 방어: 개요 및 식세포",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포(Phagocytes)는 '먹다'를 의미하는 그리스어 'Phago'와 '세포'를 의미하는 'Cyte'에서 유래했습니다. 식세포에는 조직과 장기에 상주하는 고정 대식세포(Fixed macrophages)와 조직을 돌아다니며 감염 부위에 모이는 자유(유리) 대식세포(Free (wandering) macrophages)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IV. 식균 작용의 메커니즘",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "식균 작용은 다음 단계를 거쳐 진행됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 주화성(Chemotaxis): 화학적 신호가 식세포를 미생물로 유인합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 부착(Adherence): 식세포가 미생물 표면에 부착합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 섭취(Ingestion): 미생물이 혈청 단백질로 코팅되어(옵소닌화, Opsonization) 섭취가 용이해집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 소화(Digestion): 미생물이 식포-리소좀(phagolysosome) 내부에서 소화됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "V. 미생물의 식균 작용 회피 전략",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "일부 미생물은 숙주의 방어 체계를 회피하기 위한 다양한 병원성 인자(Virulence factors)를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 부착 억제: M 단백질, 캡슐 (예: Streptococcus pyogenes, S. pneumoniae)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식세포 사멸: 백혈구용해소(leukocidins) (예: Staphylococcus aureus)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식세포 용해: 막 공격 복합체(membrane attack complex) (예: Listeria monocytogenes)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포 탈출: (예: Shigella, Rickettsia)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포-리소좀 융합 방지: (예: HIV, Mycobacterium tuberculosis)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포-리소좀 내 생존: (예: Coxiella burnetii)",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 2차 방어선으로서 혈액의 구성 요소와 식세포의 역할에 대해 설명합니다. 혈액의 주요 구성 요소(적혈구, 백혈구, 혈소판)와 조혈 작용을 소개하고, 백혈구를 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 분류하여 각 유형의 기능과 특징을 설명합니다. 또한, 림프계의 구성 요소와 병원균 제거에서의 역할을 다루고, 식세포의 정의와 고정/자유 대식세포의 종류를 설명합니다. 이어서 식균 작용의 네 가지 주요 단계(주화성, 부착, 섭취, 소화)를 자세히 설명하며, 특히 옵소닌화의 중요성을 강조합니다. 마지막으로, 미생물이 식균 작용을 회피하기 위해 사용하는 다양한 전략(부착 억제, 식세포 사멸, 식포 탈출 등)과 관련 미생물 예를 제시합니다.",
                  "keyConcepts": [
                    {
                      "term": "혈액의 구성 요소",
                      "definition": "혈액을 구성하는 주요 성분으로, 혈장 내에 부유하는 적혈구, 백혈구, 혈소판을 포함하며, 조혈 작용을 통해 생성됩니다."
                    },
                    {
                      "term": "백혈구의 종류와 기능",
                      "definition": "감염 및 알레르기 반응에 관여하는 면역 세포로, 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 나뉘며 각각 특정한 면역 기능을 수행합니다."
                    },
                    {
                      "term": "림프계의 역할",
                      "definition": "림프, 림프관, 림프 조직, 적골수로 구성되며 림프구와 식세포를 포함하여 병원균을 림프절로 운반하고 파괴함으로써 면역 방어에 기여하는 시스템입니다."
                    },
                    {
                      "term": "식균 작용",
                      "definition": "식세포가 미생물이나 세포 잔해를 섭취하고 소화하여 제거하는 과정으로, 주화성, 부착, 섭취(옵소닌화 포함), 소화의 단계를 거칩니다."
                    },
                    {
                      "term": "미생물의 식균 작용 회피",
                      "definition": "미생물이 숙주의 식균 작용으로부터 자신을 보호하기 위해 사용하는 다양한 전략으로, 부착 억제, 식세포 사멸, 식포 탈출, 식포-리소좀 융합 방지, 식포-리소좀 내 생존 등이 있습니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "조혈 작용 (Hematopoiesis)",
                      "definition": "적골수 줄기세포에서 혈액 세포(적혈구, 백혈구, 혈소판)가 생성되는 과정입니다."
                    },
                    {
                      "term": "과립구 (Granulocytes)",
                      "definition": "세포질 내에 과립을 가진 백혈구로, 호중구, 호염기구, 호산구가 포함됩니다."
                    },
                    {
                      "term": "무과립구 (Agranulocytes)",
                      "definition": "세포질 내에 과립이 뚜렷하지 않은 백혈구로, 단핵구, 수지상 세포, 림프구가 포함됩니다."
                    },
                    {
                      "term": "식세포 (Phagocytes)",
                      "definition": "미생물이나 이물질을 섭취하고 소화하는 세포(예: 대식세포, 호중구)를 총칭합니다."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포에 의한 섭취가 용이해지는 과정입니다."
                    },
                    {
                      "term": "주화성 (Chemotaxis)",
                      "definition": "화학적 신호에 의해 세포가 특정 방향으로 이동하는 현상으로, 식세포가 미생물로 유인되는 과정입니다."
                    },
                    {
                      "term": "병원성 인자 (Virulence factors)",
                      "definition": "미생물이 숙주에게 질병을 일으키거나 숙주의 면역 체계를 회피하는 데 도움이 되는 특징 또는 물질입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "I. 혈액의 구성 요소",
                      "id": "i-혈액의-구성-요소",
                      "children": [
                        {
                          "text": "과립구 (Granulocytes)",
                          "id": "과립구-granulocytes",
                          "children": null
                        },
                        {
                          "text": "무과립구 (Agranulocytes)",
                          "id": "무과립구-agranulocytes",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "II. 림프계",
                      "id": "ii-림프계",
                      "children": null
                    },
                    {
                      "text": "III. 숙주 방어: 개요 및 식세포",
                      "id": "iii-숙주-방어-개요-및-식세포",
                      "children": null
                    },
                    {
                      "text": "IV. 식균 작용의 메커니즘",
                      "id": "iv-식균-작용의-메커니즘",
                      "children": null
                    },
                    {
                      "text": "V. 미생물의 식균 작용 회피 전략",
                      "id": "v-미생물의-식균-작용-회피-전략",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 과립구에 해당하지 않는 백혈구는 무엇입니까?",
                    "options": [
                      "단핵구",
                      "호중구",
                      "호염기구",
                      "호산구"
                    ],
                    "answerIndex": 0,
                    "explanation": "단핵구는 무과립구에 속하며, 조직에서 대식세포로 성숙하여 식균 작용을 합니다. 호중구, 호염기구, 호산구는 모두 과립구에 해당합니다."
                  },
                  {
                    "question": "식균 작용의 단계 중, 미생물이 혈청 단백질로 코팅되어 식세포에 의한 섭취가 용이해지는 과정을 무엇이라고 합니까?",
                    "options": [
                      "주화성",
                      "부착",
                      "옵소닌화",
                      "소화"
                    ],
                    "answerIndex": 2,
                    "explanation": "옵소닌화는 미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포의 섭취(Ingestion)를 돕는 과정입니다."
                  },
                  {
                    "question": "다음 미생물 중 식포-리소좀 융합을 방지하여 식균 작용을 회피하는 것으로 알려진 것은 무엇입니까?",
                    "options": [
                      "Streptococcus pyogenes",
                      "Staphylococcus aureus",
                      "Listeria monocytogenes",
                      "Mycobacterium tuberculosis"
                    ],
                    "answerIndex": 3,
                    "explanation": "Mycobacterium tuberculosis는 식포-리소좀 융합을 방지하여 식세포 내에서 생존함으로써 식균 작용을 회피합니다. Streptococcus pyogenes는 부착을 억제하고, Staphylococcus aureus는 백혈구용해소를 통해 식세포를 사멸시키며, Listeria monocytogenes는 식세포를 용해시킵니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 3719 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "염증: 개요",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "염증",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "염증의 네 가지 징후 및 증상: 발적(redness), 부종(edema), 통증(pain), 열(heat).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "손상 인자를 파괴하거나 신체에 미치는 영향을 제한합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "손상 인자에 의해 손상된 조직을 복구하고 대체합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 유발 물질",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "염증은 간에서 급성기 단백질을 활성화시켜 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주요 염증 매개체는 다음과 같습니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "히스타민 (Histamine): 비만 세포, 호염기구, 혈소판에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "키닌 (Kinins): 혈장 내에 존재하며 호중구를 유인하여 화학주성(chemotaxis)을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로스타글란딘 (Prostaglandins): 손상된 세포에서 분비되며 히스타민과 키닌의 효과를 강화하고 식세포가 모세혈관 벽을 통과하는 것을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류코트리엔 (Leukotrienes): 비만 세포와 호염기구에서 분비되며 혈관 투과성을 증가시키고 식세포가 병원체에 부착되는 것을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 (Complement): 혈장 내에 존재하며 히스타민 분비를 자극하고 식세포를 유인하며 식균 작용을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인 (Cytokines): 고정된 대식세포에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 과정 단계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 16.9a-b 염증 과정: 조직 손상, 혈관 반응 및 식균 작용을 포함합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 과정",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조직 손상이 발생하면 손상된 세포에서 히스타민, 키닌, 프로스타글란딘, 류코트리엔, 사이토카인과 같은 화학 물질이 방출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액 응고가 형성되기 시작하고 농양(abscess)이 형성되기 시작합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "식세포 이동 및 식균 작용",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "마지네이션(Margination)은 염증 부위의 사이토카인에 반응하여 식세포가 혈관에 달라붙는 현상입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포는 다이아페데시스(diapedesis)를 통해 혈관 내피 세포 사이를 비집고 나옵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "조직 복구",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "모든 유해 물질이 제거되거나 중화될 때까지 완료될 수 없습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "기질(Stroma)은 복구되는 지지 결합 조직입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "실질(Parenchyma)은 복구되는 조직의 기능적인 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "발열",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "비정상적으로 높은 체온입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "시상하부(Hypothalamus)는 일반적으로 37°C로 설정되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인이 시상하부로 하여금 프로스타글란딘을 방출하게 하여 시상하부의 온도를 더 높게 재설정합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "몸은 혈관을 수축시키고 떨림(shivering)이 발생하여 체온이 상승합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "체온이 떨어지면 (위기, crisis) 혈관 확장과 땀이 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 시스템",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "간에서 생산되는 혈청 단백질로, 미생물 파괴에 면역계를 보조합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 활성화라고 불리는 과정에서 캐스케이드(cascade) 방식으로 작용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "단백질은 대문자 C로 표시되며 발견 순서대로 번호가 매겨집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 단편은 소문자 a와 b로 표시됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체: 활성화",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "고전적 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 항원에 결합하여 C1을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C1은 분열하여 C2와 C4를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C2a와 C4b가 결합하여 C3을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3a는 염증에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3b는 세포 용해(cytolysis)와 옵소닌화(opsonization)에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "대체 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액 내 C3가 미생물 표면의 B, D, P 인자와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3는 C3a와 C3b로 분열하며, 고전적 경로와 동일하게 기능합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "렉틴 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "대식세포가 병원체를 섭취하여 사이토카인을 방출하고, 이는 간에서 렉틴 생산을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "만노스 결합 렉틴(Mannose-binding lectin, MBL)이 만노스에 결합하여 C2와 C4를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C2a와 C4b가 C3을 활성화하며, 이는 고전적 경로 및 대체 경로와 동일하게 기능합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 활성화의 결과",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "세포 용해",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 보체 단백질이 막 공격 복합체(Membrane Attack Complex, MAC)를 형성합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "옵소닌화",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포가 미생물에 부착되는 것을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 보체 단백질이 비만 세포에 결합하여 히스타민을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 16.12 보체 활성화의 결과. 그림 16.13 보체에 의해 자극된 염증.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 시스템은 신체가 감염과 병원체를 퇴치하는 또 다른 방법입니다. 선천성 면역의 이 구성 요소는 다른 면역 반응을 '보완'합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체는 혈청에 순환하는 30개 이상의 단백질 그룹으로, 캐스케이드 방식으로 활성화됩니다: 한 보체 단백질이 다음 단백질을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 캐스케이드는 병원체에 의해 직접 활성화되거나 항체-항원 반응에 의해 활성화될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 단백질들은 함께 (1) 세포 용해, (2) 강화된 식균 작용, (3) 염증을 통해 미생물을 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체: 결과",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "보체 활성화의 조절",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 단백질은 보체 단백질을 쉽게 분해하여 숙주 세포 손상을 최소화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체와 질병",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 단백질의 부족은 감염에 대한 취약성을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 시스템 회피",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "캡슐은 보체 활성화를 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인터페론",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "세포에서 생산되는 사이토카인으로, 항바이러스 활동을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IFN-α 및 IFN-β: 바이러스 감염에 반응하여 세포에서 생산되며, 이웃 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IFN-γ: 호중구와 대식세포가 박테리아를 죽이도록 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "알파 및 베타 인터페론(IFN)의 항바이러스 작용",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "철 결합 단백질",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "트랜스페린(Transferrin): 혈액 및 조직액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "락토페린(Lactoferrin): 우유, 침, 점액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "페리틴(Ferritin): 간, 비장, 적골수에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "헤모글로빈(Hemoglobin): 적혈구에 위치합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "박테리아는 철 결합 단백질과 경쟁하기 위해 시데로포어(siderophores)를 생산합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항균 펩타이드",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "미생물의 단백질 및 당 분자에 반응하여 생산되는 짧은 펩타이드입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포벽 합성을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "원형질막에 구멍을 형성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "광범위한 활성 스펙트럼을 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "기타 요인",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "유전적 저항성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "선택적 생존 이점을 부여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "예: 겸상 적혈구 특성 및 열대열원충(Plasmodium falciparum).",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "연령",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "매우 어린 연령과 노인들은 질병에 더 취약합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "건강 프로토콜 준수",
                    "level": 2
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 핵심 구성 요소인 염증, 발열, 보체 시스템, 인터페론, 철 결합 단백질 및 항균 펩타이드에 대해 설명합니다. 염증의 징후, 매개체, 과정 및 조직 복구를 다루고, 발열의 메커니즘과 체온 조절을 설명합니다. 또한 보체 시스템의 세 가지 활성화 경로(고전적, 대체, 렉틴)와 그 결과(세포 용해, 옵소닌화, 염증)를 상세히 제시합니다. 마지막으로, 인터페론의 항바이러스 역할, 철 결합 단백질의 기능, 항균 펩타이드의 작용 방식, 그리고 유전적 저항성 및 연령과 같은 기타 면역 관련 요인들을 소개합니다.",
                  "keyConcepts": [
                    {
                      "term": "염증 (Inflammation)",
                      "definition": "손상된 조직을 파괴하거나 유해 물질의 영향을 제한하고, 손상된 조직을 복구 및 대체하는 신체의 방어 반응입니다. 발적, 부종, 통증, 열의 네 가지 주요 징후를 가집니다."
                    },
                    {
                      "term": "발열 (Fever)",
                      "definition": "비정상적으로 높은 체온으로, 사이토카인에 의해 시상하부의 체온 설정점이 높아져 발생합니다. 병원체 성장을 억제하고 면역 반응을 강화하는 데 도움을 줄 수 있습니다."
                    },
                    {
                      "term": "보체 시스템 (Complement System)",
                      "definition": "간에서 생산되는 30개 이상의 혈청 단백질로 구성된 캐스케이드 시스템입니다. 병원체 파괴를 돕기 위해 세포 용해, 옵소닌화, 염증을 유발하는 세 가지 활성화 경로(고전적, 대체, 렉틴)를 통해 작동합니다."
                    },
                    {
                      "term": "인터페론 (Interferons)",
                      "definition": "세포에서 생산되는 사이토카인으로, 특히 IFN-α와 IFN-β는 바이러스 감염에 반응하여 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질을 생산하도록 유도하는 항바이러스 활성을 가집니다."
                    },
                    {
                      "term": "항균 물질 (Antimicrobial Substances)",
                      "definition": "철 결합 단백질(트랜스페린, 락토페린, 페리틴, 헤모글로빈)과 항균 펩타이드를 포함하며, 미생물의 성장을 억제하거나 직접 파괴하여 숙주를 보호하는 역할을 합니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "히스타민 (Histamine)",
                      "definition": "비만 세포 등에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발하는 혈관 활성 매개체입니다."
                    },
                    {
                      "term": "다이아페데시스 (Diapedesis)",
                      "definition": "식세포가 혈관 내피 세포 사이를 비집고 나와 조직 손상 부위로 이동하는 과정입니다."
                    },
                    {
                      "term": "마지네이션 (Margination)",
                      "definition": "염증 부위의 사이토카인에 반응하여 식세포가 혈관 내피에 달라붙는 현상입니다."
                    },
                    {
                      "term": "막 공격 복합체 (Membrane Attack Complex, MAC)",
                      "definition": "활성화된 보체 단백질에 의해 형성되며, 미생물 세포막에 구멍을 뚫어 세포 용해를 유발하는 구조입니다."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "보체 단백질(C3b) 등이 미생물을 코팅하여 식세포가 미생물을 더 쉽게 인식하고 식균 작용을 하도록 촉진하는 과정입니다."
                    },
                    {
                      "term": "시데로포어 (Siderophores)",
                      "definition": "박테리아가 숙주의 철 결합 단백질과 경쟁하여 철을 획득하기 위해 생산하는 물질입니다."
                    },
                    {
                      "term": "항바이러스 단백질 (Antiviral Proteins, AVPs)",
                      "definition": "인터페론의 유도에 의해 세포에서 생산되며, 바이러스 복제를 억제하는 단백질입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "염증",
                      "id": "inflammation",
                      "children": [
                        {
                          "text": "개요 및 징후",
                          "id": "inflammation-overview-signs",
                          "children": null
                        },
                        {
                          "text": "염증 반응 유발 물질",
                          "id": "inflammation-mediators",
                          "children": null
                        },
                        {
                          "text": "염증 과정 단계",
                          "id": "inflammation-steps",
                          "children": null
                        },
                        {
                          "text": "식세포 이동 및 식균 작용",
                          "id": "phagocyte-migration-phagocytosis",
                          "children": null
                        },
                        {
                          "text": "조직 복구",
                          "id": "tissue-repair",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "발열",
                      "id": "fever",
                      "children": [
                        {
                          "text": "체온 조절 및 발열 메커니즘",
                          "id": "fever-mechanism",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "보체 시스템",
                      "id": "complement-system",
                      "children": [
                        {
                          "text": "개요 및 기능",
                          "id": "complement-overview",
                          "children": null
                        },
                        {
                          "text": "보체 활성화 경로",
                          "id": "complement-activation-pathways",
                          "children": [
                            {
                              "text": "고전적 경로",
                              "id": "classical-pathway",
                              "children": null
                            },
                            {
                              "text": "대체 경로",
                              "id": "alternative-pathway",
                              "children": null
                            },
                            {
                              "text": "렉틴 경로",
                              "id": "lectin-pathway",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "보체 활성화의 결과",
                          "id": "complement-activation-outcomes",
                          "children": [
                            {
                              "text": "세포 용해",
                              "id": "cytolysis",
                              "children": null
                            },
                            {
                              "text": "옵소닌화",
                              "id": "opsonization",
                              "children": null
                            },
                            {
                              "text": "염증",
                              "id": "complement-inflammation",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "보체 조절 및 질병",
                          "id": "complement-regulation-disease",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항균 물질",
                      "id": "antimicrobial-substances",
                      "children": [
                        {
                          "text": "인터페론",
                          "id": "interferons",
                          "children": null
                        },
                        {
                          "text": "철 결합 단백질",
                          "id": "iron-binding-proteins",
                          "children": null
                        },
                        {
                          "text": "항균 펩타이드",
                          "id": "antimicrobial-peptides",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "기타 요인",
                      "id": "other-factors",
                      "children": [
                        {
                          "text": "유전적 저항성",
                          "id": "genetic-resistance",
                          "children": null
                        },
                        {
                          "text": "연령",
                          "id": "age",
                          "children": null
                        },
                        {
                          "text": "건강 프로토콜 준수",
                          "id": "observing-healthy-protocols",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "염증의 네 가지 주요 징후에 해당하지 않는 것은 무엇입니까?",
                    "options": [
                      "발적",
                      "부종",
                      "가려움",
                      "열"
                    ],
                    "answerIndex": 2,
                    "explanation": "염증의 네 가지 주요 징후는 발적(redness), 부종(swelling), 통증(pain), 열(heat)입니다. 가려움은 일반적인 염증의 주요 징후에 해당하지 않습니다."
                  },
                  {
                    "question": "보체 활성화의 세 가지 주요 결과에 속하지 않는 것은 무엇입니까?",
                    "options": [
                      "세포 용해 (Cytolysis)",
                      "옵소닌화 (Opsonization)",
                      "항체 생산 (Antibody production)",
                      "염증 (Inflammation)"
                    ],
                    "answerIndex": 2,
                    "explanation": "보체 활성화의 주요 결과는 세포 용해, 옵소닌화, 염증입니다. 항체 생산은 보체 시스템의 직접적인 결과가 아닌 적응 면역 반응의 일부입니다."
                  },
                  {
                    "question": "인터페론(IFN-α 및 IFN-β)의 주요 역할은 무엇입니까?",
                    "options": [
                      "세균을 직접 죽인다.",
                      "발열을 유도한다.",
                      "바이러스 감염에 반응하여 항바이러스 단백질 생성을 유도한다.",
                      "조직 복구를 돕는다."
                    ],
                    "answerIndex": 2,
                    "explanation": "IFN-α와 IFN-β는 바이러스 감염에 의해 생성되어 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 개요 및 이중적 특성",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1042 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "적응성 면역 체계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "적응성 면역은 특정 병원체를 표적으로 하는 방어 체계입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 감염이나 백신 접종을 통해 획득됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것을 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 반응은 동일한 외래 물질과의 이후 상호 작용으로, '기억' 덕분에 더 빠르고 효과적입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역 체계의 이중적 특성",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "체액성 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "체액성 면역은 항원(antigens)으로 알려진 외래 분자와 싸우는 항체를 생성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 적골수에서 생성되고 성숙하는 림프구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 항원을 인식하고 항체를 만듭니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 조류의 파브리시우스 낭(bursa of Fabricius)에서 이름을 따왔습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "애니메이션: 체액성 면역 개요",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포성 면역 (세포 매개 면역)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포성 면역은 T 림프구를 생성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 림프구는 식세포에 의해 처리된 항원 펩타이드를 인식합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 흉선에서 성숙합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 표면의 T 세포 수용체(TCRs)가 항원과 접촉하면 T 세포는 항체 대신 사이토카인을 분비합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 및 B 세포 발달",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "체액성 면역과 세포성 면역의 공격 대상 비교",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포성 면역은 세포 내부에 있는 항원을 공격합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 바이러스나 M. leprae, L. monocytogenes와 같은 일부 세포 내 세균에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "체액성 면역은 세포 외부의 침입자와 위협에 맞서 싸웁니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 세포 외 세균과 독소, 그리고 숙주 세포에 들어가기 전의 바이러스를 포함합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "제공된 텍스트는 특정 병원체를 표적으로 하는 방어 체계인 적응성 면역에 대해 설명합니다. 적응성 면역은 감염이나 백신을 통해 획득되며, 일차 반응과 이차 반응으로 구분됩니다. 또한, 적응성 면역의 이중적 특성으로 체액성 면역(B 세포, 항체 생성, 세포 외부 위협 방어)과 세포성 면역(T 세포, 사이토카인 분비, 세포 내부 위협 방어)을 상세히 다루고, 각 면역 체계가 공격하는 대상의 차이점을 비교합니다.",
                  "keyConcepts": [
                    {
                      "term": "적응성 면역",
                      "definition": "특정 병원체를 표적으로 삼는 방어 체계로, 감염이나 백신 접종을 통해 획득되며, 기억을 통해 더 빠르고 효과적인 이차 반응을 가능하게 합니다."
                    },
                    {
                      "term": "체액성 면역",
                      "definition": "B 세포가 항원을 인식하고 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸우는 면역 반응입니다."
                    },
                    {
                      "term": "세포성 면역",
                      "definition": "T 림프구가 식세포에 의해 처리된 항원 펩타이드를 인식하고 사이토카인을 분비하여 세포 내부에 있는 항원(예: 바이러스, 일부 세포 내 세균)을 공격하는 면역 반응입니다."
                    },
                    {
                      "term": "일차 반응 및 이차 반응",
                      "definition": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것이며, 이차 반응은 동일한 물질과의 이후 상호 작용으로, 기억 덕분에 더 빠르고 효과적입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "항원 (Antigen)",
                      "definition": "면역 반응, 특히 항체 생성을 유도하는 외래 분자입니다."
                    },
                    {
                      "term": "항체 (Antibody)",
                      "definition": "B 세포에 의해 생성되며 특정 항원과 결합하여 중화하거나 제거하는 Y자 모양의 단백질입니다."
                    },
                    {
                      "term": "B 세포 (B cell)",
                      "definition": "적골수에서 생성 및 성숙하며 항원을 인식하고 항체를 만드는 림프구입니다."
                    },
                    {
                      "term": "T 세포 (T cell)",
                      "definition": "흉선에서 성숙하며 항원 제시 세포에 의해 처리된 항원 펩타이드를 인식하고 항체 대신 사이토카인을 분비하는 림프구입니다."
                    },
                    {
                      "term": "사이토카인 (Cytokine)",
                      "definition": "T 세포 등 면역 세포가 분비하는 작은 단백질로, 면역 반응과 염증을 조절하는 신호 분자 역할을 합니다."
                    },
                    {
                      "term": "T 세포 수용체 (TCR)",
                      "definition": "T 세포 표면에 위치하며 특정 항원 펩타이드를 인식하고 결합하는 수용체입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "적응성 면역 체계",
                      "id": "adaptive-immune-system",
                      "children": [
                        {
                          "text": "적응성 면역의 정의 및 획득 경로",
                          "id": "definition-acquisition-of-adaptive-immunity",
                          "children": null
                        },
                        {
                          "text": "일차 반응과 이차 반응",
                          "id": "primary-and-secondary-response",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역 체계의 이중적 특성",
                      "id": "dual-nature-of-adaptive-immune-system",
                      "children": [
                        {
                          "text": "체액성 면역",
                          "id": "humoral-immunity",
                          "children": [
                            {
                              "text": "항체 생성 및 항원 공격",
                              "id": "antibody-production-and-antigen-attack",
                              "children": null
                            },
                            {
                              "text": "B 세포의 역할 및 특징",
                              "id": "role-and-characteristics-of-b-cells",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "세포성 면역 (세포 매개 면역)",
                          "id": "cellular-immunity",
                          "children": [
                            {
                              "text": "T 림프구 생성 및 역할",
                              "id": "t-lymphocyte-production-and-role",
                              "children": null
                            },
                            {
                              "text": "T 세포의 성숙 및 항원 인식",
                              "id": "t-cell-maturation-and-antigen-recognition",
                              "children": null
                            },
                            {
                              "text": "T 세포 수용체(TCR) 및 사이토카인 분비",
                              "id": "tcr-and-cytokine-secretion",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "체액성 면역과 세포성 면역의 공격 대상 비교",
                          "id": "comparison-of-humoral-and-cellular-immunity-targets",
                          "children": [
                            {
                              "text": "세포성 면역의 대상 (세포 내부 항원)",
                              "id": "targets-of-cellular-immunity",
                              "children": null
                            },
                            {
                              "text": "체액성 면역의 대상 (세포 외부 위협)",
                              "id": "targets-of-humoral-immunity",
                              "children": null
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "적응성 면역의 주요 특징은 무엇입니까?",
                    "options": [
                      "비특이적 방어",
                      "특정 병원체를 표적으로 함",
                      "즉각적인 반응",
                      "항상 식세포 작용을 포함함"
                    ],
                    "answerIndex": 1,
                    "explanation": "적응성 면역은 특정 병원체를 표적으로 삼는 방어 체계입니다."
                  },
                  {
                    "question": "항체를 생성하고 세포 외부의 위협을 공격하는 면역 유형은 무엇입니까?",
                    "options": [
                      "선천성 면역",
                      "세포성 면역",
                      "체액성 면역",
                      "비특이적 면역"
                    ],
                    "answerIndex": 2,
                    "explanation": "체액성 면역은 B 세포가 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸웁니다."
                  },
                  {
                    "question": "T 세포는 어디에서 성숙합니까?",
                    "options": [
                      "적골수",
                      "비장",
                      "림프절",
                      "흉선"
                    ],
                    "answerIndex": 3,
                    "explanation": "T 세포는 흉선(thymus)에서 성숙합니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 사이토카인, 항원 및 항체",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1989 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "사이토카인: 면역 세포의 화학적 전달자",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인은 자극에 반응하여 생성되는 화학적 전달자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인터루킨(Interleukins): 백혈구 사이의 사이토카인입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "케모카인(Chemokines): 백혈구의 이동을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인터페론(Interferons, IFNs): 숙주 세포의 바이러스 감염을 방해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "종양 괴사 인자(Tumor necrosis factor, TNF): 자가면역 질환의 염증과 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "조혈 사이토카인(Hematopoietic cytokines): 적혈구와 백혈구로 발달하는 줄기세포를 조절합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인의 과잉 생산은 사이토카인 폭풍(cytokine storm)으로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "주요 사이토카인 및 그 역할",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-4: TH2 세포에서 생성되며, 미감염 TH 세포와 B 세포에 작용하여 TH2 세포 증식을 유도하고 IgE로의 클래스 전환을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-12: 수지상 세포, 대식세포, 호중구에서 생성되며, 미감염 TH 세포와 NK 세포에 작용하여 TH1 세포의 성장과 기능을 자극하고 IFN-γ 및 TNF-α를 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-17: TH17 세포에서 생성되며, 호중구에 작용하여 염증을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-22: TH17 세포에서 생성되며, 상피세포에 작용하여 항균 단백질 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감마 인터페론(IFN-γ): TH1 세포에서 생성되며, CTL(세포독성 T 림프구)과 대식세포에 작용하여 식세포 작용을 촉진하고 대식세포 및 체액성 면역 반응을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "케모카인: 다양한 세포(대식세포, 상피세포)에서 생성되며, 호중구에 작용하여 화학주성(chemotaxis)을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "TNF-알파(TNF-α): 대식세포, TH 세포, NK 세포에서 생성되며, 종양 세포에 작용하여 염증을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "GM-CSF: 대식세포, T 세포, NK 세포에서 생성되며, 골수 줄기세포에 작용하여 대식세포와 과립구 수를 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항원은 항체 생성을 유발하는 물질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일반적으로 침입하는 미생물이나 이물질의 구성 요소입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체는 항원상의 에피토프(epitopes) 또는 항원결정인자(antigenic determinants)와 상호작용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "합텐",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "합텐은 면역 반응을 유발하기에는 너무 작은 항원입니다; 운반 분자에 부착되어야 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항체",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체는 면역글로불린(Immunoglobulins, Ig)이라고 불리는 구형 단백질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가(Valence)는 항체에 있는 항원 결합 부위의 수를 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이중가(Bivalent) 항체는 두 개의 결합 부위를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전형적인 항체 분자의 구조",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "네 개의 단백질 사슬이 Y자 모양을 이룹니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "두 개의 동일한 경쇄(light chains)와 두 개의 동일한 중쇄(heavy chains)가 이황화 결합으로 연결되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가변(V) 부위는 팔의 끝 부분에 위치하며 에피토프와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "정상(Fc) 부위는 줄기 부분으로, 특정 Ig 클래스에 대해 동일합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역글로불린은 5가지 클래스(IgG, IgM, IgA, IgD, IgE)로 나뉩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역글로불린 클래스 요약",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "IgG",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체(Monomer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 80%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액, 림프, 장에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "태반을 통과하여 태아를 보호하고; 보체(complement)를 활성화하며; 식세포 작용을 강화하고; 독소와 바이러스를 중화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgM",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다섯 개의 단량체가 J 사슬로 연결된 오량체(Pentamer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 6%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈관 내에 남아있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포와 바이러스의 응집을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감염에 대한 첫 번째 반응이며; 수명이 짧습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgA",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청에서는 단량체, 분비물에서는 이량체(Dimer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 13%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "점막, 침, 눈물, 모유에서 흔히 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "미생물이 점막에 부착하는 것을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgD",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 0.02%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IgG와 유사한 구조를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액, 림프, B 세포에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "명확히 정의된 기능은 없으나; B 세포의 면역 반응을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgE",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 0.002%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비만세포, 호염기구, 혈액에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원과 결합하면 히스타민 방출을 유발하고; 기생충을 용해합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본 문서는 적응성 면역의 핵심 요소인 사이토카인, 항원, 항체에 대해 설명합니다. 사이토카인은 면역 세포 간의 화학적 전달자로, 다양한 종류(인터루킨, 케모카인, 인터페론, TNF 등)와 기능(염증 유발, 백혈구 이동 유도, 바이러스 감염 방해 등)을 가지며, 과잉 생산 시 사이토카인 폭풍을 유발할 수 있습니다. 항원은 항체 생성을 유발하는 물질이며, 항체가 결합하는 특정 부위를 에피토프라고 합니다. 합텐은 면역 반응을 유발하기에 너무 작아 운반 분자에 부착해야 하는 항원입니다. 항체는 면역글로불린(Ig)이라는 단백질로, Y자 모양의 구조를 가지며 가변부위와 정상부위로 구성됩니다. IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 클래스가 있으며, 각 클래스는 고유한 구조적 특성과 면역 기능을 수행합니다.",
                  "keyConcepts": [
                    {
                      "term": "사이토카인 (Cytokines)",
                      "definition": "면역 세포 간의 통신을 담당하는 화학적 전달 물질로, 다양한 면역 반응을 조절합니다."
                    },
                    {
                      "term": "항원 (Antigens)",
                      "definition": "면역 반응, 특히 항체 생성을 유발하는 물질입니다."
                    },
                    {
                      "term": "항체 (Antibodies/Immunoglobulins)",
                      "definition": "항원에 특이적으로 결합하여 항원을 중화하거나 제거하는 면역 단백질입니다."
                    },
                    {
                      "term": "면역글로불린 클래스 (Immunoglobulin Classes)",
                      "definition": "항체의 기능과 구조에 따라 IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 분류로 나뉩니다."
                    },
                    {
                      "term": "사이토카인 폭풍 (Cytokine Storm)",
                      "definition": "사이토카인이 과도하게 생산되어 전신 염증 반응과 조직 손상을 유발할 수 있는 심각한 면역 반응입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "인터루킨 (Interleukins)",
                      "definition": "백혈구 사이에서 작용하는 사이토카인입니다."
                    },
                    {
                      "term": "케모카인 (Chemokines)",
                      "definition": "백혈구의 이동(화학주성)을 유도하는 사이토카인입니다."
                    },
                    {
                      "term": "인터페론 (Interferons, IFNs)",
                      "definition": "바이러스 감염을 방해하는 사이토카인입니다."
                    },
                    {
                      "term": "종양 괴사 인자 (Tumor Necrosis Factor, TNF)",
                      "definition": "염증 반응과 관련된 사이토카인입니다."
                    },
                    {
                      "term": "에피토프 (Epitopes)",
                      "definition": "항원 상에서 항체가 특이적으로 결합하는 특정 부위 또는 항원결정인자입니다."
                    },
                    {
                      "term": "합텐 (Haptens)",
                      "definition": "단독으로는 면역 반응을 유발하지 못하지만, 운반 분자에 부착되면 면역원성을 획득하는 작은 분자입니다."
                    },
                    {
                      "term": "가변 부위 (Variable regions)",
                      "definition": "항체 팔의 끝 부분에 위치하며 항원의 에피토프와 결합하는 부위입니다."
                    },
                    {
                      "term": "정상 부위 (Constant region, Fc)",
                      "definition": "항체 분자의 줄기 부분으로, 특정 Ig 클래스에 대해 동일하며 면역 세포와의 상호작용에 관여합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "사이토카인: 면역 세포의 화학적 전달자",
                      "id": "cytokines-chemical-messengers-of-immune-cells",
                      "children": [
                        {
                          "text": "사이토카인의 정의 및 종류",
                          "id": "cytokines-definition-types",
                          "children": null
                        },
                        {
                          "text": "주요 사이토카인 및 그 역할",
                          "id": "key-cytokines-roles",
                          "children": null
                        },
                        {
                          "text": "사이토카인 폭풍",
                          "id": "cytokine-storm",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원",
                      "id": "antigens",
                      "children": [
                        {
                          "text": "항원의 정의",
                          "id": "antigens-definition",
                          "children": null
                        },
                        {
                          "text": "에피토프",
                          "id": "epitopes",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "합텐",
                      "id": "haptens",
                      "children": null
                    },
                    {
                      "text": "항체",
                      "id": "antibodies",
                      "children": [
                        {
                          "text": "항체의 정의 및 구조",
                          "id": "antibodies-definition-structure",
                          "children": null
                        },
                        {
                          "text": "전형적인 항체 분자의 구조",
                          "id": "typical-antibody-structure",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역글로불린 클래스 요약",
                      "id": "summary-of-immunoglobulin-classes",
                      "children": [
                        {
                          "text": "IgG",
                          "id": "igg",
                          "children": null
                        },
                        {
                          "text": "IgM",
                          "id": "igm",
                          "children": null
                        },
                        {
                          "text": "IgA",
                          "id": "iga",
                          "children": null
                        },
                        {
                          "text": "IgD",
                          "id": "igd",
                          "children": null
                        },
                        {
                          "text": "IgE",
                          "id": "ige",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "사이토카인 폭풍(Cytokine storm)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
                    "options": [
                      "면역 세포가 바이러스 감염을 방해하기 위해 사이토카인을 과도하게 생산하는 현상",
                      "염증 반응을 억제하기 위해 사이토카인이 부족하게 생산되는 현상",
                      "사이토카인이 과도하게 생산되어 조직 손상과 장기 부전을 초래할 수 있는 현상",
                      "항체 생산을 촉진하기 위해 특정 사이토카인이 의도적으로 증가하는 현상"
                    ],
                    "answerIndex": 2,
                    "explanation": "사이토카인 폭풍은 사이토카인이 과도하게 생산되어 전신 염증 반응, 조직 손상 및 장기 부전을 초래할 수 있는 현상입니다."
                  },
                  {
                    "question": "다음 면역글로불린(Ig) 클래스 중, 태반을 통과하여 태아를 보호하고 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 하는 것은 무엇입니까?",
                    "options": [
                      "IgM",
                      "IgA",
                      "IgG",
                      "IgE"
                    ],
                    "answerIndex": 2,
                    "explanation": "IgG는 태반을 통과하여 태아를 보호하며, 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 수행합니다."
                  },
                  {
                    "question": "합텐(Hapten)에 대한 설명으로 옳은 것은 무엇입니까?",
                    "options": [
                      "항체를 생산하는 모든 물질을 의미한다.",
                      "면역 반응을 유발하기에 너무 작아서 운반 분자에 부착해야 하는 항원이다.",
                      "항체와 상호작용하는 항원의 특정 부위를 의미한다.",
                      "혈액에 가장 많이 존재하는 면역글로불린의 한 종류이다."
                    ],
                    "answerIndex": 1,
                    "explanation": "합텐은 단독으로는 면역 반응을 유발하기에 너무 작지만, 운반 분자에 부착되면 면역원성을 획득하여 항체 생성을 유도할 수 있는 물질입니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 체액성 면역 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2199 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "항체 생성 세포의 활성화 및 클론 선택",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "주조직적합복합체(MHC)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "주조직적합복합체(MHC) 유전자는 세포 표면에 존재하는 분자를 암호화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Class I MHC는 모든 유핵 동물 세포의 막에 존재하며, '자기(self)'를 식별하는 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Class II MHC는 B 세포를 포함한 전문 항원제시세포(APCs)의 표면에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "B 세포의 활성화 및 클론 선택 과정",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "비활성 B 세포는 항원에 결합하는 표면 면역글로불린(Ig)을 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 항원을 내재화하고 처리합니다. 처리된 항원 조각들은 MHC Class II 분자에 제시됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 제시된 항원 조각을 T 도우미 세포(TH cell)가 접촉하고, B 세포를 활성화시키는 사이토카인을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 B 세포는 증식(클론 확장)을 겪습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "클론 선택은 활성화된 B 세포를 다음 두 가지로 분화시킵니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1. 항체를 생산하는 형질세포(Plasma cells)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2. 기억 세포(Memory cells)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "또한, 클론 제거(Clonal deletion) 과정을 통해 유해한 B 세포는 제거됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포는 특정 항원에 대한 표면 면역글로불린을 가진 성숙한 B 세포로 분화합니다. B 세포가 특정 항원을 만나면 증식합니다. 일부 B 세포는 장수하는 기억 세포로 증식하여, 나중에 항체를 생산하는 형질세포로 자극될 수 있습니다. 다른 B 세포는 항체 생산 형질세포로 증식하며, 이 형질세포는 혈액 순환계로 항체를 분비합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "T 세포 의존성 및 비의존성 항원",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 의존성 항원은 항체를 생산하기 위해 T 도우미 세포(TH cell)의 도움이 필요한 항원입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 직접 자극할 수 있습니다. 이러한 항원은 일반적으로 약한 면역 반응을 유발하며, 주로 IgM을 생산하고 기억 세포는 생성되지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원-항체 결합 및 그 결과",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 항원에 결합할 때 항원-항체 복합체가 형성됩니다. 이 결합의 강도를 친화도(affinity)라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원-항체 결합은 외래 분자나 세포를 파괴하도록 표지함으로써 숙주를 보호합니다. 주요 보호 메커니즘은 다음과 같습니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1. **응집(Agglutination)**: 감염 단위의 수를 줄여 처리해야 할 대상을 감소시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2. **옵소닌화(Opsonization)**: 항원으로 항원을 코팅하여 식균작용을 강화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "3. **항체 의존성 세포 매개성 세포독성(Antibody-dependent cell-mediated cytotoxicity, ADCC)**: 항체가 표적 세포에 부착되어 대식세포, 호산구, NK 세포에 의한 파괴를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "4. **중화(Neutralization)**: 박테리아와 바이러스가 점막에 부착되는 것을 차단하고 독소가 부착되는 것을 막습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "5. **보체계 활성화(Activation of the complement system)**: 염증 및 세포 용해를 유발합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본 문서는 적응성 면역 중 체액성 면역 반응에 초점을 맞춰 항체 생성 세포의 활성화 및 클론 선택 과정을 설명합니다. MHC(주조직적합복합체)의 역할, B 세포가 항원을 인식하고 T 도우미 세포의 도움을 받아 활성화되며 형질세포와 기억 세포로 분화하는 과정이 상세히 다뤄집니다. 또한, T 세포 의존성 및 비의존성 항원의 특징과 항원-항체 결합이 숙주를 보호하는 응집, 옵소닌화, ADCC, 중화, 보체계 활성화 등 다양한 메커니즘을 제시합니다.",
                  "keyConcepts": [
                    {
                      "term": "MHC (주조직적합복합체)",
                      "definition": "세포 표면에 존재하며, Class I은 '자기' 식별, Class II는 항원제시세포에서 항원 조각을 T 세포에 제시하는 역할을 하는 분자를 암호화하는 유전자 복합체."
                    },
                    {
                      "term": "B 세포 활성화",
                      "definition": "비활성 B 세포가 항원을 인식하고, T 도우미 세포의 사이토카인 도움을 받아 증식하고 분화하는 과정."
                    },
                    {
                      "term": "클론 선택 (Clonal Selection)",
                      "definition": "특정 항원에 반응하는 B 세포 클론이 선택적으로 증식하여 항체 생성 형질세포와 기억 세포로 분화하는 면역 과정."
                    },
                    {
                      "term": "T 세포 의존성/비의존성 항원",
                      "definition": "항체 생산에 T 도우미 세포의 도움이 필요한지 여부에 따라 항원을 분류하는 방식. 비의존성 항원은 약한 IgM 반응과 기억 세포 부재를 특징으로 함."
                    },
                    {
                      "term": "항체 기능",
                      "definition": "항원-항체 복합체 형성 후 숙주를 보호하는 다양한 메커니즘 (응집, 옵소닌화, ADCC, 중화, 보체계 활성화)."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "MHC (주조직적합복합체)",
                      "definition": "세포 표면에 항원 펩타이드를 제시하는 데 관여하는 단백질 복합체."
                    },
                    {
                      "term": "T 도우미 세포 (T Helper Cell, TH cell)",
                      "definition": "B 세포 활성화 및 다른 면역 세포 기능을 조절하는 사이토카인을 분비하는 림프구."
                    },
                    {
                      "term": "사이토카인 (Cytokines)",
                      "definition": "세포 간 신호 전달에 관여하며 면역 반응을 조절하는 작은 단백질."
                    },
                    {
                      "term": "형질세포 (Plasma Cell)",
                      "definition": "활성화된 B 세포로부터 분화하여 다량의 항체를 생산하고 분비하는 세포."
                    },
                    {
                      "term": "기억 세포 (Memory Cell)",
                      "definition": "면역 반응 후 장기간 생존하며, 동일한 항원 재침입 시 빠르고 강력한 2차 면역 반응을 유도하는 림프구."
                    },
                    {
                      "term": "응집 (Agglutination)",
                      "definition": "항체가 여러 항원 입자(예: 세균)를 서로 묶어 침전시키는 과정."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "항체가 항원 표면을 코팅하여 식세포가 이를 더 쉽게 인식하고 포식할 수 있도록 돕는 과정."
                    }
                  ],
                  "outline": [
                    {
                      "text": "항체 생성 세포의 활성화 및 클론 선택",
                      "id": "항체-생성-세포의-활성화-및-클론-선택",
                      "children": [
                        {
                          "text": "주조직적합복합체(MHC)",
                          "id": "주조직적합복합체-mhc",
                          "children": null
                        },
                        {
                          "text": "B 세포의 활성화 및 클론 선택 과정",
                          "id": "b-세포의-활성화-및-클론-선택-과정",
                          "children": null
                        },
                        {
                          "text": "T 세포 의존성 및 비의존성 항원",
                          "id": "t-세포-의존성-및-비의존성-항원",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원-항체 결합 및 그 결과",
                      "id": "항원-항체-결합-및-그-결과",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 MHC Class II 분자가 주로 발견되는 세포와 그 역할은 무엇입니까?",
                    "options": [
                      "모든 유핵 동물 세포의 막; '자기' 식별",
                      "전문 항원제시세포(APCs)의 표면; 항원 조각 제시",
                      "적혈구; 산소 운반",
                      "신경 세포; 신경 신호 전달"
                    ],
                    "answerIndex": 1,
                    "explanation": "MHC Class II는 B 세포를 포함한 전문 항원제시세포의 표면에 존재하며, 처리된 항원 조각을 T 도우미 세포에 제시하는 역할을 합니다."
                  },
                  {
                    "question": "B 세포가 항원을 내재화하고 처리한 후, T 도우미 세포의 도움을 받아 활성화될 때 T 도우미 세포가 방출하는 물질은 무엇입니까?",
                    "options": [
                      "항체",
                      "항원",
                      "사이토카인",
                      "면역글로불린"
                    ],
                    "answerIndex": 2,
                    "explanation": "T 도우미 세포는 제시된 항원 조각을 인식한 후 사이토카인을 방출하여 B 세포의 활성화를 유도합니다."
                  },
                  {
                    "question": "T 세포 비의존성 항원에 대한 면역 반응의 특징으로 옳지 않은 것은 무엇입니까?",
                    "options": [
                      "T 세포의 도움 없이 B 세포를 직접 자극한다.",
                      "주로 IgM 항체를 생산한다.",
                      "약한 면역 반응을 유발한다.",
                      "강력한 기억 세포 반응을 생성한다."
                    ],
                    "answerIndex": 3,
                    "explanation": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 자극하지만, 일반적으로 약한 면역 반응을 유발하고 기억 세포가 생성되지 않습니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 세포성 면역 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2963 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "세포성 면역 반응 과정",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 세포내 병원체와 싸웁니다. T 세포는 흉선에서 성숙하며, 흉선 선택을 통해 미성숙 T 세포가 제거됩니다. 성숙한 T 세포는 흉선에서 림프 조직으로 이동하며, T 세포 수용체(TCR)를 통해 항원에 부착합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "위장관으로 들어오는 병원체는 파이어스 패치(Peyer's patches) 위에 위치한 미세주름 세포(M cells)를 통과합니다. 이 세포들은 항원을 림프구와 항원제시세포(APCs)로 전달합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원제시세포 (APCs)",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "수지상 세포 (Dendritic cells, DCs)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "수지상 세포는 미생물을 삼켜 분해하고 T 세포에 제시합니다. 이들은 피부, 생식기, 림프절, 비장, 흉선 및 혈액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "대식세포 (Macrophages)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "대식세포는 사이토카인 또는 항원 물질의 섭취에 의해 활성화됩니다. 이들은 림프 조직으로 이동하여 T 세포에 항원을 제시합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원 처리 및 제시: MHC",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "T 세포의 종류",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 분화군(Clusters of differentiation, CD) 표지자를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CD4+ T 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4+ T 세포는 T 도우미 세포(TH)라고도 불립니다. 이들은 B 세포와 사이토카인 신호를 주고받으며 항원과 직접 상호작용합니다. B 세포 및 APC의 MHC class II 분자에 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CD8+ T 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "CD8+ T 세포는 세포독성 T 림프구(Cytotoxic T lymphocytes, CTL)라고 불립니다. 이들은 MHC class I 분자에 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4+ 세포의 TCR은 APC의 항원 조각과 MHC class II에 결합하여 인식합니다. APC 또는 TH는 보조 자극 분자를 분비하여 CD4+ 세포를 활성화합니다. 활성화된 TH 세포는 사이토카인을 생성하고 TH1, TH2, TH17 세포 및 기억 세포로 분화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH17 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH17 세포는 IL-17을 생성하여 염증 반응에 기여하고, 세포외 세균 및 곰팡이에 대한 방어를 위해 호중구를 모집합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH1 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH1 세포는 IFN-γ를 생성하여 대식세포를 활성화하고, 보체를 강화하며, 식세포 작용을 촉진하는 항체 생성을 자극합니다. TH1 세포는 세포성 면역의 중요한 요소이며, 이들의 사이토카인(예: IFN-γ 및 IL-2)은 CD8+ T 세포와 NK 세포를 활성화하여 감염된 숙주 세포를 죽임으로써 세포내 병원체를 제어합니다. 또한, 대식세포와 같은 항원제시세포의 식세포 작용을 강화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH2 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH2 세포는 B 세포를 활성화하여 IgE를 생성하게 하고 호산구를 활성화합니다. 특히 IgE 생성을 통한 알레르기 반응에 중요하며, 헬민스와 같은 세포외 기생충을 제어하기 위해 호산구를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "조절 T 세포 (Treg)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 T 세포(Treg)는 CD4+ 세포의 하위 집합으로, 추가적인 CD25 분자를 가지고 있습니다. 이들은 자가 반응성 T 세포를 억제하여 자기 관용을 유지하고, 소화에 필요한 장내 세균을 보호하며, 태아를 보호합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 T 림프구 (CD8+ T 세포)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "전구 세포독성 T 세포(CTLp)는 TH 세포와 보조 자극 신호의 도움으로 활성화되어 세포독성 T 림프구(CTLs)가 됩니다. CTLs는 감염에 의해 변형된 자가 세포를 인식하고 죽입니다. 감염된 자가 세포는 MHC class I 분자와 함께 표면에 내인성 항원을 운반합니다. CTL은 퍼포린(perforin)과 그랜자임(granzymes)을 방출하여 감염된 세포의 세포자멸사를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포자멸사 (Apoptosis)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포자멸사는 프로그램된 세포 사멸입니다. 이는 감염성 바이러스가 다른 세포로 퍼지는 것을 방지합니다. 세포는 게놈을 조각으로 절단하며, 세포막은 수포(blebbing)를 통해 바깥쪽으로 부풀어 오릅니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "정상 세포는 세포독성 T 림프구(CTL)에 의해 반응을 유발하지 않지만, 바이러스 감염 세포나 암세포는 비정상적인 내인성 항원을 생성합니다. 이 비정상적인 항원은 MHC class I 분자와 결합하여 세포 표면에 제시됩니다. TH1 세포의 결합은 사이토카인 분비를 촉진합니다. 이 사이토카인은 전구 CTL을 활성화하여 CTL 클론을 생성합니다. CTL은 세포자멸사를 통해 바이러스 감염 세포의 파괴를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역계에 의한 세포외 살상",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "자연살해 (NK) 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "자연살해(NK) 세포는 과립성 백혈구로, MHC class I 자가 항원을 발현하지 않는 세포를 파괴합니다. 이들은 바이러스 감염 세포와 종양 세포를 죽이고 기생충을 공격합니다. 항상 항원에 의해 자극되는 것은 아니며, 표적 세포에 구멍을 형성하여 용해 또는 세포자멸사를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포성 면역에 관여하는 주요 세포 기능",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH1) 세포: 세포 매개 면역 관련 세포(대식세포, CTLs, 자연살해 세포)를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH2) 세포: 호산구, IgM, IgE 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH17) 세포: 호중구를 모집하고 항균 단백질 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구 (CTL): 세포자멸사를 유도하여 접촉하는 표적 세포를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 T (Treg) 세포: 면역 반응을 조절하고 자기 관용을 유지하는 데 도움을 줍니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 대식세포: 식세포 활동이 강화되고 암세포를 공격합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자연살해 (NK) 세포: 표적 세포를 공격하고 파괴하며, 항체 의존성 세포 매개 세포독성(ADCC)에 참여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항체 의존성 세포 매개 세포독성 (ADCC)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "원생동물과 헬민스는 식세포 작용으로 삼키기에는 너무 큽니다. 원생동물 또는 헬민스 표적 세포는 항체로 코팅됩니다. 면역계 세포는 항체의 Fc 영역에 부착합니다. 표적 세포는 면역계 세포가 분비하는 화학 물질에 의해 용해됩니다. 많은 기생충과 같이 식세포에 의해 섭취하기에는 너무 큰 유기체는 외부에서 공격받아야 합니다. 호산구는 기생성 흡충의 유충 단계에 부착합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 세포성 면역의 과정을 상세히 설명하며, T 세포, 항원제시세포(APCs) 및 이들의 상호작용에 중점을 둡니다. T 세포의 성숙 과정과 다양한 T 세포 유형(TH1, TH2, TH17, 세포독성 T 림프구, 조절 T 세포)의 기능, 그리고 이들이 세포내 병원체 퇴치, 면역 반응 조절 및 특정 면역 반응 매개에 어떻게 기여하는지 다룹니다. 또한, 자연살해(NK) 세포의 세포외 살상 역할과 대형 기생충에 대한 항체 의존성 세포 매개 세포독성(ADCC) 기전도 설명합니다.",
                  "keyConcepts": [
                    {
                      "term": "T 세포의 성숙 및 기능",
                      "definition": "흉선에서 성숙하며, 세포내 병원체와 싸우고 항원제시세포(APCs)가 제시하는 항원에 특이적으로 반응하는 림프구."
                    },
                    {
                      "term": "항원제시세포 (APCs)",
                      "definition": "미생물을 삼켜 분해하고 그 항원 조각을 MHC 분자를 통해 T 세포에 제시하여 T 세포 반응을 유도하는 세포 (예: 수지상 세포, 대식세포)."
                    },
                    {
                      "term": "T 세포 유형 및 역할",
                      "definition": "CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)는 다른 면역 세포의 활성화를 돕고, CD8+ T 세포(세포독성 T 림프구)는 감염된 세포를 직접 파괴하며, 조절 T 세포는 면역 반응을 억제하여 자기 관용을 유지한다."
                    },
                    {
                      "term": "세포독성 T 림프구 (CTLs) 및 세포자멸사 (Apoptosis)",
                      "definition": "CTL은 감염된 자가 세포를 인식하여 퍼포린과 그랜자임을 방출, 세포자멸사(프로그램된 세포 사멸)를 유도하여 바이러스 확산을 막는다."
                    },
                    {
                      "term": "자연살해(NK) 세포 및 항체 의존성 세포 매개 세포독성 (ADCC)",
                      "definition": "NK 세포는 MHC class I을 발현하지 않는 세포를 파괴하며, ADCC는 항체로 코팅된 표적 세포를 면역 세포가 용해시키는 기전으로, 특히 대형 기생충에 효과적이다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "T 세포 (T cell)",
                      "definition": "흉선에서 성숙하며 세포내 병원체와 싸우는 림프구."
                    },
                    {
                      "term": "항원제시세포 (Antigen-Presenting Cells, APCs)",
                      "definition": "미생물을 삼켜 분해하고 T 세포에 항원을 제시하는 세포 (예: 수지상 세포, 대식세포)."
                    },
                    {
                      "term": "MHC (Major Histocompatibility Complex)",
                      "definition": "항원 제시를 위해 세포 표면에 항원 조각을 표시하는 분자."
                    },
                    {
                      "term": "T 도우미 세포 (T Helper cells, TH)",
                      "definition": "CD4+ T 세포로, B 세포와 사이토카인 신호를 주고받으며 다른 면역 세포의 활성화를 돕는다."
                    },
                    {
                      "term": "세포독성 T 림프구 (Cytotoxic T Lymphocytes, CTLs)",
                      "definition": "CD8+ T 세포로, 감염된 자가 세포를 인식하고 세포자멸사를 유도하여 파괴한다."
                    },
                    {
                      "term": "세포자멸사 (Apoptosis)",
                      "definition": "프로그램된 세포 사멸로, 감염성 바이러스가 다른 세포로 퍼지는 것을 방지한다."
                    },
                    {
                      "term": "자연살해 세포 (Natural Killer cells, NK cells)",
                      "definition": "MHC class I 자가 항원을 발현하지 않는 세포를 파괴하며, 바이러스 감염 세포, 종양 세포 및 기생충을 공격한다."
                    },
                    {
                      "term": "항체 의존성 세포 매개 세포독성 (Antibody-Dependent Cell-mediated Cytotoxicity, ADCC)",
                      "definition": "항체로 코팅된 표적 세포를 면역 세포가 파괴하는 기전."
                    }
                  ],
                  "outline": [
                    {
                      "text": "세포성 면역 반응 과정",
                      "id": "세포성-면역-반응-과정",
                      "children": [
                        {
                          "text": "T 세포의 역할과 성숙",
                          "id": "t-세포의-역할과-성숙",
                          "children": null
                        },
                        {
                          "text": "소화관 내 병원체 처리",
                          "id": "소화관-내-병원체-처리",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원제시세포 (APCs)",
                      "id": "항원제시세포-apcs",
                      "children": [
                        {
                          "text": "수지상 세포 (Dendritic cells, DCs)",
                          "id": "수지상-세포-dendritic-cells-dcs",
                          "children": null
                        },
                        {
                          "text": "대식세포 (Macrophages)",
                          "id": "대식세포-macrophages",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원 처리 및 제시: MHC",
                      "id": "항원-처리-및-제시-mhc",
                      "children": null
                    },
                    {
                      "text": "T 세포의 종류",
                      "id": "t-세포의-종류",
                      "children": [
                        {
                          "text": "CD4+ T 세포",
                          "id": "cd4-t-세포",
                          "children": null
                        },
                        {
                          "text": "CD8+ T 세포",
                          "id": "cd8-t-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
                      "id": "t-도우미-세포-cd4-t-세포의-활성화-및-분화",
                      "children": [
                        {
                          "text": "TH17 세포",
                          "id": "th17-세포",
                          "children": null
                        },
                        {
                          "text": "TH1 세포",
                          "id": "th1-세포",
                          "children": null
                        },
                        {
                          "text": "TH2 세포",
                          "id": "th2-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "조절 T 세포 (Treg)",
                      "id": "조절-t-세포-treg",
                      "children": null
                    },
                    {
                      "text": "세포독성 T 림프구 (CD8+ T 세포)",
                      "id": "세포독성-t-림프구-cd8-t-세포",
                      "children": [
                        {
                          "text": "세포자멸사 (Apoptosis)",
                          "id": "세포자멸사-apoptosis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역계에 의한 세포외 살상",
                      "id": "면역계에-의한-세포외-살상",
                      "children": [
                        {
                          "text": "자연살해 (NK) 세포",
                          "id": "자연살해-nk-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포성 면역에 관여하는 주요 세포 기능",
                      "id": "세포성-면역에-관여하는-주요-세포-기능",
                      "children": null
                    },
                    {
                      "text": "항체 의존성 세포 매개 세포독성 (ADCC)",
                      "id": "항체-의존성-세포-매개-세포독성-adcc",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "T 세포가 성숙하는 주요 장소는 어디인가요?",
                    "options": [
                      "골수",
                      "비장",
                      "흉선",
                      "림프절"
                    ],
                    "answerIndex": 2,
                    "explanation": "T 세포는 흉선(thymus)에서 성숙 과정을 거칩니다."
                  },
                  {
                    "question": "다음 중 세포독성 T 림프구(CTL)의 주된 기능은 무엇인가요?",
                    "options": [
                      "B 세포 활성화",
                      "대식세포 활성화",
                      "감염된 자가 세포 파괴",
                      "염증 반응 촉진"
                    ],
                    "answerIndex": 2,
                    "explanation": "세포독성 T 림프구(CTL)는 감염된 자가 세포나 암세포를 인식하고 세포자멸사를 유도하여 파괴하는 역할을 합니다."
                  },
                  {
                    "question": "다음 중 항원제시세포(APC)에 해당하지 않는 것은 무엇인가요?",
                    "options": [
                      "수지상 세포",
                      "대식세포",
                      "T 도우미 세포",
                      "B 세포"
                    ],
                    "answerIndex": 2,
                    "explanation": "수지상 세포, 대식세포, B 세포는 모두 항원제시세포(APC)의 역할을 수행합니다. T 도우미 세포는 APC에 의해 활성화되는 세포이지, 스스로 항원을 제시하는 세포는 아닙니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75f3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1056 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역학적 기억",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 (기억 또는 아남네스틱) 반응은 항원에 두 번째 노출된 후에 발생합니다. 이 반응은 더 빠르고, 며칠 동안 지속되며, 그 규모가 훨씬 더 큽니다. 초기 노출에 반응하여 생성된 기억 세포는 이차 노출에 의해 활성화됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "초기 IgM 반응이 IgG, IgE 또는 IgA로 전환되는 '클래스 전환(Class switching)' 현상이 이차 반응에서 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체 역가(Antibody titer)는 혈청 내 항체의 상대적인 양을 나타내며, 체액 면역 반응의 강도를 반영합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "체액 면역",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "일차 면역 반응",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "제공된 텍스트에는 일차 면역 반응에 대한 구체적인 내용은 포함되어 있지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이차 면역 반응",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 면역 반응은 '면역학적 기억' 섹션에서 상세히 설명된 바와 같이, 항원에 대한 두 번째 노출 시 발생하는 빠르고 강력하며 지속적인 반응입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역의 유형",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "자연 획득 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "자연 획득 능동 면역은 감염을 통해 발생하며, 신체가 항원에 직접 노출되어 면역 반응을 일으키고 기억 세포를 형성하는 것을 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자연 획득 수동 면역은 태반을 통해 또는 초유를 통해 어머니로부터 항체를 전달받아 발생하는 면역입니다. 이는 일시적인 면역을 제공합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인공 획득 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "인공 획득 능동 면역은 예방 접종(백신 접종)을 통해 발생합니다. 이는 약화되거나 비활성화된 항원을 주입하여 신체 스스로 면역 반응을 일으키고 기억 세포를 형성하도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인공 획득 수동 면역은 항체 주사를 통해 발생합니다. 이는 특정 질병에 대한 즉각적인 보호를 제공하지만, 신체가 스스로 면역 반응을 일으킨 것이 아니므로 기억 세포가 형성되지 않아 일시적입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "관련 용어",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청(Antiserum)은 항체를 포함하는 혈액 유래 액체입니다. 혈청학(Serology)은 항체와 항원 간의 반응을 연구하는 학문입니다. 글로불린(Globulins)은 혈청 단백질을 총칭하며, 감마(γ) 글로불린은 항체를 포함하는 혈청 분획입니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 면역학적 기억과 적응성 면역의 다양한 유형에 대해 설명합니다. 면역학적 기억은 항원에 두 번째 노출되었을 때 발생하는 이차 면역 반응(더 빠르고 강력하며 지속적)의 특징과 클래스 전환, 그리고 항체 역가의 개념을 포함합니다. 적응성 면역은 자연 획득(능동/수동)과 인공 획득(능동/수동) 면역으로 분류되며, 각각의 특징과 발생 원리를 다룹니다. 또한, 혈청, 혈청학, 글로불린, 감마 글로불린과 같은 관련 용어의 정의도 제공합니다.",
                  "keyConcepts": [
                    {
                      "term": "면역학적 기억",
                      "definition": "항원에 대한 첫 노출 후 형성되어, 재노출 시 더 빠르고 강력한 이차 면역 반응을 유도하는 능력."
                    },
                    {
                      "term": "이차 면역 반응",
                      "definition": "항원에 두 번째 노출되었을 때 나타나는 면역 반응으로, 일차 반응보다 빠르고 강하며 오래 지속되는 특징을 가집니다."
                    },
                    {
                      "term": "적응성 면역의 유형",
                      "definition": "면역 획득 방식에 따라 자연 획득 능동/수동 면역과 인공 획득 능동/수동 면역으로 나뉩니다."
                    },
                    {
                      "term": "클래스 전환",
                      "definition": "초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "이차 (기억 또는 아남네스틱) 반응",
                      "definition": "항원에 두 번째 노출되었을 때 발생하는 면역 반응."
                    },
                    {
                      "term": "클래스 전환",
                      "definition": "면역 반응 시 초기 IgM 항체에서 IgG, IgE, IgA 등 다른 항체 유형으로 전환되는 현상."
                    },
                    {
                      "term": "항체 역가",
                      "definition": "혈청 내 항체의 상대적인 양을 나타내는 지표."
                    },
                    {
                      "term": "자연 획득 능동 면역",
                      "definition": "감염을 통해 자연적으로 항원에 노출되어 획득하는 면역."
                    },
                    {
                      "term": "인공 획득 능동 면역",
                      "definition": "예방 접종(백신)을 통해 인위적으로 항원에 노출되어 획득하는 면역."
                    },
                    {
                      "term": "혈청",
                      "definition": "항체를 포함하는 혈액 유래 액체."
                    },
                    {
                      "term": "감마 글로불린",
                      "definition": "항체를 포함하는 혈청 단백질 분획."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역학적 기억",
                      "id": "immunological-memory",
                      "children": [
                        {
                          "text": "이차 면역 반응의 특성",
                          "id": "secondary-immune-response-characteristics",
                          "children": null
                        },
                        {
                          "text": "클래스 전환 및 기억 세포",
                          "id": "class-switching-and-memory-cells",
                          "children": null
                        },
                        {
                          "text": "항체 역가",
                          "id": "antibody-titer",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "체액 면역",
                      "id": "humoral-immunity",
                      "children": [
                        {
                          "text": "일차 면역 반응",
                          "id": "primary-immune-response",
                          "children": null
                        },
                        {
                          "text": "이차 면역 반응",
                          "id": "secondary-immune-response-humoral",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역의 유형",
                      "id": "types-of-adaptive-immunity",
                      "children": [
                        {
                          "text": "자연 획득 면역",
                          "id": "naturally-acquired-immunity",
                          "children": [
                            {
                              "text": "자연 획득 능동 면역",
                              "id": "naturally-acquired-active-immunity",
                              "children": null
                            },
                            {
                              "text": "자연 획득 수동 면역",
                              "id": "naturally-acquired-passive-immunity",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "인공 획득 면역",
                          "id": "artificially-acquired-immunity",
                          "children": [
                            {
                              "text": "인공 획득 능동 면역",
                              "id": "artificially-acquired-active-immunity",
                              "children": null
                            },
                            {
                              "text": "인공 획득 수동 면역",
                              "id": "artificially-acquired-passive-immunity",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "관련 용어",
                          "id": "related-terms",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "이차 면역 반응의 주요 특징이 아닌 것은 무엇입니까?",
                    "options": [
                      "일차 반응보다 느리게 발생한다.",
                      "더 오랫동안 지속된다.",
                      "규모가 더 크다.",
                      "기억 세포에 의해 활성화된다."
                    ],
                    "answerIndex": 0,
                    "explanation": "이차 면역 반응은 일차 반응보다 '더 빠르게' 발생하며, 더 오랫동안 지속되고 규모가 더 크다는 특징을 가집니다."
                  },
                  {
                    "question": "예방 접종(백신 접종)을 통해 획득하는 면역 유형은 무엇입니까?",
                    "options": [
                      "자연 획득 능동 면역",
                      "자연 획득 수동 면역",
                      "인공 획득 능동 면역",
                      "인공 획득 수동 면역"
                    ],
                    "answerIndex": 2,
                    "explanation": "예방 접종은 인위적으로 항원을 주입하여 신체 스스로 면역 반응을 일으키도록 유도하는 '인공 획득 능동 면역'에 해당합니다."
                  },
                  {
                    "question": "면역학적 기억에서 '클래스 전환'은 무엇을 의미합니까?",
                    "options": [
                      "면역 세포의 종류가 바뀌는 것",
                      "초기 IgM 반응이 다른 유형의 항체(IgG, IgE, IgA)로 바뀌는 것",
                      "항체가 항원에 결합하는 방식이 바뀌는 것",
                      "면역 반응의 강도가 약해지는 것"
                    ],
                    "answerIndex": 1,
                    "explanation": "클래스 전환은 초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상을 말합니다."
                  }
                ]
              },
              {
                "title": "면역학의 실제 적용: 백신",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 3538 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "백신 개요",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역학의 실제 적용 중 하나인 백신은 질병 예방에 있어 핵심적인 역할을 합니다. 백신의 역사는 천연두 접종법(Variolation)에서 시작되었는데, 이는 천연두를 피부에 접종하여 질병을 예방하는 방식이었습니다. 이후 제너(Jenner)는 우두를 접종하여 천연두를 예방하는 방법을 발견했습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "백신(Vaccine)이라는 용어는 파스퇴르(Pasteur)에 의해 만들어졌으며, 'vacca'(소)에서 유래했습니다. 백신은 면역을 유도하는 유기체 또는 유기체의 일부 현탁액으로 정의됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 기능 및 원리",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 접종은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이는 실제 병원체에 노출되었을 때 빠르고 강렬한 이차 면역 반응을 생성하는 데 기여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "집단 면역(Herd immunity)은 인구 대부분의 면역 상태를 의미하며, 감수성 있는 개체의 부족으로 질병 발생이 산발적으로 나타나게 하여 전염병 확산을 막는 중요한 효과를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CDC 권장 세균성 질환 백신",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "미국 질병통제예방센터(CDC)는 다양한 세균성 질환 예방을 위한 백신을 권장하고 있습니다. 이에는 헤모필루스 인플루엔자 b형 수막염, 수막구균성 수막염, 폐렴구균성 폐렴, 파상풍, 디프테리아, 백일해 백신 등이 포함됩니다. 각 백신은 특정 연령대 또는 위험군에 대한 권장 사항과 추가 접종 여부가 명시되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CDC 권장 바이러스성 질환 백신",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "CDC는 또한 수두, A형 간염, B형 간염, 대상포진, 인유두종바이러스, 인플루엔자, 홍역, 유행성 이하선염, 소아마비, 광견병, 로타바이러스, 풍진, 천연두 등 다양한 바이러스성 질환 예방을 위한 백신을 권장하고 있습니다. 이들 백신 역시 접종 대상, 시기, 그리고 추가 접종의 필요성에 대한 구체적인 지침을 따릅니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 종류 및 특성",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "약독화 생백신 (Live attenuated vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "약독화 생백신은 약화된 병원체를 사용하여 실제 감염과 유사한 면역 반응을 유도하며, 평생 지속되는 세포성 및 체액성 면역을 부여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "불활성화 사백신 (Inactivated killed vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "불활성화 사백신은 생백신보다 안전하지만, 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "서브유닛 백신 (Subunit vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "서브유닛 백신은 항원성 조각을 사용하여 면역 반응을 자극합니다. 유전적 변형을 통해 생산되는 서브유닛 백신을 재조합 백신(Recombinant vaccines)이라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "톡소이드 (Toxoids)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "톡소이드는 불활성화된 독소이며, 항독소(Antitoxins)는 독소에 대한 항체를 포함하는 혈청입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "VLP 백신은 온전한 바이러스와 유사하지만 바이러스 유전 물질을 포함하지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다당류 백신 (Polysaccharide vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다당류 백신은 병원체의 캡슐 분자로 만들어지며 면역원성이 강하지 않습니다. 캡슐 다당류에 대한 면역 반응이 약한 어린이 질병에 사용되는 백신을 접합 백신(Conjugated vaccines)이라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "핵산(DNA) 백신은 DNA에 암호화된 단백질 항원을 생성하기 위해 주사된 DNA를 사용하며, 체액성 및 세포성 면역을 모두 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "재조합 벡터 백신 (Recombinant vector vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "재조합 벡터 백신은 항원을 코딩하는 유전자를 전달하도록 유전적으로 변형된 비병원성 바이러스 또는 박테리아를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "RNA 백신 (RNA vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "RNA 백신은 새로운 유형의 백신으로, 특정 항원 단백질을 생산하도록 세포에 지시하는 RNA 서열을 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신 생산, 전달 방법 및 제형",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 개발은 동물 숙주를 사용하지 않는 방향으로 발전하고 있으며, 식물을 백신 공급원으로 활용하는 연구도 진행 중입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "경구 백신 및 건조 백신(피부 패치)의 개발이 증가하고 있으며, 나노패치(Nanopatch)는 건조 형태의 백신을 피부에 전달하여 냉장 보관이 필요 없으며 다수의 항원제시세포(APC)를 활용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다중 조합 백신, 만성 질환 백신 개발, 그리고 세포성 면역 개발을 위한 \"역 백신학(Reverse vaccinology)\" 연구도 활발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 미국에서는 명반(Alums)과 모노포스포릴 지질 A(monophosphoryl lipid A)만이 승인되어 있으며, 선천 면역 반응을 개선하는 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "마이크로바이옴과 경구 백신 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "젖산균인 비피도박테리움(Bifidobacterium)은 장내 마이크로바이옴의 정상적인 일부이며, 마이크로바이옴이 경구 백신에 대한 반응을 향상시킬 수 있다는 연구가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 안전성",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "드물게 백신이 질병을 유발할 수 있지만, MMR 백신이 자폐증과 연관되어 있다는 의학적 또는 과학적 증거는 없습니다. 백신은 어린이의 감염성 질환을 예방하는 가장 안전하고 효과적인 수단으로 간주됩니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 백신의 역사적 배경, 기능, 다양한 종류, 생산 및 전달 방법, 그리고 안전성에 대해 설명합니다. 백신은 일차 면역 반응을 유도하여 항체와 기억 세포를 형성하고, 이를 통해 집단 면역을 구축하여 질병 확산을 막는 원리를 가지고 있습니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 여러 유형의 백신이 각자의 특성과 함께 소개되며, 아쥬반트의 역할과 백신 안전성에 대한 중요한 정보도 포함되어 있습니다.",
                  "keyConcepts": [
                    {
                      "term": "집단 면역 (Herd Immunity)",
                      "definition": "인구 대부분이 면역을 가지게 되어 감수성 개체의 부족으로 질병 발생이 산발적으로 나타나게 하는 현상으로, 전염병 확산을 막는 데 중요합니다."
                    },
                    {
                      "term": "백신의 종류 (Types of Vaccines)",
                      "definition": "약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 다양한 백신 유형이 있으며, 각각 다른 방식으로 면역 반응을 유도합니다."
                    },
                    {
                      "term": "아쥬반트 (Adjuvants)",
                      "definition": "백신의 효능을 높이고 면역 반응을 강화하기 위해 백신에 첨가되는 화학 물질입니다. 주로 선천 면역 반응을 개선하는 역할을 합니다."
                    },
                    {
                      "term": "기억 세포 (Memory Cells)",
                      "definition": "백신 접종 후 형성되는 면역 세포로, 실제 병원체에 재노출되었을 때 빠르고 강렬한 이차 면역 반응을 가능하게 하여 장기적인 면역력을 제공합니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "천연두 접종법 (Variolation)",
                      "definition": "천연두를 피부에 접종하여 면역을 유도하던 초기 질병 예방 방법입니다."
                    },
                    {
                      "term": "백신 접종 (Vaccination)",
                      "definition": "면역을 유도하기 위해 유기체 또는 유기체의 일부를 현탁액 형태로 인체에 주입하는 행위를 말합니다."
                    },
                    {
                      "term": "약독화 생백신 (Live Attenuated Vaccine)",
                      "definition": "병원체를 약화시켜 만든 백신으로, 실제 감염과 유사한 면역 반응을 유도하며 세포성 및 체액성 면역을 부여합니다."
                    },
                    {
                      "term": "불활성화 사백신 (Inactivated Killed Vaccine)",
                      "definition": "죽은 병원체나 그 일부를 사용하여 만든 백신으로, 약독화 생백신보다 안전하지만 주로 체액성 면역을 유도하고 반복적인 추가 접종이 필요합니다."
                    },
                    {
                      "term": "서브유닛 백신 (Subunit Vaccine)",
                      "definition": "병원체의 특정 항원성 조각만을 사용하여 만든 백신으로, 면역 반응을 자극합니다."
                    },
                    {
                      "term": "톡소이드 (Toxoid)",
                      "definition": "독소의 독성을 제거하고 면역원성만 남긴 백신으로, 독소에 의해 발생하는 질병을 예방하는 데 사용됩니다."
                    },
                    {
                      "term": "아쥬반트 (Adjuvant)",
                      "definition": "백신의 면역 반응을 강화하기 위해 첨가되는 물질로, 백신의 효능을 높이고 선천 면역 반응을 개선합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "백신 개요",
                      "id": "백신-개요",
                      "children": [
                        {
                          "text": "백신의 역사",
                          "id": "백신의-역사",
                          "children": null
                        },
                        {
                          "text": "백신의 정의",
                          "id": "백신의-정의",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신의 기능 및 원리",
                      "id": "백신의-기능-및-원리",
                      "children": [
                        {
                          "text": "면역 반응 유도",
                          "id": "면역-반응-유도",
                          "children": null
                        },
                        {
                          "text": "집단 면역",
                          "id": "집단-면역",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "CDC 권장 백신",
                      "id": "cdc-권장-백신",
                      "children": [
                        {
                          "text": "세균성 질환 백신",
                          "id": "세균성-질환-백신",
                          "children": null
                        },
                        {
                          "text": "바이러스성 질환 백신",
                          "id": "바이러스성-질환-백신",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신의 종류 및 특성",
                      "id": "백신의-종류-및-특성",
                      "children": [
                        {
                          "text": "약독화 생백신 (Live attenuated vaccines)",
                          "id": "약독화-생백신-live-attenuated-vaccines",
                          "children": null
                        },
                        {
                          "text": "불활성화 사백신 (Inactivated killed vaccines)",
                          "id": "불활성화-사백신-inactivated-killed-vaccines",
                          "children": null
                        },
                        {
                          "text": "서브유닛 백신 (Subunit vaccines)",
                          "id": "서브유닛-백신-subunit-vaccines",
                          "children": null
                        },
                        {
                          "text": "톡소이드 (Toxoids)",
                          "id": "톡소이드-toxoids",
                          "children": null
                        },
                        {
                          "text": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
                          "id": "바이러스-유사-입자-vlp-백신-virus-like-particle-vlp-vaccines",
                          "children": null
                        },
                        {
                          "text": "다당류 백신 (Polysaccharide vaccines)",
                          "id": "다당류-백신-polysaccharide-vaccines",
                          "children": null
                        },
                        {
                          "text": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
                          "id": "핵산-dna-백신-nucleic-acid-dna-vaccines",
                          "children": null
                        },
                        {
                          "text": "재조합 벡터 백신 (Recombinant vector vaccines)",
                          "id": "재조합-벡터-백신-recombinant-vector-vaccines",
                          "children": null
                        },
                        {
                          "text": "RNA 백신 (RNA vaccines)",
                          "id": "rna-백신-rna-vaccines",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신 생산, 전달 방법 및 제형",
                      "id": "백신-생산-전달-방법-및-제형",
                      "children": [
                        {
                          "text": "생산 기술의 발전",
                          "id": "생산-기술의-발전",
                          "children": null
                        },
                        {
                          "text": "새로운 전달 방식",
                          "id": "새로운-전달-방식",
                          "children": null
                        },
                        {
                          "text": "아쥬반트의 역할",
                          "id": "아쥬반트의-역할",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "마이크로바이옴과 경구 백신 반응",
                      "id": "마이크로바이옴과-경구-백신-반응",
                      "children": null
                    },
                    {
                      "text": "백신의 안전성",
                      "id": "백신의-안전성",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "백신 접종이 유도하는 주요 면역학적 반응은 무엇이며, 이 반응의 결과로 형성되는 중요한 세포는 무엇입니까?",
                    "options": [
                      "일차 면역 반응, 기억 세포",
                      "이차 면역 반응, 비만 세포",
                      "알레르기 반응, 형질 세포",
                      "자가면역 반응, T 세포"
                    ],
                    "answerIndex": 0,
                    "explanation": "백신은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이 기억 세포 덕분에 실제 병원체 노출 시 빠르고 강렬한 이차 면역 반응이 가능해집니다."
                  },
                  {
                    "question": "다음 중 약독화 생백신과 불활성화 사백신의 주요 차이점에 대한 설명으로 올바른 것은 무엇입니까?",
                    "options": [
                      "약독화 생백신은 평생 면역을 부여하지만, 불활성화 사백신은 추가 접종이 필요하다.",
                      "약독화 생백신은 주로 체액성 면역을 유도하고, 불활성화 사백신은 세포성 면역을 유도한다.",
                      "약독화 생백신은 불활성화 사백신보다 안전하다.",
                      "약독화 생백신은 유전 물질을 포함하지 않지만, 불활성화 사백신은 포함한다."
                    ],
                    "answerIndex": 0,
                    "explanation": "약독화 생백신은 실제 감염과 유사하게 평생 지속되는 세포성 및 체액성 면역을 부여하는 경향이 있는 반면, 불활성화 사백신은 더 안전하지만 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다."
                  },
                  {
                    "question": "백신에 첨가되어 효능을 향상시키고 선천 면역 반응을 개선하는 화학 첨가제는 무엇이라고 불립니까?",
                    "options": [
                      "항독소",
                      "톡소이드",
                      "아쥬반트",
                      "폴리사카라이드"
                    ],
                    "answerIndex": 2,
                    "explanation": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 선천 면역 반응을 개선하는 역할을 합니다."
                  }
                ]
              },
              {
                "title": "면역학의 실제 적용: 진단 면역학",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 2187 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "진단 면역학 개요",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "민감도(Sensitivity): 검사가 진양성 표본에 대해 반응할 확률",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "특이도(Specificity): 양성 검사가 진음성 표본에 대해 반응하지 않을 확률",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역학 기반 진단 검사는 체액 항체와 항원의 상호작용을 이용한다. 알려진 항체를 통해 미지의 병원체를 식별하거나, 알려진 병원체를 통해 미지의 항체를 식별할 수 있다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "단일클론 항체 (Monoclonal Antibodies)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "하이브리도마(Hybridoma): \"불멸의\" 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합한 세포.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "하이브리도마는 단일클론 항체(Mabs)를 생산한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Mabs는 균일하고, 특이성이 높으며, 대량 생산이 가능하다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "진단 도구 및 인체 치료에 사용된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류마티스 관절염에서 TNF를 중화하거나, 비만세포와 호염기구에 IgE 결합을 막아 알레르기성 천식을 치료하는 데 활용된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주로 쥐 세포에서 유래하여 부작용을 일으킬 수 있다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "키메라 단일클론 항체: 쥐의 가변 영역과 인간의 불변 영역을 가진 Mabs.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인간화 항체: 쥐 항원 결합 부위를 제외하고 대부분 인간 유래인 Mabs.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "완전 인간 항체: 쥐에 삽입된 인간 유전자로부터 생산된 Mabs.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "단일클론 항체의 생산",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "침강 반응 (Precipitation Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "가용성 항원과 항체가 반응하여 격자(lattices)라고 불리는 크고 서로 맞물린 응집체를 형성하는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원-항체 복합체가 형성된 후, 용액에서 침전되는 격자가 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강링 테스트(Precipitin ring test): 최적의 항원-항체 비율 지점에서 흐린 선이 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역확산 테스트(Immunodiffusion tests): 한천 젤 배지에서 수행되는 침강 반응이다. 최적의 항원-항체 비율 지점에서 침전물이 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 전기영동(Immunoelectrophoresis): 전기영동과 면역확산을 결합한 것으로, 인간 혈청의 단백질을 분리한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "응집 반응 (Agglutination Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "입자성 항원이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 응집 테스트(Direct agglutination tests): 큰 세포성 항원에 대한 항체를 검출한다. 혈청 항체 농도(역가, titer)를 측정하며, 역가 증가는 질병에 대한 더 큰 면역을 나타낸다. 혈청 전환(Seroconversion)은 질병이 진행됨에 따라 역가에 유의미한 변화가 나타나는 것을 의미한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접(수동) 응집 테스트(Indirect (passive) agglutination tests): 항체가 입자에 부착된 가용성 항원과 반응하거나 그 반대로 반응한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈구 응집(Hemagglutination): 적혈구 표면 항원과 보체 항체의 응집으로, 혈액형 판별에 사용된다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 면역학 학습 목표 (1)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "응집 테스트와 침강 테스트의 차이점을 구별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈구 응집을 정의한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "중화 테스트가 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강 테스트와 중화 테스트의 차이점을 구별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 고정 테스트의 기본 원리를 설명한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "중화 반응 (Neutralization Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스성 혈구 응집(Viral hemagglutination): 바이러스가 항원-항체 반응 없이 적혈구를 응집시키는 현상 (예: 볼거리, 홍역, 인플루엔자).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체(항독소)에 의해 외독소나 바이러스의 유해한 효과가 차단되는 항원-항체 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스성 혈구 응집 억제 테스트(Viral hemagglutination inhibition test): 바이러스 아형을 분류하는 데 사용된다. 바이러스와 적혈구를 환자의 혈청과 혼합한다. 혈청에 바이러스에 대한 항체가 포함되어 있으면, 항체가 바이러스를 중화하여 혈구 응집을 억제한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 고정 반응 (Complement-Fixation Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 고정(Complement fixation): 보체 혈청 단백질이 항원-항체 복합체에 결합하고 고정되는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "소량의 항체를 검출할 수 있다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강 또는 응집 반응에 적합하지 않은 항체에도 사용될 수 있다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 면역학 학습 목표 (2)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 및 간접 형광 항체 테스트를 비교하고 대조한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 및 간접 ELISA 테스트가 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "웨스턴 블롯이 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "단일클론 항체의 중요성을 설명한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "형광 염료를 항체와 결합시킨다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 FA 테스트: 임상 검체에서 미생물을 식별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접 FA 테스트: 혈청에서 특정 항체를 검출한다. 항인간 면역 혈청 글로불린(anti-HISG)을 추가하며, 결과가 양성이면 혈청 내 모든 항체와 반응한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "형광 활성화 세포 분류기(Fluorescence-activated cell sorter, FACS): 레이저 빔이 세포를 포함하는 액적에 닿으면, 감지기가 표면 분자의 크기와 형광을 측정한다. 세포에 전하를 부여하여 세포를 분리한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "효소결합 면역흡착 분석법 (ELISA)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 ELISA: 항원을 검출한다. 항원을 포함하는 샘플을 항체와 혼합한다. 효소 연결 항체가 항원과 반응한다. 연결된 효소를 위한 기질을 추가하여 색이 생성되는 것으로 검출한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접 ELISA: 항체를 검출한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "웨스턴 블롯 (Western Blotting)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "전기영동과 블롯을 통해 단백질을 식별한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 및 치료 면역학의 미래",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "인간의 판단과 인력이 덜 필요한 테스트가 개발될 것이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "PCR 및 DNA 프로브가 활용될 것이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "개발도상국을 위한 저렴하고 간단한 테스트가 필요하다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "질병 예방 및 치료에 기여할 것이다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 면역학의 실제 적용, 특히 진단 면역학에 대해 설명합니다. 검사의 민감도와 특이도 같은 기본 개념부터 시작하여, 단일클론 항체의 생산, 종류 및 치료적 활용에 대해 다룹니다. 또한, 침강 반응, 응집 반응, 중화 반응, 보체 고정 반응, 형광 항체 기법, ELISA, 웨스턴 블롯 등 다양한 면역학 기반 진단 테스트의 원리와 적용 방법을 상세히 설명합니다. 마지막으로 진단 및 치료 면역학의 미래 방향에 대해서도 간략하게 언급합니다.",
                  "keyConcepts": [
                    {
                      "term": "진단 면역학의 기본 원리",
                      "definition": "검사의 민감도(Sensitivity)와 특이도(Specificity)는 진단 검사의 정확성을 나타내는 핵심 지표이며, 항원-항체 상호작용이 면역학 기반 진단 테스트의 근간을 이룬다."
                    },
                    {
                      "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                      "definition": "하이브리도마 기술을 통해 대량 생산되는 균일하고 고도로 특이적인 항체로, 진단 및 류마티스 관절염, 알레르기성 천식 등 다양한 질병의 치료에 활용된다. 쥐 유래 항체는 부작용을 일으킬 수 있어 키메라, 인간화, 완전 인간 항체 등으로 발전하고 있다."
                    },
                    {
                      "term": "면역 반응 기반 진단 테스트 유형",
                      "definition": "침강(Precipitation), 응집(Agglutination), 중화(Neutralization), 보체 고정(Complement-Fixation), 형광 항체(Fluorescent-Antibody), ELISA(Enzyme-Linked Immunosorbent Assay), 웨스턴 블롯(Western Blotting) 등 항원-항체 반응을 시각적으로 또는 정량적으로 확인하여 질병을 진단하는 다양한 기법들이 있다."
                    },
                    {
                      "term": "항체 역가 측정",
                      "definition": "직접 응집 테스트 등을 통해 혈청 내 특정 항체의 농도(역가)를 측정하는 것으로, 역가 증가는 질병에 대한 면역력 증가를 나타내며, 혈청 전환은 질병 진행에 따른 역가의 유의미한 변화를 의미한다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "민감도 (Sensitivity)",
                      "definition": "검사가 진양성 표본에 대해 반응할 확률"
                    },
                    {
                      "term": "특이도 (Specificity)",
                      "definition": "양성 검사가 진음성 표본에 대해 반응하지 않을 확률"
                    },
                    {
                      "term": "하이브리도마 (Hybridoma)",
                      "definition": "암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포"
                    },
                    {
                      "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                      "definition": "하이브리도마에서 생산되는 균일하고 특이성이 높은 항체로, 진단 및 치료에 사용된다."
                    },
                    {
                      "term": "침강 반응 (Precipitation Reactions)",
                      "definition": "가용성 항원과 항체가 반응하여 불용성 복합체(격자)를 형성하고 침전되는 반응"
                    },
                    {
                      "term": "응집 반응 (Agglutination Reactions)",
                      "definition": "입자성 항원(예: 세포)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응"
                    },
                    {
                      "term": "중화 반응 (Neutralization Reactions)",
                      "definition": "항체가 독소나 바이러스의 유해한 효과를 차단하는 항원-항체 반응"
                    },
                    {
                      "term": "보체 고정 반응 (Complement-Fixation Reactions)",
                      "definition": "보체 단백질이 항원-항체 복합체에 결합하고 고정되는 반응으로, 소량의 항체도 검출 가능하다."
                    },
                    {
                      "term": "효소결합 면역흡착 분석법 (ELISA)",
                      "definition": "효소와 항체를 이용하여 항원 또는 항체를 검출하는 면역학적 분석법으로, 색 변화를 통해 결과를 확인한다."
                    },
                    {
                      "term": "웨스턴 블롯 (Western Blotting)",
                      "definition": "전기영동으로 분리된 단백질을 막에 옮겨 특정 항체를 이용하여 식별하는 기법"
                    }
                  ],
                  "outline": [
                    {
                      "text": "진단 면역학 개요",
                      "id": "진단-면역학-개요",
                      "children": null
                    },
                    {
                      "text": "단일클론 항체 (Monoclonal Antibodies)",
                      "id": "단일클론-항체-monoclonal-antibodies",
                      "children": [
                        {
                          "text": "단일클론 항체의 생산",
                          "id": "단일클론-항체의-생산",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "침강 반응 (Precipitation Reactions)",
                      "id": "침강-반응-precipitation-reactions",
                      "children": null
                    },
                    {
                      "text": "응집 반응 (Agglutination Reactions)",
                      "id": "응집-반응-agglutination-reactions",
                      "children": null
                    },
                    {
                      "text": "진단 면역학 학습 목표 (1)",
                      "id": "진단-면역학-학습-목표-1",
                      "children": null
                    },
                    {
                      "text": "중화 반응 (Neutralization Reactions)",
                      "id": "중화-반응-neutralization-reactions",
                      "children": null
                    },
                    {
                      "text": "보체 고정 반응 (Complement-Fixation Reactions)",
                      "id": "보체-고정-반응-complement-fixation-reactions",
                      "children": null
                    },
                    {
                      "text": "진단 면역학 학습 목표 (2)",
                      "id": "진단-면역학-학습-목표-2",
                      "children": null
                    },
                    {
                      "text": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
                      "id": "형광-항체-기법-fluorescent-antibody-techniques",
                      "children": null
                    },
                    {
                      "text": "효소결합 면역흡착 분석법 (ELISA)",
                      "id": "효소결합-면역흡착-분석법-elisa",
                      "children": null
                    },
                    {
                      "text": "웨스턴 블롯 (Western Blotting)",
                      "id": "웨스턴-블롯-western-blotting",
                      "children": null
                    },
                    {
                      "text": "진단 및 치료 면역학의 미래",
                      "id": "진단-및-치료-면역학의-미래",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 하이브리도마(Hybridoma)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
                    "options": [
                      "암성 B 세포와 항체 생산 정상 B 세포를 결합한 세포",
                      "항원을 직접 생산하는 세포",
                      "체내에서 바이러스성 감염을 중화하는 세포",
                      "면역 반응을 억제하는 데 사용되는 세포"
                    ],
                    "answerIndex": 0,
                    "explanation": "하이브리도마는 '불멸의' 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포입니다."
                  },
                  {
                    "question": "침강 반응(Precipitation Reactions)과 응집 반응(Agglutination Reactions)의 주요 차이점은 무엇입니까?",
                    "options": [
                      "침강 반응은 가용성 항원을, 응집 반응은 입자성 항원을 사용한다.",
                      "침강 반응은 항체를 검출하고, 응집 반응은 항원을 검출한다.",
                      "침강 반응은 육안으로 볼 수 없지만, 응집 반응은 육안으로 볼 수 있다.",
                      "침강 반응은 보체를 필요로 하지만, 응집 반응은 그렇지 않다."
                    ],
                    "answerIndex": 0,
                    "explanation": "침강 반응은 가용성 항원과 항체의 상호작용으로 불용성 복합체가 형성되는 것이고, 응집 반응은 입자성 항원(예: 세포 또는 입자에 부착된 항원)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 것입니다."
                  },
                  {
                    "question": "효소결합 면역흡착 분석법(ELISA)에 대한 설명으로 옳지 않은 것은 무엇입니까?",
                    "options": [
                      "직접 ELISA는 항원을 검출하는 데 사용된다.",
                      "간접 ELISA는 항체를 검출하는 데 사용된다.",
                      "효소 연결 항체가 항원 또는 항체와 반응하여 색 변화를 유도한다.",
                      "ELISA는 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법이다."
                    ],
                    "answerIndex": 3,
                    "explanation": "ELISA는 효소와 항체를 이용하여 항원 또는 항체를 검출하며 색 변화를 통해 결과를 확인합니다. 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법은 웨스턴 블롯(Western Blotting)입니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 과민 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 3760 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "과민 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "과민 반응(Hypersensitivity)은 정상 범위를 넘어선 과도한 항원(알레르겐) 반응을 의미합니다. 이는 이전에 항원에 노출되어 민감해진 경우에 발생합니다. 과민 반응은 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 유형으로 분류됩니다. 과민 반응을 연구하는 학문은 면역병리학(Immunopathology)이라고 합니다. 위생 가설(Hygiene hypothesis)은 병원균에 대한 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다고 제안합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "과민 반응의 유형",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "제1형 (아나필락시스형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 30분 미만이 소요됩니다. IgE 항체가 비만세포나 호염기구에 결합하여 비만세포 또는 호염기구의 탈과립을 유발하고 히스타민과 같은 반응성 물질을 방출하게 합니다. 약물 주사 및 곤충 독에 의한 아나필락시스 쇼크, 건초열, 천식과 같은 일반적인 알레르기 증상이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제2형 (세포 독성형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 5-12시간이 소요됩니다. 항원이 표적 세포에 결합하는 IgM 및 IgG 항체 형성을 유발하며, 보체의 작용과 결합하여 표적 세포를 파괴합니다. 수혈 반응, Rh 부적합성이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제3형 (면역 복합체형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 3-8시간이 소요됩니다. 항체와 항원이 복합체를 형성하여 손상적인 염증을 유발합니다. 아르투스 반응, 혈청병이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제4형 (지연형 세포 매개성 또는 지연형 과민 반응)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 24-48시간이 소요됩니다. 항원이 세포독성 T 림프구(CTLs)를 활성화시켜 표적 세포를 사멸시킵니다. 이식 조직 거부 반응, 옻나무에 의한 접촉 피부염, 특정 만성 질환(예: 결핵) 등이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제1형 (아나필락시스형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이 반응은 항원에 민감해진 사람이 해당 항원에 재노출된 후 수 분 내에 발생합니다. 항원이 IgE 항체와 결합하며, IgE는 비만세포와 호염기구에 부착됩니다. 비만세포와 호염기구는 탈과립을 겪으며 다음과 같은 매개체를 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 히스타민: 혈액 모세혈관의 투과성을 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 류코트리엔: 평활근의 지속적인 수축을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 프로스타글란딘: 평활근에 영향을 미치고 점액 분비를 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원에 반응하여 생성된 IgE 항체는 비만세포와 호염기구를 감싸게 됩니다. 항원이 동일한 특이성을 가진 두 개의 인접한 항체 분자 사이의 간격을 연결할 때, 세포는 탈과립을 겪고 히스타민 및 기타 매개체를 방출합니다. 이는 항원과 반응하여 히스타민 및 기타 반응성 매개체 과립을 방출한 탈과립 비만세포의 모습입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전신 아나필락시스 (아나필락시스 쇼크)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항원에 민감해진 개체가 다시 노출될 때 발생합니다. 순환계 허탈 및 사망에 이를 수 있으며, 에피네프린으로 치료합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "국소 아나필락시스",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "주로 섭취되거나 흡입된 항원과 관련이 있습니다. 증상은 침입 경로에 따라 다르며, 두드러기, 건초열, 천식 등이 포함됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "아나필락시스 반응 예방",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "알레르겐을 식별하기 위한 피부 검사는 항원을 표피 아래에 접종하여 빠른 염증 반응(팽진)을 확인합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "탈감작(Desensitization)은 항원을 피부 아래에 증가하는 용량으로 주사하는 방법입니다. 이는 IgG를 생성하게 하는데, 이 IgG는 블로킹 항체(blocking antibodies) 역할을 하여 항원을 가로채고 중화시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제2형 (세포 독성형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "IgG 또는 IgM 항체와 항원성 세포의 결합에 의한 보체 활성화로 발생합니다. 이는 세포 용해 또는 대식세포에 의한 손상을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "ABO 혈액형 시스템",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "적혈구에 있는 특정 탄수화물 항원에 대해 항체가 형성됩니다. A 항원, B 항원 또는 둘 다를 가질 수 있습니다. O형 적혈구는 항원이 없습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "Rh 혈액형 시스템",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "인구의 85%에서 적혈구에 Rh 인자 항원(Rh+)이 발견됩니다. Rh+ 혈액이 Rh- 수혈자에게 주입되면 수혈자의 몸에서 항Rh 항체 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "용혈성 신생아 질환 (HDNB)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "Rh- 어머니가 Rh+ 태아를 임신할 경우 어머니의 몸에서 항Rh 항체가 생성됩니다. 첫 Rh+ 태아를 임신한 Rh- 어머니의 경우, 분만 중 태아의 Rh 항원이 어머니의 혈액으로 들어갈 수 있습니다. 이 태아 Rh 항원에 반응하여 어머니는 항Rh 항체를 생산할 것입니다. 두 번째 Rh+ 태아를 임신하게 되면, 어머니의 항Rh 항체가 태반을 통과하여 태아의 적혈구를 손상시킬 것입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "약물 유발 세포 독성 반응",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "혈소판 감소성 자반증 (Thrombocytopenic purpura)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "혈소판이 약물과 결합하여 항원성 복합체를 형성합니다. 항체와 보체가 혈소판을 파괴합니다. 약물(합텐)이 혈소판에 결합하여 합텐-혈소판 복합체를 형성합니다. 이 복합체는 합텐에 대한 항체 형성을 유도합니다. 항체와 보체의 작용은 혈소판 파괴를 일으킵s니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "무과립구증 (Agranulocytosis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "약물 유발 과립구의 면역 파괴입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "용혈성 빈혈 (Hemolytic anemia)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "약물 유발 적혈구의 면역 파괴입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제3형 (면역 복합체형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 혈청 내 가용성 항원에 대해 형성됩니다. 세포 아래 기저막에 침착되는 면역 복합체를 형성하여 보체를 활성화시키고 염증을 유발합니다. 면역 복합체는 혈관벽에 침착됩니다. 면역 복합체의 존재는 보체를 활성화시키고 호중구와 같은 염증 세포를 유인합니다. 호중구에서 방출된 효소는 기저막의 내피 세포에 손상을 입힙니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "아르투스 반응 (Arthus reaction)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "톡소이드 함유 백신의 드문 부작용입니다. 주사된 항원에 대해 이미 순환하는 IgG를 가진 환자에서 보체 활성화로 인해 사구체 및 기타 혈관벽에서 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "혈청병 (Serum sickness)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "이종 혈청 주입으로 인한 부종 및 염증과 함께 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제4형 (지연형 세포 매개성) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포에 의해 유발되는 세포 매개 면역 반응입니다. 이는 지연형 과민 반응으로 알려져 있습니다. 항원은 식세포화되어 T 세포 수용체에 제시되어 민감화를 유발합니다. 항원에 재노출되면 기억 세포가 파괴적인 사이토카인을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "알레르기성 접촉 피부염 (Allergic contact dermatitis)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "합텐이 피부의 단백질과 결합하여 면역 반응을 일으킵니다. 옻나무, 화장품, 금속, 라텍스 등에 대한 알레르기 반응이 여기에 해당합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본문은 면역 시스템 관련 질환 중 '과민 반응'에 대해 설명합니다. 과민 반응은 정상 범위를 넘어선 과도한 면역 반응으로, 이전 항원 노출로 인해 민감해진 상태에서 발생합니다. 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 주요 유형으로 분류되며, 각 유형은 발현 시간, 기전, 임상 증상 및 예시가 다릅니다. 제1형은 즉각적인 알레르기 반응(예: 아나필락시스 쇼크)을, 제2형은 세포 파괴(예: 수혈 부작용)를, 제3형은 면역 복합체 침착으로 인한 염증(예: 혈청병)을, 제4형은 T세포 매개 지연 반응(예: 접촉 피부염)을 특징으로 합니다. 각 유형의 발생 기전과 예방 및 치료법이 상세히 다루어집니다.",
                  "keyConcepts": [
                    {
                      "term": "과민 반응 (Hypersensitivity)",
                      "definition": "정상 범위를 넘어선 과도한 항원 반응으로, 이전에 항원에 노출되어 민감해진 경우에 발생합니다."
                    },
                    {
                      "term": "아나필락시스 (Anaphylaxis)",
                      "definition": "제1형 과민 반응의 심각한 형태로, 비만세포 및 호염기구의 탈과립으로 인한 매개체 방출로 발생하며, 전신 또는 국소적으로 나타나 생명을 위협할 수 있습니다."
                    },
                    {
                      "term": "위생 가설 (Hygiene Hypothesis)",
                      "definition": "병원균 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다는 가설입니다."
                    },
                    {
                      "term": "탈감작 (Desensitization)",
                      "definition": "알레르기 반응을 예방하기 위해 항원을 점진적으로 증가시켜 주사하는 치료법으로, 블로킹 항체(IgG) 생성을 유도하여 알레르겐을 중화시킵니다."
                    },
                    {
                      "term": "용혈성 신생아 질환 (HDNB)",
                      "definition": "Rh 혈액형 불일치로 인해 Rh- 어머니가 Rh+ 태아에 대한 항체를 생성하여 두 번째 Rh+ 태아의 적혈구를 파괴하는 질환입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "알레르겐 (Allergen)",
                      "definition": "알레르기 반응을 유발하는 항원입니다."
                    },
                    {
                      "term": "면역병리학 (Immunopathology)",
                      "definition": "과민 반응을 연구하는 학문입니다."
                    },
                    {
                      "term": "히스타민 (Histamine)",
                      "definition": "제1형 과민 반응 시 비만세포에서 방출되어 혈관 투과성을 증가시키는 주요 염증 매개체입니다."
                    },
                    {
                      "term": "류코트리엔 (Leukotrienes)",
                      "definition": "제1형 과민 반응 시 방출되어 평활근의 지속적인 수축을 유발하는 매개체입니다."
                    },
                    {
                      "term": "프로스타글란딘 (Prostaglandins)",
                      "definition": "제1형 과민 반응 시 방출되어 평활근에 영향을 미치고 점액 분비를 증가시키는 매개체입니다."
                    },
                    {
                      "term": "보체 (Complement)",
                      "definition": "면역 반응에서 항체와 함께 작용하여 세포 파괴를 돕는 단백질 시스템입니다."
                    },
                    {
                      "term": "합텐 (Hapten)",
                      "definition": "단독으로는 면역 반응을 유발하지 못하지만, 단백질과 결합 시 항원성을 띠는 작은 분자입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "과민 반응의 개요",
                      "id": "hypersensitivity-overview",
                      "children": [
                        {
                          "text": "정의 및 특징",
                          "id": "definition-features",
                          "children": null
                        },
                        {
                          "text": "과민 반응의 네 가지 유형",
                          "id": "four-types-hypersensitivity",
                          "children": null
                        },
                        {
                          "text": "면역병리학 및 위생 가설",
                          "id": "immunopathology-hygiene-hypothesis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "과민 반응 유형별 상세 설명",
                      "id": "detailed-hypersensitivity-types",
                      "children": [
                        {
                          "text": "제1형 과민 반응 (아나필락시스형)",
                          "id": "type-i-anaphylactic",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-i-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "매개체 (히스타민, 류코트리엔, 프로스타글란딘)",
                              "id": "type-i-mediators",
                              "children": null
                            },
                            {
                              "text": "전신 아나필락시스 및 국소 아나필락시스",
                              "id": "systemic-local-anaphylaxis",
                              "children": null
                            },
                            {
                              "text": "예방 및 치료",
                              "id": "type-i-prevention-treatment",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제2형 과민 반응 (세포 독성형)",
                          "id": "type-ii-cytotoxic",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-ii-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "ABO 혈액형 시스템",
                              "id": "abo-blood-group",
                              "children": null
                            },
                            {
                              "text": "Rh 혈액형 시스템 및 용혈성 신생아 질환",
                              "id": "rh-blood-group-hdnb",
                              "children": null
                            },
                            {
                              "text": "약물 유발 세포 독성 반응",
                              "id": "drug-induced-cytotoxic",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제3형 과민 반응 (면역 복합체형)",
                          "id": "type-iii-immune-complex",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-iii-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "아르투스 반응",
                              "id": "arthus-reaction",
                              "children": null
                            },
                            {
                              "text": "혈청병",
                              "id": "serum-sickness",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제4형 과민 반응 (지연형 세포 매개성)",
                          "id": "type-iv-delayed-cell-mediated",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-iv-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "알레르기성 접촉 피부염",
                              "id": "allergic-contact-dermatitis",
                              "children": null
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "제1형 과민 반응 시 혈액 모세혈관의 투과성을 증가시키는 주요 매개체는 무엇입니까?",
                    "options": [
                      "히스타민",
                      "류코트리엔",
                      "프로스타글란딘",
                      "사이토카인"
                    ],
                    "answerIndex": 0,
                    "explanation": "제1형 과민 반응은 비만세포의 탈과립을 통해 히스타민을 방출하며, 히스타민은 혈액 모세혈관의 투과성을 증가시키는 역할을 합니다."
                  },
                  {
                    "question": "이식 조직 거부 반응 및 접촉 피부염과 주로 관련된 과민 반응 유형은 무엇입니까?",
                    "options": [
                      "제1형 (아나필락시스형)",
                      "제2형 (세포 독성형)",
                      "제3형 (면역 복합체형)",
                      "제4형 (지연형 세포 매개성)"
                    ],
                    "answerIndex": 3,
                    "explanation": "제4형 과민 반응은 T세포에 의해 매개되는 지연형 반응으로, 이식 조직 거부 반응과 접촉 피부염이 대표적인 예시입니다."
                  },
                  {
                    "question": "아나필락시스 반응 예방을 위한 탈감작의 주요 기전은 무엇입니까?",
                    "options": [
                      "히스타민 방출 억제",
                      "IgE 항체 생성 촉진",
                      "비만세포 탈과립 유도",
                      "IgG 블로킹 항체 생성"
                    ],
                    "answerIndex": 3,
                    "explanation": "탈감작은 증가하는 용량의 항원 주사를 통해 IgG 블로킹 항체를 생성하게 하여, 이 항체가 알레르겐을 가로채고 중화시켜 IgE 매개 반응을 예방합니다."
                  }
                ]
              },
              {
                "title": "자가면역 질환의 이해: 유형 및 주요 사례",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1640 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "자가면역 질환 (AUTOIMMUNE DISEASES)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 체계가 자가 항원에 반응하여 장기에 손상을 입히는 질환입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자가면역은 자가 관용(self-tolerance)의 상실을 의미합니다. 이는 면역 체계가 자신과 비자신을 구별하는 능력을 잃어버릴 때 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자가면역 반응은 세포독성(Cytotoxic), 면역 복합체(Immune complex), 또는 세포 매개성(Cell-mediated)의 형태로 나타날 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 자가면역 반응 (CYTOTOXIC AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 세포 표면 항원과 반응하여 세포를 손상시키거나 기능을 방해하는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다발성 경화증 (Multiple sclerosis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "자가항체, T 세포, 그리고 대식세포가 신경의 미엘린 수초를 공격하여 신경 임펄스 전달을 손상시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "증상은 피로와 쇠약부터 심한 마비에 이릅니다. 원인은 알려지지 않았지만, 유전적 취약성 및/또는 감염성 물질과 관련될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "그레이브스병 (Graves' disease)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "갑상선 내 비정상 항체가 과도한 양의 호르몬을 생성하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "중증 근무력증 (Myasthenia gravis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 아세틸콜린 수용체를 코팅하여 근육이 신경 신호를 받지 못하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 복합체 자가면역 반응 (IMMUNE COMPLEX AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체와 보체의 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전신성 홍반성 루푸스 (Systemic lupus erythematosus)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "신장 사구체에 면역 복합체가 형성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "류마티스 관절염 (Rheumatoid arthritis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "관절에 면역 복합체가 형성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포 매개성 자가면역 반응 (CELL-MEDIATED AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조직을 공격하는 T 세포에 의해 매개되는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인슐린 의존성 당뇨병 (Insulin-dependent diabetes mellitus, 1형 당뇨병)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포가 인슐린 분비 세포를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "건선 및 건선성 관절염 (Psoriasis and psoriatic arthritis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "피부의 자가면역 질환입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "주요 자가면역 질환 및 원인 (SELECTED AUTOIMMUNE DISORDERS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다음은 몇 가지 주요 자가면역 질환과 가능한 원인입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "만성 피로 증후군: 신경 세포의 아세틸콜린 수용체에 항체가 부착되어 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류마티스 관절염: 연쇄상구균 항체에 대한 교차 반응.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "전신성 홍반성 루푸스: DNA에 대한 항체를 포함하는 면역 복합체.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다발성 경화증: T 세포와 대식세포가 미엘린 수초를 공격.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1형 당뇨병: T 세포가 인슐린 분비 세포를 파괴.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "길랑-바레 증후군: T 세포가 신경 세포의 미엘린 수초 파괴를 유발하는 사이토카인을 생성.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "건선: T 세포가 각질 형성 세포(피부 세포) 성장을 유도할 수 있는 사이토카인을 생성.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그레이브스병: 갑상선 특정 수용체에 부착된 항체가 갑상선을 비대하게 하고 과도한 호르몬을 생성하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "중증 근무력증: 아세틸콜린 수용체에 대한 항체.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "크론병: 항균 항체가 장 점막과 반응.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "염증성 장 질환: 항균 항체가 장 점막과 반응.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "자가면역 질환은 면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 상태입니다. 이는 자가 관용의 상실로 인해 발생하며, 세포독성, 면역 복합체, 세포 매개성 반응의 세 가지 주요 유형으로 분류될 수 있습니다. 각 유형은 특정 질병과 관련이 있으며, 신경, 갑상선, 관절, 췌장 등 다양한 장기에 영향을 미칩니다. 주요 자가면역 질환으로는 다발성 경화증, 그레이브스병, 중증 근무력증, 전신성 홍반성 루푸스, 류마티스 관절염, 1형 당뇨병, 건선 등이 있으며, 각 질환의 원인과 면역학적 메커니즘이 설명됩니다.",
                  "keyConcepts": [
                    {
                      "term": "자가면역",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 현상입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "자가 관용",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 자신의 항원에 반응하지 않고 구별하는 능력입니다. 자가면역 질환은 이 자가 관용의 상실로 발생합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "세포독성 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "항체가 세포 표면 항원과 반응하여 세포를 파괴하거나 기능을 손상시키는 유형의 자가면역 반응입니다. (예: 다발성 경화증, 그레이브스병, 중증 근무력증)",
                        "hard": null
                      }
                    },
                    {
                      "term": "면역 복합체 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "항체와 항원이 결합하여 형성된 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형의 자가면역 반응입니다. (예: 전신성 홍반성 루푸스, 류마티스 관절염)",
                        "hard": null
                      }
                    },
                    {
                      "term": "세포 매개성 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "T 세포가 직접 조직을 공격하여 손상을 일으키는 유형의 자가면역 반응입니다. (예: 1형 당뇨병, 건선)",
                        "hard": null
                      }
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "자가 항원",
                      "definition": "자신의 신체에 존재하는 항원으로, 면역 체계가 실수로 공격하는 대상이 됩니다."
                    },
                    {
                      "term": "미엘린 수초",
                      "definition": "신경 세포를 둘러싸고 있는 절연성 막으로, 손상 시 신경 신호 전달에 문제가 발생합니다."
                    },
                    {
                      "term": "아세틸콜린 수용체",
                      "definition": "신경 전달 물질인 아세틸콜린이 결합하는 근육 세포 표면의 단백질로, 중증 근무력증에서 항체에 의해 기능이 저해됩니다."
                    },
                    {
                      "term": "면역 복합체",
                      "definition": "항체와 항원이 결합하여 형성된 복합체로, 특정 조직에 침착되어 염증을 유발할 수 있습니다."
                    },
                    {
                      "term": "T 세포",
                      "definition": "세포 매개 면역 반응을 담당하는 림프구의 일종으로, 일부 자가면역 질환에서 직접 조직을 공격합니다."
                    },
                    {
                      "term": "사구체",
                      "definition": "신장의 혈액 여과 단위로, 전신성 홍반성 루푸스에서 면역 복합체가 형성되는 주요 부위입니다."
                    },
                    {
                      "term": "사이토카인",
                      "definition": "면역 세포 간의 신호 전달에 관여하는 단백질로, 일부 자가면역 질환에서 조직 손상을 유발할 수 있습니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "자가면역 질환 개요",
                      "id": "autoimmune-diseases-overview",
                      "children": [
                        {
                          "text": "자가면역의 정의 및 특징",
                          "id": "definition-and-characteristics-of-autoimmunity",
                          "children": null
                        },
                        {
                          "text": "주요 반응 유형",
                          "id": "main-types-of-reactions",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포독성 자가면역 반응",
                      "id": "cytotoxic-autoimmune-reactions",
                      "children": [
                        {
                          "text": "다발성 경화증",
                          "id": "multiple-sclerosis",
                          "children": null
                        },
                        {
                          "text": "그레이브스병",
                          "id": "graves-disease",
                          "children": null
                        },
                        {
                          "text": "중증 근무력증",
                          "id": "myasthenia-gravis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 복합체 자가면역 반응",
                      "id": "immune-complex-autoimmune-reactions",
                      "children": [
                        {
                          "text": "전신성 홍반성 루푸스",
                          "id": "systemic-lupus-erythematosus",
                          "children": null
                        },
                        {
                          "text": "류마티스 관절염",
                          "id": "rheumatoid-arthritis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포 매개성 자가면역 반응",
                      "id": "cell-mediated-autoimmune-reactions",
                      "children": [
                        {
                          "text": "인슐린 의존성 당뇨병 (1형 당뇨병)",
                          "id": "insulin-dependent-diabetes-mellitus-type-1",
                          "children": null
                        },
                        {
                          "text": "건선 및 건선성 관절염",
                          "id": "psoriasis-and-psoriatic-arthritis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "주요 자가면역 질환 및 원인",
                      "id": "selected-autoimmune-disorders-and-causes",
                      "children": [
                        {
                          "text": "만성 피로 증후군",
                          "id": "chronic-fatigue-syndrome",
                          "children": null
                        },
                        {
                          "text": "류마티스 관절염",
                          "id": "rheumatoid-arthritis-cause",
                          "children": null
                        },
                        {
                          "text": "전신성 홍반성 루푸스",
                          "id": "systemic-lupus-erythematosus-cause",
                          "children": null
                        },
                        {
                          "text": "다발성 경화증",
                          "id": "multiple-sclerosis-cause",
                          "children": null
                        },
                        {
                          "text": "1형 당뇨병",
                          "id": "type-1-diabetes-cause",
                          "children": null
                        },
                        {
                          "text": "길랑-바레 증후군",
                          "id": "guillain-barre-syndrome",
                          "children": null
                        },
                        {
                          "text": "건선",
                          "id": "psoriasis-cause",
                          "children": null
                        },
                        {
                          "text": "그레이브스병",
                          "id": "graves-disease-cause",
                          "children": null
                        },
                        {
                          "text": "중증 근무력증",
                          "id": "myasthenia-gravis-cause",
                          "children": null
                        },
                        {
                          "text": "크론병",
                          "id": "crohns-disease",
                          "children": null
                        },
                        {
                          "text": "염증성 장 질환",
                          "id": "inflammatory-bowel-disease",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "자가면역 질환에서 면역 체계가 공격하는 대상은 무엇입니까?",
                    "options": [
                      "외부 병원체",
                      "알레르기 유발 물질",
                      "자가 항원",
                      "독성 물질"
                    ],
                    "answerIndex": 2,
                    "explanation": "자가면역 질환은 면역 체계가 자신의 신체 조직, 즉 자가 항원을 외부 침입자로 오인하여 공격하는 상태입니다."
                  },
                  {
                    "question": "다음 중 세포독성 자가면역 반응에 해당하는 질환이 아닌 것은 무엇입니까?",
                    "options": [
                      "다발성 경화증",
                      "그레이브스병",
                      "중증 근무력증",
                      "류마티스 관절염"
                    ],
                    "answerIndex": 3,
                    "explanation": "류마티스 관절염은 면역 복합체가 관절에 형성되어 발생하는 면역 복합체 자가면역 반응에 해당합니다. 다발성 경화증, 그레이브스병, 중증 근무력증은 세포독성 자가면역 반응의 예시입니다."
                  },
                  {
                    "question": "1형 당뇨병(인슐린 의존성 당뇨병)의 주요 원인으로 설명된 면역 반응은 무엇입니까?",
                    "options": [
                      "항체에 의한 아세틸콜린 수용체 코팅",
                      "면역 복합체의 신장 사구체 침착",
                      "T 세포에 의한 인슐린 분비 세포 파괴",
                      "갑상선 항체의 과도한 호르몬 생성 유발"
                    ],
                    "answerIndex": 2,
                    "explanation": "1형 당뇨병은 T 세포가 인슐린을 분비하는 췌장의 세포를 파괴하여 발생하는 세포 매개성 자가면역 반응입니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1848 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "인간 백혈구 항원(HLA) 복합체 관련 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조직적합성 항원(Histocompatibility antigens): 세포 표면에 존재하는 자가 항원입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주요 조직적합성 복합체(MHC): 조직적합성 항원을 암호화하는 유전자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인간 백혈구 항원(HLA) 복합체: 인간의 MHC 유전자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "특정 HLA는 특정 질병에 대한 감수성 증가와 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HLA 타이핑 및 이식 수술",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "HLA 타이핑은 HLA를 식별하고 비교하는 과정입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이식 수술에서 공여자와 수혜자는 조직 타이핑을 통해 일치해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "표준화된 항혈청 또는 HLA에 특이적인 단일클론 항체를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HLA 타이핑 과정: 검사 중인 림프구에 항-HLA 항체가 부착됩니다. 보체와 트립판 블루 염료가 추가되면, 보체에 의해 손상된 세포가 염료를 흡수합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 특권 부위 및 면역 특권 조직",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이식편은 T 세포, 대식세포, 그리고 보체 고정 항체에 의해 공격받을 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 특권 부위 및 면역 특권 조직으로의 이식은 면역 반응을 일으키지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "예시로는 각막 이식, 심장 판막 이식이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "줄기세포",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포는 여러 다른 세포 유형을 생성할 수 있는 마스터 세포입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "배아 줄기세포(ESCs)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "배반포에서 채취되며, 조직과 장기를 재생하는 데 사용됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다능성(Pluripotent)으로, 모든 종류의 세포를 생성할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "성체 줄기세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "분화된 성체 조직에 있는 줄기세포입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "유전자 도입을 통해 유도만능줄기세포(induced pluripotent stem cells)가 될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포 배양 과정: (1일) 일반적으로 시험관 아기 시술에서 폐기된 수정란인 배아가 사용됩니다. (1-5일) 배아는 반복적으로 분열하여 속이 빈 세포 덩어리인 배반포 단계를 형성합니다. 배아줄기세포는 배반포의 속세포덩어리에서 채취되어 배양 배지의 피더(feeder) 세포 위에서 성장합니다. 줄기세포주와 줄기세포 그룹은 배양 배지에서 콜로니를 형성합니다. 다양한 조건과 배양 배지에 추가된 성장 인자는 줄기세포가 신체의 다양한 조직(예: 혈액 및 림프 세포, 췌장 섬 세포, 신경 세포)을 위한 줄기세포주가 되도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "골수 이식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조혈모세포 이식으로도 알려져 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "수혜자가 건강한 혈액 세포를 생산할 수 있도록 하는 것이 목표입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역능력 있는 세포를 포함하는 이식된 골수로 인해 이식편대숙주병(Graft-versus-host, GVH)이 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이식편(Grafts)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "자가이식(Autograft): 자신의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동계이식(Isograft): 일란성 쌍둥이의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동종이식(Allografts): 다른 사람의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이종이식(Xenotransplantation product): 비인간 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비인간 항원에 대한 반응인 초급성 거부 반응을 극복해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이식 거부 반응 방지를 위한 면역 억제",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이식된 조직에 대한 세포 매개 면역 반응을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이클로스포린(Cyclosporine)과 타크로리무스(tacrolimus)는 IL-2를 억제하여 세포독성 T 세포를 방해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "시롤리무스(Sirolimus)는 세포성 및 체액성 면역을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "마이코페놀레이트(Mycophenolate)는 T 세포와 B 세포의 증식을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바실리시맙(Basiliximab)은 IL-2를 차단하는 키메라 단일클론 항체입니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "제공된 텍스트는 인간 백혈구 항원(HLA) 복합체의 역할과 이식 면역학에서 이의 중요성을 설명합니다. HLA 타이핑을 통한 조직 일치의 필요성, 면역 반응을 일으키지 않는 면역 특권 부위, 그리고 배아 및 성체 줄기세포의 종류와 활용에 대해 다룹니다. 또한, 자가이식, 동계이식, 동종이식, 이종이식과 같은 다양한 이식편의 유형과 이식편대숙주병(GVH)과 같은 이식 관련 합병증을 설명합니다. 마지막으로, 이식 거부 반응을 방지하기 위한 사이클로스포린, 타크로리무스, 시롤리무스, 마이코페놀레이트, 바실리시맙 등 주요 면역 억제제와 그 작용 기전을 소개합니다.",
                  "keyConcepts": [
                    {
                      "term": "인간 백혈구 항원(HLA) 복합체",
                      "definition": "인간의 주요 조직적합성 복합체(MHC) 유전자로, 이식 수술에서 조직 일치에 결정적인 역할을 하며 특정 질병 감수성과 관련이 있습니다."
                    },
                    {
                      "term": "줄기세포",
                      "definition": "다양한 세포 유형으로 분화할 수 있는 마스터 세포로, 배아 줄기세포와 성체 줄기세포로 나뉩니다. 조직 재생 및 치료에 잠재적으로 활용됩니다."
                    },
                    {
                      "term": "이식편의 종류",
                      "definition": "조직의 출처에 따라 자가이식(자신의 조직), 동계이식(일란성 쌍둥이), 동종이식(다른 사람), 이종이식(비인간 조직)으로 분류됩니다."
                    },
                    {
                      "term": "이식 거부 반응 및 GVH 질환",
                      "definition": "이식된 조직에 대한 수혜자의 면역 반응(이식 거부 반응) 또는 이식된 면역 세포가 수혜자의 조직을 공격하는 현상(이식편대숙주병)입니다."
                    },
                    {
                      "term": "면역 억제",
                      "definition": "이식 거부 반응을 방지하기 위해 특정 약물을 사용하여 수혜자의 면역 반응을 억제하는 치료법입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "조직적합성 항원",
                      "definition": "세포 표면에 존재하는 자가 항원입니다."
                    },
                    {
                      "term": "주요 조직적합성 복합체(MHC)",
                      "definition": "조직적합성 항원을 암호화하는 유전자입니다."
                    },
                    {
                      "term": "인간 백혈구 항원(HLA) 복합체",
                      "definition": "인간의 MHC 유전자입니다."
                    },
                    {
                      "term": "면역 특권 부위",
                      "definition": "이식 시 면역 반응을 일으키지 않는 신체 부위 또는 조직입니다."
                    },
                    {
                      "term": "이식편대숙주병(GVH)",
                      "definition": "이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격하는 질환입니다."
                    },
                    {
                      "term": "자가이식",
                      "definition": "자신의 조직을 사용하는 이식 방법입니다."
                    },
                    {
                      "term": "면역 억제제",
                      "definition": "이식 거부 반응을 방지하기 위해 면역 반응을 억제하는 약물입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "인간 백혈구 항원(HLA) 복합체 관련 반응",
                      "id": "인간-백혈구-항원-hla-복합체-관련-반응",
                      "children": [
                        {
                          "text": "조직적합성 항원",
                          "id": "조직적합성-항원",
                          "children": null
                        },
                        {
                          "text": "주요 조직적합성 복합체(MHC)",
                          "id": "주요-조직적합성-복합체-mhc",
                          "children": null
                        },
                        {
                          "text": "인간 백혈구 항원(HLA) 복합체",
                          "id": "인간-백혈구-항원-hla-복합체",
                          "children": null
                        },
                        {
                          "text": "특정 질병에 대한 감수성",
                          "id": "특정-질병에-대한-감수성",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "HLA 타이핑 및 이식 수술",
                      "id": "hla-타이핑-및-이식-수술",
                      "children": [
                        {
                          "text": "HLA 타이핑의 역할",
                          "id": "hla-타이핑의-역할",
                          "children": null
                        },
                        {
                          "text": "조직 타이핑의 중요성",
                          "id": "조직-타이핑의-중요성",
                          "children": null
                        },
                        {
                          "text": "HLA 타이핑 과정",
                          "id": "hla-타이핑-과정",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 특권 부위 및 면역 특권 조직",
                      "id": "면역-특권-부위-및-면역-특권-조직",
                      "children": [
                        {
                          "text": "이식 거부 반응의 메커니즘",
                          "id": "이식-거부-반응의-메커니즘",
                          "children": null
                        },
                        {
                          "text": "면역 특권 부위의 특징",
                          "id": "면역-특권-부위의-특징",
                          "children": null
                        },
                        {
                          "text": "예시: 각막 이식, 심장 판막 이식",
                          "id": "예시-각막-이식-심장-판막-이식",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "줄기세포",
                      "id": "줄기세포",
                      "children": [
                        {
                          "text": "줄기세포의 정의",
                          "id": "줄기세포의-정의",
                          "children": null
                        },
                        {
                          "text": "배아 줄기세포(ESCs)",
                          "id": "배아-줄기세포-escs",
                          "children": null
                        },
                        {
                          "text": "성체 줄기세포",
                          "id": "성체-줄기세포",
                          "children": null
                        },
                        {
                          "text": "줄기세포 배양 및 분화",
                          "id": "줄기세포-배양-및-분화",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "골수 이식",
                      "id": "골수-이식",
                      "children": [
                        {
                          "text": "조혈모세포 이식",
                          "id": "조혈모세포-이식",
                          "children": null
                        },
                        {
                          "text": "골수 이식의 목표",
                          "id": "골수-이식의-목표",
                          "children": null
                        },
                        {
                          "text": "이식편대숙주병(GVH)",
                          "id": "이식편대숙주병-gvh",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "이식편(Grafts)",
                      "id": "이식편-grafts",
                      "children": [
                        {
                          "text": "자가이식(Autograft)",
                          "id": "자가이식-autograft",
                          "children": null
                        },
                        {
                          "text": "동계이식(Isograft)",
                          "id": "동계이식-isograft",
                          "children": null
                        },
                        {
                          "text": "동종이식(Allografts)",
                          "id": "동종이식-allografts",
                          "children": null
                        },
                        {
                          "text": "이종이식(Xenotransplantation)",
                          "id": "이종이식-xenotransplantation",
                          "children": null
                        },
                        {
                          "text": "초급성 거부 반응 극복",
                          "id": "초급성-거부-반응-극복",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "이식 거부 반응 방지를 위한 면역 억제",
                      "id": "이식-거부-반응-방지를-위한-면역-억제",
                      "children": [
                        {
                          "text": "면역 억제의 목적",
                          "id": "면역-억제의-목적",
                          "children": null
                        },
                        {
                          "text": "주요 면역 억제제 및 작용 기전",
                          "id": "주요-면역-억제제-및-작용-기전",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "이식 수술에서 공여자와 수혜자의 조직 일치가 중요한 주된 이유는 무엇입니까?",
                    "options": [
                      "감염 위험을 줄이기 위해",
                      "수술 시간을 단축하기 위해",
                      "이식 거부 반응을 최소화하기 위해",
                      "환자의 회복 속도를 높이기 위해"
                    ],
                    "answerIndex": 2,
                    "explanation": "HLA 타이핑을 통한 조직 일치는 이식된 조직에 대한 수혜자의 면역 반응, 즉 거부 반응을 줄이는 데 필수적입니다."
                  },
                  {
                    "question": "다음 중 '이식편대숙주병(Graft-versus-host disease, GVH)'이 발생할 수 있는 이식 유형은 무엇입니까?",
                    "options": [
                      "자가이식 (Autograft)",
                      "동계이식 (Isograft)",
                      "골수 이식 (Bone marrow transplant)",
                      "각막 이식 (Cornea transplant)"
                    ],
                    "answerIndex": 2,
                    "explanation": "이식편대숙주병은 이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격할 때 발생합니다."
                  },
                  {
                    "question": "다음 중 면역 억제제 시롤리무스(Sirolimus)의 주요 작용 기전은 무엇입니까?",
                    "options": [
                      "IL-2 생성을 억제하여 세포독성 T 세포를 방해한다.",
                      "T 세포와 B 세포의 증식을 억제한다.",
                      "세포성 및 체액성 면역을 모두 억제한다.",
                      "IL-2를 차단하는 키메라 단일클론 항체이다."
                    ],
                    "answerIndex": 2,
                    "explanation": "텍스트에 따르면 시롤리무스는 세포성 및 체액성 면역을 모두 억제한다고 명시되어 있습니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1530 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역 시스템과 암",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "암세포는 면역 감시에 의해 제거됩니다. 암세포는 비자기로 표시되는 종양 관련 항원을 가지고 있습니다. CTL(활성화된 TC 세포)과 대식세포는 암세포를 용해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그러나 면역 시스템의 암 제거에는 몇 가지 제한 사항이 있습니다. 면역 시스템이 표적으로 삼을 항원성 에피토프가 없거나, 종양 세포가 너무 빠르게 증식하거나, 종양이 혈관화되어 면역 시스템에 보이지 않게 될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "암에 대한 면역 요법",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "암 치료를 위한 다양한 면역 요법이 개발되었습니다. 박테리아 내독소(Coley's toxins)는 암의 혈액 공급을 방해하는 TNF를 자극하여 사용될 수 있습니다. HPV(자궁경부암, 항문암, 인후암) 및 B형 간염(간암)과 같은 바이러스 관련 암에 대한 예방 백신이 사용됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "또한 단클론항체(Monoclonal antibodies)가 사용되는데, 예를 들어 유방암 치료제 허셉틴이 있습니다. 면역독소(Immunotoxin)는 단클론항체와 독성 물질을 결합하여 건강한 세포에 손상을 주지 않고 종양을 표적하여 죽입니다. 면역 관문 억제제와 CAR T 세포와 같은 세포 치료법도 암 치료에 활용되고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 결핍증",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 결핍증은 충분한 면역 반응이 부재하는 상태를 말합니다. 이는 선천성 면역 결핍증과 후천성 면역 결핍증으로 나눌 수 있습니다. 선천성 면역 결핍증은 결함이 있거나 없는 유전자 때문에 발생하며, 후천성 면역 결핍증은 약물, 암, 감염 등으로 인해 개인의 삶 동안 발병합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 결핍 질환",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "선천성 면역 결핍 질환은 유전적 유전자 결함에 의해 발생합니다. T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있으며, 항원 수용체 유전자 재배열의 결함 또한 SCID를 유발할 수 있습니다. T세포 항원 수용체로부터의 신호 전달 결함이나 T세포 발달을 차단하는 흉선 기능의 유전적 결함 역시 중증 면역 결핍증을 초래할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "림프구 발달의 결함이 중증 복합 면역 결핍증을 초래할 수 있음",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.12 나병균에 감염된 누드(털 없는) 쥐의 뒷발. M. leprae 박테리아 위치.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본문은 면역 시스템이 암과 싸우는 방식, 그 한계, 그리고 다양한 암 면역 요법에 대해 설명합니다. 또한 면역 결핍증을 선천성 및 후천성으로 구분하고, T세포 발달 또는 항원 수용체 결함으로 인한 SCID와 같은 선천성 면역 결핍 질환의 구체적인 원인을 다룹니다.",
                  "keyConcepts": [
                    {
                      "term": "면역 감시",
                      "definition": "면역 시스템이 암세포를 인식하고 제거하는 과정."
                    },
                    {
                      "term": "면역 요법",
                      "definition": "면역 시스템을 활용하여 암을 치료하는 방법으로, 백신, 단클론항체, 면역관문억제제, 세포 치료 등이 포함됩니다."
                    },
                    {
                      "term": "선천성 면역 결핍증",
                      "definition": "유전적 결함으로 인해 발생하는 면역 반응의 부재."
                    },
                    {
                      "term": "후천성 면역 결핍증",
                      "definition": "약물, 암, 감염 등으로 인해 개인의 삶 동안 발병하는 면역 결핍."
                    },
                    {
                      "term": "중증 복합 면역 결핍증 (SCID)",
                      "definition": "T세포 발달 결함이나 항원 수용체 유전자 재배열 결함 등으로 인해 발생하는 심각한 면역 결핍 질환."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "종양 관련 항원",
                      "definition": "암세포 표면에 존재하며 면역 시스템이 비자기로 인식하는 항원."
                    },
                    {
                      "term": "세포독성 T 림프구 (CTLs)",
                      "definition": "활성화된 T 세포로, 암세포나 감염된 세포를 직접 용해(파괴)하는 역할을 합니다."
                    },
                    {
                      "term": "코리 독소",
                      "definition": "박테리아 내독소로, TNF 분비를 자극하여 암의 혈액 공급을 방해하는 데 사용되었던 물질."
                    },
                    {
                      "term": "단클론항체 (Mab)",
                      "definition": "특정 항원에만 결합하도록 만들어진 항체로, 암 치료에 사용될 수 있습니다 (예: 허셉틴)."
                    },
                    {
                      "term": "면역독소",
                      "definition": "단클론항체와 독성 물질을 결합하여 암세포만을 표적하여 죽이는 치료제."
                    },
                    {
                      "term": "면역 관문 억제제",
                      "definition": "면역 반응을 억제하는 경로를 차단하여 면역 시스템이 암세포를 더 효과적으로 공격하도록 돕는 약물."
                    },
                    {
                      "term": "CAR T 세포",
                      "definition": "환자의 T 세포를 유전자 조작하여 암세포를 인식하고 공격하도록 만든 세포 치료제."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역 시스템과 암",
                      "id": "면역-시스템과-암",
                      "children": [
                        {
                          "text": "면역 감시를 통한 암세포 제거",
                          "id": "면역-감시를-통한-암세포-제거",
                          "children": null
                        },
                        {
                          "text": "면역 시스템의 암 제거 제한 사항",
                          "id": "면역-시스템의-암-제거-제한-사항",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
                      "id": "세포독성-t-림프구ctl와-암세포의-상호작용",
                      "children": null
                    },
                    {
                      "text": "암에 대한 면역 요법",
                      "id": "암에-대한-면역-요법",
                      "children": [
                        {
                          "text": "박테리아 내독소",
                          "id": "박테리아-내독소",
                          "children": null
                        },
                        {
                          "text": "백신",
                          "id": "백신",
                          "children": null
                        },
                        {
                          "text": "단클론항체 및 면역독소",
                          "id": "단클론항체-및-면역독소",
                          "children": null
                        },
                        {
                          "text": "면역 관문 억제제",
                          "id": "면역-관문-억제제",
                          "children": null
                        },
                        {
                          "text": "세포 치료",
                          "id": "세포-치료",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 결핍증",
                      "id": "면역-결핍증",
                      "children": [
                        {
                          "text": "선천성 면역 결핍증",
                          "id": "선천성-면역-결핍증",
                          "children": null
                        },
                        {
                          "text": "후천성 면역 결핍증",
                          "id": "후천성-면역-결핍증",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 결핍 질환",
                      "id": "면역-결핍-질환",
                      "children": [
                        {
                          "text": "선천성 면역 결핍 질환의 원인",
                          "id": "선천성-면역-결핍-질환의-원인",
                          "children": null
                        },
                        {
                          "text": "T세포 발달 및 항원 수용체 관련 결함",
                          "id": "t세포-발달-및-항원-수용체-관련-결함",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "림프구 발달 결함과 중증 복합 면역 결핍증 (SCID)",
                      "id": "림프구-발달-결함과-중증-복합-면역-결핍증-scid",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "면역 시스템이 암세포를 제거하는 데 있어 주요 제한 사항이 아닌 것은 무엇입니까?",
                    "options": [
                      "면역 시스템이 표적으로 삼을 항원성 에피토프가 없음",
                      "종양 세포가 너무 빠르게 증식함",
                      "종양이 혈관화되어 면역 시스템에 보이지 않게 됨",
                      "대식세포가 암세포를 용해하지 못함"
                    ],
                    "answerIndex": 3,
                    "explanation": "본문에서는 CTL(활성화된 TC 세포)과 대식세포가 암세포를 용해한다고 명시되어 있으므로, 대식세포가 암세포를 용해하지 못하는 것은 면역 시스템의 제한 사항이 아닙니다."
                  },
                  {
                    "question": "다음 중 암에 대한 면역 요법으로 언급되지 않은 것은 무엇입니까?",
                    "options": [
                      "박테리아 내독소 (Coley's toxins)",
                      "예방 백신 (HPV, B형 간염)",
                      "항생제",
                      "CAR T 세포 치료"
                    ],
                    "answerIndex": 2,
                    "explanation": "본문에서 박테리아 내독소, 예방 백신, CAR T 세포 치료는 암에 대한 면역 요법으로 언급되었지만, 항생제는 언급되지 않았습니다. 항생제는 주로 세균 감염 치료에 사용됩니다."
                  },
                  {
                    "question": "중증 복합 면역 결핍증(SCID)의 주요 원인이 될 수 있는 유전적 결함은 무엇입니까?",
                    "options": [
                      "B세포의 과도한 증식",
                      "T세포 발달의 결함",
                      "항체 생산 능력의 증가",
                      "대식세포 기능의 활성화"
                    ],
                    "answerIndex": 1,
                    "explanation": "본문에서는 'T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있습니다'라고 명확히 언급되어 있습니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 5576 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "후천성 면역 결핍 증후군 (AIDS)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "1981년, 미국에서 젊은 동성애 남성들 사이에서 폐포자충 폐렴, 카포시 육종, 그리고 면역 기능 상실 사례들이 집단으로 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1983년, 면역 기능 상실을 유발하는 바이러스(HIV)가 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 T 보조 세포를 선택적으로 감염시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "AIDS의 기원",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 서아프리카와 중앙아프리카의 침팬지(약 1908년, 부시미트로부터)로부터 인간 개체군으로 넘어왔습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "도시화와 성적 문란의 증가로 아프리카 전역으로 퍼졌습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가장 오래된 HIV 샘플은 1920년 콩고민주공화국의 킨샤사에서 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1976년에 사망한 노르웨이 선원은 서구 세계에서 알려진 첫 번째 사례입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1969년 미주리주의 한 환자로부터 채취한 샘플에서 HIV 감염이 확인되었습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 구조",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "렌티바이러스(Lentivirus) 속에 속합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "레트로바이러스(Retrovirus)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "두 개의 동일한 양성 가닥 RNA 유전체 분자, 역전사 효소, 인지질 외피를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "gp120 당단백질 스파이크를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 구조 및 CD4+ T 세포 감염: gp120 당단백질 스파이크는 CD4+ 세포의 수용체에 부착합니다. gp41 막관통 당단백질은 CD4+ 세포의 융합 수용체에 부착하여 융합을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 감염성과 병원성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "수지상 세포에 의해 퍼지고 림프 기관으로 운반되며, 활성화된 T 세포와 접촉합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "gp120은 CD4+ 수용체 및 CCR5 또는 CXCR4 공동수용체와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4 분자는 T 보조 세포, 대식세포, 수지상 세포에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 세포와 융합하여 세포 안으로 들어갑니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "부착: gp120 스파이크는 세포의 수용체 및 CCR5 또는 CXCR4 공동수용체에 부착합니다. 융합: gp41은 HIV와 세포의 융합에 참여합니다. 진입: 세포와의 융합 후, 진입 구멍이 생성됩니다. 진입 후, 바이러스 외피는 뒤에 남고 HIV는 탈피하여 새로운 바이러스 합성을 지시할 RNA 핵을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포 내에서 바이러스 RNA는 역전사 효소를 사용하여 DNA로 전사됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "DNA는 숙주 염색체 DNA에 통합됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활동성 감염: 새로운 바이러스가 숙주 세포에서 출아합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "잠복 감염: DNA는 프로바이러스 형태로 염색체에 숨겨져 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일부는 HIV의 저장소 역할을 하는 기억 T 세포가 됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 빠른 항원성 변화와 높은 돌연변이율을 겪습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.14 CD4+ T 세포의 잠복 및 활동성 HIV 감염. 잠복 감염: 바이러스 DNA는 세포 DNA에 프로바이러스로 통합되며, 나중에 활성화되어 감염성 바이러스를 생성할 수 있습니다. 활동성 감염: 프로바이러스가 활성화되어 새로운 바이러스의 합성을 제어할 수 있게 합니다. 최종 조립은 세포막에서 이루어지며, 바이러스가 세포에서 출아할 때 바이러스 외피 단백질을 가져갑니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.15 대식세포 및 수지상 세포의 잠복 및 활동성 HIV 감염. 잠복 감염된 대식세포: HIV는 프로바이러스 또는 액포 내 완전한 비리온 형태로 지속될 수 있습니다. 활성화된 대식세포: 프로바이러스로부터 새로운 바이러스가 생성됩니다. 완성된 비리온은 방출되거나 액포 내 대식세포에 지속될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 아형",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침팬지와 고릴라를 감염시키는 바이러스와 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사례의 99%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그룹 M (대다수)이 90%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-2:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "서아프리카 외에서는 자주 발견되지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1보다 병원성이 낮습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1보다 바이러스 부하와 사망률이 낮고 무증상 기간이 더 깁니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 감염의 단계",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "1단계: 무증상 또는 림프절병증.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2단계: CD4+ T 세포가 꾸준히 감소하며, 감염된 소수의 세포만이 바이러스를 방출합니다. 심각한 질병 증상은 거의 없습니다 (지속적인 감염, 발열, 구강 백반증).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "3단계: AIDS가 발병합니다. CD4+ 수치가 200 cells/μl 미만이며, 지표 질환이 나타납니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 감염의 진행 및 병원성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "초기에는 강력하고 효과적인 면역 반응이 나타납니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구(CTLs)가 바이러스 수를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일단 HIV가 잠복 감염된 CD4+ T 세포의 저장소를 형성하면 감염을 제거하는 것은 불가능합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 개발에 어려움이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 노출에 대한 반응의 변이",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 감염 생존에 대한 연령의 영향:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "고령자와 어린이는 면역 체계가 완전히 기능하지 않아 감염에 더 취약합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "노출되었지만 감염되지 않은 인구:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "CCR5 돌연변이를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "장기 생존자:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "낮은 바이러스 부하를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "효과적인 CTLs를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "기회 감염",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "진단 방법",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 전환은 감염과 항체 출현 사이의 기간입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "최대 3개월이 소요됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 항체는 ELISA로 검출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 Western blotting 또는 APTIMA (RNA 검사)로 검출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈장 바이러스 부하 (PVL)는 PCR 또는 핵산 혼성화로 결정됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 전파",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 세포 밖에서 6시간 생존합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 세포 내에서 1.5일 이상 생존할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "전파 경로: 친밀한 성 접촉, 모유, 태반 감염, 오염된 주사바늘, 장기 이식, 수혈.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항문 성교는 가장 위험한 형태의 성 접촉입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전 세계 AIDS 현황",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "전 세계적으로 3천 5백만 명이 감염되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사하라 이남 아프리카에 70%가 집중되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이성애자 간 전파가 HIV 전파의 가장 흔한 방식입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동유럽과 중앙 및 동남아시아 사례의 ⅓은 주사 약물 사용으로 인한 것입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전 세계 지역별 HIV 감염 및 AIDS 분포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "70",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "AIDS 예방 및 치료",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "생물의학적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "콘돔 사용, 보건 서비스/HIV 검사, 주사바늘 프로그램.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "행동적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "성 교육, 안전한 영아 수유 프로그램, 상담.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "구조적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 취약성을 줄이기 위해 사회, 경제, 정치, 환경적 요인에 변화를 줍니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이제 선진국에서는 치료 가능한 만성 질환으로 간주됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "고활성 항레트로바이러스 치료 (HAART)를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "내성 균주의 생존을 최소화하기 위해 약물 조합을 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "73",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 관리",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.18 HIV 생명 주기를 억제하는 약물: 융합/진입 억제제 (엔푸비르타이드, 마라비록), 역전사 효소 억제제 (테노포비르, 엠트리시타빈), 통합효소 억제제 (랄테그라비르), 프로테아제 억제제 (아타자나비르, 인디나비르, 사퀴나비르) 등이 있습니다. 이 약물들은 HIV의 gp41, gp120, CCR5, CD4 수용체 및 역전사 효소 등에 작용하여 바이러스 복제를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 치료 약물의 종류",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "융합/세포 진입 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스 외피의 gp41 영역을 표적으로 하여 바이러스가 세포와 융합하는 것을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "엔푸비르타이드(Enfuvirtide)와 마라비록(Maraviroc)이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "역전사 효소 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "뉴클레오사이드 역전사 효소 억제제 (NRTIs) - 테노포비르(Tenofovir)와 엠트리시타빈(Emtricitabrine)이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비뉴클레오사이드 역전사 효소 억제제 (NNRTIs) - 에파비렌즈(Efavirenz)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "77",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "통합효소 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 통합효소가 cDNA를 숙주 염색체에 통합하는 것을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "랄테그라비르(Raltegravir)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로테아제 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스 전구 단백질을 구조 및 기능 단백질로 분해하는 프로테아제를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "아타자나비르(Atazanavir), 인디나비르(Indinavir), 사퀴나비르(Saquinavir)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "성숙 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "테더린(Tetherins)은 바이러스를 세포에 묶어 방출 및 확산을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감염 과정에서 HIV는 많은 돌연변이를 축적하여 약물 내성 변이체의 증식으로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 백신 개발의 과제",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "모방할 자연 면역 모델이 없습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "연구 동물이 부족합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "레트로바이러스 메커니즘에 대한 이해가 부족합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "높은 돌연변이율로 인해 내성 균주가 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이상적인 백신은 다음과 같아야 합니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "잠복 바이러스 저장소가 확립되기 전에 면역을 유도해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구(CTLs)의 생성을 자극해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "합리적인 가격이어야 합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 후천성 면역 결핍 증후군(AIDS)의 기원, 원인 바이러스인 HIV의 구조, 감염 메커니즘 및 병원성, 바이러스 아형, 감염 단계, 진단 방법, 전파 경로, 전 세계적 현황, 예방 및 치료법, 그리고 백신 개발의 과제에 대해 상세히 설명합니다. HIV는 CD4+ T 세포를 선택적으로 감염시키는 레트로바이러스이며, 잠복 감염과 활동성 감염 단계를 거치며 면역 체계를 파괴합니다. HAART(고활성 항레트로바이러스 치료)를 통해 HIV 복제를 억제하고 환자의 삶의 질을 향상시킬 수 있지만, 바이러스의 높은 돌연변이율로 인해 백신 개발에는 어려움이 있습니다.",
                  "keyConcepts": [
                    {
                      "term": "HIV (Human Immunodeficiency Virus)",
                      "definition": {
                        "easy": null,
                        "medium": "AIDS의 원인 바이러스로, 인체의 면역 체계를 공격하고 파괴하는 레트로바이러스입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "CD4+ T 세포",
                      "definition": {
                        "easy": null,
                        "medium": "HIV가 주로 감염시키고 파괴하는 면역 세포로, 이 세포의 감소는 면역 결핍을 초래합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "역전사 효소 (Reverse Transcriptase)",
                      "definition": {
                        "easy": null,
                        "medium": "HIV를 포함한 레트로바이러스가 자신의 RNA 유전체를 DNA로 역전사하는 데 사용하는 효소입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "HAART (Highly Active Antiretroviral Therapy)",
                      "definition": {
                        "easy": null,
                        "medium": "HIV 감염 치료를 위해 여러 종류의 항레트로바이러스 약물을 병용하는 치료법으로, 바이러스 복제를 효과적으로 억제합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "기회 감염 (Opportunistic Infections)",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 약해진 상태에서 일반적으로 건강한 사람에게는 질병을 일으키지 않는 미생물에 의해 발생하는 감염입니다.",
                        "hard": null
                      }
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "AIDS (Acquired Immunodeficiency Syndrome)",
                      "definition": "후천성 면역 결핍 증후군. HIV 감염의 마지막 단계로, 심각한 면역 결핍과 기회 감염 및 특정 암을 특징으로 합니다."
                    },
                    {
                      "term": "레트로바이러스 (Retrovirus)",
                      "definition": "RNA 유전체를 가지고 있으며, 역전사 효소를 사용하여 RNA를 DNA로 전환하고 이를 숙주 게놈에 통합시키는 바이러스입니다."
                    },
                    {
                      "term": "gp120 및 gp41",
                      "definition": "HIV 외피에 존재하는 당단백질 스파이크로, gp120은 CD4 수용체에 부착하고 gp41은 바이러스와 세포막의 융합을 촉진합니다."
                    },
                    {
                      "term": "프로바이러스 (Provirus)",
                      "definition": "레트로바이러스의 DNA 유전체가 숙주 세포의 염색체 DNA에 통합된 형태입니다."
                    },
                    {
                      "term": "혈청 전환 (Seroconversion)",
                      "definition": "감염 후 특정 병원체에 대한 항체가 혈액에서 처음으로 검출되는 시기입니다."
                    },
                    {
                      "term": "CD4+ T 세포 수치",
                      "definition": "면역 상태를 나타내는 중요한 지표로, AIDS 진단 기준 중 하나는 이 수치가 200 cells/μl 미만인 경우입니다."
                    },
                    {
                      "term": "CCR5 돌연변이",
                      "definition": "일부 개인에게서 발견되는 유전적 돌연변이로, HIV가 세포에 진입하는 데 필요한 공동수용체인 CCR5를 변경하여 HIV 감염에 대한 저항성을 부여합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "후천성 면역 결핍 증후군 (AIDS)",
                      "id": "후천성-면역-결핍-증후군-aids",
                      "children": null
                    },
                    {
                      "text": "AIDS의 기원",
                      "id": "aids의-기원",
                      "children": null
                    },
                    {
                      "text": "HIV의 구조",
                      "id": "hiv의-구조",
                      "children": null
                    },
                    {
                      "text": "HIV의 감염성과 병원성",
                      "id": "hiv의-감염성과-병원성",
                      "children": null
                    },
                    {
                      "text": "HIV의 아형",
                      "id": "hiv의-아형",
                      "children": null
                    },
                    {
                      "text": "HIV 감염의 단계",
                      "id": "hiv-감염의-단계",
                      "children": null
                    },
                    {
                      "text": "HIV 감염의 진행 및 병원성",
                      "id": "hiv-감염의-진행-및-병원성",
                      "children": null
                    },
                    {
                      "text": "HIV 노출에 대한 반응의 변이",
                      "id": "hiv-노출에-대한-반응의-변이",
                      "children": null
                    },
                    {
                      "text": "기회 감염",
                      "id": "기회-감염",
                      "children": null
                    },
                    {
                      "text": "진단 방법",
                      "id": "진단-방법",
                      "children": null
                    },
                    {
                      "text": "HIV 전파",
                      "id": "hiv-전파",
                      "children": null
                    },
                    {
                      "text": "전 세계 AIDS 현황",
                      "id": "전-세계-aids-현황",
                      "children": null
                    },
                    {
                      "text": "전 세계 지역별 HIV 감염 및 AIDS 분포",
                      "id": "전-세계-지역별-hiv-감염-및-aids-분포",
                      "children": null
                    },
                    {
                      "text": "AIDS 예방 및 치료",
                      "id": "aids-예방-및-치료",
                      "children": [
                        {
                          "text": "HIV 관리",
                          "id": "hiv-관리",
                          "children": null
                        },
                        {
                          "text": "HIV 치료 약물의 종류",
                          "id": "hiv-치료-약물의-종류",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "HIV 백신 개발의 과제",
                      "id": "hiv-백신-개발의-과제",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "HIV가 주로 감염시키고 파괴하는 면역 세포는 무엇입니까?",
                    "options": [
                      "B 세포",
                      "CD4+ T 세포",
                      "대식세포",
                      "자연 살해(NK) 세포"
                    ],
                    "answerIndex": 1,
                    "explanation": "HIV는 CD4+ 수용체를 가진 세포를 감염시키며, 특히 CD4+ T 세포는 HIV 감염의 주요 표적 세포입니다. 이 세포의 파괴는 면역 결핍을 초래합니다."
                  },
                  {
                    "question": "HIV 감염 진단에 사용되는 방법 중 HIV 항체를 검출하는 검사는 무엇입니까?",
                    "options": [
                      "PCR",
                      "Western blotting",
                      "ELISA",
                      "핵산 혼성화"
                    ],
                    "answerIndex": 2,
                    "explanation": "HIV 항체는 ELISA(효소결합 면역흡착법)를 통해 검출됩니다. Western blotting은 항체 검출을 확인하는 데 사용될 수 있으며, PCR과 핵산 혼성화는 바이러스 자체(RNA 또는 DNA)를 검출하는 데 사용됩니다."
                  },
                  {
                    "question": "HAART(고활성 항레트로바이러스 치료)의 주요 특징은 무엇입니까?",
                    "options": [
                      "단일 약물을 고용량으로 투여합니다.",
                      "수술적 방법으로 바이러스를 제거합니다.",
                      "여러 종류의 항레트로바이러스 약물을 병용합니다.",
                      "면역 증강제만을 사용하여 면역력을 높입니다."
                    ],
                    "answerIndex": 2,
                    "explanation": "HAART는 여러 종류의 항레트로바이러스 약물을 병용하여 HIV 복제를 다양한 단계에서 억제하고 약물 내성 균주의 출현을 최소화하는 치료법입니다."
                  }
                ]
              }
            ],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "analyze_overall_structure",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "start_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "",
            "holistic_chapters": [],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "analyze_overall_structure",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [],
            "final_result": ""
          }
        },
        {
          "node": "generate_chapter_content",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "all_pdf_texts": [
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "text": "16. INNATE IMMUNITY: \nNONSPECIFIC DEFENSES OF \nTHE HOST\nHongsup Yoon, Ph.D.\nMicrobiology\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n2\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n3\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n4\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n• White blood cell (WBC) \ncounts measure \nleukocytes in the blood\n• High WBC counts may \nindicate bacterial \ninfections, autoimmune \ndiseases, or side effects \nof medications\n• Low WBC counts may \nindicate viral infections, \npneumonia, \nautoimmune diseases, \nor cancers\n\nTHE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse.\n14\nHOST DEFENSE: THE BIG PICTURE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n16\nPHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\n\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice.\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n23\nFORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\n\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\n\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n31\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\n\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\n\nPHAGOCYTOSIS: OVERVIEW\n\nPHAGOCYTOSIS: MECHANISM\n\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\n\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n39\nINFLAMMATION: OVERVIEW\n\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\n\nFigure 16.9a-b  The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ntaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\n\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n49\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n51\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\n\nCOMPLEMENT: ACTIVATION\n\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\n\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\n\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\n\nFigure 16.12  Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13  Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBIAL PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n68\nSUMMARY (1/3)\n• The growth of microorganisms can be controlled by physical, chemical, \nmechanical, and biological means.\n• The body’s first line of defense against infections is a physical barrier and \nthe nonspecific chemicals of the skin and mucous membranes. \n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways.\n• A microbe’s penetration of the first line of defense encourages production \nof phagocytes, inflammation, fever, and antimicrobial substances. \n• Blood consists of plasma (fluid) and formed elements (cells and cell \nfragments). Leukocytes (white blood cells) are divided into granulocytes \n(neutrophils, basophils,  eosinophils) and agranulocytes. During many \ninfections, the number of leukocytes increases (leukocytosis); some  \ninfections are characterized by leucopenia (decrease in leukocytes). \nSUMMARY (2/3)\n• Phagocytosis is the ingestion of microorganisms or particulate matter by a \ncell. Phagocytosis is performed by phagocytes, certain types of white \nblood cells or their  derivatives. Among the granulocytes, neutrophils are \nthe most important phagocytes. Granulocytes predominate during the \nearly stages of infection, whereas monocytes  predominate as the \ninfection subsides. \n• Inflammation is a bodily response to cell damage; it is characterized by \nredness,  pain, heat, swelling, and sometimes the loss of function. TNF -α \nstimulates production of acute -phase proteins. \n• A tissue is repaired when the stroma (supporting tissue) or parenchyma \n(functioning  tissue) produces new cells. Stromal repair by fibroblasts \nproduces scar tissue. \n• Fever is an abnormally high body temperature produced in response to a \nbacterial or  viral infection. \nSUMMARY (3/3)\n• The complement system consists of a group of serum proteins that \nactivate one another to destroy invading microorganisms. Complement \nproteins are activated in a cascade. Complement is activated via the \nclassical pathway, the alternative pathway, and the lectin pathway. \n• IFN-α and IFN-β are antiviral proteins produced in response to viral \ninfection. The mode of action of IFN -α and IFN-β is to induce uninfected \ncells to produce antiviral proteins (AVPs) that prevent viral replication. IFN -\nα and IFN-β are host-cell-specific but not virus-specific. IFN-γ activates \nneutrophils and macrophages to kill bacteria. \n• Iron-binding proteins transport and store iron and deprive most pathogens \nof the  available iron.\n• Antimicrobial peptides (AMPs) inhibit cell wall synthesis; form pores in \nplasma  membranes, resulting in lysis; and destroy DNA and RNA."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "text": "17. ADAPTIVE IMMUNITY: \nSPECIFIC DEFENSES OF \nTHE HOST\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n2\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n3\nTHE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n5\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\n\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n11\nCYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n14\nAntibody A\nEpitopes (antigenic \ndeterminants)\non antigen\nAntigens:\ncomponents\nof cell wall\nAntibody B\nBacterial cell\nBinding sites\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\n\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\n\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n34\nCELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\n\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\n\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\n\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\n\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\n\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n51\nIMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\n \n\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\n\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n55\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\n\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Summary\n58\nFigure 17.20  The Dual Nature of the Adaptive Immune System.\n\nSUMMARY (1/3)\n• Adaptive immunity is the body’s ability to react specifically to a microbial \ninfection. The body’s response to the first contact with an antigen is called the \nprimary response. Subsequent contact with the same antigen results in a \nsecondary or memory response to that antigen.\n• Humoral immunity involves antibodies, which are found in serum and lymph and \nare produced by B cells. Lymphocytes that mature in red bone marrow become \nB cells. \n• Cellular immunity involves T cells. Lymphocytes that migrate through the thymus \nbecome T cells. T cell receptors recognize antigens presented on MHC. Cellular \nimmunity responds to intracellular antigens; humoral immunity responds to \nantigens in body fluids.\n• Cells of the immune system communicate with each other by means of \nchemicals called cytokines. Interleukins (IL) are cytokines that serve as \ncommunicators between leukocytes. Chemokines cause leukocytes to migrate \nto an infection. Some interferons stimulate the immune response; others protect \ncells against viruses. Tumor necrosis factor promotes the inflammatory reaction. \nHematopoietic cytokines promote development of white blood cells. \nOverproduction of cytokines leads to a cytokine storm, which results in tissue \ndamage.\nSUMMARY (2/3)\n• An antigen (or immunogen) is a chemical substance that causes the body \nto produce specific antibodies. Antibodies are formed against specific \nregions on antigens called epitopes, or antigenic determinants.\n• An antibody, or immunoglobulin, is a protein produced by B cells in \nresponse to an  antigen and is capable of combining specifically with that \nantigen. IgG antibodies are the most prevalent in serum; they provide \nnaturally acquired passive immunity, neutralize bacterial toxins, participate \nin complement fixation, and enhance phagocytosis.\n• T cells mature in the thymus gland. Thymic selection removes T cells that \ndon’t recognize MHC molecules of the host and T cells that will attack host \ncells presenting self-proteins in MHC. Helper T cells recognize antigens \nprocessed by antigen-presenting cells and presented in MHC II. Cytotoxic \nT cells recognize antigens processed by all host cells and presented in \nMHC I.\nSUMMARY (3/3)\n• APCs include B cells, dendritic cells, and macrophages. Dendritic cells are \nthe primary APCs. Dendritic cells are the primary APCs. APCs carry \nantigens to lymphoid tissues where T cells that recognize the antigen are \nlocated.\n• T helper (CD4+ T) cells differentiate into TH1 cells, which are involved in \ncellular immunity; TH2 cells, which are involved in humoral immunity and \nare associated with allergic reactions and parasitic infections; and TH17 \ncells, which activate innate immunity.\n• T regulatory cells (Treg) suppress T cells against self. Cytotoxic \nlymphocytes (CTLs), or CD8+ T cells, are activated by endogenous \nantigens and MHC class I on a target cell and are transformed into effector \nand memory CTLs.\n• CTLs lyse or induce apoptosis in the target cell."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n18. PRACTICAL \nAPPLICATIONS OF \nIMMUNOLOGY – PART I\n2\nRECENT VIRUS OUTBREAKS\n• 2002 SARS outbreak (~9.5 % mortality rate)\n• 2004 Global spread of H5N1 avian influenza (60% mortality rate)\n• 2009 H1N1/09 swine Flu pandemic\n• 2015 MERS in Korea (~40 % mortality rate)\n• 2018 Influenza B outbreak in Korea\n• 2019 COV-19 (SARS-CoV2) pandemic (~2 – 3 % mortality rate)\n?\nHISTORICAL PANDEMIC: BLACK DEATH\nKilled 30 – 60% of European\n\nEDWARD JENNER (1749 – 1823)\n\nMILKMAID (AROUND THE TIME OF JENNER)\n\nVACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\n\nVACCINES: FUNCTION\n\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -drug \nusers, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1  Influenza viruses are grown in embryonated eggs.\n\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\n\nRNA VACCINES\nVACCINES: TYPES\n\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\n\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren\nDIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nPRODUCTION OF MONOCLONAL \nANTIBODIES\n\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\n\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\n\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\n\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\n\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\n\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\n\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\n\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy\nSUMMARY (1/6)\n• Edward Jenner developed the modern practice of vaccination when he \ninoculated people with cowpox virus to protect them against smallpox. \n• Herd immunity results when most of a population is immune to a disease.\n• Bacteria have unique cell structures that can be targets for antibiotics, \nimmunity, and phage infection.\n•  Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Humans utilize \nand harness microorganisms and their products.\n• Attenuated vaccines consist of attenuated (weakened) microorganisms; \nattenuated virus vaccines generally provide lifelong immunity. Inactivated \nvaccines consist of killed bacteria or viruses. Subunit vaccines consist of \nantigenic fragments of a microorganism; these include  recombinant \nvaccines and toxoids. \nSUMMARY (2/6)\n• Conjugated vaccines combine the desired antigen with a protein that \nboosts the immune response. Nucleic acid (DNA) vaccines cause the \nrecipient to make the antigenic protein.\n• Viruses for vaccines may be grown in animals, cell cultures, or chick \nembryos. Recombinant vaccines and nucleic acid vaccines do not need to \nbe grown in cells or animals. Genetically modified plants may someday \nprovide edible vaccines.\n• Combining several vaccines would eliminate the number of injections. Dry \nskin patch vaccines don’t need refrigeration.\n• Adjuvants improve the effectiveness of some antigens. \n• Vaccines are the safest and most effective means of controlling infectious \ndiseases.\nSUMMARY (3/6)\n• Many tests based on the interactions of antibodies and antigens have \nbeen developed to determine the presence of antibodies or antigens in a \npatient. The sensitivity of a diagnostic test is determined by the percentage \nof positive samples it correctly detects; and its specificity is determined by \nthe percentage of false positive  results it gives.\n• Hybridomas are produced in the laboratory by fusing a cancerous cell with \nan antibody-secreting plasma cell. A hybridoma cell culture produces large \nquantities of the plasma cell’s antibodies, called monoclonal antibodies. \nMonoclonal antibodies are used in serological identification tests, to \nprevent tissue  rejections, and to make immunotoxins to treat cancer.\n• The interaction of soluble antigens with IgG or IgM antibodies leads to \nprecipitation  reactions. Precipitation reactions depend on the formation of \nlattices and occur best when antigen and antibody are present in optimal \nproportions. Excesses of either component decrease lattice formation and \nsubsequent precipitation.\nSUMMARY (4/6)\n• Immunodiffusion procedures are precipitation reactions carried out in an \nagar gel  medium. Immunoelectrophoresis combines electrophoresis with \nimmunodiffusion for the analysis of serum proteins.\n• The interaction of particulate antigens (cells that carry antigens) with \nantibodies leads to agglutination reactions. Diseases may be diagnosed \nby combining the patient’s serum with a known antigen. Diseases can be \ndiagnosed by a rising titer or seroconversion (from no antibodies to the \npresence of antibodies). Direct agglutination reactions can be used to \ndetermine antibody titer. Antibodies cause visible agglutination of soluble \nantigens affixed to latex spheres in indirect or passive agglutination tests. \nHemagglutination reactions involve agglutination reactions using red blood \ncells.  Hemagglutination reactions are used in blood typing, the diagnosis \nof certain diseases, and the identification of viruses. \nSUMMARY (5/6)\n• In neutralization reactions, the harmful effects of a bacterial exotoxin or \nvirus are  eliminated by a specific antibody. An antitoxin is an antibody \nproduced in response to a bacterial exotoxin or a toxoid that neutralizes \nthe exotoxin. In a virus neutralization test, the presence of antibodies \nagainst a virus can be detected by the antibodies’ ability to prevent \ncytopathic effects of viruses in cell cultures. Antibodies against certain \nviruses can be detected by their ability to interfere with viral \nhemagglutination in viral hemagglutination inhibition tests.\n• Complement-fixation reactions are serological tests based on the \ndepletion of a fixed amount of complement in the presence of an antigen –\nantibody reaction.\n• Fluorescent-antibody techniques use antibodies labeled with fluorescent \ndyes. Direct fluorescent-antibody tests are used to identify specific \nmicroorganisms. \nSUMMARY (6/6)\n• Indirect fluorescent-antibody tests are used to demonstrate the presence \nof antibody  in serum. A fluorescence-activated cell sorter can be used to \ndetect and count cells labeled with fluorescent antibodies.\n• ELISA techniques use antibodies linked to an enzyme. Antigen –antibody \nreactions are detected by enzyme activity. If the indicator enzyme is \npresent in the test well, an antigen –antibody reaction has occurred. The \ndirect ELISA is used to detect antigens against a specific antibody bound \nin a test well. The indirect ELISA is used to detect antibodies against an \nantigen bound in a test well.\n• Serum antibodies separated by electrophoresis are identified with an \nenzyme-linked  antibody. \n• The use of monoclonal antibodies will continue to make new diagnostic \ntests possible."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n19. DISORDERS \nASSOCIATED WITH THE \nIMMUNE SYSTEM – PART 1\n2\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n3\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n4\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Dysbiosis: \nimbalance that \ncauses adverse \neffects in humans\n• Antibiotic therapy \nkills normal gut \nmicrobiota, causing \nClostridium difficile \nto proliferate\n• Possible cause of \nIBDs such as \nulcerative colitis and \nCrohn's disease\n\nBIG PICTURE: THE HYGIENE HYPOTHESIS\n• Allergies and asthma\n• Observation that tribal populations and children growing up on farms \nhave less prevalence of allergies than children in urban settings\n• Possibly due to wider range of microbial exposures in farm setting; also \nled to lower asthma rates\n• Inflammatory bowel diseases\n• Possible link of lack of normal microbiota metabolic products leading to \nchronic inflammatory state\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Treating Crohn's \ndisease with worms\n• Whipworm eggs \nsuppress T helper cell \npathways\n• Fecal transplants for C. \ndifficile infections\n• Taking gut microbiota \nfrom a healthy \nindividual and \ntransplanting it into the \npatient\n\nHYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\n\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\n\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\n\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\n\nFigure 19.8  Allergic contact dermatitis.\n\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n21\nAUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\n\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555) \nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n28\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\n\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2\nSUMMARY (1/3)\n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Hay fever, \ntransplant rejection, and autoimmunity are examples of harmful immune  \nreactions. Immunosuppression is inhibition of the immune system. \nSuperantigens activate many T cell receptors that can cause adverse host \nresponses.\n• Hypersensitivity reactions represent immunological responses to an \nantigen (allergen) that lead to tissue damage rather than immunity. \nHypersensitivity reactions occur when a person has been sensitized to an \nantigen. Hypersensitivity reactions can be divided into four classes: types \nI, II, and III are immediate reactions based on humoral immunity, and type \nIV is a delayed reaction  based on cell -mediated immunity. \n• Childhood exposure to microbes may decrease development of allergies.\nSUMMARY (2/3)\n• Autoimmunity results from a loss of self -tolerance. Self-tolerance occurs \nduring fetal development; T cells that will target host cells are eliminated \n(clonal deletion) or inactivated. Autoimmunity may be due to antibodies \nagainst infectious agents. Graves’ disease and myasthenia gravis are \ncytotoxic autoimmune reactions in which  antibodies react to cell -surface \nantigens.\n• Systemic lupus erythematosus and rheumatoid arthritis are immune \ncomplex autoimmune reactions in which the deposition of immune \ncomplexes results in tissue damage. Multiple sclerosis, insulin -dependent \ndiabetes mellitus, and psoriasis are cell -mediated autoimmune reactions \nmediated by T cells.\nSUMMARY (3/3)\n• MHC self molecules located on cell surfaces express genetic differences \namong individuals; these antigens are called HLAs in humans. To prevent \nthe rejection of transplants, HLA and ABO blood group antigens of the \ndonor and recipient are matched as closely as possible. Transplants \nrecognized as foreign antigens may be lysed by T cells and attacked by \nmacrophages and complement -fixing antibodies. Transplantation to a \nprivileged site (such as the cornea) or of a privileged tissue (such as pig \nheart valves) does not cause an immune response. Pluripotent stem cells \ndifferentiate into a variety of tissues that may provide tissues for \ntransplant.\n• Four types of transplants have been defined on the basis of genetic \nrelationships between the donor and the recipient: autografts, isografts, \nallografts, and xenotransplants. Bone marrow transplants (with \nimmunocompetent cells) can cause graft -versus-host  disease.  \nSuccessful transplant surgery often requires immunosuppressant drugs to \nprevent an immune response to the transplanted tissue. \nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n40\nTHE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\n\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n46\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\n\nFigure 19.12  A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES\n\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n52\nACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\n\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14  Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15  Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\n\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\n\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n\n70\n\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\n\nHIV MANAGEMENT\n\nFigure 19.18  Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\n\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\n\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable\nSUMMARY (1/3)\n• Cancer cells are normal cells that have undergone transformation, divide \nuncontrollably, and possess tumor-associated antigens. The response of the \nimmune system to cancer is called immunological surveillance. TC cells \nrecognize and lyse cancerous cells. Cancer cells can escape detection and \ndestruction by the immune system. Cancer cells may grow faster than the \nimmune system can respond.\n• Novel therapeutic strategies, such as immune checkpoint inhibitors and CAR T \ncell therapy, are effective approaches to treat patients with cancer.\n• Vaccines against liver and cervical cancer are available; a therapeutic vaccine \nagainst prostate cancer also has been approved. Herceptin consists of \nmonoclonal antibodies against a breast cancer growth factor. Immunotoxins are \nchemical poisons linked to a monoclonal antibody; the antibody  selectively \nlocates the cancer cell for release of the poison.\n• Immunodeficiencies can be congenital or acquired. Congenital \nimmunodeficiencies are due to defective or absent genes. A variety of drugs, \ncancers, and infectious diseases can cause acquired  immunodeficiencies. \n• HIV is thought to have originated in central Africa and was brought to other \ncountries by modern transportation and unsafe sexual practices.\nSUMMARY (2/3)\n• AIDS is the final stage of HIV infection. HIV is a retrovirus with single -\nstranded RNA, reverse transcriptase, and a phospholipid envelope with \ngp120 spikes. HIV spikes attach to CD4+ and coreceptors on host cells; \nthe CD4+ receptor is found on  T helper cells, macrophages, and dendritic \ncells. Viral RNA is transcribed to DNA by reverse transcriptase. The viral \nDNA becomes  integrated into the host chromosome to direct synthesis of \nnew viruses or to remain latent as a provirus. HIV evades the immune \nsystem in latency, in vacuoles, by using cell–cell fusion, and by antigenic \nchange. HIV-1 accounts for most HIV infections. Subtype B of HIV -1 is the \nmost common type in the United States. HIV infection is categorized by \nsymptoms: phase 1 (asymptomatic), phase 2 (indicator opportunistic \ninfections), and phase 3 (CD4+  cells <200 cells/μ1). The progression from \nHIV infection to AIDS takes about 10 years. The life of an AIDS patient can \nbe prolonged by the proper treatment of opportunistic  infections. People \nlacking CCR5 are resistant to HIV infection. Elite controllers are long -term \nsurvivors who may hold the key to HIV treatment. \nSUMMARY (3/3)\n• HIV antibodies are detected by ELISA and Western blotting. Plasma viral \nload tests detect viral nucleic acid and are used to quantify HIV in blood.\n• HIV is transmitted by sexual contact, breast milk, contaminated needles, \ntransplacental infection, artificial insemination, and blood transfusion. In \ndeveloped countries, blood transfusions are not a likely source of infection \nbecause blood is tested for HIV antibodies. \n• Heterosexual intercourse is the primary method of HIV transmission.\n• Discouraging sexual promiscuity and using condoms and sterile needles \nprevent the transmission of HIV. Vaccine development is difficult because \nthe virus remains inside host cells and there is no model of natural \nimmunity to mimic. Current chemotherapeutic agents target the virus \nenzymes, including reverse transcriptase, integrase, and protease. Other \ninhibitors include cell entry inhibitors, maturation inhibitors, and tetherins."
              }
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [
              {
                "title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2042 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역의 개념",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역은 질병을 막는 능력을 의미하며, 감수성은 질병에 대한 저항력이 부족한 상태를 뜻합니다. 면역은 크게 두 가지로 나뉩니다. 선천성 면역은 모든 병원체에 대한 방어 기전으로, 신속하며 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 면역 또는 저항력으로, 반응 속도가 느리지만 기억 구성 요소를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "선천성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "선천성 면역은 자연 면역, 타고난 면역이라고도 불립니다. 식세포, 수지상 세포, 비만 세포, 자연 살해 세포 등 다양한 선천성 면역 세포들이 관여합니다. 이들은 감염이 발생하기 전부터 존재하며 면역 파수꾼 역할을 합니다. 일부 선천성 면역 세포는 항원을 T 세포에 제시하여 적응성 면역을 활성화시키기도 합니다. 또한, 조직 항상성과 염증에 중요하며, 치유자이자 파괴자 역할을 동시에 수행할 수 있습니다. 병원체 패턴, 사이토카인, 매개체에 의해 활성화되며, 항원에 대해 특이적이지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "적응성 면역은 특이적 면역, 후천성 면역이라고도 불립니다. 림프구인 T 세포와 B 세포가 주요 적응성 면역 세포입니다. 이들은 이차 림프 기관에서 미성숙한 형태로 존재하며, 클론 선택과 증식을 통해 특정 항원에 반응하는 세포로 발달합니다. 적응성 면역은 기억 기능을 가지며, 자가 관용 능력을 통해 자신의 몸을 공격하지 않습니다. 항원 제시 세포에 의해 활성화되며, 항원에 대해 매우 특이적입니다. 적응성 면역은 세포 매개 면역과 체액성 면역으로 나뉩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "숙주 세포에 있는 톨 유사 수용체(TLR)는 병원체 관련 분자 패턴(PAMP)에 결합합니다. TLR이 PAMP에 결합하면 숙주 세포에서 사이토카인 방출을 유도하여 면역 반응의 강도와 지속 시간을 조절합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다양한 PAMP 인식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "포유류 TLR은 다양한 PAMP를 인식합니다. 세균성 PAMP에는 그람 음성 세균 세포벽의 지질다당류(TLR4), 세균 리보솜 RNA(TLR13), 세균 DNA의 비메틸화 CpG(TLR9), 지단백질(TLR2/1, TLR2/6), 편모 단백질(TLR5) 등이 있습니다. 바이러스성 PAMP에는 이중 가닥 RNA(TLR3), 단일 가닥 RNA(TLR7, TLR8), 비메틸화 CpG DNA(TLR9) 등이 있습니다. 기생충성 PAMP에는 지단백질(TLR2/1, TLR2/6), 비메틸화 CpG DNA(TLR9), 단일 가닥 RNA(TLR7), 액틴 결합 단백질 프로필린(TLR11/12) 등이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TLR의 위치 및 내인성 PAMP 인식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "TLR은 세포 표면과 세포 내막에 존재하여 다양한 세포 위치에서 미생물을 인식합니다. TLR은 또한 내인성 PAMP도 인식할 수 있습니다. 세포 스트레스 시 유도되는 샤페론인 열충격 단백질(HSP)과 풍부한 게놈 DNA 결합 단백질인 고이동성 그룹 박스 1(HMGB1) 단백질 등이 내인성 PAMP의 예시입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TLR 신호 전달 경로",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "TLR이 미생물 리간드를 인식하면 여러 신호 전달 경로와 궁극적으로는 전사 인자가 활성화되어, 염증 및 항바이러스 반응에 중요한 유전자의 발현을 유도합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "면역은 질병에 저항하는 능력으로, 선천성 면역과 적응성 면역으로 나뉩니다. 선천성 면역은 모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 특이적 반응으로, 느리지만 기억 기능을 가집니다. 톨 유사 수용체(TLR)는 숙주 세포에서 병원체 관련 분자 패턴(PAMP)을 인식하여 사이토카인 방출을 유도하고 면역 반응을 조절합니다. TLR은 세포 표면과 세포 내막에 존재하며, 다양한 세균, 바이러스, 기생충 PAMP뿐만 아니라 내인성 PAMP도 인식하여 염증 및 항바이러스 반응에 중요한 유전자 발현을 유도하는 신호 전달 경로를 활성화합니다.",
                  "keyConcepts": [
                    {
                      "term": "선천성 면역",
                      "definition": "모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재하는 면역 방어 체계."
                    },
                    {
                      "term": "적응성 면역",
                      "definition": "특정 병원체에 대한 특이적 반응을 보이며, 기억 기능을 통해 재감염 시 더 빠르고 강력하게 반응하는 면역 방어 체계."
                    },
                    {
                      "term": "톨 유사 수용체 (TLR)",
                      "definition": "숙주 세포에 존재하며, 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 유도하는 주요 패턴 인식 수용체."
                    },
                    {
                      "term": "병원체 관련 분자 패턴 (PAMP)",
                      "definition": "미생물에 공통적으로 존재하는 특징적인 분자 구조로, 숙주의 톨 유사 수용체(TLR)에 의해 인식되어 면역 반응을 유발한다."
                    },
                    {
                      "term": "사이토카인",
                      "definition": "면역 세포 간의 신호 전달을 매개하고 면역 반응의 강도와 지속 시간을 조절하는 단백질."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "면역 (Immunity)",
                      "definition": "질병을 막는 능력."
                    },
                    {
                      "term": "감수성 (Susceptibility)",
                      "definition": "질병에 대한 저항력 부족."
                    },
                    {
                      "term": "식세포 (Phagocytes)",
                      "definition": "미생물이나 이물질을 삼켜 제거하는 면역 세포."
                    },
                    {
                      "term": "기억 구성 요소 (Memory component)",
                      "definition": "적응성 면역이 이전에 노출된 병원체를 기억하여 재감염 시 더 빠르고 강력하게 반응하는 능력."
                    },
                    {
                      "term": "자가 관용 (Self tolerance)",
                      "definition": "면역 시스템이 자신의 세포와 조직을 공격하지 않고 구분하는 능력."
                    },
                    {
                      "term": "전사 인자 (Transcription factors)",
                      "definition": "DNA에 결합하여 특정 유전자의 전사(발현)를 조절하는 단백질."
                    },
                    {
                      "term": "내인성 PAMP (Endogenous PAMPs)",
                      "definition": "병원체가 아닌 숙주 세포 자체에서 발생한 손상 또는 스트레스 신호로 TLR이 인식할 수 있는 분자."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역의 개념",
                      "id": "면역의-개념",
                      "children": [
                        {
                          "text": "면역 및 감수성 정의",
                          "id": "면역-및-감수성-정의",
                          "children": null
                        },
                        {
                          "text": "선천성 면역과 적응성 면역의 특징",
                          "id": "선천성-면역과-적응성-면역의-특징",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "선천성 면역",
                      "id": "선천성-면역",
                      "children": [
                        {
                          "text": "선천성 면역의 다른 이름",
                          "id": "선천성-면역의-다른-이름",
                          "children": null
                        },
                        {
                          "text": "선천성 면역 세포의 종류 및 특징",
                          "id": "선천성-면역-세포의-종류-및-특징",
                          "children": null
                        },
                        {
                          "text": "적응성 면역과의 연계성",
                          "id": "적응성-면역과의-연계성",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역",
                      "id": "적응성-면역",
                      "children": [
                        {
                          "text": "적응성 면역의 다른 이름",
                          "id": "적응성-면역의-다른-이름",
                          "children": null
                        },
                        {
                          "text": "적응성 면역 세포의 종류 및 특징",
                          "id": "적응성-면역-세포의-종류-및-특징",
                          "children": null
                        },
                        {
                          "text": "클론 선택, 기억, 자가 관용",
                          "id": "클론-선택-기억-자가-관용",
                          "children": null
                        },
                        {
                          "text": "세포 매개 및 체액성 면역",
                          "id": "세포-매개-및-체액성-면역",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
                      "id": "톨-유사-수용체-tlr-및-병원체-관련-분자-패턴-pamp",
                      "children": [
                        {
                          "text": "TLR과 PAMP의 상호작용",
                          "id": "tlr과-pamp의-상호작용",
                          "children": null
                        },
                        {
                          "text": "사이토카인 방출 및 면역 반응 조절",
                          "id": "사이토카인-방출-및-면역-반응-조절",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "다양한 PAMP 인식",
                      "id": "다양한-pamp-인식",
                      "children": [
                        {
                          "text": "포유류 TLR의 PAMP 인식 범위",
                          "id": "포유류-tlr의-pamp-인식-범위",
                          "children": null
                        },
                        {
                          "text": "세균성 PAMP의 종류",
                          "id": "세균성-pamp의-종류",
                          "children": null
                        },
                        {
                          "text": "바이러스성 PAMP의 종류",
                          "id": "바이러스성-pamp의-종류",
                          "children": null
                        },
                        {
                          "text": "기생충성 PAMP의 종류",
                          "id": "기생충성-pamp의-종류",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "TLR의 위치 및 내인성 PAMP 인식",
                      "id": "tlr의-위치-및-내인성-pamp-인식",
                      "children": [
                        {
                          "text": "세포 표면 및 세포 내막에서의 TLR 위치",
                          "id": "세포-표면-및-세포-내막에서의-tlr-위치",
                          "children": null
                        },
                        {
                          "text": "내인성 PAMP의 인식 (HSP, HMGB1)",
                          "id": "내인성-pamp의-인식-hsp-hmgb1",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "TLR 신호 전달 경로",
                      "id": "tlr-신호-전달-경로",
                      "children": [
                        {
                          "text": "미생물 리간드 인식의 결과",
                          "id": "미생물-리간드-인식의-결과",
                          "children": null
                        },
                        {
                          "text": "염증 및 항바이러스 반응 유도",
                          "id": "염증-및-항바이러스-반응-유도",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "선천성 면역과 적응성 면역의 주요 차이점은 무엇인가요?",
                    "options": [
                      "선천성 면역은 태어날 때부터 존재하며 비특이적인 반면, 적응성 면역은 특정 병원체에 특이적이며 기억 기능을 가집니다.",
                      "선천성 면역은 특정 병원체에 특이적이지만 반응이 느리고, 적응성 면역은 모든 병원체에 빠르게 반응합니다.",
                      "선천성 면역은 기억 기능이 있지만 T세포와 B세포가 관여하지 않고, 적응성 면역은 기억 기능이 없습니다.",
                      "선천성 면역은 항원 제시 세포에 의해 활성화되고, 적응성 면역은 병원체 패턴에 의해 활성화됩니다."
                    ],
                    "answerIndex": 0,
                    "explanation": "선천성 면역은 타고난 비특이적 방어이며, 적응성 면역은 특정 항원에 대한 후천적, 기억 기반 방어입니다."
                  },
                  {
                    "question": "톨 유사 수용체(TLR)의 주요 기능은 무엇인가요?",
                    "options": [
                      "항체를 생산하여 병원체를 직접 중화시키는 기능",
                      "병원체 관련 분자 패턴(PAMP)을 인식하고 사이토카인 방출을 유도하여 면역 반응을 조절하는 기능",
                      "감염된 세포를 직접 파괴하는 자연 살해 세포의 기능을 억제하는 기능",
                      "면역 반응 후 기억 세포를 형성하여 다음 감염에 대비하는 기능"
                    ],
                    "answerIndex": 1,
                    "explanation": "TLR은 숙주 세포에서 PAMP를 인식하여 사이토카인 방출을 유도하고 면역 반응의 강도와 지속 시간을 조절하는 역할을 합니다."
                  },
                  {
                    "question": "다음 중 세균성 PAMP에 해당하지 않는 것은 무엇인가요?",
                    "options": [
                      "지질다당류 (Lipopolysaccharide)",
                      "세균 리보솜 RNA (Bacterial ribosomal RNA)",
                      "이중 가닥 RNA (Double-stranded RNA)",
                      "비메틸화 CpG (Unmethylated CpG in the bacterial DNA)"
                    ],
                    "answerIndex": 2,
                    "explanation": "이중 가닥 RNA(Double-stranded RNA)는 바이러스성 PAMP에 해당합니다. 지질다당류, 세균 리보솜 RNA, 비메틸화 CpG는 세균성 PAMP입니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 1284 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "물리적 요인",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "피부는 선천성 면역의 중요한 물리적 방어선입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "진피는 결합 조직으로 구성된 내부 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성된 외부 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "피부가 벗겨지고 건조한 상태를 유지하는 것은 미생물 성장을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "점막은 위장관, 호흡기, 비뇨생식기를 덮는 상피층입니다. 점액은 미생물을 가두고 관이 건조해지는 것을 막는 점성 당단백질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "누액 기관은 눈물을 배출하여 눈을 씻어냅니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "섬모 승강기는 점액에 갇힌 미생물을 폐에서 멀리 운반합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "귀지는 미생물이 귀에 들어가는 것을 막습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "소변은 흐름을 통해 요도를 청소합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "연동 운동, 배변, 구토, 설사 또한 미생물 배출에 기여하는 물리적 방어 기전입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "화학적 요인",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "피지는 보호막을 형성하고 피부의 pH를 3~5로 낮춥니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "땀, 눈물, 침, 소변에 있는 리소자임은 세균 세포벽을 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "위액의 낮은 pH (1.2~3.0)는 대부분의 세균과 독소를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "질 분비물의 낮은 pH (3~5)는 미생물을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "정상 미생물총과 선천성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "정상 미생물총은 미생물 길항 작용 (경쟁적 배제)을 통해 병원균과 경쟁합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 공간과 영양분에 대한 경쟁 우위를 점하거나, 병원균에 해로운 물질을 생산하거나, 병원균 생존에 영향을 미치는 조건을 변경함으로써 이루어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "공생은 한 유기체는 이득을 얻고 다른 유기체 (숙주)는 해를 입지 않는 관계를 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로바이오틱스는 유익한 효과를 발휘하기 위해 투여되는 살아있는 미생물 배양물입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "무균 쥐를 사육하기 위해서는 엄격한 무균 상태가 요구됩니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 1차 방어선인 물리적 및 화학적 장벽과 정상 미생물총의 역할을 다룹니다. 피부, 점막, 누액 기관, 섬모 승강기, 귀지, 소변, 연동 운동, 배변, 구토, 설사 등 다양한 물리적 요인들이 미생물 침입을 막는 역할을 합니다. 또한, 피지, 리소자임, 위액 및 질 분비물의 낮은 pH와 같은 화학적 요인들이 미생물 성장을 억제하거나 파괴합니다. 정상 미생물총은 경쟁적 배제를 통해 병원균과 경쟁하며 숙주 방어에 기여합니다. 마지막으로, 마이크로바이옴이 선천성 면역 형성에 중요한 영향을 미친다는 점이 강조됩니다.",
                  "keyConcepts": [
                    {
                      "term": "선천성 면역의 물리적 방어선",
                      "definition": "피부, 점막, 눈물, 섬모 등 신체 외부 및 내부 표면에서 미생물 침입을 물리적으로 막는 방어 기전."
                    },
                    {
                      "term": "선천성 면역의 화학적 방어선",
                      "definition": "피지, 리소자임, 위액, 질 분비물 등의 화학 물질이 미생물 성장을 억제하거나 파괴하는 방어 기전."
                    },
                    {
                      "term": "정상 미생물총의 역할",
                      "definition": "인체에 상주하는 유익한 미생물들이 공간 및 영양분 경쟁, 유해 물질 생산 등을 통해 병원균의 침입과 증식을 억제하는 현상 (미생물 길항 작용)."
                    },
                    {
                      "term": "마이크로바이옴과 선천성 면역",
                      "definition": "인체 내 미생물 군집인 마이크로바이옴이 숙주의 선천성 면역 시스템 발달 및 기능에 중요한 영향을 미친다는 개념."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "케라틴",
                      "definition": "피부 표피에 존재하는 보호 단백질로, 피부의 물리적 장벽을 형성하는 데 기여한다."
                    },
                    {
                      "term": "점액",
                      "definition": "점막에서 분비되는 점성 당단백질로, 미생물을 가두고 점막이 건조해지는 것을 방지한다."
                    },
                    {
                      "term": "누액 기관",
                      "definition": "눈물을 생성하고 배출하여 눈을 지속적으로 씻어내 미생물을 제거하는 역할을 하는 기관."
                    },
                    {
                      "term": "섬모 승강기",
                      "definition": "호흡기 점막의 섬모가 움직여 점액에 갇힌 미생물을 폐에서 멀리 이동시키는 메커니즘."
                    },
                    {
                      "term": "리소자임",
                      "definition": "땀, 눈물, 침, 소변 등에 존재하는 효소로, 세균의 세포벽을 파괴하여 항균 작용을 한다."
                    },
                    {
                      "term": "미생물 길항 작용",
                      "definition": "정상 미생물총이 공간, 영양분 경쟁 또는 병원균에 해로운 물질 생산을 통해 병원균의 성장을 억제하는 현상."
                    },
                    {
                      "term": "공생",
                      "definition": "두 유기체가 함께 살아가며 한 유기체는 이득을 얻지만 다른 유기체(숙주)는 해를 입지 않는 관계."
                    }
                  ],
                  "outline": [
                    {
                      "text": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                      "id": "선천성-면역-1차-방어선",
                      "children": [
                        {
                          "text": "물리적 요인",
                          "id": "물리적-요인",
                          "children": [
                            {
                              "text": "피부",
                              "id": "피부",
                              "children": null
                            },
                            {
                              "text": "점막",
                              "id": "점막",
                              "children": null
                            },
                            {
                              "text": "누액 기관",
                              "id": "누액-기관",
                              "children": null
                            },
                            {
                              "text": "기타 물리적 방어 (섬모 승강기, 귀지, 소변, 연동 운동 등)",
                              "id": "기타-물리적-방어",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "화학적 요인",
                          "id": "화학적-요인",
                          "children": [
                            {
                              "text": "피지",
                              "id": "피지",
                              "children": null
                            },
                            {
                              "text": "리소자임",
                              "id": "리소자임",
                              "children": null
                            },
                            {
                              "text": "위액의 낮은 pH",
                              "id": "위액의-낮은-ph",
                              "children": null
                            },
                            {
                              "text": "질 분비물의 낮은 pH",
                              "id": "질-분비물의-낮은-ph",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "정상 미생물총과 선천성 면역",
                          "id": "정상-미생물총과-선천성-면역",
                          "children": [
                            {
                              "text": "미생물 길항 작용",
                              "id": "미생물-길항-작용",
                              "children": null
                            },
                            {
                              "text": "공생 및 프로바이오틱스",
                              "id": "공생-및-프로바이오틱스",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
                          "id": "마이크로바이옴-탐구",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "피부의 표피층에 포함되어 미생물 성장을 억제하는 보호 단백질은 무엇입니까?",
                    "options": [
                      "케라틴",
                      "콜라겐",
                      "엘라스틴",
                      "멜라닌"
                    ],
                    "answerIndex": 0,
                    "explanation": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성되어 있으며, 이는 미생물 성장을 억제하는 데 기여합니다."
                  },
                  {
                    "question": "선천성 면역의 화학적 방어선 중, 땀, 눈물, 침, 소변에 존재하며 세균 세포벽을 파괴하는 효소는 무엇입니까?",
                    "options": [
                      "펩신",
                      "아밀레이스",
                      "리소자임",
                      "트립신"
                    ],
                    "answerIndex": 2,
                    "explanation": "리소자임은 땀, 눈물, 침, 소변에 존재하며 세균의 세포벽을 파괴하는 강력한 항균 효소입니다."
                  },
                  {
                    "question": "정상 미생물총이 병원균과 경쟁하여 성장을 억제하는 주요 메커니즘을 설명하는 용어는 무엇입니까?",
                    "options": [
                      "변이원성",
                      "미생물 길항 작용",
                      "자가면역",
                      "과민 반응"
                    ],
                    "answerIndex": 1,
                    "explanation": "정상 미생물총은 '미생물 길항 작용' 또는 '경쟁적 배제'를 통해 공간, 영양분 경쟁 및 유해 물질 생산으로 병원균의 성장을 억제합니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2110 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "I. 혈액의 구성 요소",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액은 혈장 내에 부유하는 세포 및 세포 조각으로 구성됩니다. 주요 구성 요소는 적혈구(red blood cells), 백혈구(white blood cells), 혈소판(platelets)이며, 이들은 적골수 줄기세포에서 조혈 작용(hematopoiesis)을 통해 생성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "과립구 (Granulocytes)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "과립구는 세포질 내에 광학 현미경으로 볼 수 있는 과립을 가진 백혈구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호중구(Neutrophils): 식균 작용을 하며 감염 초기 단계에서 활동합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호염기구(Basophils): 히스타민을 방출하며 알레르기 반응에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호산구(Eosinophils): 식균 작용을 하며 기생충과 연충류에 대해 독성을 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "무과립구 (Agranulocytes)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "무과립구는 세포질 내에 과립이 있지만 광학 현미경으로 보이지 않는 백혈구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 단핵구(Monocytes): 조직에서 대식세포(macrophages)로 성숙하여 식균 작용을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 수지상 세포(Dendritic cells): 피부, 점막, 흉선에서 발견되며 식균 작용을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 림프구(Lymphocytes): T세포, B세포, NK세포를 포함하며 적응 면역에 중요한 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "II. 림프계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "림프계는 림프, 림프관, 림프 조직, 적골수로 구성됩니다. 림프구와 식세포를 포함하며, 림프는 미생물을 림프절로 운반하여 림프구와 대식세포가 병원균을 파괴하도록 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "림프계의 주요 구성 요소 및 기관에는 흉관(좌측 림프관), 우측 림프관, 좌측 쇄골하정맥, 우측 쇄골하정맥, 편도, 흉선, 림프절, 비장, 대장, 소장, 파이어판(Peyer’s patch), 림프관, 적골수, 림프 모세혈관 등이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "III. 숙주 방어: 개요 및 식세포",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포(Phagocytes)는 '먹다'를 의미하는 그리스어 'Phago'와 '세포'를 의미하는 'Cyte'에서 유래했습니다. 식세포에는 조직과 장기에 상주하는 고정 대식세포(Fixed macrophages)와 조직을 돌아다니며 감염 부위에 모이는 자유(유리) 대식세포(Free (wandering) macrophages)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IV. 식균 작용의 메커니즘",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "식균 작용은 다음 단계를 거쳐 진행됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 주화성(Chemotaxis): 화학적 신호가 식세포를 미생물로 유인합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 부착(Adherence): 식세포가 미생물 표면에 부착합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 섭취(Ingestion): 미생물이 혈청 단백질로 코팅되어(옵소닌화, Opsonization) 섭취가 용이해집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 소화(Digestion): 미생물이 식포-리소좀(phagolysosome) 내부에서 소화됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "V. 미생물의 식균 작용 회피 전략",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "일부 미생물은 숙주의 방어 체계를 회피하기 위한 다양한 병원성 인자(Virulence factors)를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 부착 억제: M 단백질, 캡슐 (예: Streptococcus pyogenes, S. pneumoniae)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식세포 사멸: 백혈구용해소(leukocidins) (예: Staphylococcus aureus)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식세포 용해: 막 공격 복합체(membrane attack complex) (예: Listeria monocytogenes)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포 탈출: (예: Shigella, Rickettsia)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포-리소좀 융합 방지: (예: HIV, Mycobacterium tuberculosis)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포-리소좀 내 생존: (예: Coxiella burnetii)",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 2차 방어선으로서 혈액의 구성 요소와 식세포의 역할에 대해 설명합니다. 혈액의 주요 구성 요소(적혈구, 백혈구, 혈소판)와 조혈 작용을 소개하고, 백혈구를 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 분류하여 각 유형의 기능과 특징을 설명합니다. 또한, 림프계의 구성 요소와 병원균 제거에서의 역할을 다루고, 식세포의 정의와 고정/자유 대식세포의 종류를 설명합니다. 이어서 식균 작용의 네 가지 주요 단계(주화성, 부착, 섭취, 소화)를 자세히 설명하며, 특히 옵소닌화의 중요성을 강조합니다. 마지막으로, 미생물이 식균 작용을 회피하기 위해 사용하는 다양한 전략(부착 억제, 식세포 사멸, 식포 탈출 등)과 관련 미생물 예를 제시합니다.",
                  "keyConcepts": [
                    {
                      "term": "혈액의 구성 요소",
                      "definition": "혈액을 구성하는 주요 성분으로, 혈장 내에 부유하는 적혈구, 백혈구, 혈소판을 포함하며, 조혈 작용을 통해 생성됩니다."
                    },
                    {
                      "term": "백혈구의 종류와 기능",
                      "definition": "감염 및 알레르기 반응에 관여하는 면역 세포로, 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 나뉘며 각각 특정한 면역 기능을 수행합니다."
                    },
                    {
                      "term": "림프계의 역할",
                      "definition": "림프, 림프관, 림프 조직, 적골수로 구성되며 림프구와 식세포를 포함하여 병원균을 림프절로 운반하고 파괴함으로써 면역 방어에 기여하는 시스템입니다."
                    },
                    {
                      "term": "식균 작용",
                      "definition": "식세포가 미생물이나 세포 잔해를 섭취하고 소화하여 제거하는 과정으로, 주화성, 부착, 섭취(옵소닌화 포함), 소화의 단계를 거칩니다."
                    },
                    {
                      "term": "미생물의 식균 작용 회피",
                      "definition": "미생물이 숙주의 식균 작용으로부터 자신을 보호하기 위해 사용하는 다양한 전략으로, 부착 억제, 식세포 사멸, 식포 탈출, 식포-리소좀 융합 방지, 식포-리소좀 내 생존 등이 있습니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "조혈 작용 (Hematopoiesis)",
                      "definition": "적골수 줄기세포에서 혈액 세포(적혈구, 백혈구, 혈소판)가 생성되는 과정입니다."
                    },
                    {
                      "term": "과립구 (Granulocytes)",
                      "definition": "세포질 내에 과립을 가진 백혈구로, 호중구, 호염기구, 호산구가 포함됩니다."
                    },
                    {
                      "term": "무과립구 (Agranulocytes)",
                      "definition": "세포질 내에 과립이 뚜렷하지 않은 백혈구로, 단핵구, 수지상 세포, 림프구가 포함됩니다."
                    },
                    {
                      "term": "식세포 (Phagocytes)",
                      "definition": "미생물이나 이물질을 섭취하고 소화하는 세포(예: 대식세포, 호중구)를 총칭합니다."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포에 의한 섭취가 용이해지는 과정입니다."
                    },
                    {
                      "term": "주화성 (Chemotaxis)",
                      "definition": "화학적 신호에 의해 세포가 특정 방향으로 이동하는 현상으로, 식세포가 미생물로 유인되는 과정입니다."
                    },
                    {
                      "term": "병원성 인자 (Virulence factors)",
                      "definition": "미생물이 숙주에게 질병을 일으키거나 숙주의 면역 체계를 회피하는 데 도움이 되는 특징 또는 물질입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "I. 혈액의 구성 요소",
                      "id": "i-혈액의-구성-요소",
                      "children": [
                        {
                          "text": "과립구 (Granulocytes)",
                          "id": "과립구-granulocytes",
                          "children": null
                        },
                        {
                          "text": "무과립구 (Agranulocytes)",
                          "id": "무과립구-agranulocytes",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "II. 림프계",
                      "id": "ii-림프계",
                      "children": null
                    },
                    {
                      "text": "III. 숙주 방어: 개요 및 식세포",
                      "id": "iii-숙주-방어-개요-및-식세포",
                      "children": null
                    },
                    {
                      "text": "IV. 식균 작용의 메커니즘",
                      "id": "iv-식균-작용의-메커니즘",
                      "children": null
                    },
                    {
                      "text": "V. 미생물의 식균 작용 회피 전략",
                      "id": "v-미생물의-식균-작용-회피-전략",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 과립구에 해당하지 않는 백혈구는 무엇입니까?",
                    "options": [
                      "단핵구",
                      "호중구",
                      "호염기구",
                      "호산구"
                    ],
                    "answerIndex": 0,
                    "explanation": "단핵구는 무과립구에 속하며, 조직에서 대식세포로 성숙하여 식균 작용을 합니다. 호중구, 호염기구, 호산구는 모두 과립구에 해당합니다."
                  },
                  {
                    "question": "식균 작용의 단계 중, 미생물이 혈청 단백질로 코팅되어 식세포에 의한 섭취가 용이해지는 과정을 무엇이라고 합니까?",
                    "options": [
                      "주화성",
                      "부착",
                      "옵소닌화",
                      "소화"
                    ],
                    "answerIndex": 2,
                    "explanation": "옵소닌화는 미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포의 섭취(Ingestion)를 돕는 과정입니다."
                  },
                  {
                    "question": "다음 미생물 중 식포-리소좀 융합을 방지하여 식균 작용을 회피하는 것으로 알려진 것은 무엇입니까?",
                    "options": [
                      "Streptococcus pyogenes",
                      "Staphylococcus aureus",
                      "Listeria monocytogenes",
                      "Mycobacterium tuberculosis"
                    ],
                    "answerIndex": 3,
                    "explanation": "Mycobacterium tuberculosis는 식포-리소좀 융합을 방지하여 식세포 내에서 생존함으로써 식균 작용을 회피합니다. Streptococcus pyogenes는 부착을 억제하고, Staphylococcus aureus는 백혈구용해소를 통해 식세포를 사멸시키며, Listeria monocytogenes는 식세포를 용해시킵니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 3719 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "염증: 개요",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "염증",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "염증의 네 가지 징후 및 증상: 발적(redness), 부종(edema), 통증(pain), 열(heat).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "손상 인자를 파괴하거나 신체에 미치는 영향을 제한합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "손상 인자에 의해 손상된 조직을 복구하고 대체합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 유발 물질",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "염증은 간에서 급성기 단백질을 활성화시켜 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주요 염증 매개체는 다음과 같습니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "히스타민 (Histamine): 비만 세포, 호염기구, 혈소판에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "키닌 (Kinins): 혈장 내에 존재하며 호중구를 유인하여 화학주성(chemotaxis)을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로스타글란딘 (Prostaglandins): 손상된 세포에서 분비되며 히스타민과 키닌의 효과를 강화하고 식세포가 모세혈관 벽을 통과하는 것을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류코트리엔 (Leukotrienes): 비만 세포와 호염기구에서 분비되며 혈관 투과성을 증가시키고 식세포가 병원체에 부착되는 것을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 (Complement): 혈장 내에 존재하며 히스타민 분비를 자극하고 식세포를 유인하며 식균 작용을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인 (Cytokines): 고정된 대식세포에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 과정 단계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 16.9a-b 염증 과정: 조직 손상, 혈관 반응 및 식균 작용을 포함합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 과정",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조직 손상이 발생하면 손상된 세포에서 히스타민, 키닌, 프로스타글란딘, 류코트리엔, 사이토카인과 같은 화학 물질이 방출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액 응고가 형성되기 시작하고 농양(abscess)이 형성되기 시작합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "식세포 이동 및 식균 작용",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "마지네이션(Margination)은 염증 부위의 사이토카인에 반응하여 식세포가 혈관에 달라붙는 현상입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포는 다이아페데시스(diapedesis)를 통해 혈관 내피 세포 사이를 비집고 나옵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "조직 복구",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "모든 유해 물질이 제거되거나 중화될 때까지 완료될 수 없습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "기질(Stroma)은 복구되는 지지 결합 조직입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "실질(Parenchyma)은 복구되는 조직의 기능적인 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "발열",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "비정상적으로 높은 체온입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "시상하부(Hypothalamus)는 일반적으로 37°C로 설정되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인이 시상하부로 하여금 프로스타글란딘을 방출하게 하여 시상하부의 온도를 더 높게 재설정합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "몸은 혈관을 수축시키고 떨림(shivering)이 발생하여 체온이 상승합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "체온이 떨어지면 (위기, crisis) 혈관 확장과 땀이 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 시스템",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "간에서 생산되는 혈청 단백질로, 미생물 파괴에 면역계를 보조합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 활성화라고 불리는 과정에서 캐스케이드(cascade) 방식으로 작용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "단백질은 대문자 C로 표시되며 발견 순서대로 번호가 매겨집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 단편은 소문자 a와 b로 표시됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체: 활성화",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "고전적 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 항원에 결합하여 C1을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C1은 분열하여 C2와 C4를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C2a와 C4b가 결합하여 C3을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3a는 염증에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3b는 세포 용해(cytolysis)와 옵소닌화(opsonization)에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "대체 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액 내 C3가 미생물 표면의 B, D, P 인자와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3는 C3a와 C3b로 분열하며, 고전적 경로와 동일하게 기능합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "렉틴 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "대식세포가 병원체를 섭취하여 사이토카인을 방출하고, 이는 간에서 렉틴 생산을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "만노스 결합 렉틴(Mannose-binding lectin, MBL)이 만노스에 결합하여 C2와 C4를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C2a와 C4b가 C3을 활성화하며, 이는 고전적 경로 및 대체 경로와 동일하게 기능합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 활성화의 결과",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "세포 용해",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 보체 단백질이 막 공격 복합체(Membrane Attack Complex, MAC)를 형성합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "옵소닌화",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포가 미생물에 부착되는 것을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 보체 단백질이 비만 세포에 결합하여 히스타민을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 16.12 보체 활성화의 결과. 그림 16.13 보체에 의해 자극된 염증.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 시스템은 신체가 감염과 병원체를 퇴치하는 또 다른 방법입니다. 선천성 면역의 이 구성 요소는 다른 면역 반응을 '보완'합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체는 혈청에 순환하는 30개 이상의 단백질 그룹으로, 캐스케이드 방식으로 활성화됩니다: 한 보체 단백질이 다음 단백질을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 캐스케이드는 병원체에 의해 직접 활성화되거나 항체-항원 반응에 의해 활성화될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 단백질들은 함께 (1) 세포 용해, (2) 강화된 식균 작용, (3) 염증을 통해 미생물을 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체: 결과",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "보체 활성화의 조절",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 단백질은 보체 단백질을 쉽게 분해하여 숙주 세포 손상을 최소화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체와 질병",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 단백질의 부족은 감염에 대한 취약성을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 시스템 회피",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "캡슐은 보체 활성화를 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인터페론",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "세포에서 생산되는 사이토카인으로, 항바이러스 활동을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IFN-α 및 IFN-β: 바이러스 감염에 반응하여 세포에서 생산되며, 이웃 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IFN-γ: 호중구와 대식세포가 박테리아를 죽이도록 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "알파 및 베타 인터페론(IFN)의 항바이러스 작용",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "철 결합 단백질",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "트랜스페린(Transferrin): 혈액 및 조직액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "락토페린(Lactoferrin): 우유, 침, 점액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "페리틴(Ferritin): 간, 비장, 적골수에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "헤모글로빈(Hemoglobin): 적혈구에 위치합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "박테리아는 철 결합 단백질과 경쟁하기 위해 시데로포어(siderophores)를 생산합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항균 펩타이드",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "미생물의 단백질 및 당 분자에 반응하여 생산되는 짧은 펩타이드입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포벽 합성을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "원형질막에 구멍을 형성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "광범위한 활성 스펙트럼을 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "기타 요인",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "유전적 저항성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "선택적 생존 이점을 부여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "예: 겸상 적혈구 특성 및 열대열원충(Plasmodium falciparum).",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "연령",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "매우 어린 연령과 노인들은 질병에 더 취약합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "건강 프로토콜 준수",
                    "level": 2
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 핵심 구성 요소인 염증, 발열, 보체 시스템, 인터페론, 철 결합 단백질 및 항균 펩타이드에 대해 설명합니다. 염증의 징후, 매개체, 과정 및 조직 복구를 다루고, 발열의 메커니즘과 체온 조절을 설명합니다. 또한 보체 시스템의 세 가지 활성화 경로(고전적, 대체, 렉틴)와 그 결과(세포 용해, 옵소닌화, 염증)를 상세히 제시합니다. 마지막으로, 인터페론의 항바이러스 역할, 철 결합 단백질의 기능, 항균 펩타이드의 작용 방식, 그리고 유전적 저항성 및 연령과 같은 기타 면역 관련 요인들을 소개합니다.",
                  "keyConcepts": [
                    {
                      "term": "염증 (Inflammation)",
                      "definition": "손상된 조직을 파괴하거나 유해 물질의 영향을 제한하고, 손상된 조직을 복구 및 대체하는 신체의 방어 반응입니다. 발적, 부종, 통증, 열의 네 가지 주요 징후를 가집니다."
                    },
                    {
                      "term": "발열 (Fever)",
                      "definition": "비정상적으로 높은 체온으로, 사이토카인에 의해 시상하부의 체온 설정점이 높아져 발생합니다. 병원체 성장을 억제하고 면역 반응을 강화하는 데 도움을 줄 수 있습니다."
                    },
                    {
                      "term": "보체 시스템 (Complement System)",
                      "definition": "간에서 생산되는 30개 이상의 혈청 단백질로 구성된 캐스케이드 시스템입니다. 병원체 파괴를 돕기 위해 세포 용해, 옵소닌화, 염증을 유발하는 세 가지 활성화 경로(고전적, 대체, 렉틴)를 통해 작동합니다."
                    },
                    {
                      "term": "인터페론 (Interferons)",
                      "definition": "세포에서 생산되는 사이토카인으로, 특히 IFN-α와 IFN-β는 바이러스 감염에 반응하여 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질을 생산하도록 유도하는 항바이러스 활성을 가집니다."
                    },
                    {
                      "term": "항균 물질 (Antimicrobial Substances)",
                      "definition": "철 결합 단백질(트랜스페린, 락토페린, 페리틴, 헤모글로빈)과 항균 펩타이드를 포함하며, 미생물의 성장을 억제하거나 직접 파괴하여 숙주를 보호하는 역할을 합니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "히스타민 (Histamine)",
                      "definition": "비만 세포 등에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발하는 혈관 활성 매개체입니다."
                    },
                    {
                      "term": "다이아페데시스 (Diapedesis)",
                      "definition": "식세포가 혈관 내피 세포 사이를 비집고 나와 조직 손상 부위로 이동하는 과정입니다."
                    },
                    {
                      "term": "마지네이션 (Margination)",
                      "definition": "염증 부위의 사이토카인에 반응하여 식세포가 혈관 내피에 달라붙는 현상입니다."
                    },
                    {
                      "term": "막 공격 복합체 (Membrane Attack Complex, MAC)",
                      "definition": "활성화된 보체 단백질에 의해 형성되며, 미생물 세포막에 구멍을 뚫어 세포 용해를 유발하는 구조입니다."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "보체 단백질(C3b) 등이 미생물을 코팅하여 식세포가 미생물을 더 쉽게 인식하고 식균 작용을 하도록 촉진하는 과정입니다."
                    },
                    {
                      "term": "시데로포어 (Siderophores)",
                      "definition": "박테리아가 숙주의 철 결합 단백질과 경쟁하여 철을 획득하기 위해 생산하는 물질입니다."
                    },
                    {
                      "term": "항바이러스 단백질 (Antiviral Proteins, AVPs)",
                      "definition": "인터페론의 유도에 의해 세포에서 생산되며, 바이러스 복제를 억제하는 단백질입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "염증",
                      "id": "inflammation",
                      "children": [
                        {
                          "text": "개요 및 징후",
                          "id": "inflammation-overview-signs",
                          "children": null
                        },
                        {
                          "text": "염증 반응 유발 물질",
                          "id": "inflammation-mediators",
                          "children": null
                        },
                        {
                          "text": "염증 과정 단계",
                          "id": "inflammation-steps",
                          "children": null
                        },
                        {
                          "text": "식세포 이동 및 식균 작용",
                          "id": "phagocyte-migration-phagocytosis",
                          "children": null
                        },
                        {
                          "text": "조직 복구",
                          "id": "tissue-repair",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "발열",
                      "id": "fever",
                      "children": [
                        {
                          "text": "체온 조절 및 발열 메커니즘",
                          "id": "fever-mechanism",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "보체 시스템",
                      "id": "complement-system",
                      "children": [
                        {
                          "text": "개요 및 기능",
                          "id": "complement-overview",
                          "children": null
                        },
                        {
                          "text": "보체 활성화 경로",
                          "id": "complement-activation-pathways",
                          "children": [
                            {
                              "text": "고전적 경로",
                              "id": "classical-pathway",
                              "children": null
                            },
                            {
                              "text": "대체 경로",
                              "id": "alternative-pathway",
                              "children": null
                            },
                            {
                              "text": "렉틴 경로",
                              "id": "lectin-pathway",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "보체 활성화의 결과",
                          "id": "complement-activation-outcomes",
                          "children": [
                            {
                              "text": "세포 용해",
                              "id": "cytolysis",
                              "children": null
                            },
                            {
                              "text": "옵소닌화",
                              "id": "opsonization",
                              "children": null
                            },
                            {
                              "text": "염증",
                              "id": "complement-inflammation",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "보체 조절 및 질병",
                          "id": "complement-regulation-disease",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항균 물질",
                      "id": "antimicrobial-substances",
                      "children": [
                        {
                          "text": "인터페론",
                          "id": "interferons",
                          "children": null
                        },
                        {
                          "text": "철 결합 단백질",
                          "id": "iron-binding-proteins",
                          "children": null
                        },
                        {
                          "text": "항균 펩타이드",
                          "id": "antimicrobial-peptides",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "기타 요인",
                      "id": "other-factors",
                      "children": [
                        {
                          "text": "유전적 저항성",
                          "id": "genetic-resistance",
                          "children": null
                        },
                        {
                          "text": "연령",
                          "id": "age",
                          "children": null
                        },
                        {
                          "text": "건강 프로토콜 준수",
                          "id": "observing-healthy-protocols",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "염증의 네 가지 주요 징후에 해당하지 않는 것은 무엇입니까?",
                    "options": [
                      "발적",
                      "부종",
                      "가려움",
                      "열"
                    ],
                    "answerIndex": 2,
                    "explanation": "염증의 네 가지 주요 징후는 발적(redness), 부종(swelling), 통증(pain), 열(heat)입니다. 가려움은 일반적인 염증의 주요 징후에 해당하지 않습니다."
                  },
                  {
                    "question": "보체 활성화의 세 가지 주요 결과에 속하지 않는 것은 무엇입니까?",
                    "options": [
                      "세포 용해 (Cytolysis)",
                      "옵소닌화 (Opsonization)",
                      "항체 생산 (Antibody production)",
                      "염증 (Inflammation)"
                    ],
                    "answerIndex": 2,
                    "explanation": "보체 활성화의 주요 결과는 세포 용해, 옵소닌화, 염증입니다. 항체 생산은 보체 시스템의 직접적인 결과가 아닌 적응 면역 반응의 일부입니다."
                  },
                  {
                    "question": "인터페론(IFN-α 및 IFN-β)의 주요 역할은 무엇입니까?",
                    "options": [
                      "세균을 직접 죽인다.",
                      "발열을 유도한다.",
                      "바이러스 감염에 반응하여 항바이러스 단백질 생성을 유도한다.",
                      "조직 복구를 돕는다."
                    ],
                    "answerIndex": 2,
                    "explanation": "IFN-α와 IFN-β는 바이러스 감염에 의해 생성되어 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 개요 및 이중적 특성",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1042 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "적응성 면역 체계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "적응성 면역은 특정 병원체를 표적으로 하는 방어 체계입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 감염이나 백신 접종을 통해 획득됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것을 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 반응은 동일한 외래 물질과의 이후 상호 작용으로, '기억' 덕분에 더 빠르고 효과적입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역 체계의 이중적 특성",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "체액성 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "체액성 면역은 항원(antigens)으로 알려진 외래 분자와 싸우는 항체를 생성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 적골수에서 생성되고 성숙하는 림프구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 항원을 인식하고 항체를 만듭니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 조류의 파브리시우스 낭(bursa of Fabricius)에서 이름을 따왔습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "애니메이션: 체액성 면역 개요",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포성 면역 (세포 매개 면역)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포성 면역은 T 림프구를 생성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 림프구는 식세포에 의해 처리된 항원 펩타이드를 인식합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 흉선에서 성숙합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 표면의 T 세포 수용체(TCRs)가 항원과 접촉하면 T 세포는 항체 대신 사이토카인을 분비합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 및 B 세포 발달",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "체액성 면역과 세포성 면역의 공격 대상 비교",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포성 면역은 세포 내부에 있는 항원을 공격합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 바이러스나 M. leprae, L. monocytogenes와 같은 일부 세포 내 세균에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "체액성 면역은 세포 외부의 침입자와 위협에 맞서 싸웁니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 세포 외 세균과 독소, 그리고 숙주 세포에 들어가기 전의 바이러스를 포함합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "제공된 텍스트는 특정 병원체를 표적으로 하는 방어 체계인 적응성 면역에 대해 설명합니다. 적응성 면역은 감염이나 백신을 통해 획득되며, 일차 반응과 이차 반응으로 구분됩니다. 또한, 적응성 면역의 이중적 특성으로 체액성 면역(B 세포, 항체 생성, 세포 외부 위협 방어)과 세포성 면역(T 세포, 사이토카인 분비, 세포 내부 위협 방어)을 상세히 다루고, 각 면역 체계가 공격하는 대상의 차이점을 비교합니다.",
                  "keyConcepts": [
                    {
                      "term": "적응성 면역",
                      "definition": "특정 병원체를 표적으로 삼는 방어 체계로, 감염이나 백신 접종을 통해 획득되며, 기억을 통해 더 빠르고 효과적인 이차 반응을 가능하게 합니다."
                    },
                    {
                      "term": "체액성 면역",
                      "definition": "B 세포가 항원을 인식하고 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸우는 면역 반응입니다."
                    },
                    {
                      "term": "세포성 면역",
                      "definition": "T 림프구가 식세포에 의해 처리된 항원 펩타이드를 인식하고 사이토카인을 분비하여 세포 내부에 있는 항원(예: 바이러스, 일부 세포 내 세균)을 공격하는 면역 반응입니다."
                    },
                    {
                      "term": "일차 반응 및 이차 반응",
                      "definition": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것이며, 이차 반응은 동일한 물질과의 이후 상호 작용으로, 기억 덕분에 더 빠르고 효과적입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "항원 (Antigen)",
                      "definition": "면역 반응, 특히 항체 생성을 유도하는 외래 분자입니다."
                    },
                    {
                      "term": "항체 (Antibody)",
                      "definition": "B 세포에 의해 생성되며 특정 항원과 결합하여 중화하거나 제거하는 Y자 모양의 단백질입니다."
                    },
                    {
                      "term": "B 세포 (B cell)",
                      "definition": "적골수에서 생성 및 성숙하며 항원을 인식하고 항체를 만드는 림프구입니다."
                    },
                    {
                      "term": "T 세포 (T cell)",
                      "definition": "흉선에서 성숙하며 항원 제시 세포에 의해 처리된 항원 펩타이드를 인식하고 항체 대신 사이토카인을 분비하는 림프구입니다."
                    },
                    {
                      "term": "사이토카인 (Cytokine)",
                      "definition": "T 세포 등 면역 세포가 분비하는 작은 단백질로, 면역 반응과 염증을 조절하는 신호 분자 역할을 합니다."
                    },
                    {
                      "term": "T 세포 수용체 (TCR)",
                      "definition": "T 세포 표면에 위치하며 특정 항원 펩타이드를 인식하고 결합하는 수용체입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "적응성 면역 체계",
                      "id": "adaptive-immune-system",
                      "children": [
                        {
                          "text": "적응성 면역의 정의 및 획득 경로",
                          "id": "definition-acquisition-of-adaptive-immunity",
                          "children": null
                        },
                        {
                          "text": "일차 반응과 이차 반응",
                          "id": "primary-and-secondary-response",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역 체계의 이중적 특성",
                      "id": "dual-nature-of-adaptive-immune-system",
                      "children": [
                        {
                          "text": "체액성 면역",
                          "id": "humoral-immunity",
                          "children": [
                            {
                              "text": "항체 생성 및 항원 공격",
                              "id": "antibody-production-and-antigen-attack",
                              "children": null
                            },
                            {
                              "text": "B 세포의 역할 및 특징",
                              "id": "role-and-characteristics-of-b-cells",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "세포성 면역 (세포 매개 면역)",
                          "id": "cellular-immunity",
                          "children": [
                            {
                              "text": "T 림프구 생성 및 역할",
                              "id": "t-lymphocyte-production-and-role",
                              "children": null
                            },
                            {
                              "text": "T 세포의 성숙 및 항원 인식",
                              "id": "t-cell-maturation-and-antigen-recognition",
                              "children": null
                            },
                            {
                              "text": "T 세포 수용체(TCR) 및 사이토카인 분비",
                              "id": "tcr-and-cytokine-secretion",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "체액성 면역과 세포성 면역의 공격 대상 비교",
                          "id": "comparison-of-humoral-and-cellular-immunity-targets",
                          "children": [
                            {
                              "text": "세포성 면역의 대상 (세포 내부 항원)",
                              "id": "targets-of-cellular-immunity",
                              "children": null
                            },
                            {
                              "text": "체액성 면역의 대상 (세포 외부 위협)",
                              "id": "targets-of-humoral-immunity",
                              "children": null
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "적응성 면역의 주요 특징은 무엇입니까?",
                    "options": [
                      "비특이적 방어",
                      "특정 병원체를 표적으로 함",
                      "즉각적인 반응",
                      "항상 식세포 작용을 포함함"
                    ],
                    "answerIndex": 1,
                    "explanation": "적응성 면역은 특정 병원체를 표적으로 삼는 방어 체계입니다."
                  },
                  {
                    "question": "항체를 생성하고 세포 외부의 위협을 공격하는 면역 유형은 무엇입니까?",
                    "options": [
                      "선천성 면역",
                      "세포성 면역",
                      "체액성 면역",
                      "비특이적 면역"
                    ],
                    "answerIndex": 2,
                    "explanation": "체액성 면역은 B 세포가 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸웁니다."
                  },
                  {
                    "question": "T 세포는 어디에서 성숙합니까?",
                    "options": [
                      "적골수",
                      "비장",
                      "림프절",
                      "흉선"
                    ],
                    "answerIndex": 3,
                    "explanation": "T 세포는 흉선(thymus)에서 성숙합니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 사이토카인, 항원 및 항체",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1989 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "사이토카인: 면역 세포의 화학적 전달자",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인은 자극에 반응하여 생성되는 화학적 전달자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인터루킨(Interleukins): 백혈구 사이의 사이토카인입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "케모카인(Chemokines): 백혈구의 이동을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인터페론(Interferons, IFNs): 숙주 세포의 바이러스 감염을 방해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "종양 괴사 인자(Tumor necrosis factor, TNF): 자가면역 질환의 염증과 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "조혈 사이토카인(Hematopoietic cytokines): 적혈구와 백혈구로 발달하는 줄기세포를 조절합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인의 과잉 생산은 사이토카인 폭풍(cytokine storm)으로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "주요 사이토카인 및 그 역할",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-4: TH2 세포에서 생성되며, 미감염 TH 세포와 B 세포에 작용하여 TH2 세포 증식을 유도하고 IgE로의 클래스 전환을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-12: 수지상 세포, 대식세포, 호중구에서 생성되며, 미감염 TH 세포와 NK 세포에 작용하여 TH1 세포의 성장과 기능을 자극하고 IFN-γ 및 TNF-α를 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-17: TH17 세포에서 생성되며, 호중구에 작용하여 염증을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-22: TH17 세포에서 생성되며, 상피세포에 작용하여 항균 단백질 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감마 인터페론(IFN-γ): TH1 세포에서 생성되며, CTL(세포독성 T 림프구)과 대식세포에 작용하여 식세포 작용을 촉진하고 대식세포 및 체액성 면역 반응을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "케모카인: 다양한 세포(대식세포, 상피세포)에서 생성되며, 호중구에 작용하여 화학주성(chemotaxis)을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "TNF-알파(TNF-α): 대식세포, TH 세포, NK 세포에서 생성되며, 종양 세포에 작용하여 염증을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "GM-CSF: 대식세포, T 세포, NK 세포에서 생성되며, 골수 줄기세포에 작용하여 대식세포와 과립구 수를 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항원은 항체 생성을 유발하는 물질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일반적으로 침입하는 미생물이나 이물질의 구성 요소입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체는 항원상의 에피토프(epitopes) 또는 항원결정인자(antigenic determinants)와 상호작용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "합텐",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "합텐은 면역 반응을 유발하기에는 너무 작은 항원입니다; 운반 분자에 부착되어야 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항체",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체는 면역글로불린(Immunoglobulins, Ig)이라고 불리는 구형 단백질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가(Valence)는 항체에 있는 항원 결합 부위의 수를 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이중가(Bivalent) 항체는 두 개의 결합 부위를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전형적인 항체 분자의 구조",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "네 개의 단백질 사슬이 Y자 모양을 이룹니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "두 개의 동일한 경쇄(light chains)와 두 개의 동일한 중쇄(heavy chains)가 이황화 결합으로 연결되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가변(V) 부위는 팔의 끝 부분에 위치하며 에피토프와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "정상(Fc) 부위는 줄기 부분으로, 특정 Ig 클래스에 대해 동일합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역글로불린은 5가지 클래스(IgG, IgM, IgA, IgD, IgE)로 나뉩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역글로불린 클래스 요약",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "IgG",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체(Monomer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 80%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액, 림프, 장에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "태반을 통과하여 태아를 보호하고; 보체(complement)를 활성화하며; 식세포 작용을 강화하고; 독소와 바이러스를 중화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgM",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다섯 개의 단량체가 J 사슬로 연결된 오량체(Pentamer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 6%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈관 내에 남아있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포와 바이러스의 응집을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감염에 대한 첫 번째 반응이며; 수명이 짧습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgA",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청에서는 단량체, 분비물에서는 이량체(Dimer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 13%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "점막, 침, 눈물, 모유에서 흔히 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "미생물이 점막에 부착하는 것을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgD",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 0.02%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IgG와 유사한 구조를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액, 림프, B 세포에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "명확히 정의된 기능은 없으나; B 세포의 면역 반응을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgE",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 0.002%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비만세포, 호염기구, 혈액에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원과 결합하면 히스타민 방출을 유발하고; 기생충을 용해합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본 문서는 적응성 면역의 핵심 요소인 사이토카인, 항원, 항체에 대해 설명합니다. 사이토카인은 면역 세포 간의 화학적 전달자로, 다양한 종류(인터루킨, 케모카인, 인터페론, TNF 등)와 기능(염증 유발, 백혈구 이동 유도, 바이러스 감염 방해 등)을 가지며, 과잉 생산 시 사이토카인 폭풍을 유발할 수 있습니다. 항원은 항체 생성을 유발하는 물질이며, 항체가 결합하는 특정 부위를 에피토프라고 합니다. 합텐은 면역 반응을 유발하기에 너무 작아 운반 분자에 부착해야 하는 항원입니다. 항체는 면역글로불린(Ig)이라는 단백질로, Y자 모양의 구조를 가지며 가변부위와 정상부위로 구성됩니다. IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 클래스가 있으며, 각 클래스는 고유한 구조적 특성과 면역 기능을 수행합니다.",
                  "keyConcepts": [
                    {
                      "term": "사이토카인 (Cytokines)",
                      "definition": "면역 세포 간의 통신을 담당하는 화학적 전달 물질로, 다양한 면역 반응을 조절합니다."
                    },
                    {
                      "term": "항원 (Antigens)",
                      "definition": "면역 반응, 특히 항체 생성을 유발하는 물질입니다."
                    },
                    {
                      "term": "항체 (Antibodies/Immunoglobulins)",
                      "definition": "항원에 특이적으로 결합하여 항원을 중화하거나 제거하는 면역 단백질입니다."
                    },
                    {
                      "term": "면역글로불린 클래스 (Immunoglobulin Classes)",
                      "definition": "항체의 기능과 구조에 따라 IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 분류로 나뉩니다."
                    },
                    {
                      "term": "사이토카인 폭풍 (Cytokine Storm)",
                      "definition": "사이토카인이 과도하게 생산되어 전신 염증 반응과 조직 손상을 유발할 수 있는 심각한 면역 반응입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "인터루킨 (Interleukins)",
                      "definition": "백혈구 사이에서 작용하는 사이토카인입니다."
                    },
                    {
                      "term": "케모카인 (Chemokines)",
                      "definition": "백혈구의 이동(화학주성)을 유도하는 사이토카인입니다."
                    },
                    {
                      "term": "인터페론 (Interferons, IFNs)",
                      "definition": "바이러스 감염을 방해하는 사이토카인입니다."
                    },
                    {
                      "term": "종양 괴사 인자 (Tumor Necrosis Factor, TNF)",
                      "definition": "염증 반응과 관련된 사이토카인입니다."
                    },
                    {
                      "term": "에피토프 (Epitopes)",
                      "definition": "항원 상에서 항체가 특이적으로 결합하는 특정 부위 또는 항원결정인자입니다."
                    },
                    {
                      "term": "합텐 (Haptens)",
                      "definition": "단독으로는 면역 반응을 유발하지 못하지만, 운반 분자에 부착되면 면역원성을 획득하는 작은 분자입니다."
                    },
                    {
                      "term": "가변 부위 (Variable regions)",
                      "definition": "항체 팔의 끝 부분에 위치하며 항원의 에피토프와 결합하는 부위입니다."
                    },
                    {
                      "term": "정상 부위 (Constant region, Fc)",
                      "definition": "항체 분자의 줄기 부분으로, 특정 Ig 클래스에 대해 동일하며 면역 세포와의 상호작용에 관여합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "사이토카인: 면역 세포의 화학적 전달자",
                      "id": "cytokines-chemical-messengers-of-immune-cells",
                      "children": [
                        {
                          "text": "사이토카인의 정의 및 종류",
                          "id": "cytokines-definition-types",
                          "children": null
                        },
                        {
                          "text": "주요 사이토카인 및 그 역할",
                          "id": "key-cytokines-roles",
                          "children": null
                        },
                        {
                          "text": "사이토카인 폭풍",
                          "id": "cytokine-storm",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원",
                      "id": "antigens",
                      "children": [
                        {
                          "text": "항원의 정의",
                          "id": "antigens-definition",
                          "children": null
                        },
                        {
                          "text": "에피토프",
                          "id": "epitopes",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "합텐",
                      "id": "haptens",
                      "children": null
                    },
                    {
                      "text": "항체",
                      "id": "antibodies",
                      "children": [
                        {
                          "text": "항체의 정의 및 구조",
                          "id": "antibodies-definition-structure",
                          "children": null
                        },
                        {
                          "text": "전형적인 항체 분자의 구조",
                          "id": "typical-antibody-structure",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역글로불린 클래스 요약",
                      "id": "summary-of-immunoglobulin-classes",
                      "children": [
                        {
                          "text": "IgG",
                          "id": "igg",
                          "children": null
                        },
                        {
                          "text": "IgM",
                          "id": "igm",
                          "children": null
                        },
                        {
                          "text": "IgA",
                          "id": "iga",
                          "children": null
                        },
                        {
                          "text": "IgD",
                          "id": "igd",
                          "children": null
                        },
                        {
                          "text": "IgE",
                          "id": "ige",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "사이토카인 폭풍(Cytokine storm)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
                    "options": [
                      "면역 세포가 바이러스 감염을 방해하기 위해 사이토카인을 과도하게 생산하는 현상",
                      "염증 반응을 억제하기 위해 사이토카인이 부족하게 생산되는 현상",
                      "사이토카인이 과도하게 생산되어 조직 손상과 장기 부전을 초래할 수 있는 현상",
                      "항체 생산을 촉진하기 위해 특정 사이토카인이 의도적으로 증가하는 현상"
                    ],
                    "answerIndex": 2,
                    "explanation": "사이토카인 폭풍은 사이토카인이 과도하게 생산되어 전신 염증 반응, 조직 손상 및 장기 부전을 초래할 수 있는 현상입니다."
                  },
                  {
                    "question": "다음 면역글로불린(Ig) 클래스 중, 태반을 통과하여 태아를 보호하고 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 하는 것은 무엇입니까?",
                    "options": [
                      "IgM",
                      "IgA",
                      "IgG",
                      "IgE"
                    ],
                    "answerIndex": 2,
                    "explanation": "IgG는 태반을 통과하여 태아를 보호하며, 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 수행합니다."
                  },
                  {
                    "question": "합텐(Hapten)에 대한 설명으로 옳은 것은 무엇입니까?",
                    "options": [
                      "항체를 생산하는 모든 물질을 의미한다.",
                      "면역 반응을 유발하기에 너무 작아서 운반 분자에 부착해야 하는 항원이다.",
                      "항체와 상호작용하는 항원의 특정 부위를 의미한다.",
                      "혈액에 가장 많이 존재하는 면역글로불린의 한 종류이다."
                    ],
                    "answerIndex": 1,
                    "explanation": "합텐은 단독으로는 면역 반응을 유발하기에 너무 작지만, 운반 분자에 부착되면 면역원성을 획득하여 항체 생성을 유도할 수 있는 물질입니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 체액성 면역 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2199 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "항체 생성 세포의 활성화 및 클론 선택",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "주조직적합복합체(MHC)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "주조직적합복합체(MHC) 유전자는 세포 표면에 존재하는 분자를 암호화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Class I MHC는 모든 유핵 동물 세포의 막에 존재하며, '자기(self)'를 식별하는 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Class II MHC는 B 세포를 포함한 전문 항원제시세포(APCs)의 표면에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "B 세포의 활성화 및 클론 선택 과정",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "비활성 B 세포는 항원에 결합하는 표면 면역글로불린(Ig)을 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 항원을 내재화하고 처리합니다. 처리된 항원 조각들은 MHC Class II 분자에 제시됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 제시된 항원 조각을 T 도우미 세포(TH cell)가 접촉하고, B 세포를 활성화시키는 사이토카인을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 B 세포는 증식(클론 확장)을 겪습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "클론 선택은 활성화된 B 세포를 다음 두 가지로 분화시킵니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1. 항체를 생산하는 형질세포(Plasma cells)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2. 기억 세포(Memory cells)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "또한, 클론 제거(Clonal deletion) 과정을 통해 유해한 B 세포는 제거됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포는 특정 항원에 대한 표면 면역글로불린을 가진 성숙한 B 세포로 분화합니다. B 세포가 특정 항원을 만나면 증식합니다. 일부 B 세포는 장수하는 기억 세포로 증식하여, 나중에 항체를 생산하는 형질세포로 자극될 수 있습니다. 다른 B 세포는 항체 생산 형질세포로 증식하며, 이 형질세포는 혈액 순환계로 항체를 분비합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "T 세포 의존성 및 비의존성 항원",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 의존성 항원은 항체를 생산하기 위해 T 도우미 세포(TH cell)의 도움이 필요한 항원입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 직접 자극할 수 있습니다. 이러한 항원은 일반적으로 약한 면역 반응을 유발하며, 주로 IgM을 생산하고 기억 세포는 생성되지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원-항체 결합 및 그 결과",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 항원에 결합할 때 항원-항체 복합체가 형성됩니다. 이 결합의 강도를 친화도(affinity)라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원-항체 결합은 외래 분자나 세포를 파괴하도록 표지함으로써 숙주를 보호합니다. 주요 보호 메커니즘은 다음과 같습니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1. **응집(Agglutination)**: 감염 단위의 수를 줄여 처리해야 할 대상을 감소시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2. **옵소닌화(Opsonization)**: 항원으로 항원을 코팅하여 식균작용을 강화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "3. **항체 의존성 세포 매개성 세포독성(Antibody-dependent cell-mediated cytotoxicity, ADCC)**: 항체가 표적 세포에 부착되어 대식세포, 호산구, NK 세포에 의한 파괴를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "4. **중화(Neutralization)**: 박테리아와 바이러스가 점막에 부착되는 것을 차단하고 독소가 부착되는 것을 막습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "5. **보체계 활성화(Activation of the complement system)**: 염증 및 세포 용해를 유발합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본 문서는 적응성 면역 중 체액성 면역 반응에 초점을 맞춰 항체 생성 세포의 활성화 및 클론 선택 과정을 설명합니다. MHC(주조직적합복합체)의 역할, B 세포가 항원을 인식하고 T 도우미 세포의 도움을 받아 활성화되며 형질세포와 기억 세포로 분화하는 과정이 상세히 다뤄집니다. 또한, T 세포 의존성 및 비의존성 항원의 특징과 항원-항체 결합이 숙주를 보호하는 응집, 옵소닌화, ADCC, 중화, 보체계 활성화 등 다양한 메커니즘을 제시합니다.",
                  "keyConcepts": [
                    {
                      "term": "MHC (주조직적합복합체)",
                      "definition": "세포 표면에 존재하며, Class I은 '자기' 식별, Class II는 항원제시세포에서 항원 조각을 T 세포에 제시하는 역할을 하는 분자를 암호화하는 유전자 복합체."
                    },
                    {
                      "term": "B 세포 활성화",
                      "definition": "비활성 B 세포가 항원을 인식하고, T 도우미 세포의 사이토카인 도움을 받아 증식하고 분화하는 과정."
                    },
                    {
                      "term": "클론 선택 (Clonal Selection)",
                      "definition": "특정 항원에 반응하는 B 세포 클론이 선택적으로 증식하여 항체 생성 형질세포와 기억 세포로 분화하는 면역 과정."
                    },
                    {
                      "term": "T 세포 의존성/비의존성 항원",
                      "definition": "항체 생산에 T 도우미 세포의 도움이 필요한지 여부에 따라 항원을 분류하는 방식. 비의존성 항원은 약한 IgM 반응과 기억 세포 부재를 특징으로 함."
                    },
                    {
                      "term": "항체 기능",
                      "definition": "항원-항체 복합체 형성 후 숙주를 보호하는 다양한 메커니즘 (응집, 옵소닌화, ADCC, 중화, 보체계 활성화)."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "MHC (주조직적합복합체)",
                      "definition": "세포 표면에 항원 펩타이드를 제시하는 데 관여하는 단백질 복합체."
                    },
                    {
                      "term": "T 도우미 세포 (T Helper Cell, TH cell)",
                      "definition": "B 세포 활성화 및 다른 면역 세포 기능을 조절하는 사이토카인을 분비하는 림프구."
                    },
                    {
                      "term": "사이토카인 (Cytokines)",
                      "definition": "세포 간 신호 전달에 관여하며 면역 반응을 조절하는 작은 단백질."
                    },
                    {
                      "term": "형질세포 (Plasma Cell)",
                      "definition": "활성화된 B 세포로부터 분화하여 다량의 항체를 생산하고 분비하는 세포."
                    },
                    {
                      "term": "기억 세포 (Memory Cell)",
                      "definition": "면역 반응 후 장기간 생존하며, 동일한 항원 재침입 시 빠르고 강력한 2차 면역 반응을 유도하는 림프구."
                    },
                    {
                      "term": "응집 (Agglutination)",
                      "definition": "항체가 여러 항원 입자(예: 세균)를 서로 묶어 침전시키는 과정."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "항체가 항원 표면을 코팅하여 식세포가 이를 더 쉽게 인식하고 포식할 수 있도록 돕는 과정."
                    }
                  ],
                  "outline": [
                    {
                      "text": "항체 생성 세포의 활성화 및 클론 선택",
                      "id": "항체-생성-세포의-활성화-및-클론-선택",
                      "children": [
                        {
                          "text": "주조직적합복합체(MHC)",
                          "id": "주조직적합복합체-mhc",
                          "children": null
                        },
                        {
                          "text": "B 세포의 활성화 및 클론 선택 과정",
                          "id": "b-세포의-활성화-및-클론-선택-과정",
                          "children": null
                        },
                        {
                          "text": "T 세포 의존성 및 비의존성 항원",
                          "id": "t-세포-의존성-및-비의존성-항원",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원-항체 결합 및 그 결과",
                      "id": "항원-항체-결합-및-그-결과",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 MHC Class II 분자가 주로 발견되는 세포와 그 역할은 무엇입니까?",
                    "options": [
                      "모든 유핵 동물 세포의 막; '자기' 식별",
                      "전문 항원제시세포(APCs)의 표면; 항원 조각 제시",
                      "적혈구; 산소 운반",
                      "신경 세포; 신경 신호 전달"
                    ],
                    "answerIndex": 1,
                    "explanation": "MHC Class II는 B 세포를 포함한 전문 항원제시세포의 표면에 존재하며, 처리된 항원 조각을 T 도우미 세포에 제시하는 역할을 합니다."
                  },
                  {
                    "question": "B 세포가 항원을 내재화하고 처리한 후, T 도우미 세포의 도움을 받아 활성화될 때 T 도우미 세포가 방출하는 물질은 무엇입니까?",
                    "options": [
                      "항체",
                      "항원",
                      "사이토카인",
                      "면역글로불린"
                    ],
                    "answerIndex": 2,
                    "explanation": "T 도우미 세포는 제시된 항원 조각을 인식한 후 사이토카인을 방출하여 B 세포의 활성화를 유도합니다."
                  },
                  {
                    "question": "T 세포 비의존성 항원에 대한 면역 반응의 특징으로 옳지 않은 것은 무엇입니까?",
                    "options": [
                      "T 세포의 도움 없이 B 세포를 직접 자극한다.",
                      "주로 IgM 항체를 생산한다.",
                      "약한 면역 반응을 유발한다.",
                      "강력한 기억 세포 반응을 생성한다."
                    ],
                    "answerIndex": 3,
                    "explanation": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 자극하지만, 일반적으로 약한 면역 반응을 유발하고 기억 세포가 생성되지 않습니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 세포성 면역 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2963 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "세포성 면역 반응 과정",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 세포내 병원체와 싸웁니다. T 세포는 흉선에서 성숙하며, 흉선 선택을 통해 미성숙 T 세포가 제거됩니다. 성숙한 T 세포는 흉선에서 림프 조직으로 이동하며, T 세포 수용체(TCR)를 통해 항원에 부착합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "위장관으로 들어오는 병원체는 파이어스 패치(Peyer's patches) 위에 위치한 미세주름 세포(M cells)를 통과합니다. 이 세포들은 항원을 림프구와 항원제시세포(APCs)로 전달합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원제시세포 (APCs)",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "수지상 세포 (Dendritic cells, DCs)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "수지상 세포는 미생물을 삼켜 분해하고 T 세포에 제시합니다. 이들은 피부, 생식기, 림프절, 비장, 흉선 및 혈액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "대식세포 (Macrophages)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "대식세포는 사이토카인 또는 항원 물질의 섭취에 의해 활성화됩니다. 이들은 림프 조직으로 이동하여 T 세포에 항원을 제시합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원 처리 및 제시: MHC",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "T 세포의 종류",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 분화군(Clusters of differentiation, CD) 표지자를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CD4+ T 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4+ T 세포는 T 도우미 세포(TH)라고도 불립니다. 이들은 B 세포와 사이토카인 신호를 주고받으며 항원과 직접 상호작용합니다. B 세포 및 APC의 MHC class II 분자에 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CD8+ T 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "CD8+ T 세포는 세포독성 T 림프구(Cytotoxic T lymphocytes, CTL)라고 불립니다. 이들은 MHC class I 분자에 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4+ 세포의 TCR은 APC의 항원 조각과 MHC class II에 결합하여 인식합니다. APC 또는 TH는 보조 자극 분자를 분비하여 CD4+ 세포를 활성화합니다. 활성화된 TH 세포는 사이토카인을 생성하고 TH1, TH2, TH17 세포 및 기억 세포로 분화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH17 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH17 세포는 IL-17을 생성하여 염증 반응에 기여하고, 세포외 세균 및 곰팡이에 대한 방어를 위해 호중구를 모집합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH1 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH1 세포는 IFN-γ를 생성하여 대식세포를 활성화하고, 보체를 강화하며, 식세포 작용을 촉진하는 항체 생성을 자극합니다. TH1 세포는 세포성 면역의 중요한 요소이며, 이들의 사이토카인(예: IFN-γ 및 IL-2)은 CD8+ T 세포와 NK 세포를 활성화하여 감염된 숙주 세포를 죽임으로써 세포내 병원체를 제어합니다. 또한, 대식세포와 같은 항원제시세포의 식세포 작용을 강화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH2 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH2 세포는 B 세포를 활성화하여 IgE를 생성하게 하고 호산구를 활성화합니다. 특히 IgE 생성을 통한 알레르기 반응에 중요하며, 헬민스와 같은 세포외 기생충을 제어하기 위해 호산구를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "조절 T 세포 (Treg)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 T 세포(Treg)는 CD4+ 세포의 하위 집합으로, 추가적인 CD25 분자를 가지고 있습니다. 이들은 자가 반응성 T 세포를 억제하여 자기 관용을 유지하고, 소화에 필요한 장내 세균을 보호하며, 태아를 보호합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 T 림프구 (CD8+ T 세포)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "전구 세포독성 T 세포(CTLp)는 TH 세포와 보조 자극 신호의 도움으로 활성화되어 세포독성 T 림프구(CTLs)가 됩니다. CTLs는 감염에 의해 변형된 자가 세포를 인식하고 죽입니다. 감염된 자가 세포는 MHC class I 분자와 함께 표면에 내인성 항원을 운반합니다. CTL은 퍼포린(perforin)과 그랜자임(granzymes)을 방출하여 감염된 세포의 세포자멸사를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포자멸사 (Apoptosis)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포자멸사는 프로그램된 세포 사멸입니다. 이는 감염성 바이러스가 다른 세포로 퍼지는 것을 방지합니다. 세포는 게놈을 조각으로 절단하며, 세포막은 수포(blebbing)를 통해 바깥쪽으로 부풀어 오릅니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "정상 세포는 세포독성 T 림프구(CTL)에 의해 반응을 유발하지 않지만, 바이러스 감염 세포나 암세포는 비정상적인 내인성 항원을 생성합니다. 이 비정상적인 항원은 MHC class I 분자와 결합하여 세포 표면에 제시됩니다. TH1 세포의 결합은 사이토카인 분비를 촉진합니다. 이 사이토카인은 전구 CTL을 활성화하여 CTL 클론을 생성합니다. CTL은 세포자멸사를 통해 바이러스 감염 세포의 파괴를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역계에 의한 세포외 살상",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "자연살해 (NK) 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "자연살해(NK) 세포는 과립성 백혈구로, MHC class I 자가 항원을 발현하지 않는 세포를 파괴합니다. 이들은 바이러스 감염 세포와 종양 세포를 죽이고 기생충을 공격합니다. 항상 항원에 의해 자극되는 것은 아니며, 표적 세포에 구멍을 형성하여 용해 또는 세포자멸사를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포성 면역에 관여하는 주요 세포 기능",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH1) 세포: 세포 매개 면역 관련 세포(대식세포, CTLs, 자연살해 세포)를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH2) 세포: 호산구, IgM, IgE 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH17) 세포: 호중구를 모집하고 항균 단백질 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구 (CTL): 세포자멸사를 유도하여 접촉하는 표적 세포를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 T (Treg) 세포: 면역 반응을 조절하고 자기 관용을 유지하는 데 도움을 줍니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 대식세포: 식세포 활동이 강화되고 암세포를 공격합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자연살해 (NK) 세포: 표적 세포를 공격하고 파괴하며, 항체 의존성 세포 매개 세포독성(ADCC)에 참여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항체 의존성 세포 매개 세포독성 (ADCC)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "원생동물과 헬민스는 식세포 작용으로 삼키기에는 너무 큽니다. 원생동물 또는 헬민스 표적 세포는 항체로 코팅됩니다. 면역계 세포는 항체의 Fc 영역에 부착합니다. 표적 세포는 면역계 세포가 분비하는 화학 물질에 의해 용해됩니다. 많은 기생충과 같이 식세포에 의해 섭취하기에는 너무 큰 유기체는 외부에서 공격받아야 합니다. 호산구는 기생성 흡충의 유충 단계에 부착합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 세포성 면역의 과정을 상세히 설명하며, T 세포, 항원제시세포(APCs) 및 이들의 상호작용에 중점을 둡니다. T 세포의 성숙 과정과 다양한 T 세포 유형(TH1, TH2, TH17, 세포독성 T 림프구, 조절 T 세포)의 기능, 그리고 이들이 세포내 병원체 퇴치, 면역 반응 조절 및 특정 면역 반응 매개에 어떻게 기여하는지 다룹니다. 또한, 자연살해(NK) 세포의 세포외 살상 역할과 대형 기생충에 대한 항체 의존성 세포 매개 세포독성(ADCC) 기전도 설명합니다.",
                  "keyConcepts": [
                    {
                      "term": "T 세포의 성숙 및 기능",
                      "definition": "흉선에서 성숙하며, 세포내 병원체와 싸우고 항원제시세포(APCs)가 제시하는 항원에 특이적으로 반응하는 림프구."
                    },
                    {
                      "term": "항원제시세포 (APCs)",
                      "definition": "미생물을 삼켜 분해하고 그 항원 조각을 MHC 분자를 통해 T 세포에 제시하여 T 세포 반응을 유도하는 세포 (예: 수지상 세포, 대식세포)."
                    },
                    {
                      "term": "T 세포 유형 및 역할",
                      "definition": "CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)는 다른 면역 세포의 활성화를 돕고, CD8+ T 세포(세포독성 T 림프구)는 감염된 세포를 직접 파괴하며, 조절 T 세포는 면역 반응을 억제하여 자기 관용을 유지한다."
                    },
                    {
                      "term": "세포독성 T 림프구 (CTLs) 및 세포자멸사 (Apoptosis)",
                      "definition": "CTL은 감염된 자가 세포를 인식하여 퍼포린과 그랜자임을 방출, 세포자멸사(프로그램된 세포 사멸)를 유도하여 바이러스 확산을 막는다."
                    },
                    {
                      "term": "자연살해(NK) 세포 및 항체 의존성 세포 매개 세포독성 (ADCC)",
                      "definition": "NK 세포는 MHC class I을 발현하지 않는 세포를 파괴하며, ADCC는 항체로 코팅된 표적 세포를 면역 세포가 용해시키는 기전으로, 특히 대형 기생충에 효과적이다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "T 세포 (T cell)",
                      "definition": "흉선에서 성숙하며 세포내 병원체와 싸우는 림프구."
                    },
                    {
                      "term": "항원제시세포 (Antigen-Presenting Cells, APCs)",
                      "definition": "미생물을 삼켜 분해하고 T 세포에 항원을 제시하는 세포 (예: 수지상 세포, 대식세포)."
                    },
                    {
                      "term": "MHC (Major Histocompatibility Complex)",
                      "definition": "항원 제시를 위해 세포 표면에 항원 조각을 표시하는 분자."
                    },
                    {
                      "term": "T 도우미 세포 (T Helper cells, TH)",
                      "definition": "CD4+ T 세포로, B 세포와 사이토카인 신호를 주고받으며 다른 면역 세포의 활성화를 돕는다."
                    },
                    {
                      "term": "세포독성 T 림프구 (Cytotoxic T Lymphocytes, CTLs)",
                      "definition": "CD8+ T 세포로, 감염된 자가 세포를 인식하고 세포자멸사를 유도하여 파괴한다."
                    },
                    {
                      "term": "세포자멸사 (Apoptosis)",
                      "definition": "프로그램된 세포 사멸로, 감염성 바이러스가 다른 세포로 퍼지는 것을 방지한다."
                    },
                    {
                      "term": "자연살해 세포 (Natural Killer cells, NK cells)",
                      "definition": "MHC class I 자가 항원을 발현하지 않는 세포를 파괴하며, 바이러스 감염 세포, 종양 세포 및 기생충을 공격한다."
                    },
                    {
                      "term": "항체 의존성 세포 매개 세포독성 (Antibody-Dependent Cell-mediated Cytotoxicity, ADCC)",
                      "definition": "항체로 코팅된 표적 세포를 면역 세포가 파괴하는 기전."
                    }
                  ],
                  "outline": [
                    {
                      "text": "세포성 면역 반응 과정",
                      "id": "세포성-면역-반응-과정",
                      "children": [
                        {
                          "text": "T 세포의 역할과 성숙",
                          "id": "t-세포의-역할과-성숙",
                          "children": null
                        },
                        {
                          "text": "소화관 내 병원체 처리",
                          "id": "소화관-내-병원체-처리",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원제시세포 (APCs)",
                      "id": "항원제시세포-apcs",
                      "children": [
                        {
                          "text": "수지상 세포 (Dendritic cells, DCs)",
                          "id": "수지상-세포-dendritic-cells-dcs",
                          "children": null
                        },
                        {
                          "text": "대식세포 (Macrophages)",
                          "id": "대식세포-macrophages",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원 처리 및 제시: MHC",
                      "id": "항원-처리-및-제시-mhc",
                      "children": null
                    },
                    {
                      "text": "T 세포의 종류",
                      "id": "t-세포의-종류",
                      "children": [
                        {
                          "text": "CD4+ T 세포",
                          "id": "cd4-t-세포",
                          "children": null
                        },
                        {
                          "text": "CD8+ T 세포",
                          "id": "cd8-t-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
                      "id": "t-도우미-세포-cd4-t-세포의-활성화-및-분화",
                      "children": [
                        {
                          "text": "TH17 세포",
                          "id": "th17-세포",
                          "children": null
                        },
                        {
                          "text": "TH1 세포",
                          "id": "th1-세포",
                          "children": null
                        },
                        {
                          "text": "TH2 세포",
                          "id": "th2-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "조절 T 세포 (Treg)",
                      "id": "조절-t-세포-treg",
                      "children": null
                    },
                    {
                      "text": "세포독성 T 림프구 (CD8+ T 세포)",
                      "id": "세포독성-t-림프구-cd8-t-세포",
                      "children": [
                        {
                          "text": "세포자멸사 (Apoptosis)",
                          "id": "세포자멸사-apoptosis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역계에 의한 세포외 살상",
                      "id": "면역계에-의한-세포외-살상",
                      "children": [
                        {
                          "text": "자연살해 (NK) 세포",
                          "id": "자연살해-nk-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포성 면역에 관여하는 주요 세포 기능",
                      "id": "세포성-면역에-관여하는-주요-세포-기능",
                      "children": null
                    },
                    {
                      "text": "항체 의존성 세포 매개 세포독성 (ADCC)",
                      "id": "항체-의존성-세포-매개-세포독성-adcc",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "T 세포가 성숙하는 주요 장소는 어디인가요?",
                    "options": [
                      "골수",
                      "비장",
                      "흉선",
                      "림프절"
                    ],
                    "answerIndex": 2,
                    "explanation": "T 세포는 흉선(thymus)에서 성숙 과정을 거칩니다."
                  },
                  {
                    "question": "다음 중 세포독성 T 림프구(CTL)의 주된 기능은 무엇인가요?",
                    "options": [
                      "B 세포 활성화",
                      "대식세포 활성화",
                      "감염된 자가 세포 파괴",
                      "염증 반응 촉진"
                    ],
                    "answerIndex": 2,
                    "explanation": "세포독성 T 림프구(CTL)는 감염된 자가 세포나 암세포를 인식하고 세포자멸사를 유도하여 파괴하는 역할을 합니다."
                  },
                  {
                    "question": "다음 중 항원제시세포(APC)에 해당하지 않는 것은 무엇인가요?",
                    "options": [
                      "수지상 세포",
                      "대식세포",
                      "T 도우미 세포",
                      "B 세포"
                    ],
                    "answerIndex": 2,
                    "explanation": "수지상 세포, 대식세포, B 세포는 모두 항원제시세포(APC)의 역할을 수행합니다. T 도우미 세포는 APC에 의해 활성화되는 세포이지, 스스로 항원을 제시하는 세포는 아닙니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75f3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1056 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역학적 기억",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 (기억 또는 아남네스틱) 반응은 항원에 두 번째 노출된 후에 발생합니다. 이 반응은 더 빠르고, 며칠 동안 지속되며, 그 규모가 훨씬 더 큽니다. 초기 노출에 반응하여 생성된 기억 세포는 이차 노출에 의해 활성화됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "초기 IgM 반응이 IgG, IgE 또는 IgA로 전환되는 '클래스 전환(Class switching)' 현상이 이차 반응에서 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체 역가(Antibody titer)는 혈청 내 항체의 상대적인 양을 나타내며, 체액 면역 반응의 강도를 반영합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "체액 면역",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "일차 면역 반응",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "제공된 텍스트에는 일차 면역 반응에 대한 구체적인 내용은 포함되어 있지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이차 면역 반응",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 면역 반응은 '면역학적 기억' 섹션에서 상세히 설명된 바와 같이, 항원에 대한 두 번째 노출 시 발생하는 빠르고 강력하며 지속적인 반응입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역의 유형",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "자연 획득 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "자연 획득 능동 면역은 감염을 통해 발생하며, 신체가 항원에 직접 노출되어 면역 반응을 일으키고 기억 세포를 형성하는 것을 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자연 획득 수동 면역은 태반을 통해 또는 초유를 통해 어머니로부터 항체를 전달받아 발생하는 면역입니다. 이는 일시적인 면역을 제공합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인공 획득 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "인공 획득 능동 면역은 예방 접종(백신 접종)을 통해 발생합니다. 이는 약화되거나 비활성화된 항원을 주입하여 신체 스스로 면역 반응을 일으키고 기억 세포를 형성하도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인공 획득 수동 면역은 항체 주사를 통해 발생합니다. 이는 특정 질병에 대한 즉각적인 보호를 제공하지만, 신체가 스스로 면역 반응을 일으킨 것이 아니므로 기억 세포가 형성되지 않아 일시적입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "관련 용어",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청(Antiserum)은 항체를 포함하는 혈액 유래 액체입니다. 혈청학(Serology)은 항체와 항원 간의 반응을 연구하는 학문입니다. 글로불린(Globulins)은 혈청 단백질을 총칭하며, 감마(γ) 글로불린은 항체를 포함하는 혈청 분획입니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 면역학적 기억과 적응성 면역의 다양한 유형에 대해 설명합니다. 면역학적 기억은 항원에 두 번째 노출되었을 때 발생하는 이차 면역 반응(더 빠르고 강력하며 지속적)의 특징과 클래스 전환, 그리고 항체 역가의 개념을 포함합니다. 적응성 면역은 자연 획득(능동/수동)과 인공 획득(능동/수동) 면역으로 분류되며, 각각의 특징과 발생 원리를 다룹니다. 또한, 혈청, 혈청학, 글로불린, 감마 글로불린과 같은 관련 용어의 정의도 제공합니다.",
                  "keyConcepts": [
                    {
                      "term": "면역학적 기억",
                      "definition": "항원에 대한 첫 노출 후 형성되어, 재노출 시 더 빠르고 강력한 이차 면역 반응을 유도하는 능력."
                    },
                    {
                      "term": "이차 면역 반응",
                      "definition": "항원에 두 번째 노출되었을 때 나타나는 면역 반응으로, 일차 반응보다 빠르고 강하며 오래 지속되는 특징을 가집니다."
                    },
                    {
                      "term": "적응성 면역의 유형",
                      "definition": "면역 획득 방식에 따라 자연 획득 능동/수동 면역과 인공 획득 능동/수동 면역으로 나뉩니다."
                    },
                    {
                      "term": "클래스 전환",
                      "definition": "초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "이차 (기억 또는 아남네스틱) 반응",
                      "definition": "항원에 두 번째 노출되었을 때 발생하는 면역 반응."
                    },
                    {
                      "term": "클래스 전환",
                      "definition": "면역 반응 시 초기 IgM 항체에서 IgG, IgE, IgA 등 다른 항체 유형으로 전환되는 현상."
                    },
                    {
                      "term": "항체 역가",
                      "definition": "혈청 내 항체의 상대적인 양을 나타내는 지표."
                    },
                    {
                      "term": "자연 획득 능동 면역",
                      "definition": "감염을 통해 자연적으로 항원에 노출되어 획득하는 면역."
                    },
                    {
                      "term": "인공 획득 능동 면역",
                      "definition": "예방 접종(백신)을 통해 인위적으로 항원에 노출되어 획득하는 면역."
                    },
                    {
                      "term": "혈청",
                      "definition": "항체를 포함하는 혈액 유래 액체."
                    },
                    {
                      "term": "감마 글로불린",
                      "definition": "항체를 포함하는 혈청 단백질 분획."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역학적 기억",
                      "id": "immunological-memory",
                      "children": [
                        {
                          "text": "이차 면역 반응의 특성",
                          "id": "secondary-immune-response-characteristics",
                          "children": null
                        },
                        {
                          "text": "클래스 전환 및 기억 세포",
                          "id": "class-switching-and-memory-cells",
                          "children": null
                        },
                        {
                          "text": "항체 역가",
                          "id": "antibody-titer",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "체액 면역",
                      "id": "humoral-immunity",
                      "children": [
                        {
                          "text": "일차 면역 반응",
                          "id": "primary-immune-response",
                          "children": null
                        },
                        {
                          "text": "이차 면역 반응",
                          "id": "secondary-immune-response-humoral",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역의 유형",
                      "id": "types-of-adaptive-immunity",
                      "children": [
                        {
                          "text": "자연 획득 면역",
                          "id": "naturally-acquired-immunity",
                          "children": [
                            {
                              "text": "자연 획득 능동 면역",
                              "id": "naturally-acquired-active-immunity",
                              "children": null
                            },
                            {
                              "text": "자연 획득 수동 면역",
                              "id": "naturally-acquired-passive-immunity",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "인공 획득 면역",
                          "id": "artificially-acquired-immunity",
                          "children": [
                            {
                              "text": "인공 획득 능동 면역",
                              "id": "artificially-acquired-active-immunity",
                              "children": null
                            },
                            {
                              "text": "인공 획득 수동 면역",
                              "id": "artificially-acquired-passive-immunity",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "관련 용어",
                          "id": "related-terms",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "이차 면역 반응의 주요 특징이 아닌 것은 무엇입니까?",
                    "options": [
                      "일차 반응보다 느리게 발생한다.",
                      "더 오랫동안 지속된다.",
                      "규모가 더 크다.",
                      "기억 세포에 의해 활성화된다."
                    ],
                    "answerIndex": 0,
                    "explanation": "이차 면역 반응은 일차 반응보다 '더 빠르게' 발생하며, 더 오랫동안 지속되고 규모가 더 크다는 특징을 가집니다."
                  },
                  {
                    "question": "예방 접종(백신 접종)을 통해 획득하는 면역 유형은 무엇입니까?",
                    "options": [
                      "자연 획득 능동 면역",
                      "자연 획득 수동 면역",
                      "인공 획득 능동 면역",
                      "인공 획득 수동 면역"
                    ],
                    "answerIndex": 2,
                    "explanation": "예방 접종은 인위적으로 항원을 주입하여 신체 스스로 면역 반응을 일으키도록 유도하는 '인공 획득 능동 면역'에 해당합니다."
                  },
                  {
                    "question": "면역학적 기억에서 '클래스 전환'은 무엇을 의미합니까?",
                    "options": [
                      "면역 세포의 종류가 바뀌는 것",
                      "초기 IgM 반응이 다른 유형의 항체(IgG, IgE, IgA)로 바뀌는 것",
                      "항체가 항원에 결합하는 방식이 바뀌는 것",
                      "면역 반응의 강도가 약해지는 것"
                    ],
                    "answerIndex": 1,
                    "explanation": "클래스 전환은 초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상을 말합니다."
                  }
                ]
              },
              {
                "title": "면역학의 실제 적용: 백신",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 3538 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "백신 개요",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역학의 실제 적용 중 하나인 백신은 질병 예방에 있어 핵심적인 역할을 합니다. 백신의 역사는 천연두 접종법(Variolation)에서 시작되었는데, 이는 천연두를 피부에 접종하여 질병을 예방하는 방식이었습니다. 이후 제너(Jenner)는 우두를 접종하여 천연두를 예방하는 방법을 발견했습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "백신(Vaccine)이라는 용어는 파스퇴르(Pasteur)에 의해 만들어졌으며, 'vacca'(소)에서 유래했습니다. 백신은 면역을 유도하는 유기체 또는 유기체의 일부 현탁액으로 정의됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 기능 및 원리",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 접종은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이는 실제 병원체에 노출되었을 때 빠르고 강렬한 이차 면역 반응을 생성하는 데 기여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "집단 면역(Herd immunity)은 인구 대부분의 면역 상태를 의미하며, 감수성 있는 개체의 부족으로 질병 발생이 산발적으로 나타나게 하여 전염병 확산을 막는 중요한 효과를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CDC 권장 세균성 질환 백신",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "미국 질병통제예방센터(CDC)는 다양한 세균성 질환 예방을 위한 백신을 권장하고 있습니다. 이에는 헤모필루스 인플루엔자 b형 수막염, 수막구균성 수막염, 폐렴구균성 폐렴, 파상풍, 디프테리아, 백일해 백신 등이 포함됩니다. 각 백신은 특정 연령대 또는 위험군에 대한 권장 사항과 추가 접종 여부가 명시되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CDC 권장 바이러스성 질환 백신",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "CDC는 또한 수두, A형 간염, B형 간염, 대상포진, 인유두종바이러스, 인플루엔자, 홍역, 유행성 이하선염, 소아마비, 광견병, 로타바이러스, 풍진, 천연두 등 다양한 바이러스성 질환 예방을 위한 백신을 권장하고 있습니다. 이들 백신 역시 접종 대상, 시기, 그리고 추가 접종의 필요성에 대한 구체적인 지침을 따릅니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 종류 및 특성",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "약독화 생백신 (Live attenuated vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "약독화 생백신은 약화된 병원체를 사용하여 실제 감염과 유사한 면역 반응을 유도하며, 평생 지속되는 세포성 및 체액성 면역을 부여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "불활성화 사백신 (Inactivated killed vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "불활성화 사백신은 생백신보다 안전하지만, 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "서브유닛 백신 (Subunit vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "서브유닛 백신은 항원성 조각을 사용하여 면역 반응을 자극합니다. 유전적 변형을 통해 생산되는 서브유닛 백신을 재조합 백신(Recombinant vaccines)이라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "톡소이드 (Toxoids)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "톡소이드는 불활성화된 독소이며, 항독소(Antitoxins)는 독소에 대한 항체를 포함하는 혈청입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "VLP 백신은 온전한 바이러스와 유사하지만 바이러스 유전 물질을 포함하지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다당류 백신 (Polysaccharide vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다당류 백신은 병원체의 캡슐 분자로 만들어지며 면역원성이 강하지 않습니다. 캡슐 다당류에 대한 면역 반응이 약한 어린이 질병에 사용되는 백신을 접합 백신(Conjugated vaccines)이라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "핵산(DNA) 백신은 DNA에 암호화된 단백질 항원을 생성하기 위해 주사된 DNA를 사용하며, 체액성 및 세포성 면역을 모두 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "재조합 벡터 백신 (Recombinant vector vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "재조합 벡터 백신은 항원을 코딩하는 유전자를 전달하도록 유전적으로 변형된 비병원성 바이러스 또는 박테리아를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "RNA 백신 (RNA vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "RNA 백신은 새로운 유형의 백신으로, 특정 항원 단백질을 생산하도록 세포에 지시하는 RNA 서열을 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신 생산, 전달 방법 및 제형",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 개발은 동물 숙주를 사용하지 않는 방향으로 발전하고 있으며, 식물을 백신 공급원으로 활용하는 연구도 진행 중입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "경구 백신 및 건조 백신(피부 패치)의 개발이 증가하고 있으며, 나노패치(Nanopatch)는 건조 형태의 백신을 피부에 전달하여 냉장 보관이 필요 없으며 다수의 항원제시세포(APC)를 활용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다중 조합 백신, 만성 질환 백신 개발, 그리고 세포성 면역 개발을 위한 \"역 백신학(Reverse vaccinology)\" 연구도 활발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 미국에서는 명반(Alums)과 모노포스포릴 지질 A(monophosphoryl lipid A)만이 승인되어 있으며, 선천 면역 반응을 개선하는 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "마이크로바이옴과 경구 백신 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "젖산균인 비피도박테리움(Bifidobacterium)은 장내 마이크로바이옴의 정상적인 일부이며, 마이크로바이옴이 경구 백신에 대한 반응을 향상시킬 수 있다는 연구가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 안전성",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "드물게 백신이 질병을 유발할 수 있지만, MMR 백신이 자폐증과 연관되어 있다는 의학적 또는 과학적 증거는 없습니다. 백신은 어린이의 감염성 질환을 예방하는 가장 안전하고 효과적인 수단으로 간주됩니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 백신의 역사적 배경, 기능, 다양한 종류, 생산 및 전달 방법, 그리고 안전성에 대해 설명합니다. 백신은 일차 면역 반응을 유도하여 항체와 기억 세포를 형성하고, 이를 통해 집단 면역을 구축하여 질병 확산을 막는 원리를 가지고 있습니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 여러 유형의 백신이 각자의 특성과 함께 소개되며, 아쥬반트의 역할과 백신 안전성에 대한 중요한 정보도 포함되어 있습니다.",
                  "keyConcepts": [
                    {
                      "term": "집단 면역 (Herd Immunity)",
                      "definition": "인구 대부분이 면역을 가지게 되어 감수성 개체의 부족으로 질병 발생이 산발적으로 나타나게 하는 현상으로, 전염병 확산을 막는 데 중요합니다."
                    },
                    {
                      "term": "백신의 종류 (Types of Vaccines)",
                      "definition": "약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 다양한 백신 유형이 있으며, 각각 다른 방식으로 면역 반응을 유도합니다."
                    },
                    {
                      "term": "아쥬반트 (Adjuvants)",
                      "definition": "백신의 효능을 높이고 면역 반응을 강화하기 위해 백신에 첨가되는 화학 물질입니다. 주로 선천 면역 반응을 개선하는 역할을 합니다."
                    },
                    {
                      "term": "기억 세포 (Memory Cells)",
                      "definition": "백신 접종 후 형성되는 면역 세포로, 실제 병원체에 재노출되었을 때 빠르고 강렬한 이차 면역 반응을 가능하게 하여 장기적인 면역력을 제공합니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "천연두 접종법 (Variolation)",
                      "definition": "천연두를 피부에 접종하여 면역을 유도하던 초기 질병 예방 방법입니다."
                    },
                    {
                      "term": "백신 접종 (Vaccination)",
                      "definition": "면역을 유도하기 위해 유기체 또는 유기체의 일부를 현탁액 형태로 인체에 주입하는 행위를 말합니다."
                    },
                    {
                      "term": "약독화 생백신 (Live Attenuated Vaccine)",
                      "definition": "병원체를 약화시켜 만든 백신으로, 실제 감염과 유사한 면역 반응을 유도하며 세포성 및 체액성 면역을 부여합니다."
                    },
                    {
                      "term": "불활성화 사백신 (Inactivated Killed Vaccine)",
                      "definition": "죽은 병원체나 그 일부를 사용하여 만든 백신으로, 약독화 생백신보다 안전하지만 주로 체액성 면역을 유도하고 반복적인 추가 접종이 필요합니다."
                    },
                    {
                      "term": "서브유닛 백신 (Subunit Vaccine)",
                      "definition": "병원체의 특정 항원성 조각만을 사용하여 만든 백신으로, 면역 반응을 자극합니다."
                    },
                    {
                      "term": "톡소이드 (Toxoid)",
                      "definition": "독소의 독성을 제거하고 면역원성만 남긴 백신으로, 독소에 의해 발생하는 질병을 예방하는 데 사용됩니다."
                    },
                    {
                      "term": "아쥬반트 (Adjuvant)",
                      "definition": "백신의 면역 반응을 강화하기 위해 첨가되는 물질로, 백신의 효능을 높이고 선천 면역 반응을 개선합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "백신 개요",
                      "id": "백신-개요",
                      "children": [
                        {
                          "text": "백신의 역사",
                          "id": "백신의-역사",
                          "children": null
                        },
                        {
                          "text": "백신의 정의",
                          "id": "백신의-정의",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신의 기능 및 원리",
                      "id": "백신의-기능-및-원리",
                      "children": [
                        {
                          "text": "면역 반응 유도",
                          "id": "면역-반응-유도",
                          "children": null
                        },
                        {
                          "text": "집단 면역",
                          "id": "집단-면역",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "CDC 권장 백신",
                      "id": "cdc-권장-백신",
                      "children": [
                        {
                          "text": "세균성 질환 백신",
                          "id": "세균성-질환-백신",
                          "children": null
                        },
                        {
                          "text": "바이러스성 질환 백신",
                          "id": "바이러스성-질환-백신",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신의 종류 및 특성",
                      "id": "백신의-종류-및-특성",
                      "children": [
                        {
                          "text": "약독화 생백신 (Live attenuated vaccines)",
                          "id": "약독화-생백신-live-attenuated-vaccines",
                          "children": null
                        },
                        {
                          "text": "불활성화 사백신 (Inactivated killed vaccines)",
                          "id": "불활성화-사백신-inactivated-killed-vaccines",
                          "children": null
                        },
                        {
                          "text": "서브유닛 백신 (Subunit vaccines)",
                          "id": "서브유닛-백신-subunit-vaccines",
                          "children": null
                        },
                        {
                          "text": "톡소이드 (Toxoids)",
                          "id": "톡소이드-toxoids",
                          "children": null
                        },
                        {
                          "text": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
                          "id": "바이러스-유사-입자-vlp-백신-virus-like-particle-vlp-vaccines",
                          "children": null
                        },
                        {
                          "text": "다당류 백신 (Polysaccharide vaccines)",
                          "id": "다당류-백신-polysaccharide-vaccines",
                          "children": null
                        },
                        {
                          "text": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
                          "id": "핵산-dna-백신-nucleic-acid-dna-vaccines",
                          "children": null
                        },
                        {
                          "text": "재조합 벡터 백신 (Recombinant vector vaccines)",
                          "id": "재조합-벡터-백신-recombinant-vector-vaccines",
                          "children": null
                        },
                        {
                          "text": "RNA 백신 (RNA vaccines)",
                          "id": "rna-백신-rna-vaccines",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신 생산, 전달 방법 및 제형",
                      "id": "백신-생산-전달-방법-및-제형",
                      "children": [
                        {
                          "text": "생산 기술의 발전",
                          "id": "생산-기술의-발전",
                          "children": null
                        },
                        {
                          "text": "새로운 전달 방식",
                          "id": "새로운-전달-방식",
                          "children": null
                        },
                        {
                          "text": "아쥬반트의 역할",
                          "id": "아쥬반트의-역할",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "마이크로바이옴과 경구 백신 반응",
                      "id": "마이크로바이옴과-경구-백신-반응",
                      "children": null
                    },
                    {
                      "text": "백신의 안전성",
                      "id": "백신의-안전성",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "백신 접종이 유도하는 주요 면역학적 반응은 무엇이며, 이 반응의 결과로 형성되는 중요한 세포는 무엇입니까?",
                    "options": [
                      "일차 면역 반응, 기억 세포",
                      "이차 면역 반응, 비만 세포",
                      "알레르기 반응, 형질 세포",
                      "자가면역 반응, T 세포"
                    ],
                    "answerIndex": 0,
                    "explanation": "백신은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이 기억 세포 덕분에 실제 병원체 노출 시 빠르고 강렬한 이차 면역 반응이 가능해집니다."
                  },
                  {
                    "question": "다음 중 약독화 생백신과 불활성화 사백신의 주요 차이점에 대한 설명으로 올바른 것은 무엇입니까?",
                    "options": [
                      "약독화 생백신은 평생 면역을 부여하지만, 불활성화 사백신은 추가 접종이 필요하다.",
                      "약독화 생백신은 주로 체액성 면역을 유도하고, 불활성화 사백신은 세포성 면역을 유도한다.",
                      "약독화 생백신은 불활성화 사백신보다 안전하다.",
                      "약독화 생백신은 유전 물질을 포함하지 않지만, 불활성화 사백신은 포함한다."
                    ],
                    "answerIndex": 0,
                    "explanation": "약독화 생백신은 실제 감염과 유사하게 평생 지속되는 세포성 및 체액성 면역을 부여하는 경향이 있는 반면, 불활성화 사백신은 더 안전하지만 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다."
                  },
                  {
                    "question": "백신에 첨가되어 효능을 향상시키고 선천 면역 반응을 개선하는 화학 첨가제는 무엇이라고 불립니까?",
                    "options": [
                      "항독소",
                      "톡소이드",
                      "아쥬반트",
                      "폴리사카라이드"
                    ],
                    "answerIndex": 2,
                    "explanation": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 선천 면역 반응을 개선하는 역할을 합니다."
                  }
                ]
              },
              {
                "title": "면역학의 실제 적용: 진단 면역학",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 2187 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "진단 면역학 개요",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "민감도(Sensitivity): 검사가 진양성 표본에 대해 반응할 확률",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "특이도(Specificity): 양성 검사가 진음성 표본에 대해 반응하지 않을 확률",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역학 기반 진단 검사는 체액 항체와 항원의 상호작용을 이용한다. 알려진 항체를 통해 미지의 병원체를 식별하거나, 알려진 병원체를 통해 미지의 항체를 식별할 수 있다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "단일클론 항체 (Monoclonal Antibodies)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "하이브리도마(Hybridoma): \"불멸의\" 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합한 세포.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "하이브리도마는 단일클론 항체(Mabs)를 생산한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Mabs는 균일하고, 특이성이 높으며, 대량 생산이 가능하다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "진단 도구 및 인체 치료에 사용된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류마티스 관절염에서 TNF를 중화하거나, 비만세포와 호염기구에 IgE 결합을 막아 알레르기성 천식을 치료하는 데 활용된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주로 쥐 세포에서 유래하여 부작용을 일으킬 수 있다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "키메라 단일클론 항체: 쥐의 가변 영역과 인간의 불변 영역을 가진 Mabs.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인간화 항체: 쥐 항원 결합 부위를 제외하고 대부분 인간 유래인 Mabs.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "완전 인간 항체: 쥐에 삽입된 인간 유전자로부터 생산된 Mabs.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "단일클론 항체의 생산",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "침강 반응 (Precipitation Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "가용성 항원과 항체가 반응하여 격자(lattices)라고 불리는 크고 서로 맞물린 응집체를 형성하는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원-항체 복합체가 형성된 후, 용액에서 침전되는 격자가 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강링 테스트(Precipitin ring test): 최적의 항원-항체 비율 지점에서 흐린 선이 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역확산 테스트(Immunodiffusion tests): 한천 젤 배지에서 수행되는 침강 반응이다. 최적의 항원-항체 비율 지점에서 침전물이 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 전기영동(Immunoelectrophoresis): 전기영동과 면역확산을 결합한 것으로, 인간 혈청의 단백질을 분리한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "응집 반응 (Agglutination Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "입자성 항원이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 응집 테스트(Direct agglutination tests): 큰 세포성 항원에 대한 항체를 검출한다. 혈청 항체 농도(역가, titer)를 측정하며, 역가 증가는 질병에 대한 더 큰 면역을 나타낸다. 혈청 전환(Seroconversion)은 질병이 진행됨에 따라 역가에 유의미한 변화가 나타나는 것을 의미한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접(수동) 응집 테스트(Indirect (passive) agglutination tests): 항체가 입자에 부착된 가용성 항원과 반응하거나 그 반대로 반응한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈구 응집(Hemagglutination): 적혈구 표면 항원과 보체 항체의 응집으로, 혈액형 판별에 사용된다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 면역학 학습 목표 (1)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "응집 테스트와 침강 테스트의 차이점을 구별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈구 응집을 정의한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "중화 테스트가 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강 테스트와 중화 테스트의 차이점을 구별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 고정 테스트의 기본 원리를 설명한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "중화 반응 (Neutralization Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스성 혈구 응집(Viral hemagglutination): 바이러스가 항원-항체 반응 없이 적혈구를 응집시키는 현상 (예: 볼거리, 홍역, 인플루엔자).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체(항독소)에 의해 외독소나 바이러스의 유해한 효과가 차단되는 항원-항체 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스성 혈구 응집 억제 테스트(Viral hemagglutination inhibition test): 바이러스 아형을 분류하는 데 사용된다. 바이러스와 적혈구를 환자의 혈청과 혼합한다. 혈청에 바이러스에 대한 항체가 포함되어 있으면, 항체가 바이러스를 중화하여 혈구 응집을 억제한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 고정 반응 (Complement-Fixation Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 고정(Complement fixation): 보체 혈청 단백질이 항원-항체 복합체에 결합하고 고정되는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "소량의 항체를 검출할 수 있다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강 또는 응집 반응에 적합하지 않은 항체에도 사용될 수 있다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 면역학 학습 목표 (2)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 및 간접 형광 항체 테스트를 비교하고 대조한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 및 간접 ELISA 테스트가 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "웨스턴 블롯이 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "단일클론 항체의 중요성을 설명한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "형광 염료를 항체와 결합시킨다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 FA 테스트: 임상 검체에서 미생물을 식별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접 FA 테스트: 혈청에서 특정 항체를 검출한다. 항인간 면역 혈청 글로불린(anti-HISG)을 추가하며, 결과가 양성이면 혈청 내 모든 항체와 반응한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "형광 활성화 세포 분류기(Fluorescence-activated cell sorter, FACS): 레이저 빔이 세포를 포함하는 액적에 닿으면, 감지기가 표면 분자의 크기와 형광을 측정한다. 세포에 전하를 부여하여 세포를 분리한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "효소결합 면역흡착 분석법 (ELISA)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 ELISA: 항원을 검출한다. 항원을 포함하는 샘플을 항체와 혼합한다. 효소 연결 항체가 항원과 반응한다. 연결된 효소를 위한 기질을 추가하여 색이 생성되는 것으로 검출한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접 ELISA: 항체를 검출한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "웨스턴 블롯 (Western Blotting)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "전기영동과 블롯을 통해 단백질을 식별한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 및 치료 면역학의 미래",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "인간의 판단과 인력이 덜 필요한 테스트가 개발될 것이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "PCR 및 DNA 프로브가 활용될 것이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "개발도상국을 위한 저렴하고 간단한 테스트가 필요하다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "질병 예방 및 치료에 기여할 것이다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 면역학의 실제 적용, 특히 진단 면역학에 대해 설명합니다. 검사의 민감도와 특이도 같은 기본 개념부터 시작하여, 단일클론 항체의 생산, 종류 및 치료적 활용에 대해 다룹니다. 또한, 침강 반응, 응집 반응, 중화 반응, 보체 고정 반응, 형광 항체 기법, ELISA, 웨스턴 블롯 등 다양한 면역학 기반 진단 테스트의 원리와 적용 방법을 상세히 설명합니다. 마지막으로 진단 및 치료 면역학의 미래 방향에 대해서도 간략하게 언급합니다.",
                  "keyConcepts": [
                    {
                      "term": "진단 면역학의 기본 원리",
                      "definition": "검사의 민감도(Sensitivity)와 특이도(Specificity)는 진단 검사의 정확성을 나타내는 핵심 지표이며, 항원-항체 상호작용이 면역학 기반 진단 테스트의 근간을 이룬다."
                    },
                    {
                      "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                      "definition": "하이브리도마 기술을 통해 대량 생산되는 균일하고 고도로 특이적인 항체로, 진단 및 류마티스 관절염, 알레르기성 천식 등 다양한 질병의 치료에 활용된다. 쥐 유래 항체는 부작용을 일으킬 수 있어 키메라, 인간화, 완전 인간 항체 등으로 발전하고 있다."
                    },
                    {
                      "term": "면역 반응 기반 진단 테스트 유형",
                      "definition": "침강(Precipitation), 응집(Agglutination), 중화(Neutralization), 보체 고정(Complement-Fixation), 형광 항체(Fluorescent-Antibody), ELISA(Enzyme-Linked Immunosorbent Assay), 웨스턴 블롯(Western Blotting) 등 항원-항체 반응을 시각적으로 또는 정량적으로 확인하여 질병을 진단하는 다양한 기법들이 있다."
                    },
                    {
                      "term": "항체 역가 측정",
                      "definition": "직접 응집 테스트 등을 통해 혈청 내 특정 항체의 농도(역가)를 측정하는 것으로, 역가 증가는 질병에 대한 면역력 증가를 나타내며, 혈청 전환은 질병 진행에 따른 역가의 유의미한 변화를 의미한다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "민감도 (Sensitivity)",
                      "definition": "검사가 진양성 표본에 대해 반응할 확률"
                    },
                    {
                      "term": "특이도 (Specificity)",
                      "definition": "양성 검사가 진음성 표본에 대해 반응하지 않을 확률"
                    },
                    {
                      "term": "하이브리도마 (Hybridoma)",
                      "definition": "암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포"
                    },
                    {
                      "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                      "definition": "하이브리도마에서 생산되는 균일하고 특이성이 높은 항체로, 진단 및 치료에 사용된다."
                    },
                    {
                      "term": "침강 반응 (Precipitation Reactions)",
                      "definition": "가용성 항원과 항체가 반응하여 불용성 복합체(격자)를 형성하고 침전되는 반응"
                    },
                    {
                      "term": "응집 반응 (Agglutination Reactions)",
                      "definition": "입자성 항원(예: 세포)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응"
                    },
                    {
                      "term": "중화 반응 (Neutralization Reactions)",
                      "definition": "항체가 독소나 바이러스의 유해한 효과를 차단하는 항원-항체 반응"
                    },
                    {
                      "term": "보체 고정 반응 (Complement-Fixation Reactions)",
                      "definition": "보체 단백질이 항원-항체 복합체에 결합하고 고정되는 반응으로, 소량의 항체도 검출 가능하다."
                    },
                    {
                      "term": "효소결합 면역흡착 분석법 (ELISA)",
                      "definition": "효소와 항체를 이용하여 항원 또는 항체를 검출하는 면역학적 분석법으로, 색 변화를 통해 결과를 확인한다."
                    },
                    {
                      "term": "웨스턴 블롯 (Western Blotting)",
                      "definition": "전기영동으로 분리된 단백질을 막에 옮겨 특정 항체를 이용하여 식별하는 기법"
                    }
                  ],
                  "outline": [
                    {
                      "text": "진단 면역학 개요",
                      "id": "진단-면역학-개요",
                      "children": null
                    },
                    {
                      "text": "단일클론 항체 (Monoclonal Antibodies)",
                      "id": "단일클론-항체-monoclonal-antibodies",
                      "children": [
                        {
                          "text": "단일클론 항체의 생산",
                          "id": "단일클론-항체의-생산",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "침강 반응 (Precipitation Reactions)",
                      "id": "침강-반응-precipitation-reactions",
                      "children": null
                    },
                    {
                      "text": "응집 반응 (Agglutination Reactions)",
                      "id": "응집-반응-agglutination-reactions",
                      "children": null
                    },
                    {
                      "text": "진단 면역학 학습 목표 (1)",
                      "id": "진단-면역학-학습-목표-1",
                      "children": null
                    },
                    {
                      "text": "중화 반응 (Neutralization Reactions)",
                      "id": "중화-반응-neutralization-reactions",
                      "children": null
                    },
                    {
                      "text": "보체 고정 반응 (Complement-Fixation Reactions)",
                      "id": "보체-고정-반응-complement-fixation-reactions",
                      "children": null
                    },
                    {
                      "text": "진단 면역학 학습 목표 (2)",
                      "id": "진단-면역학-학습-목표-2",
                      "children": null
                    },
                    {
                      "text": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
                      "id": "형광-항체-기법-fluorescent-antibody-techniques",
                      "children": null
                    },
                    {
                      "text": "효소결합 면역흡착 분석법 (ELISA)",
                      "id": "효소결합-면역흡착-분석법-elisa",
                      "children": null
                    },
                    {
                      "text": "웨스턴 블롯 (Western Blotting)",
                      "id": "웨스턴-블롯-western-blotting",
                      "children": null
                    },
                    {
                      "text": "진단 및 치료 면역학의 미래",
                      "id": "진단-및-치료-면역학의-미래",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 하이브리도마(Hybridoma)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
                    "options": [
                      "암성 B 세포와 항체 생산 정상 B 세포를 결합한 세포",
                      "항원을 직접 생산하는 세포",
                      "체내에서 바이러스성 감염을 중화하는 세포",
                      "면역 반응을 억제하는 데 사용되는 세포"
                    ],
                    "answerIndex": 0,
                    "explanation": "하이브리도마는 '불멸의' 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포입니다."
                  },
                  {
                    "question": "침강 반응(Precipitation Reactions)과 응집 반응(Agglutination Reactions)의 주요 차이점은 무엇입니까?",
                    "options": [
                      "침강 반응은 가용성 항원을, 응집 반응은 입자성 항원을 사용한다.",
                      "침강 반응은 항체를 검출하고, 응집 반응은 항원을 검출한다.",
                      "침강 반응은 육안으로 볼 수 없지만, 응집 반응은 육안으로 볼 수 있다.",
                      "침강 반응은 보체를 필요로 하지만, 응집 반응은 그렇지 않다."
                    ],
                    "answerIndex": 0,
                    "explanation": "침강 반응은 가용성 항원과 항체의 상호작용으로 불용성 복합체가 형성되는 것이고, 응집 반응은 입자성 항원(예: 세포 또는 입자에 부착된 항원)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 것입니다."
                  },
                  {
                    "question": "효소결합 면역흡착 분석법(ELISA)에 대한 설명으로 옳지 않은 것은 무엇입니까?",
                    "options": [
                      "직접 ELISA는 항원을 검출하는 데 사용된다.",
                      "간접 ELISA는 항체를 검출하는 데 사용된다.",
                      "효소 연결 항체가 항원 또는 항체와 반응하여 색 변화를 유도한다.",
                      "ELISA는 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법이다."
                    ],
                    "answerIndex": 3,
                    "explanation": "ELISA는 효소와 항체를 이용하여 항원 또는 항체를 검출하며 색 변화를 통해 결과를 확인합니다. 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법은 웨스턴 블롯(Western Blotting)입니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 과민 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 3760 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "과민 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "과민 반응(Hypersensitivity)은 정상 범위를 넘어선 과도한 항원(알레르겐) 반응을 의미합니다. 이는 이전에 항원에 노출되어 민감해진 경우에 발생합니다. 과민 반응은 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 유형으로 분류됩니다. 과민 반응을 연구하는 학문은 면역병리학(Immunopathology)이라고 합니다. 위생 가설(Hygiene hypothesis)은 병원균에 대한 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다고 제안합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "과민 반응의 유형",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "제1형 (아나필락시스형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 30분 미만이 소요됩니다. IgE 항체가 비만세포나 호염기구에 결합하여 비만세포 또는 호염기구의 탈과립을 유발하고 히스타민과 같은 반응성 물질을 방출하게 합니다. 약물 주사 및 곤충 독에 의한 아나필락시스 쇼크, 건초열, 천식과 같은 일반적인 알레르기 증상이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제2형 (세포 독성형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 5-12시간이 소요됩니다. 항원이 표적 세포에 결합하는 IgM 및 IgG 항체 형성을 유발하며, 보체의 작용과 결합하여 표적 세포를 파괴합니다. 수혈 반응, Rh 부적합성이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제3형 (면역 복합체형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 3-8시간이 소요됩니다. 항체와 항원이 복합체를 형성하여 손상적인 염증을 유발합니다. 아르투스 반응, 혈청병이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제4형 (지연형 세포 매개성 또는 지연형 과민 반응)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 24-48시간이 소요됩니다. 항원이 세포독성 T 림프구(CTLs)를 활성화시켜 표적 세포를 사멸시킵니다. 이식 조직 거부 반응, 옻나무에 의한 접촉 피부염, 특정 만성 질환(예: 결핵) 등이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제1형 (아나필락시스형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이 반응은 항원에 민감해진 사람이 해당 항원에 재노출된 후 수 분 내에 발생합니다. 항원이 IgE 항체와 결합하며, IgE는 비만세포와 호염기구에 부착됩니다. 비만세포와 호염기구는 탈과립을 겪으며 다음과 같은 매개체를 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 히스타민: 혈액 모세혈관의 투과성을 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 류코트리엔: 평활근의 지속적인 수축을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 프로스타글란딘: 평활근에 영향을 미치고 점액 분비를 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원에 반응하여 생성된 IgE 항체는 비만세포와 호염기구를 감싸게 됩니다. 항원이 동일한 특이성을 가진 두 개의 인접한 항체 분자 사이의 간격을 연결할 때, 세포는 탈과립을 겪고 히스타민 및 기타 매개체를 방출합니다. 이는 항원과 반응하여 히스타민 및 기타 반응성 매개체 과립을 방출한 탈과립 비만세포의 모습입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전신 아나필락시스 (아나필락시스 쇼크)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항원에 민감해진 개체가 다시 노출될 때 발생합니다. 순환계 허탈 및 사망에 이를 수 있으며, 에피네프린으로 치료합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "국소 아나필락시스",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "주로 섭취되거나 흡입된 항원과 관련이 있습니다. 증상은 침입 경로에 따라 다르며, 두드러기, 건초열, 천식 등이 포함됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "아나필락시스 반응 예방",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "알레르겐을 식별하기 위한 피부 검사는 항원을 표피 아래에 접종하여 빠른 염증 반응(팽진)을 확인합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "탈감작(Desensitization)은 항원을 피부 아래에 증가하는 용량으로 주사하는 방법입니다. 이는 IgG를 생성하게 하는데, 이 IgG는 블로킹 항체(blocking antibodies) 역할을 하여 항원을 가로채고 중화시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제2형 (세포 독성형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "IgG 또는 IgM 항체와 항원성 세포의 결합에 의한 보체 활성화로 발생합니다. 이는 세포 용해 또는 대식세포에 의한 손상을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "ABO 혈액형 시스템",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "적혈구에 있는 특정 탄수화물 항원에 대해 항체가 형성됩니다. A 항원, B 항원 또는 둘 다를 가질 수 있습니다. O형 적혈구는 항원이 없습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "Rh 혈액형 시스템",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "인구의 85%에서 적혈구에 Rh 인자 항원(Rh+)이 발견됩니다. Rh+ 혈액이 Rh- 수혈자에게 주입되면 수혈자의 몸에서 항Rh 항체 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "용혈성 신생아 질환 (HDNB)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "Rh- 어머니가 Rh+ 태아를 임신할 경우 어머니의 몸에서 항Rh 항체가 생성됩니다. 첫 Rh+ 태아를 임신한 Rh- 어머니의 경우, 분만 중 태아의 Rh 항원이 어머니의 혈액으로 들어갈 수 있습니다. 이 태아 Rh 항원에 반응하여 어머니는 항Rh 항체를 생산할 것입니다. 두 번째 Rh+ 태아를 임신하게 되면, 어머니의 항Rh 항체가 태반을 통과하여 태아의 적혈구를 손상시킬 것입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "약물 유발 세포 독성 반응",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "혈소판 감소성 자반증 (Thrombocytopenic purpura)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "혈소판이 약물과 결합하여 항원성 복합체를 형성합니다. 항체와 보체가 혈소판을 파괴합니다. 약물(합텐)이 혈소판에 결합하여 합텐-혈소판 복합체를 형성합니다. 이 복합체는 합텐에 대한 항체 형성을 유도합니다. 항체와 보체의 작용은 혈소판 파괴를 일으킵s니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "무과립구증 (Agranulocytosis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "약물 유발 과립구의 면역 파괴입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "용혈성 빈혈 (Hemolytic anemia)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "약물 유발 적혈구의 면역 파괴입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제3형 (면역 복합체형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 혈청 내 가용성 항원에 대해 형성됩니다. 세포 아래 기저막에 침착되는 면역 복합체를 형성하여 보체를 활성화시키고 염증을 유발합니다. 면역 복합체는 혈관벽에 침착됩니다. 면역 복합체의 존재는 보체를 활성화시키고 호중구와 같은 염증 세포를 유인합니다. 호중구에서 방출된 효소는 기저막의 내피 세포에 손상을 입힙니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "아르투스 반응 (Arthus reaction)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "톡소이드 함유 백신의 드문 부작용입니다. 주사된 항원에 대해 이미 순환하는 IgG를 가진 환자에서 보체 활성화로 인해 사구체 및 기타 혈관벽에서 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "혈청병 (Serum sickness)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "이종 혈청 주입으로 인한 부종 및 염증과 함께 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제4형 (지연형 세포 매개성) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포에 의해 유발되는 세포 매개 면역 반응입니다. 이는 지연형 과민 반응으로 알려져 있습니다. 항원은 식세포화되어 T 세포 수용체에 제시되어 민감화를 유발합니다. 항원에 재노출되면 기억 세포가 파괴적인 사이토카인을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "알레르기성 접촉 피부염 (Allergic contact dermatitis)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "합텐이 피부의 단백질과 결합하여 면역 반응을 일으킵니다. 옻나무, 화장품, 금속, 라텍스 등에 대한 알레르기 반응이 여기에 해당합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본문은 면역 시스템 관련 질환 중 '과민 반응'에 대해 설명합니다. 과민 반응은 정상 범위를 넘어선 과도한 면역 반응으로, 이전 항원 노출로 인해 민감해진 상태에서 발생합니다. 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 주요 유형으로 분류되며, 각 유형은 발현 시간, 기전, 임상 증상 및 예시가 다릅니다. 제1형은 즉각적인 알레르기 반응(예: 아나필락시스 쇼크)을, 제2형은 세포 파괴(예: 수혈 부작용)를, 제3형은 면역 복합체 침착으로 인한 염증(예: 혈청병)을, 제4형은 T세포 매개 지연 반응(예: 접촉 피부염)을 특징으로 합니다. 각 유형의 발생 기전과 예방 및 치료법이 상세히 다루어집니다.",
                  "keyConcepts": [
                    {
                      "term": "과민 반응 (Hypersensitivity)",
                      "definition": "정상 범위를 넘어선 과도한 항원 반응으로, 이전에 항원에 노출되어 민감해진 경우에 발생합니다."
                    },
                    {
                      "term": "아나필락시스 (Anaphylaxis)",
                      "definition": "제1형 과민 반응의 심각한 형태로, 비만세포 및 호염기구의 탈과립으로 인한 매개체 방출로 발생하며, 전신 또는 국소적으로 나타나 생명을 위협할 수 있습니다."
                    },
                    {
                      "term": "위생 가설 (Hygiene Hypothesis)",
                      "definition": "병원균 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다는 가설입니다."
                    },
                    {
                      "term": "탈감작 (Desensitization)",
                      "definition": "알레르기 반응을 예방하기 위해 항원을 점진적으로 증가시켜 주사하는 치료법으로, 블로킹 항체(IgG) 생성을 유도하여 알레르겐을 중화시킵니다."
                    },
                    {
                      "term": "용혈성 신생아 질환 (HDNB)",
                      "definition": "Rh 혈액형 불일치로 인해 Rh- 어머니가 Rh+ 태아에 대한 항체를 생성하여 두 번째 Rh+ 태아의 적혈구를 파괴하는 질환입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "알레르겐 (Allergen)",
                      "definition": "알레르기 반응을 유발하는 항원입니다."
                    },
                    {
                      "term": "면역병리학 (Immunopathology)",
                      "definition": "과민 반응을 연구하는 학문입니다."
                    },
                    {
                      "term": "히스타민 (Histamine)",
                      "definition": "제1형 과민 반응 시 비만세포에서 방출되어 혈관 투과성을 증가시키는 주요 염증 매개체입니다."
                    },
                    {
                      "term": "류코트리엔 (Leukotrienes)",
                      "definition": "제1형 과민 반응 시 방출되어 평활근의 지속적인 수축을 유발하는 매개체입니다."
                    },
                    {
                      "term": "프로스타글란딘 (Prostaglandins)",
                      "definition": "제1형 과민 반응 시 방출되어 평활근에 영향을 미치고 점액 분비를 증가시키는 매개체입니다."
                    },
                    {
                      "term": "보체 (Complement)",
                      "definition": "면역 반응에서 항체와 함께 작용하여 세포 파괴를 돕는 단백질 시스템입니다."
                    },
                    {
                      "term": "합텐 (Hapten)",
                      "definition": "단독으로는 면역 반응을 유발하지 못하지만, 단백질과 결합 시 항원성을 띠는 작은 분자입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "과민 반응의 개요",
                      "id": "hypersensitivity-overview",
                      "children": [
                        {
                          "text": "정의 및 특징",
                          "id": "definition-features",
                          "children": null
                        },
                        {
                          "text": "과민 반응의 네 가지 유형",
                          "id": "four-types-hypersensitivity",
                          "children": null
                        },
                        {
                          "text": "면역병리학 및 위생 가설",
                          "id": "immunopathology-hygiene-hypothesis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "과민 반응 유형별 상세 설명",
                      "id": "detailed-hypersensitivity-types",
                      "children": [
                        {
                          "text": "제1형 과민 반응 (아나필락시스형)",
                          "id": "type-i-anaphylactic",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-i-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "매개체 (히스타민, 류코트리엔, 프로스타글란딘)",
                              "id": "type-i-mediators",
                              "children": null
                            },
                            {
                              "text": "전신 아나필락시스 및 국소 아나필락시스",
                              "id": "systemic-local-anaphylaxis",
                              "children": null
                            },
                            {
                              "text": "예방 및 치료",
                              "id": "type-i-prevention-treatment",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제2형 과민 반응 (세포 독성형)",
                          "id": "type-ii-cytotoxic",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-ii-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "ABO 혈액형 시스템",
                              "id": "abo-blood-group",
                              "children": null
                            },
                            {
                              "text": "Rh 혈액형 시스템 및 용혈성 신생아 질환",
                              "id": "rh-blood-group-hdnb",
                              "children": null
                            },
                            {
                              "text": "약물 유발 세포 독성 반응",
                              "id": "drug-induced-cytotoxic",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제3형 과민 반응 (면역 복합체형)",
                          "id": "type-iii-immune-complex",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-iii-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "아르투스 반응",
                              "id": "arthus-reaction",
                              "children": null
                            },
                            {
                              "text": "혈청병",
                              "id": "serum-sickness",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제4형 과민 반응 (지연형 세포 매개성)",
                          "id": "type-iv-delayed-cell-mediated",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-iv-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "알레르기성 접촉 피부염",
                              "id": "allergic-contact-dermatitis",
                              "children": null
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "제1형 과민 반응 시 혈액 모세혈관의 투과성을 증가시키는 주요 매개체는 무엇입니까?",
                    "options": [
                      "히스타민",
                      "류코트리엔",
                      "프로스타글란딘",
                      "사이토카인"
                    ],
                    "answerIndex": 0,
                    "explanation": "제1형 과민 반응은 비만세포의 탈과립을 통해 히스타민을 방출하며, 히스타민은 혈액 모세혈관의 투과성을 증가시키는 역할을 합니다."
                  },
                  {
                    "question": "이식 조직 거부 반응 및 접촉 피부염과 주로 관련된 과민 반응 유형은 무엇입니까?",
                    "options": [
                      "제1형 (아나필락시스형)",
                      "제2형 (세포 독성형)",
                      "제3형 (면역 복합체형)",
                      "제4형 (지연형 세포 매개성)"
                    ],
                    "answerIndex": 3,
                    "explanation": "제4형 과민 반응은 T세포에 의해 매개되는 지연형 반응으로, 이식 조직 거부 반응과 접촉 피부염이 대표적인 예시입니다."
                  },
                  {
                    "question": "아나필락시스 반응 예방을 위한 탈감작의 주요 기전은 무엇입니까?",
                    "options": [
                      "히스타민 방출 억제",
                      "IgE 항체 생성 촉진",
                      "비만세포 탈과립 유도",
                      "IgG 블로킹 항체 생성"
                    ],
                    "answerIndex": 3,
                    "explanation": "탈감작은 증가하는 용량의 항원 주사를 통해 IgG 블로킹 항체를 생성하게 하여, 이 항체가 알레르겐을 가로채고 중화시켜 IgE 매개 반응을 예방합니다."
                  }
                ]
              },
              {
                "title": "자가면역 질환의 이해: 유형 및 주요 사례",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1640 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "자가면역 질환 (AUTOIMMUNE DISEASES)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 체계가 자가 항원에 반응하여 장기에 손상을 입히는 질환입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자가면역은 자가 관용(self-tolerance)의 상실을 의미합니다. 이는 면역 체계가 자신과 비자신을 구별하는 능력을 잃어버릴 때 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자가면역 반응은 세포독성(Cytotoxic), 면역 복합체(Immune complex), 또는 세포 매개성(Cell-mediated)의 형태로 나타날 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 자가면역 반응 (CYTOTOXIC AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 세포 표면 항원과 반응하여 세포를 손상시키거나 기능을 방해하는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다발성 경화증 (Multiple sclerosis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "자가항체, T 세포, 그리고 대식세포가 신경의 미엘린 수초를 공격하여 신경 임펄스 전달을 손상시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "증상은 피로와 쇠약부터 심한 마비에 이릅니다. 원인은 알려지지 않았지만, 유전적 취약성 및/또는 감염성 물질과 관련될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "그레이브스병 (Graves' disease)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "갑상선 내 비정상 항체가 과도한 양의 호르몬을 생성하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "중증 근무력증 (Myasthenia gravis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 아세틸콜린 수용체를 코팅하여 근육이 신경 신호를 받지 못하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 복합체 자가면역 반응 (IMMUNE COMPLEX AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체와 보체의 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전신성 홍반성 루푸스 (Systemic lupus erythematosus)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "신장 사구체에 면역 복합체가 형성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "류마티스 관절염 (Rheumatoid arthritis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "관절에 면역 복합체가 형성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포 매개성 자가면역 반응 (CELL-MEDIATED AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조직을 공격하는 T 세포에 의해 매개되는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인슐린 의존성 당뇨병 (Insulin-dependent diabetes mellitus, 1형 당뇨병)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포가 인슐린 분비 세포를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "건선 및 건선성 관절염 (Psoriasis and psoriatic arthritis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "피부의 자가면역 질환입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "주요 자가면역 질환 및 원인 (SELECTED AUTOIMMUNE DISORDERS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다음은 몇 가지 주요 자가면역 질환과 가능한 원인입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "만성 피로 증후군: 신경 세포의 아세틸콜린 수용체에 항체가 부착되어 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류마티스 관절염: 연쇄상구균 항체에 대한 교차 반응.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "전신성 홍반성 루푸스: DNA에 대한 항체를 포함하는 면역 복합체.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다발성 경화증: T 세포와 대식세포가 미엘린 수초를 공격.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1형 당뇨병: T 세포가 인슐린 분비 세포를 파괴.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "길랑-바레 증후군: T 세포가 신경 세포의 미엘린 수초 파괴를 유발하는 사이토카인을 생성.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "건선: T 세포가 각질 형성 세포(피부 세포) 성장을 유도할 수 있는 사이토카인을 생성.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그레이브스병: 갑상선 특정 수용체에 부착된 항체가 갑상선을 비대하게 하고 과도한 호르몬을 생성하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "중증 근무력증: 아세틸콜린 수용체에 대한 항체.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "크론병: 항균 항체가 장 점막과 반응.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "염증성 장 질환: 항균 항체가 장 점막과 반응.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "자가면역 질환은 면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 상태입니다. 이는 자가 관용의 상실로 인해 발생하며, 세포독성, 면역 복합체, 세포 매개성 반응의 세 가지 주요 유형으로 분류될 수 있습니다. 각 유형은 특정 질병과 관련이 있으며, 신경, 갑상선, 관절, 췌장 등 다양한 장기에 영향을 미칩니다. 주요 자가면역 질환으로는 다발성 경화증, 그레이브스병, 중증 근무력증, 전신성 홍반성 루푸스, 류마티스 관절염, 1형 당뇨병, 건선 등이 있으며, 각 질환의 원인과 면역학적 메커니즘이 설명됩니다.",
                  "keyConcepts": [
                    {
                      "term": "자가면역",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 현상입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "자가 관용",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 자신의 항원에 반응하지 않고 구별하는 능력입니다. 자가면역 질환은 이 자가 관용의 상실로 발생합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "세포독성 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "항체가 세포 표면 항원과 반응하여 세포를 파괴하거나 기능을 손상시키는 유형의 자가면역 반응입니다. (예: 다발성 경화증, 그레이브스병, 중증 근무력증)",
                        "hard": null
                      }
                    },
                    {
                      "term": "면역 복합체 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "항체와 항원이 결합하여 형성된 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형의 자가면역 반응입니다. (예: 전신성 홍반성 루푸스, 류마티스 관절염)",
                        "hard": null
                      }
                    },
                    {
                      "term": "세포 매개성 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "T 세포가 직접 조직을 공격하여 손상을 일으키는 유형의 자가면역 반응입니다. (예: 1형 당뇨병, 건선)",
                        "hard": null
                      }
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "자가 항원",
                      "definition": "자신의 신체에 존재하는 항원으로, 면역 체계가 실수로 공격하는 대상이 됩니다."
                    },
                    {
                      "term": "미엘린 수초",
                      "definition": "신경 세포를 둘러싸고 있는 절연성 막으로, 손상 시 신경 신호 전달에 문제가 발생합니다."
                    },
                    {
                      "term": "아세틸콜린 수용체",
                      "definition": "신경 전달 물질인 아세틸콜린이 결합하는 근육 세포 표면의 단백질로, 중증 근무력증에서 항체에 의해 기능이 저해됩니다."
                    },
                    {
                      "term": "면역 복합체",
                      "definition": "항체와 항원이 결합하여 형성된 복합체로, 특정 조직에 침착되어 염증을 유발할 수 있습니다."
                    },
                    {
                      "term": "T 세포",
                      "definition": "세포 매개 면역 반응을 담당하는 림프구의 일종으로, 일부 자가면역 질환에서 직접 조직을 공격합니다."
                    },
                    {
                      "term": "사구체",
                      "definition": "신장의 혈액 여과 단위로, 전신성 홍반성 루푸스에서 면역 복합체가 형성되는 주요 부위입니다."
                    },
                    {
                      "term": "사이토카인",
                      "definition": "면역 세포 간의 신호 전달에 관여하는 단백질로, 일부 자가면역 질환에서 조직 손상을 유발할 수 있습니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "자가면역 질환 개요",
                      "id": "autoimmune-diseases-overview",
                      "children": [
                        {
                          "text": "자가면역의 정의 및 특징",
                          "id": "definition-and-characteristics-of-autoimmunity",
                          "children": null
                        },
                        {
                          "text": "주요 반응 유형",
                          "id": "main-types-of-reactions",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포독성 자가면역 반응",
                      "id": "cytotoxic-autoimmune-reactions",
                      "children": [
                        {
                          "text": "다발성 경화증",
                          "id": "multiple-sclerosis",
                          "children": null
                        },
                        {
                          "text": "그레이브스병",
                          "id": "graves-disease",
                          "children": null
                        },
                        {
                          "text": "중증 근무력증",
                          "id": "myasthenia-gravis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 복합체 자가면역 반응",
                      "id": "immune-complex-autoimmune-reactions",
                      "children": [
                        {
                          "text": "전신성 홍반성 루푸스",
                          "id": "systemic-lupus-erythematosus",
                          "children": null
                        },
                        {
                          "text": "류마티스 관절염",
                          "id": "rheumatoid-arthritis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포 매개성 자가면역 반응",
                      "id": "cell-mediated-autoimmune-reactions",
                      "children": [
                        {
                          "text": "인슐린 의존성 당뇨병 (1형 당뇨병)",
                          "id": "insulin-dependent-diabetes-mellitus-type-1",
                          "children": null
                        },
                        {
                          "text": "건선 및 건선성 관절염",
                          "id": "psoriasis-and-psoriatic-arthritis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "주요 자가면역 질환 및 원인",
                      "id": "selected-autoimmune-disorders-and-causes",
                      "children": [
                        {
                          "text": "만성 피로 증후군",
                          "id": "chronic-fatigue-syndrome",
                          "children": null
                        },
                        {
                          "text": "류마티스 관절염",
                          "id": "rheumatoid-arthritis-cause",
                          "children": null
                        },
                        {
                          "text": "전신성 홍반성 루푸스",
                          "id": "systemic-lupus-erythematosus-cause",
                          "children": null
                        },
                        {
                          "text": "다발성 경화증",
                          "id": "multiple-sclerosis-cause",
                          "children": null
                        },
                        {
                          "text": "1형 당뇨병",
                          "id": "type-1-diabetes-cause",
                          "children": null
                        },
                        {
                          "text": "길랑-바레 증후군",
                          "id": "guillain-barre-syndrome",
                          "children": null
                        },
                        {
                          "text": "건선",
                          "id": "psoriasis-cause",
                          "children": null
                        },
                        {
                          "text": "그레이브스병",
                          "id": "graves-disease-cause",
                          "children": null
                        },
                        {
                          "text": "중증 근무력증",
                          "id": "myasthenia-gravis-cause",
                          "children": null
                        },
                        {
                          "text": "크론병",
                          "id": "crohns-disease",
                          "children": null
                        },
                        {
                          "text": "염증성 장 질환",
                          "id": "inflammatory-bowel-disease",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "자가면역 질환에서 면역 체계가 공격하는 대상은 무엇입니까?",
                    "options": [
                      "외부 병원체",
                      "알레르기 유발 물질",
                      "자가 항원",
                      "독성 물질"
                    ],
                    "answerIndex": 2,
                    "explanation": "자가면역 질환은 면역 체계가 자신의 신체 조직, 즉 자가 항원을 외부 침입자로 오인하여 공격하는 상태입니다."
                  },
                  {
                    "question": "다음 중 세포독성 자가면역 반응에 해당하는 질환이 아닌 것은 무엇입니까?",
                    "options": [
                      "다발성 경화증",
                      "그레이브스병",
                      "중증 근무력증",
                      "류마티스 관절염"
                    ],
                    "answerIndex": 3,
                    "explanation": "류마티스 관절염은 면역 복합체가 관절에 형성되어 발생하는 면역 복합체 자가면역 반응에 해당합니다. 다발성 경화증, 그레이브스병, 중증 근무력증은 세포독성 자가면역 반응의 예시입니다."
                  },
                  {
                    "question": "1형 당뇨병(인슐린 의존성 당뇨병)의 주요 원인으로 설명된 면역 반응은 무엇입니까?",
                    "options": [
                      "항체에 의한 아세틸콜린 수용체 코팅",
                      "면역 복합체의 신장 사구체 침착",
                      "T 세포에 의한 인슐린 분비 세포 파괴",
                      "갑상선 항체의 과도한 호르몬 생성 유발"
                    ],
                    "answerIndex": 2,
                    "explanation": "1형 당뇨병은 T 세포가 인슐린을 분비하는 췌장의 세포를 파괴하여 발생하는 세포 매개성 자가면역 반응입니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1848 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "인간 백혈구 항원(HLA) 복합체 관련 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조직적합성 항원(Histocompatibility antigens): 세포 표면에 존재하는 자가 항원입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주요 조직적합성 복합체(MHC): 조직적합성 항원을 암호화하는 유전자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인간 백혈구 항원(HLA) 복합체: 인간의 MHC 유전자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "특정 HLA는 특정 질병에 대한 감수성 증가와 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HLA 타이핑 및 이식 수술",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "HLA 타이핑은 HLA를 식별하고 비교하는 과정입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이식 수술에서 공여자와 수혜자는 조직 타이핑을 통해 일치해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "표준화된 항혈청 또는 HLA에 특이적인 단일클론 항체를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HLA 타이핑 과정: 검사 중인 림프구에 항-HLA 항체가 부착됩니다. 보체와 트립판 블루 염료가 추가되면, 보체에 의해 손상된 세포가 염료를 흡수합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 특권 부위 및 면역 특권 조직",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이식편은 T 세포, 대식세포, 그리고 보체 고정 항체에 의해 공격받을 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 특권 부위 및 면역 특권 조직으로의 이식은 면역 반응을 일으키지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "예시로는 각막 이식, 심장 판막 이식이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "줄기세포",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포는 여러 다른 세포 유형을 생성할 수 있는 마스터 세포입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "배아 줄기세포(ESCs)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "배반포에서 채취되며, 조직과 장기를 재생하는 데 사용됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다능성(Pluripotent)으로, 모든 종류의 세포를 생성할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "성체 줄기세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "분화된 성체 조직에 있는 줄기세포입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "유전자 도입을 통해 유도만능줄기세포(induced pluripotent stem cells)가 될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포 배양 과정: (1일) 일반적으로 시험관 아기 시술에서 폐기된 수정란인 배아가 사용됩니다. (1-5일) 배아는 반복적으로 분열하여 속이 빈 세포 덩어리인 배반포 단계를 형성합니다. 배아줄기세포는 배반포의 속세포덩어리에서 채취되어 배양 배지의 피더(feeder) 세포 위에서 성장합니다. 줄기세포주와 줄기세포 그룹은 배양 배지에서 콜로니를 형성합니다. 다양한 조건과 배양 배지에 추가된 성장 인자는 줄기세포가 신체의 다양한 조직(예: 혈액 및 림프 세포, 췌장 섬 세포, 신경 세포)을 위한 줄기세포주가 되도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "골수 이식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조혈모세포 이식으로도 알려져 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "수혜자가 건강한 혈액 세포를 생산할 수 있도록 하는 것이 목표입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역능력 있는 세포를 포함하는 이식된 골수로 인해 이식편대숙주병(Graft-versus-host, GVH)이 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이식편(Grafts)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "자가이식(Autograft): 자신의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동계이식(Isograft): 일란성 쌍둥이의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동종이식(Allografts): 다른 사람의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이종이식(Xenotransplantation product): 비인간 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비인간 항원에 대한 반응인 초급성 거부 반응을 극복해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이식 거부 반응 방지를 위한 면역 억제",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이식된 조직에 대한 세포 매개 면역 반응을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이클로스포린(Cyclosporine)과 타크로리무스(tacrolimus)는 IL-2를 억제하여 세포독성 T 세포를 방해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "시롤리무스(Sirolimus)는 세포성 및 체액성 면역을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "마이코페놀레이트(Mycophenolate)는 T 세포와 B 세포의 증식을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바실리시맙(Basiliximab)은 IL-2를 차단하는 키메라 단일클론 항체입니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "제공된 텍스트는 인간 백혈구 항원(HLA) 복합체의 역할과 이식 면역학에서 이의 중요성을 설명합니다. HLA 타이핑을 통한 조직 일치의 필요성, 면역 반응을 일으키지 않는 면역 특권 부위, 그리고 배아 및 성체 줄기세포의 종류와 활용에 대해 다룹니다. 또한, 자가이식, 동계이식, 동종이식, 이종이식과 같은 다양한 이식편의 유형과 이식편대숙주병(GVH)과 같은 이식 관련 합병증을 설명합니다. 마지막으로, 이식 거부 반응을 방지하기 위한 사이클로스포린, 타크로리무스, 시롤리무스, 마이코페놀레이트, 바실리시맙 등 주요 면역 억제제와 그 작용 기전을 소개합니다.",
                  "keyConcepts": [
                    {
                      "term": "인간 백혈구 항원(HLA) 복합체",
                      "definition": "인간의 주요 조직적합성 복합체(MHC) 유전자로, 이식 수술에서 조직 일치에 결정적인 역할을 하며 특정 질병 감수성과 관련이 있습니다."
                    },
                    {
                      "term": "줄기세포",
                      "definition": "다양한 세포 유형으로 분화할 수 있는 마스터 세포로, 배아 줄기세포와 성체 줄기세포로 나뉩니다. 조직 재생 및 치료에 잠재적으로 활용됩니다."
                    },
                    {
                      "term": "이식편의 종류",
                      "definition": "조직의 출처에 따라 자가이식(자신의 조직), 동계이식(일란성 쌍둥이), 동종이식(다른 사람), 이종이식(비인간 조직)으로 분류됩니다."
                    },
                    {
                      "term": "이식 거부 반응 및 GVH 질환",
                      "definition": "이식된 조직에 대한 수혜자의 면역 반응(이식 거부 반응) 또는 이식된 면역 세포가 수혜자의 조직을 공격하는 현상(이식편대숙주병)입니다."
                    },
                    {
                      "term": "면역 억제",
                      "definition": "이식 거부 반응을 방지하기 위해 특정 약물을 사용하여 수혜자의 면역 반응을 억제하는 치료법입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "조직적합성 항원",
                      "definition": "세포 표면에 존재하는 자가 항원입니다."
                    },
                    {
                      "term": "주요 조직적합성 복합체(MHC)",
                      "definition": "조직적합성 항원을 암호화하는 유전자입니다."
                    },
                    {
                      "term": "인간 백혈구 항원(HLA) 복합체",
                      "definition": "인간의 MHC 유전자입니다."
                    },
                    {
                      "term": "면역 특권 부위",
                      "definition": "이식 시 면역 반응을 일으키지 않는 신체 부위 또는 조직입니다."
                    },
                    {
                      "term": "이식편대숙주병(GVH)",
                      "definition": "이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격하는 질환입니다."
                    },
                    {
                      "term": "자가이식",
                      "definition": "자신의 조직을 사용하는 이식 방법입니다."
                    },
                    {
                      "term": "면역 억제제",
                      "definition": "이식 거부 반응을 방지하기 위해 면역 반응을 억제하는 약물입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "인간 백혈구 항원(HLA) 복합체 관련 반응",
                      "id": "인간-백혈구-항원-hla-복합체-관련-반응",
                      "children": [
                        {
                          "text": "조직적합성 항원",
                          "id": "조직적합성-항원",
                          "children": null
                        },
                        {
                          "text": "주요 조직적합성 복합체(MHC)",
                          "id": "주요-조직적합성-복합체-mhc",
                          "children": null
                        },
                        {
                          "text": "인간 백혈구 항원(HLA) 복합체",
                          "id": "인간-백혈구-항원-hla-복합체",
                          "children": null
                        },
                        {
                          "text": "특정 질병에 대한 감수성",
                          "id": "특정-질병에-대한-감수성",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "HLA 타이핑 및 이식 수술",
                      "id": "hla-타이핑-및-이식-수술",
                      "children": [
                        {
                          "text": "HLA 타이핑의 역할",
                          "id": "hla-타이핑의-역할",
                          "children": null
                        },
                        {
                          "text": "조직 타이핑의 중요성",
                          "id": "조직-타이핑의-중요성",
                          "children": null
                        },
                        {
                          "text": "HLA 타이핑 과정",
                          "id": "hla-타이핑-과정",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 특권 부위 및 면역 특권 조직",
                      "id": "면역-특권-부위-및-면역-특권-조직",
                      "children": [
                        {
                          "text": "이식 거부 반응의 메커니즘",
                          "id": "이식-거부-반응의-메커니즘",
                          "children": null
                        },
                        {
                          "text": "면역 특권 부위의 특징",
                          "id": "면역-특권-부위의-특징",
                          "children": null
                        },
                        {
                          "text": "예시: 각막 이식, 심장 판막 이식",
                          "id": "예시-각막-이식-심장-판막-이식",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "줄기세포",
                      "id": "줄기세포",
                      "children": [
                        {
                          "text": "줄기세포의 정의",
                          "id": "줄기세포의-정의",
                          "children": null
                        },
                        {
                          "text": "배아 줄기세포(ESCs)",
                          "id": "배아-줄기세포-escs",
                          "children": null
                        },
                        {
                          "text": "성체 줄기세포",
                          "id": "성체-줄기세포",
                          "children": null
                        },
                        {
                          "text": "줄기세포 배양 및 분화",
                          "id": "줄기세포-배양-및-분화",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "골수 이식",
                      "id": "골수-이식",
                      "children": [
                        {
                          "text": "조혈모세포 이식",
                          "id": "조혈모세포-이식",
                          "children": null
                        },
                        {
                          "text": "골수 이식의 목표",
                          "id": "골수-이식의-목표",
                          "children": null
                        },
                        {
                          "text": "이식편대숙주병(GVH)",
                          "id": "이식편대숙주병-gvh",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "이식편(Grafts)",
                      "id": "이식편-grafts",
                      "children": [
                        {
                          "text": "자가이식(Autograft)",
                          "id": "자가이식-autograft",
                          "children": null
                        },
                        {
                          "text": "동계이식(Isograft)",
                          "id": "동계이식-isograft",
                          "children": null
                        },
                        {
                          "text": "동종이식(Allografts)",
                          "id": "동종이식-allografts",
                          "children": null
                        },
                        {
                          "text": "이종이식(Xenotransplantation)",
                          "id": "이종이식-xenotransplantation",
                          "children": null
                        },
                        {
                          "text": "초급성 거부 반응 극복",
                          "id": "초급성-거부-반응-극복",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "이식 거부 반응 방지를 위한 면역 억제",
                      "id": "이식-거부-반응-방지를-위한-면역-억제",
                      "children": [
                        {
                          "text": "면역 억제의 목적",
                          "id": "면역-억제의-목적",
                          "children": null
                        },
                        {
                          "text": "주요 면역 억제제 및 작용 기전",
                          "id": "주요-면역-억제제-및-작용-기전",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "이식 수술에서 공여자와 수혜자의 조직 일치가 중요한 주된 이유는 무엇입니까?",
                    "options": [
                      "감염 위험을 줄이기 위해",
                      "수술 시간을 단축하기 위해",
                      "이식 거부 반응을 최소화하기 위해",
                      "환자의 회복 속도를 높이기 위해"
                    ],
                    "answerIndex": 2,
                    "explanation": "HLA 타이핑을 통한 조직 일치는 이식된 조직에 대한 수혜자의 면역 반응, 즉 거부 반응을 줄이는 데 필수적입니다."
                  },
                  {
                    "question": "다음 중 '이식편대숙주병(Graft-versus-host disease, GVH)'이 발생할 수 있는 이식 유형은 무엇입니까?",
                    "options": [
                      "자가이식 (Autograft)",
                      "동계이식 (Isograft)",
                      "골수 이식 (Bone marrow transplant)",
                      "각막 이식 (Cornea transplant)"
                    ],
                    "answerIndex": 2,
                    "explanation": "이식편대숙주병은 이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격할 때 발생합니다."
                  },
                  {
                    "question": "다음 중 면역 억제제 시롤리무스(Sirolimus)의 주요 작용 기전은 무엇입니까?",
                    "options": [
                      "IL-2 생성을 억제하여 세포독성 T 세포를 방해한다.",
                      "T 세포와 B 세포의 증식을 억제한다.",
                      "세포성 및 체액성 면역을 모두 억제한다.",
                      "IL-2를 차단하는 키메라 단일클론 항체이다."
                    ],
                    "answerIndex": 2,
                    "explanation": "텍스트에 따르면 시롤리무스는 세포성 및 체액성 면역을 모두 억제한다고 명시되어 있습니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1530 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역 시스템과 암",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "암세포는 면역 감시에 의해 제거됩니다. 암세포는 비자기로 표시되는 종양 관련 항원을 가지고 있습니다. CTL(활성화된 TC 세포)과 대식세포는 암세포를 용해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그러나 면역 시스템의 암 제거에는 몇 가지 제한 사항이 있습니다. 면역 시스템이 표적으로 삼을 항원성 에피토프가 없거나, 종양 세포가 너무 빠르게 증식하거나, 종양이 혈관화되어 면역 시스템에 보이지 않게 될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "암에 대한 면역 요법",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "암 치료를 위한 다양한 면역 요법이 개발되었습니다. 박테리아 내독소(Coley's toxins)는 암의 혈액 공급을 방해하는 TNF를 자극하여 사용될 수 있습니다. HPV(자궁경부암, 항문암, 인후암) 및 B형 간염(간암)과 같은 바이러스 관련 암에 대한 예방 백신이 사용됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "또한 단클론항체(Monoclonal antibodies)가 사용되는데, 예를 들어 유방암 치료제 허셉틴이 있습니다. 면역독소(Immunotoxin)는 단클론항체와 독성 물질을 결합하여 건강한 세포에 손상을 주지 않고 종양을 표적하여 죽입니다. 면역 관문 억제제와 CAR T 세포와 같은 세포 치료법도 암 치료에 활용되고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 결핍증",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 결핍증은 충분한 면역 반응이 부재하는 상태를 말합니다. 이는 선천성 면역 결핍증과 후천성 면역 결핍증으로 나눌 수 있습니다. 선천성 면역 결핍증은 결함이 있거나 없는 유전자 때문에 발생하며, 후천성 면역 결핍증은 약물, 암, 감염 등으로 인해 개인의 삶 동안 발병합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 결핍 질환",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "선천성 면역 결핍 질환은 유전적 유전자 결함에 의해 발생합니다. T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있으며, 항원 수용체 유전자 재배열의 결함 또한 SCID를 유발할 수 있습니다. T세포 항원 수용체로부터의 신호 전달 결함이나 T세포 발달을 차단하는 흉선 기능의 유전적 결함 역시 중증 면역 결핍증을 초래할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "림프구 발달의 결함이 중증 복합 면역 결핍증을 초래할 수 있음",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.12 나병균에 감염된 누드(털 없는) 쥐의 뒷발. M. leprae 박테리아 위치.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본문은 면역 시스템이 암과 싸우는 방식, 그 한계, 그리고 다양한 암 면역 요법에 대해 설명합니다. 또한 면역 결핍증을 선천성 및 후천성으로 구분하고, T세포 발달 또는 항원 수용체 결함으로 인한 SCID와 같은 선천성 면역 결핍 질환의 구체적인 원인을 다룹니다.",
                  "keyConcepts": [
                    {
                      "term": "면역 감시",
                      "definition": "면역 시스템이 암세포를 인식하고 제거하는 과정."
                    },
                    {
                      "term": "면역 요법",
                      "definition": "면역 시스템을 활용하여 암을 치료하는 방법으로, 백신, 단클론항체, 면역관문억제제, 세포 치료 등이 포함됩니다."
                    },
                    {
                      "term": "선천성 면역 결핍증",
                      "definition": "유전적 결함으로 인해 발생하는 면역 반응의 부재."
                    },
                    {
                      "term": "후천성 면역 결핍증",
                      "definition": "약물, 암, 감염 등으로 인해 개인의 삶 동안 발병하는 면역 결핍."
                    },
                    {
                      "term": "중증 복합 면역 결핍증 (SCID)",
                      "definition": "T세포 발달 결함이나 항원 수용체 유전자 재배열 결함 등으로 인해 발생하는 심각한 면역 결핍 질환."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "종양 관련 항원",
                      "definition": "암세포 표면에 존재하며 면역 시스템이 비자기로 인식하는 항원."
                    },
                    {
                      "term": "세포독성 T 림프구 (CTLs)",
                      "definition": "활성화된 T 세포로, 암세포나 감염된 세포를 직접 용해(파괴)하는 역할을 합니다."
                    },
                    {
                      "term": "코리 독소",
                      "definition": "박테리아 내독소로, TNF 분비를 자극하여 암의 혈액 공급을 방해하는 데 사용되었던 물질."
                    },
                    {
                      "term": "단클론항체 (Mab)",
                      "definition": "특정 항원에만 결합하도록 만들어진 항체로, 암 치료에 사용될 수 있습니다 (예: 허셉틴)."
                    },
                    {
                      "term": "면역독소",
                      "definition": "단클론항체와 독성 물질을 결합하여 암세포만을 표적하여 죽이는 치료제."
                    },
                    {
                      "term": "면역 관문 억제제",
                      "definition": "면역 반응을 억제하는 경로를 차단하여 면역 시스템이 암세포를 더 효과적으로 공격하도록 돕는 약물."
                    },
                    {
                      "term": "CAR T 세포",
                      "definition": "환자의 T 세포를 유전자 조작하여 암세포를 인식하고 공격하도록 만든 세포 치료제."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역 시스템과 암",
                      "id": "면역-시스템과-암",
                      "children": [
                        {
                          "text": "면역 감시를 통한 암세포 제거",
                          "id": "면역-감시를-통한-암세포-제거",
                          "children": null
                        },
                        {
                          "text": "면역 시스템의 암 제거 제한 사항",
                          "id": "면역-시스템의-암-제거-제한-사항",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
                      "id": "세포독성-t-림프구ctl와-암세포의-상호작용",
                      "children": null
                    },
                    {
                      "text": "암에 대한 면역 요법",
                      "id": "암에-대한-면역-요법",
                      "children": [
                        {
                          "text": "박테리아 내독소",
                          "id": "박테리아-내독소",
                          "children": null
                        },
                        {
                          "text": "백신",
                          "id": "백신",
                          "children": null
                        },
                        {
                          "text": "단클론항체 및 면역독소",
                          "id": "단클론항체-및-면역독소",
                          "children": null
                        },
                        {
                          "text": "면역 관문 억제제",
                          "id": "면역-관문-억제제",
                          "children": null
                        },
                        {
                          "text": "세포 치료",
                          "id": "세포-치료",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 결핍증",
                      "id": "면역-결핍증",
                      "children": [
                        {
                          "text": "선천성 면역 결핍증",
                          "id": "선천성-면역-결핍증",
                          "children": null
                        },
                        {
                          "text": "후천성 면역 결핍증",
                          "id": "후천성-면역-결핍증",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 결핍 질환",
                      "id": "면역-결핍-질환",
                      "children": [
                        {
                          "text": "선천성 면역 결핍 질환의 원인",
                          "id": "선천성-면역-결핍-질환의-원인",
                          "children": null
                        },
                        {
                          "text": "T세포 발달 및 항원 수용체 관련 결함",
                          "id": "t세포-발달-및-항원-수용체-관련-결함",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "림프구 발달 결함과 중증 복합 면역 결핍증 (SCID)",
                      "id": "림프구-발달-결함과-중증-복합-면역-결핍증-scid",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "면역 시스템이 암세포를 제거하는 데 있어 주요 제한 사항이 아닌 것은 무엇입니까?",
                    "options": [
                      "면역 시스템이 표적으로 삼을 항원성 에피토프가 없음",
                      "종양 세포가 너무 빠르게 증식함",
                      "종양이 혈관화되어 면역 시스템에 보이지 않게 됨",
                      "대식세포가 암세포를 용해하지 못함"
                    ],
                    "answerIndex": 3,
                    "explanation": "본문에서는 CTL(활성화된 TC 세포)과 대식세포가 암세포를 용해한다고 명시되어 있으므로, 대식세포가 암세포를 용해하지 못하는 것은 면역 시스템의 제한 사항이 아닙니다."
                  },
                  {
                    "question": "다음 중 암에 대한 면역 요법으로 언급되지 않은 것은 무엇입니까?",
                    "options": [
                      "박테리아 내독소 (Coley's toxins)",
                      "예방 백신 (HPV, B형 간염)",
                      "항생제",
                      "CAR T 세포 치료"
                    ],
                    "answerIndex": 2,
                    "explanation": "본문에서 박테리아 내독소, 예방 백신, CAR T 세포 치료는 암에 대한 면역 요법으로 언급되었지만, 항생제는 언급되지 않았습니다. 항생제는 주로 세균 감염 치료에 사용됩니다."
                  },
                  {
                    "question": "중증 복합 면역 결핍증(SCID)의 주요 원인이 될 수 있는 유전적 결함은 무엇입니까?",
                    "options": [
                      "B세포의 과도한 증식",
                      "T세포 발달의 결함",
                      "항체 생산 능력의 증가",
                      "대식세포 기능의 활성화"
                    ],
                    "answerIndex": 1,
                    "explanation": "본문에서는 'T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있습니다'라고 명확히 언급되어 있습니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 5576 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "후천성 면역 결핍 증후군 (AIDS)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "1981년, 미국에서 젊은 동성애 남성들 사이에서 폐포자충 폐렴, 카포시 육종, 그리고 면역 기능 상실 사례들이 집단으로 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1983년, 면역 기능 상실을 유발하는 바이러스(HIV)가 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 T 보조 세포를 선택적으로 감염시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "AIDS의 기원",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 서아프리카와 중앙아프리카의 침팬지(약 1908년, 부시미트로부터)로부터 인간 개체군으로 넘어왔습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "도시화와 성적 문란의 증가로 아프리카 전역으로 퍼졌습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가장 오래된 HIV 샘플은 1920년 콩고민주공화국의 킨샤사에서 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1976년에 사망한 노르웨이 선원은 서구 세계에서 알려진 첫 번째 사례입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1969년 미주리주의 한 환자로부터 채취한 샘플에서 HIV 감염이 확인되었습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 구조",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "렌티바이러스(Lentivirus) 속에 속합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "레트로바이러스(Retrovirus)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "두 개의 동일한 양성 가닥 RNA 유전체 분자, 역전사 효소, 인지질 외피를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "gp120 당단백질 스파이크를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 구조 및 CD4+ T 세포 감염: gp120 당단백질 스파이크는 CD4+ 세포의 수용체에 부착합니다. gp41 막관통 당단백질은 CD4+ 세포의 융합 수용체에 부착하여 융합을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 감염성과 병원성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "수지상 세포에 의해 퍼지고 림프 기관으로 운반되며, 활성화된 T 세포와 접촉합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "gp120은 CD4+ 수용체 및 CCR5 또는 CXCR4 공동수용체와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4 분자는 T 보조 세포, 대식세포, 수지상 세포에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 세포와 융합하여 세포 안으로 들어갑니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "부착: gp120 스파이크는 세포의 수용체 및 CCR5 또는 CXCR4 공동수용체에 부착합니다. 융합: gp41은 HIV와 세포의 융합에 참여합니다. 진입: 세포와의 융합 후, 진입 구멍이 생성됩니다. 진입 후, 바이러스 외피는 뒤에 남고 HIV는 탈피하여 새로운 바이러스 합성을 지시할 RNA 핵을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포 내에서 바이러스 RNA는 역전사 효소를 사용하여 DNA로 전사됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "DNA는 숙주 염색체 DNA에 통합됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활동성 감염: 새로운 바이러스가 숙주 세포에서 출아합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "잠복 감염: DNA는 프로바이러스 형태로 염색체에 숨겨져 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일부는 HIV의 저장소 역할을 하는 기억 T 세포가 됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 빠른 항원성 변화와 높은 돌연변이율을 겪습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.14 CD4+ T 세포의 잠복 및 활동성 HIV 감염. 잠복 감염: 바이러스 DNA는 세포 DNA에 프로바이러스로 통합되며, 나중에 활성화되어 감염성 바이러스를 생성할 수 있습니다. 활동성 감염: 프로바이러스가 활성화되어 새로운 바이러스의 합성을 제어할 수 있게 합니다. 최종 조립은 세포막에서 이루어지며, 바이러스가 세포에서 출아할 때 바이러스 외피 단백질을 가져갑니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.15 대식세포 및 수지상 세포의 잠복 및 활동성 HIV 감염. 잠복 감염된 대식세포: HIV는 프로바이러스 또는 액포 내 완전한 비리온 형태로 지속될 수 있습니다. 활성화된 대식세포: 프로바이러스로부터 새로운 바이러스가 생성됩니다. 완성된 비리온은 방출되거나 액포 내 대식세포에 지속될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 아형",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침팬지와 고릴라를 감염시키는 바이러스와 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사례의 99%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그룹 M (대다수)이 90%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-2:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "서아프리카 외에서는 자주 발견되지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1보다 병원성이 낮습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1보다 바이러스 부하와 사망률이 낮고 무증상 기간이 더 깁니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 감염의 단계",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "1단계: 무증상 또는 림프절병증.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2단계: CD4+ T 세포가 꾸준히 감소하며, 감염된 소수의 세포만이 바이러스를 방출합니다. 심각한 질병 증상은 거의 없습니다 (지속적인 감염, 발열, 구강 백반증).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "3단계: AIDS가 발병합니다. CD4+ 수치가 200 cells/μl 미만이며, 지표 질환이 나타납니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 감염의 진행 및 병원성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "초기에는 강력하고 효과적인 면역 반응이 나타납니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구(CTLs)가 바이러스 수를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일단 HIV가 잠복 감염된 CD4+ T 세포의 저장소를 형성하면 감염을 제거하는 것은 불가능합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 개발에 어려움이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 노출에 대한 반응의 변이",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 감염 생존에 대한 연령의 영향:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "고령자와 어린이는 면역 체계가 완전히 기능하지 않아 감염에 더 취약합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "노출되었지만 감염되지 않은 인구:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "CCR5 돌연변이를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "장기 생존자:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "낮은 바이러스 부하를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "효과적인 CTLs를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "기회 감염",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "진단 방법",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 전환은 감염과 항체 출현 사이의 기간입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "최대 3개월이 소요됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 항체는 ELISA로 검출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 Western blotting 또는 APTIMA (RNA 검사)로 검출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈장 바이러스 부하 (PVL)는 PCR 또는 핵산 혼성화로 결정됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 전파",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 세포 밖에서 6시간 생존합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 세포 내에서 1.5일 이상 생존할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "전파 경로: 친밀한 성 접촉, 모유, 태반 감염, 오염된 주사바늘, 장기 이식, 수혈.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항문 성교는 가장 위험한 형태의 성 접촉입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전 세계 AIDS 현황",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "전 세계적으로 3천 5백만 명이 감염되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사하라 이남 아프리카에 70%가 집중되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이성애자 간 전파가 HIV 전파의 가장 흔한 방식입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동유럽과 중앙 및 동남아시아 사례의 ⅓은 주사 약물 사용으로 인한 것입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전 세계 지역별 HIV 감염 및 AIDS 분포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "70",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "AIDS 예방 및 치료",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "생물의학적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "콘돔 사용, 보건 서비스/HIV 검사, 주사바늘 프로그램.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "행동적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "성 교육, 안전한 영아 수유 프로그램, 상담.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "구조적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 취약성을 줄이기 위해 사회, 경제, 정치, 환경적 요인에 변화를 줍니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이제 선진국에서는 치료 가능한 만성 질환으로 간주됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "고활성 항레트로바이러스 치료 (HAART)를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "내성 균주의 생존을 최소화하기 위해 약물 조합을 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "73",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 관리",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.18 HIV 생명 주기를 억제하는 약물: 융합/진입 억제제 (엔푸비르타이드, 마라비록), 역전사 효소 억제제 (테노포비르, 엠트리시타빈), 통합효소 억제제 (랄테그라비르), 프로테아제 억제제 (아타자나비르, 인디나비르, 사퀴나비르) 등이 있습니다. 이 약물들은 HIV의 gp41, gp120, CCR5, CD4 수용체 및 역전사 효소 등에 작용하여 바이러스 복제를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 치료 약물의 종류",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "융합/세포 진입 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스 외피의 gp41 영역을 표적으로 하여 바이러스가 세포와 융합하는 것을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "엔푸비르타이드(Enfuvirtide)와 마라비록(Maraviroc)이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "역전사 효소 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "뉴클레오사이드 역전사 효소 억제제 (NRTIs) - 테노포비르(Tenofovir)와 엠트리시타빈(Emtricitabrine)이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비뉴클레오사이드 역전사 효소 억제제 (NNRTIs) - 에파비렌즈(Efavirenz)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "77",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "통합효소 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 통합효소가 cDNA를 숙주 염색체에 통합하는 것을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "랄테그라비르(Raltegravir)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로테아제 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스 전구 단백질을 구조 및 기능 단백질로 분해하는 프로테아제를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "아타자나비르(Atazanavir), 인디나비르(Indinavir), 사퀴나비르(Saquinavir)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "성숙 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "테더린(Tetherins)은 바이러스를 세포에 묶어 방출 및 확산을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감염 과정에서 HIV는 많은 돌연변이를 축적하여 약물 내성 변이체의 증식으로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 백신 개발의 과제",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "모방할 자연 면역 모델이 없습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "연구 동물이 부족합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "레트로바이러스 메커니즘에 대한 이해가 부족합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "높은 돌연변이율로 인해 내성 균주가 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이상적인 백신은 다음과 같아야 합니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "잠복 바이러스 저장소가 확립되기 전에 면역을 유도해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구(CTLs)의 생성을 자극해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "합리적인 가격이어야 합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 후천성 면역 결핍 증후군(AIDS)의 기원, 원인 바이러스인 HIV의 구조, 감염 메커니즘 및 병원성, 바이러스 아형, 감염 단계, 진단 방법, 전파 경로, 전 세계적 현황, 예방 및 치료법, 그리고 백신 개발의 과제에 대해 상세히 설명합니다. HIV는 CD4+ T 세포를 선택적으로 감염시키는 레트로바이러스이며, 잠복 감염과 활동성 감염 단계를 거치며 면역 체계를 파괴합니다. HAART(고활성 항레트로바이러스 치료)를 통해 HIV 복제를 억제하고 환자의 삶의 질을 향상시킬 수 있지만, 바이러스의 높은 돌연변이율로 인해 백신 개발에는 어려움이 있습니다.",
                  "keyConcepts": [
                    {
                      "term": "HIV (Human Immunodeficiency Virus)",
                      "definition": {
                        "easy": null,
                        "medium": "AIDS의 원인 바이러스로, 인체의 면역 체계를 공격하고 파괴하는 레트로바이러스입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "CD4+ T 세포",
                      "definition": {
                        "easy": null,
                        "medium": "HIV가 주로 감염시키고 파괴하는 면역 세포로, 이 세포의 감소는 면역 결핍을 초래합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "역전사 효소 (Reverse Transcriptase)",
                      "definition": {
                        "easy": null,
                        "medium": "HIV를 포함한 레트로바이러스가 자신의 RNA 유전체를 DNA로 역전사하는 데 사용하는 효소입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "HAART (Highly Active Antiretroviral Therapy)",
                      "definition": {
                        "easy": null,
                        "medium": "HIV 감염 치료를 위해 여러 종류의 항레트로바이러스 약물을 병용하는 치료법으로, 바이러스 복제를 효과적으로 억제합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "기회 감염 (Opportunistic Infections)",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 약해진 상태에서 일반적으로 건강한 사람에게는 질병을 일으키지 않는 미생물에 의해 발생하는 감염입니다.",
                        "hard": null
                      }
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "AIDS (Acquired Immunodeficiency Syndrome)",
                      "definition": "후천성 면역 결핍 증후군. HIV 감염의 마지막 단계로, 심각한 면역 결핍과 기회 감염 및 특정 암을 특징으로 합니다."
                    },
                    {
                      "term": "레트로바이러스 (Retrovirus)",
                      "definition": "RNA 유전체를 가지고 있으며, 역전사 효소를 사용하여 RNA를 DNA로 전환하고 이를 숙주 게놈에 통합시키는 바이러스입니다."
                    },
                    {
                      "term": "gp120 및 gp41",
                      "definition": "HIV 외피에 존재하는 당단백질 스파이크로, gp120은 CD4 수용체에 부착하고 gp41은 바이러스와 세포막의 융합을 촉진합니다."
                    },
                    {
                      "term": "프로바이러스 (Provirus)",
                      "definition": "레트로바이러스의 DNA 유전체가 숙주 세포의 염색체 DNA에 통합된 형태입니다."
                    },
                    {
                      "term": "혈청 전환 (Seroconversion)",
                      "definition": "감염 후 특정 병원체에 대한 항체가 혈액에서 처음으로 검출되는 시기입니다."
                    },
                    {
                      "term": "CD4+ T 세포 수치",
                      "definition": "면역 상태를 나타내는 중요한 지표로, AIDS 진단 기준 중 하나는 이 수치가 200 cells/μl 미만인 경우입니다."
                    },
                    {
                      "term": "CCR5 돌연변이",
                      "definition": "일부 개인에게서 발견되는 유전적 돌연변이로, HIV가 세포에 진입하는 데 필요한 공동수용체인 CCR5를 변경하여 HIV 감염에 대한 저항성을 부여합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "후천성 면역 결핍 증후군 (AIDS)",
                      "id": "후천성-면역-결핍-증후군-aids",
                      "children": null
                    },
                    {
                      "text": "AIDS의 기원",
                      "id": "aids의-기원",
                      "children": null
                    },
                    {
                      "text": "HIV의 구조",
                      "id": "hiv의-구조",
                      "children": null
                    },
                    {
                      "text": "HIV의 감염성과 병원성",
                      "id": "hiv의-감염성과-병원성",
                      "children": null
                    },
                    {
                      "text": "HIV의 아형",
                      "id": "hiv의-아형",
                      "children": null
                    },
                    {
                      "text": "HIV 감염의 단계",
                      "id": "hiv-감염의-단계",
                      "children": null
                    },
                    {
                      "text": "HIV 감염의 진행 및 병원성",
                      "id": "hiv-감염의-진행-및-병원성",
                      "children": null
                    },
                    {
                      "text": "HIV 노출에 대한 반응의 변이",
                      "id": "hiv-노출에-대한-반응의-변이",
                      "children": null
                    },
                    {
                      "text": "기회 감염",
                      "id": "기회-감염",
                      "children": null
                    },
                    {
                      "text": "진단 방법",
                      "id": "진단-방법",
                      "children": null
                    },
                    {
                      "text": "HIV 전파",
                      "id": "hiv-전파",
                      "children": null
                    },
                    {
                      "text": "전 세계 AIDS 현황",
                      "id": "전-세계-aids-현황",
                      "children": null
                    },
                    {
                      "text": "전 세계 지역별 HIV 감염 및 AIDS 분포",
                      "id": "전-세계-지역별-hiv-감염-및-aids-분포",
                      "children": null
                    },
                    {
                      "text": "AIDS 예방 및 치료",
                      "id": "aids-예방-및-치료",
                      "children": [
                        {
                          "text": "HIV 관리",
                          "id": "hiv-관리",
                          "children": null
                        },
                        {
                          "text": "HIV 치료 약물의 종류",
                          "id": "hiv-치료-약물의-종류",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "HIV 백신 개발의 과제",
                      "id": "hiv-백신-개발의-과제",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "HIV가 주로 감염시키고 파괴하는 면역 세포는 무엇입니까?",
                    "options": [
                      "B 세포",
                      "CD4+ T 세포",
                      "대식세포",
                      "자연 살해(NK) 세포"
                    ],
                    "answerIndex": 1,
                    "explanation": "HIV는 CD4+ 수용체를 가진 세포를 감염시키며, 특히 CD4+ T 세포는 HIV 감염의 주요 표적 세포입니다. 이 세포의 파괴는 면역 결핍을 초래합니다."
                  },
                  {
                    "question": "HIV 감염 진단에 사용되는 방법 중 HIV 항체를 검출하는 검사는 무엇입니까?",
                    "options": [
                      "PCR",
                      "Western blotting",
                      "ELISA",
                      "핵산 혼성화"
                    ],
                    "answerIndex": 2,
                    "explanation": "HIV 항체는 ELISA(효소결합 면역흡착법)를 통해 검출됩니다. Western blotting은 항체 검출을 확인하는 데 사용될 수 있으며, PCR과 핵산 혼성화는 바이러스 자체(RNA 또는 DNA)를 검출하는 데 사용됩니다."
                  },
                  {
                    "question": "HAART(고활성 항레트로바이러스 치료)의 주요 특징은 무엇입니까?",
                    "options": [
                      "단일 약물을 고용량으로 투여합니다.",
                      "수술적 방법으로 바이러스를 제거합니다.",
                      "여러 종류의 항레트로바이러스 약물을 병용합니다.",
                      "면역 증강제만을 사용하여 면역력을 높입니다."
                    ],
                    "answerIndex": 2,
                    "explanation": "HAART는 여러 종류의 항레트로바이러스 약물을 병용하여 HIV 복제를 다양한 단계에서 억제하고 약물 내성 균주의 출현을 최소화하는 치료법입니다."
                  }
                ]
              }
            ],
            "final_result": ""
          }
        },
        {
          "node": "finish_processing",
          "status": "completed",
          "state_snapshot": {
            "run_id": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4",
            "pdf_file_paths": [
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
              "temp_pdf_uploads/9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf"
            ],
            "all_pdf_texts": [
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "text": "16. INNATE IMMUNITY: \nNONSPECIFIC DEFENSES OF \nTHE HOST\nHongsup Yoon, Ph.D.\nMicrobiology\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n2\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n3\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n4\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n\nBIG PICTURE: IMMUNITY\n• White blood cell (WBC) \ncounts measure \nleukocytes in the blood\n• High WBC counts may \nindicate bacterial \ninfections, autoimmune \ndiseases, or side effects \nof medications\n• Low WBC counts may \nindicate viral infections, \npneumonia, \nautoimmune diseases, \nor cancers\n\nTHE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse.\n14\nHOST DEFENSE: THE BIG PICTURE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n16\nPHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\n\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice.\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n23\nFORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\n\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\n\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n31\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\n\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\n\nPHAGOCYTOSIS: OVERVIEW\n\nPHAGOCYTOSIS: MECHANISM\n\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\n\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n39\nINFLAMMATION: OVERVIEW\n\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\n\nFigure 16.9a-b  The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ntaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\n\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\n\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n49\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n51\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\n\nCOMPLEMENT: ACTIVATION\n\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\n\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\n\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\n\nFigure 16.12  Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13  Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\n\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBIAL PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols\nCONTENTS\n• Introduction\n• First Line of Defense\n• Second Line of Defense\n• Formed Elements in Blood\n• Phagocytes\n• Inflammation\n• Fever\n• Antimicrobial Substances\n• SUMMARY\n68\nSUMMARY (1/3)\n• The growth of microorganisms can be controlled by physical, chemical, \nmechanical, and biological means.\n• The body’s first line of defense against infections is a physical barrier and \nthe nonspecific chemicals of the skin and mucous membranes. \n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways.\n• A microbe’s penetration of the first line of defense encourages production \nof phagocytes, inflammation, fever, and antimicrobial substances. \n• Blood consists of plasma (fluid) and formed elements (cells and cell \nfragments). Leukocytes (white blood cells) are divided into granulocytes \n(neutrophils, basophils,  eosinophils) and agranulocytes. During many \ninfections, the number of leukocytes increases (leukocytosis); some  \ninfections are characterized by leucopenia (decrease in leukocytes). \nSUMMARY (2/3)\n• Phagocytosis is the ingestion of microorganisms or particulate matter by a \ncell. Phagocytosis is performed by phagocytes, certain types of white \nblood cells or their  derivatives. Among the granulocytes, neutrophils are \nthe most important phagocytes. Granulocytes predominate during the \nearly stages of infection, whereas monocytes  predominate as the \ninfection subsides. \n• Inflammation is a bodily response to cell damage; it is characterized by \nredness,  pain, heat, swelling, and sometimes the loss of function. TNF -α \nstimulates production of acute -phase proteins. \n• A tissue is repaired when the stroma (supporting tissue) or parenchyma \n(functioning  tissue) produces new cells. Stromal repair by fibroblasts \nproduces scar tissue. \n• Fever is an abnormally high body temperature produced in response to a \nbacterial or  viral infection. \nSUMMARY (3/3)\n• The complement system consists of a group of serum proteins that \nactivate one another to destroy invading microorganisms. Complement \nproteins are activated in a cascade. Complement is activated via the \nclassical pathway, the alternative pathway, and the lectin pathway. \n• IFN-α and IFN-β are antiviral proteins produced in response to viral \ninfection. The mode of action of IFN -α and IFN-β is to induce uninfected \ncells to produce antiviral proteins (AVPs) that prevent viral replication. IFN -\nα and IFN-β are host-cell-specific but not virus-specific. IFN-γ activates \nneutrophils and macrophages to kill bacteria. \n• Iron-binding proteins transport and store iron and deprive most pathogens \nof the  available iron.\n• Antimicrobial peptides (AMPs) inhibit cell wall synthesis; form pores in \nplasma  membranes, resulting in lysis; and destroy DNA and RNA."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "text": "17. ADAPTIVE IMMUNITY: \nSPECIFIC DEFENSES OF \nTHE HOST\n1\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n2\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n3\nTHE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n5\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\n\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n11\nCYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n14\nAntibody A\nEpitopes (antigenic \ndeterminants)\non antigen\nAntigens:\ncomponents\nof cell wall\nAntibody B\nBacterial cell\nBinding sites\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\n\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\n\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n34\nCELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\n\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\n\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\n\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\n\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\n\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n51\nIMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\n \n\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\n\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Types of Adaptive Immunity\n• Summary\n55\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\n\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies\n\nCONTENTS\n• Introduction\n• Dual Nature of the Adaptive Immune System\n• Cytokines\n• Humoral Immunity\n• Cellular Immunity\n• Immunological Memory\n• Summary\n58\nFigure 17.20  The Dual Nature of the Adaptive Immune System.\n\nSUMMARY (1/3)\n• Adaptive immunity is the body’s ability to react specifically to a microbial \ninfection. The body’s response to the first contact with an antigen is called the \nprimary response. Subsequent contact with the same antigen results in a \nsecondary or memory response to that antigen.\n• Humoral immunity involves antibodies, which are found in serum and lymph and \nare produced by B cells. Lymphocytes that mature in red bone marrow become \nB cells. \n• Cellular immunity involves T cells. Lymphocytes that migrate through the thymus \nbecome T cells. T cell receptors recognize antigens presented on MHC. Cellular \nimmunity responds to intracellular antigens; humoral immunity responds to \nantigens in body fluids.\n• Cells of the immune system communicate with each other by means of \nchemicals called cytokines. Interleukins (IL) are cytokines that serve as \ncommunicators between leukocytes. Chemokines cause leukocytes to migrate \nto an infection. Some interferons stimulate the immune response; others protect \ncells against viruses. Tumor necrosis factor promotes the inflammatory reaction. \nHematopoietic cytokines promote development of white blood cells. \nOverproduction of cytokines leads to a cytokine storm, which results in tissue \ndamage.\nSUMMARY (2/3)\n• An antigen (or immunogen) is a chemical substance that causes the body \nto produce specific antibodies. Antibodies are formed against specific \nregions on antigens called epitopes, or antigenic determinants.\n• An antibody, or immunoglobulin, is a protein produced by B cells in \nresponse to an  antigen and is capable of combining specifically with that \nantigen. IgG antibodies are the most prevalent in serum; they provide \nnaturally acquired passive immunity, neutralize bacterial toxins, participate \nin complement fixation, and enhance phagocytosis.\n• T cells mature in the thymus gland. Thymic selection removes T cells that \ndon’t recognize MHC molecules of the host and T cells that will attack host \ncells presenting self-proteins in MHC. Helper T cells recognize antigens \nprocessed by antigen-presenting cells and presented in MHC II. Cytotoxic \nT cells recognize antigens processed by all host cells and presented in \nMHC I.\nSUMMARY (3/3)\n• APCs include B cells, dendritic cells, and macrophages. Dendritic cells are \nthe primary APCs. Dendritic cells are the primary APCs. APCs carry \nantigens to lymphoid tissues where T cells that recognize the antigen are \nlocated.\n• T helper (CD4+ T) cells differentiate into TH1 cells, which are involved in \ncellular immunity; TH2 cells, which are involved in humoral immunity and \nare associated with allergic reactions and parasitic infections; and TH17 \ncells, which activate innate immunity.\n• T regulatory cells (Treg) suppress T cells against self. Cytotoxic \nlymphocytes (CTLs), or CD8+ T cells, are activated by endogenous \nantigens and MHC class I on a target cell and are transformed into effector \nand memory CTLs.\n• CTLs lyse or induce apoptosis in the target cell."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n18. PRACTICAL \nAPPLICATIONS OF \nIMMUNOLOGY – PART I\n2\nRECENT VIRUS OUTBREAKS\n• 2002 SARS outbreak (~9.5 % mortality rate)\n• 2004 Global spread of H5N1 avian influenza (60% mortality rate)\n• 2009 H1N1/09 swine Flu pandemic\n• 2015 MERS in Korea (~40 % mortality rate)\n• 2018 Influenza B outbreak in Korea\n• 2019 COV-19 (SARS-CoV2) pandemic (~2 – 3 % mortality rate)\n?\nHISTORICAL PANDEMIC: BLACK DEATH\nKilled 30 – 60% of European\n\nEDWARD JENNER (1749 – 1823)\n\nMILKMAID (AROUND THE TIME OF JENNER)\n\nVACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\n\nVACCINES: FUNCTION\n\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -drug \nusers, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1  Influenza viruses are grown in embryonated eggs.\n\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\n\nRNA VACCINES\nVACCINES: TYPES\n\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\n\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren\nDIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nMONOCLONAL ANTIBODIES\n\nPRODUCTION OF MONOCLONAL \nANTIBODIES\n\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\n\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\n\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\n\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\n\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\n\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\n\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\n\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\n\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy\nSUMMARY (1/6)\n• Edward Jenner developed the modern practice of vaccination when he \ninoculated people with cowpox virus to protect them against smallpox. \n• Herd immunity results when most of a population is immune to a disease.\n• Bacteria have unique cell structures that can be targets for antibiotics, \nimmunity, and phage infection.\n•  Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Humans utilize \nand harness microorganisms and their products.\n• Attenuated vaccines consist of attenuated (weakened) microorganisms; \nattenuated virus vaccines generally provide lifelong immunity. Inactivated \nvaccines consist of killed bacteria or viruses. Subunit vaccines consist of \nantigenic fragments of a microorganism; these include  recombinant \nvaccines and toxoids. \nSUMMARY (2/6)\n• Conjugated vaccines combine the desired antigen with a protein that \nboosts the immune response. Nucleic acid (DNA) vaccines cause the \nrecipient to make the antigenic protein.\n• Viruses for vaccines may be grown in animals, cell cultures, or chick \nembryos. Recombinant vaccines and nucleic acid vaccines do not need to \nbe grown in cells or animals. Genetically modified plants may someday \nprovide edible vaccines.\n• Combining several vaccines would eliminate the number of injections. Dry \nskin patch vaccines don’t need refrigeration.\n• Adjuvants improve the effectiveness of some antigens. \n• Vaccines are the safest and most effective means of controlling infectious \ndiseases.\nSUMMARY (3/6)\n• Many tests based on the interactions of antibodies and antigens have \nbeen developed to determine the presence of antibodies or antigens in a \npatient. The sensitivity of a diagnostic test is determined by the percentage \nof positive samples it correctly detects; and its specificity is determined by \nthe percentage of false positive  results it gives.\n• Hybridomas are produced in the laboratory by fusing a cancerous cell with \nan antibody-secreting plasma cell. A hybridoma cell culture produces large \nquantities of the plasma cell’s antibodies, called monoclonal antibodies. \nMonoclonal antibodies are used in serological identification tests, to \nprevent tissue  rejections, and to make immunotoxins to treat cancer.\n• The interaction of soluble antigens with IgG or IgM antibodies leads to \nprecipitation  reactions. Precipitation reactions depend on the formation of \nlattices and occur best when antigen and antibody are present in optimal \nproportions. Excesses of either component decrease lattice formation and \nsubsequent precipitation.\nSUMMARY (4/6)\n• Immunodiffusion procedures are precipitation reactions carried out in an \nagar gel  medium. Immunoelectrophoresis combines electrophoresis with \nimmunodiffusion for the analysis of serum proteins.\n• The interaction of particulate antigens (cells that carry antigens) with \nantibodies leads to agglutination reactions. Diseases may be diagnosed \nby combining the patient’s serum with a known antigen. Diseases can be \ndiagnosed by a rising titer or seroconversion (from no antibodies to the \npresence of antibodies). Direct agglutination reactions can be used to \ndetermine antibody titer. Antibodies cause visible agglutination of soluble \nantigens affixed to latex spheres in indirect or passive agglutination tests. \nHemagglutination reactions involve agglutination reactions using red blood \ncells.  Hemagglutination reactions are used in blood typing, the diagnosis \nof certain diseases, and the identification of viruses. \nSUMMARY (5/6)\n• In neutralization reactions, the harmful effects of a bacterial exotoxin or \nvirus are  eliminated by a specific antibody. An antitoxin is an antibody \nproduced in response to a bacterial exotoxin or a toxoid that neutralizes \nthe exotoxin. In a virus neutralization test, the presence of antibodies \nagainst a virus can be detected by the antibodies’ ability to prevent \ncytopathic effects of viruses in cell cultures. Antibodies against certain \nviruses can be detected by their ability to interfere with viral \nhemagglutination in viral hemagglutination inhibition tests.\n• Complement-fixation reactions are serological tests based on the \ndepletion of a fixed amount of complement in the presence of an antigen –\nantibody reaction.\n• Fluorescent-antibody techniques use antibodies labeled with fluorescent \ndyes. Direct fluorescent-antibody tests are used to identify specific \nmicroorganisms. \nSUMMARY (6/6)\n• Indirect fluorescent-antibody tests are used to demonstrate the presence \nof antibody  in serum. A fluorescence-activated cell sorter can be used to \ndetect and count cells labeled with fluorescent antibodies.\n• ELISA techniques use antibodies linked to an enzyme. Antigen –antibody \nreactions are detected by enzyme activity. If the indicator enzyme is \npresent in the test well, an antigen –antibody reaction has occurred. The \ndirect ELISA is used to detect antigens against a specific antibody bound \nin a test well. The indirect ELISA is used to detect antibodies against an \nantigen bound in a test well.\n• Serum antibodies separated by electrophoresis are identified with an \nenzyme-linked  antibody. \n• The use of monoclonal antibodies will continue to make new diagnostic \ntests possible."
              },
              {
                "filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "text": "GENERAL \nMICROBIOLOGY\nHongsup Yoon, Ph.D.\nHGU\nSpring Semester\n1\n19. DISORDERS \nASSOCIATED WITH THE \nIMMUNE SYSTEM – PART 1\n2\nLEARNING GOALS IN THIS LECTURE\nWe will learn about\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n3\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n4\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Dysbiosis: \nimbalance that \ncauses adverse \neffects in humans\n• Antibiotic therapy \nkills normal gut \nmicrobiota, causing \nClostridium difficile \nto proliferate\n• Possible cause of \nIBDs such as \nulcerative colitis and \nCrohn's disease\n\nBIG PICTURE: THE HYGIENE HYPOTHESIS\n• Allergies and asthma\n• Observation that tribal populations and children growing up on farms \nhave less prevalence of allergies than children in urban settings\n• Possibly due to wider range of microbial exposures in farm setting; also \nled to lower asthma rates\n• Inflammatory bowel diseases\n• Possible link of lack of normal microbiota metabolic products leading to \nchronic inflammatory state\nBIG PICTURE: HUMAN MICROBIOME AND \nIBD\n• Treating Crohn's \ndisease with worms\n• Whipworm eggs \nsuppress T helper cell \npathways\n• Fecal transplants for C. \ndifficile infections\n• Taking gut microbiota \nfrom a healthy \nindividual and \ntransplanting it into the \npatient\n\nHYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\n\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\n\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\n\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\n\nFigure 19.8  Allergic contact dermatitis.\n\nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n21\nAUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\n\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555) \nAGENDA\n• Hypersensitivity\n• Autoimmune Diseases\n• Reactions Related to the Human Leukocyte Antigen (HLA) Complex\n28\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\n\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2\nSUMMARY (1/3)\n• Microorganisms, cellular and viral, can interact with both human and non -\nhuman hosts in beneficial, neutral, or detrimental ways. Hay fever, \ntransplant rejection, and autoimmunity are examples of harmful immune  \nreactions. Immunosuppression is inhibition of the immune system. \nSuperantigens activate many T cell receptors that can cause adverse host \nresponses.\n• Hypersensitivity reactions represent immunological responses to an \nantigen (allergen) that lead to tissue damage rather than immunity. \nHypersensitivity reactions occur when a person has been sensitized to an \nantigen. Hypersensitivity reactions can be divided into four classes: types \nI, II, and III are immediate reactions based on humoral immunity, and type \nIV is a delayed reaction  based on cell -mediated immunity. \n• Childhood exposure to microbes may decrease development of allergies.\nSUMMARY (2/3)\n• Autoimmunity results from a loss of self -tolerance. Self-tolerance occurs \nduring fetal development; T cells that will target host cells are eliminated \n(clonal deletion) or inactivated. Autoimmunity may be due to antibodies \nagainst infectious agents. Graves’ disease and myasthenia gravis are \ncytotoxic autoimmune reactions in which  antibodies react to cell -surface \nantigens.\n• Systemic lupus erythematosus and rheumatoid arthritis are immune \ncomplex autoimmune reactions in which the deposition of immune \ncomplexes results in tissue damage. Multiple sclerosis, insulin -dependent \ndiabetes mellitus, and psoriasis are cell -mediated autoimmune reactions \nmediated by T cells.\nSUMMARY (3/3)\n• MHC self molecules located on cell surfaces express genetic differences \namong individuals; these antigens are called HLAs in humans. To prevent \nthe rejection of transplants, HLA and ABO blood group antigens of the \ndonor and recipient are matched as closely as possible. Transplants \nrecognized as foreign antigens may be lysed by T cells and attacked by \nmacrophages and complement -fixing antibodies. Transplantation to a \nprivileged site (such as the cornea) or of a privileged tissue (such as pig \nheart valves) does not cause an immune response. Pluripotent stem cells \ndifferentiate into a variety of tissues that may provide tissues for \ntransplant.\n• Four types of transplants have been defined on the basis of genetic \nrelationships between the donor and the recipient: autografts, isografts, \nallografts, and xenotransplants. Bone marrow transplants (with \nimmunocompetent cells) can cause graft -versus-host  disease.  \nSuccessful transplant surgery often requires immunosuppressant drugs to \nprevent an immune response to the transplanted tissue. \nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n40\nTHE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\n\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n46\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\n\nFigure 19.12  A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES\n\nAGENDA\n• Immune System And Cancer\n• Immunodeficiencies\n• Special focus on Acquired Immunodeficiency Syndrome (AIDS)\n52\nACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\n\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14  Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15  Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\n\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\n\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n\n70\n\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\n\nHIV MANAGEMENT\n\nFigure 19.18  Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\n\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\n\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable\nSUMMARY (1/3)\n• Cancer cells are normal cells that have undergone transformation, divide \nuncontrollably, and possess tumor-associated antigens. The response of the \nimmune system to cancer is called immunological surveillance. TC cells \nrecognize and lyse cancerous cells. Cancer cells can escape detection and \ndestruction by the immune system. Cancer cells may grow faster than the \nimmune system can respond.\n• Novel therapeutic strategies, such as immune checkpoint inhibitors and CAR T \ncell therapy, are effective approaches to treat patients with cancer.\n• Vaccines against liver and cervical cancer are available; a therapeutic vaccine \nagainst prostate cancer also has been approved. Herceptin consists of \nmonoclonal antibodies against a breast cancer growth factor. Immunotoxins are \nchemical poisons linked to a monoclonal antibody; the antibody  selectively \nlocates the cancer cell for release of the poison.\n• Immunodeficiencies can be congenital or acquired. Congenital \nimmunodeficiencies are due to defective or absent genes. A variety of drugs, \ncancers, and infectious diseases can cause acquired  immunodeficiencies. \n• HIV is thought to have originated in central Africa and was brought to other \ncountries by modern transportation and unsafe sexual practices.\nSUMMARY (2/3)\n• AIDS is the final stage of HIV infection. HIV is a retrovirus with single -\nstranded RNA, reverse transcriptase, and a phospholipid envelope with \ngp120 spikes. HIV spikes attach to CD4+ and coreceptors on host cells; \nthe CD4+ receptor is found on  T helper cells, macrophages, and dendritic \ncells. Viral RNA is transcribed to DNA by reverse transcriptase. The viral \nDNA becomes  integrated into the host chromosome to direct synthesis of \nnew viruses or to remain latent as a provirus. HIV evades the immune \nsystem in latency, in vacuoles, by using cell–cell fusion, and by antigenic \nchange. HIV-1 accounts for most HIV infections. Subtype B of HIV -1 is the \nmost common type in the United States. HIV infection is categorized by \nsymptoms: phase 1 (asymptomatic), phase 2 (indicator opportunistic \ninfections), and phase 3 (CD4+  cells <200 cells/μ1). The progression from \nHIV infection to AIDS takes about 10 years. The life of an AIDS patient can \nbe prolonged by the proper treatment of opportunistic  infections. People \nlacking CCR5 are resistant to HIV infection. Elite controllers are long -term \nsurvivors who may hold the key to HIV treatment. \nSUMMARY (3/3)\n• HIV antibodies are detected by ELISA and Western blotting. Plasma viral \nload tests detect viral nucleic acid and are used to quantify HIV in blood.\n• HIV is transmitted by sexual contact, breast milk, contaminated needles, \ntransplacental infection, artificial insemination, and blood transfusion. In \ndeveloped countries, blood transfusions are not a likely source of infection \nbecause blood is tested for HIV antibodies. \n• Heterosexual intercourse is the primary method of HIV transmission.\n• Discouraging sexual promiscuity and using condoms and sterile needles \nprevent the transmission of HIV. Vaccine development is difficult because \nthe virus remains inside host cells and there is no model of natural \nimmunity to mimic. Current chemotherapeutic agents target the virus \nenzymes, including reverse transcriptase, integrase, and protease. Other \ninhibitors include cell entry inhibitors, maturation inhibitors, and tetherins."
              }
            ],
            "notebook_title": "인체 면역 시스템: 방어 기전, 응용 및 질환",
            "holistic_chapters": [
              {
                "chapter_title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "면역의 개념, 질병에 대한 저항력(면역)과 취약성(감수성)을 정의하고, 선천성 면역과 적응성 면역의 주요 특징과 차이점을 소개합니다. 특히 톨유사수용체(TLR)가 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 조절하는 메커니즘을 설명합니다.",
                "chapter_full_text": "THE CONCEPT OF IMMUNITY\n• Immunity: ability to ward off disease\n• Susceptibility: lack of resistance to a disease\n• Innate immunity: defenses against any pathogen; rapid, present at birth\n• Adaptive immunity: immunity or resistance to a specific pathogen; slower \nto respond, has memory component\nINNATE IMMUNITY\n• Also known as natural, native, inborn immunity\n• Immunology of innate immune cells\n• Innate immune cells: Phagocytes, dendritic cells, mast cells, natural killer cells, etc.\n• Present even before an infection occurs\n• Immune sentinels\n• Some innate immune cells can present antigens to T cells and prime the adaptive \nimmunity\n• Important for tissue homeostasis and inflammation\n• Can be healers and destroyers\n• Activated by pathogenic pattern, cytokines, mediators\n• Not specific for antigens\nADAPTIVE IMMUNITY\n• Adaptive immunity: \n• Also known as specific, acquired immunity\n• Immunology of adaptive immune cells (lymphocytes)\n• Adaptive immune cells: T and B cells\n• Immature cells in secondary lymphatic organs\n• Clonal selection, expansion\n• Can have memory\n• Self tolerance\n• Activated by antigen-presenting cells\n• Specific for antigens\n• Divided into cell-mediated and humoral immunity\nTHE CONCEPT OF IMMUNITY\n• Toll-like receptors (TLRs) on host cells attach to pathogen-associated \nmolecular patterns (PAMPs)\n• TLRs bound to PAMPs induce the release of cytokines from the host cell \nthat regulate the intensity and duration of immune responses\nTOLL-LIKE RECEPTORS\n• Mammalian TLRs recognize a variety of PAMPs\n• Bacterial PAMPs\n• Lipopolysaccharide from gram -negative bacterial cell wall (TLR4)\n• Bacterial ribosomal RNA (TLR13)\n• Unmethylated CpG in the bacterial DNA (TLR9)\n• Lipoproteins (TLR2/1, TLR2/6)\n• Flagellin (TLR5)\n• Viral PAMPs\n• Double-stranded RNA (TLR3)\n• Single-stranded RNA (TLR7, TLR8)\n• Unmethylated CpG DNA (TLR9)\n• Parasitic PAMPs\n• Lipoproteins (TLR2/1, TLR2/6)\n• Unmethylated CpG DNA (TLR9)\n• Single-stranded RNA (TLR7)\n• Actin-binding protein profilin (TLR11/12)\nFitzgerald et al., Cell. 2020 12\nTOLL-LIKE RECEPTORS\n• TLRs are found on the cell surface and \non intracellular membranes to recognize \nmicrobes in different cellular locations\n• TLRs can also recognize endogenous \nPAMPs\n• Heat shock proteins (HSPs) – chaperones \ninduced in cell stress\n• High-mobility group box 1 (HMGB1) proteins \n– abundant genomic DNA binding proteins\n13\nTOLL-LIKE RECEPTORS\n• TLR recognition of microbial ligands \nresults in the activation of several \nsignaling pathways and ultimately \ntranscription factors, which induce the \nexpression of genes whose products are \nimportant for inflammatory and antiviral \nresponse."
              },
              {
                "chapter_title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "피부, 점막, 섬모 에스컬레이터, 눈물샘 장치 등 인체의 1차 물리적 방어선과 피지, 리소자임, 위액, 질 분비물 등 화학적 방어선이 미생물 성장을 억제하고 파괴하는 방법을 설명합니다. 또한 정상 미생물총이 경쟁적 배제를 통해 병원체로부터 숙주를 보호하는 역할을 다룹니다.",
                "chapter_full_text": "PHYSICAL FACTORS\n• Skin\n• Dermis: inner portion made of connective tissue\n• Epidermis: outer portion made of tightly packed epithelial cells containing keratin, \na protective protein\n• Shedding and dryness of skin inhibits microbial growth\nPHYSICAL FACTORS\n• Mucous \nmembranes\n• Epithelial layer that \nlines the \ngastrointestinal, \nrespiratory, and \ngenitourinary tracts\n• Mucus: viscous \nglycoproteins that \ntrap microbes and \nprevent tracts from \ndrying out\n• Lacrimal \napparatus: drains \ntears; washes eye\nLacrimal glands\nUpper eyelid\nLacrimal canal\nNasolacrimal\nduct\nPHYSICAL FACTORS\n• Ciliary escalator transports microbes trapped in mucus away from the \nlungs\n• Earwax prevents microbes from entering the ear\n• Urine cleans the urethra via flow\n• Peristalsis, defecation, vomiting, diarrhea\nTrapped\nparticles\nin mucus\nCilia\nGoblet cells\nCiliated cells\nComputer-enhanced\nCHEMICAL FACTORS\n• Sebum forms a protective film and lowers the pH (3 –5) of skin\n• Lysozyme in perspiration, tears, saliva, and urine destroys bacterial cell \nwalls\n• Low pH (1.2–3.0) of gastric juice destroys most bacteria and toxins\n• Low pH (3–5) of vaginal secretions inhibit microbes\nNORMAL MICROBIOTA AND INNATE \nIMMUNITY\n• Normal microbiota compete with pathogens via microbial antagonism \n(competitive exclusion)\n• Competitive advantage for space and nutrients\n• Produce substances harmful to pathogens\n• Alter conditions that affect pathogen survival\n• Commensalism: one organism benefits while the other (host) is \nunharmed\n• Probiotics: live microbial cultures administered to exert a beneficial effect\nEXPLORING THE MICROBIOME: THE \nMICROBIOME’S SHAPING OF INNATE IMMUNITY\n• Strict asepsis is required to raise germ -free mice."
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "혈액 내 형성 요소(적혈구, 백혈구, 혈소판)와 혈액 생성 과정을 설명합니다. 특히 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상세포, 림프구)를 포함한 백혈구의 종류와 기능, 림프계의 역할을 다룹니다. 또한 식세포의 종류(고정/자유 대식세포)와 화학주성, 부착, 섭취, 소화 과정을 포함한 식작용 메커니즘, 그리고 미생물이 식작용을 회피하는 전략을 설명합니다.",
                "chapter_full_text": "FORMED ELEMENTS IN BLOOD\n• Cells and cell fragments suspended in plasma\n• Erythrocytes (red blood cells)\n• Leukocytes (white blood cells)\n• Platelets\n• Created in red bone marrow stem cells via hematopoiesis\nFORMED ELEMENTS IN BLOOD\n• Granulocytes are leukocytes with \ngranules in their cytoplasm that are \nvisible with a light microscope\n• Neutrophils: phagocytic; work in early \nstages of infection\n• Basophils: release histamine; work in \nallergic responses\n• Eosinophils: phagocytic; toxic against \nparasites and helminths\nFORMED ELEMENTS IN BLOOD\n• Agranulocytes are leukocytes with \ngranules in their cytoplasm that are not \nvisible with a light microscope\n• Monocytes: mature into macrophages in \ntissues where they are phagocytic\n• Dendritic cells: found in the skin, mucous \nmembranes, and thymus; phagocytic\n• Lymphocytes: T cells, B cells, and NK cells; \nplay a role in adaptive immunity\nTHE LYMPHATIC SYSTEM\n• Lymph, lymphatic vessels, \nlymphoid tissue, and red bone \nmarrow\n• Contains lymphocytes and \nphagocytic cells\n• Lymph carries microbes to lymph \nnodes where lymphocytes and \nmacrophages destroy the \npathogen\nThoracic (left\nlymphatic) duct\nRight\nlymphatic duct\nLeft\nsubclavian\nvein\nRight\nsubclavian\nvein\nTonsil\nThymus\nLymph node\nThoracic duct\nSpleen\nLarge intestine\nSmall intestine\nPeyer’s patch\nLymphatic vessel\nRed bone marrow\nLYMPHATIC CAPILLARIES\nHOST DEFENSES: OVERVIEW\nPHAGOCYTES\n• Phago: from the Greek, meaning \neat\n• Cyte: from the Greek, meaning \ncell\n• Fixed macrophages are \nresidents in tissues and organs\n• Free (wandering) macrophages \nroam tissues and gather at sites of \ninfection\nTHE MECHANISM OF PHAGOCYTOSIS\n• Chemotaxis\n• Chemical signals attract phagocytes to \nmicroorganisms\n• Adherence\n• Attachment of a phagocyte to the surface \nof the microorganism\n• Ingestion\n• Opsonization: microorganism is coated \nwith serum proteins, making ingestion \neasier\n• Digestion\n• Microorganism is digested inside a \nphagolysosome\nPHAGOCYTOSIS: OVERVIEW\nPHAGOCYTOSIS: MECHANISM\nInhibit adherence: \nM protein, capsules\nStreptococcus pyogenes, S. pneumoniae\nKill phagocytes: \nleukocidins\nStaphylococcus aureus\nLyse phagocytes: \nmembrane attack complex\nListeria monocytogenes\nEscape phagosome Shigella, Rickettsia\nPrevent phagosome–\nlysosome fusion\nHIV, Mycobacterium tuberculosis\nSurvive in phagolysosome Coxiella burnetii\nMICROBIAL EVASION OF PHAGOCYTOSIS\nVIRULENCE FACTORS: HIDING FROM HOST \nDEFENSES\nVIRULENCE FACTORS: INACTIVATING HOST \nDEFENSE"
              },
              {
                "chapter_title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf",
                "chapter_content_summary": "염증의 4가지 주요 증상(발적, 부종, 통증, 열)과 그 목적(손상 요인 제거, 조직 복구)을 설명합니다. 보체 시스템의 활성화 경로(고전적, 대체, 렉틴 경로)와 그 결과(세포 용해, 옵손화, 염증 유발)를 다룹니다. 또한 인터페론(IFN), 철 결합 단백질, 항균 펩타드 등 다른 항균 물질의 역할과 유전적 저항성 및 나이와 같은 추가 방어 요인을 소개합니다.",
                "chapter_full_text": "INFLAMMATION: OVERVIEW\nINFLAMMATION\n• Four signs and symptoms: redness, swelling ( edema), pain, heat\n• Destroys injurious agent or limits its effects on the body\n• Repairs and replaces tissue damaged by the injurious agent\nINFLAMMATION\n• Inflammation activates acute-phase proteins by the liver that cause \nvasodilation and increased permeability of blood vessels\n• Histamine\n• Kinins\n• Prostaglandins\n• Leukotrienes\n• Cytokines\nINFLAMMATION\nVasoactive Mediator Source Effect\nHistamine Mast cells, basophils, \nand platelets\nVasodilation and increased permeability \nof blood vessels\nKinins Blood plasma Chemotaxis by attracting neutrophils\nProstaglandins Damaged cells Intensify the effects of histamine and \nkinins and help\nphagocytes move through capillary walls\nLeukotrienes Mast cells and basophils Increase permeability of blood vessels and \nhelp attach\nphagocytes to pathogens\nComplement (See \nFigure 6.12)\nBlood plasma Stimulates release of histamine, attracts \nphagocytes, and promotes phagocytosis\nCytokines Fixed macrophages Vasodilation and increased permeability \nof blood vessels\nINFLAMMATION: STEPS\nFigure 16.9a-b The process of inflammation.\nTissue damage\nEpidermis\nDermis\nSubcu-\ncutaneous\ntissue\nBacteria\nBlood\nvessel\nNerve\nVascular reactions and phagocytosis\nChemicals such as histamine,\nkinins, prostaglandins,\nleukotrienes, and cytokines\n(represented as blue dots) are\nreleased by damaged cells.\nBlood clot forms.\nAbscess starts to form\n(orange area).\nTHE PROCESS OF INFLAMMATION\nPHAGOCYTE MIGRATION AND \nPHAGOCYTOSIS\n• Margination is the sticking of phagocytes to blood vessels in response to \ncytokines at the site of inflammation\n• Phagocytes squeeze between endothelial cells of blood vessels via \ndiapedesis\nTISSUE REPAIR\n• Cannot be completed until \nall harmful substances are \nremoved or neutralized\n• Stroma is the supporting \nconnective tissue that is \nrepaired\n• Parenchyma is the \nfunctioning part of the \ntissue that is repaired\nFEVER\n• Abnormally high body temperature\n• Hypothalamus is normally set at 37 °C\n• Cytokines cause the hypothalamus to release prostaglandins that reset \nthe hypothalamus to a higher temperature\n• Body constricts the blood vessels, and shivering occurs (which raises \ntemperature)\n• As body temperature falls (crisis), vasodilation and sweating occurs\nTHE COMPLEMENT SYSTEM\n• Serum proteins produced by the liver that assist the immune system in \ndestroying microbes\n• Act in a cascade in a process called complement activation\n• Proteins are designated with uppercase C and numbered in order of \ndiscovery\n• Activated fragments are indicated with lowercase a and b\nCOMPLEMENT: OVERVIEW\nCOMPLEMENT: ACTIVATION\nTHE CLASSICAL PATHWAY\n• Antibodies bind to antigens, activating C1\n• C1 splits and activates C2 and C4\n• C2a and C4b combine and activate C3\n• C3a functions in inflammation\n• C3b functions in cytolysis and opsonization\nTHE ALTERNATIVE PATHWAY\n• C3 present in the blood combines with factors \nB, D, and P on microbe surface\n• C3 splits into C3a and C3b, functioning the \nsame as in the classical pathway\nTHE LECTIN PATHWAY\n• Macrophages ingest pathogens, releasing \ncytokines that stimulate lectin production \nin the liver\n• Mannose-binding lectin (MBL) binds to \nmannose, activating C2 and C4\n• C2a and C4b activate C3, which functions \nthe same as in the classical and \nalternative pathways\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Cytolysis\n• Activated complement \nproteins create a \nmembrane attack \ncomplex (MAC)\n• Opsonization\n• Promotes attachment of \na phagocyte to a microbe\n• Inflammation\n• Activated complement \nproteins bind to mast \ncells, releasing histamine\nFigure 16.12 Outcomes of Complement Activation\noutcomes of complement activation\nC3\nSplits into activated C3a and C3b\ncytolysis opsonization inflammation\nC3a C3b\nC5\nC5a C5b\nC6\nC7 C8\nC9\nChannel\nC6\nC7 C5b\nC8 C9\nC3b protein\nPhagocyte\nMicrobe\nC3a C3b C3a C3b\nC5\nC5a C5b\nC3a\nC3a\nreceptor Mast cell\nC5a\nreceptor\nMicrobes burst as extracellular \nfluid flows in through transmembrane channel\nformed by membrane attack complex.\nCoating microbes with C3b\nenhances phagocytosis.\nBlood vessels become more\npermeable, and chemotactic agents\nattract phagocytes to area.\nThe complement system is another way the body fights infection and destroys pathogens. This component of innate immunity \n“complements” other immune reactions.\nComplement is a group of over 30 proteins circulating in serum that are activated in a cascade: one complement protein triggers \nthe next.\nThe cascade can be activated by a pathogen directly or by an antibody–antigen reaction.\nTogether these proteins destroy microbes by (1) cytolysis, (2) enhanced phagocytosis, and (3) inflammation.\nC5a\nHistamine\nKEY CONCEPTS\nMicrobes Phagocytesa\nFigure 16.13 Inflammation stimulated by complement.\nMast cell\nC5a\nC5a receptor\nHistamine\nNeutrophil\nMacrophageC5a\nC3a\nHistamine-\nreleasing\nmast cell C3a receptor\nHistamine-\ncontaining\ngranule\nPhagocytes\nCOMPLEMENT: RESULTS\nOUTCOMES OF COMPLEMENT ACTIVATION\n• Regulation of complement\n• Regulatory proteins readily break down complement proteins, minimizing host cell \ndestruction\n• Complement and disease\n• Lack of complement proteins causes susceptibility to infections\n• Evading the complement system\n• Capsules prevent complement activation\nINTERFERONS   \n• Cytokines produced by cells; have antiviral activity\n• IFN-α and IFN-β: produced by cells in response to viral infections; cause \nneighboring cells to produce antiviral proteins (AVPs) that inhibit viral \nreplication\n• IFN-: causes neutrophils and macrophages \nto kill bacteria\nANTIVIRAL ACTION OF ALPHA AND BETA \nINTERFERONS (IFNS)   \nIRON-BINDING PROTEINS\n• Transferrin: found in blood and tissue fluids\n• Lactoferrin: found in milk, saliva, and mucus\n• Ferritin: found in the liver, spleen, and red bone marrow\n• Hemoglobin: located in red blood cells\n• Bacteria produce siderophores to compete with iron-binding proteins\nANTIMICROBILE PEPTIDES\n• Short peptides produced in response to protein and sugar molecules on \nmicrobes\n• Inhibit cell wall synthesis\n• Form pores in the plasma membrane\n• Broad spectrum of activity\nOTHER FACTORS\n• Genetic resistance\n• Confers a selective survival advantage\n• E.g., sickle cell trait and Plasmodium falciparum\n• Age\n• Very young and elderly are more susceptible to disease\n• Observing healthy protocols"
              },
              {
                "chapter_title": "적응성 면역: 개요 및 이중적 특성",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "특정 병원체를 표적으로 하는 적응성 면역의 개념, 감염 또는 백신 접종을 통해 획득되는 특성, 그리고 1차 및 2차 반응의 차이를 설명합니다. 또한 항체를 생성하는 B 세포가 관여하는 체액성 면역과 T 림프구가 관여하는 세포성 면역이라는 적응성 면역의 이중적 특성을 소개합니다.",
                "chapter_full_text": "THE ADAPTIVE IMMUNE SYSTEM\n• Adaptive immunity: defenses that target a specific pathogen\n• Acquired through infection or vaccination\n• Primary response: first time the immune system combats a particular foreign \nsubstance\n• Secondary response: later interactions with the same foreign substance; faster and \nmore effective due to \"memory\"\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Humoral immunity\n• Produces antibodies that combat foreign molecules known as antigens\n• B cells are lymphocytes that are created and mature in red bone marrow\n• Recognize antigens and make antibodies\n• Named for bursa of Fabricius in birds\nANIMATION: HUMORAL IMMUNITY: \nOVERVIEW \nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity (cell-mediated immunity) \n• Produces T lymphocytes\n• Recognize antigenic peptides processed by phagocytic cells\n• Mature in the thymus\n• T cell receptors (TCRs) on the T cell surface contact antigens, causing the T cells \nto secrete cytokines instead of antibodies\nT CELL AND B CELL DEVELOPMENT\nDUAL NATURE OF THE ADAPTIVE IMMUNE \nSYSTEM\n• Cellular immunity attacks antigens found inside cells\n• Viruses; some intracellular bacteria such as M. leprae and L. monocytogenes\n• Humoral immunity fights invaders and threats outside cells\n• Extracellular bacteria and toxins\n• Viruses before they enter a host cell"
              },
              {
                "chapter_title": "적응성 면역: 사이토카인, 항원 및 항체",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역 세포 간의 화학적 전달자인 사이토카인(인터류킨, 케모카인, 인터페론, 종양 괴사 인자 등)의 종류와 역할을 설명합니다. 항원(항체 생성을 유도하는 물질)과 항체(면역글로불린, Ig)의 개념, 항체의 에피토프 결합, 햅텐의 역할, 항체의 구조(가변/불변 영역) 및 5가지 주요 면역글로불린(IgG, IgM, IgA, IgD, IgE)의 특성과 기능을 상세히 다룹니다.",
                "chapter_full_text": "CYTOKINES: CHEMICAL MESSENGERS OF \nIMMUNE CELLS\n• Cytokines are chemical messengers produced in response to a stimulus\n• Interleukins: cytokines between leukocytes\n• Chemokines: induce migration of leukocytes\n• Interferons (IFNs): interfere with viral infections of host cells\n• Tumor necrosis factor (TNF): involved in the inflammation of autoimmune \ndiseases\n• Hematopoietic cytokines: control stem cells that develop into red and white blood \ncells\n• Overproduction of cytokines leads to a cytokine storm\n12\nCytokine Source Target Cell(s) Effect\nI L-4 TH2 Naïve TH; B cells Proliferate TH2 cells; Class switching to I g E\nI L-12 Dendritic cells, \nmacrophages, \nneutrophils\nNaïve TH; N K cells Stimulates growth and function of TH1 cells; \nStimulates I F N-γ and T N F-α\nI L-17 TH17 Neutrophils Inflammation\nI L-22 TH17 Epithelial cells Stimulates epithelial cells to make \nantimicrobial proteins\nGamma \ninterferon \n(I F N-γ)\nTH1 C T L, macrophages Promote phagocytosis; activate\nmacrophages and humoral response\nChemokines Varies; macrophages \nand epithelial cells\nNeutrophils Chemotaxis\nT N F-alpha \n(T N F-α)\nMacrophages, TH, N \nK cells\nTumor cells Inflammation\nG M-C S F Macrophages, T \ncells, N K cells\nMyeloid stem cells Increase macrophages and granulocytes\nKEY CYTOKINES AND THEIR ROLES\nANTIGENS\n• Antigens: substances \nthat cause the production \nof antibodies\n• Usually components of \ninvading microbes or \nforeign substances\n• Antibodies interact with \nepitopes, or antigenic \ndeterminants, on the \nantigen\nHAPTENS\n• Haptens: antigens \ntoo small to \nprovoke immune \nresponses; attach \nto carrier molecules\nANTIBODIES\n• Globular proteins called immunoglobulins (Ig)\n• Valence is the number of antigen-binding sites on an antibody\n• Bivalent antibodies have two binding sites\nANTIBODIES\n• Four protein chains form a Y-shape\n• Two identical light chains and two identical heavy chains joined by disulfide links\n• Variable (v) regions are at the ends of the arms; bind epitopes\n• Constant (Fc) region is the stem, which is identical for a particular Ig class\n• Five classes of Ig (IgG, IgM, IgA, IgD, IgE)\nTHE STRUCTURE OF A TYPICAL ANTIBODY \nMOLECULE\nIgG\n• Monomer\n• 80% of serum antibodies\n• In the blood, lymph, and intestine\n• Cross the placenta and protect fetus; trigger complement; enhance \nphagocytosis; neutralize toxins and viruses\nIgM\n• Pentamer made of five monomers held with a J chain\n• 6% of serum antibodies\n• Remain in blood vessels\n• Cause clumping of cells and viruses\n• First response to an infection; short -lived\nIgA\n• Monomer in serum; dimer in secretions\n• 13% of serum antibodies\n• Common in mucous membranes, saliva, tears, and breast milk\n• Prevent microbial attachment to mucous membranes\nIgD\n• Monomer\n• 0.02% of serum antibodies\n• Structure similar to IgG\n• In blood, in lymph, and on B cells\n• No well-defined function; assists in the immune response on B cells\nIgE\n• Monomer\n• 0.002% of serum antibodies\n• On mast cells, on basophils, and in blood\n• Cause the release of histamines when bound to antigen; lysis of parasitic \nworms\nA SUMMARY OF IMMUNOGLOBULIN \nCLASSES"
              },
              {
                "chapter_title": "적응성 면역: 체액성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "B 세포의 활성화 및 클론 선택 과정을 설명합니다. 특히 주조직적합복합체(MHC)의 역할, B 세포가 항원을 처리하고 MHC 클래스 II 분자에 제시하는 과정, T 도우미 세포(TH)의 활성화를 통한 B 세포의 증식(클론 확장)을 다룹니다. 또한 항원-항체 결합의 결과로 나타나는 응집, 옵손화, 항체 의존성 세포 매개성 세포독성(ADCC), 중화, 보체 시스템 활성화 등 다양한 보호 메커니즘을 설명합니다.",
                "chapter_full_text": "ACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Major histocompatibility complex (MHC) genes encode molecules on \nthe cell surface\n• Class I MHC are on the membrane of all nucleated animal cells\n• Identify \"self\"\n• Class II MHC are on the surface of professional antigen-presenting cells (APCs), \nincluding B cells\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• Inactive B cells contain surface Ig that bind to antigen\n• B cell internalizes and processes antigen\n• Antigen fragments are displayed on MHC class II molecules\n• T helper cell (TH) contacts the displayed antigen fragment and releases \ncytokines that activate B cells\n• B cell undergoes proliferation ( clonal expansion)\nExtracellular\nantigens\nB cell\nreceptors\nAntigen\nfragments\nMHC class II with\nantigen displayed\non surface Cytokines\nTH cell\nB cellB cell\nPlasma cell Antibodies\nB cell receptors \nrecognize and \nattach to antigen.\nAntigen is\ninternalized into \nthe B cell. \nFragments of the \nantigen are presented \non MHC proteins on \nthe surface of the cell.\nA T helper cell that recognizes\nthis antigen fragment is \nactivated and releases \ncytokines, activating the B cell. \nThe activated B cell begins \nclonal expansion, producing an \narmy of antibody-producing \nplasma cells and memory cells.\n• Clonal selection \ndifferentiates \nactivated B cells \ninto:\n• Antibody-producing \nplasma cells\n• Memory cells\n• Clonal deletion \neliminates harmful B \ncells\nStem cells differentiate into mature B cells,\neach bearing surface immunoglobulins\nagainst a specific antigen.\nB cell II encounters its specific antigen\nand proliferates.\nStem cell\nB cell\nI II\nImmunoglobin\nAntigens\nSome B cells proliferate into long-lived\nmemory cells, which at a later date can be\nstimulated to become antibody-\nproducing plasma cells.\nMemory\ncell\nPlasma\ncell\nOther B cells proliferate\ninto antibody-producing\nplasma cells.\nPlasma cells secrete antibodies\ninto circulation.\nBlood vessel of cardiovascular system\nACTIVATION AND CLONAL SELECTION OF \nANTIBODY-PRODUCING CELLS\n• T-dependent antigen\n• Antigen that requires a TH \ncell to produce antibodies\n• T-independent antigens\n• Stimulate the B cell \nwithout the help of T cells\n• Provoke a weak immune \nresponse, usually \nproducing IgM\n• No memory cells \ngenerated\nPolysaccharide\n(T-independent antigen)\nEpitopes\nB cell receptors\nCLONAL SELECTION OF ANTIBODY-\nPRODUCING CELLS\nANTIGEN PROCESSING AND \nPRESENTATION: OVERVIEW\nHUMORAL IMMUNITY: CLONAL SELECTION \nAND EXPANSION\nANTIGEN-ANTIBODY BINDING AND ITS \nRESULTS\nReduces number of infectious\nunits to be dealt with\nAntibody Bacteria\nAgglutination\nPROTECTIVE MECHANISM\nOF BINDING ANTIBODIES\nTO ANTIGENS\nOpsonization Antibody-dependent cell -mediated cytotoxicity\nActivation of complement\nBacterium Lysis\nComplement\nCauses inflammation and cell lysis\nAntibodies attached to target cell\ncause destruction by macrophages, \neosinophils, and NK cells\nEpitopes\nEosinophil\nPerforin\nand lytic\nenzymes\nLarge target cell (parasite)\nNeutralization\nBlocks adhesion of bacteria\nand viruses to mucosa\nBlocks attachment\nof toxin\nToxin\nBacterium\nVirus\nPhagocyte\nCoating antigen with antibody\nenhances phagocytosis\n• An antigen–antibody \ncomplex forms when \nantibodies bind to antigens\n• Strength of the bond is the \naffinity\n• Protects the host by tagging \nforeign molecules or cells for \ndestruction\n• Agglutination\n• Opsonization\n• Antibody-dependent cell-\nmediated cytotoxicity\n• Neutralization\n• Activation of the \ncomplement system\nHUMORAL IMMUNITY: ANTIBODY FUNCTION"
              },
              {
                "chapter_title": "적응성 면역: 세포성 면역 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "T 세포가 세포 내 병원체와 싸우는 방식과 T 세포의 성숙 및 이동 과정을 설명합니다. 항원 제시 세포(APC)의 종류(수지상세포, 대식세포)와 역할, CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)와 CD8+ T 세포(세포독성 T 림프구, CTL)의 종류와 기능을 상세히 다룹니다. CTL이 감염된 세포를 인식하고 아폽토시스를 유도하는 메커니즘을 설명하며, 자연 살해(NK) 세포의 역할도 소개합니다.",
                "chapter_full_text": "CELULAR IMMUNITY RESPONSE PROCESS\n• T cells combat intracellular pathogens\n• Mature in the thymus\n• Thymic selection eliminates immature T cells\n• Migrate from the thymus to lymphoid tissues\n• Attach to antigens via T-cell receptors (TCRs)\nCELULAR IMMUNITY RESPONSE PROCESS\n• Pathogens entering the \ngastrointestinal tract pass \nthrough microfold cells (M \ncells) located over Peyer's \npatches\n• Transfer antigens to lymphocytes \nand antigen-presenting cells \n(APCs)\nANTIGEN-PRESENTING CELLS (APCs)\n• Dendritic cells (DCs)\n• Engulf and degrade \nmicrobes and display them \nto T cells\n• Found in the skin, genital \ntract, lymph nodes, spleen, \nthymus, and blood\n• Macrophages\n• Activated by cytokines or \nthe ingestion of antigenic \nmaterial\n• Migrate to the lymph tissue, \npresenting antigen to T \ncells\nANTIGEN PROCESSING AND \nPRESENTATION: MHC\nCLASSES OF T CELLS\n• Clusters of differentiation (CD)\n• CD4+\n• T helper cells (TH)\n• Cytokine signaling with B cells; interact directly with antigens\n• Bind MHC class II molecules on B cells and APCs\n• CD8+\n• Cytoxic T lymphocytes (CTL)\n• Bind MHC class I molecules\nT HELPER CELLS (CD4+ T CELLS)\n• TCR on the CD4+ cell recognize and bind to the antigen fragment and \nMHC class II on APC\n• APC or TH secrete a costimulatory molecule, activating the CD4 + cell\n• TH cells produce cytokines and differentiate into:\n• TH1cells\n• TH2 cells\n• TH17 cells\n• Memory cells\nT HELPER CELLS (CD4+ T CELLS)\n• TH17 cells produce IL-17 \nand contribute to \ninflammation\n• TH1 cells produce IFN-, \nwhich activates \nmacrophages, enhances \ncomplement, and \nstimulates antibody \nproduction that promotes \nphagocytosis \n• TH2 cells activate B cells \nto produce IgE; activate \neosinophils\nAntigen-presenting\ncell\nTH cells of various\nclasses\nTH17 cells secrete cytokines that\npromote inflammatory responses;\nrecruit neutrophils for protection\nagainst extracellular bacteria\nand fungi.\nFungi\nExtracellular bacteria Neutrophil\nIL-17\nIL-4 TH2 cells\nMast cell\nBasophil\nEosinophil\nImportant in allergic responses, \nespecially by production of IgE. \nActivate eosinophils to control \nextracellular parasites such as \nhelminths (see ADCC discussion).\nMacrophage\nIntracellular\nbacteria and\nprotozoa\nTH1 cells are an important element of cellular immunity. \nTheir cytokines (such as IFN-γ and IL-2) activate CD8+ T \ncells and NK cells, which control intracellular pathogens \nby killing infected host cells. They also enhance \nphagocytosis by antigen-presenting cells such as \nmacrophages. \nHelminth\nF-γ\nT HELPER CELLS (CD4+ T CELLS)\nANTIGEN PROCESSING AND \nPRESENTATION: STEPS\nT REGULATORY CELLS\n• T regulatory cells (Treg)  \n• Subset of CD4+ cells; carry an additional CD25 molecule  \n• Suppress T cells against self; protect intestinal bacteria required for \ndigestion; protect fetus\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\n• Precursor T cytotoxic cells (C T L p) are activated to become cytotoxic T lymphocytes (C \nT Ls)\n• Activated into cytotoxic T lymphocyte (CTL) with the help of TH cell and costimulatory signals\n• CTLs recognize and kill self-cells altered by infection\n• Self-cells carry endogenous antigens on a surface presented with MHC class I molecules\n• CTL releases perforin and granzymes that induce apoptosis in the infected cell\nProcessed\nantigen\nProcessed antigen\npresented with\nMHC class I MHC \nclass I\nT cell\nreceptors\nVirus-infected cell (example\nof endogenous antigen)\nVirus-infected cell TH1 cell\nCytokines\nCTLp CTL\nInfected target \ncell is lysed \nA normal cell will not trigger a response \nby a cytotoxic T lymphocyte (CTL), but a\nvirus-infected cell (shown here) or a cancer cell \nproduces abnormal endogenous antigens.\nThe abnormal antigen is presented on the cell \nsurface in association with MHC class I \nmolecules. Binding of a TH1 cell promotes \nsecretion of cytokines.\nThe cytokines activate a \nprecursor CTL, which \nproduces a clone of \nCTLs.\nThe CTL induces \ndestruction of the virus-\ninfected cell by \napoptosis.\n• Apoptosis\n• Programmed cell death\n• Prevents the spread of \ninfectious viruses into other \ncells\n• Cells cut their genome into \nfragments, causing the \nmembranes to bulge \noutward via blebbing\nCYTOTOXIC T LYMPHOCYTES (CD8+ T \nCELLS)\nCELL-MEDIATED IMMUNITY: CYTOTOXIC T \nCELLS\nEXTRACELLULAR KILLING BY THE IMMUNE \nSYSTEM\n• Natural killer (NK) cells\n• Granular leukocytes destroy cells that don't express MHC class I self-antigens\n• Kill virus-infected and tumor cells and attack parasites\n• Not always stimulated by an antigen\n• Form pores in the target cell, leading to lysis or apoptosis\nPRINCIPAL CELLS THAT FUNCTION IN \nCELL-MEDIATED IMMUNITY\nCell Function\nT Helper (TH1) Cell Activates cells related to cellmediated immunity: \nmacrophages, C T Ls, and natural killer cells\nT Helper (TH2) Cell Stimulates production of eosinophils, I g M, and I g E\nT Helper (TH17) Cell Recruits neutrophils; stimulates production of antimicrobial \nproteins\nCytotoxic T Lymphocyte (C \nT L)\nDestroys target cells on contact by inducing apoptosis\nT Regulatory (Treg) Cell Regulates immune response and helps maintain self-\ntolerance\nActivated Macrophage Enhanced phagocytic activity; attacks cancer cells\nNatural Killer (N K) Cell Attacks and destroys target cells; participates in antibody-\ndependent cell-mediated cytotoxicity\nANTIBODY-DEPENDENT CELL-MEDIATED \nCYTOTOXICITY (ADCC)\n• Protozoans and helminths are too large to \nbe phagocytized\n• Protozoan or helminth target cell is coated with \nantibodies\n• Immune system cells attach to the Fc regions \nof antibodies\n• Target cell is lysed by chemicals secreted by \nthe immune system cell\nMacrophage\nCytotoxic cytokines\nLytic enzymes\nPerforin enzymes\nEosinophil\nKEY\nExtracellular\ndamage\nFc region\nLarge\nparasite Epitope\nAntibody\nOrganisms, such as many parasites, that are too large for ingestion\nby phagocytic cells must be attacked externally. \nEosinophils\nFluke\nEosinophils adhering to the larval stage of a\nparasitic fluke"
              },
              {
                "chapter_title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf",
                "chapter_content_summary": "면역학적 기억, 즉 항원에 대한 2차 노출 시 나타나는 더 빠르고 효과적인 2차(기억 또는 재감염) 반응을 설명합니다. 항체 역가와 클래스 전환의 개념을 다룹니다. 또한 자연 획득 능동 면역, 자연 획득 수동 면역, 인공 획득 능동 면역(백신), 인공 획득 수동 면역(항체 주입) 등 적응성 면역의 다양한 유형을 소개합니다.",
                "chapter_full_text": "IMMUNOLOGICAL MEMORY\n• Secondary (memory or anamnestic) \nresponse occurs after the second \nexposure to an antigen\n• Class switching, where initial I g M \nresponse shifts to I g G, I g E, or I g A, occurs\n• More rapid, lasts many days, greater in \nmagnitude\n• Memory cells produced in response to the \ninitial exposure are activated by the \nsecondary exposure\n• Antibody titer is the relative amount \nof antibody in the serum\n• Reflects intensity of the humoral response\nHUMORAL IMMUNITY: PRIMARY IMMUNE \nRESPONSE\nHUMORAL IMMUNITY: SECONDARY \nIMMUNE RESPONSE\nTYPES OF ADAPTIVE IMMUNITY\n• Naturally acquired active \nimmunity\n• Resulting from infection\n• Naturally acquired passive \nimmunity\n• Transplacental or via colostrum\n• Artificially acquired active \nimmunity\n• Injection of vaccination \n(immunization)\n• Artificially acquired passive \nimmunity\n• Injection of antibodies\nTYPES OF ADAPTIVE IMMUNITY\n• Antiserum: blood-derived \nfluids containing antibodies\n• Serology: the study of \nreactions between \nantibodies and antigens\n• Globulins: serum proteins \n• Gamma () globulin: serum \nfraction containing antibodies"
              },
              {
                "chapter_title": "면역학의 실제 적용: 백신",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "백신의 역사와 원리, 면역 유도 및 집단 면역의 중요성을 설명합니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신(재조합 백신, 톡소이드, 바이러스 유사 입자 백신), 다당류 백신, 접합 백신, 핵산 백신(DNA/RNA 백신) 등 다양한 백신 유형의 특성을 다룹니다. 또한 백신 생산, 전달 방법, 보조제 사용, 백신의 안전성에 대한 최신 동향을 포함합니다.",
                "chapter_full_text": "VACCINES\n• Variolation: inoculation of smallpox into the skin \n• Jenner inoculated cowpox to prevent smallpox\n• Termed vaccination by Pasteur\n• vacca = cow\n• Vaccine: suspension of organisms or fractions of organisms that induce \nimmunity\nVACCINES: FUNCTION\nPRINCIPLES AND EFFECTS OF \nVACCINATION\n• Provokes a primary immune response\n• Leads to the formation of antibodies and memory cells\n• Produces a rapid, intense secondary response\n• Herd immunity: immunity in most of the population\n• Outbreaks are sporadic due to the lack of susceptible individuals\nDisease(s) Vaccine Recommendation Booster\nHaemophilus influenzae\ntype b meningitis\nPolysaccharide from \nHaemophilus\ninfluenzae type b\nChildren 2-18 months. None recommended\nMeningococcal meningitis Purified polysaccharide \nfrom Neisseria \nmeningitidis\nFor people with substantial \nrisk of infection;\nrecommended for college \nfreshmen, especially if living \nin dormitories.\nNeed not established\nPneumococcal pneumonia Purified polysaccharide \nfrom 13 or 23 strains o\nP V23 for adults with certain \nchronic diseases; people \nover 65; P V13 for children \n2-18 months; years 4-6.\nNone if first dose\nadministered ≥ 24 months\nTetanus, diphtheria, and \npertussis\nD T a P (children younger \nthan 3), T dap (older \nchildren and adults), Td\n(booster for tetanus and \npertussis)\nD T a P (children 2-18 \nmonths; 4-6 years); Tdap \n(similar to Td; single dose \nfor children aged 11-12 \nyears and adults).\nTdap or Td every 10 years\nCDC-RECOMMENDED VACCINES TO PREVENT \nBACTERIAL DISEASES\nDisease(s) Vaccine Recommendation Booster\nChickenpox Attenuated virus For infants aged 12 months. (Duration of immunity \nnot known)\nHepatitis A Attenuated virus Children at age 1 year; live in or travel to \nendemic area; homosexual men; street -\ndrug users; receive blood -clotting factors.\nDuration of protection \nestimated at about 10 \nyears\nHepatitis B Antigenic fragments of virus For infants and children; for adults, \nespecially health care workers, \nhomosexual men, injecting street -\ndrug users, heterosexual people with multiple \npartners, and household contacts of \nhepatitis B carriers.\nDuration of protection at \nleast 7 years; need for \nboosters\nuncertain\nHerpes zoster Attenuated virus Adults over age 60. None recommended\nHuman\npapillomavirus\nAntigenic fragments of virus Boys and girls ages 11-12. Duration at least 5 \nyears\nInfluenza Injected vaccine, inactivated virus (A nasally \nadministered vaccine with attenuated virus \nis not available for the 2016 -2017 flu \nseason.)\nEveryone over 6 months of age. Annual\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nDisease(s) Vaccine Recommendation Booster\nMeasles Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nMumps Attenuated virus For infants aged 15 months. Adults if exposed during outbreak\nPoliomyeliti\ns\nKilled virus For children; for adults, as risk to \nexposure warrants.\n(Duration of immunity not known)\nRabies Killed virus For field biologists in contact with \nwildlife in endemic areas; for \nveterinarians; for people exposed to \nrabies virus by bites.\nEvery 2 years\nRotavirus Rota Teq®, modified \nrotaviruses; Rotarix® vaccine, \nattenuated strain\nOral, for infants up to 8 months None recommended\nRubella Attenuated virus For infants aged 15 months; for \nwomen of childbearing age who are \nnot pregnant.\nAdults if exposed during outbreak\nSmallpox Live vaccinia virus Certain military and health care \npersonnel.\nDuration of protection estimated at \nabout 3 to 5 years\nCDC-RECOMMENDED VACCINES TO PREVENT VIRIAL \nDISEASES\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Live attenuated vaccines\n• Weakened pathogen\n• Closely mimic an actual infection\n• Confers lifelong cellular and humoral immunity\n• Inactivated killed vaccines\n• Safer than live vaccines\n• Require repeated booster doses\n• Induce mostly humoral immunity\nFigure 18.1 Influenza viruses are grown in embryonated eggs.\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Subunit vaccines use antigenic fragments to stimulate an immune \nresponse\n• Recombinant vaccines: subunit vaccines produced by genetic modification\n• Toxoids: inactivated toxins\n• Antitoxins: serums containing antibodies against the toxin\n• Virus-like particle (VLP) vaccines: resemble intact viruses but do not contain viral \ngenetic material\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Polysaccharide vaccines \n• made from molecules in pathogen’s capsule; not very immunogenic \n• Conjugated vaccines: \n• used for diseases in children with poor immune response to capsular \npolysaccharides\nTYPES OF VACCINES AND THEIR \nCHARACTERISTICS\n• Nucleic acid (D N A) \nvaccines\n• Injected naked D N A produces \nthe protein antigen encoded in \nthe D N A\n• Stimulate humoral and cellular \nimmunity\n• Recombinant vector \nvaccines\n• Avirulent viruses or bacteria \nare genetically modified to \ndeliver genes coding for \nantigens\nRNA VACCINES\nVACCINES: TYPES\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Develop vaccines without the use of animal host\n• Use of plants as source for vaccines\n• More oral vaccines\n• Dry vaccines (skin patch)\n• Nanopatch\n : delivers a dry formulation of a vaccine to the skin\n• Skin contains high numbers of A P Cs\n• Requires no refrigeration\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Multiple-combination vaccines\n• Vaccines for chronic diseases\n• “Reverse vaccinology” for the development of cellular immunity\nVACCINE PRODUCTION, DELIVERY \nMETHODS, AND FORMULATIONS\n• Adjuvants are chemical additives added to vaccines to improve \neffectiveness\n• Alums and a monophosphoryl lipid A are the only approved adjuvants in the United \nStates\n• Improve the innate immune response\nEXPLORING THE MICROBIOME: MICROBIOME \nMAY ENHANCE RESPONSE TO ORAL VACCINES\n• The lactic-acid bacterium, Bifidobacterium, is a normal part of the \nintestinal microbiome.\nSAFETY OF VACCINES\n• On rare occasions, vaccines can cause the disease\n• No medical or scientific proof of MMR vaccines being linked to autism\n• Safest and most effective means of preventing infectious disease in \nchildren"
              },
              {
                "chapter_title": "면역학의 실제 적용: 진단 면역학",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf",
                "chapter_content_summary": "진단 면역학적 검사의 민감도와 특이성을 정의하고, 항원-항체 반응을 이용한 다양한 진단 기법을 소개합니다. 단클론 항체(Mabs)의 생산 및 응용, 침전 반응, 응집 반응(직접/간접 응집, 혈액형 검사), 중화 반응, 보체 고정 반응, 형광 항체 기술(직접/간접 FA, FACS), 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯팅 등 주요 진단 방법의 원리와 활용을 상세히 다룹니다.",
                "chapter_full_text": "DIAGNOSTIC IMMUNOLOGY\n• Sensitivity: probability that the test is reactive if the specimen is a true \npositive\n• Specificity: probability that a positive test will not be reactive if a \nspecimen is a true negative\n• Immunologic-based diagnostic tests\n• Interactions of humoral antibodies with antigens\n• Known antibody can identify an unknown pathogen\n• Known pathogen can identify an unknown antibody\nMONOCLONAL ANTIBODIES\n• Hybridoma: \"immortal\" cancerous B cell (myeloma) combined with an \nantibody-producing normal B cell\n• Hybridoma produces monoclonal antibodies (Mabs)\nMONOCLONAL ANTIBODIES\n• Mabs are uniform, highly specific, and produced in large quantities\n• Used in diagnostic tools\n• Used in human therapy \n• Neutralize TNF with rheumatoid arthritis\n• Treat allergic asthma by preventing the binding of IgE on mast cells and basophils\n• Often derived from mouse cells, leading to side effects\nMONOCLONAL ANTIBODIES\n• Chimeric monoclonal antibodies: Mabs with a mouse variable region \nand human constant region\n• Humanized antibodies: Mabs that are mostly human, except for mouse \nantigen-binding sites\n• Fully human antibodies: Mabs produced from a human gene on a \nmouse\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nMONOCLONAL ANTIBODIES\nPRODUCTION OF MONOCLONAL \nANTIBODIES\nPRECIPITATION REACTIONS\n• Reaction of soluble antigens with antibodies to form large, interlocking \naggregates called lattices\n• Antigen-antibody complex forms, followed by the formation of a lattice that \nprecipitates from solution\n• Precipitin ring test: a cloudy line forms where there is the optimal ratio of \nantigen and antibody\nAntibodyAntigen\nZone of\nantibody\nexcess\nZone of\nequivalence\nPrecipitate\nformed\nZone of\nantigen\nexcess\nA PRECIPITATION CURVE\nAntigens \n(soluble)\nZone of equivalence: \nvisible precipitate\nAntibodies\nPrecipitation\nband\nA PRECIPITIN RING TEST\nPRECIPITATION REACTIONS\n• Immunodiffusion tests are precipitation reactions carried out in an agar \ngel medium\n• Precipitate develops at the point where the optimal antigen-antibody ratio occurs\n• Immunoelectrophoresis combines electrophoresis with immunodiffusion\n• Separates proteins in human serum\nAGGLUTINATION REACTIONS\n• Particulate antigens binding to antibodies to form visible aggregates\n• Direct agglutination tests\n• Detect antibodies against large cellular antigens\n• Measure concentration of serum antibody (known as titer)\n• Rise in titer indicates a greater immunity to disease\n• Seroconversion is a significant change in titer as a disease progresses\nEpitopes\nIgM\nBacterium\nAN AGGLUTINATION REACTION\nMEASURING ANTIBODY TITER WITH THE \nDIRECT AGGLUTINATION TEST\nAGGLUTINATION REACTIONS\n• Indirect (passive) agglutination tests\n• Antibody reacts with the soluble antigen adhering to the particles or vice versa\n• Hemagglutination \n• Agglutination of RBC surface antigens and complementary antibodies; used in \nblood typing\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Differentiate agglutination from precipitation tests.\n• Define hemagglutination.\n• Explain how a neutralization test works.\n• Differentiate precipitation from neutralization tests.\n• Explain the basis for the complement -fixation test.\nNEUTRALIZATION REACTIONS\n• Viral hemagglutination occurs when viruses agglutinate R  B Cs without an \nantigen-antibody reaction\n• Mumps, measles, influenza\nNEUTRALIZATION REACTIONS\n• Antigen-antibody reaction where the harmful effects of an exotoxin or a \nvirus are blocked by antibodies to the toxin (antitoxin)\n• Viral hemagglutination inhibition test is used for subtyping viruses\n• Viruses and RBCs are mixed with the patient's serum\n• If the serum contains antibodies to a virus, they neutralize the virus and inhibit hemagglutination\nCOMPLEMENT-FIXATION \nREACTIONS\n• Complement fixation: complement serum \nprotein binds to and is fixed to the antigen –\nantibody complex\n• Detects small amount of antibody\n• Works for antibodies that do not work with \nprecipitation or agglutination reactions\nDIAGNOSTIC IMMUNOLOGY\nLearning Objectives\n• Compare and contrast direct and indirect fluorescent -antibody tests.\n• Explain how direct and indirect ELISA tests work.\n• Explain how Western blotting works.\n• Explain the importance of monoclonal antibodies.\nFLUORESCENT-ANTIBODY TECHNIQUES\n• Combine fluorescent dyes \nwith antibodies \n• Direct FA tests\n• Identify a microorganism in \na clinical specimen\n• Indirect FA tests\n• Detect a specific antibody in \nserum\n• Anti-human immune \nserum globulin (anti-\nHISG) is added and will \nreact with any antibody in \nserum if the result is \npositive\nFLUORESCENT-ANTIBODY \nTECHNIQUES\n• Fluorescence-activated cell sorter \n(FACS)\n• Laser beam strikes a droplet containing a cell\n• Detector determines size and fluorescence of \nsurface molecules\n• Imparts a charge to the cell, separating cells\nENZYME-LINKED IMMUNOSORBENT ASSAY \n(ELISA)\n• Direct ELISA\n• Detects antigens\n• Sample containing antigens is mixed with antibody\n• Enzyme-linked antibodies react with the antigen \n• Detected by adding a substrate for the linked enzyme; a color is produced\n• Indirect ELISA\n• Detects antibodies\nTHE ELISA METHOD\nWESTERN BLOTTING (IMMUNOBLOTTING)\n• Western blotting\n• Identifies proteins via electrophoresis and a blot\nWESTERN BLOTTING\nTHE FUTURE OF DIAGNOSTIC AND \nTHERAPEUTIC IMMUNOLOGY\n• Tests that require less human judgment and personnel\n• PCR and DNA probes\n• Inexpensive and simple tests for developing countries\n• Disease prevention and therapy"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 과민 반응",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "과민 반응의 개념과 4가지 유형(아나필락시스, 세포독성, 면역 복합체, 지연성 세포 매개)을 설명합니다. IgE 항체와 비만세포/호염기구의 탈과립을 통한 히스타민 등 매개체 방출이 특징인 1형(아나필락시스) 반응, IgG 또는 IgM 항체와 항원성 세포의 결합으로 세포 용해를 유발하는 2형(세포독성) 반응(ABO 혈액형, Rh 부적합), 혈청 내 용해성 항원과 항체의 면역 복합체가 조직에 침착하여 염증을 유발하는 3형(면역 복합체) 반응, 그리고 T 세포에 의해 유발되는 24-48시간 지연성 4형(지연성 세포 매개) 반응의 메커니즘과 예시를 다룹니다.",
                "chapter_full_text": "HYPERSENSITIVITY\n• Antigenic response beyond normal\n• Occurs when sensitized by previous exposure to an antigen (allergen)\n• Four types of hypersensitivity: anaphylactic, cytotoxic, immune complex, \ndelayed cell-mediated\n• Study of hypersensitivity reactions is called immunopathology.\n• Hygiene hypothesis suggests that limiting exposure to pathogens may \nlower immune tolerance and the ability to cope with harmless antigens\nTYPES OF HYPERSENSITIVITY\nType of Reaction Time Before \nClinical Signs\nCharacteristics Examples\nType Ⅰ \n(Anaphylactic)\n< 30 minutes lgE binds to mast cells or basophils; \ncauses degranulation of mast cell or \nbasophil and release of reactive \nsubstances such as histamine.\nAnaphylactic shock from drug injections \nand insect venom: common allergic \nconditions, such as hay fever, asthma\nType Ⅱ \n(Cytotoxic) \n5-12 hours Antigen causes formation of lgM and \nlgG antikndies that bind to target cell; \nwhen combined with action of \ncomplement, destroys target cell. \nTransfusion reactions, Rh incompatibility\nType Ⅲ (Immune \nComplex) \n3-8 hours Antibodies and antigens form \ncomplexes that cause damaging \ninflammation. \nArthus reactions, serum sickness\nType Ⅳ (Delayed \nCell- Mediated, or \nDelayed \nHypersensitivity)\n24-48 hours Antigens activate C T Ls that kills \ntarget cell.\nRejection of transplanted tissues; contact \ndermatitis, such as poison ivy; certain \nchronic diseases, such as tuberculosis\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Occurs minutes after a person sensitized \nto an antigen is reexposed to that \nantigen\n• Antigens combine with IgE antibodies\n• IgE attaches to mast cells and \nbasophils\n• Mast cells and basophils undergo \ndegranulation, which releases mediators\n• Histamine: increases the permeability of blood \ncapillaries\n• Leukotrienes: cause prolonged contraction of \nsmooth muscles\n• Prostaglandins: affect smooth muscle and \nincrease mucus secretion\nHistamine granule\nMast cell or\nbasophil Granule\nIgE\nIgE antibodies, produced in response to an antigen, coat mast cells \nand basophils. When an antigen bridges the gap between two \nadjacent antibody molecules of the same specificity, the cell \nundergoes degranulation and releases histamine and other mediators.\nA degranulated mast cell that has reacted with an antigen and\nreleased granules of histamine and other reactive mediators\nHistamine and\nother mediators\nAntigen\nMast cells\nTYPE I (ANAPHYLACTIC) REACTIONS\n• Systemic anaphylaxis (anaphylactic shock)\n• Results when an individual sensitized to an antigen is exposed to it again\n• May result in circulatory collapse and death\n• Treated with epinephrine\n• Localized anaphylaxis\n• Usually associated with ingested or inhaled antigens\n• Symptoms depend on the route of entry\n• Hives, hay fever, and asthma\nPREVENTING ANAPHYLACTIC REACTIONS\n• Antigens are inoculated \nbeneath the epidermis to \ntest for a rapid inflammatory \nreaction (wheal)\n• Desensitization: increasing \ndosages of antigen injected \nbeneath the skin\n• Produces IgG, which act as \nblocking antibodies to \nintercept and neutralize \nantigens\nA SKIN TEST TO IDENTIFY ALLERGENS\nTYPE II (CYTOTOXIC) REACTIONS\n• Activation of complement by the combination of IgG or IgM antibodies \nwith an antigenic cell\n• Causes cell lysis or damage by macrophages\n• ABO blood group system\n• Antibodies form against certain carbohydrate antigens on RBCs\n• A antigens, B antigens, or both\n• Type O RBCs have no antigens\nRh+ father. Rh– mother carrying\nher first Rh+ fetus. Rh\nantigens from the\ndeveloping fetus can\nenter the mother's\nblood during delivery.\nIn response to the fetal\nRh antigens, the mother\nwill produce anti-Rh\nantibodies.\nIf the woman becomes\npregnant with another\nRh+ fetus, her anti-Rh\nantibodies will cross the\nplacenta and damage\nfetal red blood cells.\nPlacenta\n• Rh blood group \nsystem\n• Rh factor antigen (Rh+) \nfound on RBCs of 85% \nof the population\n• Rh+ blood given to an \nRh– recipient will \nstimulate anti-Rh \nantibodies in the \nrecipient\n• Hemolytic disease of \nthe newborn (HDNB)\n• Rh– mother with an \nRh+ fetus causes the \nmother to produce anti-\nRh antibodies\n• Second Rh+ fetus will \nreceive anti-Rh \nantibodies, damaging \nfetal RBCs\nTYPE II (CYTOTOXIC) REACTIONS\n• Drug-induced cytotoxic reactions\n• Thrombocytopenic purpura\n• Platelets combine with drugs, forming a \ncomplex that is antigenic\n• Antibody and complement destroy platelets\n• Agranulocytosis\n• Drug-induced immune destruction of \ngranulocytes\n• Hemolytic anemia\n• Drug-induced immune destruction of RBCs\nPlatelet Drug (hapten)\nDrug binds to platelet,\nforming hapten–platelet\ncomplex.\nComplex induces for-\nmation of antibodies\nagainst hapten.\nHapten–platelet\ncomplex\nAction of antibodies\nand complement causes\nplatelet destruction.\nAnti-hapten antibody\nComplement\nTYPE II (CYTOTOXIC) REACTIONS\nTYPE III (IMMUNE COMPLEX) REACTIONS\nImmune complexes are \ndeposited in wall of \nblood vessel.\nPresence of immune\ncomplexes activates\ncomplement and attracts\ninflammatory cells such as\nneutrophils.\nEnzymes released from\nneutrophils cause\ndamage to endothelial\ncells of basement\nmembrane.\nEndothelial\ncell\nNeutrophils\nBasement\nmembrane of\nblood vessel\nAg\nImmune\ncomplexes\nEnzyme\n• Antibodies form against soluble \nantigens in the serum\n• Form immune complexes that lodge \nin the basement membranes \nbeneath the cells\n• Activate complement, causing \ninflammation\n• Arthus reaction\n• Rare side-effect of toxoid-containing \nvaccines\n• Occurs in glomeruli and other \nvessel walls due to complement \nactivation in a patient with already \ncirculating IgG to an injected antigen\n• Serum sickness can occur with \nswelling and inflammation due to \ninjection of foreign serum.\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Cell-mediated immune responses caused by T cells\n• Delayed hypersensitivity\n• Antigens are phagocytized and presented to receptors on T cells, causing \nsensitization\n• Reexposure to antigen cause memory cells to release destructive \ncytokines\nTYPE IV (DELAYED CELL-MEDIATED) \nREACTIONS\n• Allergic contact dermatitis\n• Haptens combine with proteins in the \nskin, producing an immune response\n• Allergic response to poison ivy, \ncosmetics, metals, and latex\nFigure 19.8 Allergic contact dermatitis."
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 자가면역 질환",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "자가면역 질환의 개념과 자가 관용 상실을 설명합니다. 자가 항원에 반응하여 조직 손상을 일으키는 자가면역 질환을 세포독성(예: 그레이브스병, 중증 근무력증), 면역 복합체(예: 전신성 홍반성 루푸스, 류마티스 관절염), 세포 매개(예: 인슐린 의존성 당뇨병, 건선)의 세 가지 유형으로 분류하여 각 유형의 특징과 관련 질환을 소개합니다.",
                "chapter_full_text": "AUTOIMMUNE DISEASES\n• Immune system responds to self antigens, causing damage to the organs\n• Autoimmunity is loss of self-tolerance\n• Ability to discriminate self from nonself\n• Cytotoxic, immune complex, or cell -mediated\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Multiple sclerosis\n• Autoantibodies, T cells, and macrophages attack myelin sheath of \nnerves\n• Compromises nerve impulse transduction\n• Symptoms range from fatigue and weakness to severe paralysis.\n• Etiology unknown; may involve genetic susceptibility and/or infective \nagent(s)\nCYTOTOXIC AUTOIMMUNE REACTIONS\n• Antibodies react with \ncell-surface antigens\n• Graves' disease\n• Abnormal antibodies in \nthe thyroid produce \nexcessive amounts of \nhormones\n• Myasthenia gravis\n• Antibodies coat \nacetylcholine receptors; \nmuscles fail to receive \nnerve signals\nIMMUNE COMPLEX AUTOIMMUNE \nREACTIONS\n• Immune complexes of antibodies and complement deposit in tissues\n• Systemic lupus erythematosus\n• Immune complexes form in the kidney glomeruli\n• Rheumatoid arthritis\n• Immune complexes form in the joints\nCELL-MEDIATED AUTOIMMUNE REACTIONS\n• Mediated by T cells that attack tissues\n• Insulin-dependent diabetes mellitus\n• T cell destruction of insulin-secreting cells\n• Psoriasis and psoriatic arthritis\n• Autoimmune disorders of the skin\nSELECTED AUTOIMMUNE DISORDERS\nAutoimmune Disease Possible Cause \nChronic fatigue syndrome May be due to antibodies attaching to acetylcholine receptors in nerve cells (see Chapter 22, \npage 671)\nRheumatoid arthritis Cross-reaction with antibodies against streptococcal antigen \nSystemic lupus erythematosus Immune complexes involving antibodies against D N A\nMultiple sclerosis T cells and macrophages attack the myelin sheath \nType Ⅰ diabetes T cells destroy insulin-secreting cells\nGuillain-Barré syndrome T cells produce cytokines that cause destruction of the myelin sheath of nerve cells (see \nChapter 22, pages 658 and 664, and Chapter 25, page 763)\nPsoriasis T cells produce cytokines that can induce keratinocyte (skin cells) growth\nGraves’ disease Antibodies attached to certain receptors in the thyroid gland cause it to enlarge and produce \nexcessive hormones\nMyasthenia gravis Antibodies against acetylcholine receptors\nCrohn’s disease Antibacterial antibodies react with intestinal mucosa\nInflammatory bowel disease Antibacterial antibodies react with intestinal mucosa (see the Big Picture, pages 554-555)"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "주조직적합복합체(MHC) 유전자와 인간 백혈구 항원(HLA) 복합체의 개념을 설명하고, 이식 수술에서 HLA 일치의 중요성을 강조합니다. 특권 부위 및 특권 조직 이식의 특성, 배아 줄기세포와 성체 줄기세포의 역할, 자가이식, 동계이식, 동종이식, 이종이식 등 다양한 이식 유형을 정의합니다. 또한 이식 거부 반응을 예방하기 위한 골수 이식의 고려 사항(이식편대숙주병)과 면역 억제 약물의 작용 방식을 다룹니다.",
                "chapter_full_text": "REACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• Histocompatibility antigens: self antigens on cell surfaces\n• Major histocompatibility complex (MHC) : genes encoding \nhistocompatibility antigens\n• Human leukocyte antigen (HLA) complex : MHC genes in humans\n• Certain HLAs are related to increased susceptibility to specific diseases\nDISEASES RELATED TO SPECIFIC HUMAN \nLEUKOCYTE ANTIGENS (HLAs)\nREACTIONS RELATED TO THE HUMAN \nLEUKOCYTE ANTIGEN (HLA) COMPLEX\n• HLA typing identifies and \ncompares HLAs\n• In transplant surgery, the donor \nand the recipient must be \nmatched by tissue typing\n• Uses standardized antisera or \nmonoclonal antibodies specific for \nHLAs\nLymphocyte\nbeing tested\nAnti-HLA antibodies\nattach to HLAs on\nlymphocyte.\nComplement\nand\ntrypan blue dye\nare added.\nCell damaged\nby complement\ntakes up dye.\nHLA\nPRIVILEGED SITES AND PRIVILEGED \nTISSUE\n• Transplants may be attacked by T cells, macrophages, and complement -\nfixing antibodies.\n• Transplants to a privileged site and privileged tissue do not cause an \nimmune response.\n• Cornea transplants, heart valve transplants\nSTEM CELLS\n• Stem cells are master cells capable of \ngenerating many different cell types\n• Embryonic stem cells (ESCs)\n• Harvested from blastocysts; used to \nregenerate tissues and organs\n• Pluripotent—can generate all types of \ncells\n• Adult stem cells\n• Stem cells in adult tissues that have \ndifferentiated\n• Can become induced pluripotent stem \ncells by introducing genes\n(1 day) Embryo, usually a fertilized egg discarded from attempt at \nin vitro fertilization.\nEmbryoblast (inner cell \nmass of embryonic cells)\nOuter cell mass\n(1–5 days) Blastocyst stage; the embryo divides repeatedly and  \nforms a hollow ball of cells about the size of the period at the end \nof a sentence.\nStem cell lines\nBlood and \nlymphatic cells\nPancreatic \nislet cells\nNerve cells\nEmbryonic stem cells from embryoblast are grown on feeder cells \nin culture medium. Stem cell lines and groups of stem cells form \ncolonies in culture medium. Different conditions, as well as growth \nfactors added to culture medium, direct stem cells to become stem \ncell lines for various tissues of the body (e.g., blood and lymphatic \ncells, pancreatic islet cells, nerve cells). \nBONE MARROW TRANSPLANTS\n• Also known as hematopoietic stem cell transplants\n• Goal is to enable the recipient to produce healthy blood cells\n• Graft-versus-host (G V H) disease can result from transplanted bone marrow that \ncontains immunocompetent cells.\nGRAFTS\n• Autograft: use of one's own tissue\n• Isograft: use of identical twin's tissue\n• Allografts: use of tissue from another person\n• Xenotransplantation product: use of nonhuman tissue\n• Must overcome hyperacute rejection: response to nonhuman antigens\nIMMUNOSUPPRESSION TO PREVENT \nTRANSPLANT REJECTION \n• Prevents a cell-mediated immune response to transplanted tissues\n• Cyclosporine and tacrolimus suppress IL -2, disrupting cytotoxic T cells\n• Sirolimus inhibits cellular and humoral immunity\n• Mycophenolate inhibits the proliferation of T cells and B cells\n• Basiliximab is a chimeric monoclonal antibody that blocks IL -2"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "암세포에 대한 면역 감시의 역할과 암세포가 면역 시스템을 회피하는 한계를 설명합니다. 암 면역 요법(세균 독소, 백신, 단클론 항체, CAR T 세포 치료 등)의 다양한 접근 방식을 소개합니다. 또한 선천성 및 후천성 면역 결핍증의 개념과 원인을 다루고, 림프구 발달 결함으로 인한 중증 복합 면역 결핍증(SCID)과 같은 질환을 포함합니다.",
                "chapter_full_text": "THE IMMUNE SYSTEM AND CANCER\n• Cancer cells are removed by immune surveillance\n• Cancer cells have tumor-associated antigens that mark them as nonself\n• CTLs (activated TC cells) and macrophages lyse cancer cells\n• Limitations\n• No antigenic epitope for the immune system to target\n• Tumor cells reproduce too rapidly\n• Tumor becomes vascularized and invisible to the immune system\nTHE INTERACTION BETWEEN A CYTOTOXIC \nT LYMPHOCYTE (CTL) AND A CANCER CELL\nIMMUNOTHERAPY FOR CANCER\n• Endotoxins from bacteria (Coley 's toxins) stimulate TNF that interferes with \nthe blood supply of cancers\n• Vaccines used for prophylaxis\n• Cervical, anal, and throat cancer (H P V), liver cancer (hepatitis B)\n• Monoclonal antibodies\n• Herceptin for breast cancer\n• Immunotoxin combines a Mab with a toxic agent\n• Targets and kills a tumor without damage to healthy cells\n• Immune checkpoint inhibitors -> VIDEO\n• Cellular therapies\n• CAR T cell -> VIDEO\nIMMUNODEFICIENCIES\n• Absence of a sufficient immune response\n• Congenital immunodeficiencies: due to defective or missing genes\n• Acquired immunodeficiencies: develop during an individual 's life\n• Due to drugs, cancers, and infections\nIMMUNODEFICIENCY DISEASES\n• Congenital immunodeficiency diseases are caused by inherited gene \ndefects.\n• Defects in T-cell development can result in severe combined \nimmunodeficiencies (SCID).\n• Defects in antigen receptor gene rearrangement can result in SCID.\n• Defects in signaling from T-cell antigen receptors can cause severe \nimmunodeficiency.\n• Genetic defects in thymic function that block T-cell development result in \nsevere immunodeficiencies.\n48\nDEFECTS IN LYMPHOCYTE DEVELOPMENT CAN RESULT IN \nSEVERE COMBINED IMMUNODEFICIENCIES\n49\nFigure 19.12 A nude (hairless) mouse infected with Mycobacterium leprae in the hind foot.\nSite of \nM. leprae bacteria\nIMMUNODEFICIENCIES"
              },
              {
                "chapter_title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "source_pdf_filename": "9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf",
                "chapter_content_summary": "후천성 면역 결핍 증후군(AIDS)의 역사와 원인 바이러스(HIV)의 발견을 다룹니다. HIV의 구조, 감염성 및 병원성(CD4+ T 세포 감염, 잠복 및 활성 감염), HIV 아형, 그리고 HIV 감염의 단계(1단계, 2단계, 3단계/AIDS)를 설명합니다. HIV 감염의 진행, 진단 방법, 전파 경로, 전 세계적 확산, 그리고 AIDS의 예방 및 치료 전략(HAART, 다양한 약물 유형) 및 HIV 백신 개발의 과제를 상세히 다룹니다.",
                "chapter_full_text": "ACQUIRED IMMUNODEFICIENCY \nSYNDROME (AIDS)\n• 1981: in the United States, a cluster of cases of Pneumocystis \npneumonia, Kaposi's sarcoma, and loss of immune function are \ndiscovered in young homosexual men \n• 1983: the discovery of a virus causing the loss of immune function (HIV)\n• Selectively infects T helper cells\nTHE ORIGIN OF AIDS\n• HIV crossed over into the human population in west \nand central Africa from chimpanzees (around 1908, \nfrom bushmeat)\n• Spread throughout Africa as a result of urbanization \nand increased sexual promiscuity\n• Earliest known H I V sample comes from Kinshasa, D  R \nC, in 1920\n• Norwegian sailor who died in 1976 is the first known \ncase in Western world\n• A 1969 sample from a patient in Missouri confirmed H I V \ninfection\nTHE STRUCTURE OF HIV\n• Genus Lentivirus\n• Retrovirus\n• Two identical + stranded RNA genome \nmolecules, reverse transcriptase \nenzyme, phospholipid envelope\n• gp120 glycoprotein spikes\nGlycoprotein spike:\ngp120\ngp41\ntransmembrane\nglycoprotein\nEnvelope\nReverse\ntranscriptase\nenzyme\nEnvelope\nRNA\nCapsid\nCore with\nprotein coat\nStructure of HIV and infection \nof a CD4+ T cell. The gp120 glyco-\nprotein spike on the membrane\nattaches to a receptor on the CD4+\ncell. The gp41 transmembrane\nglycoprotein probably facilitates\nfusion by attaching to a fusion\nreceptor on the CD4+ cell.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Spread by dendritic \ncells and carried to \nthe lymphoid organs; \ncontacts activated T \ncells\n• gp120 combines with \nCD4+ receptor and \nCCR5 or CXCR4 \ncoreceptors\n• CD4 molecules are \ncarried on T helper \ncells, macrophages, \nand dendritic cells\n• Virus fuses and \nenters into the cell\ngp41\ngp120\nCCR5 or\nCXCR4\ncoreceptor\nCD4 receptor\nCD4+ T cell\nViral envelope Envelope\nremains\nbehind\nAttachment. The gp120 spike\nattaches to a receptor and to a\nCCR5 or CXCR4 coreceptor\non the cell. \nFusion. The gp41 participates\nin fusion of the HIV with the \ncell.\nEntry. Following fusion with the\ncell, an entry pore is created.\nAfter entry, the viral envelope\nremains behind and the HIV \nuncoats, releasing the RNA \ncore for directing synthesis of \nthe new viruses.\nTHE INFECTIVENESS AND PATHOGENICITY \nOF HIV\n• Inside the cell, viral RNA is transcribed into DNA using reverse \ntranscriptase\n• DNA is integrated into the host's chromosomal DNA\n• Active infection: new viruses bud from the host cell\n• Latent infection: DNA is hidden in the chromosome as a provirus\n• Some become memory T cells that serve as the reservoir for HIV\n• Virus undergoes rapid antigenic changes and a high rate of mutation\nFigure 19.14 Latent and active HIV infection in CD4+ T cells.\nLatent infection. Viral DNA is integrated into\ncellular DNA as a provirus that can later be\nactivated to produce infective viruses. \nCD4+ T cell\nProvirus\nProvirus\nHIV\nChromosomal DNA\nCD4 receptor\nCCR5 or CXCR4\nreceptor\nVirus beginning\nto bud from T cell\nViral envelope\nproteins\nViral\nproteins\ngp120\ngp41\nmRNA\nViral RNA\ngp41\ngp120\nActive infection. The provirus is activated, allowing it to control the \nsynthesis of new viruses. Final assembly takes place at the cell membrane,\ntaking up the viral envelope proteins as the virus buds from the cell. \nProgeny HIV\nFigure 19.15 Latent and active HIV infection in macrophages and dendritic cells.\nChromosomal DNA\nHIV\nHIV\nMacrophage\nVacuole\nLatently infected macrophage. HIV can\npersist either as a provirus or as a complete\nvirion in vacuoles.  \nProvirus\nProvirus\nmRNA Viral RNA\nVacuole fuses with \nplasma membrane \nand releases virus.\nActivated macrophage. New viruses are produced\nfrom provirus. Completed virions are either released \nor persist in the macrophage within vacuoles.\nHIV being released\nSUBTYPES OF HIV\n• HIV-1 \n• Related to viruses that infect chimpanzees and gorillas\n• 99% of cases\n• Group M (majority) accounts for 90%\n• HIV-2\n• Not often encountered outside of West Africa\n• Less pathogenic than HIV - 1\n• Longer asymptomatic period with lower viral load and mortality rate than HIV - 1\nTHE STAGES OF HIV INFECTION\n• Phase 1: asymptomatic or lymphadenopathy\n• Phase 2: CD4+ T cells decline steadily; only a few infected cells release \nthe virus; few serious disease symptoms (persistent infections, fever, and \noral leukoplakia) \n• Phase 3: AIDS develops; the CD4+ is count below 200 cells/μl; indicator \nconditions\nTHE PROGRESSION OF HIV INFECTION\nTHE INFECTIVENESS AND PATHOGENICITY \nOF H I V INFECTION\n• Initial strong and effective immune response\n• CTLs suppress viral numbers\n• Once HIV establishes a pool of latently infected CD4 + T cells, it is \nimpossible to clear the infection\n• Challenge to make a vaccine\nVARIATIONS IN RESPONSE TO HIV \nEXPOSURE\n• Impact of age on survival with H I V infection\n• Older adults and young children do not a have fully functional immune system, \nmaking them more susceptible\n• Exposed, but not infected population\n• CCR5 mutation\n• Long-term survivors\n• Low viral load\n• Effective CTLs\nOPPORTUNISTIC INFECTIONS\nDIAGNOSTIC METHODS\n• Seroconversion is the period of time between infection and the \nappearance of antibodies\n• Takes up to 3 months\n• HIV antibodies detected by ELISA\n• Viruses detected by Western blotting or APTIMA (RNA testing)\n• Plasma viral load (PVL) is determined by PCR or nucleic acid \nhybridization\nHIV TRANSMISSION\n• HIV survives 6 hours outside a cell\n• HIV can survive more than 1.5 days inside a cell\n• Routes of transmission: intimate sexual contact, breast milk, transplacental \ninfection, contaminated needles, organ transplants, and blood transfusion\n• Anal-receptive intercourse is the most dangerous form of sexual contact\nAIDS WORLDWIDE\n• 35 million infected worldwide\n• 70% in sub-Saharan Africa\n• Heterosexual transmission is the most common mode of H  I V \ntransmission.\n• ⅓ of cases in Eastern Europe and Central and Southeast Asia are from \ninjected drugs.\nDISTRIBUTION OF HIV INFECTION AND AIDS \nIN REGIONS OF THE WORLD\n70\nPREVENTING AND TREATING AIDS\n• Biomedical interventions\n• Use of condoms, health services/HIV testing, needle programs\n• Behavioral intervention\n• Sex education, safe infant feeding programs, counseling\n• Structural interventions\n• Making changes in social, economic, political, and environmental factors to reduce \nvulnerability to HIV \nPREVENTING AND TREATING AIDS\n• Now considered a treatable chronic disease in the developed world\n• Highly active antiretroviral therapy ( HAART)\n• Use combinations of drugs to minimize survival of resistant strains\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n73\nHIV MANAGEMENT\nFigure 19.18 Drugs that inhibit HIV life cycle.\nFusion/entry inhibitors\nReverse transcriptase\ninhibitors\nIntegrase inhibitors\nProtease inhibitors\nEnfuvirtide\nMaraviroc\nTenofovir\nEmtricitabine\nRaltegravir\nAtazanavir\nIndinavir\nSaquinavir\nHIV\ngp41\ngp120 CCR5\nCD4 receptor\nCD4+ T CELL\nNucleus\nReverse transcriptase\nPREVENTING AND TREATING AIDS\n• Fusion/cell entry inhibitors\n• Targets the gp41 region of the viral envelope that prevents fusion of the virus with \nthe cell\n• Enfuvirtide and maraviroc\n• Reverse transcriptase inhibitors\n• Nucleoside reverse transcriptase inhibitors (NRTIs)\n• Tenofovir and emtricitabrine\n• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) \n• Efavirenz\nDRUGS THAT BLOCK HIV REPLICATION LEAD TO A \nRAPID DECREASE IN TITER OF INFECTIOUS VIRUS \nAND AN INCREASE IN CD4+ T CELLS\n77\nPREVENTING AND TREATING AIDS\n• Integrase inhibitors\n• Inhibit HIV integrase that integrates \ncDNA into the host chromosome\n• Raltegravir\n• Protease inhibitors\n• Inhibit proteases that cleave viral \nprecursor proteins into structural and \nfunctional proteins\n• Atazanavir, indinavir, and saquinavir\n• Maturation inhibitors\n• Tetherins\n• Tether viruses to the cells, preventing \ntheir release and spread\nIN THE COURSE OF INFECTION HIV ACCUMULATES \nMANY MUTATIONS, WHICH RESULT IN THE \nOUTGROWTH OF DRUG-RESISTANT VARIANTS\nTHE CHALLENGES OF DEVELOPING HIV \nVACCINES\n• No model of natural immunity to mimic\n• Lack of a research animal\n• Lack of understanding of the mechanisms of retroviruses\n• High mutation rate, leading to resistant strains\n• An ideal vaccine would:\n• Induce immunity before reservoirs of latent virus are established\n• Stimulate production of CTLs\n• Be affordable"
              }
            ],
            "generated_content": [
              {
                "title": "면역 시스템의 이해: 선천성 및 적응성 면역",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2042 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역의 개념",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역은 질병을 막는 능력을 의미하며, 감수성은 질병에 대한 저항력이 부족한 상태를 뜻합니다. 면역은 크게 두 가지로 나뉩니다. 선천성 면역은 모든 병원체에 대한 방어 기전으로, 신속하며 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 면역 또는 저항력으로, 반응 속도가 느리지만 기억 구성 요소를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "선천성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "선천성 면역은 자연 면역, 타고난 면역이라고도 불립니다. 식세포, 수지상 세포, 비만 세포, 자연 살해 세포 등 다양한 선천성 면역 세포들이 관여합니다. 이들은 감염이 발생하기 전부터 존재하며 면역 파수꾼 역할을 합니다. 일부 선천성 면역 세포는 항원을 T 세포에 제시하여 적응성 면역을 활성화시키기도 합니다. 또한, 조직 항상성과 염증에 중요하며, 치유자이자 파괴자 역할을 동시에 수행할 수 있습니다. 병원체 패턴, 사이토카인, 매개체에 의해 활성화되며, 항원에 대해 특이적이지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "적응성 면역은 특이적 면역, 후천성 면역이라고도 불립니다. 림프구인 T 세포와 B 세포가 주요 적응성 면역 세포입니다. 이들은 이차 림프 기관에서 미성숙한 형태로 존재하며, 클론 선택과 증식을 통해 특정 항원에 반응하는 세포로 발달합니다. 적응성 면역은 기억 기능을 가지며, 자가 관용 능력을 통해 자신의 몸을 공격하지 않습니다. 항원 제시 세포에 의해 활성화되며, 항원에 대해 매우 특이적입니다. 적응성 면역은 세포 매개 면역과 체액성 면역으로 나뉩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "숙주 세포에 있는 톨 유사 수용체(TLR)는 병원체 관련 분자 패턴(PAMP)에 결합합니다. TLR이 PAMP에 결합하면 숙주 세포에서 사이토카인 방출을 유도하여 면역 반응의 강도와 지속 시간을 조절합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다양한 PAMP 인식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "포유류 TLR은 다양한 PAMP를 인식합니다. 세균성 PAMP에는 그람 음성 세균 세포벽의 지질다당류(TLR4), 세균 리보솜 RNA(TLR13), 세균 DNA의 비메틸화 CpG(TLR9), 지단백질(TLR2/1, TLR2/6), 편모 단백질(TLR5) 등이 있습니다. 바이러스성 PAMP에는 이중 가닥 RNA(TLR3), 단일 가닥 RNA(TLR7, TLR8), 비메틸화 CpG DNA(TLR9) 등이 있습니다. 기생충성 PAMP에는 지단백질(TLR2/1, TLR2/6), 비메틸화 CpG DNA(TLR9), 단일 가닥 RNA(TLR7), 액틴 결합 단백질 프로필린(TLR11/12) 등이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TLR의 위치 및 내인성 PAMP 인식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "TLR은 세포 표면과 세포 내막에 존재하여 다양한 세포 위치에서 미생물을 인식합니다. TLR은 또한 내인성 PAMP도 인식할 수 있습니다. 세포 스트레스 시 유도되는 샤페론인 열충격 단백질(HSP)과 풍부한 게놈 DNA 결합 단백질인 고이동성 그룹 박스 1(HMGB1) 단백질 등이 내인성 PAMP의 예시입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TLR 신호 전달 경로",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "TLR이 미생물 리간드를 인식하면 여러 신호 전달 경로와 궁극적으로는 전사 인자가 활성화되어, 염증 및 항바이러스 반응에 중요한 유전자의 발현을 유도합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "면역은 질병에 저항하는 능력으로, 선천성 면역과 적응성 면역으로 나뉩니다. 선천성 면역은 모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재합니다. 반면, 적응성 면역은 특정 병원체에 대한 특이적 반응으로, 느리지만 기억 기능을 가집니다. 톨 유사 수용체(TLR)는 숙주 세포에서 병원체 관련 분자 패턴(PAMP)을 인식하여 사이토카인 방출을 유도하고 면역 반응을 조절합니다. TLR은 세포 표면과 세포 내막에 존재하며, 다양한 세균, 바이러스, 기생충 PAMP뿐만 아니라 내인성 PAMP도 인식하여 염증 및 항바이러스 반응에 중요한 유전자 발현을 유도하는 신호 전달 경로를 활성화합니다.",
                  "keyConcepts": [
                    {
                      "term": "선천성 면역",
                      "definition": "모든 병원체에 대해 신속하고 비특이적으로 작용하며, 태어날 때부터 존재하는 면역 방어 체계."
                    },
                    {
                      "term": "적응성 면역",
                      "definition": "특정 병원체에 대한 특이적 반응을 보이며, 기억 기능을 통해 재감염 시 더 빠르고 강력하게 반응하는 면역 방어 체계."
                    },
                    {
                      "term": "톨 유사 수용체 (TLR)",
                      "definition": "숙주 세포에 존재하며, 병원체 관련 분자 패턴(PAMP)을 인식하여 면역 반응을 유도하는 주요 패턴 인식 수용체."
                    },
                    {
                      "term": "병원체 관련 분자 패턴 (PAMP)",
                      "definition": "미생물에 공통적으로 존재하는 특징적인 분자 구조로, 숙주의 톨 유사 수용체(TLR)에 의해 인식되어 면역 반응을 유발한다."
                    },
                    {
                      "term": "사이토카인",
                      "definition": "면역 세포 간의 신호 전달을 매개하고 면역 반응의 강도와 지속 시간을 조절하는 단백질."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "면역 (Immunity)",
                      "definition": "질병을 막는 능력."
                    },
                    {
                      "term": "감수성 (Susceptibility)",
                      "definition": "질병에 대한 저항력 부족."
                    },
                    {
                      "term": "식세포 (Phagocytes)",
                      "definition": "미생물이나 이물질을 삼켜 제거하는 면역 세포."
                    },
                    {
                      "term": "기억 구성 요소 (Memory component)",
                      "definition": "적응성 면역이 이전에 노출된 병원체를 기억하여 재감염 시 더 빠르고 강력하게 반응하는 능력."
                    },
                    {
                      "term": "자가 관용 (Self tolerance)",
                      "definition": "면역 시스템이 자신의 세포와 조직을 공격하지 않고 구분하는 능력."
                    },
                    {
                      "term": "전사 인자 (Transcription factors)",
                      "definition": "DNA에 결합하여 특정 유전자의 전사(발현)를 조절하는 단백질."
                    },
                    {
                      "term": "내인성 PAMP (Endogenous PAMPs)",
                      "definition": "병원체가 아닌 숙주 세포 자체에서 발생한 손상 또는 스트레스 신호로 TLR이 인식할 수 있는 분자."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역의 개념",
                      "id": "면역의-개념",
                      "children": [
                        {
                          "text": "면역 및 감수성 정의",
                          "id": "면역-및-감수성-정의",
                          "children": null
                        },
                        {
                          "text": "선천성 면역과 적응성 면역의 특징",
                          "id": "선천성-면역과-적응성-면역의-특징",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "선천성 면역",
                      "id": "선천성-면역",
                      "children": [
                        {
                          "text": "선천성 면역의 다른 이름",
                          "id": "선천성-면역의-다른-이름",
                          "children": null
                        },
                        {
                          "text": "선천성 면역 세포의 종류 및 특징",
                          "id": "선천성-면역-세포의-종류-및-특징",
                          "children": null
                        },
                        {
                          "text": "적응성 면역과의 연계성",
                          "id": "적응성-면역과의-연계성",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역",
                      "id": "적응성-면역",
                      "children": [
                        {
                          "text": "적응성 면역의 다른 이름",
                          "id": "적응성-면역의-다른-이름",
                          "children": null
                        },
                        {
                          "text": "적응성 면역 세포의 종류 및 특징",
                          "id": "적응성-면역-세포의-종류-및-특징",
                          "children": null
                        },
                        {
                          "text": "클론 선택, 기억, 자가 관용",
                          "id": "클론-선택-기억-자가-관용",
                          "children": null
                        },
                        {
                          "text": "세포 매개 및 체액성 면역",
                          "id": "세포-매개-및-체액성-면역",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "톨 유사 수용체 (TLR) 및 병원체 관련 분자 패턴 (PAMP)",
                      "id": "톨-유사-수용체-tlr-및-병원체-관련-분자-패턴-pamp",
                      "children": [
                        {
                          "text": "TLR과 PAMP의 상호작용",
                          "id": "tlr과-pamp의-상호작용",
                          "children": null
                        },
                        {
                          "text": "사이토카인 방출 및 면역 반응 조절",
                          "id": "사이토카인-방출-및-면역-반응-조절",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "다양한 PAMP 인식",
                      "id": "다양한-pamp-인식",
                      "children": [
                        {
                          "text": "포유류 TLR의 PAMP 인식 범위",
                          "id": "포유류-tlr의-pamp-인식-범위",
                          "children": null
                        },
                        {
                          "text": "세균성 PAMP의 종류",
                          "id": "세균성-pamp의-종류",
                          "children": null
                        },
                        {
                          "text": "바이러스성 PAMP의 종류",
                          "id": "바이러스성-pamp의-종류",
                          "children": null
                        },
                        {
                          "text": "기생충성 PAMP의 종류",
                          "id": "기생충성-pamp의-종류",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "TLR의 위치 및 내인성 PAMP 인식",
                      "id": "tlr의-위치-및-내인성-pamp-인식",
                      "children": [
                        {
                          "text": "세포 표면 및 세포 내막에서의 TLR 위치",
                          "id": "세포-표면-및-세포-내막에서의-tlr-위치",
                          "children": null
                        },
                        {
                          "text": "내인성 PAMP의 인식 (HSP, HMGB1)",
                          "id": "내인성-pamp의-인식-hsp-hmgb1",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "TLR 신호 전달 경로",
                      "id": "tlr-신호-전달-경로",
                      "children": [
                        {
                          "text": "미생물 리간드 인식의 결과",
                          "id": "미생물-리간드-인식의-결과",
                          "children": null
                        },
                        {
                          "text": "염증 및 항바이러스 반응 유도",
                          "id": "염증-및-항바이러스-반응-유도",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "선천성 면역과 적응성 면역의 주요 차이점은 무엇인가요?",
                    "options": [
                      "선천성 면역은 태어날 때부터 존재하며 비특이적인 반면, 적응성 면역은 특정 병원체에 특이적이며 기억 기능을 가집니다.",
                      "선천성 면역은 특정 병원체에 특이적이지만 반응이 느리고, 적응성 면역은 모든 병원체에 빠르게 반응합니다.",
                      "선천성 면역은 기억 기능이 있지만 T세포와 B세포가 관여하지 않고, 적응성 면역은 기억 기능이 없습니다.",
                      "선천성 면역은 항원 제시 세포에 의해 활성화되고, 적응성 면역은 병원체 패턴에 의해 활성화됩니다."
                    ],
                    "answerIndex": 0,
                    "explanation": "선천성 면역은 타고난 비특이적 방어이며, 적응성 면역은 특정 항원에 대한 후천적, 기억 기반 방어입니다."
                  },
                  {
                    "question": "톨 유사 수용체(TLR)의 주요 기능은 무엇인가요?",
                    "options": [
                      "항체를 생산하여 병원체를 직접 중화시키는 기능",
                      "병원체 관련 분자 패턴(PAMP)을 인식하고 사이토카인 방출을 유도하여 면역 반응을 조절하는 기능",
                      "감염된 세포를 직접 파괴하는 자연 살해 세포의 기능을 억제하는 기능",
                      "면역 반응 후 기억 세포를 형성하여 다음 감염에 대비하는 기능"
                    ],
                    "answerIndex": 1,
                    "explanation": "TLR은 숙주 세포에서 PAMP를 인식하여 사이토카인 방출을 유도하고 면역 반응의 강도와 지속 시간을 조절하는 역할을 합니다."
                  },
                  {
                    "question": "다음 중 세균성 PAMP에 해당하지 않는 것은 무엇인가요?",
                    "options": [
                      "지질다당류 (Lipopolysaccharide)",
                      "세균 리보솜 RNA (Bacterial ribosomal RNA)",
                      "이중 가닥 RNA (Double-stranded RNA)",
                      "비메틸화 CpG (Unmethylated CpG in the bacterial DNA)"
                    ],
                    "answerIndex": 2,
                    "explanation": "이중 가닥 RNA(Double-stranded RNA)는 바이러스성 PAMP에 해당합니다. 지질다당류, 세균 리보솜 RNA, 비메틸화 CpG는 세균성 PAMP입니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 1284 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "물리적 요인",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "피부는 선천성 면역의 중요한 물리적 방어선입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "진피는 결합 조직으로 구성된 내부 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성된 외부 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "피부가 벗겨지고 건조한 상태를 유지하는 것은 미생물 성장을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "점막은 위장관, 호흡기, 비뇨생식기를 덮는 상피층입니다. 점액은 미생물을 가두고 관이 건조해지는 것을 막는 점성 당단백질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "누액 기관은 눈물을 배출하여 눈을 씻어냅니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "섬모 승강기는 점액에 갇힌 미생물을 폐에서 멀리 운반합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "귀지는 미생물이 귀에 들어가는 것을 막습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "소변은 흐름을 통해 요도를 청소합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "연동 운동, 배변, 구토, 설사 또한 미생물 배출에 기여하는 물리적 방어 기전입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "화학적 요인",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "피지는 보호막을 형성하고 피부의 pH를 3~5로 낮춥니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "땀, 눈물, 침, 소변에 있는 리소자임은 세균 세포벽을 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "위액의 낮은 pH (1.2~3.0)는 대부분의 세균과 독소를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "질 분비물의 낮은 pH (3~5)는 미생물을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "정상 미생물총과 선천성 면역",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "정상 미생물총은 미생물 길항 작용 (경쟁적 배제)을 통해 병원균과 경쟁합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 공간과 영양분에 대한 경쟁 우위를 점하거나, 병원균에 해로운 물질을 생산하거나, 병원균 생존에 영향을 미치는 조건을 변경함으로써 이루어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "공생은 한 유기체는 이득을 얻고 다른 유기체 (숙주)는 해를 입지 않는 관계를 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로바이오틱스는 유익한 효과를 발휘하기 위해 투여되는 살아있는 미생물 배양물입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "무균 쥐를 사육하기 위해서는 엄격한 무균 상태가 요구됩니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 1차 방어선인 물리적 및 화학적 장벽과 정상 미생물총의 역할을 다룹니다. 피부, 점막, 누액 기관, 섬모 승강기, 귀지, 소변, 연동 운동, 배변, 구토, 설사 등 다양한 물리적 요인들이 미생물 침입을 막는 역할을 합니다. 또한, 피지, 리소자임, 위액 및 질 분비물의 낮은 pH와 같은 화학적 요인들이 미생물 성장을 억제하거나 파괴합니다. 정상 미생물총은 경쟁적 배제를 통해 병원균과 경쟁하며 숙주 방어에 기여합니다. 마지막으로, 마이크로바이옴이 선천성 면역 형성에 중요한 영향을 미친다는 점이 강조됩니다.",
                  "keyConcepts": [
                    {
                      "term": "선천성 면역의 물리적 방어선",
                      "definition": "피부, 점막, 눈물, 섬모 등 신체 외부 및 내부 표면에서 미생물 침입을 물리적으로 막는 방어 기전."
                    },
                    {
                      "term": "선천성 면역의 화학적 방어선",
                      "definition": "피지, 리소자임, 위액, 질 분비물 등의 화학 물질이 미생물 성장을 억제하거나 파괴하는 방어 기전."
                    },
                    {
                      "term": "정상 미생물총의 역할",
                      "definition": "인체에 상주하는 유익한 미생물들이 공간 및 영양분 경쟁, 유해 물질 생산 등을 통해 병원균의 침입과 증식을 억제하는 현상 (미생물 길항 작용)."
                    },
                    {
                      "term": "마이크로바이옴과 선천성 면역",
                      "definition": "인체 내 미생물 군집인 마이크로바이옴이 숙주의 선천성 면역 시스템 발달 및 기능에 중요한 영향을 미친다는 개념."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "케라틴",
                      "definition": "피부 표피에 존재하는 보호 단백질로, 피부의 물리적 장벽을 형성하는 데 기여한다."
                    },
                    {
                      "term": "점액",
                      "definition": "점막에서 분비되는 점성 당단백질로, 미생물을 가두고 점막이 건조해지는 것을 방지한다."
                    },
                    {
                      "term": "누액 기관",
                      "definition": "눈물을 생성하고 배출하여 눈을 지속적으로 씻어내 미생물을 제거하는 역할을 하는 기관."
                    },
                    {
                      "term": "섬모 승강기",
                      "definition": "호흡기 점막의 섬모가 움직여 점액에 갇힌 미생물을 폐에서 멀리 이동시키는 메커니즘."
                    },
                    {
                      "term": "리소자임",
                      "definition": "땀, 눈물, 침, 소변 등에 존재하는 효소로, 세균의 세포벽을 파괴하여 항균 작용을 한다."
                    },
                    {
                      "term": "미생물 길항 작용",
                      "definition": "정상 미생물총이 공간, 영양분 경쟁 또는 병원균에 해로운 물질 생산을 통해 병원균의 성장을 억제하는 현상."
                    },
                    {
                      "term": "공생",
                      "definition": "두 유기체가 함께 살아가며 한 유기체는 이득을 얻지만 다른 유기체(숙주)는 해를 입지 않는 관계."
                    }
                  ],
                  "outline": [
                    {
                      "text": "선천성 면역: 1차 방어선 - 물리적 및 화학적 장벽",
                      "id": "선천성-면역-1차-방어선",
                      "children": [
                        {
                          "text": "물리적 요인",
                          "id": "물리적-요인",
                          "children": [
                            {
                              "text": "피부",
                              "id": "피부",
                              "children": null
                            },
                            {
                              "text": "점막",
                              "id": "점막",
                              "children": null
                            },
                            {
                              "text": "누액 기관",
                              "id": "누액-기관",
                              "children": null
                            },
                            {
                              "text": "기타 물리적 방어 (섬모 승강기, 귀지, 소변, 연동 운동 등)",
                              "id": "기타-물리적-방어",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "화학적 요인",
                          "id": "화학적-요인",
                          "children": [
                            {
                              "text": "피지",
                              "id": "피지",
                              "children": null
                            },
                            {
                              "text": "리소자임",
                              "id": "리소자임",
                              "children": null
                            },
                            {
                              "text": "위액의 낮은 pH",
                              "id": "위액의-낮은-ph",
                              "children": null
                            },
                            {
                              "text": "질 분비물의 낮은 pH",
                              "id": "질-분비물의-낮은-ph",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "정상 미생물총과 선천성 면역",
                          "id": "정상-미생물총과-선천성-면역",
                          "children": [
                            {
                              "text": "미생물 길항 작용",
                              "id": "미생물-길항-작용",
                              "children": null
                            },
                            {
                              "text": "공생 및 프로바이오틱스",
                              "id": "공생-및-프로바이오틱스",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "마이크로바이옴 탐구: 선천성 면역 형성에서 마이크로바이옴의 역할",
                          "id": "마이크로바이옴-탐구",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "피부의 표피층에 포함되어 미생물 성장을 억제하는 보호 단백질은 무엇입니까?",
                    "options": [
                      "케라틴",
                      "콜라겐",
                      "엘라스틴",
                      "멜라닌"
                    ],
                    "answerIndex": 0,
                    "explanation": "표피는 보호 단백질인 케라틴을 함유한 밀집된 상피 세포로 구성되어 있으며, 이는 미생물 성장을 억제하는 데 기여합니다."
                  },
                  {
                    "question": "선천성 면역의 화학적 방어선 중, 땀, 눈물, 침, 소변에 존재하며 세균 세포벽을 파괴하는 효소는 무엇입니까?",
                    "options": [
                      "펩신",
                      "아밀레이스",
                      "리소자임",
                      "트립신"
                    ],
                    "answerIndex": 2,
                    "explanation": "리소자임은 땀, 눈물, 침, 소변에 존재하며 세균의 세포벽을 파괴하는 강력한 항균 효소입니다."
                  },
                  {
                    "question": "정상 미생물총이 병원균과 경쟁하여 성장을 억제하는 주요 메커니즘을 설명하는 용어는 무엇입니까?",
                    "options": [
                      "변이원성",
                      "미생물 길항 작용",
                      "자가면역",
                      "과민 반응"
                    ],
                    "answerIndex": 1,
                    "explanation": "정상 미생물총은 '미생물 길항 작용' 또는 '경쟁적 배제'를 통해 공간, 영양분 경쟁 및 유해 물질 생산으로 병원균의 성장을 억제합니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 2차 방어선 - 혈액 구성 요소 및 식세포",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 2110 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "I. 혈액의 구성 요소",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액은 혈장 내에 부유하는 세포 및 세포 조각으로 구성됩니다. 주요 구성 요소는 적혈구(red blood cells), 백혈구(white blood cells), 혈소판(platelets)이며, 이들은 적골수 줄기세포에서 조혈 작용(hematopoiesis)을 통해 생성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "과립구 (Granulocytes)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "과립구는 세포질 내에 광학 현미경으로 볼 수 있는 과립을 가진 백혈구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호중구(Neutrophils): 식균 작용을 하며 감염 초기 단계에서 활동합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호염기구(Basophils): 히스타민을 방출하며 알레르기 반응에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 호산구(Eosinophils): 식균 작용을 하며 기생충과 연충류에 대해 독성을 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "무과립구 (Agranulocytes)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "무과립구는 세포질 내에 과립이 있지만 광학 현미경으로 보이지 않는 백혈구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 단핵구(Monocytes): 조직에서 대식세포(macrophages)로 성숙하여 식균 작용을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 수지상 세포(Dendritic cells): 피부, 점막, 흉선에서 발견되며 식균 작용을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 림프구(Lymphocytes): T세포, B세포, NK세포를 포함하며 적응 면역에 중요한 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "II. 림프계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "림프계는 림프, 림프관, 림프 조직, 적골수로 구성됩니다. 림프구와 식세포를 포함하며, 림프는 미생물을 림프절로 운반하여 림프구와 대식세포가 병원균을 파괴하도록 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "림프계의 주요 구성 요소 및 기관에는 흉관(좌측 림프관), 우측 림프관, 좌측 쇄골하정맥, 우측 쇄골하정맥, 편도, 흉선, 림프절, 비장, 대장, 소장, 파이어판(Peyer’s patch), 림프관, 적골수, 림프 모세혈관 등이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "III. 숙주 방어: 개요 및 식세포",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포(Phagocytes)는 '먹다'를 의미하는 그리스어 'Phago'와 '세포'를 의미하는 'Cyte'에서 유래했습니다. 식세포에는 조직과 장기에 상주하는 고정 대식세포(Fixed macrophages)와 조직을 돌아다니며 감염 부위에 모이는 자유(유리) 대식세포(Free (wandering) macrophages)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IV. 식균 작용의 메커니즘",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "식균 작용은 다음 단계를 거쳐 진행됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 주화성(Chemotaxis): 화학적 신호가 식세포를 미생물로 유인합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 부착(Adherence): 식세포가 미생물 표면에 부착합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 섭취(Ingestion): 미생물이 혈청 단백질로 코팅되어(옵소닌화, Opsonization) 섭취가 용이해집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 소화(Digestion): 미생물이 식포-리소좀(phagolysosome) 내부에서 소화됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "V. 미생물의 식균 작용 회피 전략",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "일부 미생물은 숙주의 방어 체계를 회피하기 위한 다양한 병원성 인자(Virulence factors)를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 부착 억제: M 단백질, 캡슐 (예: Streptococcus pyogenes, S. pneumoniae)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식세포 사멸: 백혈구용해소(leukocidins) (예: Staphylococcus aureus)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식세포 용해: 막 공격 복합체(membrane attack complex) (예: Listeria monocytogenes)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포 탈출: (예: Shigella, Rickettsia)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포-리소좀 융합 방지: (예: HIV, Mycobacterium tuberculosis)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 식포-리소좀 내 생존: (예: Coxiella burnetii)",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 2차 방어선으로서 혈액의 구성 요소와 식세포의 역할에 대해 설명합니다. 혈액의 주요 구성 요소(적혈구, 백혈구, 혈소판)와 조혈 작용을 소개하고, 백혈구를 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 분류하여 각 유형의 기능과 특징을 설명합니다. 또한, 림프계의 구성 요소와 병원균 제거에서의 역할을 다루고, 식세포의 정의와 고정/자유 대식세포의 종류를 설명합니다. 이어서 식균 작용의 네 가지 주요 단계(주화성, 부착, 섭취, 소화)를 자세히 설명하며, 특히 옵소닌화의 중요성을 강조합니다. 마지막으로, 미생물이 식균 작용을 회피하기 위해 사용하는 다양한 전략(부착 억제, 식세포 사멸, 식포 탈출 등)과 관련 미생물 예를 제시합니다.",
                  "keyConcepts": [
                    {
                      "term": "혈액의 구성 요소",
                      "definition": "혈액을 구성하는 주요 성분으로, 혈장 내에 부유하는 적혈구, 백혈구, 혈소판을 포함하며, 조혈 작용을 통해 생성됩니다."
                    },
                    {
                      "term": "백혈구의 종류와 기능",
                      "definition": "감염 및 알레르기 반응에 관여하는 면역 세포로, 과립구(호중구, 호염기구, 호산구)와 무과립구(단핵구, 수지상 세포, 림프구)로 나뉘며 각각 특정한 면역 기능을 수행합니다."
                    },
                    {
                      "term": "림프계의 역할",
                      "definition": "림프, 림프관, 림프 조직, 적골수로 구성되며 림프구와 식세포를 포함하여 병원균을 림프절로 운반하고 파괴함으로써 면역 방어에 기여하는 시스템입니다."
                    },
                    {
                      "term": "식균 작용",
                      "definition": "식세포가 미생물이나 세포 잔해를 섭취하고 소화하여 제거하는 과정으로, 주화성, 부착, 섭취(옵소닌화 포함), 소화의 단계를 거칩니다."
                    },
                    {
                      "term": "미생물의 식균 작용 회피",
                      "definition": "미생물이 숙주의 식균 작용으로부터 자신을 보호하기 위해 사용하는 다양한 전략으로, 부착 억제, 식세포 사멸, 식포 탈출, 식포-리소좀 융합 방지, 식포-리소좀 내 생존 등이 있습니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "조혈 작용 (Hematopoiesis)",
                      "definition": "적골수 줄기세포에서 혈액 세포(적혈구, 백혈구, 혈소판)가 생성되는 과정입니다."
                    },
                    {
                      "term": "과립구 (Granulocytes)",
                      "definition": "세포질 내에 과립을 가진 백혈구로, 호중구, 호염기구, 호산구가 포함됩니다."
                    },
                    {
                      "term": "무과립구 (Agranulocytes)",
                      "definition": "세포질 내에 과립이 뚜렷하지 않은 백혈구로, 단핵구, 수지상 세포, 림프구가 포함됩니다."
                    },
                    {
                      "term": "식세포 (Phagocytes)",
                      "definition": "미생물이나 이물질을 섭취하고 소화하는 세포(예: 대식세포, 호중구)를 총칭합니다."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포에 의한 섭취가 용이해지는 과정입니다."
                    },
                    {
                      "term": "주화성 (Chemotaxis)",
                      "definition": "화학적 신호에 의해 세포가 특정 방향으로 이동하는 현상으로, 식세포가 미생물로 유인되는 과정입니다."
                    },
                    {
                      "term": "병원성 인자 (Virulence factors)",
                      "definition": "미생물이 숙주에게 질병을 일으키거나 숙주의 면역 체계를 회피하는 데 도움이 되는 특징 또는 물질입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "I. 혈액의 구성 요소",
                      "id": "i-혈액의-구성-요소",
                      "children": [
                        {
                          "text": "과립구 (Granulocytes)",
                          "id": "과립구-granulocytes",
                          "children": null
                        },
                        {
                          "text": "무과립구 (Agranulocytes)",
                          "id": "무과립구-agranulocytes",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "II. 림프계",
                      "id": "ii-림프계",
                      "children": null
                    },
                    {
                      "text": "III. 숙주 방어: 개요 및 식세포",
                      "id": "iii-숙주-방어-개요-및-식세포",
                      "children": null
                    },
                    {
                      "text": "IV. 식균 작용의 메커니즘",
                      "id": "iv-식균-작용의-메커니즘",
                      "children": null
                    },
                    {
                      "text": "V. 미생물의 식균 작용 회피 전략",
                      "id": "v-미생물의-식균-작용-회피-전략",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 과립구에 해당하지 않는 백혈구는 무엇입니까?",
                    "options": [
                      "단핵구",
                      "호중구",
                      "호염기구",
                      "호산구"
                    ],
                    "answerIndex": 0,
                    "explanation": "단핵구는 무과립구에 속하며, 조직에서 대식세포로 성숙하여 식균 작용을 합니다. 호중구, 호염기구, 호산구는 모두 과립구에 해당합니다."
                  },
                  {
                    "question": "식균 작용의 단계 중, 미생물이 혈청 단백질로 코팅되어 식세포에 의한 섭취가 용이해지는 과정을 무엇이라고 합니까?",
                    "options": [
                      "주화성",
                      "부착",
                      "옵소닌화",
                      "소화"
                    ],
                    "answerIndex": 2,
                    "explanation": "옵소닌화는 미생물이 혈청 단백질(옵소닌)로 코팅되어 식세포의 섭취(Ingestion)를 돕는 과정입니다."
                  },
                  {
                    "question": "다음 미생물 중 식포-리소좀 융합을 방지하여 식균 작용을 회피하는 것으로 알려진 것은 무엇입니까?",
                    "options": [
                      "Streptococcus pyogenes",
                      "Staphylococcus aureus",
                      "Listeria monocytogenes",
                      "Mycobacterium tuberculosis"
                    ],
                    "answerIndex": 3,
                    "explanation": "Mycobacterium tuberculosis는 식포-리소좀 융합을 방지하여 식세포 내에서 생존함으로써 식균 작용을 회피합니다. Streptococcus pyogenes는 부착을 억제하고, Staphylococcus aureus는 백혈구용해소를 통해 식세포를 사멸시키며, Listeria monocytogenes는 식세포를 용해시킵니다."
                  }
                ]
              },
              {
                "title": "선천성 면역: 2차 방어선 - 염증, 발열 및 항균 물질",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_393a71ae-9b7e-428f-9ea3-140a8ff48315_16. Innate immunity - Nonspecific Defenses of the Host.pdf, Text length: 3719 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "염증: 개요",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "염증",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "염증의 네 가지 징후 및 증상: 발적(redness), 부종(edema), 통증(pain), 열(heat).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "손상 인자를 파괴하거나 신체에 미치는 영향을 제한합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "손상 인자에 의해 손상된 조직을 복구하고 대체합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 유발 물질",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "염증은 간에서 급성기 단백질을 활성화시켜 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주요 염증 매개체는 다음과 같습니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "히스타민 (Histamine): 비만 세포, 호염기구, 혈소판에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "키닌 (Kinins): 혈장 내에 존재하며 호중구를 유인하여 화학주성(chemotaxis)을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로스타글란딘 (Prostaglandins): 손상된 세포에서 분비되며 히스타민과 키닌의 효과를 강화하고 식세포가 모세혈관 벽을 통과하는 것을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류코트리엔 (Leukotrienes): 비만 세포와 호염기구에서 분비되며 혈관 투과성을 증가시키고 식세포가 병원체에 부착되는 것을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 (Complement): 혈장 내에 존재하며 히스타민 분비를 자극하고 식세포를 유인하며 식균 작용을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인 (Cytokines): 고정된 대식세포에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 과정 단계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 16.9a-b 염증 과정: 조직 손상, 혈관 반응 및 식균 작용을 포함합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증 과정",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조직 손상이 발생하면 손상된 세포에서 히스타민, 키닌, 프로스타글란딘, 류코트리엔, 사이토카인과 같은 화학 물질이 방출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액 응고가 형성되기 시작하고 농양(abscess)이 형성되기 시작합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "식세포 이동 및 식균 작용",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "마지네이션(Margination)은 염증 부위의 사이토카인에 반응하여 식세포가 혈관에 달라붙는 현상입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포는 다이아페데시스(diapedesis)를 통해 혈관 내피 세포 사이를 비집고 나옵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "조직 복구",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "모든 유해 물질이 제거되거나 중화될 때까지 완료될 수 없습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "기질(Stroma)은 복구되는 지지 결합 조직입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "실질(Parenchyma)은 복구되는 조직의 기능적인 부분입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "발열",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "비정상적으로 높은 체온입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "시상하부(Hypothalamus)는 일반적으로 37°C로 설정되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인이 시상하부로 하여금 프로스타글란딘을 방출하게 하여 시상하부의 온도를 더 높게 재설정합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "몸은 혈관을 수축시키고 떨림(shivering)이 발생하여 체온이 상승합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "체온이 떨어지면 (위기, crisis) 혈관 확장과 땀이 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 시스템",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "간에서 생산되는 혈청 단백질로, 미생물 파괴에 면역계를 보조합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 활성화라고 불리는 과정에서 캐스케이드(cascade) 방식으로 작용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "단백질은 대문자 C로 표시되며 발견 순서대로 번호가 매겨집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 단편은 소문자 a와 b로 표시됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체: 활성화",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "고전적 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 항원에 결합하여 C1을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C1은 분열하여 C2와 C4를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C2a와 C4b가 결합하여 C3을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3a는 염증에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3b는 세포 용해(cytolysis)와 옵소닌화(opsonization)에 관여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "대체 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액 내 C3가 미생물 표면의 B, D, P 인자와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C3는 C3a와 C3b로 분열하며, 고전적 경로와 동일하게 기능합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "렉틴 경로",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "대식세포가 병원체를 섭취하여 사이토카인을 방출하고, 이는 간에서 렉틴 생산을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "만노스 결합 렉틴(Mannose-binding lectin, MBL)이 만노스에 결합하여 C2와 C4를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "C2a와 C4b가 C3을 활성화하며, 이는 고전적 경로 및 대체 경로와 동일하게 기능합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 활성화의 결과",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "세포 용해",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 보체 단백질이 막 공격 복합체(Membrane Attack Complex, MAC)를 형성합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "옵소닌화",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "식세포가 미생물에 부착되는 것을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "염증",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 보체 단백질이 비만 세포에 결합하여 히스타민을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 16.12 보체 활성화의 결과. 그림 16.13 보체에 의해 자극된 염증.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 시스템은 신체가 감염과 병원체를 퇴치하는 또 다른 방법입니다. 선천성 면역의 이 구성 요소는 다른 면역 반응을 '보완'합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체는 혈청에 순환하는 30개 이상의 단백질 그룹으로, 캐스케이드 방식으로 활성화됩니다: 한 보체 단백질이 다음 단백질을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 캐스케이드는 병원체에 의해 직접 활성화되거나 항체-항원 반응에 의해 활성화될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 단백질들은 함께 (1) 세포 용해, (2) 강화된 식균 작용, (3) 염증을 통해 미생물을 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체: 결과",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "보체 활성화의 조절",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 단백질은 보체 단백질을 쉽게 분해하여 숙주 세포 손상을 최소화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체와 질병",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 단백질의 부족은 감염에 대한 취약성을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 시스템 회피",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "캡슐은 보체 활성화를 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인터페론",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "세포에서 생산되는 사이토카인으로, 항바이러스 활동을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IFN-α 및 IFN-β: 바이러스 감염에 반응하여 세포에서 생산되며, 이웃 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IFN-γ: 호중구와 대식세포가 박테리아를 죽이도록 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "알파 및 베타 인터페론(IFN)의 항바이러스 작용",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "철 결합 단백질",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "트랜스페린(Transferrin): 혈액 및 조직액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "락토페린(Lactoferrin): 우유, 침, 점액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "페리틴(Ferritin): 간, 비장, 적골수에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "헤모글로빈(Hemoglobin): 적혈구에 위치합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "박테리아는 철 결합 단백질과 경쟁하기 위해 시데로포어(siderophores)를 생산합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항균 펩타이드",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "미생물의 단백질 및 당 분자에 반응하여 생산되는 짧은 펩타이드입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포벽 합성을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "원형질막에 구멍을 형성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "광범위한 활성 스펙트럼을 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "기타 요인",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "유전적 저항성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "선택적 생존 이점을 부여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "예: 겸상 적혈구 특성 및 열대열원충(Plasmodium falciparum).",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "연령",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "매우 어린 연령과 노인들은 질병에 더 취약합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "건강 프로토콜 준수",
                    "level": 2
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 선천성 면역의 핵심 구성 요소인 염증, 발열, 보체 시스템, 인터페론, 철 결합 단백질 및 항균 펩타이드에 대해 설명합니다. 염증의 징후, 매개체, 과정 및 조직 복구를 다루고, 발열의 메커니즘과 체온 조절을 설명합니다. 또한 보체 시스템의 세 가지 활성화 경로(고전적, 대체, 렉틴)와 그 결과(세포 용해, 옵소닌화, 염증)를 상세히 제시합니다. 마지막으로, 인터페론의 항바이러스 역할, 철 결합 단백질의 기능, 항균 펩타이드의 작용 방식, 그리고 유전적 저항성 및 연령과 같은 기타 면역 관련 요인들을 소개합니다.",
                  "keyConcepts": [
                    {
                      "term": "염증 (Inflammation)",
                      "definition": "손상된 조직을 파괴하거나 유해 물질의 영향을 제한하고, 손상된 조직을 복구 및 대체하는 신체의 방어 반응입니다. 발적, 부종, 통증, 열의 네 가지 주요 징후를 가집니다."
                    },
                    {
                      "term": "발열 (Fever)",
                      "definition": "비정상적으로 높은 체온으로, 사이토카인에 의해 시상하부의 체온 설정점이 높아져 발생합니다. 병원체 성장을 억제하고 면역 반응을 강화하는 데 도움을 줄 수 있습니다."
                    },
                    {
                      "term": "보체 시스템 (Complement System)",
                      "definition": "간에서 생산되는 30개 이상의 혈청 단백질로 구성된 캐스케이드 시스템입니다. 병원체 파괴를 돕기 위해 세포 용해, 옵소닌화, 염증을 유발하는 세 가지 활성화 경로(고전적, 대체, 렉틴)를 통해 작동합니다."
                    },
                    {
                      "term": "인터페론 (Interferons)",
                      "definition": "세포에서 생산되는 사이토카인으로, 특히 IFN-α와 IFN-β는 바이러스 감염에 반응하여 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질을 생산하도록 유도하는 항바이러스 활성을 가집니다."
                    },
                    {
                      "term": "항균 물질 (Antimicrobial Substances)",
                      "definition": "철 결합 단백질(트랜스페린, 락토페린, 페리틴, 헤모글로빈)과 항균 펩타이드를 포함하며, 미생물의 성장을 억제하거나 직접 파괴하여 숙주를 보호하는 역할을 합니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "히스타민 (Histamine)",
                      "definition": "비만 세포 등에서 분비되며 혈관 확장 및 혈관 투과성 증가를 유발하는 혈관 활성 매개체입니다."
                    },
                    {
                      "term": "다이아페데시스 (Diapedesis)",
                      "definition": "식세포가 혈관 내피 세포 사이를 비집고 나와 조직 손상 부위로 이동하는 과정입니다."
                    },
                    {
                      "term": "마지네이션 (Margination)",
                      "definition": "염증 부위의 사이토카인에 반응하여 식세포가 혈관 내피에 달라붙는 현상입니다."
                    },
                    {
                      "term": "막 공격 복합체 (Membrane Attack Complex, MAC)",
                      "definition": "활성화된 보체 단백질에 의해 형성되며, 미생물 세포막에 구멍을 뚫어 세포 용해를 유발하는 구조입니다."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "보체 단백질(C3b) 등이 미생물을 코팅하여 식세포가 미생물을 더 쉽게 인식하고 식균 작용을 하도록 촉진하는 과정입니다."
                    },
                    {
                      "term": "시데로포어 (Siderophores)",
                      "definition": "박테리아가 숙주의 철 결합 단백질과 경쟁하여 철을 획득하기 위해 생산하는 물질입니다."
                    },
                    {
                      "term": "항바이러스 단백질 (Antiviral Proteins, AVPs)",
                      "definition": "인터페론의 유도에 의해 세포에서 생산되며, 바이러스 복제를 억제하는 단백질입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "염증",
                      "id": "inflammation",
                      "children": [
                        {
                          "text": "개요 및 징후",
                          "id": "inflammation-overview-signs",
                          "children": null
                        },
                        {
                          "text": "염증 반응 유발 물질",
                          "id": "inflammation-mediators",
                          "children": null
                        },
                        {
                          "text": "염증 과정 단계",
                          "id": "inflammation-steps",
                          "children": null
                        },
                        {
                          "text": "식세포 이동 및 식균 작용",
                          "id": "phagocyte-migration-phagocytosis",
                          "children": null
                        },
                        {
                          "text": "조직 복구",
                          "id": "tissue-repair",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "발열",
                      "id": "fever",
                      "children": [
                        {
                          "text": "체온 조절 및 발열 메커니즘",
                          "id": "fever-mechanism",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "보체 시스템",
                      "id": "complement-system",
                      "children": [
                        {
                          "text": "개요 및 기능",
                          "id": "complement-overview",
                          "children": null
                        },
                        {
                          "text": "보체 활성화 경로",
                          "id": "complement-activation-pathways",
                          "children": [
                            {
                              "text": "고전적 경로",
                              "id": "classical-pathway",
                              "children": null
                            },
                            {
                              "text": "대체 경로",
                              "id": "alternative-pathway",
                              "children": null
                            },
                            {
                              "text": "렉틴 경로",
                              "id": "lectin-pathway",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "보체 활성화의 결과",
                          "id": "complement-activation-outcomes",
                          "children": [
                            {
                              "text": "세포 용해",
                              "id": "cytolysis",
                              "children": null
                            },
                            {
                              "text": "옵소닌화",
                              "id": "opsonization",
                              "children": null
                            },
                            {
                              "text": "염증",
                              "id": "complement-inflammation",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "보체 조절 및 질병",
                          "id": "complement-regulation-disease",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항균 물질",
                      "id": "antimicrobial-substances",
                      "children": [
                        {
                          "text": "인터페론",
                          "id": "interferons",
                          "children": null
                        },
                        {
                          "text": "철 결합 단백질",
                          "id": "iron-binding-proteins",
                          "children": null
                        },
                        {
                          "text": "항균 펩타이드",
                          "id": "antimicrobial-peptides",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "기타 요인",
                      "id": "other-factors",
                      "children": [
                        {
                          "text": "유전적 저항성",
                          "id": "genetic-resistance",
                          "children": null
                        },
                        {
                          "text": "연령",
                          "id": "age",
                          "children": null
                        },
                        {
                          "text": "건강 프로토콜 준수",
                          "id": "observing-healthy-protocols",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "염증의 네 가지 주요 징후에 해당하지 않는 것은 무엇입니까?",
                    "options": [
                      "발적",
                      "부종",
                      "가려움",
                      "열"
                    ],
                    "answerIndex": 2,
                    "explanation": "염증의 네 가지 주요 징후는 발적(redness), 부종(swelling), 통증(pain), 열(heat)입니다. 가려움은 일반적인 염증의 주요 징후에 해당하지 않습니다."
                  },
                  {
                    "question": "보체 활성화의 세 가지 주요 결과에 속하지 않는 것은 무엇입니까?",
                    "options": [
                      "세포 용해 (Cytolysis)",
                      "옵소닌화 (Opsonization)",
                      "항체 생산 (Antibody production)",
                      "염증 (Inflammation)"
                    ],
                    "answerIndex": 2,
                    "explanation": "보체 활성화의 주요 결과는 세포 용해, 옵소닌화, 염증입니다. 항체 생산은 보체 시스템의 직접적인 결과가 아닌 적응 면역 반응의 일부입니다."
                  },
                  {
                    "question": "인터페론(IFN-α 및 IFN-β)의 주요 역할은 무엇입니까?",
                    "options": [
                      "세균을 직접 죽인다.",
                      "발열을 유도한다.",
                      "바이러스 감염에 반응하여 항바이러스 단백질 생성을 유도한다.",
                      "조직 복구를 돕는다."
                    ],
                    "answerIndex": 2,
                    "explanation": "IFN-α와 IFN-β는 바이러스 감염에 의해 생성되어 주변 세포가 바이러스 복제를 억제하는 항바이러스 단백질(AVPs)을 생산하도록 유도합니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 개요 및 이중적 특성",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1042 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "적응성 면역 체계",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "적응성 면역은 특정 병원체를 표적으로 하는 방어 체계입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 감염이나 백신 접종을 통해 획득됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것을 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 반응은 동일한 외래 물질과의 이후 상호 작용으로, '기억' 덕분에 더 빠르고 효과적입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역 체계의 이중적 특성",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "체액성 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "체액성 면역은 항원(antigens)으로 알려진 외래 분자와 싸우는 항체를 생성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 적골수에서 생성되고 성숙하는 림프구입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 항원을 인식하고 항체를 만듭니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 조류의 파브리시우스 낭(bursa of Fabricius)에서 이름을 따왔습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "애니메이션: 체액성 면역 개요",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포성 면역 (세포 매개 면역)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포성 면역은 T 림프구를 생성합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 림프구는 식세포에 의해 처리된 항원 펩타이드를 인식합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 흉선에서 성숙합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 표면의 T 세포 수용체(TCRs)가 항원과 접촉하면 T 세포는 항체 대신 사이토카인을 분비합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 및 B 세포 발달",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "체액성 면역과 세포성 면역의 공격 대상 비교",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포성 면역은 세포 내부에 있는 항원을 공격합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 바이러스나 M. leprae, L. monocytogenes와 같은 일부 세포 내 세균에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "체액성 면역은 세포 외부의 침입자와 위협에 맞서 싸웁니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이는 세포 외 세균과 독소, 그리고 숙주 세포에 들어가기 전의 바이러스를 포함합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "제공된 텍스트는 특정 병원체를 표적으로 하는 방어 체계인 적응성 면역에 대해 설명합니다. 적응성 면역은 감염이나 백신을 통해 획득되며, 일차 반응과 이차 반응으로 구분됩니다. 또한, 적응성 면역의 이중적 특성으로 체액성 면역(B 세포, 항체 생성, 세포 외부 위협 방어)과 세포성 면역(T 세포, 사이토카인 분비, 세포 내부 위협 방어)을 상세히 다루고, 각 면역 체계가 공격하는 대상의 차이점을 비교합니다.",
                  "keyConcepts": [
                    {
                      "term": "적응성 면역",
                      "definition": "특정 병원체를 표적으로 삼는 방어 체계로, 감염이나 백신 접종을 통해 획득되며, 기억을 통해 더 빠르고 효과적인 이차 반응을 가능하게 합니다."
                    },
                    {
                      "term": "체액성 면역",
                      "definition": "B 세포가 항원을 인식하고 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸우는 면역 반응입니다."
                    },
                    {
                      "term": "세포성 면역",
                      "definition": "T 림프구가 식세포에 의해 처리된 항원 펩타이드를 인식하고 사이토카인을 분비하여 세포 내부에 있는 항원(예: 바이러스, 일부 세포 내 세균)을 공격하는 면역 반응입니다."
                    },
                    {
                      "term": "일차 반응 및 이차 반응",
                      "definition": "일차 반응은 면역 체계가 특정 외래 물질과 처음으로 싸우는 것이며, 이차 반응은 동일한 물질과의 이후 상호 작용으로, 기억 덕분에 더 빠르고 효과적입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "항원 (Antigen)",
                      "definition": "면역 반응, 특히 항체 생성을 유도하는 외래 분자입니다."
                    },
                    {
                      "term": "항체 (Antibody)",
                      "definition": "B 세포에 의해 생성되며 특정 항원과 결합하여 중화하거나 제거하는 Y자 모양의 단백질입니다."
                    },
                    {
                      "term": "B 세포 (B cell)",
                      "definition": "적골수에서 생성 및 성숙하며 항원을 인식하고 항체를 만드는 림프구입니다."
                    },
                    {
                      "term": "T 세포 (T cell)",
                      "definition": "흉선에서 성숙하며 항원 제시 세포에 의해 처리된 항원 펩타이드를 인식하고 항체 대신 사이토카인을 분비하는 림프구입니다."
                    },
                    {
                      "term": "사이토카인 (Cytokine)",
                      "definition": "T 세포 등 면역 세포가 분비하는 작은 단백질로, 면역 반응과 염증을 조절하는 신호 분자 역할을 합니다."
                    },
                    {
                      "term": "T 세포 수용체 (TCR)",
                      "definition": "T 세포 표면에 위치하며 특정 항원 펩타이드를 인식하고 결합하는 수용체입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "적응성 면역 체계",
                      "id": "adaptive-immune-system",
                      "children": [
                        {
                          "text": "적응성 면역의 정의 및 획득 경로",
                          "id": "definition-acquisition-of-adaptive-immunity",
                          "children": null
                        },
                        {
                          "text": "일차 반응과 이차 반응",
                          "id": "primary-and-secondary-response",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역 체계의 이중적 특성",
                      "id": "dual-nature-of-adaptive-immune-system",
                      "children": [
                        {
                          "text": "체액성 면역",
                          "id": "humoral-immunity",
                          "children": [
                            {
                              "text": "항체 생성 및 항원 공격",
                              "id": "antibody-production-and-antigen-attack",
                              "children": null
                            },
                            {
                              "text": "B 세포의 역할 및 특징",
                              "id": "role-and-characteristics-of-b-cells",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "세포성 면역 (세포 매개 면역)",
                          "id": "cellular-immunity",
                          "children": [
                            {
                              "text": "T 림프구 생성 및 역할",
                              "id": "t-lymphocyte-production-and-role",
                              "children": null
                            },
                            {
                              "text": "T 세포의 성숙 및 항원 인식",
                              "id": "t-cell-maturation-and-antigen-recognition",
                              "children": null
                            },
                            {
                              "text": "T 세포 수용체(TCR) 및 사이토카인 분비",
                              "id": "tcr-and-cytokine-secretion",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "체액성 면역과 세포성 면역의 공격 대상 비교",
                          "id": "comparison-of-humoral-and-cellular-immunity-targets",
                          "children": [
                            {
                              "text": "세포성 면역의 대상 (세포 내부 항원)",
                              "id": "targets-of-cellular-immunity",
                              "children": null
                            },
                            {
                              "text": "체액성 면역의 대상 (세포 외부 위협)",
                              "id": "targets-of-humoral-immunity",
                              "children": null
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "적응성 면역의 주요 특징은 무엇입니까?",
                    "options": [
                      "비특이적 방어",
                      "특정 병원체를 표적으로 함",
                      "즉각적인 반응",
                      "항상 식세포 작용을 포함함"
                    ],
                    "answerIndex": 1,
                    "explanation": "적응성 면역은 특정 병원체를 표적으로 삼는 방어 체계입니다."
                  },
                  {
                    "question": "항체를 생성하고 세포 외부의 위협을 공격하는 면역 유형은 무엇입니까?",
                    "options": [
                      "선천성 면역",
                      "세포성 면역",
                      "체액성 면역",
                      "비특이적 면역"
                    ],
                    "answerIndex": 2,
                    "explanation": "체액성 면역은 B 세포가 항체를 생성하여 세포 외부의 외래 분자(항원)와 싸웁니다."
                  },
                  {
                    "question": "T 세포는 어디에서 성숙합니까?",
                    "options": [
                      "적골수",
                      "비장",
                      "림프절",
                      "흉선"
                    ],
                    "answerIndex": 3,
                    "explanation": "T 세포는 흉선(thymus)에서 성숙합니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 사이토카인, 항원 및 항체",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1989 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "사이토카인: 면역 세포의 화학적 전달자",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인은 자극에 반응하여 생성되는 화학적 전달자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인터루킨(Interleukins): 백혈구 사이의 사이토카인입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "케모카인(Chemokines): 백혈구의 이동을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인터페론(Interferons, IFNs): 숙주 세포의 바이러스 감염을 방해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "종양 괴사 인자(Tumor necrosis factor, TNF): 자가면역 질환의 염증과 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "조혈 사이토카인(Hematopoietic cytokines): 적혈구와 백혈구로 발달하는 줄기세포를 조절합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이토카인의 과잉 생산은 사이토카인 폭풍(cytokine storm)으로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "주요 사이토카인 및 그 역할",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-4: TH2 세포에서 생성되며, 미감염 TH 세포와 B 세포에 작용하여 TH2 세포 증식을 유도하고 IgE로의 클래스 전환을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-12: 수지상 세포, 대식세포, 호중구에서 생성되며, 미감염 TH 세포와 NK 세포에 작용하여 TH1 세포의 성장과 기능을 자극하고 IFN-γ 및 TNF-α를 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-17: TH17 세포에서 생성되며, 호중구에 작용하여 염증을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IL-22: TH17 세포에서 생성되며, 상피세포에 작용하여 항균 단백질 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감마 인터페론(IFN-γ): TH1 세포에서 생성되며, CTL(세포독성 T 림프구)과 대식세포에 작용하여 식세포 작용을 촉진하고 대식세포 및 체액성 면역 반응을 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "케모카인: 다양한 세포(대식세포, 상피세포)에서 생성되며, 호중구에 작용하여 화학주성(chemotaxis)을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "TNF-알파(TNF-α): 대식세포, TH 세포, NK 세포에서 생성되며, 종양 세포에 작용하여 염증을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "GM-CSF: 대식세포, T 세포, NK 세포에서 생성되며, 골수 줄기세포에 작용하여 대식세포와 과립구 수를 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항원은 항체 생성을 유발하는 물질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일반적으로 침입하는 미생물이나 이물질의 구성 요소입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체는 항원상의 에피토프(epitopes) 또는 항원결정인자(antigenic determinants)와 상호작용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "합텐",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "합텐은 면역 반응을 유발하기에는 너무 작은 항원입니다; 운반 분자에 부착되어야 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항체",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체는 면역글로불린(Immunoglobulins, Ig)이라고 불리는 구형 단백질입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가(Valence)는 항체에 있는 항원 결합 부위의 수를 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이중가(Bivalent) 항체는 두 개의 결합 부위를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전형적인 항체 분자의 구조",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "네 개의 단백질 사슬이 Y자 모양을 이룹니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "두 개의 동일한 경쇄(light chains)와 두 개의 동일한 중쇄(heavy chains)가 이황화 결합으로 연결되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가변(V) 부위는 팔의 끝 부분에 위치하며 에피토프와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "정상(Fc) 부위는 줄기 부분으로, 특정 Ig 클래스에 대해 동일합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역글로불린은 5가지 클래스(IgG, IgM, IgA, IgD, IgE)로 나뉩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역글로불린 클래스 요약",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "IgG",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체(Monomer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 80%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액, 림프, 장에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "태반을 통과하여 태아를 보호하고; 보체(complement)를 활성화하며; 식세포 작용을 강화하고; 독소와 바이러스를 중화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgM",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다섯 개의 단량체가 J 사슬로 연결된 오량체(Pentamer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 6%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈관 내에 남아있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포와 바이러스의 응집을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감염에 대한 첫 번째 반응이며; 수명이 짧습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgA",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청에서는 단량체, 분비물에서는 이량체(Dimer)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 13%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "점막, 침, 눈물, 모유에서 흔히 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "미생물이 점막에 부착하는 것을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgD",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 0.02%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "IgG와 유사한 구조를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈액, 림프, B 세포에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "명확히 정의된 기능은 없으나; B 세포의 면역 반응을 돕습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "IgE",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "단량체입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 항체의 0.002%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비만세포, 호염기구, 혈액에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원과 결합하면 히스타민 방출을 유발하고; 기생충을 용해합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본 문서는 적응성 면역의 핵심 요소인 사이토카인, 항원, 항체에 대해 설명합니다. 사이토카인은 면역 세포 간의 화학적 전달자로, 다양한 종류(인터루킨, 케모카인, 인터페론, TNF 등)와 기능(염증 유발, 백혈구 이동 유도, 바이러스 감염 방해 등)을 가지며, 과잉 생산 시 사이토카인 폭풍을 유발할 수 있습니다. 항원은 항체 생성을 유발하는 물질이며, 항체가 결합하는 특정 부위를 에피토프라고 합니다. 합텐은 면역 반응을 유발하기에 너무 작아 운반 분자에 부착해야 하는 항원입니다. 항체는 면역글로불린(Ig)이라는 단백질로, Y자 모양의 구조를 가지며 가변부위와 정상부위로 구성됩니다. IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 클래스가 있으며, 각 클래스는 고유한 구조적 특성과 면역 기능을 수행합니다.",
                  "keyConcepts": [
                    {
                      "term": "사이토카인 (Cytokines)",
                      "definition": "면역 세포 간의 통신을 담당하는 화학적 전달 물질로, 다양한 면역 반응을 조절합니다."
                    },
                    {
                      "term": "항원 (Antigens)",
                      "definition": "면역 반응, 특히 항체 생성을 유발하는 물질입니다."
                    },
                    {
                      "term": "항체 (Antibodies/Immunoglobulins)",
                      "definition": "항원에 특이적으로 결합하여 항원을 중화하거나 제거하는 면역 단백질입니다."
                    },
                    {
                      "term": "면역글로불린 클래스 (Immunoglobulin Classes)",
                      "definition": "항체의 기능과 구조에 따라 IgG, IgM, IgA, IgD, IgE의 다섯 가지 주요 분류로 나뉩니다."
                    },
                    {
                      "term": "사이토카인 폭풍 (Cytokine Storm)",
                      "definition": "사이토카인이 과도하게 생산되어 전신 염증 반응과 조직 손상을 유발할 수 있는 심각한 면역 반응입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "인터루킨 (Interleukins)",
                      "definition": "백혈구 사이에서 작용하는 사이토카인입니다."
                    },
                    {
                      "term": "케모카인 (Chemokines)",
                      "definition": "백혈구의 이동(화학주성)을 유도하는 사이토카인입니다."
                    },
                    {
                      "term": "인터페론 (Interferons, IFNs)",
                      "definition": "바이러스 감염을 방해하는 사이토카인입니다."
                    },
                    {
                      "term": "종양 괴사 인자 (Tumor Necrosis Factor, TNF)",
                      "definition": "염증 반응과 관련된 사이토카인입니다."
                    },
                    {
                      "term": "에피토프 (Epitopes)",
                      "definition": "항원 상에서 항체가 특이적으로 결합하는 특정 부위 또는 항원결정인자입니다."
                    },
                    {
                      "term": "합텐 (Haptens)",
                      "definition": "단독으로는 면역 반응을 유발하지 못하지만, 운반 분자에 부착되면 면역원성을 획득하는 작은 분자입니다."
                    },
                    {
                      "term": "가변 부위 (Variable regions)",
                      "definition": "항체 팔의 끝 부분에 위치하며 항원의 에피토프와 결합하는 부위입니다."
                    },
                    {
                      "term": "정상 부위 (Constant region, Fc)",
                      "definition": "항체 분자의 줄기 부분으로, 특정 Ig 클래스에 대해 동일하며 면역 세포와의 상호작용에 관여합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "사이토카인: 면역 세포의 화학적 전달자",
                      "id": "cytokines-chemical-messengers-of-immune-cells",
                      "children": [
                        {
                          "text": "사이토카인의 정의 및 종류",
                          "id": "cytokines-definition-types",
                          "children": null
                        },
                        {
                          "text": "주요 사이토카인 및 그 역할",
                          "id": "key-cytokines-roles",
                          "children": null
                        },
                        {
                          "text": "사이토카인 폭풍",
                          "id": "cytokine-storm",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원",
                      "id": "antigens",
                      "children": [
                        {
                          "text": "항원의 정의",
                          "id": "antigens-definition",
                          "children": null
                        },
                        {
                          "text": "에피토프",
                          "id": "epitopes",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "합텐",
                      "id": "haptens",
                      "children": null
                    },
                    {
                      "text": "항체",
                      "id": "antibodies",
                      "children": [
                        {
                          "text": "항체의 정의 및 구조",
                          "id": "antibodies-definition-structure",
                          "children": null
                        },
                        {
                          "text": "전형적인 항체 분자의 구조",
                          "id": "typical-antibody-structure",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역글로불린 클래스 요약",
                      "id": "summary-of-immunoglobulin-classes",
                      "children": [
                        {
                          "text": "IgG",
                          "id": "igg",
                          "children": null
                        },
                        {
                          "text": "IgM",
                          "id": "igm",
                          "children": null
                        },
                        {
                          "text": "IgA",
                          "id": "iga",
                          "children": null
                        },
                        {
                          "text": "IgD",
                          "id": "igd",
                          "children": null
                        },
                        {
                          "text": "IgE",
                          "id": "ige",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "사이토카인 폭풍(Cytokine storm)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
                    "options": [
                      "면역 세포가 바이러스 감염을 방해하기 위해 사이토카인을 과도하게 생산하는 현상",
                      "염증 반응을 억제하기 위해 사이토카인이 부족하게 생산되는 현상",
                      "사이토카인이 과도하게 생산되어 조직 손상과 장기 부전을 초래할 수 있는 현상",
                      "항체 생산을 촉진하기 위해 특정 사이토카인이 의도적으로 증가하는 현상"
                    ],
                    "answerIndex": 2,
                    "explanation": "사이토카인 폭풍은 사이토카인이 과도하게 생산되어 전신 염증 반응, 조직 손상 및 장기 부전을 초래할 수 있는 현상입니다."
                  },
                  {
                    "question": "다음 면역글로불린(Ig) 클래스 중, 태반을 통과하여 태아를 보호하고 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 하는 것은 무엇입니까?",
                    "options": [
                      "IgM",
                      "IgA",
                      "IgG",
                      "IgE"
                    ],
                    "answerIndex": 2,
                    "explanation": "IgG는 태반을 통과하여 태아를 보호하며, 보체 활성화, 식세포 작용 강화, 독소 및 바이러스 중화 기능을 수행합니다."
                  },
                  {
                    "question": "합텐(Hapten)에 대한 설명으로 옳은 것은 무엇입니까?",
                    "options": [
                      "항체를 생산하는 모든 물질을 의미한다.",
                      "면역 반응을 유발하기에 너무 작아서 운반 분자에 부착해야 하는 항원이다.",
                      "항체와 상호작용하는 항원의 특정 부위를 의미한다.",
                      "혈액에 가장 많이 존재하는 면역글로불린의 한 종류이다."
                    ],
                    "answerIndex": 1,
                    "explanation": "합텐은 단독으로는 면역 반응을 유발하기에 너무 작지만, 운반 분자에 부착되면 면역원성을 획득하여 항체 생성을 유도할 수 있는 물질입니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 체액성 면역 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2199 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "항체 생성 세포의 활성화 및 클론 선택",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "주조직적합복합체(MHC)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "주조직적합복합체(MHC) 유전자는 세포 표면에 존재하는 분자를 암호화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Class I MHC는 모든 유핵 동물 세포의 막에 존재하며, '자기(self)'를 식별하는 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Class II MHC는 B 세포를 포함한 전문 항원제시세포(APCs)의 표면에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "B 세포의 활성화 및 클론 선택 과정",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "비활성 B 세포는 항원에 결합하는 표면 면역글로불린(Ig)을 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "B 세포는 항원을 내재화하고 처리합니다. 처리된 항원 조각들은 MHC Class II 분자에 제시됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이 제시된 항원 조각을 T 도우미 세포(TH cell)가 접촉하고, B 세포를 활성화시키는 사이토카인을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 B 세포는 증식(클론 확장)을 겪습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "클론 선택은 활성화된 B 세포를 다음 두 가지로 분화시킵니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1. 항체를 생산하는 형질세포(Plasma cells)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2. 기억 세포(Memory cells)",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "또한, 클론 제거(Clonal deletion) 과정을 통해 유해한 B 세포는 제거됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포는 특정 항원에 대한 표면 면역글로불린을 가진 성숙한 B 세포로 분화합니다. B 세포가 특정 항원을 만나면 증식합니다. 일부 B 세포는 장수하는 기억 세포로 증식하여, 나중에 항체를 생산하는 형질세포로 자극될 수 있습니다. 다른 B 세포는 항체 생산 형질세포로 증식하며, 이 형질세포는 혈액 순환계로 항체를 분비합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "T 세포 의존성 및 비의존성 항원",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 의존성 항원은 항체를 생산하기 위해 T 도우미 세포(TH cell)의 도움이 필요한 항원입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 직접 자극할 수 있습니다. 이러한 항원은 일반적으로 약한 면역 반응을 유발하며, 주로 IgM을 생산하고 기억 세포는 생성되지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원-항체 결합 및 그 결과",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 항원에 결합할 때 항원-항체 복합체가 형성됩니다. 이 결합의 강도를 친화도(affinity)라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원-항체 결합은 외래 분자나 세포를 파괴하도록 표지함으로써 숙주를 보호합니다. 주요 보호 메커니즘은 다음과 같습니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1. **응집(Agglutination)**: 감염 단위의 수를 줄여 처리해야 할 대상을 감소시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2. **옵소닌화(Opsonization)**: 항원으로 항원을 코팅하여 식균작용을 강화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "3. **항체 의존성 세포 매개성 세포독성(Antibody-dependent cell-mediated cytotoxicity, ADCC)**: 항체가 표적 세포에 부착되어 대식세포, 호산구, NK 세포에 의한 파괴를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "4. **중화(Neutralization)**: 박테리아와 바이러스가 점막에 부착되는 것을 차단하고 독소가 부착되는 것을 막습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "5. **보체계 활성화(Activation of the complement system)**: 염증 및 세포 용해를 유발합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본 문서는 적응성 면역 중 체액성 면역 반응에 초점을 맞춰 항체 생성 세포의 활성화 및 클론 선택 과정을 설명합니다. MHC(주조직적합복합체)의 역할, B 세포가 항원을 인식하고 T 도우미 세포의 도움을 받아 활성화되며 형질세포와 기억 세포로 분화하는 과정이 상세히 다뤄집니다. 또한, T 세포 의존성 및 비의존성 항원의 특징과 항원-항체 결합이 숙주를 보호하는 응집, 옵소닌화, ADCC, 중화, 보체계 활성화 등 다양한 메커니즘을 제시합니다.",
                  "keyConcepts": [
                    {
                      "term": "MHC (주조직적합복합체)",
                      "definition": "세포 표면에 존재하며, Class I은 '자기' 식별, Class II는 항원제시세포에서 항원 조각을 T 세포에 제시하는 역할을 하는 분자를 암호화하는 유전자 복합체."
                    },
                    {
                      "term": "B 세포 활성화",
                      "definition": "비활성 B 세포가 항원을 인식하고, T 도우미 세포의 사이토카인 도움을 받아 증식하고 분화하는 과정."
                    },
                    {
                      "term": "클론 선택 (Clonal Selection)",
                      "definition": "특정 항원에 반응하는 B 세포 클론이 선택적으로 증식하여 항체 생성 형질세포와 기억 세포로 분화하는 면역 과정."
                    },
                    {
                      "term": "T 세포 의존성/비의존성 항원",
                      "definition": "항체 생산에 T 도우미 세포의 도움이 필요한지 여부에 따라 항원을 분류하는 방식. 비의존성 항원은 약한 IgM 반응과 기억 세포 부재를 특징으로 함."
                    },
                    {
                      "term": "항체 기능",
                      "definition": "항원-항체 복합체 형성 후 숙주를 보호하는 다양한 메커니즘 (응집, 옵소닌화, ADCC, 중화, 보체계 활성화)."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "MHC (주조직적합복합체)",
                      "definition": "세포 표면에 항원 펩타이드를 제시하는 데 관여하는 단백질 복합체."
                    },
                    {
                      "term": "T 도우미 세포 (T Helper Cell, TH cell)",
                      "definition": "B 세포 활성화 및 다른 면역 세포 기능을 조절하는 사이토카인을 분비하는 림프구."
                    },
                    {
                      "term": "사이토카인 (Cytokines)",
                      "definition": "세포 간 신호 전달에 관여하며 면역 반응을 조절하는 작은 단백질."
                    },
                    {
                      "term": "형질세포 (Plasma Cell)",
                      "definition": "활성화된 B 세포로부터 분화하여 다량의 항체를 생산하고 분비하는 세포."
                    },
                    {
                      "term": "기억 세포 (Memory Cell)",
                      "definition": "면역 반응 후 장기간 생존하며, 동일한 항원 재침입 시 빠르고 강력한 2차 면역 반응을 유도하는 림프구."
                    },
                    {
                      "term": "응집 (Agglutination)",
                      "definition": "항체가 여러 항원 입자(예: 세균)를 서로 묶어 침전시키는 과정."
                    },
                    {
                      "term": "옵소닌화 (Opsonization)",
                      "definition": "항체가 항원 표면을 코팅하여 식세포가 이를 더 쉽게 인식하고 포식할 수 있도록 돕는 과정."
                    }
                  ],
                  "outline": [
                    {
                      "text": "항체 생성 세포의 활성화 및 클론 선택",
                      "id": "항체-생성-세포의-활성화-및-클론-선택",
                      "children": [
                        {
                          "text": "주조직적합복합체(MHC)",
                          "id": "주조직적합복합체-mhc",
                          "children": null
                        },
                        {
                          "text": "B 세포의 활성화 및 클론 선택 과정",
                          "id": "b-세포의-활성화-및-클론-선택-과정",
                          "children": null
                        },
                        {
                          "text": "T 세포 의존성 및 비의존성 항원",
                          "id": "t-세포-의존성-및-비의존성-항원",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원-항체 결합 및 그 결과",
                      "id": "항원-항체-결합-및-그-결과",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 MHC Class II 분자가 주로 발견되는 세포와 그 역할은 무엇입니까?",
                    "options": [
                      "모든 유핵 동물 세포의 막; '자기' 식별",
                      "전문 항원제시세포(APCs)의 표면; 항원 조각 제시",
                      "적혈구; 산소 운반",
                      "신경 세포; 신경 신호 전달"
                    ],
                    "answerIndex": 1,
                    "explanation": "MHC Class II는 B 세포를 포함한 전문 항원제시세포의 표면에 존재하며, 처리된 항원 조각을 T 도우미 세포에 제시하는 역할을 합니다."
                  },
                  {
                    "question": "B 세포가 항원을 내재화하고 처리한 후, T 도우미 세포의 도움을 받아 활성화될 때 T 도우미 세포가 방출하는 물질은 무엇입니까?",
                    "options": [
                      "항체",
                      "항원",
                      "사이토카인",
                      "면역글로불린"
                    ],
                    "answerIndex": 2,
                    "explanation": "T 도우미 세포는 제시된 항원 조각을 인식한 후 사이토카인을 방출하여 B 세포의 활성화를 유도합니다."
                  },
                  {
                    "question": "T 세포 비의존성 항원에 대한 면역 반응의 특징으로 옳지 않은 것은 무엇입니까?",
                    "options": [
                      "T 세포의 도움 없이 B 세포를 직접 자극한다.",
                      "주로 IgM 항체를 생산한다.",
                      "약한 면역 반응을 유발한다.",
                      "강력한 기억 세포 반응을 생성한다."
                    ],
                    "answerIndex": 3,
                    "explanation": "T 세포 비의존성 항원은 T 세포의 도움 없이 B 세포를 자극하지만, 일반적으로 약한 면역 반응을 유발하고 기억 세포가 생성되지 않습니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 세포성 면역 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 2963 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "세포성 면역 반응 과정",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 세포내 병원체와 싸웁니다. T 세포는 흉선에서 성숙하며, 흉선 선택을 통해 미성숙 T 세포가 제거됩니다. 성숙한 T 세포는 흉선에서 림프 조직으로 이동하며, T 세포 수용체(TCR)를 통해 항원에 부착합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "위장관으로 들어오는 병원체는 파이어스 패치(Peyer's patches) 위에 위치한 미세주름 세포(M cells)를 통과합니다. 이 세포들은 항원을 림프구와 항원제시세포(APCs)로 전달합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원제시세포 (APCs)",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "수지상 세포 (Dendritic cells, DCs)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "수지상 세포는 미생물을 삼켜 분해하고 T 세포에 제시합니다. 이들은 피부, 생식기, 림프절, 비장, 흉선 및 혈액에서 발견됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "대식세포 (Macrophages)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "대식세포는 사이토카인 또는 항원 물질의 섭취에 의해 활성화됩니다. 이들은 림프 조직으로 이동하여 T 세포에 항원을 제시합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항원 처리 및 제시: MHC",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "T 세포의 종류",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포는 분화군(Clusters of differentiation, CD) 표지자를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CD4+ T 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4+ T 세포는 T 도우미 세포(TH)라고도 불립니다. 이들은 B 세포와 사이토카인 신호를 주고받으며 항원과 직접 상호작용합니다. B 세포 및 APC의 MHC class II 분자에 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CD8+ T 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "CD8+ T 세포는 세포독성 T 림프구(Cytotoxic T lymphocytes, CTL)라고 불립니다. 이들은 MHC class I 분자에 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4+ 세포의 TCR은 APC의 항원 조각과 MHC class II에 결합하여 인식합니다. APC 또는 TH는 보조 자극 분자를 분비하여 CD4+ 세포를 활성화합니다. 활성화된 TH 세포는 사이토카인을 생성하고 TH1, TH2, TH17 세포 및 기억 세포로 분화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH17 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH17 세포는 IL-17을 생성하여 염증 반응에 기여하고, 세포외 세균 및 곰팡이에 대한 방어를 위해 호중구를 모집합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH1 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH1 세포는 IFN-γ를 생성하여 대식세포를 활성화하고, 보체를 강화하며, 식세포 작용을 촉진하는 항체 생성을 자극합니다. TH1 세포는 세포성 면역의 중요한 요소이며, 이들의 사이토카인(예: IFN-γ 및 IL-2)은 CD8+ T 세포와 NK 세포를 활성화하여 감염된 숙주 세포를 죽임으로써 세포내 병원체를 제어합니다. 또한, 대식세포와 같은 항원제시세포의 식세포 작용을 강화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "TH2 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "TH2 세포는 B 세포를 활성화하여 IgE를 생성하게 하고 호산구를 활성화합니다. 특히 IgE 생성을 통한 알레르기 반응에 중요하며, 헬민스와 같은 세포외 기생충을 제어하기 위해 호산구를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "조절 T 세포 (Treg)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 T 세포(Treg)는 CD4+ 세포의 하위 집합으로, 추가적인 CD25 분자를 가지고 있습니다. 이들은 자가 반응성 T 세포를 억제하여 자기 관용을 유지하고, 소화에 필요한 장내 세균을 보호하며, 태아를 보호합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 T 림프구 (CD8+ T 세포)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "전구 세포독성 T 세포(CTLp)는 TH 세포와 보조 자극 신호의 도움으로 활성화되어 세포독성 T 림프구(CTLs)가 됩니다. CTLs는 감염에 의해 변형된 자가 세포를 인식하고 죽입니다. 감염된 자가 세포는 MHC class I 분자와 함께 표면에 내인성 항원을 운반합니다. CTL은 퍼포린(perforin)과 그랜자임(granzymes)을 방출하여 감염된 세포의 세포자멸사를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포자멸사 (Apoptosis)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "세포자멸사는 프로그램된 세포 사멸입니다. 이는 감염성 바이러스가 다른 세포로 퍼지는 것을 방지합니다. 세포는 게놈을 조각으로 절단하며, 세포막은 수포(blebbing)를 통해 바깥쪽으로 부풀어 오릅니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "정상 세포는 세포독성 T 림프구(CTL)에 의해 반응을 유발하지 않지만, 바이러스 감염 세포나 암세포는 비정상적인 내인성 항원을 생성합니다. 이 비정상적인 항원은 MHC class I 분자와 결합하여 세포 표면에 제시됩니다. TH1 세포의 결합은 사이토카인 분비를 촉진합니다. 이 사이토카인은 전구 CTL을 활성화하여 CTL 클론을 생성합니다. CTL은 세포자멸사를 통해 바이러스 감염 세포의 파괴를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역계에 의한 세포외 살상",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "자연살해 (NK) 세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "자연살해(NK) 세포는 과립성 백혈구로, MHC class I 자가 항원을 발현하지 않는 세포를 파괴합니다. 이들은 바이러스 감염 세포와 종양 세포를 죽이고 기생충을 공격합니다. 항상 항원에 의해 자극되는 것은 아니며, 표적 세포에 구멍을 형성하여 용해 또는 세포자멸사를 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포성 면역에 관여하는 주요 세포 기능",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH1) 세포: 세포 매개 면역 관련 세포(대식세포, CTLs, 자연살해 세포)를 활성화합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH2) 세포: 호산구, IgM, IgE 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "T 도우미 (TH17) 세포: 호중구를 모집하고 항균 단백질 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구 (CTL): 세포자멸사를 유도하여 접촉하는 표적 세포를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "조절 T (Treg) 세포: 면역 반응을 조절하고 자기 관용을 유지하는 데 도움을 줍니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활성화된 대식세포: 식세포 활동이 강화되고 암세포를 공격합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자연살해 (NK) 세포: 표적 세포를 공격하고 파괴하며, 항체 의존성 세포 매개 세포독성(ADCC)에 참여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "항체 의존성 세포 매개 세포독성 (ADCC)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "원생동물과 헬민스는 식세포 작용으로 삼키기에는 너무 큽니다. 원생동물 또는 헬민스 표적 세포는 항체로 코팅됩니다. 면역계 세포는 항체의 Fc 영역에 부착합니다. 표적 세포는 면역계 세포가 분비하는 화학 물질에 의해 용해됩니다. 많은 기생충과 같이 식세포에 의해 섭취하기에는 너무 큰 유기체는 외부에서 공격받아야 합니다. 호산구는 기생성 흡충의 유충 단계에 부착합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 세포성 면역의 과정을 상세히 설명하며, T 세포, 항원제시세포(APCs) 및 이들의 상호작용에 중점을 둡니다. T 세포의 성숙 과정과 다양한 T 세포 유형(TH1, TH2, TH17, 세포독성 T 림프구, 조절 T 세포)의 기능, 그리고 이들이 세포내 병원체 퇴치, 면역 반응 조절 및 특정 면역 반응 매개에 어떻게 기여하는지 다룹니다. 또한, 자연살해(NK) 세포의 세포외 살상 역할과 대형 기생충에 대한 항체 의존성 세포 매개 세포독성(ADCC) 기전도 설명합니다.",
                  "keyConcepts": [
                    {
                      "term": "T 세포의 성숙 및 기능",
                      "definition": "흉선에서 성숙하며, 세포내 병원체와 싸우고 항원제시세포(APCs)가 제시하는 항원에 특이적으로 반응하는 림프구."
                    },
                    {
                      "term": "항원제시세포 (APCs)",
                      "definition": "미생물을 삼켜 분해하고 그 항원 조각을 MHC 분자를 통해 T 세포에 제시하여 T 세포 반응을 유도하는 세포 (예: 수지상 세포, 대식세포)."
                    },
                    {
                      "term": "T 세포 유형 및 역할",
                      "definition": "CD4+ T 세포(T 도우미 세포: TH1, TH2, TH17)는 다른 면역 세포의 활성화를 돕고, CD8+ T 세포(세포독성 T 림프구)는 감염된 세포를 직접 파괴하며, 조절 T 세포는 면역 반응을 억제하여 자기 관용을 유지한다."
                    },
                    {
                      "term": "세포독성 T 림프구 (CTLs) 및 세포자멸사 (Apoptosis)",
                      "definition": "CTL은 감염된 자가 세포를 인식하여 퍼포린과 그랜자임을 방출, 세포자멸사(프로그램된 세포 사멸)를 유도하여 바이러스 확산을 막는다."
                    },
                    {
                      "term": "자연살해(NK) 세포 및 항체 의존성 세포 매개 세포독성 (ADCC)",
                      "definition": "NK 세포는 MHC class I을 발현하지 않는 세포를 파괴하며, ADCC는 항체로 코팅된 표적 세포를 면역 세포가 용해시키는 기전으로, 특히 대형 기생충에 효과적이다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "T 세포 (T cell)",
                      "definition": "흉선에서 성숙하며 세포내 병원체와 싸우는 림프구."
                    },
                    {
                      "term": "항원제시세포 (Antigen-Presenting Cells, APCs)",
                      "definition": "미생물을 삼켜 분해하고 T 세포에 항원을 제시하는 세포 (예: 수지상 세포, 대식세포)."
                    },
                    {
                      "term": "MHC (Major Histocompatibility Complex)",
                      "definition": "항원 제시를 위해 세포 표면에 항원 조각을 표시하는 분자."
                    },
                    {
                      "term": "T 도우미 세포 (T Helper cells, TH)",
                      "definition": "CD4+ T 세포로, B 세포와 사이토카인 신호를 주고받으며 다른 면역 세포의 활성화를 돕는다."
                    },
                    {
                      "term": "세포독성 T 림프구 (Cytotoxic T Lymphocytes, CTLs)",
                      "definition": "CD8+ T 세포로, 감염된 자가 세포를 인식하고 세포자멸사를 유도하여 파괴한다."
                    },
                    {
                      "term": "세포자멸사 (Apoptosis)",
                      "definition": "프로그램된 세포 사멸로, 감염성 바이러스가 다른 세포로 퍼지는 것을 방지한다."
                    },
                    {
                      "term": "자연살해 세포 (Natural Killer cells, NK cells)",
                      "definition": "MHC class I 자가 항원을 발현하지 않는 세포를 파괴하며, 바이러스 감염 세포, 종양 세포 및 기생충을 공격한다."
                    },
                    {
                      "term": "항체 의존성 세포 매개 세포독성 (Antibody-Dependent Cell-mediated Cytotoxicity, ADCC)",
                      "definition": "항체로 코팅된 표적 세포를 면역 세포가 파괴하는 기전."
                    }
                  ],
                  "outline": [
                    {
                      "text": "세포성 면역 반응 과정",
                      "id": "세포성-면역-반응-과정",
                      "children": [
                        {
                          "text": "T 세포의 역할과 성숙",
                          "id": "t-세포의-역할과-성숙",
                          "children": null
                        },
                        {
                          "text": "소화관 내 병원체 처리",
                          "id": "소화관-내-병원체-처리",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원제시세포 (APCs)",
                      "id": "항원제시세포-apcs",
                      "children": [
                        {
                          "text": "수지상 세포 (Dendritic cells, DCs)",
                          "id": "수지상-세포-dendritic-cells-dcs",
                          "children": null
                        },
                        {
                          "text": "대식세포 (Macrophages)",
                          "id": "대식세포-macrophages",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "항원 처리 및 제시: MHC",
                      "id": "항원-처리-및-제시-mhc",
                      "children": null
                    },
                    {
                      "text": "T 세포의 종류",
                      "id": "t-세포의-종류",
                      "children": [
                        {
                          "text": "CD4+ T 세포",
                          "id": "cd4-t-세포",
                          "children": null
                        },
                        {
                          "text": "CD8+ T 세포",
                          "id": "cd8-t-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "T 도우미 세포 (CD4+ T 세포)의 활성화 및 분화",
                      "id": "t-도우미-세포-cd4-t-세포의-활성화-및-분화",
                      "children": [
                        {
                          "text": "TH17 세포",
                          "id": "th17-세포",
                          "children": null
                        },
                        {
                          "text": "TH1 세포",
                          "id": "th1-세포",
                          "children": null
                        },
                        {
                          "text": "TH2 세포",
                          "id": "th2-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "조절 T 세포 (Treg)",
                      "id": "조절-t-세포-treg",
                      "children": null
                    },
                    {
                      "text": "세포독성 T 림프구 (CD8+ T 세포)",
                      "id": "세포독성-t-림프구-cd8-t-세포",
                      "children": [
                        {
                          "text": "세포자멸사 (Apoptosis)",
                          "id": "세포자멸사-apoptosis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역계에 의한 세포외 살상",
                      "id": "면역계에-의한-세포외-살상",
                      "children": [
                        {
                          "text": "자연살해 (NK) 세포",
                          "id": "자연살해-nk-세포",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포성 면역에 관여하는 주요 세포 기능",
                      "id": "세포성-면역에-관여하는-주요-세포-기능",
                      "children": null
                    },
                    {
                      "text": "항체 의존성 세포 매개 세포독성 (ADCC)",
                      "id": "항체-의존성-세포-매개-세포독성-adcc",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "T 세포가 성숙하는 주요 장소는 어디인가요?",
                    "options": [
                      "골수",
                      "비장",
                      "흉선",
                      "림프절"
                    ],
                    "answerIndex": 2,
                    "explanation": "T 세포는 흉선(thymus)에서 성숙 과정을 거칩니다."
                  },
                  {
                    "question": "다음 중 세포독성 T 림프구(CTL)의 주된 기능은 무엇인가요?",
                    "options": [
                      "B 세포 활성화",
                      "대식세포 활성화",
                      "감염된 자가 세포 파괴",
                      "염증 반응 촉진"
                    ],
                    "answerIndex": 2,
                    "explanation": "세포독성 T 림프구(CTL)는 감염된 자가 세포나 암세포를 인식하고 세포자멸사를 유도하여 파괴하는 역할을 합니다."
                  },
                  {
                    "question": "다음 중 항원제시세포(APC)에 해당하지 않는 것은 무엇인가요?",
                    "options": [
                      "수지상 세포",
                      "대식세포",
                      "T 도우미 세포",
                      "B 세포"
                    ],
                    "answerIndex": 2,
                    "explanation": "수지상 세포, 대식세포, B 세포는 모두 항원제시세포(APC)의 역할을 수행합니다. T 도우미 세포는 APC에 의해 활성화되는 세포이지, 스스로 항원을 제시하는 세포는 아닙니다."
                  }
                ]
              },
              {
                "title": "적응성 면역: 면역학적 기억 및 면역 유형",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75f3de4_584e931f-b0a7-4a8b-b188-5fcad4c15f87_17. Adaptive immunity - Specific Defenses of the Host.pdf, Text length: 1056 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역학적 기억",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 (기억 또는 아남네스틱) 반응은 항원에 두 번째 노출된 후에 발생합니다. 이 반응은 더 빠르고, 며칠 동안 지속되며, 그 규모가 훨씬 더 큽니다. 초기 노출에 반응하여 생성된 기억 세포는 이차 노출에 의해 활성화됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "초기 IgM 반응이 IgG, IgE 또는 IgA로 전환되는 '클래스 전환(Class switching)' 현상이 이차 반응에서 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체 역가(Antibody titer)는 혈청 내 항체의 상대적인 양을 나타내며, 체액 면역 반응의 강도를 반영합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "체액 면역",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "일차 면역 반응",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "제공된 텍스트에는 일차 면역 반응에 대한 구체적인 내용은 포함되어 있지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이차 면역 반응",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "이차 면역 반응은 '면역학적 기억' 섹션에서 상세히 설명된 바와 같이, 항원에 대한 두 번째 노출 시 발생하는 빠르고 강력하며 지속적인 반응입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "적응성 면역의 유형",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "자연 획득 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "자연 획득 능동 면역은 감염을 통해 발생하며, 신체가 항원에 직접 노출되어 면역 반응을 일으키고 기억 세포를 형성하는 것을 의미합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자연 획득 수동 면역은 태반을 통해 또는 초유를 통해 어머니로부터 항체를 전달받아 발생하는 면역입니다. 이는 일시적인 면역을 제공합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인공 획득 면역",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "인공 획득 능동 면역은 예방 접종(백신 접종)을 통해 발생합니다. 이는 약화되거나 비활성화된 항원을 주입하여 신체 스스로 면역 반응을 일으키고 기억 세포를 형성하도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인공 획득 수동 면역은 항체 주사를 통해 발생합니다. 이는 특정 질병에 대한 즉각적인 보호를 제공하지만, 신체가 스스로 면역 반응을 일으킨 것이 아니므로 기억 세포가 형성되지 않아 일시적입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "관련 용어",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청(Antiserum)은 항체를 포함하는 혈액 유래 액체입니다. 혈청학(Serology)은 항체와 항원 간의 반응을 연구하는 학문입니다. 글로불린(Globulins)은 혈청 단백질을 총칭하며, 감마(γ) 글로불린은 항체를 포함하는 혈청 분획입니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 면역학적 기억과 적응성 면역의 다양한 유형에 대해 설명합니다. 면역학적 기억은 항원에 두 번째 노출되었을 때 발생하는 이차 면역 반응(더 빠르고 강력하며 지속적)의 특징과 클래스 전환, 그리고 항체 역가의 개념을 포함합니다. 적응성 면역은 자연 획득(능동/수동)과 인공 획득(능동/수동) 면역으로 분류되며, 각각의 특징과 발생 원리를 다룹니다. 또한, 혈청, 혈청학, 글로불린, 감마 글로불린과 같은 관련 용어의 정의도 제공합니다.",
                  "keyConcepts": [
                    {
                      "term": "면역학적 기억",
                      "definition": "항원에 대한 첫 노출 후 형성되어, 재노출 시 더 빠르고 강력한 이차 면역 반응을 유도하는 능력."
                    },
                    {
                      "term": "이차 면역 반응",
                      "definition": "항원에 두 번째 노출되었을 때 나타나는 면역 반응으로, 일차 반응보다 빠르고 강하며 오래 지속되는 특징을 가집니다."
                    },
                    {
                      "term": "적응성 면역의 유형",
                      "definition": "면역 획득 방식에 따라 자연 획득 능동/수동 면역과 인공 획득 능동/수동 면역으로 나뉩니다."
                    },
                    {
                      "term": "클래스 전환",
                      "definition": "초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "이차 (기억 또는 아남네스틱) 반응",
                      "definition": "항원에 두 번째 노출되었을 때 발생하는 면역 반응."
                    },
                    {
                      "term": "클래스 전환",
                      "definition": "면역 반응 시 초기 IgM 항체에서 IgG, IgE, IgA 등 다른 항체 유형으로 전환되는 현상."
                    },
                    {
                      "term": "항체 역가",
                      "definition": "혈청 내 항체의 상대적인 양을 나타내는 지표."
                    },
                    {
                      "term": "자연 획득 능동 면역",
                      "definition": "감염을 통해 자연적으로 항원에 노출되어 획득하는 면역."
                    },
                    {
                      "term": "인공 획득 능동 면역",
                      "definition": "예방 접종(백신)을 통해 인위적으로 항원에 노출되어 획득하는 면역."
                    },
                    {
                      "term": "혈청",
                      "definition": "항체를 포함하는 혈액 유래 액체."
                    },
                    {
                      "term": "감마 글로불린",
                      "definition": "항체를 포함하는 혈청 단백질 분획."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역학적 기억",
                      "id": "immunological-memory",
                      "children": [
                        {
                          "text": "이차 면역 반응의 특성",
                          "id": "secondary-immune-response-characteristics",
                          "children": null
                        },
                        {
                          "text": "클래스 전환 및 기억 세포",
                          "id": "class-switching-and-memory-cells",
                          "children": null
                        },
                        {
                          "text": "항체 역가",
                          "id": "antibody-titer",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "체액 면역",
                      "id": "humoral-immunity",
                      "children": [
                        {
                          "text": "일차 면역 반응",
                          "id": "primary-immune-response",
                          "children": null
                        },
                        {
                          "text": "이차 면역 반응",
                          "id": "secondary-immune-response-humoral",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "적응성 면역의 유형",
                      "id": "types-of-adaptive-immunity",
                      "children": [
                        {
                          "text": "자연 획득 면역",
                          "id": "naturally-acquired-immunity",
                          "children": [
                            {
                              "text": "자연 획득 능동 면역",
                              "id": "naturally-acquired-active-immunity",
                              "children": null
                            },
                            {
                              "text": "자연 획득 수동 면역",
                              "id": "naturally-acquired-passive-immunity",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "인공 획득 면역",
                          "id": "artificially-acquired-immunity",
                          "children": [
                            {
                              "text": "인공 획득 능동 면역",
                              "id": "artificially-acquired-active-immunity",
                              "children": null
                            },
                            {
                              "text": "인공 획득 수동 면역",
                              "id": "artificially-acquired-passive-immunity",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "관련 용어",
                          "id": "related-terms",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "이차 면역 반응의 주요 특징이 아닌 것은 무엇입니까?",
                    "options": [
                      "일차 반응보다 느리게 발생한다.",
                      "더 오랫동안 지속된다.",
                      "규모가 더 크다.",
                      "기억 세포에 의해 활성화된다."
                    ],
                    "answerIndex": 0,
                    "explanation": "이차 면역 반응은 일차 반응보다 '더 빠르게' 발생하며, 더 오랫동안 지속되고 규모가 더 크다는 특징을 가집니다."
                  },
                  {
                    "question": "예방 접종(백신 접종)을 통해 획득하는 면역 유형은 무엇입니까?",
                    "options": [
                      "자연 획득 능동 면역",
                      "자연 획득 수동 면역",
                      "인공 획득 능동 면역",
                      "인공 획득 수동 면역"
                    ],
                    "answerIndex": 2,
                    "explanation": "예방 접종은 인위적으로 항원을 주입하여 신체 스스로 면역 반응을 일으키도록 유도하는 '인공 획득 능동 면역'에 해당합니다."
                  },
                  {
                    "question": "면역학적 기억에서 '클래스 전환'은 무엇을 의미합니까?",
                    "options": [
                      "면역 세포의 종류가 바뀌는 것",
                      "초기 IgM 반응이 다른 유형의 항체(IgG, IgE, IgA)로 바뀌는 것",
                      "항체가 항원에 결합하는 방식이 바뀌는 것",
                      "면역 반응의 강도가 약해지는 것"
                    ],
                    "answerIndex": 1,
                    "explanation": "클래스 전환은 초기 IgM 항체 반응이 IgG, IgE, IgA와 같은 다른 유형의 항체 반응으로 바뀌는 현상을 말합니다."
                  }
                ]
              },
              {
                "title": "면역학의 실제 적용: 백신",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 3538 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "백신 개요",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역학의 실제 적용 중 하나인 백신은 질병 예방에 있어 핵심적인 역할을 합니다. 백신의 역사는 천연두 접종법(Variolation)에서 시작되었는데, 이는 천연두를 피부에 접종하여 질병을 예방하는 방식이었습니다. 이후 제너(Jenner)는 우두를 접종하여 천연두를 예방하는 방법을 발견했습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "백신(Vaccine)이라는 용어는 파스퇴르(Pasteur)에 의해 만들어졌으며, 'vacca'(소)에서 유래했습니다. 백신은 면역을 유도하는 유기체 또는 유기체의 일부 현탁액으로 정의됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 기능 및 원리",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 접종은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이는 실제 병원체에 노출되었을 때 빠르고 강렬한 이차 면역 반응을 생성하는 데 기여합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "집단 면역(Herd immunity)은 인구 대부분의 면역 상태를 의미하며, 감수성 있는 개체의 부족으로 질병 발생이 산발적으로 나타나게 하여 전염병 확산을 막는 중요한 효과를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CDC 권장 세균성 질환 백신",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "미국 질병통제예방센터(CDC)는 다양한 세균성 질환 예방을 위한 백신을 권장하고 있습니다. 이에는 헤모필루스 인플루엔자 b형 수막염, 수막구균성 수막염, 폐렴구균성 폐렴, 파상풍, 디프테리아, 백일해 백신 등이 포함됩니다. 각 백신은 특정 연령대 또는 위험군에 대한 권장 사항과 추가 접종 여부가 명시되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "CDC 권장 바이러스성 질환 백신",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "CDC는 또한 수두, A형 간염, B형 간염, 대상포진, 인유두종바이러스, 인플루엔자, 홍역, 유행성 이하선염, 소아마비, 광견병, 로타바이러스, 풍진, 천연두 등 다양한 바이러스성 질환 예방을 위한 백신을 권장하고 있습니다. 이들 백신 역시 접종 대상, 시기, 그리고 추가 접종의 필요성에 대한 구체적인 지침을 따릅니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 종류 및 특성",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "약독화 생백신 (Live attenuated vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "약독화 생백신은 약화된 병원체를 사용하여 실제 감염과 유사한 면역 반응을 유도하며, 평생 지속되는 세포성 및 체액성 면역을 부여합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "불활성화 사백신 (Inactivated killed vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "불활성화 사백신은 생백신보다 안전하지만, 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "서브유닛 백신 (Subunit vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "서브유닛 백신은 항원성 조각을 사용하여 면역 반응을 자극합니다. 유전적 변형을 통해 생산되는 서브유닛 백신을 재조합 백신(Recombinant vaccines)이라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "톡소이드 (Toxoids)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "톡소이드는 불활성화된 독소이며, 항독소(Antitoxins)는 독소에 대한 항체를 포함하는 혈청입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "VLP 백신은 온전한 바이러스와 유사하지만 바이러스 유전 물질을 포함하지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다당류 백신 (Polysaccharide vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다당류 백신은 병원체의 캡슐 분자로 만들어지며 면역원성이 강하지 않습니다. 캡슐 다당류에 대한 면역 반응이 약한 어린이 질병에 사용되는 백신을 접합 백신(Conjugated vaccines)이라고 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "핵산(DNA) 백신은 DNA에 암호화된 단백질 항원을 생성하기 위해 주사된 DNA를 사용하며, 체액성 및 세포성 면역을 모두 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "재조합 벡터 백신 (Recombinant vector vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "재조합 벡터 백신은 항원을 코딩하는 유전자를 전달하도록 유전적으로 변형된 비병원성 바이러스 또는 박테리아를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "RNA 백신 (RNA vaccines)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "RNA 백신은 새로운 유형의 백신으로, 특정 항원 단백질을 생산하도록 세포에 지시하는 RNA 서열을 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신 생산, 전달 방법 및 제형",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 개발은 동물 숙주를 사용하지 않는 방향으로 발전하고 있으며, 식물을 백신 공급원으로 활용하는 연구도 진행 중입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "경구 백신 및 건조 백신(피부 패치)의 개발이 증가하고 있으며, 나노패치(Nanopatch)는 건조 형태의 백신을 피부에 전달하여 냉장 보관이 필요 없으며 다수의 항원제시세포(APC)를 활용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다중 조합 백신, 만성 질환 백신 개발, 그리고 세포성 면역 개발을 위한 \"역 백신학(Reverse vaccinology)\" 연구도 활발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 미국에서는 명반(Alums)과 모노포스포릴 지질 A(monophosphoryl lipid A)만이 승인되어 있으며, 선천 면역 반응을 개선하는 역할을 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "마이크로바이옴과 경구 백신 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "젖산균인 비피도박테리움(Bifidobacterium)은 장내 마이크로바이옴의 정상적인 일부이며, 마이크로바이옴이 경구 백신에 대한 반응을 향상시킬 수 있다는 연구가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "백신의 안전성",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "드물게 백신이 질병을 유발할 수 있지만, MMR 백신이 자폐증과 연관되어 있다는 의학적 또는 과학적 증거는 없습니다. 백신은 어린이의 감염성 질환을 예방하는 가장 안전하고 효과적인 수단으로 간주됩니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 백신의 역사적 배경, 기능, 다양한 종류, 생산 및 전달 방법, 그리고 안전성에 대해 설명합니다. 백신은 일차 면역 반응을 유도하여 항체와 기억 세포를 형성하고, 이를 통해 집단 면역을 구축하여 질병 확산을 막는 원리를 가지고 있습니다. 약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 여러 유형의 백신이 각자의 특성과 함께 소개되며, 아쥬반트의 역할과 백신 안전성에 대한 중요한 정보도 포함되어 있습니다.",
                  "keyConcepts": [
                    {
                      "term": "집단 면역 (Herd Immunity)",
                      "definition": "인구 대부분이 면역을 가지게 되어 감수성 개체의 부족으로 질병 발생이 산발적으로 나타나게 하는 현상으로, 전염병 확산을 막는 데 중요합니다."
                    },
                    {
                      "term": "백신의 종류 (Types of Vaccines)",
                      "definition": "약독화 생백신, 불활성화 사백신, 서브유닛 백신, 톡소이드, 핵산 백신 등 다양한 백신 유형이 있으며, 각각 다른 방식으로 면역 반응을 유도합니다."
                    },
                    {
                      "term": "아쥬반트 (Adjuvants)",
                      "definition": "백신의 효능을 높이고 면역 반응을 강화하기 위해 백신에 첨가되는 화학 물질입니다. 주로 선천 면역 반응을 개선하는 역할을 합니다."
                    },
                    {
                      "term": "기억 세포 (Memory Cells)",
                      "definition": "백신 접종 후 형성되는 면역 세포로, 실제 병원체에 재노출되었을 때 빠르고 강렬한 이차 면역 반응을 가능하게 하여 장기적인 면역력을 제공합니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "천연두 접종법 (Variolation)",
                      "definition": "천연두를 피부에 접종하여 면역을 유도하던 초기 질병 예방 방법입니다."
                    },
                    {
                      "term": "백신 접종 (Vaccination)",
                      "definition": "면역을 유도하기 위해 유기체 또는 유기체의 일부를 현탁액 형태로 인체에 주입하는 행위를 말합니다."
                    },
                    {
                      "term": "약독화 생백신 (Live Attenuated Vaccine)",
                      "definition": "병원체를 약화시켜 만든 백신으로, 실제 감염과 유사한 면역 반응을 유도하며 세포성 및 체액성 면역을 부여합니다."
                    },
                    {
                      "term": "불활성화 사백신 (Inactivated Killed Vaccine)",
                      "definition": "죽은 병원체나 그 일부를 사용하여 만든 백신으로, 약독화 생백신보다 안전하지만 주로 체액성 면역을 유도하고 반복적인 추가 접종이 필요합니다."
                    },
                    {
                      "term": "서브유닛 백신 (Subunit Vaccine)",
                      "definition": "병원체의 특정 항원성 조각만을 사용하여 만든 백신으로, 면역 반응을 자극합니다."
                    },
                    {
                      "term": "톡소이드 (Toxoid)",
                      "definition": "독소의 독성을 제거하고 면역원성만 남긴 백신으로, 독소에 의해 발생하는 질병을 예방하는 데 사용됩니다."
                    },
                    {
                      "term": "아쥬반트 (Adjuvant)",
                      "definition": "백신의 면역 반응을 강화하기 위해 첨가되는 물질로, 백신의 효능을 높이고 선천 면역 반응을 개선합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "백신 개요",
                      "id": "백신-개요",
                      "children": [
                        {
                          "text": "백신의 역사",
                          "id": "백신의-역사",
                          "children": null
                        },
                        {
                          "text": "백신의 정의",
                          "id": "백신의-정의",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신의 기능 및 원리",
                      "id": "백신의-기능-및-원리",
                      "children": [
                        {
                          "text": "면역 반응 유도",
                          "id": "면역-반응-유도",
                          "children": null
                        },
                        {
                          "text": "집단 면역",
                          "id": "집단-면역",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "CDC 권장 백신",
                      "id": "cdc-권장-백신",
                      "children": [
                        {
                          "text": "세균성 질환 백신",
                          "id": "세균성-질환-백신",
                          "children": null
                        },
                        {
                          "text": "바이러스성 질환 백신",
                          "id": "바이러스성-질환-백신",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신의 종류 및 특성",
                      "id": "백신의-종류-및-특성",
                      "children": [
                        {
                          "text": "약독화 생백신 (Live attenuated vaccines)",
                          "id": "약독화-생백신-live-attenuated-vaccines",
                          "children": null
                        },
                        {
                          "text": "불활성화 사백신 (Inactivated killed vaccines)",
                          "id": "불활성화-사백신-inactivated-killed-vaccines",
                          "children": null
                        },
                        {
                          "text": "서브유닛 백신 (Subunit vaccines)",
                          "id": "서브유닛-백신-subunit-vaccines",
                          "children": null
                        },
                        {
                          "text": "톡소이드 (Toxoids)",
                          "id": "톡소이드-toxoids",
                          "children": null
                        },
                        {
                          "text": "바이러스 유사 입자 (VLP) 백신 (Virus-like particle (VLP) vaccines)",
                          "id": "바이러스-유사-입자-vlp-백신-virus-like-particle-vlp-vaccines",
                          "children": null
                        },
                        {
                          "text": "다당류 백신 (Polysaccharide vaccines)",
                          "id": "다당류-백신-polysaccharide-vaccines",
                          "children": null
                        },
                        {
                          "text": "핵산 (DNA) 백신 (Nucleic acid (DNA) vaccines)",
                          "id": "핵산-dna-백신-nucleic-acid-dna-vaccines",
                          "children": null
                        },
                        {
                          "text": "재조합 벡터 백신 (Recombinant vector vaccines)",
                          "id": "재조합-벡터-백신-recombinant-vector-vaccines",
                          "children": null
                        },
                        {
                          "text": "RNA 백신 (RNA vaccines)",
                          "id": "rna-백신-rna-vaccines",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "백신 생산, 전달 방법 및 제형",
                      "id": "백신-생산-전달-방법-및-제형",
                      "children": [
                        {
                          "text": "생산 기술의 발전",
                          "id": "생산-기술의-발전",
                          "children": null
                        },
                        {
                          "text": "새로운 전달 방식",
                          "id": "새로운-전달-방식",
                          "children": null
                        },
                        {
                          "text": "아쥬반트의 역할",
                          "id": "아쥬반트의-역할",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "마이크로바이옴과 경구 백신 반응",
                      "id": "마이크로바이옴과-경구-백신-반응",
                      "children": null
                    },
                    {
                      "text": "백신의 안전성",
                      "id": "백신의-안전성",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "백신 접종이 유도하는 주요 면역학적 반응은 무엇이며, 이 반응의 결과로 형성되는 중요한 세포는 무엇입니까?",
                    "options": [
                      "일차 면역 반응, 기억 세포",
                      "이차 면역 반응, 비만 세포",
                      "알레르기 반응, 형질 세포",
                      "자가면역 반응, T 세포"
                    ],
                    "answerIndex": 0,
                    "explanation": "백신은 일차 면역 반응을 유발하여 항체와 기억 세포의 형성을 이끌어냅니다. 이 기억 세포 덕분에 실제 병원체 노출 시 빠르고 강렬한 이차 면역 반응이 가능해집니다."
                  },
                  {
                    "question": "다음 중 약독화 생백신과 불활성화 사백신의 주요 차이점에 대한 설명으로 올바른 것은 무엇입니까?",
                    "options": [
                      "약독화 생백신은 평생 면역을 부여하지만, 불활성화 사백신은 추가 접종이 필요하다.",
                      "약독화 생백신은 주로 체액성 면역을 유도하고, 불활성화 사백신은 세포성 면역을 유도한다.",
                      "약독화 생백신은 불활성화 사백신보다 안전하다.",
                      "약독화 생백신은 유전 물질을 포함하지 않지만, 불활성화 사백신은 포함한다."
                    ],
                    "answerIndex": 0,
                    "explanation": "약독화 생백신은 실제 감염과 유사하게 평생 지속되는 세포성 및 체액성 면역을 부여하는 경향이 있는 반면, 불활성화 사백신은 더 안전하지만 반복적인 추가 접종이 필요하며 주로 체액성 면역을 유도합니다."
                  },
                  {
                    "question": "백신에 첨가되어 효능을 향상시키고 선천 면역 반응을 개선하는 화학 첨가제는 무엇이라고 불립니까?",
                    "options": [
                      "항독소",
                      "톡소이드",
                      "아쥬반트",
                      "폴리사카라이드"
                    ],
                    "answerIndex": 2,
                    "explanation": "아쥬반트(Adjuvants)는 백신의 효능을 향상시키기 위해 첨가되는 화학 첨가제로, 선천 면역 반응을 개선하는 역할을 합니다."
                  }
                ]
              },
              {
                "title": "면역학의 실제 적용: 진단 면역학",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_2e07540e-364a-4158-894d-7fc6951e2eb6_18. Practical Applications of Immunology.pdf, Text length: 2187 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "진단 면역학 개요",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "민감도(Sensitivity): 검사가 진양성 표본에 대해 반응할 확률",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "특이도(Specificity): 양성 검사가 진음성 표본에 대해 반응하지 않을 확률",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역학 기반 진단 검사는 체액 항체와 항원의 상호작용을 이용한다. 알려진 항체를 통해 미지의 병원체를 식별하거나, 알려진 병원체를 통해 미지의 항체를 식별할 수 있다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "단일클론 항체 (Monoclonal Antibodies)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "하이브리도마(Hybridoma): \"불멸의\" 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합한 세포.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "하이브리도마는 단일클론 항체(Mabs)를 생산한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "Mabs는 균일하고, 특이성이 높으며, 대량 생산이 가능하다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "진단 도구 및 인체 치료에 사용된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류마티스 관절염에서 TNF를 중화하거나, 비만세포와 호염기구에 IgE 결합을 막아 알레르기성 천식을 치료하는 데 활용된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주로 쥐 세포에서 유래하여 부작용을 일으킬 수 있다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "키메라 단일클론 항체: 쥐의 가변 영역과 인간의 불변 영역을 가진 Mabs.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인간화 항체: 쥐 항원 결합 부위를 제외하고 대부분 인간 유래인 Mabs.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "완전 인간 항체: 쥐에 삽입된 인간 유전자로부터 생산된 Mabs.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "단일클론 항체의 생산",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "침강 반응 (Precipitation Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "가용성 항원과 항체가 반응하여 격자(lattices)라고 불리는 크고 서로 맞물린 응집체를 형성하는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원-항체 복합체가 형성된 후, 용액에서 침전되는 격자가 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강링 테스트(Precipitin ring test): 최적의 항원-항체 비율 지점에서 흐린 선이 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역확산 테스트(Immunodiffusion tests): 한천 젤 배지에서 수행되는 침강 반응이다. 최적의 항원-항체 비율 지점에서 침전물이 형성된다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 전기영동(Immunoelectrophoresis): 전기영동과 면역확산을 결합한 것으로, 인간 혈청의 단백질을 분리한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "응집 반응 (Agglutination Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "입자성 항원이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 응집 테스트(Direct agglutination tests): 큰 세포성 항원에 대한 항체를 검출한다. 혈청 항체 농도(역가, titer)를 측정하며, 역가 증가는 질병에 대한 더 큰 면역을 나타낸다. 혈청 전환(Seroconversion)은 질병이 진행됨에 따라 역가에 유의미한 변화가 나타나는 것을 의미한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접(수동) 응집 테스트(Indirect (passive) agglutination tests): 항체가 입자에 부착된 가용성 항원과 반응하거나 그 반대로 반응한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈구 응집(Hemagglutination): 적혈구 표면 항원과 보체 항체의 응집으로, 혈액형 판별에 사용된다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 면역학 학습 목표 (1)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "응집 테스트와 침강 테스트의 차이점을 구별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈구 응집을 정의한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "중화 테스트가 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강 테스트와 중화 테스트의 차이점을 구별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 고정 테스트의 기본 원리를 설명한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "중화 반응 (Neutralization Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스성 혈구 응집(Viral hemagglutination): 바이러스가 항원-항체 반응 없이 적혈구를 응집시키는 현상 (예: 볼거리, 홍역, 인플루엔자).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항체(항독소)에 의해 외독소나 바이러스의 유해한 효과가 차단되는 항원-항체 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스성 혈구 응집 억제 테스트(Viral hemagglutination inhibition test): 바이러스 아형을 분류하는 데 사용된다. 바이러스와 적혈구를 환자의 혈청과 혼합한다. 혈청에 바이러스에 대한 항체가 포함되어 있으면, 항체가 바이러스를 중화하여 혈구 응집을 억제한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "보체 고정 반응 (Complement-Fixation Reactions)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "보체 고정(Complement fixation): 보체 혈청 단백질이 항원-항체 복합체에 결합하고 고정되는 반응이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "소량의 항체를 검출할 수 있다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침강 또는 응집 반응에 적합하지 않은 항체에도 사용될 수 있다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 면역학 학습 목표 (2)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 및 간접 형광 항체 테스트를 비교하고 대조한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 및 간접 ELISA 테스트가 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "웨스턴 블롯이 어떻게 작동하는지 설명한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "단일클론 항체의 중요성을 설명한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "형광 염료를 항체와 결합시킨다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 FA 테스트: 임상 검체에서 미생물을 식별한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접 FA 테스트: 혈청에서 특정 항체를 검출한다. 항인간 면역 혈청 글로불린(anti-HISG)을 추가하며, 결과가 양성이면 혈청 내 모든 항체와 반응한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "형광 활성화 세포 분류기(Fluorescence-activated cell sorter, FACS): 레이저 빔이 세포를 포함하는 액적에 닿으면, 감지기가 표면 분자의 크기와 형광을 측정한다. 세포에 전하를 부여하여 세포를 분리한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "효소결합 면역흡착 분석법 (ELISA)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "직접 ELISA: 항원을 검출한다. 항원을 포함하는 샘플을 항체와 혼합한다. 효소 연결 항체가 항원과 반응한다. 연결된 효소를 위한 기질을 추가하여 색이 생성되는 것으로 검출한다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "간접 ELISA: 항체를 검출한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "웨스턴 블롯 (Western Blotting)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "전기영동과 블롯을 통해 단백질을 식별한다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "진단 및 치료 면역학의 미래",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "인간의 판단과 인력이 덜 필요한 테스트가 개발될 것이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "PCR 및 DNA 프로브가 활용될 것이다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "개발도상국을 위한 저렴하고 간단한 테스트가 필요하다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "질병 예방 및 치료에 기여할 것이다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 면역학의 실제 적용, 특히 진단 면역학에 대해 설명합니다. 검사의 민감도와 특이도 같은 기본 개념부터 시작하여, 단일클론 항체의 생산, 종류 및 치료적 활용에 대해 다룹니다. 또한, 침강 반응, 응집 반응, 중화 반응, 보체 고정 반응, 형광 항체 기법, ELISA, 웨스턴 블롯 등 다양한 면역학 기반 진단 테스트의 원리와 적용 방법을 상세히 설명합니다. 마지막으로 진단 및 치료 면역학의 미래 방향에 대해서도 간략하게 언급합니다.",
                  "keyConcepts": [
                    {
                      "term": "진단 면역학의 기본 원리",
                      "definition": "검사의 민감도(Sensitivity)와 특이도(Specificity)는 진단 검사의 정확성을 나타내는 핵심 지표이며, 항원-항체 상호작용이 면역학 기반 진단 테스트의 근간을 이룬다."
                    },
                    {
                      "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                      "definition": "하이브리도마 기술을 통해 대량 생산되는 균일하고 고도로 특이적인 항체로, 진단 및 류마티스 관절염, 알레르기성 천식 등 다양한 질병의 치료에 활용된다. 쥐 유래 항체는 부작용을 일으킬 수 있어 키메라, 인간화, 완전 인간 항체 등으로 발전하고 있다."
                    },
                    {
                      "term": "면역 반응 기반 진단 테스트 유형",
                      "definition": "침강(Precipitation), 응집(Agglutination), 중화(Neutralization), 보체 고정(Complement-Fixation), 형광 항체(Fluorescent-Antibody), ELISA(Enzyme-Linked Immunosorbent Assay), 웨스턴 블롯(Western Blotting) 등 항원-항체 반응을 시각적으로 또는 정량적으로 확인하여 질병을 진단하는 다양한 기법들이 있다."
                    },
                    {
                      "term": "항체 역가 측정",
                      "definition": "직접 응집 테스트 등을 통해 혈청 내 특정 항체의 농도(역가)를 측정하는 것으로, 역가 증가는 질병에 대한 면역력 증가를 나타내며, 혈청 전환은 질병 진행에 따른 역가의 유의미한 변화를 의미한다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "민감도 (Sensitivity)",
                      "definition": "검사가 진양성 표본에 대해 반응할 확률"
                    },
                    {
                      "term": "특이도 (Specificity)",
                      "definition": "양성 검사가 진음성 표본에 대해 반응하지 않을 확률"
                    },
                    {
                      "term": "하이브리도마 (Hybridoma)",
                      "definition": "암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포"
                    },
                    {
                      "term": "단일클론 항체 (Monoclonal Antibodies, Mabs)",
                      "definition": "하이브리도마에서 생산되는 균일하고 특이성이 높은 항체로, 진단 및 치료에 사용된다."
                    },
                    {
                      "term": "침강 반응 (Precipitation Reactions)",
                      "definition": "가용성 항원과 항체가 반응하여 불용성 복합체(격자)를 형성하고 침전되는 반응"
                    },
                    {
                      "term": "응집 반응 (Agglutination Reactions)",
                      "definition": "입자성 항원(예: 세포)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 반응"
                    },
                    {
                      "term": "중화 반응 (Neutralization Reactions)",
                      "definition": "항체가 독소나 바이러스의 유해한 효과를 차단하는 항원-항체 반응"
                    },
                    {
                      "term": "보체 고정 반응 (Complement-Fixation Reactions)",
                      "definition": "보체 단백질이 항원-항체 복합체에 결합하고 고정되는 반응으로, 소량의 항체도 검출 가능하다."
                    },
                    {
                      "term": "효소결합 면역흡착 분석법 (ELISA)",
                      "definition": "효소와 항체를 이용하여 항원 또는 항체를 검출하는 면역학적 분석법으로, 색 변화를 통해 결과를 확인한다."
                    },
                    {
                      "term": "웨스턴 블롯 (Western Blotting)",
                      "definition": "전기영동으로 분리된 단백질을 막에 옮겨 특정 항체를 이용하여 식별하는 기법"
                    }
                  ],
                  "outline": [
                    {
                      "text": "진단 면역학 개요",
                      "id": "진단-면역학-개요",
                      "children": null
                    },
                    {
                      "text": "단일클론 항체 (Monoclonal Antibodies)",
                      "id": "단일클론-항체-monoclonal-antibodies",
                      "children": [
                        {
                          "text": "단일클론 항체의 생산",
                          "id": "단일클론-항체의-생산",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "침강 반응 (Precipitation Reactions)",
                      "id": "침강-반응-precipitation-reactions",
                      "children": null
                    },
                    {
                      "text": "응집 반응 (Agglutination Reactions)",
                      "id": "응집-반응-agglutination-reactions",
                      "children": null
                    },
                    {
                      "text": "진단 면역학 학습 목표 (1)",
                      "id": "진단-면역학-학습-목표-1",
                      "children": null
                    },
                    {
                      "text": "중화 반응 (Neutralization Reactions)",
                      "id": "중화-반응-neutralization-reactions",
                      "children": null
                    },
                    {
                      "text": "보체 고정 반응 (Complement-Fixation Reactions)",
                      "id": "보체-고정-반응-complement-fixation-reactions",
                      "children": null
                    },
                    {
                      "text": "진단 면역학 학습 목표 (2)",
                      "id": "진단-면역학-학습-목표-2",
                      "children": null
                    },
                    {
                      "text": "형광 항체 기법 (Fluorescent-Antibody Techniques)",
                      "id": "형광-항체-기법-fluorescent-antibody-techniques",
                      "children": null
                    },
                    {
                      "text": "효소결합 면역흡착 분석법 (ELISA)",
                      "id": "효소결합-면역흡착-분석법-elisa",
                      "children": null
                    },
                    {
                      "text": "웨스턴 블롯 (Western Blotting)",
                      "id": "웨스턴-블롯-western-blotting",
                      "children": null
                    },
                    {
                      "text": "진단 및 치료 면역학의 미래",
                      "id": "진단-및-치료-면역학의-미래",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "다음 중 하이브리도마(Hybridoma)에 대한 설명으로 가장 적절한 것은 무엇입니까?",
                    "options": [
                      "암성 B 세포와 항체 생산 정상 B 세포를 결합한 세포",
                      "항원을 직접 생산하는 세포",
                      "체내에서 바이러스성 감염을 중화하는 세포",
                      "면역 반응을 억제하는 데 사용되는 세포"
                    ],
                    "answerIndex": 0,
                    "explanation": "하이브리도마는 '불멸의' 암성 B 세포(골수종)와 항체 생산 정상 B 세포를 결합하여 단일클론 항체를 생산하는 세포입니다."
                  },
                  {
                    "question": "침강 반응(Precipitation Reactions)과 응집 반응(Agglutination Reactions)의 주요 차이점은 무엇입니까?",
                    "options": [
                      "침강 반응은 가용성 항원을, 응집 반응은 입자성 항원을 사용한다.",
                      "침강 반응은 항체를 검출하고, 응집 반응은 항원을 검출한다.",
                      "침강 반응은 육안으로 볼 수 없지만, 응집 반응은 육안으로 볼 수 있다.",
                      "침강 반응은 보체를 필요로 하지만, 응집 반응은 그렇지 않다."
                    ],
                    "answerIndex": 0,
                    "explanation": "침강 반응은 가용성 항원과 항체의 상호작용으로 불용성 복합체가 형성되는 것이고, 응집 반응은 입자성 항원(예: 세포 또는 입자에 부착된 항원)이 항체와 결합하여 육안으로 보이는 응집체를 형성하는 것입니다."
                  },
                  {
                    "question": "효소결합 면역흡착 분석법(ELISA)에 대한 설명으로 옳지 않은 것은 무엇입니까?",
                    "options": [
                      "직접 ELISA는 항원을 검출하는 데 사용된다.",
                      "간접 ELISA는 항체를 검출하는 데 사용된다.",
                      "효소 연결 항체가 항원 또는 항체와 반응하여 색 변화를 유도한다.",
                      "ELISA는 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법이다."
                    ],
                    "answerIndex": 3,
                    "explanation": "ELISA는 효소와 항체를 이용하여 항원 또는 항체를 검출하며 색 변화를 통해 결과를 확인합니다. 단백질을 전기영동으로 분리한 후 막에 옮겨 식별하는 기법은 웨스턴 블롯(Western Blotting)입니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 과민 반응",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 3760 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "과민 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "과민 반응(Hypersensitivity)은 정상 범위를 넘어선 과도한 항원(알레르겐) 반응을 의미합니다. 이는 이전에 항원에 노출되어 민감해진 경우에 발생합니다. 과민 반응은 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 유형으로 분류됩니다. 과민 반응을 연구하는 학문은 면역병리학(Immunopathology)이라고 합니다. 위생 가설(Hygiene hypothesis)은 병원균에 대한 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다고 제안합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "과민 반응의 유형",
                    "level": 1
                  },
                  {
                    "type": "heading",
                    "content": "제1형 (아나필락시스형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 30분 미만이 소요됩니다. IgE 항체가 비만세포나 호염기구에 결합하여 비만세포 또는 호염기구의 탈과립을 유발하고 히스타민과 같은 반응성 물질을 방출하게 합니다. 약물 주사 및 곤충 독에 의한 아나필락시스 쇼크, 건초열, 천식과 같은 일반적인 알레르기 증상이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제2형 (세포 독성형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 5-12시간이 소요됩니다. 항원이 표적 세포에 결합하는 IgM 및 IgG 항체 형성을 유발하며, 보체의 작용과 결합하여 표적 세포를 파괴합니다. 수혈 반응, Rh 부적합성이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제3형 (면역 복합체형)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 3-8시간이 소요됩니다. 항체와 항원이 복합체를 형성하여 손상적인 염증을 유발합니다. 아르투스 반응, 혈청병이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제4형 (지연형 세포 매개성 또는 지연형 과민 반응)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "임상 증상 발현까지 24-48시간이 소요됩니다. 항원이 세포독성 T 림프구(CTLs)를 활성화시켜 표적 세포를 사멸시킵니다. 이식 조직 거부 반응, 옻나무에 의한 접촉 피부염, 특정 만성 질환(예: 결핵) 등이 여기에 해당합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제1형 (아나필락시스형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이 반응은 항원에 민감해진 사람이 해당 항원에 재노출된 후 수 분 내에 발생합니다. 항원이 IgE 항체와 결합하며, IgE는 비만세포와 호염기구에 부착됩니다. 비만세포와 호염기구는 탈과립을 겪으며 다음과 같은 매개체를 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 히스타민: 혈액 모세혈관의 투과성을 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 류코트리엔: 평활근의 지속적인 수축을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "• 프로스타글란딘: 평활근에 영향을 미치고 점액 분비를 증가시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항원에 반응하여 생성된 IgE 항체는 비만세포와 호염기구를 감싸게 됩니다. 항원이 동일한 특이성을 가진 두 개의 인접한 항체 분자 사이의 간격을 연결할 때, 세포는 탈과립을 겪고 히스타민 및 기타 매개체를 방출합니다. 이는 항원과 반응하여 히스타민 및 기타 반응성 매개체 과립을 방출한 탈과립 비만세포의 모습입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전신 아나필락시스 (아나필락시스 쇼크)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항원에 민감해진 개체가 다시 노출될 때 발생합니다. 순환계 허탈 및 사망에 이를 수 있으며, 에피네프린으로 치료합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "국소 아나필락시스",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "주로 섭취되거나 흡입된 항원과 관련이 있습니다. 증상은 침입 경로에 따라 다르며, 두드러기, 건초열, 천식 등이 포함됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "아나필락시스 반응 예방",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "알레르겐을 식별하기 위한 피부 검사는 항원을 표피 아래에 접종하여 빠른 염증 반응(팽진)을 확인합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "탈감작(Desensitization)은 항원을 피부 아래에 증가하는 용량으로 주사하는 방법입니다. 이는 IgG를 생성하게 하는데, 이 IgG는 블로킹 항체(blocking antibodies) 역할을 하여 항원을 가로채고 중화시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제2형 (세포 독성형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "IgG 또는 IgM 항체와 항원성 세포의 결합에 의한 보체 활성화로 발생합니다. 이는 세포 용해 또는 대식세포에 의한 손상을 유발합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "ABO 혈액형 시스템",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "적혈구에 있는 특정 탄수화물 항원에 대해 항체가 형성됩니다. A 항원, B 항원 또는 둘 다를 가질 수 있습니다. O형 적혈구는 항원이 없습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "Rh 혈액형 시스템",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "인구의 85%에서 적혈구에 Rh 인자 항원(Rh+)이 발견됩니다. Rh+ 혈액이 Rh- 수혈자에게 주입되면 수혈자의 몸에서 항Rh 항체 생성을 자극합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "용혈성 신생아 질환 (HDNB)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "Rh- 어머니가 Rh+ 태아를 임신할 경우 어머니의 몸에서 항Rh 항체가 생성됩니다. 첫 Rh+ 태아를 임신한 Rh- 어머니의 경우, 분만 중 태아의 Rh 항원이 어머니의 혈액으로 들어갈 수 있습니다. 이 태아 Rh 항원에 반응하여 어머니는 항Rh 항체를 생산할 것입니다. 두 번째 Rh+ 태아를 임신하게 되면, 어머니의 항Rh 항체가 태반을 통과하여 태아의 적혈구를 손상시킬 것입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "약물 유발 세포 독성 반응",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "혈소판 감소성 자반증 (Thrombocytopenic purpura)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "혈소판이 약물과 결합하여 항원성 복합체를 형성합니다. 항체와 보체가 혈소판을 파괴합니다. 약물(합텐)이 혈소판에 결합하여 합텐-혈소판 복합체를 형성합니다. 이 복합체는 합텐에 대한 항체 형성을 유도합니다. 항체와 보체의 작용은 혈소판 파괴를 일으킵s니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "무과립구증 (Agranulocytosis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "약물 유발 과립구의 면역 파괴입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "용혈성 빈혈 (Hemolytic anemia)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "약물 유발 적혈구의 면역 파괴입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제3형 (면역 복합체형) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 혈청 내 가용성 항원에 대해 형성됩니다. 세포 아래 기저막에 침착되는 면역 복합체를 형성하여 보체를 활성화시키고 염증을 유발합니다. 면역 복합체는 혈관벽에 침착됩니다. 면역 복합체의 존재는 보체를 활성화시키고 호중구와 같은 염증 세포를 유인합니다. 호중구에서 방출된 효소는 기저막의 내피 세포에 손상을 입힙니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "아르투스 반응 (Arthus reaction)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "톡소이드 함유 백신의 드문 부작용입니다. 주사된 항원에 대해 이미 순환하는 IgG를 가진 환자에서 보체 활성화로 인해 사구체 및 기타 혈관벽에서 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "혈청병 (Serum sickness)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "이종 혈청 주입으로 인한 부종 및 염증과 함께 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "제4형 (지연형 세포 매개성) 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포에 의해 유발되는 세포 매개 면역 반응입니다. 이는 지연형 과민 반응으로 알려져 있습니다. 항원은 식세포화되어 T 세포 수용체에 제시되어 민감화를 유발합니다. 항원에 재노출되면 기억 세포가 파괴적인 사이토카인을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "알레르기성 접촉 피부염 (Allergic contact dermatitis)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "합텐이 피부의 단백질과 결합하여 면역 반응을 일으킵니다. 옻나무, 화장품, 금속, 라텍스 등에 대한 알레르기 반응이 여기에 해당합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본문은 면역 시스템 관련 질환 중 '과민 반응'에 대해 설명합니다. 과민 반응은 정상 범위를 넘어선 과도한 면역 반응으로, 이전 항원 노출로 인해 민감해진 상태에서 발생합니다. 아나필락시스형(Type I), 세포 독성형(Type II), 면역 복합체형(Type III), 지연형 세포 매개성형(Type IV)의 네 가지 주요 유형으로 분류되며, 각 유형은 발현 시간, 기전, 임상 증상 및 예시가 다릅니다. 제1형은 즉각적인 알레르기 반응(예: 아나필락시스 쇼크)을, 제2형은 세포 파괴(예: 수혈 부작용)를, 제3형은 면역 복합체 침착으로 인한 염증(예: 혈청병)을, 제4형은 T세포 매개 지연 반응(예: 접촉 피부염)을 특징으로 합니다. 각 유형의 발생 기전과 예방 및 치료법이 상세히 다루어집니다.",
                  "keyConcepts": [
                    {
                      "term": "과민 반응 (Hypersensitivity)",
                      "definition": "정상 범위를 넘어선 과도한 항원 반응으로, 이전에 항원에 노출되어 민감해진 경우에 발생합니다."
                    },
                    {
                      "term": "아나필락시스 (Anaphylaxis)",
                      "definition": "제1형 과민 반응의 심각한 형태로, 비만세포 및 호염기구의 탈과립으로 인한 매개체 방출로 발생하며, 전신 또는 국소적으로 나타나 생명을 위협할 수 있습니다."
                    },
                    {
                      "term": "위생 가설 (Hygiene Hypothesis)",
                      "definition": "병원균 노출을 제한하는 것이 면역 관용을 낮추고 무해한 항원에 대처하는 능력을 저하시킬 수 있다는 가설입니다."
                    },
                    {
                      "term": "탈감작 (Desensitization)",
                      "definition": "알레르기 반응을 예방하기 위해 항원을 점진적으로 증가시켜 주사하는 치료법으로, 블로킹 항체(IgG) 생성을 유도하여 알레르겐을 중화시킵니다."
                    },
                    {
                      "term": "용혈성 신생아 질환 (HDNB)",
                      "definition": "Rh 혈액형 불일치로 인해 Rh- 어머니가 Rh+ 태아에 대한 항체를 생성하여 두 번째 Rh+ 태아의 적혈구를 파괴하는 질환입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "알레르겐 (Allergen)",
                      "definition": "알레르기 반응을 유발하는 항원입니다."
                    },
                    {
                      "term": "면역병리학 (Immunopathology)",
                      "definition": "과민 반응을 연구하는 학문입니다."
                    },
                    {
                      "term": "히스타민 (Histamine)",
                      "definition": "제1형 과민 반응 시 비만세포에서 방출되어 혈관 투과성을 증가시키는 주요 염증 매개체입니다."
                    },
                    {
                      "term": "류코트리엔 (Leukotrienes)",
                      "definition": "제1형 과민 반응 시 방출되어 평활근의 지속적인 수축을 유발하는 매개체입니다."
                    },
                    {
                      "term": "프로스타글란딘 (Prostaglandins)",
                      "definition": "제1형 과민 반응 시 방출되어 평활근에 영향을 미치고 점액 분비를 증가시키는 매개체입니다."
                    },
                    {
                      "term": "보체 (Complement)",
                      "definition": "면역 반응에서 항체와 함께 작용하여 세포 파괴를 돕는 단백질 시스템입니다."
                    },
                    {
                      "term": "합텐 (Hapten)",
                      "definition": "단독으로는 면역 반응을 유발하지 못하지만, 단백질과 결합 시 항원성을 띠는 작은 분자입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "과민 반응의 개요",
                      "id": "hypersensitivity-overview",
                      "children": [
                        {
                          "text": "정의 및 특징",
                          "id": "definition-features",
                          "children": null
                        },
                        {
                          "text": "과민 반응의 네 가지 유형",
                          "id": "four-types-hypersensitivity",
                          "children": null
                        },
                        {
                          "text": "면역병리학 및 위생 가설",
                          "id": "immunopathology-hygiene-hypothesis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "과민 반응 유형별 상세 설명",
                      "id": "detailed-hypersensitivity-types",
                      "children": [
                        {
                          "text": "제1형 과민 반응 (아나필락시스형)",
                          "id": "type-i-anaphylactic",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-i-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "매개체 (히스타민, 류코트리엔, 프로스타글란딘)",
                              "id": "type-i-mediators",
                              "children": null
                            },
                            {
                              "text": "전신 아나필락시스 및 국소 아나필락시스",
                              "id": "systemic-local-anaphylaxis",
                              "children": null
                            },
                            {
                              "text": "예방 및 치료",
                              "id": "type-i-prevention-treatment",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제2형 과민 반응 (세포 독성형)",
                          "id": "type-ii-cytotoxic",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-ii-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "ABO 혈액형 시스템",
                              "id": "abo-blood-group",
                              "children": null
                            },
                            {
                              "text": "Rh 혈액형 시스템 및 용혈성 신생아 질환",
                              "id": "rh-blood-group-hdnb",
                              "children": null
                            },
                            {
                              "text": "약물 유발 세포 독성 반응",
                              "id": "drug-induced-cytotoxic",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제3형 과민 반응 (면역 복합체형)",
                          "id": "type-iii-immune-complex",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-iii-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "아르투스 반응",
                              "id": "arthus-reaction",
                              "children": null
                            },
                            {
                              "text": "혈청병",
                              "id": "serum-sickness",
                              "children": null
                            }
                          ]
                        },
                        {
                          "text": "제4형 과민 반응 (지연형 세포 매개성)",
                          "id": "type-iv-delayed-cell-mediated",
                          "children": [
                            {
                              "text": "발생 기전 및 특징",
                              "id": "type-iv-mechanism-features",
                              "children": null
                            },
                            {
                              "text": "알레르기성 접촉 피부염",
                              "id": "allergic-contact-dermatitis",
                              "children": null
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "제1형 과민 반응 시 혈액 모세혈관의 투과성을 증가시키는 주요 매개체는 무엇입니까?",
                    "options": [
                      "히스타민",
                      "류코트리엔",
                      "프로스타글란딘",
                      "사이토카인"
                    ],
                    "answerIndex": 0,
                    "explanation": "제1형 과민 반응은 비만세포의 탈과립을 통해 히스타민을 방출하며, 히스타민은 혈액 모세혈관의 투과성을 증가시키는 역할을 합니다."
                  },
                  {
                    "question": "이식 조직 거부 반응 및 접촉 피부염과 주로 관련된 과민 반응 유형은 무엇입니까?",
                    "options": [
                      "제1형 (아나필락시스형)",
                      "제2형 (세포 독성형)",
                      "제3형 (면역 복합체형)",
                      "제4형 (지연형 세포 매개성)"
                    ],
                    "answerIndex": 3,
                    "explanation": "제4형 과민 반응은 T세포에 의해 매개되는 지연형 반응으로, 이식 조직 거부 반응과 접촉 피부염이 대표적인 예시입니다."
                  },
                  {
                    "question": "아나필락시스 반응 예방을 위한 탈감작의 주요 기전은 무엇입니까?",
                    "options": [
                      "히스타민 방출 억제",
                      "IgE 항체 생성 촉진",
                      "비만세포 탈과립 유도",
                      "IgG 블로킹 항체 생성"
                    ],
                    "answerIndex": 3,
                    "explanation": "탈감작은 증가하는 용량의 항원 주사를 통해 IgG 블로킹 항체를 생성하게 하여, 이 항체가 알레르겐을 가로채고 중화시켜 IgE 매개 반응을 예방합니다."
                  }
                ]
              },
              {
                "title": "자가면역 질환의 이해: 유형 및 주요 사례",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1640 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "자가면역 질환 (AUTOIMMUNE DISEASES)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 체계가 자가 항원에 반응하여 장기에 손상을 입히는 질환입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자가면역은 자가 관용(self-tolerance)의 상실을 의미합니다. 이는 면역 체계가 자신과 비자신을 구별하는 능력을 잃어버릴 때 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "자가면역 반응은 세포독성(Cytotoxic), 면역 복합체(Immune complex), 또는 세포 매개성(Cell-mediated)의 형태로 나타날 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 자가면역 반응 (CYTOTOXIC AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 세포 표면 항원과 반응하여 세포를 손상시키거나 기능을 방해하는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "다발성 경화증 (Multiple sclerosis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "자가항체, T 세포, 그리고 대식세포가 신경의 미엘린 수초를 공격하여 신경 임펄스 전달을 손상시킵니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "증상은 피로와 쇠약부터 심한 마비에 이릅니다. 원인은 알려지지 않았지만, 유전적 취약성 및/또는 감염성 물질과 관련될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "그레이브스병 (Graves' disease)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "갑상선 내 비정상 항체가 과도한 양의 호르몬을 생성하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "중증 근무력증 (Myasthenia gravis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "항체가 아세틸콜린 수용체를 코팅하여 근육이 신경 신호를 받지 못하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 복합체 자가면역 반응 (IMMUNE COMPLEX AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "항체와 보체의 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전신성 홍반성 루푸스 (Systemic lupus erythematosus)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "신장 사구체에 면역 복합체가 형성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "류마티스 관절염 (Rheumatoid arthritis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "관절에 면역 복합체가 형성됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포 매개성 자가면역 반응 (CELL-MEDIATED AUTOIMMUNE REACTIONS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "조직을 공격하는 T 세포에 의해 매개되는 유형입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "인슐린 의존성 당뇨병 (Insulin-dependent diabetes mellitus, 1형 당뇨병)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "T 세포가 인슐린 분비 세포를 파괴합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "건선 및 건선성 관절염 (Psoriasis and psoriatic arthritis)",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "피부의 자가면역 질환입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "주요 자가면역 질환 및 원인 (SELECTED AUTOIMMUNE DISORDERS)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "다음은 몇 가지 주요 자가면역 질환과 가능한 원인입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "만성 피로 증후군: 신경 세포의 아세틸콜린 수용체에 항체가 부착되어 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "류마티스 관절염: 연쇄상구균 항체에 대한 교차 반응.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "전신성 홍반성 루푸스: DNA에 대한 항체를 포함하는 면역 복합체.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다발성 경화증: T 세포와 대식세포가 미엘린 수초를 공격.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1형 당뇨병: T 세포가 인슐린 분비 세포를 파괴.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "길랑-바레 증후군: T 세포가 신경 세포의 미엘린 수초 파괴를 유발하는 사이토카인을 생성.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "건선: T 세포가 각질 형성 세포(피부 세포) 성장을 유도할 수 있는 사이토카인을 생성.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그레이브스병: 갑상선 특정 수용체에 부착된 항체가 갑상선을 비대하게 하고 과도한 호르몬을 생성하게 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "중증 근무력증: 아세틸콜린 수용체에 대한 항체.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "크론병: 항균 항체가 장 점막과 반응.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "염증성 장 질환: 항균 항체가 장 점막과 반응.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "자가면역 질환은 면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 상태입니다. 이는 자가 관용의 상실로 인해 발생하며, 세포독성, 면역 복합체, 세포 매개성 반응의 세 가지 주요 유형으로 분류될 수 있습니다. 각 유형은 특정 질병과 관련이 있으며, 신경, 갑상선, 관절, 췌장 등 다양한 장기에 영향을 미칩니다. 주요 자가면역 질환으로는 다발성 경화증, 그레이브스병, 중증 근무력증, 전신성 홍반성 루푸스, 류마티스 관절염, 1형 당뇨병, 건선 등이 있으며, 각 질환의 원인과 면역학적 메커니즘이 설명됩니다.",
                  "keyConcepts": [
                    {
                      "term": "자가면역",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 자신의 신체 조직을 외부 침입자로 오인하여 공격하는 현상입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "자가 관용",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 자신의 항원에 반응하지 않고 구별하는 능력입니다. 자가면역 질환은 이 자가 관용의 상실로 발생합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "세포독성 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "항체가 세포 표면 항원과 반응하여 세포를 파괴하거나 기능을 손상시키는 유형의 자가면역 반응입니다. (예: 다발성 경화증, 그레이브스병, 중증 근무력증)",
                        "hard": null
                      }
                    },
                    {
                      "term": "면역 복합체 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "항체와 항원이 결합하여 형성된 면역 복합체가 조직에 침착되어 염증과 손상을 유발하는 유형의 자가면역 반응입니다. (예: 전신성 홍반성 루푸스, 류마티스 관절염)",
                        "hard": null
                      }
                    },
                    {
                      "term": "세포 매개성 자가면역 반응",
                      "definition": {
                        "easy": null,
                        "medium": "T 세포가 직접 조직을 공격하여 손상을 일으키는 유형의 자가면역 반응입니다. (예: 1형 당뇨병, 건선)",
                        "hard": null
                      }
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "자가 항원",
                      "definition": "자신의 신체에 존재하는 항원으로, 면역 체계가 실수로 공격하는 대상이 됩니다."
                    },
                    {
                      "term": "미엘린 수초",
                      "definition": "신경 세포를 둘러싸고 있는 절연성 막으로, 손상 시 신경 신호 전달에 문제가 발생합니다."
                    },
                    {
                      "term": "아세틸콜린 수용체",
                      "definition": "신경 전달 물질인 아세틸콜린이 결합하는 근육 세포 표면의 단백질로, 중증 근무력증에서 항체에 의해 기능이 저해됩니다."
                    },
                    {
                      "term": "면역 복합체",
                      "definition": "항체와 항원이 결합하여 형성된 복합체로, 특정 조직에 침착되어 염증을 유발할 수 있습니다."
                    },
                    {
                      "term": "T 세포",
                      "definition": "세포 매개 면역 반응을 담당하는 림프구의 일종으로, 일부 자가면역 질환에서 직접 조직을 공격합니다."
                    },
                    {
                      "term": "사구체",
                      "definition": "신장의 혈액 여과 단위로, 전신성 홍반성 루푸스에서 면역 복합체가 형성되는 주요 부위입니다."
                    },
                    {
                      "term": "사이토카인",
                      "definition": "면역 세포 간의 신호 전달에 관여하는 단백질로, 일부 자가면역 질환에서 조직 손상을 유발할 수 있습니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "자가면역 질환 개요",
                      "id": "autoimmune-diseases-overview",
                      "children": [
                        {
                          "text": "자가면역의 정의 및 특징",
                          "id": "definition-and-characteristics-of-autoimmunity",
                          "children": null
                        },
                        {
                          "text": "주요 반응 유형",
                          "id": "main-types-of-reactions",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포독성 자가면역 반응",
                      "id": "cytotoxic-autoimmune-reactions",
                      "children": [
                        {
                          "text": "다발성 경화증",
                          "id": "multiple-sclerosis",
                          "children": null
                        },
                        {
                          "text": "그레이브스병",
                          "id": "graves-disease",
                          "children": null
                        },
                        {
                          "text": "중증 근무력증",
                          "id": "myasthenia-gravis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 복합체 자가면역 반응",
                      "id": "immune-complex-autoimmune-reactions",
                      "children": [
                        {
                          "text": "전신성 홍반성 루푸스",
                          "id": "systemic-lupus-erythematosus",
                          "children": null
                        },
                        {
                          "text": "류마티스 관절염",
                          "id": "rheumatoid-arthritis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포 매개성 자가면역 반응",
                      "id": "cell-mediated-autoimmune-reactions",
                      "children": [
                        {
                          "text": "인슐린 의존성 당뇨병 (1형 당뇨병)",
                          "id": "insulin-dependent-diabetes-mellitus-type-1",
                          "children": null
                        },
                        {
                          "text": "건선 및 건선성 관절염",
                          "id": "psoriasis-and-psoriatic-arthritis",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "주요 자가면역 질환 및 원인",
                      "id": "selected-autoimmune-disorders-and-causes",
                      "children": [
                        {
                          "text": "만성 피로 증후군",
                          "id": "chronic-fatigue-syndrome",
                          "children": null
                        },
                        {
                          "text": "류마티스 관절염",
                          "id": "rheumatoid-arthritis-cause",
                          "children": null
                        },
                        {
                          "text": "전신성 홍반성 루푸스",
                          "id": "systemic-lupus-erythematosus-cause",
                          "children": null
                        },
                        {
                          "text": "다발성 경화증",
                          "id": "multiple-sclerosis-cause",
                          "children": null
                        },
                        {
                          "text": "1형 당뇨병",
                          "id": "type-1-diabetes-cause",
                          "children": null
                        },
                        {
                          "text": "길랑-바레 증후군",
                          "id": "guillain-barre-syndrome",
                          "children": null
                        },
                        {
                          "text": "건선",
                          "id": "psoriasis-cause",
                          "children": null
                        },
                        {
                          "text": "그레이브스병",
                          "id": "graves-disease-cause",
                          "children": null
                        },
                        {
                          "text": "중증 근무력증",
                          "id": "myasthenia-gravis-cause",
                          "children": null
                        },
                        {
                          "text": "크론병",
                          "id": "crohns-disease",
                          "children": null
                        },
                        {
                          "text": "염증성 장 질환",
                          "id": "inflammatory-bowel-disease",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "자가면역 질환에서 면역 체계가 공격하는 대상은 무엇입니까?",
                    "options": [
                      "외부 병원체",
                      "알레르기 유발 물질",
                      "자가 항원",
                      "독성 물질"
                    ],
                    "answerIndex": 2,
                    "explanation": "자가면역 질환은 면역 체계가 자신의 신체 조직, 즉 자가 항원을 외부 침입자로 오인하여 공격하는 상태입니다."
                  },
                  {
                    "question": "다음 중 세포독성 자가면역 반응에 해당하는 질환이 아닌 것은 무엇입니까?",
                    "options": [
                      "다발성 경화증",
                      "그레이브스병",
                      "중증 근무력증",
                      "류마티스 관절염"
                    ],
                    "answerIndex": 3,
                    "explanation": "류마티스 관절염은 면역 복합체가 관절에 형성되어 발생하는 면역 복합체 자가면역 반응에 해당합니다. 다발성 경화증, 그레이브스병, 중증 근무력증은 세포독성 자가면역 반응의 예시입니다."
                  },
                  {
                    "question": "1형 당뇨병(인슐린 의존성 당뇨병)의 주요 원인으로 설명된 면역 반응은 무엇입니까?",
                    "options": [
                      "항체에 의한 아세틸콜린 수용체 코팅",
                      "면역 복합체의 신장 사구체 침착",
                      "T 세포에 의한 인슐린 분비 세포 파괴",
                      "갑상선 항체의 과도한 호르몬 생성 유발"
                    ],
                    "answerIndex": 2,
                    "explanation": "1형 당뇨병은 T 세포가 인슐린을 분비하는 췌장의 세포를 파괴하여 발생하는 세포 매개성 자가면역 반응입니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 이식 면역학 및 면역 억제",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1848 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "인간 백혈구 항원(HLA) 복합체 관련 반응",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조직적합성 항원(Histocompatibility antigens): 세포 표면에 존재하는 자가 항원입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "주요 조직적합성 복합체(MHC): 조직적합성 항원을 암호화하는 유전자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "인간 백혈구 항원(HLA) 복합체: 인간의 MHC 유전자입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "특정 HLA는 특정 질병에 대한 감수성 증가와 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HLA 타이핑 및 이식 수술",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "HLA 타이핑은 HLA를 식별하고 비교하는 과정입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이식 수술에서 공여자와 수혜자는 조직 타이핑을 통해 일치해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "표준화된 항혈청 또는 HLA에 특이적인 단일클론 항체를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HLA 타이핑 과정: 검사 중인 림프구에 항-HLA 항체가 부착됩니다. 보체와 트립판 블루 염료가 추가되면, 보체에 의해 손상된 세포가 염료를 흡수합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 특권 부위 및 면역 특권 조직",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이식편은 T 세포, 대식세포, 그리고 보체 고정 항체에 의해 공격받을 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 특권 부위 및 면역 특권 조직으로의 이식은 면역 반응을 일으키지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "예시로는 각막 이식, 심장 판막 이식이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "줄기세포",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포는 여러 다른 세포 유형을 생성할 수 있는 마스터 세포입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "배아 줄기세포(ESCs)",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "배반포에서 채취되며, 조직과 장기를 재생하는 데 사용됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "다능성(Pluripotent)으로, 모든 종류의 세포를 생성할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "성체 줄기세포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "분화된 성체 조직에 있는 줄기세포입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "유전자 도입을 통해 유도만능줄기세포(induced pluripotent stem cells)가 될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "줄기세포 배양 과정: (1일) 일반적으로 시험관 아기 시술에서 폐기된 수정란인 배아가 사용됩니다. (1-5일) 배아는 반복적으로 분열하여 속이 빈 세포 덩어리인 배반포 단계를 형성합니다. 배아줄기세포는 배반포의 속세포덩어리에서 채취되어 배양 배지의 피더(feeder) 세포 위에서 성장합니다. 줄기세포주와 줄기세포 그룹은 배양 배지에서 콜로니를 형성합니다. 다양한 조건과 배양 배지에 추가된 성장 인자는 줄기세포가 신체의 다양한 조직(예: 혈액 및 림프 세포, 췌장 섬 세포, 신경 세포)을 위한 줄기세포주가 되도록 유도합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "골수 이식",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "조혈모세포 이식으로도 알려져 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "수혜자가 건강한 혈액 세포를 생산할 수 있도록 하는 것이 목표입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "면역능력 있는 세포를 포함하는 이식된 골수로 인해 이식편대숙주병(Graft-versus-host, GVH)이 발생할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이식편(Grafts)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "자가이식(Autograft): 자신의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동계이식(Isograft): 일란성 쌍둥이의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동종이식(Allografts): 다른 사람의 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이종이식(Xenotransplantation product): 비인간 조직을 사용하는 것입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비인간 항원에 대한 반응인 초급성 거부 반응을 극복해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "이식 거부 반응 방지를 위한 면역 억제",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "이식된 조직에 대한 세포 매개 면역 반응을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사이클로스포린(Cyclosporine)과 타크로리무스(tacrolimus)는 IL-2를 억제하여 세포독성 T 세포를 방해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "시롤리무스(Sirolimus)는 세포성 및 체액성 면역을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "마이코페놀레이트(Mycophenolate)는 T 세포와 B 세포의 증식을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바실리시맙(Basiliximab)은 IL-2를 차단하는 키메라 단일클론 항체입니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "제공된 텍스트는 인간 백혈구 항원(HLA) 복합체의 역할과 이식 면역학에서 이의 중요성을 설명합니다. HLA 타이핑을 통한 조직 일치의 필요성, 면역 반응을 일으키지 않는 면역 특권 부위, 그리고 배아 및 성체 줄기세포의 종류와 활용에 대해 다룹니다. 또한, 자가이식, 동계이식, 동종이식, 이종이식과 같은 다양한 이식편의 유형과 이식편대숙주병(GVH)과 같은 이식 관련 합병증을 설명합니다. 마지막으로, 이식 거부 반응을 방지하기 위한 사이클로스포린, 타크로리무스, 시롤리무스, 마이코페놀레이트, 바실리시맙 등 주요 면역 억제제와 그 작용 기전을 소개합니다.",
                  "keyConcepts": [
                    {
                      "term": "인간 백혈구 항원(HLA) 복합체",
                      "definition": "인간의 주요 조직적합성 복합체(MHC) 유전자로, 이식 수술에서 조직 일치에 결정적인 역할을 하며 특정 질병 감수성과 관련이 있습니다."
                    },
                    {
                      "term": "줄기세포",
                      "definition": "다양한 세포 유형으로 분화할 수 있는 마스터 세포로, 배아 줄기세포와 성체 줄기세포로 나뉩니다. 조직 재생 및 치료에 잠재적으로 활용됩니다."
                    },
                    {
                      "term": "이식편의 종류",
                      "definition": "조직의 출처에 따라 자가이식(자신의 조직), 동계이식(일란성 쌍둥이), 동종이식(다른 사람), 이종이식(비인간 조직)으로 분류됩니다."
                    },
                    {
                      "term": "이식 거부 반응 및 GVH 질환",
                      "definition": "이식된 조직에 대한 수혜자의 면역 반응(이식 거부 반응) 또는 이식된 면역 세포가 수혜자의 조직을 공격하는 현상(이식편대숙주병)입니다."
                    },
                    {
                      "term": "면역 억제",
                      "definition": "이식 거부 반응을 방지하기 위해 특정 약물을 사용하여 수혜자의 면역 반응을 억제하는 치료법입니다."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "조직적합성 항원",
                      "definition": "세포 표면에 존재하는 자가 항원입니다."
                    },
                    {
                      "term": "주요 조직적합성 복합체(MHC)",
                      "definition": "조직적합성 항원을 암호화하는 유전자입니다."
                    },
                    {
                      "term": "인간 백혈구 항원(HLA) 복합체",
                      "definition": "인간의 MHC 유전자입니다."
                    },
                    {
                      "term": "면역 특권 부위",
                      "definition": "이식 시 면역 반응을 일으키지 않는 신체 부위 또는 조직입니다."
                    },
                    {
                      "term": "이식편대숙주병(GVH)",
                      "definition": "이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격하는 질환입니다."
                    },
                    {
                      "term": "자가이식",
                      "definition": "자신의 조직을 사용하는 이식 방법입니다."
                    },
                    {
                      "term": "면역 억제제",
                      "definition": "이식 거부 반응을 방지하기 위해 면역 반응을 억제하는 약물입니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "인간 백혈구 항원(HLA) 복합체 관련 반응",
                      "id": "인간-백혈구-항원-hla-복합체-관련-반응",
                      "children": [
                        {
                          "text": "조직적합성 항원",
                          "id": "조직적합성-항원",
                          "children": null
                        },
                        {
                          "text": "주요 조직적합성 복합체(MHC)",
                          "id": "주요-조직적합성-복합체-mhc",
                          "children": null
                        },
                        {
                          "text": "인간 백혈구 항원(HLA) 복합체",
                          "id": "인간-백혈구-항원-hla-복합체",
                          "children": null
                        },
                        {
                          "text": "특정 질병에 대한 감수성",
                          "id": "특정-질병에-대한-감수성",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "HLA 타이핑 및 이식 수술",
                      "id": "hla-타이핑-및-이식-수술",
                      "children": [
                        {
                          "text": "HLA 타이핑의 역할",
                          "id": "hla-타이핑의-역할",
                          "children": null
                        },
                        {
                          "text": "조직 타이핑의 중요성",
                          "id": "조직-타이핑의-중요성",
                          "children": null
                        },
                        {
                          "text": "HLA 타이핑 과정",
                          "id": "hla-타이핑-과정",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 특권 부위 및 면역 특권 조직",
                      "id": "면역-특권-부위-및-면역-특권-조직",
                      "children": [
                        {
                          "text": "이식 거부 반응의 메커니즘",
                          "id": "이식-거부-반응의-메커니즘",
                          "children": null
                        },
                        {
                          "text": "면역 특권 부위의 특징",
                          "id": "면역-특권-부위의-특징",
                          "children": null
                        },
                        {
                          "text": "예시: 각막 이식, 심장 판막 이식",
                          "id": "예시-각막-이식-심장-판막-이식",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "줄기세포",
                      "id": "줄기세포",
                      "children": [
                        {
                          "text": "줄기세포의 정의",
                          "id": "줄기세포의-정의",
                          "children": null
                        },
                        {
                          "text": "배아 줄기세포(ESCs)",
                          "id": "배아-줄기세포-escs",
                          "children": null
                        },
                        {
                          "text": "성체 줄기세포",
                          "id": "성체-줄기세포",
                          "children": null
                        },
                        {
                          "text": "줄기세포 배양 및 분화",
                          "id": "줄기세포-배양-및-분화",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "골수 이식",
                      "id": "골수-이식",
                      "children": [
                        {
                          "text": "조혈모세포 이식",
                          "id": "조혈모세포-이식",
                          "children": null
                        },
                        {
                          "text": "골수 이식의 목표",
                          "id": "골수-이식의-목표",
                          "children": null
                        },
                        {
                          "text": "이식편대숙주병(GVH)",
                          "id": "이식편대숙주병-gvh",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "이식편(Grafts)",
                      "id": "이식편-grafts",
                      "children": [
                        {
                          "text": "자가이식(Autograft)",
                          "id": "자가이식-autograft",
                          "children": null
                        },
                        {
                          "text": "동계이식(Isograft)",
                          "id": "동계이식-isograft",
                          "children": null
                        },
                        {
                          "text": "동종이식(Allografts)",
                          "id": "동종이식-allografts",
                          "children": null
                        },
                        {
                          "text": "이종이식(Xenotransplantation)",
                          "id": "이종이식-xenotransplantation",
                          "children": null
                        },
                        {
                          "text": "초급성 거부 반응 극복",
                          "id": "초급성-거부-반응-극복",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "이식 거부 반응 방지를 위한 면역 억제",
                      "id": "이식-거부-반응-방지를-위한-면역-억제",
                      "children": [
                        {
                          "text": "면역 억제의 목적",
                          "id": "면역-억제의-목적",
                          "children": null
                        },
                        {
                          "text": "주요 면역 억제제 및 작용 기전",
                          "id": "주요-면역-억제제-및-작용-기전",
                          "children": null
                        }
                      ]
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "이식 수술에서 공여자와 수혜자의 조직 일치가 중요한 주된 이유는 무엇입니까?",
                    "options": [
                      "감염 위험을 줄이기 위해",
                      "수술 시간을 단축하기 위해",
                      "이식 거부 반응을 최소화하기 위해",
                      "환자의 회복 속도를 높이기 위해"
                    ],
                    "answerIndex": 2,
                    "explanation": "HLA 타이핑을 통한 조직 일치는 이식된 조직에 대한 수혜자의 면역 반응, 즉 거부 반응을 줄이는 데 필수적입니다."
                  },
                  {
                    "question": "다음 중 '이식편대숙주병(Graft-versus-host disease, GVH)'이 발생할 수 있는 이식 유형은 무엇입니까?",
                    "options": [
                      "자가이식 (Autograft)",
                      "동계이식 (Isograft)",
                      "골수 이식 (Bone marrow transplant)",
                      "각막 이식 (Cornea transplant)"
                    ],
                    "answerIndex": 2,
                    "explanation": "이식편대숙주병은 이식된 골수(조혈모세포)에 포함된 면역능력 있는 세포가 수혜자의 조직을 공격할 때 발생합니다."
                  },
                  {
                    "question": "다음 중 면역 억제제 시롤리무스(Sirolimus)의 주요 작용 기전은 무엇입니까?",
                    "options": [
                      "IL-2 생성을 억제하여 세포독성 T 세포를 방해한다.",
                      "T 세포와 B 세포의 증식을 억제한다.",
                      "세포성 및 체액성 면역을 모두 억제한다.",
                      "IL-2를 차단하는 키메라 단일클론 항체이다."
                    ],
                    "answerIndex": 2,
                    "explanation": "텍스트에 따르면 시롤리무스는 세포성 및 체액성 면역을 모두 억제한다고 명시되어 있습니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 암 및 면역 결핍증",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 1530 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "면역 시스템과 암",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "암세포는 면역 감시에 의해 제거됩니다. 암세포는 비자기로 표시되는 종양 관련 항원을 가지고 있습니다. CTL(활성화된 TC 세포)과 대식세포는 암세포를 용해합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그러나 면역 시스템의 암 제거에는 몇 가지 제한 사항이 있습니다. 면역 시스템이 표적으로 삼을 항원성 에피토프가 없거나, 종양 세포가 너무 빠르게 증식하거나, 종양이 혈관화되어 면역 시스템에 보이지 않게 될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "암에 대한 면역 요법",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "암 치료를 위한 다양한 면역 요법이 개발되었습니다. 박테리아 내독소(Coley's toxins)는 암의 혈액 공급을 방해하는 TNF를 자극하여 사용될 수 있습니다. HPV(자궁경부암, 항문암, 인후암) 및 B형 간염(간암)과 같은 바이러스 관련 암에 대한 예방 백신이 사용됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "또한 단클론항체(Monoclonal antibodies)가 사용되는데, 예를 들어 유방암 치료제 허셉틴이 있습니다. 면역독소(Immunotoxin)는 단클론항체와 독성 물질을 결합하여 건강한 세포에 손상을 주지 않고 종양을 표적하여 죽입니다. 면역 관문 억제제와 CAR T 세포와 같은 세포 치료법도 암 치료에 활용되고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 결핍증",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "면역 결핍증은 충분한 면역 반응이 부재하는 상태를 말합니다. 이는 선천성 면역 결핍증과 후천성 면역 결핍증으로 나눌 수 있습니다. 선천성 면역 결핍증은 결함이 있거나 없는 유전자 때문에 발생하며, 후천성 면역 결핍증은 약물, 암, 감염 등으로 인해 개인의 삶 동안 발병합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "면역 결핍 질환",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "선천성 면역 결핍 질환은 유전적 유전자 결함에 의해 발생합니다. T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있으며, 항원 수용체 유전자 재배열의 결함 또한 SCID를 유발할 수 있습니다. T세포 항원 수용체로부터의 신호 전달 결함이나 T세포 발달을 차단하는 흉선 기능의 유전적 결함 역시 중증 면역 결핍증을 초래할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "림프구 발달의 결함이 중증 복합 면역 결핍증을 초래할 수 있음",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.12 나병균에 감염된 누드(털 없는) 쥐의 뒷발. M. leprae 박테리아 위치.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "본문은 면역 시스템이 암과 싸우는 방식, 그 한계, 그리고 다양한 암 면역 요법에 대해 설명합니다. 또한 면역 결핍증을 선천성 및 후천성으로 구분하고, T세포 발달 또는 항원 수용체 결함으로 인한 SCID와 같은 선천성 면역 결핍 질환의 구체적인 원인을 다룹니다.",
                  "keyConcepts": [
                    {
                      "term": "면역 감시",
                      "definition": "면역 시스템이 암세포를 인식하고 제거하는 과정."
                    },
                    {
                      "term": "면역 요법",
                      "definition": "면역 시스템을 활용하여 암을 치료하는 방법으로, 백신, 단클론항체, 면역관문억제제, 세포 치료 등이 포함됩니다."
                    },
                    {
                      "term": "선천성 면역 결핍증",
                      "definition": "유전적 결함으로 인해 발생하는 면역 반응의 부재."
                    },
                    {
                      "term": "후천성 면역 결핍증",
                      "definition": "약물, 암, 감염 등으로 인해 개인의 삶 동안 발병하는 면역 결핍."
                    },
                    {
                      "term": "중증 복합 면역 결핍증 (SCID)",
                      "definition": "T세포 발달 결함이나 항원 수용체 유전자 재배열 결함 등으로 인해 발생하는 심각한 면역 결핍 질환."
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "종양 관련 항원",
                      "definition": "암세포 표면에 존재하며 면역 시스템이 비자기로 인식하는 항원."
                    },
                    {
                      "term": "세포독성 T 림프구 (CTLs)",
                      "definition": "활성화된 T 세포로, 암세포나 감염된 세포를 직접 용해(파괴)하는 역할을 합니다."
                    },
                    {
                      "term": "코리 독소",
                      "definition": "박테리아 내독소로, TNF 분비를 자극하여 암의 혈액 공급을 방해하는 데 사용되었던 물질."
                    },
                    {
                      "term": "단클론항체 (Mab)",
                      "definition": "특정 항원에만 결합하도록 만들어진 항체로, 암 치료에 사용될 수 있습니다 (예: 허셉틴)."
                    },
                    {
                      "term": "면역독소",
                      "definition": "단클론항체와 독성 물질을 결합하여 암세포만을 표적하여 죽이는 치료제."
                    },
                    {
                      "term": "면역 관문 억제제",
                      "definition": "면역 반응을 억제하는 경로를 차단하여 면역 시스템이 암세포를 더 효과적으로 공격하도록 돕는 약물."
                    },
                    {
                      "term": "CAR T 세포",
                      "definition": "환자의 T 세포를 유전자 조작하여 암세포를 인식하고 공격하도록 만든 세포 치료제."
                    }
                  ],
                  "outline": [
                    {
                      "text": "면역 시스템과 암",
                      "id": "면역-시스템과-암",
                      "children": [
                        {
                          "text": "면역 감시를 통한 암세포 제거",
                          "id": "면역-감시를-통한-암세포-제거",
                          "children": null
                        },
                        {
                          "text": "면역 시스템의 암 제거 제한 사항",
                          "id": "면역-시스템의-암-제거-제한-사항",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "세포독성 T 림프구(CTL)와 암세포의 상호작용",
                      "id": "세포독성-t-림프구ctl와-암세포의-상호작용",
                      "children": null
                    },
                    {
                      "text": "암에 대한 면역 요법",
                      "id": "암에-대한-면역-요법",
                      "children": [
                        {
                          "text": "박테리아 내독소",
                          "id": "박테리아-내독소",
                          "children": null
                        },
                        {
                          "text": "백신",
                          "id": "백신",
                          "children": null
                        },
                        {
                          "text": "단클론항체 및 면역독소",
                          "id": "단클론항체-및-면역독소",
                          "children": null
                        },
                        {
                          "text": "면역 관문 억제제",
                          "id": "면역-관문-억제제",
                          "children": null
                        },
                        {
                          "text": "세포 치료",
                          "id": "세포-치료",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 결핍증",
                      "id": "면역-결핍증",
                      "children": [
                        {
                          "text": "선천성 면역 결핍증",
                          "id": "선천성-면역-결핍증",
                          "children": null
                        },
                        {
                          "text": "후천성 면역 결핍증",
                          "id": "후천성-면역-결핍증",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "면역 결핍 질환",
                      "id": "면역-결핍-질환",
                      "children": [
                        {
                          "text": "선천성 면역 결핍 질환의 원인",
                          "id": "선천성-면역-결핍-질환의-원인",
                          "children": null
                        },
                        {
                          "text": "T세포 발달 및 항원 수용체 관련 결함",
                          "id": "t세포-발달-및-항원-수용체-관련-결함",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "림프구 발달 결함과 중증 복합 면역 결핍증 (SCID)",
                      "id": "림프구-발달-결함과-중증-복합-면역-결핍증-scid",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "면역 시스템이 암세포를 제거하는 데 있어 주요 제한 사항이 아닌 것은 무엇입니까?",
                    "options": [
                      "면역 시스템이 표적으로 삼을 항원성 에피토프가 없음",
                      "종양 세포가 너무 빠르게 증식함",
                      "종양이 혈관화되어 면역 시스템에 보이지 않게 됨",
                      "대식세포가 암세포를 용해하지 못함"
                    ],
                    "answerIndex": 3,
                    "explanation": "본문에서는 CTL(활성화된 TC 세포)과 대식세포가 암세포를 용해한다고 명시되어 있으므로, 대식세포가 암세포를 용해하지 못하는 것은 면역 시스템의 제한 사항이 아닙니다."
                  },
                  {
                    "question": "다음 중 암에 대한 면역 요법으로 언급되지 않은 것은 무엇입니까?",
                    "options": [
                      "박테리아 내독소 (Coley's toxins)",
                      "예방 백신 (HPV, B형 간염)",
                      "항생제",
                      "CAR T 세포 치료"
                    ],
                    "answerIndex": 2,
                    "explanation": "본문에서 박테리아 내독소, 예방 백신, CAR T 세포 치료는 암에 대한 면역 요법으로 언급되었지만, 항생제는 언급되지 않았습니다. 항생제는 주로 세균 감염 치료에 사용됩니다."
                  },
                  {
                    "question": "중증 복합 면역 결핍증(SCID)의 주요 원인이 될 수 있는 유전적 결함은 무엇입니까?",
                    "options": [
                      "B세포의 과도한 증식",
                      "T세포 발달의 결함",
                      "항체 생산 능력의 증가",
                      "대식세포 기능의 활성화"
                    ],
                    "answerIndex": 1,
                    "explanation": "본문에서는 'T세포 발달의 결함은 중증 복합 면역 결핍증(SCID)을 초래할 수 있습니다'라고 명확히 언급되어 있습니다."
                  }
                ]
              },
              {
                "title": "면역 시스템 관련 질환: 후천성 면역 결핍 증후군 (AIDS)",
                "metadata": "Source: 9a6a3b99-85ea-4598-89bb-e9cbc75b3de4_da533276-2c1b-4b3d-8423-5eb4425a60a8_19. Disorders associated with the immune system.pdf, Text length: 5576 chars",
                "documentContent": [
                  {
                    "type": "heading",
                    "content": "후천성 면역 결핍 증후군 (AIDS)",
                    "level": 1
                  },
                  {
                    "type": "paragraph",
                    "content": "1981년, 미국에서 젊은 동성애 남성들 사이에서 폐포자충 폐렴, 카포시 육종, 그리고 면역 기능 상실 사례들이 집단으로 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1983년, 면역 기능 상실을 유발하는 바이러스(HIV)가 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 T 보조 세포를 선택적으로 감염시킵니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "AIDS의 기원",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 서아프리카와 중앙아프리카의 침팬지(약 1908년, 부시미트로부터)로부터 인간 개체군으로 넘어왔습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "도시화와 성적 문란의 증가로 아프리카 전역으로 퍼졌습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "가장 오래된 HIV 샘플은 1920년 콩고민주공화국의 킨샤사에서 발견되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1976년에 사망한 노르웨이 선원은 서구 세계에서 알려진 첫 번째 사례입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "1969년 미주리주의 한 환자로부터 채취한 샘플에서 HIV 감염이 확인되었습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 구조",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "렌티바이러스(Lentivirus) 속에 속합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "레트로바이러스(Retrovirus)입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "두 개의 동일한 양성 가닥 RNA 유전체 분자, 역전사 효소, 인지질 외피를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "gp120 당단백질 스파이크를 가지고 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 구조 및 CD4+ T 세포 감염: gp120 당단백질 스파이크는 CD4+ 세포의 수용체에 부착합니다. gp41 막관통 당단백질은 CD4+ 세포의 융합 수용체에 부착하여 융합을 촉진합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 감염성과 병원성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "수지상 세포에 의해 퍼지고 림프 기관으로 운반되며, 활성화된 T 세포와 접촉합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "gp120은 CD4+ 수용체 및 CCR5 또는 CXCR4 공동수용체와 결합합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "CD4 분자는 T 보조 세포, 대식세포, 수지상 세포에 존재합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 세포와 융합하여 세포 안으로 들어갑니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "부착: gp120 스파이크는 세포의 수용체 및 CCR5 또는 CXCR4 공동수용체에 부착합니다. 융합: gp41은 HIV와 세포의 융합에 참여합니다. 진입: 세포와의 융합 후, 진입 구멍이 생성됩니다. 진입 후, 바이러스 외피는 뒤에 남고 HIV는 탈피하여 새로운 바이러스 합성을 지시할 RNA 핵을 방출합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포 내에서 바이러스 RNA는 역전사 효소를 사용하여 DNA로 전사됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "DNA는 숙주 염색체 DNA에 통합됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "활동성 감염: 새로운 바이러스가 숙주 세포에서 출아합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "잠복 감염: DNA는 프로바이러스 형태로 염색체에 숨겨져 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일부는 HIV의 저장소 역할을 하는 기억 T 세포가 됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 빠른 항원성 변화와 높은 돌연변이율을 겪습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.14 CD4+ T 세포의 잠복 및 활동성 HIV 감염. 잠복 감염: 바이러스 DNA는 세포 DNA에 프로바이러스로 통합되며, 나중에 활성화되어 감염성 바이러스를 생성할 수 있습니다. 활동성 감염: 프로바이러스가 활성화되어 새로운 바이러스의 합성을 제어할 수 있게 합니다. 최종 조립은 세포막에서 이루어지며, 바이러스가 세포에서 출아할 때 바이러스 외피 단백질을 가져갑니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.15 대식세포 및 수지상 세포의 잠복 및 활동성 HIV 감염. 잠복 감염된 대식세포: HIV는 프로바이러스 또는 액포 내 완전한 비리온 형태로 지속될 수 있습니다. 활성화된 대식세포: 프로바이러스로부터 새로운 바이러스가 생성됩니다. 완성된 비리온은 방출되거나 액포 내 대식세포에 지속될 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV의 아형",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "침팬지와 고릴라를 감염시키는 바이러스와 관련이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사례의 99%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "그룹 M (대다수)이 90%를 차지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-2:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "서아프리카 외에서는 자주 발견되지 않습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1보다 병원성이 낮습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV-1보다 바이러스 부하와 사망률이 낮고 무증상 기간이 더 깁니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 감염의 단계",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "1단계: 무증상 또는 림프절병증.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "2단계: CD4+ T 세포가 꾸준히 감소하며, 감염된 소수의 세포만이 바이러스를 방출합니다. 심각한 질병 증상은 거의 없습니다 (지속적인 감염, 발열, 구강 백반증).",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "3단계: AIDS가 발병합니다. CD4+ 수치가 200 cells/μl 미만이며, 지표 질환이 나타납니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 감염의 진행 및 병원성",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "초기에는 강력하고 효과적인 면역 반응이 나타납니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구(CTLs)가 바이러스 수를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "일단 HIV가 잠복 감염된 CD4+ T 세포의 저장소를 형성하면 감염을 제거하는 것은 불가능합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "백신 개발에 어려움이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 노출에 대한 반응의 변이",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 감염 생존에 대한 연령의 영향:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "고령자와 어린이는 면역 체계가 완전히 기능하지 않아 감염에 더 취약합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "노출되었지만 감염되지 않은 인구:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "CCR5 돌연변이를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "장기 생존자:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "낮은 바이러스 부하를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "효과적인 CTLs를 가집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "기회 감염",
                    "level": 2
                  },
                  {
                    "type": "heading",
                    "content": "진단 방법",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "혈청 전환은 감염과 항체 출현 사이의 기간입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "최대 3개월이 소요됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 항체는 ELISA로 검출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스는 Western blotting 또는 APTIMA (RNA 검사)로 검출됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "혈장 바이러스 부하 (PVL)는 PCR 또는 핵산 혼성화로 결정됩니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 전파",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 세포 밖에서 6시간 생존합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV는 세포 내에서 1.5일 이상 생존할 수 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "전파 경로: 친밀한 성 접촉, 모유, 태반 감염, 오염된 주사바늘, 장기 이식, 수혈.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "항문 성교는 가장 위험한 형태의 성 접촉입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전 세계 AIDS 현황",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "전 세계적으로 3천 5백만 명이 감염되었습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "사하라 이남 아프리카에 70%가 집중되어 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이성애자 간 전파가 HIV 전파의 가장 흔한 방식입니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "동유럽과 중앙 및 동남아시아 사례의 ⅓은 주사 약물 사용으로 인한 것입니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "전 세계 지역별 HIV 감염 및 AIDS 분포",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "70",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "AIDS 예방 및 치료",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "생물의학적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "콘돔 사용, 보건 서비스/HIV 검사, 주사바늘 프로그램.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "행동적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "성 교육, 안전한 영아 수유 프로그램, 상담.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "구조적 개입:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 취약성을 줄이기 위해 사회, 경제, 정치, 환경적 요인에 변화를 줍니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이제 선진국에서는 치료 가능한 만성 질환으로 간주됩니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "고활성 항레트로바이러스 치료 (HAART)를 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "내성 균주의 생존을 최소화하기 위해 약물 조합을 사용합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "73",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 관리",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "그림 19.18 HIV 생명 주기를 억제하는 약물: 융합/진입 억제제 (엔푸비르타이드, 마라비록), 역전사 효소 억제제 (테노포비르, 엠트리시타빈), 통합효소 억제제 (랄테그라비르), 프로테아제 억제제 (아타자나비르, 인디나비르, 사퀴나비르) 등이 있습니다. 이 약물들은 HIV의 gp41, gp120, CCR5, CD4 수용체 및 역전사 효소 등에 작용하여 바이러스 복제를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 치료 약물의 종류",
                    "level": 3
                  },
                  {
                    "type": "paragraph",
                    "content": "융합/세포 진입 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스 외피의 gp41 영역을 표적으로 하여 바이러스가 세포와 융합하는 것을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "엔푸비르타이드(Enfuvirtide)와 마라비록(Maraviroc)이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "역전사 효소 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "뉴클레오사이드 역전사 효소 억제제 (NRTIs) - 테노포비르(Tenofovir)와 엠트리시타빈(Emtricitabrine)이 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "비뉴클레오사이드 역전사 효소 억제제 (NNRTIs) - 에파비렌즈(Efavirenz)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 복제를 차단하는 약물은 감염성 바이러스 역가 감소와 CD4+ T 세포 증가로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "77",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "통합효소 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "HIV 통합효소가 cDNA를 숙주 염색체에 통합하는 것을 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "랄테그라비르(Raltegravir)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "프로테아제 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "바이러스 전구 단백질을 구조 및 기능 단백질로 분해하는 프로테아제를 억제합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "아타자나비르(Atazanavir), 인디나비르(Indinavir), 사퀴나비르(Saquinavir)가 있습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "성숙 억제제:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "테더린(Tetherins)은 바이러스를 세포에 묶어 방출 및 확산을 방지합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "감염 과정에서 HIV는 많은 돌연변이를 축적하여 약물 내성 변이체의 증식으로 이어집니다.",
                    "level": null
                  },
                  {
                    "type": "heading",
                    "content": "HIV 백신 개발의 과제",
                    "level": 2
                  },
                  {
                    "type": "paragraph",
                    "content": "모방할 자연 면역 모델이 없습니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "연구 동물이 부족합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "레트로바이러스 메커니즘에 대한 이해가 부족합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "높은 돌연변이율로 인해 내성 균주가 발생합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "이상적인 백신은 다음과 같아야 합니다:",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "잠복 바이러스 저장소가 확립되기 전에 면역을 유도해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "세포독성 T 림프구(CTLs)의 생성을 자극해야 합니다.",
                    "level": null
                  },
                  {
                    "type": "paragraph",
                    "content": "합리적인 가격이어야 합니다.",
                    "level": null
                  }
                ],
                "aiNotes": {
                  "summary": "이 문서는 후천성 면역 결핍 증후군(AIDS)의 기원, 원인 바이러스인 HIV의 구조, 감염 메커니즘 및 병원성, 바이러스 아형, 감염 단계, 진단 방법, 전파 경로, 전 세계적 현황, 예방 및 치료법, 그리고 백신 개발의 과제에 대해 상세히 설명합니다. HIV는 CD4+ T 세포를 선택적으로 감염시키는 레트로바이러스이며, 잠복 감염과 활동성 감염 단계를 거치며 면역 체계를 파괴합니다. HAART(고활성 항레트로바이러스 치료)를 통해 HIV 복제를 억제하고 환자의 삶의 질을 향상시킬 수 있지만, 바이러스의 높은 돌연변이율로 인해 백신 개발에는 어려움이 있습니다.",
                  "keyConcepts": [
                    {
                      "term": "HIV (Human Immunodeficiency Virus)",
                      "definition": {
                        "easy": null,
                        "medium": "AIDS의 원인 바이러스로, 인체의 면역 체계를 공격하고 파괴하는 레트로바이러스입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "CD4+ T 세포",
                      "definition": {
                        "easy": null,
                        "medium": "HIV가 주로 감염시키고 파괴하는 면역 세포로, 이 세포의 감소는 면역 결핍을 초래합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "역전사 효소 (Reverse Transcriptase)",
                      "definition": {
                        "easy": null,
                        "medium": "HIV를 포함한 레트로바이러스가 자신의 RNA 유전체를 DNA로 역전사하는 데 사용하는 효소입니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "HAART (Highly Active Antiretroviral Therapy)",
                      "definition": {
                        "easy": null,
                        "medium": "HIV 감염 치료를 위해 여러 종류의 항레트로바이러스 약물을 병용하는 치료법으로, 바이러스 복제를 효과적으로 억제합니다.",
                        "hard": null
                      }
                    },
                    {
                      "term": "기회 감염 (Opportunistic Infections)",
                      "definition": {
                        "easy": null,
                        "medium": "면역 체계가 약해진 상태에서 일반적으로 건강한 사람에게는 질병을 일으키지 않는 미생물에 의해 발생하는 감염입니다.",
                        "hard": null
                      }
                    }
                  ],
                  "importantTerms": [
                    {
                      "term": "AIDS (Acquired Immunodeficiency Syndrome)",
                      "definition": "후천성 면역 결핍 증후군. HIV 감염의 마지막 단계로, 심각한 면역 결핍과 기회 감염 및 특정 암을 특징으로 합니다."
                    },
                    {
                      "term": "레트로바이러스 (Retrovirus)",
                      "definition": "RNA 유전체를 가지고 있으며, 역전사 효소를 사용하여 RNA를 DNA로 전환하고 이를 숙주 게놈에 통합시키는 바이러스입니다."
                    },
                    {
                      "term": "gp120 및 gp41",
                      "definition": "HIV 외피에 존재하는 당단백질 스파이크로, gp120은 CD4 수용체에 부착하고 gp41은 바이러스와 세포막의 융합을 촉진합니다."
                    },
                    {
                      "term": "프로바이러스 (Provirus)",
                      "definition": "레트로바이러스의 DNA 유전체가 숙주 세포의 염색체 DNA에 통합된 형태입니다."
                    },
                    {
                      "term": "혈청 전환 (Seroconversion)",
                      "definition": "감염 후 특정 병원체에 대한 항체가 혈액에서 처음으로 검출되는 시기입니다."
                    },
                    {
                      "term": "CD4+ T 세포 수치",
                      "definition": "면역 상태를 나타내는 중요한 지표로, AIDS 진단 기준 중 하나는 이 수치가 200 cells/μl 미만인 경우입니다."
                    },
                    {
                      "term": "CCR5 돌연변이",
                      "definition": "일부 개인에게서 발견되는 유전적 돌연변이로, HIV가 세포에 진입하는 데 필요한 공동수용체인 CCR5를 변경하여 HIV 감염에 대한 저항성을 부여합니다."
                    }
                  ],
                  "outline": [
                    {
                      "text": "후천성 면역 결핍 증후군 (AIDS)",
                      "id": "후천성-면역-결핍-증후군-aids",
                      "children": null
                    },
                    {
                      "text": "AIDS의 기원",
                      "id": "aids의-기원",
                      "children": null
                    },
                    {
                      "text": "HIV의 구조",
                      "id": "hiv의-구조",
                      "children": null
                    },
                    {
                      "text": "HIV의 감염성과 병원성",
                      "id": "hiv의-감염성과-병원성",
                      "children": null
                    },
                    {
                      "text": "HIV의 아형",
                      "id": "hiv의-아형",
                      "children": null
                    },
                    {
                      "text": "HIV 감염의 단계",
                      "id": "hiv-감염의-단계",
                      "children": null
                    },
                    {
                      "text": "HIV 감염의 진행 및 병원성",
                      "id": "hiv-감염의-진행-및-병원성",
                      "children": null
                    },
                    {
                      "text": "HIV 노출에 대한 반응의 변이",
                      "id": "hiv-노출에-대한-반응의-변이",
                      "children": null
                    },
                    {
                      "text": "기회 감염",
                      "id": "기회-감염",
                      "children": null
                    },
                    {
                      "text": "진단 방법",
                      "id": "진단-방법",
                      "children": null
                    },
                    {
                      "text": "HIV 전파",
                      "id": "hiv-전파",
                      "children": null
                    },
                    {
                      "text": "전 세계 AIDS 현황",
                      "id": "전-세계-aids-현황",
                      "children": null
                    },
                    {
                      "text": "전 세계 지역별 HIV 감염 및 AIDS 분포",
                      "id": "전-세계-지역별-hiv-감염-및-aids-분포",
                      "children": null
                    },
                    {
                      "text": "AIDS 예방 및 치료",
                      "id": "aids-예방-및-치료",
                      "children": [
                        {
                          "text": "HIV 관리",
                          "id": "hiv-관리",
                          "children": null
                        },
                        {
                          "text": "HIV 치료 약물의 종류",
                          "id": "hiv-치료-약물의-종류",
                          "children": null
                        }
                      ]
                    },
                    {
                      "text": "HIV 백신 개발의 과제",
                      "id": "hiv-백신-개발의-과제",
                      "children": null
                    }
                  ]
                },
                "quiz": [
                  {
                    "question": "HIV가 주로 감염시키고 파괴하는 면역 세포는 무엇입니까?",
                    "options": [
                      "B 세포",
                      "CD4+ T 세포",
                      "대식세포",
                      "자연 살해(NK) 세포"
                    ],
                    "answerIndex": 1,
                    "explanation": "HIV는 CD4+ 수용체를 가진 세포를 감염시키며, 특히 CD4+ T 세포는 HIV 감염의 주요 표적 세포입니다. 이 세포의 파괴는 면역 결핍을 초래합니다."
                  },
                  {
                    "question": "HIV 감염 진단에 사용되는 방법 중 HIV 항체를 검출하는 검사는 무엇입니까?",
                    "options": [
                      "PCR",
                      "Western blotting",
                      "ELISA",
                      "핵산 혼성화"
                    ],
                    "answerIndex": 2,
                    "explanation": "HIV 항체는 ELISA(효소결합 면역흡착법)를 통해 검출됩니다. Western blotting은 항체 검출을 확인하는 데 사용될 수 있으며, PCR과 핵산 혼성화는 바이러스 자체(RNA 또는 DNA)를 검출하는 데 사용됩니다."
                  },
                  {
                    "question": "HAART(고활성 항레트로바이러스 치료)의 주요 특징은 무엇입니까?",
                    "options": [
                      "단일 약물을 고용량으로 투여합니다.",
                      "수술적 방법으로 바이러스를 제거합니다.",
                      "여러 종류의 항레트로바이러스 약물을 병용합니다.",
                      "면역 증강제만을 사용하여 면역력을 높입니다."
                    ],
                    "answerIndex": 2,
                    "explanation": "HAART는 여러 종류의 항레트로바이러스 약물을 병용하여 HIV 복제를 다양한 단계에서 억제하고 약물 내성 균주의 출현을 최소화하는 치료법입니다."
                  }
                ]
              }
            ],
            "final_result": "'인체 면역 시스템: 방어 기전, 응용 및 질환' 노트북(ID: 5)에 16개의 챕터가 성공적으로 처리 및 저장되었습니다."
          }
        }
      ],
      "final_result": "'인체 면역 시스템: 방어 기전, 응용 및 질환' 노트북(ID: 5)에 16개의 챕터가 성공적으로 처리 및 저장되었습니다."
    }
  }
]